FN Thomson Reuters Web of Science™ VR 1.0 PT J AU Pope, C North-Lee, B Davis, B AF Pope, Charlene North-Lee, Bertha Davis, Boyd TI Dropped Cues in Patient-Physician Interactions: How Discourse Analysis Finds Areas for Coaching SO INTERNATIONAL JOURNAL OF QUALITATIVE METHODS LA English DT Meeting Abstract C1 [Pope, Charlene; North-Lee, Bertha] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Davis, Boyd] Univ North Carolina Charlotte, Charlotte, NC USA. NR 0 TC 0 Z9 0 U1 4 U2 4 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1609-4069 J9 INT J QUAL METH JI Int. J. Qual. Meth. PD DEC PY 2017 VL 16 IS 1 PG 1 WC Social Sciences, Interdisciplinary SC Social Sciences - Other Topics GA EL7CA UT WOS:000394777500099 ER PT J AU Salazar, R Dwivedi, AK Royall, DR AF Salazar, Ricardo Dwivedi, Alok Kumar Royall, Donald R. TI Cross-Ethnic Differences in the Severity of Neuropsychiatric Symptoms in Persons With Mild Cognitive Impairment and Alzheimer's Disease SO JOURNAL OF NEUROPSYCHIATRY AND CLINICAL NEUROSCIENCES LA English DT Article ID BRIEF CLINICAL FORM; MEXICAN-AMERICANS; NPI-Q; DEMENTIA; HISPANICS; PREVALENCE; DEPRESSION; POPULATION; VALIDATION; INVENTORY AB In this cross-sectional study, we examined the neuropsychiatric profile of mild cognitive impairment (MCI) and Alzheimer's disease (AD) using the Neuropsychiatric Inventory Questionnaire (NPI-Q). Data were available on 875 controls, 339 MCI cases, and 975 AD participants. Surprisingly, differences in neuropsychiatric symptom (NPS) severity by ethnicity in subjects with AD, but not with MCI, were found. More so, in Hispanics with AD, a higher frequency in most of the individual NPI-Q symptom items of the scale was observed, except for apathy. After adjustment for clinical features, some individual NPI-Q symptoms also showed an association with Hispanic ethnicity in the control group that nearly reached statistical significance. There may be cross-ethnic differences in the neuropsychiatric presentation of AD in Hispanics versus non-Hispanic whites. Future studies are needed to clarify the etiology of these differences, and to assess the need for ethnicity-specific treatment and care-giving interventions. C1 [Salazar, Ricardo] Texas Tech Univ Hlth Sci Ctr El Paso, Div Geriatr Psychiat & Behav Neurosci, Dept Psychiat, El Paso, TX 79905 USA. Texas Tech Univ Hlth Sci Ctr El Paso, Paul L Foster Sch Med, El Paso, TX 79905 USA. Texas Tech Univ Hlth Sci Ctr El Paso, Paul L Foster Sch Med, Dept Biomed Sci, Div Biostat & Epidemiol, El Paso, TX 79905 USA. Texas Tech Univ Hlth Sci Ctr El Paso, Biostat & Epidemiol Consulting Lab, El Paso, TX 79905 USA. Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat & Behav Med, San Antonio, TX 78229 USA. Univ Texas Hlth Sci Ctr San Antonio, Depts Med Family & Community Med, San Antonio, TX 78229 USA. South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA. RP Salazar, R (reprint author), Texas Tech Univ Hlth Sci Ctr El Paso, Div Geriatr Psychiat & Behav Neurosci, Dept Psychiat, El Paso, TX 79905 USA. FU Texas Alzheimer's Research and Care Consortium (TARCC) - state of Texas through the Texas Council on Alzheimer's Disease and Related Disorders FX This study was made possible by the Texas Alzheimer's Research and Care Consortium (TARCC) funded by the state of Texas through the Texas Council on Alzheimer's Disease and Related Disorders. NR 41 TC 0 Z9 0 U1 42 U2 42 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0895-0172 EI 1545-7222 J9 J NEUROPSYCH CLIN N JI J. Neuropsychiatr. Clin. Neurosci. PD WIN PY 2017 VL 29 IS 1 BP 13 EP 21 DI 10.1176/appi.neuropsych.15120423 PG 9 WC Clinical Neurology; Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA EP0WO UT WOS:000397107600003 PM 27417070 ER PT J AU Turgeman, L May, JH Sciulli, R AF Turgeman, Lior May, Jerrold H. Sciulli, Roberta TI Insights from a machine learning model for predicting the hospital Length of Stay (LOS) at the time of admission SO EXPERT SYSTEMS WITH APPLICATIONS LA English DT Article DE Cubist decision tree; Continuous association rule mining algorithm (CARMA); Support vector machine (SVM); Decision function; Error distribution; Length of Stay (LOS) ID CONGESTIVE-HEART-FAILURE; PHASE-TYPE DISTRIBUTIONS; ELDERLY PATIENTS; READMISSION; MORTALITY; SURVIVAL; ANEMIA; ADULTS; COSTS; COPD AB A model that accurately predicts, at the time of admission, the Length of Stay (LOS) for hospitalized patients could be an effective tool for healthcare providers. It could enable early interventions to prevent complications, enabling more efficient utilization of manpower and facilities in hospitals. In this study, we apply a regression tree (Cubist) model for predicting the LOS, based on static inputs, that is, values that are known at the time of admission and that do not change during patient's hospital stay. The model was trained and validated on de-identified administrative data from the Veterans Health Administration (VHA) hospitals in Pittsburgh, PA. We chose to use a Cubist model because it produced more accurate predictions than did alternative techniques. In addition, tree models enable us to examine the classification rules learned from the data, in order to better understand the factors that are most correlated with hospital LOS. Cubist recursively partitions the data set as it estimates linear regressions for each partition, and the error level differs for different partitions, so that it is possible to deduce what are the characteristics of patients whose LOS can be accurately predicted at admission, and what are the characteristics of patients for whom the LOS estimate at that point in time is more highly uncertain. For example, our model indicates that the prediction error is greater for patients who had more admissions in the recent past, and for those who had longer previous hospital stays. Our approach suggests that mapping the cases into a higher dimensional space, using a Radial Basis Function (RBF) kernel, helps to separate them by their level of Cubist error, using a Support Vector Machine (SVM). (C) 2017 Elsevier Ltd. All rights reserved. C1 [Turgeman, Lior; May, Jerrold H.] Univ Pittsburgh, Joseph M Katz Grad Sch Business, Mervis Hall, Pittsburgh, PA 15260 USA. [Sciulli, Roberta] Vet Affairs Pittsburgh Healthcare Syst, Vet Engn Resource Ctr, Pittsburgh, PA 15215 USA. RP Turgeman, L (reprint author), IBM Res, Univ Haifa Campus, Haifa, Israel. EM tur.lior@gmail.com; jerrymay@katz.pitt.edu; RLS150@PITT.EDU FU U.S. Department of Veterans Affairs [VA244-13-C-0581, VA240-14-D-0038]; University of Pittsburgh FX This work was supported by the U.S. Department of Veterans Affairs, through master contract numbers VA244-13-C-0581 and VA240-14-D-0038 with the University of Pittsburgh. This work is an outcome of a continuing partnership between the Katz Graduate School of Business and the Pittsburgh Veterans Engineering Resource Center (VERC). Inpatient admissions data were pulled from the VA corporate data warehouse by Dr. Youxu C. Tjader. We thank the RRTICT project group of the Pittsburgh Veterans Engineering Resource Center (VERC) for helpful discussions. NR 52 TC 0 Z9 0 U1 11 U2 11 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0957-4174 EI 1873-6793 J9 EXPERT SYST APPL JI Expert Syst. Appl. PD JUL 15 PY 2017 VL 78 BP 376 EP 385 DI 10.1016/j.eswa.2017.02.023 PG 10 WC Computer Science, Artificial Intelligence; Engineering, Electrical & Electronic; Operations Research & Management Science SC Computer Science; Engineering; Operations Research & Management Science GA ER5XK UT WOS:000398877400027 ER PT J AU Lynn, DD Zukin, LM Dellavalle, R AF Lynn, Darren D. Zukin, Leonid M. Dellavalle, Robert TI The safety and efficacy of Diphoterine for ocular and cutaneous burns in humans SO CUTANEOUS AND OCULAR TOXICOLOGY LA English DT Review DE Prevor; amphoteric; chemical burn; alkaloid burn; acid burn ID DECONTAMINATION SOLUTION; SPLASH DECONTAMINATION; ACTIVE DECONTAMINATION; EMERGENCY TREATMENT; CHEMICAL SPLASHES; EYE BURNS; SKIN AB Context: Diphoterine, developed by the French company Prevor, is a polyvalent, chelating, amphoteric and slightly hypertonic solution used in the management of chemical cutaneous and ocular burns. While used extensively in Europe and Canada, it is has not been approved by the United States Occupational Safety and Health Administration (OSHA) as an alternative to the water-rinse method due to a lack of evidence of its safety and efficacy on human subjects. An unbiased and extensive systematic review was undertaken in order to better understand Diphoterine's safety and efficaciousness on humans.Objective: Review the safety and efficacy of Diphoterine for treating chemical burns of the skin and eyes in humans.Methods: Data sources: Information sources included Pubmed, the National Library of Medicine's Medline Database and the Publications sections of the Prevor website. Search terms included Diphoterine, chemical burn, ocular burn and cutaneous burn. Study selection: Any study type published through a peer-reviewed journal up to May 2016 was considered eligible. Published data must have included Diphoterine in the treatment of chemical burns on the skin or eyes as well as meet other specified criteria. Acceptable studies had to use either a quantitative (e.g. number of work days lost) or qualitative (e.g. level of erythema) approach when measuring cutaneous or ocular lesion outcomes. Data extraction: Independent assessment of article inclusion by two authors using predefined criteria.Results and Conclusion: Diphoterine is safe and highly effective in improving healing time, healing sequelae and pain management of chemical burns on the skin and eyes of humans. Outcomes are significantly improved when compared to water or a physiologic solution equivalent. We recommend that this product be readily available to emergency responders and companies that expose their employees to hazardous chemical substances in order to improve healing sequelae, pain management and lost work days from these types of burns. C1 [Lynn, Darren D.] Univ Colorado, Denver Sch Med, Dept Dermatol, Anschutz Med Campus, Aurora, CO 80045 USA. [Zukin, Leonid M.] Univ Colorado, Denver Sch Med, Dept Opthamol, Aurora, CO USA. [Dellavalle, Robert] US Dept Vet Affairs, Eastern Colorado Hlth Care Syst, Dermatol Serv, Denver, CO USA. RP Lynn, DD (reprint author), Univ Colorado, Denver Sch Med, Dept Dermatol, Anschutz Med Campus, Aurora, CO 80045 USA. EM darren.lynn@ucdenver.edu NR 17 TC 0 Z9 0 U1 0 U2 0 PU TAYLOR & FRANCIS LTD PI ABINGDON PA 2-4 PARK SQUARE, MILTON PARK, ABINGDON OR14 4RN, OXON, ENGLAND SN 1556-9527 EI 1556-9535 J9 CUTAN OCUL TOXICOL JI Cutan. Ocul. Toxicol. PD JUN PY 2017 VL 36 IS 2 BP 185 EP 192 DI 10.1080/15569527.2016.1217423 PG 8 WC Ophthalmology; Toxicology SC Ophthalmology; Toxicology GA ES4JV UT WOS:000399501400015 PM 27486965 ER PT J AU Krivinko, JM Erickson, SL Abrahamson, EE Wills, ZP Ikonomovic, MD Penzes, P Sweet, RA AF Krivinko, Josh M. Erickson, Susan L. Abrahamson, Eric E. Wills, Zachary P. Ikonomovic, Milos D. Penzes, Peter Sweet, Robert A. TI Kalirin reduction rescues psychosis-associated behavioral deficits in APPswe/PSEN1dE9 transgenic mice SO NEUROBIOLOGY OF AGING LA English DT Article DE Psychosis; Alzheimer disease; Kalirin ID AMYLOID PRECURSOR PROTEIN; PLACEBO-CONTROLLED TRIALS; INCREASED FAMILIAL RISK; ALZHEIMERS-DISEASE; MOUSE MODEL; COGNITIVE IMPAIRMENT; PSYCHOLOGICAL SYMPTOMS; P21-ACTIVATED KINASES; PREPULSE INHIBITION; MENTAL-RETARDATION AB Psychosis in Alzheimer's disease (AD+P) represents a distinct clinical and neurobiological AD phenotype and is associated with more rapid cognitive decline, higher rates of abnormal behaviors, and increased caregiver burden compared with AD without psychosis. On a molecular level, AD+P is associated with greater reductions in the protein kalirin, a guanine exchange factor which has also been linked to the psychotic disease, schizophrenia. In this study, we sought to determine the molecular and behavioral consequences of kalirin reduction in APPswe/PSEN1dE9 mice. We evaluated mice with and without kalirin reduction during tasks measuring psychosis-associated behaviors and spatial memory. We found that kalirin reduction in APPswe/PSEN1dE9 mice significantly attenuated psychosis-associated behavior at 12 months of age without changing spatial memory performance. The 12-month-old APPswe/PSEN1dE9 mice with reduced kalirin levels also had increased levels of the active, phosphorylated forms of p21 protein (Cdc42/Rac) eactivated kinases (PAKs), which function in signaling pathways for maintenance of dendritic spine density, morphology, and function. Published by Elsevier Inc. C1 [Krivinko, Josh M.; Erickson, Susan L.; Ikonomovic, Milos D.; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Abrahamson, Eric E.; Ikonomovic, Milos D.; Sweet, Robert A.] Univ Pittsburgh, Sch Med, Dept Neurol, Pittsburgh, PA 15261 USA. [Wills, Zachary P.] Univ Pittsburgh, Sch Med, Dept Neurobiol, Pittsburgh, PA USA. [Ikonomovic, Milos D.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Penzes, Peter] Northwestern Univ, Dept Physiol, Feinberg Sch Med, Chicago, IL 60611 USA. [Penzes, Peter] Northwestern Univ, Dept Psychiat & Behav Sci, Feinberg Sch Med, Chicago, IL 60611 USA. [Sweet, Robert A.] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. RP Sweet, RA (reprint author), Biomed Sci Tower,Rm W-1645,3811 OHara St, Pittsburgh, PA 15213 USA. EM sweetra@upmc.edu FU [BX000452]; [MH071533]; [AG014449]; [MH071316]; [MH097216]; [MH107966] FX The authors would like to thank Dr. Patrick Murray for his input on the design of the experiments and Dr. Floh Thiels for her input on the behavioral test battery. All behavioral testing was conducted in the Rodent Behavioral Assessment Core in the Department of Neurobiology at the University of Pittsburgh. This work was supported by grants BX000452 (R.A.S.), MH071533 (R.A.S.), AG014449 (M.D.I.), MH071316 (P.P.), MH097216 (P.P.), and MH107966 (Z.W.). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health, the National Institutes of Health, the Department of Veterans Affairs, or the United States Government. NR 63 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 EI 1558-1497 J9 NEUROBIOL AGING JI Neurobiol. Aging PD JUN PY 2017 VL 54 BP 59 EP 70 DI 10.1016/j.neurobiolaging.2017.02.006 PG 12 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA ES4JZ UT WOS:000399501800007 PM 28319837 ER PT J AU Geerling, JC Yokota, S Rukhadze, I Roe, D Chamberlin, NL AF Geerling, Joel C. Yokota, Shigefumi Rukhadze, Irma Roe, Dan Chamberlin, Nancy L. TI Kolliker-Fuse GABAergic and glutamatergic neurons project to distinct targets SO JOURNAL OF COMPARATIVE NEUROLOGY LA English DT Article DE respiratory; whisking; FoxP2; trigeminal; parabrachial; PBel; RRID: AB_10015246; RRID: AB_2107107; RRID: AB_2107133 ID VENTRAL RESPIRATORY GROUP; PARABRACHIAL NUCLEUS; BRAIN-STEM; LATERAL LEMNISCUS; TOPOGRAPHIC ORGANIZATION; EFFERENT CONNECTIONS; FOXP2 EXPRESSION; PHRENIC NUCLEUS; RAT; MATH1 AB The Kolliker-Fuse nucleus (KF) is known primarily for its respiratory function as the "pneumotaxic center" or 'pontine respiratory group." Considered part of the parabrachial (PB) complex, KF contains glutamatergic neurons that project to respiratory-related targets in the medulla and spinal cord (Yokota, Oka, Tsumori, Nakamura, & Yasui, 2007). Here we describe an unexpected population of neurons in the caudal KF and adjacent lateral crescent subnucleus (PBlc), which are -aminobutyric acid (GABA)ergic and have an entirely different pattern of projections than glutamatergic KF neurons. First, immunofluorescence, in situ hybridization, and Cre-reporter labeling revealed that many of these GABAergic neurons express FoxP2 in both rats and mice. Next, using Cre-dependent axonal tracing in Vgat-IRES-Cre and Vglut2-IRES-Cre mice, we identified different projection patterns from GABAergic and glutamatergic neurons in this region. GABAergic neurons in KF and PBlc project heavily and almost exclusively to trigeminal sensory nuclei, with minimal projections to cardiorespiratory nuclei in the brainstem, and none to the spinal cord. In contrast, glutamatergic KF neurons project heavily to the autonomic, respiratory, and motor regions of the medulla and spinal cord previously identified as efferent targets mediating KF cardiorespiratory effects. These findings identify a novel, GABAergic subpopulation of KF/PB neurons with a distinct efferent projection pattern targeting the brainstem trigeminal sensory system. Rather than regulating breathing, we propose that these neurons influence vibrissal sensorimotor function. C1 [Geerling, Joel C.; Yokota, Shigefumi; Rukhadze, Irma; Roe, Dan; Chamberlin, Nancy L.] Beth Israel Deaconess Med Ctr, Dept Neurol, 330 Brookline Ave, Boston, MA 02215 USA. [Geerling, Joel C.; Yokota, Shigefumi; Rukhadze, Irma; Roe, Dan; Chamberlin, Nancy L.] Harvard Med Sch, Boston, MA USA. [Geerling, Joel C.; Rukhadze, Irma; Chamberlin, Nancy L.] Beth Israel Deaconess Med Ctr, Div Sleep Med, Boston, MA 02215 USA. [Geerling, Joel C.] Univ Iowa Hosp & Clin, Dept Neurol, Iowa City, IA 52242 USA. [Yokota, Shigefumi] Shimane Univ, Sch Med, Dept Anat & Morphol Neurosci, Izumo, Shimane, Japan. [Rukhadze, Irma] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Rukhadze, Irma] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. RP Geerling, JC; Chamberlin, NL (reprint author), Beth Israel Deaconess Med Ctr, Dept Neurol, 330 Brookline Ave, Boston, MA 02215 USA. EM jgeerlin@bidmc.harvard.edu; nchamber@bidmc.harvard.edu OI Geerling, Joel/0000-0001-9956-4006 FU National Institutes of Health [P01 HL095491, NS070682] FX National Institutes of Health, Grant/Award Numbers: P01 HL095491 (to N.L.C.) and R25 #NS070682 (to J.C.G.). NR 59 TC 0 Z9 0 U1 1 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0021-9967 EI 1096-9861 J9 J COMP NEUROL JI J. Comp. Neurol. PD JUN 1 PY 2017 VL 525 IS 8 BP 1844 EP 1860 DI 10.1002/cne.24164 PG 17 WC Neurosciences; Zoology SC Neurosciences & Neurology; Zoology GA ER2JL UT WOS:000398620100006 PM 28032634 ER PT J AU Xu, DH Zhu, ZW Xiao, HP Wakefield, MR Bai, Q Nicholl, MB Ding, VA Fang, YJ AF Xu, Dixon H. Zhu, Ziwen Xiao, Huaping Wakefield, Mark R. Bai, Qian Nicholl, Michael B. Ding, Vivi A. Fang, Yujiang TI Unveil the mysterious mask of cytokine-based immunotherapy for melanoma SO CANCER LETTERS LA English DT Review DE Cytokine; Melanoma; Immunotherapy ID CD8(+) T-CELLS; DIFFERENTIATION-ASSOCIATED GENE-7; DOSE RECOMBINANT INTERLEUKIN-2; ACTIVATED KILLER-CELLS; INHIBITS TUMOR-GROWTH; LONG-TERM SURVIVAL; METASTATIC MELANOMA; MALIGNANT-MELANOMA; NK CELLS; ANTITUMOR-ACTIVITY AB Melanoma is the leading cause of death among all skin cancers and its incidence continues to rise rapidly worldwide in the past decades. The available treatment options for melanoma remain limited despite extensive clinical research. Melanoma is an immunogenic tumor and great advances in immunology in recent decades allow for the development of immunotherapeutic agents against melanoma. In recent years, immunotherapy utilizing cytokines has been particularly successful in certain cancers and holds promise for patients with advanced melanoma. In this review, an overview of the current status and emerging perspectives on cytokine immunotherapy for melanoma are discussed in details. Such a study will be helpful to unveil the mysterious mask of cytokine-based immunotherapy for melanoma. (C) 2017 Elsevier B.V. All rights reserved. C1 [Xu, Dixon H.; Xiao, Huaping; Ding, Vivi A.; Fang, Yujiang] Des Moines Univ, Dept Microbiol Immunol & Pathol, Des Moines, IA 50312 USA. [Zhu, Ziwen; Wakefield, Mark R.; Bai, Qian; Fang, Yujiang] Univ Missouri, Sch Med, Dept Surg, Columbia, MO 65212 USA. [Xiao, Huaping] Xiangnan Univ, Affiliated Hosp, Chenzhou, Hunan, Peoples R China. [Nicholl, Michael B.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Fang, YJ (reprint author), Des Moines Univ, Coll Osteopath Med, Dept Microbiol Immunol & Pathol, Des Moines, IA 50312 USA. EM yujiang.fang@dmu.edu FU Iowa Science Foundation [ISF 16-8, IOER 05-14-01, IOER 112-3749, IOER 112-3114] FX This study was supported by grants for Yujiang Fang (Iowa Science Foundation Grant ISF 16-8, IOER 05-14-01, IOER 112-3749 and IOER 112-3114). NR 153 TC 0 Z9 0 U1 6 U2 6 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3835 EI 1872-7980 J9 CANCER LETT JI Cancer Lett. PD MAY 28 PY 2017 VL 394 BP 43 EP 51 DI 10.1016/j.canlet.2017.02.022 PG 9 WC Oncology SC Oncology GA ES5ZZ UT WOS:000399626900005 PM 28254411 ER PT J AU Raghuram, V Weber, S Raber, J Chen, DH Bird, TD Maylie, J Adelman, JP AF Raghuram, Vijeta Weber, Sydney Raber, Jacob Chen, Dong-Hui Bird, Thomas D. Maylie, James Adelman, John P. TI Assessment of mutations in KCNN2 and ZNF135 to patient neurological symptoms SO NEUROREPORT LA English DT Article DE apamin; ataxia; CRISPR-Cas system; human exome sequencing; neuroscience; SK potassium channel; transgenic mice; ZNF135 ID CA2+-ACTIVATED K+ CHANNELS; CONDUCTANCE AB Exome sequencing from a patient with neurological and developmental symptoms revealed two mutations in separate genes. One was a homozygous transition mutation that results in an in-frame, premature translational stop codon in the ZNF135 gene predicted to encode a transcriptional repressor. Another mutation was heterozygous, a single nucleotide duplication in the KCNN2 gene that encodes a Ca2+ -activated K+ channel, SK2, and leads to a translational frame shift and a premature stop codon. Heterologous expression studies, brain slice recordings, and coordination tests from a transgenic mouse line carrying the SK2 mutation suggest that it does not contribute to the patient's symptoms. ZNF135 is expressed in human brain and it is likely that the homozygous mutation underlies the human phenotype. Copyright (C) 2017 The Author(s). Published by Wolters Kluwer Health, Inc. C1 [Raghuram, Vijeta; Adelman, John P.] Oregon Hlth & Sci Univ, Vollum Inst, L474,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA. [Weber, Sydney; Raber, Jacob] Oregon Hlth & Sci Univ, Dept Behav Neurosci, Portland, OR 97201 USA. [Maylie, James] Oregon Hlth & Sci Univ, Dept Obstet & Gynecol, Portland, OR 97201 USA. [Chen, Dong-Hui; Bird, Thomas D.] Univ Washington, Geriatr Res GRECC, Dept Neurol, VA Puget Sound Healthcare Syst, Seattle, WA 98195 USA. RP Adelman, JP (reprint author), Oregon Hlth & Sci Univ, Vollum Inst, L474,3181 SW Sam Jackson Pk Rd, Portland, OR 97201 USA. EM adelman@ohsu.edu FU NIH FX This work was supported by NIH grants to J.M. and J.P.A. NR 7 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0959-4965 EI 1473-558X J9 NEUROREPORT JI Neuroreport PD MAY 3 PY 2017 VL 28 IS 7 BP 375 EP 379 DI 10.1097/WNR.0000000000000754 PG 5 WC Neurosciences SC Neurosciences & Neurology GA ES2CI UT WOS:000399333000002 PM 28240725 ER PT J AU Nedjat-Haiem, FR Carrion, IV Gonzalez, K Ell, K Thompson, B Mishra, SI AF Nedjat-Haiem, Frances R. Carrion, Iraida V. Gonzalez, Krystana Ell, Kathleen Thompson, Beti Mishra, Shiraz I. TI Exploring Health Care Providers' Views About Initiating End-of-Life Care Communication SO AMERICAN JOURNAL OF HOSPICE & PALLIATIVE MEDICINE LA English DT Article DE health care providers; end-of-life care; communication; qualitative research; social work ID DISCUSSIONS; PERCEPTIONS; PHYSICIANS; DECISION; NEEDS AB Numerous factors impede effective and timely end-of-life (EOL) care communication. These factors include delays in communication until patients are seriously ill and/or close to death. Gaps in patient-provider communication negatively affect advance care planning and limit referrals to palliative and hospice care. Confusion about the roles of various health care providers also limits communication, especially when providers do not coordinate care with other health care providers in various disciplines. Although providers receive education regarding EOL communication and care coordination, little is known about the roles of all health care providers, including nonphysician support staff working with physicians to discuss the possibility of dying and help patients prepare for death. This study explores the perspectives of physicians, nurses, social workers, and chaplains on engaging seriously ill patients and families in EOL care communication. Qualitative data were from 79 (medical and nonmedical) providers practicing at 2 medical centers in Central Los Angeles. Three themes that describe providers' perceptions of their roles and responsibility in talking with seriously ill patients emerged: (1) providers' roles for engaging in EOL discussions, (2) responsibility of physicians for initiating and leading discussions, and (3) need for team co-management patient care. Providers highlighted the importance of beginning discussions early by having physicians lead them, specifically due to their medical training and need to clarify medical information regarding patients' prognosis. Although physicians are a vital part of leading EOL communication, and are at the center of communication of medical information, an interdisciplinary approach that involves nurses, social workers, and chaplains could significantly improve patient care. C1 [Nedjat-Haiem, Frances R.; Gonzalez, Krystana] New Mexico State Univ, Sch Social Work, POB 30001,MSC 3SW, Las Cruces, NM 88003 USA. [Nedjat-Haiem, Frances R.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Carrion, Iraida V.] Univ S Florida, Sch Social Work, Tampa, FL USA. [Ell, Kathleen] Univ Southern Calif, Sch Social Work, Los Angeles, CA USA. [Thompson, Beti] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA. [Mishra, Shiraz I.] Univ New Mexico, Sch Med, Albuquerque, NM 87131 USA. RP Nedjat-Haiem, FR (reprint author), New Mexico State Univ, Sch Social Work, POB 30001,MSC 3SW, Las Cruces, NM 88003 USA. EM nedjatha@gmail.com FU American Cancer Society Doctoral Training Grants in Oncology Social Work [DSW-06-220-01-SW]; US Department of Veterans Affairs, Hartford/VA Social Work Scholars Program FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This research was supported by the American Cancer Society Doctoral Training Grants in Oncology Social Work DSW-06-220-01-SW (F. R. Nedjat-Haiem, PI) and US Department of Veterans Affairs, Hartford/VA Social Work Scholars Program. NR 28 TC 0 Z9 0 U1 1 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 1049-9091 EI 1938-2715 J9 AM J HOSP PALLIAT ME JI Am. J. Hosp. Palliat. Med. PD MAY PY 2017 VL 34 IS 4 BP 308 EP 317 DI 10.1177/1049909115627773 PG 10 WC Health Care Sciences & Services SC Health Care Sciences & Services GA ER5JM UT WOS:000398837800003 PM 26878869 ER PT J AU Wong, SPY O'Hare, AM AF Wong, Susan P. Y. O'Hare, Ann M. TI Families' Perception of End-of-Life Care for Patients With Serious Illness SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article ID AGGRESSIVE CANCER CARE; HEALTH-CARE; DIALYSIS; QUALITY; PERSPECTIVES; DISEASE; ADULTS; HEMODIALYSIS; HOSPICE; DEATH AB If 'progress' refers to the long-held Enlightenment idea and ideal that rationality and its tools can unequivocally improve life and reduce suffering, then 'postprogress' characterizes today's medicine.. Postprogress suggests that technical ability and more and more interventions, while they extend wanted life for many, also bring with them existential quandaries about one's own relationship to medicine, to suffering, to more life, and of the apparent control that can be exercised over the timing of death. -Sharon R. Kaufman, Ordinary Medicine(1) C1 [O'Hare, Ann M.] Univ Washington, 1660 S Columbian Way, Seattle, WA 98108 USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP O'Hare, AM (reprint author), Univ Washington, 1660 S Columbian Way, Seattle, WA 98108 USA. EM ann.ohare@va.gov FU Clinical Scientist in Nephrology Fellowship from the American Kidney Fund; National Institutes of Health; Centers for Disease Control and Prevention; VA Health Services Research and Development Service FX Dr Wong is supported by the Clinical Scientist in Nephrology Fellowship from the American Kidney Fund. Dr O'Hare receives research funding from the National Institutes of Health, Centers for Disease Control and Prevention, and VA Health Services Research and Development Service. NR 32 TC 0 Z9 0 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAY PY 2017 VL 69 IS 5 BP 564 EP 567 DI 10.1053/j.ajkd.2016.10.014 PG 4 WC Urology & Nephrology SC Urology & Nephrology GA ES4EZ UT WOS:000399484200004 PM 27932044 ER PT J AU Garimella, PS Li, KF Naviaux, JC Shlipak, MG Abdelmalek, JA Castro, E Capparelli, EV Naviaux, RK Ix, JH AF Garimella, Pranav S. Li, Kefeng Naviaux, Jane C. Shlipak, Michael G. Abdelmalek, Joseph A. Castro, Erick Capparelli, Edmund V. Naviaux, Robert K. Ix, Joachim H. TI Utility of Spot Urine Specimens to Assess Tubular Secretion SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Letter ID KIDNEY-FUNCTION DECLINE; PROGRESSION; HEALTH C1 [Garimella, Pranav S.; Li, Kefeng; Naviaux, Jane C.; Abdelmalek, Joseph A.; Capparelli, Edmund V.; Naviaux, Robert K.; Ix, Joachim H.] Univ Calif San Diego, San Diego, CA 92103 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, San Francisco, CA USA. [Castro, Erick] Vet Med Res Fdn, San Diego, CA USA. RP Ix, JH (reprint author), Univ Calif San Diego, San Diego, CA 92103 USA. EM joeix@ucsd.edu FU American Heart Association Established Investigator Award [14EIA18560026]; National Institute of Diabetes and Digestive and Kidney Diseases [R01 DK098234] FX This work was supported by research awards from the American Heart Association Established Investigator Award to J.H.I. (14EIA18560026) and the National Institute of Diabetes and Digestive and Kidney Diseases to J.H.I. and M.G.S. (R01 DK098234). The funders had no role in study design; collection, analysis, and interpretation of data; writing the report; or the decision to submit the report for publication. NR 8 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAY PY 2017 VL 69 IS 5 BP 709 EP 711 DI 10.1053/j.ajkd.2016.12.016 PG 3 WC Urology & Nephrology SC Urology & Nephrology GA ES4EZ UT WOS:000399484200028 PM 28284759 ER PT J AU Lin, TY Shekar, AO Li, N Yeh, MW Saab, S Wilson, M Leung, AM AF Lin, Tiffany Y. Shekar, Anshula O. Li, Ning Yeh, Michael W. Saab, Sammy Wilson, Mark Leung, Angela M. TI Incidence of abnormal liver biochemical tests in hyperthyroidism SO CLINICAL ENDOCRINOLOGY LA English DT Article ID GRAVES-DISEASE; THYROTROPIN RECEPTOR; SERIAL CHANGES; THYROTOXICOSIS; PROPYLTHIOURACIL; ASSOCIATIONS; METHIMAZOLE; THERAPY; COHORT AB ObjectiveAbnormal serum liver function tests are common in patients with untreated thyrotoxicosis, even prior to the initiation of antithyroidal medications that may worsen the severity of the abnormal serum liver biochemistries. There is a wide range of the incidence of these abnormalities in the published literature. The aim of this study was to assess the risks factors and threshold of thyrotoxicosis severity for developing an abnormal liver biochemical test upon the diagnosis of new thyrotoxicosis. DesignSingle-institution retrospective cohort study. PatientsPatients of 18 years old receiving medical care at a large, academic, urban US medical centre between 2002-2016. MeasurementsInclusion criteria were a serum thyroid stimulating hormone (TSH) concentration of <03 mIU/l or ICD-9 code for thyrotoxicosis, with thyrotoxicosis confirmed by either a concurrent elevated serum triiodothyronine (T3) or thyroxine (T4) concentration ([total or free] within 3 months), and an available liver biochemical test(s) within 6 months of thyrotoxicosis. The biochemical liver tests assessed were serum aspartate transaminotransferase (AST), alanine aminotransferase (ALT), alkaline phosphatase (AP), gamma-glutamyltransferase (GGT), total bilirubin, and conjugated bilirubin concentrations. ResultsIn this cohort of 1514 subjects, the overall incidence of any biochemical liver test abnormality within 6 months of thyrotoxicosis was 39%. An initial serum TSH concentration <002 mIU/l, male gender, and African-American race were significant predictors of an abnormal serum liver biochemical test within 6 months of the diagnosis of new-onset untreated thyrotoxicosis. ConclusionsThis study identifies risk factors for patients who develop an abnormal serum liver biochemical test result within 6 months of a diagnosis of untreated thyrotoxicosis. C1 [Lin, Tiffany Y.] Univ Calif Los Angeles, David Geffen Sch Med, 11301 Wilshire Blvd 111D, Los Angeles, CA 90073 USA. [Shekar, Anshula O.] Univ Calif Los Angeles, Dept Med, David Geffen Sch Med, 11301 Wilshire Blvd 111D, Los Angeles, CA 90073 USA. [Li, Ning] Univ Calif Los Angeles, Dept Biomath, David Geffen Sch Med, Los Angeles, CA 90073 USA. [Yeh, Michael W.] Univ Calif Los Angeles, Sect Endocrine Surg, Dept Surg, David Geffen Sch Med, Los Angeles, CA 90073 USA. [Saab, Sammy] Univ Calif Los Angeles, Div Gastroenterol, Dept Med, David Geffen Sch Med, Los Angeles, CA 90073 USA. [Wilson, Mark] Sansum Clin, Santa Barbara, CA USA. [Leung, Angela M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Endocrinol Diabet & Hypertens, Los Angeles, CA 90073 USA. [Leung, Angela M.] VA Greater Los Angeles Healthcare Syst, Div Endocrinol, Los Angeles, CA USA. RP Leung, AM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Div Endocrinol Diabet & Hypertens, 11301 Wilshire Blvd 111D, Los Angeles, CA 90073 USA. EM amleung@mednet.ucla.edu FU NIH [K23HD068552] FX Supported by NIH K23HD068552 (AML). NR 31 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0300-0664 EI 1365-2265 J9 CLIN ENDOCRINOL JI Clin. Endocrinol. PD MAY PY 2017 VL 86 IS 5 BP 755 EP 759 DI 10.1111/cen.13312 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA ER5QF UT WOS:000398856100016 PM 28199740 ER PT J AU Sheets, KM Atta, MG Fine, DM Zook, K Mcfall, AM Estrella, MM Schwartz, GJ Lucas, GM AF Sheets, Kerry M. Atta, Mohamed G. Fine, Derek M. Zook, Katie Mcfall, Allison M. Estrella, Michelle M. Schwartz, George J. Lucas, Gregory M. TI Longitudinal Assessment of Proximal Tubular Dysfunction in HIV Seropositive and Seronegative Persons: Correlates and Implications SO JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES LA English DT Article DE HIV; proximal tubular dysfunction; tenofovir disoproxil fumarate; antiretroviral therapy; glomerular filtration rate ID TENOFOVIR DISOPROXIL FUMARATE; INFECTED PATIENTS; ANTIRETROVIRAL THERAPY; URINARY ALBUMIN; TOTAL PROTEIN; DOUBLE-BLIND; NEPHROTOXICITY; ABNORMALITIES; EMTRICITABINE; ALAFENAMIDE AB Background: Proximal tubular dysfunction (PTD) is common in HIV-positive persons and has been associated with tenofovir disoproxil fumarate (TDF). However, few studies have assessed the natural history PTD in HIV-positive and -negative individuals, or the association of PTD with the subsequent trajectory of directly measured glomerular filtration rate (mGFR). Methods: We followed 192 HIV-positive and 100 HIV-negative, nondiabetic participants for 3 years. We measured 3 PTD markers (normoglycemic glycosuria, fractional excretion of phosphorus, and tubular proteinuria) and mGFR (by iohexol disappearance from serum) annually. We used univariate and multivariate generalized estimating equation logistic regression to identify factors associated with PTD across all visits and linear mixed effects models to assess the association between baseline PTD and mGFR slope. Results: Compared with HIV-negative participants, HIV-positive persons that were not taking antiretroviral therapy were at increased risk of PTD (adjusted odds ratio 3.33; 95% confidence interval: 1.65 to 6.71), whereas those taking a TDF-based or a TDF-sparing regimen were not at significantly increased risk of PTD. Among HIV-positive participants, uncontrolled viremia was a strong correlate of PTD. Forty-nine of 55 (89%) participants with PTD at baseline had at least 1 subsequent visit without PTD. There was no association between baseline PTD and rate of decline in mGFR over time. Conclusions: Poorly controlled HIV may be a stronger risk factor for PTD than TDF use. The individual-level variability of the PTD markers over time was high, potentially limiting their usefulness for routine screening in unselected patients. Baseline PTD was not associated with subsequent mGFR slope. C1 [Sheets, Kerry M.] Johns Hopkins Bayview Med Ctr, Internal Med Residency Training Program, Baltimore, MD USA. [Atta, Mohamed G.; Fine, Derek M.] Johns Hopkins Univ, Sch Med, Div Nephrol, Baltimore, MD USA. [Zook, Katie; Lucas, Gregory M.] Johns Hopkins Univ, Sch Med, Div Infect Dis, Dept Med, Baltimore, MD USA. [Mcfall, Allison M.] Johns Hopkins Univ, Bloomberg Sch Publ Hlth, Dept Epidemiol, Baltimore, MD USA. [Estrella, Michelle M.] San Francisco VA Med Ctr, Kidney Hlth Res Collaborat, San Francisco, CA USA. [Estrella, Michelle M.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Schwartz, George J.] Univ Rochester, Med Ctr, Dept Pediat, Rochester, NY 14642 USA. RP Lucas, GM (reprint author), Johns Hopkins Univ, Sch Med, Div Infect Dis, Dept Med, Baltimore, MD USA. EM glucas@jhmi.edu FU National Institute on Drug Abuse [R01DA026770, K24DA035684]; National Institute of Allergy and Infectious Diseases [T32AI102623]; National Institute of Diabetes and Digestive and Kidney Disease [U01DK082194, P01DK056492]; Johns Hopkins Institute for Clinical and Translational Research (ICTR); National Center for Advancing Translational Sciences (NCATS), a component of the NIH [UL1-TR000424]; Johns Hopkins Center for AIDS Research [P30AI094189] FX Supported by the National Institute on Drug Abuse (R01DA026770, K24DA035684). Other support was provided by the National Institute of Allergy and Infectious Diseases (T32AI102623), the National Institute of Diabetes and Digestive and Kidney Disease (U01DK082194, P01DK056492), the Johns Hopkins Institute for Clinical and Translational Research (ICTR), which is funded in part by grant number UL1-TR000424 from the National Center for Advancing Translational Sciences (NCATS), a component of the NIH, and by the Johns Hopkins Center for AIDS Research (P30AI094189). GE Healthcare provided the iohexol used for glomerular filtration rate measurements. NR 30 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1525-4135 EI 1077-9450 J9 JAIDS-J ACQ IMM DEF JI JAIDS PD MAY 1 PY 2017 VL 75 IS 1 BP 45 EP 51 PG 7 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA ES2RV UT WOS:000399376500013 PM 28151777 ER PT J AU Kelley, D Jones, LT Wu, J Bohm, N AF Kelley, Denise Jones, Lauren Thornton Wu, Jun Bohm, Nicole TI Evaluating the safety and effectiveness of venous thromboembolism prophylaxis in patients with sickle cell disease SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS LA English DT Article DE Venous thromboembolism; Prophylaxis; Sickle cell disease; Enoxaparin; Heparin AB Nearly every component of hemostasis is altered in sickle cell disease (SCD), yet little evidence exists to guide utilization of venous thromboembolism prophylaxis (VTEP) in this population. This retrospective cohort study included 135 adult patients admitted with a diagnosis of SCD vaso-occlusive crisis to the general medicine service at a tertiary care academic medical center from August 1, 2011 to August 1, 2013. If VTEP was discontinued, the medical record was reviewed for suspicion of VTE, hemorrhage, heparin-induced thrombocytopenia (HIT), or other adverse events. The primary objective was to characterize the safety and effectiveness of VTEP in SCD. The secondary objective was to assess the correlation of VTE with risk factors documented in the general medical population. Most patients (116/135, 85.9%) were prescribed VTEP upon admission, with early discontinuation in 23 patients (19.8%). Reasons for discontinuation included suspicion of VTE (10/116, 8.6%), hemorrhage (5/116, 4.3%), and/or HIT (4/116, 3.4%). Since patients with SCD receiving standard VTEP regimens appear to have similar outcomes compared to medically ill patients in prospective studies, using these regimens appears to be safe when indicated in the opinion of the provider. Once daily injections may be preferred in order to optimize adherence. C1 [Kelley, Denise] UF Hlth Jacksonville Med Ctr, Dept Pharm, Jacksonville, FL 32209 USA. [Jones, Lauren Thornton] Ralph H Johnson VA Med Ctr, Dept Pharm, Charleston, SC 29425 USA. [Wu, Jun] Presbyterian Coll Pharm, Clinton, SC 29325 USA. [Bohm, Nicole] Med Univ South Carolina, Coll Pharm, 280 Calhoun St QE 205, Charleston, SC 29425 USA. RP Bohm, N (reprint author), Med Univ South Carolina, Coll Pharm, 280 Calhoun St QE 205, Charleston, SC 29425 USA. EM bohm@musc.edu FU South Carolina Clinical and Translational Research (SCTR) Institute through NIH [UL1 TR000062] FX This project was supported by the South Carolina Clinical and Translational Research (SCTR) Institute, with an academic home at the Medical University of South Carolina, through NIH Grant Number UL1 TR000062. I would like to acknowledge Petra A. Aldridge, MS for her contributions to statistical analysis. NR 12 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0929-5305 EI 1573-742X J9 J THROMB THROMBOLYS JI J. Thromb. Thrombolysis PD MAY PY 2017 VL 43 IS 4 BP 463 EP 468 DI 10.1007/s11239-016-1463-z PG 6 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA ER7VB UT WOS:000399021200005 PM 27943026 ER PT J AU Gatto, EM Allegri, RF Da Prat, G Mendez, PC Hanna, DS Dorschner, MO Surace, EI Zabetian, CP Mata, IF AF Gatto, Emilia M. Allegri, Ricardo F. Da Prat, Gustavo Chrem Mendez, Patricio Hanna, David S. Dorschner, Michael O. Surace, Ezequiel I. Zabetian, Cyrus P. Mata, Ignacio F. TI Intrafamilial variable phenotype including corticobasal syndrome in a family with p.P301L mutation in the MAPT gene: first report in South America SO NEUROBIOLOGY OF AGING LA English DT Article DE FTD; MAPT; P301L; Cognition; CBS ID FRONTOTEMPORAL LOBAR DEGENERATION; PROGRESSIVE SUPRANUCLEAR PALSY; PROTEIN-TAU GENE; PARKINSONS-DISEASE; DEMENTIA; NEUROPATHOLOGY; AGGREGATION; TAUOPATHIES; ASSOCIATION; DIAGNOSIS AB Frontotemporal lobar degeneration is a neuropathological disorder that causes a variety of clinical syndromes including frontotemporal dementia (FTD), progressive supranuclear palsy, and corticobasal syndrome (CBS). FTD associated with parkinsonism occurs frequently as a result of mutations in the C9orf72 gene and also in the genes coding for the protein associated with microtubule tau (MAPT) and progranulin (GRN) on chromosome 17 (FTDP-17). Herein, we report an Argentinean family, of Basque ancestry, with an extensive family history of behavioral variant of FTD. Twenty-one members over 6 generations composed the pedigree. An extensive neurologic and neurocognitive examination was performed on 2 symptomatic individuals and 3 non-symptomatic individuals. Two different phenotypes were identified among affected members, CBS in the proband and FTD in his brother. DNA was extracted from blood for these 5 individuals and whole-exome sequencing was performed on 3 of them followed by Sanger sequencing of candidate genes on the other 2. In both affected individuals, a missense mutation (p.P301L; rs63751273) in exon 10 of the MAPT gene (chr17q21.3) was identified. Among MAPT mutations, p.P301L is the most frequently associated to different phenotypes: (1) aggressive, symmetrical, andearly-onset Parkinsonism; (2) late parkinsonism associated with FTD; and (3) progressive supranuclear palsy but only exceptionally it is reported associated to CBS. This is the first report of the occurrence of the p.P301L-MAPT mutation in South America and supports the marked phenotypic heterogeneity among members of the same family as previously reported. Published by Elsevier Inc. C1 [Gatto, Emilia M.] Fdn INEBA, Dept Movement Disorders, Buenos Aires, DF, Argentina. [Gatto, Emilia M.; Da Prat, Gustavo] Dept Neurol, Sanatorio Trinidad Mitre, Buenos Aires, DF, Argentina. [Allegri, Ricardo F.; Chrem Mendez, Patricio] Inst Invest Neurol Dr Raul Carrea FLENI, Memory & Aging Ctr, Dept Cognit Neurol, Buenos Aires, DF, Argentina. [Allegri, Ricardo F.] Consejo Nacl Invest Cient & Tecn, Argentine Res Council, Buenos Aires, DF, Argentina. [Hanna, David S.; Surace, Ezequiel I.] Univ Costa CUC, Barranquilla, Colombia. [Chrem Mendez, Patricio; Dorschner, Michael O.; Zabetian, Cyrus P.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Da Prat, Gustavo; Hanna, David S.; Zabetian, Cyrus P.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Hanna, David S.] FLEN, Dept Neuropathol, Lab Biol Mol, Buenos Aires, DF, Argentina. [Chrem Mendez, Patricio; Hanna, David S.; Surace, Ezequiel I.; Mata, Ignacio F.] Vet Affairs Puget Sound Hlth Care Syst, Geriatr Res Educ & Clin Ctr, Seattle, WA USA. [Chrem Mendez, Patricio; Dorschner, Michael O.] Univ Washington, Dept Neurol, Seattle, WA 98195 USA. RP Mata, IF (reprint author), VA Puget Sound Hlth Care Syst, GRECC S 182, 1660 S Columbian Way, Seattle, WA 98108 USA. EM nachofm@uw.edu FU Parkinson's Disease Foundation; Department of Veterans Affairs [1I01BX000531]; National Institutes of Health [R01 NS065070, P50 NS062684] FX The authors would like to acknowledge all the individuals in this family for their collaboration and doctors Marcelo Kauffman and Sergio Rodriguez, Laboratorio de Neurogenetica, Hospital Ramos Mejia, Buenos Aires Argentina for their scientific collaboration. This work was supported by grants from the Parkinson's Disease Foundation, the Department of Veterans Affairs (1I01BX000531) and the National Institutes of Health (R01 NS065070, P50 NS062684). The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. NR 34 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0197-4580 EI 1558-1497 J9 NEUROBIOL AGING JI Neurobiol. Aging PD MAY PY 2017 VL 53 AR 195.e11 DI 10.1016/j.neurobiolaging.2017.02.002 PG 7 WC Geriatrics & Gerontology; Neurosciences SC Geriatrics & Gerontology; Neurosciences & Neurology GA ES4JU UT WOS:000399501300032 ER PT J AU Lee, AD Spiegel, BM Hays, RD Melmed, GY Bolus, R Khanna, D Khanna, PP Chang, L AF Lee, A. D. Spiegel, B. M. Hays, R. D. Melmed, G. Y. Bolus, R. Khanna, D. Khanna, P. P. Chang, L. TI Gastrointestinal symptom severity in irritable bowel syndrome, inflammatory bowel disease and the general population SO NEUROGASTROENTEROLOGY AND MOTILITY LA English DT Article DE gender; inflammatory bowel disease; irritable bowel syndrome; symptom severity ID PATIENT-REPORTED OUTCOMES; GASTROESOPHAGEAL-REFLUX DISEASE; COMPUTERIZED ADAPTIVE TESTS; QUALITY-OF-LIFE; ULCERATIVE-COLITIS; FECAL INCONTINENCE; BRAIN RESPONSES; RATING-SCALE; PREVALENCE; METAANALYSIS AB Background: Irritable bowel syndrome (IBS) and inflammatory bowel disease (IBD) patients report similar gastrointestinal (GI) symptoms, yet comparisons of symptom severity between groups and with the general population (GP) are lacking. Methods: We compared Patient-Reported Outcomes Measurement Information System (PROMIS (R)) GI symptom scales measuring gastro-esophageal reflux (GER), disrupted swallowing, diarrhea, bowel incontinence, nausea/vomiting, constipation, belly pain, and gas/bloating in: (i) USA GP sample, (ii) IBS patients, and (iii) IBD patients from tertiary care and community populations. Symptom severity scores were based on T-score metric with mean 5010 (standard deviation) relative to the GP. Key Results: Of 1643 patients enrolled, there were 253 IBS patients (68% F, mean age 45 +/- 15years), 213 IBD patients (46% F, mean age 41 +/- 14years), and 1177 GP subjects (57% F, mean age 46 +/- 16years). IBS patients reported greater severity of GER, disrupted swallowing, nausea/vomiting, belly pain, gas/bloating, and constipation symptoms than their IBD counterparts (all P<.05). Compared to the GP, IBD patients had worse belly pain, gas/bloating, diarrhea, and bowel incontinence, but less severe GER and disrupted swallowing (all P<.05), and IBS patients had more severe nausea/vomiting, belly pain, gas/bloating, and constipation (all P<.05). Women had more severe belly pain and gas/bloating than men, whereas men had more severe bowel incontinence (all P<.05). Conclusion & Inferences: IBS and IBD are associated with more severe GI symptoms compared to the GP excluding esophageal symptoms. Unlike IBD, IBS is not characterized by observable GI inflammation but patients report more severe upper and lower GI symptoms. C1 [Lee, A. D.; Spiegel, B. M.; Melmed, G. Y.] Cedars Sinai Med Ctr, Ctr Outcomes Res & Educ, Los Angeles, CA 90048 USA. [Lee, A. D.; Spiegel, B. M.] VA Greater Los Angeles Healthcare Syst, Dept Med, Div Gastroenterol, Los Angeles, CA USA. [Lee, A. D.; Hays, R. D.] RAND Hlth Program, Santa Monica, CA USA. [Lee, A. D.; Spiegel, B. M.; Bolus, R.] UCLA VA Ctr Outcomes Res & Educ CORE, Los Angeles, CA USA. [Lee, A. D.] Kaiser Permanente Los Angeles Med Ctr, Div Gastroenterol, Los Angeles, CA USA. [Spiegel, B. M.; Bolus, R.; Chang, L.] Univ Calif Los Angeles, David Geffen Sch Med, Div Digest Dis, Dept Med, Los Angeles, CA 90095 USA. [Spiegel, B. M.; Hays, R. D.] Univ Calif Los Angeles, Dept Med, Div Gen Internal Med, Los Angeles, CA 90024 USA. [Hays, R. D.] Univ Calif Los Angeles, Dept Hlth Serv, Fielding Sch Publ Hlth, Los Angeles, CA USA. [Khanna, D.; Khanna, P. P.] Univ Michigan, Div Rheumatol, Ann Arbor, MI 48109 USA. [Chang, L.] Univ Calif Los Angeles, David Geffen Sch Med, G Oppenheimer Ctr Neurobiol Stress & Resilience, Los Angeles, CA 90095 USA. RP Chang, L (reprint author), G Oppenheimer Ctr Neurobiol Stress & Resilience, Los Angeles, CA 90095 USA. EM linchang@ucla.edu FU NIH/NIAMS [U01 AR057936A]; National Institutes of Health through the NIH Roadmap for Medical Research Grant [AR052177]; NIAMS [K24 AR063120]; National Research Service Award (NRSA) Institutional Research Training Grant [NIAMS 1 T32 AR053463]; ACR Research and Education Foundation Clinical Investigator Fellowship [2009_11]; NIH/NIA [P30-AG028748, P30-AG021684]; NCMHD [2P20MD000182]; NIDDK [P50 DK64539] FX This research was supported by NIH/NIAMS U01 AR057936A, the National Institutes of Health through the NIH Roadmap for Medical Research Grant (AR052177). Dinesh Khanna was also supported by. NIAMS K24 AR063120 Puja Khanna was supported by Ruth L. Kirschstein National Research Service Award (NRSA) Institutional Research Training Grant NIAMS 1 T32 AR053463 and ACR Research and Education Foundation Clinical Investigator Fellowship Award 2009_11. Ron D. Hays was also supported by NIH/NIA Grants P30-AG028748 and P30-AG021684, and NCMHD Grant 2P20MD000182. Lin Chang was also supported by NIDDK P50 DK64539. NR 52 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1350-1925 EI 1365-2982 J9 NEUROGASTROENT MOTIL JI Neurogastroenterol. Motil. PD MAY PY 2017 VL 29 IS 5 AR UNSP e13003 DI 10.1111/nmo.13003 PG 9 WC Gastroenterology & Hepatology; Clinical Neurology; Neurosciences SC Gastroenterology & Hepatology; Neurosciences & Neurology GA ES6UK UT WOS:000399685100011 ER PT J AU Mori, T Crandall, CJ Ganz, DA AF Mori, T. Crandall, C. J. Ganz, D. A. TI Cost-effectiveness of denosumab versus oral alendronate for elderly osteoporotic women in Japan SO OSTEOPOROSIS INTERNATIONAL LA English DT Article DE Alendronate; Cost-effectiveness analysis; Denosumab; Osteoporosis ID HIP FRACTURE; POSTMENOPAUSAL OSTEOPOROSIS; FRAGILITY FRACTURES; METAANALYSIS; BISPHOSPHONATES; PERSISTENCE; TRENDS; RISK; MORTALITY; THERAPY AB We constructed a Markov microsimulation model among hypothetical cohorts of community-dwelling elderly osteoporotic Japanese women without prior hip or vertebral fractures over a lifetime horizon. Compared with weekly oral alendronate for 5 years, denosumab every 6 months for 5 years is cost-saving or cost-effective at a conventionally accepted threshold. The objective of the study was to examine the cost-effectiveness of subcutaneous denosumab every 6 months for 5 years compared with weekly oral alendronate for 5 years in Japan. We calculated incremental cost-effectiveness ratios [ICERs] (2016 US dollars [$] per quality-adjusted life year [QALY]), using a Markov microsimulation model among hypothetical cohorts of community-dwelling osteoporotic Japanese women without prior hip or vertebral fractures at various ages of therapy initiation (65, 70, 75, and 80 years) over a lifetime horizon from three perspectives: societal, healthcare sector, and government. Denosumab was cost-saving compared with alendronate at ages 75 and 80 years from any of the three perspectives. The ICERs of denosumab compared with alendronate were $25,700 and $5000 per QALY at ages 65 and 70 years from a societal perspective and did not exceed a willingness-to-pay of $50,000 per QALY from the other two perspectives. In deterministic sensitivity analyses, results were sensitive to changes in the effectiveness of denosumab for reducing hip fracture and clinical vertebral fracture and the rate ratio of non-persistence with denosumab compared to alendronate. In probabilistic sensitivity analyses, the probabilities of denosumab being cost-effective compared with alendronate were 89-100% at a willingness-to-pay of $50,000 per QALY. Among community-dwelling elderly osteoporotic women in Japan, denosumab every 6 months for 5 years is cost-saving or cost-effective at a conventionally accepted threshold of willingness-to-pay at all ages examined, compared with weekly alendronate for 5 years. This study provides insight to clinicians and policymakers regarding the relative economic value of osteoporosis treatments in elderly women. C1 [Mori, T.] Kameda Med Ctr, Dept Gen Internal Med, 929 Higashi Cho, Kamogawa City, Chiba 2968602, Japan. [Mori, T.] Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Primary Care & Med Educ, Tsukuba, Ibaraki, Japan. [Mori, T.] Univ Tsukuba, Dept Hlth Serv Res, Fac Med, Tsukuba, Ibaraki, Japan. [Crandall, C. J.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA 90095 USA. [Ganz, D. A.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Ganz, D. A.] Vet Affairs Greater Los Angeles Healthcare Syst, HSR&D Ctr Healthcare Innovat Implementat & Policy, Los Angeles, CA USA. [Ganz, D. A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Div Geriatr, Los Angeles, CA 90095 USA. [Ganz, D. A.] RAND Corp, Hlth Unit, Santa Monica, CA USA. RP Mori, T (reprint author), Kameda Med Ctr, Dept Gen Internal Med, 929 Higashi Cho, Kamogawa City, Chiba 2968602, Japan.; Mori, T (reprint author), Univ Tsukuba, Grad Sch Comprehens Human Sci, Dept Primary Care & Med Educ, Tsukuba, Ibaraki, Japan.; Mori, T (reprint author), Univ Tsukuba, Dept Hlth Serv Res, Fac Med, Tsukuba, Ibaraki, Japan. EM takahiromori@outlook.com NR 43 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER LONDON LTD PI LONDON PA 236 GRAYS INN RD, 6TH FLOOR, LONDON WC1X 8HL, ENGLAND SN 0937-941X EI 1433-2965 J9 OSTEOPOROSIS INT JI Osteoporosis Int. PD MAY PY 2017 VL 28 IS 5 BP 1733 EP 1744 DI 10.1007/s00198-017-3940-4 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA ES3QH UT WOS:000399443600024 PM 28210776 ER PT J AU Woolley, JD Chuang, B Fussell, C Scherer, S Biagianti, B Fulford, D Mathalon, DH Vinogradov, S AF Woolley, J. D. Chuang, B. Fussell, C. Scherer, S. Biagianti, B. Fulford, D. Mathalon, D. H. Vinogradov, S. TI Intranasal oxytocin increases facial expressivity, but not ratings of trustworthiness, in patients with schizophrenia and healthy controls SO PSYCHOLOGICAL MEDICINE LA English DT Article DE Blunted affect; facial expressivity; oxytocin; schizophrenia; social cognition; trustworthiness ID RANDOMIZED CONTROLLED-TRIAL; SOCIAL COGNITION; NEGATIVE SYMPTOMS; FLAT AFFECT; EMOTION; JUDGMENTS; RESPONSES; AMYGDALA; FACES; VALIDATION AB Background. Blunted facial affect is a common negative symptom of schizophrenia. Additionally, assessing the trustworthiness of faces is a social cognitive ability that is impaired in schizophrenia. Currently available pharmacological agents are ineffective at improving either of these symptoms, despite their clinical significance. The hypothalamic neuropeptide oxytocin has multiple prosocial effects when administered intranasally to healthy individuals and shows promise in decreasing negative symptoms and enhancing social cognition in schizophrenia. Although two small studies have investigated oxytocin's effects on ratings of facial trustworthiness in schizophrenia, its effects on facial expressivity have not been investigated in any population. Method. We investigated the effects of oxytocin on facial emotional expressivity while participants performed a facial trustworthiness rating task in 33 individuals with schizophrenia and 35 age-matched healthy controls using a double-blind, placebo-controlled, cross-over design. Participants rated the trustworthiness of presented faces interspersed with emotionally evocative photographs while being video-recorded. Participants' facial expressivity in these videos was quantified by blind raters using a well-validated manualized approach (i.e. the Facial Expression Coding System; FACES). Results. While oxytocin administration did not affect ratings of facial trustworthiness, it significantly increased facial expressivity in individuals with schizophrenia (Z=-2.33, p=0.02) and at trend level in healthy controls (Z=-1.87, p=0.06). Conclusions. These results demonstrate that oxytocin administration can increase facial expressivity in response to emotional stimuli and suggest that oxytocin may have the potential to serve as a treatment for blunted facial affect in schizophrenia. C1 [Woolley, J. D.; Chuang, B.; Fussell, C.; Mathalon, D. H.; Vinogradov, S.] San Francisco VA Med Ctr, Dept Psychiat, San Francisco, CA USA. [Woolley, J. D.; Chuang, B.; Fussell, C.; Biagianti, B.; Mathalon, D. H.; Vinogradov, S.] Univ Calif San Francisco, Dept Psychiat, 4150 Clement St,116C-1, San Francisco, CA 94121 USA. [Scherer, S.] Univ Southern Calif, Inst Creat Technol, Los Angeles, CA USA. [Fulford, D.] Boston Univ, Dept Occupat Therapy, Boston, MA 02215 USA. [Fulford, D.] Boston Univ, Dept Psychol & Brain Sci, Boston, MA 02215 USA. RP Woolley, JD (reprint author), Univ Calif San Francisco, Dept Psychiat, 4150 Clement St,116C-1, San Francisco, CA 94121 USA. EM Josh.Woolley@ucsf.edu FU Veterans Health Administration Office of Research and Development Career Development Award (CDA) [1IK2CX000758-01A1]; National Institute of Mental Health Diversity Supplement [3R01MH068725-09S1] FX Grant support was provided by the Veterans Health Administration Office of Research and Development Career Development Award (CDA) 1IK2CX000758-01A1 and National Institute of Mental Health Diversity Supplement 3R01MH068725-09S1. NR 61 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0033-2917 EI 1469-8978 J9 PSYCHOL MED JI Psychol. Med. PD MAY PY 2017 VL 47 IS 7 BP 1311 EP 1322 DI 10.1017/S0033291716003433 PG 12 WC Psychology, Clinical; Psychiatry; Psychology SC Psychology; Psychiatry GA ER4UO UT WOS:000398797100013 PM 28091349 ER PT J AU Deming, Y Li, ZR Kapoor, M Harari, O Del-Aguila, JL Black, K Carrell, D Cai, YF Fernandez, MV Budde, J Ma, SM Saef, B Howells, B Huang, KL Bertelsen, S Fagan, AM Holtzman, DM Morris, JC Kim, S Saykin, AJ De Jager, PL Albert, M Moghekar, A O'Brien, R Riemenschneider, M Petersen, RC Blennow, K Zetterberg, H Minthon, L Van Deerlin, VM Lee, VMY Shaw, LM Trojanowski, JQ Schellenberg, G Haines, JL Mayeux, R Pericak-Vance, MA Farrer, LA Peskind, ER Li, G Di Narzo, AF Kauwe, JSK Goate, AM Cruchaga, C AF Deming, Yuetiva Li, Zeran Kapoor, Manav Harari, Oscar Del-Aguila, Jorge L. Black, Kathleen Carrell, David Cai, Yefei Fernandez, Maria Victoria Budde, John Ma, Shengmei Saef, Benjamin Howells, Bill Huang, Kuan-lin Bertelsen, Sarah Fagan, Anne M. Holtzman, David M. Morris, John C. Kim, Sungeun Saykin, Andrew J. De Jager, Philip L. Albert, Marilyn Moghekar, Abhay O'Brien, Richard Riemenschneider, Matthias Petersen, Ronald C. Blennow, Kaj Zetterberg, Henrik Minthon, Lennart Van Deerlin, Vivianna M. Lee, Virginia Man-Yee Shaw, Leslie M. Trojanowski, John Q. Schellenberg, Gerard Haines, Jonathan L. Mayeux, Richard Pericak-Vance, Margaret A. Farrer, Lindsay A. Peskind, Elaine R. Li, Ge Di Narzo, Antonio F. Kauwe, John S. K. Goate, Alison M. Cruchaga, Carlos CA Alzheimer's Dis Neuroimaging Alzheimer Dis Genetic Consor TI Genome-wide association study identifies four novel loci associated with Alzheimer's endophenotypes and disease modifiers SO ACTA NEUROPATHOLOGICA LA English DT Article DE Alzheimer's disease; Endophenotype; Cerebrospinal fluid biomarkers; Genome-wide association study ID CEREBROSPINAL-FLUID A-BETA(42); MILD COGNITIVE IMPAIRMENT; RATING-SCALE SUM; TAU LEVELS; BIOMARKER SIGNATURE; COMMON VARIANTS; RISK VARIANTS; SCORE; CSF; METAANALYSIS AB More than 20 genetic loci have been associated with risk for Alzheimer's disease (AD), but reported genome-wide significant loci do not account for all the estimated heritability and provide little information about underlying biological mechanisms. Genetic studies using intermediate quantitative traits such as biomarkers, or endophenotypes, benefit from increased statistical power to identify variants that may not pass the stringent multiple test correction in case-control studies. Endophenotypes also contain additional information helpful for identifying variants and genes associated with other aspects of disease, such as rate of progression or onset, and provide context to interpret the results from genome-wide association studies (GWAS). We conducted GWAS of amyloid beta (A beta(42)), tau, and phosphorylated tau (ptau181) levels in cerebrospinal fluid (CSF) from 3146 participants across nine studies to identify novel variants associated with AD. Five genome-wide significant loci (two novel) were associated with ptau181, including loci that have also been associated with AD risk or brain-related phenotypes. Two novel loci associated with A beta(42) near GLIS1 on 1p32.3 (beta = -0.059, P = 2.08 x 10(-8)) and within SERPINB1 on 6p25 (beta = -0.025, P = 1.72 x 10(-8)) were also associated with AD risk (GLIS1: OR = 1.105, P = 3.43 x 10(-2)), disease progression (GLIS1: beta = 0.277, P = 1.92 x 10(-2)), and age at onset (SER-PINB1: beta = 0.043, P = 4.62 x 10(-3)). Bioinformatics indicate that the intronic SERPINB1 variant (rs316341) affects expression of SERPINB1 in various tissues, including the hippocampus, suggesting that SERPINB1 influences AD through an A beta-associated mechanism. Analyses of known AD risk loci suggest CLU and FERMT2 may influence CSF A beta(42) (P = 0.001 and P = 0.009, respectively) and the INPP5D locus may affect ptau181 levels (P = 0.009); larger studies are necessary to verify these results. Together the findings from this study can be used to inform future AD studies. C1 [Deming, Yuetiva; Li, Zeran; Harari, Oscar; Del-Aguila, Jorge L.; Black, Kathleen; Carrell, David; Cai, Yefei; Fernandez, Maria Victoria; Budde, John; Ma, Shengmei; Saef, Benjamin; Howells, Bill; Cruchaga, Carlos] Washington Univ, Sch Med, Dept Psychiat, 660 S Euclid Ave B8134, St Louis, MO 63110 USA. [Kapoor, Manav; Bertelsen, Sarah; Goate, Alison M.] Icahn Sch Med Mt Sinai, Dept Neurosci, Ronald M Loeb Ctr Alzheimers Dis, New York, NY 10029 USA. [Huang, Kuan-lin] Washington Univ, Sch Med, Dept Med, 660 S Euclid Ave B8134, St Louis, MO 63110 USA. [Huang, Kuan-lin] Washington Univ, Sch Med, McDonnell Genome Inst, 660 S Euclid Ave B8134, St Louis, MO 63110 USA. [Fagan, Anne M.; Holtzman, David M.; Morris, John C.] Washington Univ, Sch Med, Dept Neurol, 660 S Euclid Ave, St Louis, MO 63110 USA. [Fagan, Anne M.; Holtzman, David M.; Morris, John C.] Washington Univ, Sch Med, Knight Alzheimers Dis Res Ctr, 660 S Euclid Ave, St Louis, MO 63110 USA. [Fagan, Anne M.; Holtzman, David M.; Morris, John C.] Washington Univ, Sch Med, Hope Ctr Neurol Disorders, 660 S Euclid Ave B8111, St Louis, MO 63110 USA. [Holtzman, David M.; Morris, John C.; Cruchaga, Carlos] Washington Univ, Sch Med, Dept Dev Biol, 660 S Euclid Ave, St Louis, MO 63110 USA. [Kim, Sungeun; Saykin, Andrew J.] Indiana Univ, Sch Med, Indiana Alzheimer Dis Ctr, Indianapolis, IN USA. [Kim, Sungeun; Saykin, Andrew J.] Indiana Univ, Sch Med, Ctr Neuroimaging, Indianapolis, IN USA. [Kim, Sungeun] SUNY Coll Oswego, Dept Elect & Comp Engn, Oswego, NY 13126 USA. [De Jager, Philip L.] Brigham & Womens Hosp, Program Translat NeuroPsychiat Gen, Dept Neurol, Inst Neurosci, 75 Francis St, Boston, MA 02115 USA. [De Jager, Philip L.] Harvard Med Sch, Boston, MA 02115 USA. [De Jager, Philip L.] Harvard Univ, Broad Inst, Program Med & Populat Genet, Cambridge, MA 02142 USA. [De Jager, Philip L.] MIT, Cambridge, MA 02142 USA. [Albert, Marilyn; Moghekar, Abhay] Johns Hopkins Univ, Sch Med, Dept Neurol, Baltimore, MD 21205 USA. [O'Brien, Richard] Duke Med Ctr, Dept Neurol, Box 2900, Durham, NC 27710 USA. [Riemenschneider, Matthias] Saarland Univ, Clin Psychiat & Psychotherapy, Homburg, Germany. [Petersen, Ronald C.] Mayo Clin, Dept Neurol, Rochester, MN USA. [Blennow, Kaj; Zetterberg, Henrik] Univ Gothenburg, Dept Psychiat & Neurochem, Inst Neurosci & Physiol, Sahlgrenska Acad, Molndal, Sweden. [Blennow, Kaj; Zetterberg, Henrik] Univ Gothenburg, Clin Neurochem Lab, Dept Neurosci & Physiol, Sahlgrenska Univ Hosp, Molndal, Sweden. [Zetterberg, Henrik] UCL Inst Neurol, Dept Mol Neurosci, London, England. [Minthon, Lennart] Lund Univ, Clin Memory Res Unit, Dept Clin Sci, Lund, Sweden. [Van Deerlin, Vivianna M.; Lee, Virginia Man-Yee; Shaw, Leslie M.; Trojanowski, John Q.; Schellenberg, Gerard] Univ Penn, Dept Pathol & Lab Med, Perelman Sch Med, Philadelphia, PA USA. [Haines, Jonathan L.] Vanderbilt Univ, Dept Mol Physiol & Biophys, Vanderbilt Ctr Human Genet Res, Nashville, TN 37232 USA. [Mayeux, Richard] Columbia Univ, Dept Neurol, Taub Inst Alzheimers Dis & Aging Brain, New York, NY USA. [Mayeux, Richard] Columbia Univ, Gertrude H Sergievsky Ctr, New York, NY 10027 USA. [Pericak-Vance, Margaret A.] Univ Miami, John P Hussman Inst Human Gen, Miami, FL USA. [Pericak-Vance, Margaret A.] Univ Miami, Dr John T Macdonald Fdn, Dept Human Genet, Miami, FL USA. [Farrer, Lindsay A.] Boston Univ, Dept Biostat, Boston, MA 02215 USA. [Farrer, Lindsay A.] Boston Univ, Dept Med, Genet Program, Boston, MA 02215 USA. [Farrer, Lindsay A.] Boston Univ, Dept Ophthalmol, Boston, MA 02215 USA. [Farrer, Lindsay A.] Boston Univ, Dept Epidemiol, Boston, MA 02215 USA. [Farrer, Lindsay A.] Boston Univ, Dept Neurol, Boston, MA 02215 USA. [Peskind, Elaine R.; Li, Ge] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Peskind, Elaine R.] VA Puget Sound Hlth Care Syst, VISN Mental Illness Res Educ & Clin Ctr 20, Seattle, WA USA. [Li, Ge] VA Puget Sound Hlth Care Syst, VISN Geriatr Res Educ & Clin Ctr 20, Seattle, WA USA. [Di Narzo, Antonio F.] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY 10029 USA. [Kauwe, John S. K.] Brigham Young Univ, Dept Biol, Provo, UT 84602 USA. RP Cruchaga, C (reprint author), Washington Univ, Sch Med, Dept Psychiat, 660 S Euclid Ave B8134, St Louis, MO 63110 USA.; Cruchaga, C (reprint author), Washington Univ, Sch Med, Dept Dev Biol, 660 S Euclid Ave, St Louis, MO 63110 USA. EM ccruchaga@wustl.edu FU National Institutes of Health [R01AG044546, P01AG003991, RF1AG053303, R01AG035083, R01NS085419]; Alzheimer's Association [NIRG-11-200110]; American Federation for Aging Research; BrightFocus Foundation Alzheimer's Disease Research Grant [A2013359S]; NIH [P50 AG05681, P01 AG03991, P01 AG026276, U01AG032984]; GERAD from the Wellcome Trust [GR082604MA]; Medical Research Council [G0300429]; NCRAD [U24 AG21886]; NACC [U01 AG016976]; NIAGADS [U24-AG041689]; UPENN [P30 AG010124]; NIA [R03AG050856]; Alzheimer's Association; Michael J. Fox Foundation; ARUK Biomarkers Across Neurodegenerative Diseases (BAND); German Federal Ministry of Education and Research (BMBF) National Genome Research Network (NGFN) [01GS08125]; Helmholtz Alliance for Mental Health in an Aging Society (HELMA) [Ha-15]; [U01 AG024904]; [R01 AG19771]; [P30 AG10133]; [R01 AG048015]; [AG05136] FX This work was supported by grants from the National Institutes of Health (R01AG044546, P01AG003991, RF1AG053303, R01AG035083, and R01NS085419), and the Alzheimer's Association (NIRG-11-200110). This research was conducted while C.C. was a recipient of a New Investigator Award in Alzheimer's disease from the American Federation for Aging Research. C.C. is a recipient of a BrightFocus Foundation Alzheimer's Disease Research Grant (A2013359S). The recruitment and clinical characterization of research participants at Washington University were supported by NIH P50 AG05681, P01 AG03991, and P01 AG026276. ADGC is supported by grants from the NIH (#U01AG032984) and GERAD from the Wellcome Trust (GR082604MA) and the Medical Research Council (G0300429); additional support was provided by NCRAD (U24 AG21886), NACC (U01 AG016976), NIAGADS (U24-AG041689) and UPENN (P30 AG010124). Support for A.S. was provided by U01 AG024904, R01 AG19771, and P30 AG10133. P.D.J. received support from R01 AG048015. UW ADRC received funding from AG05136. S.K. received support from NIA R03AG050856, Alzheimer's Association, Michael J. Fox Foundation, and ARUK Biomarkers Across Neurodegenerative Diseases (BAND). M.R. received support from the German Federal Ministry of Education and Research (BMBF) National Genome Research Network (NGFN) Grant No. 01GS08125 and through the Helmholtz Alliance for Mental Health in an Aging Society (HELMA) Grant No. Ha-15. This work was supported by access to equipment made possible by the Hope Center for Neurological Disorders and the Departments of Neurology and Psychiatry at Washington University School of Medicine. NR 85 TC 0 Z9 0 U1 11 U2 11 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0001-6322 EI 1432-0533 J9 ACTA NEUROPATHOL JI Acta Neuropathol. PD MAY PY 2017 VL 133 IS 5 BP 839 EP 856 DI 10.1007/s00401-017-1685-y PG 18 WC Clinical Neurology; Neurosciences; Pathology SC Neurosciences & Neurology; Pathology GA ES2ZS UT WOS:000399397300010 PM 28247064 ER PT J AU Wood, AE Prins, A Bush, NE Hsia, JF Bourn, LE Earley, MD Walser, RD Ruzek, J AF Wood, Amanda Ernst Prins, Annabel Bush, Nigel E. Hsia, Jennifer F. Bourn, Laura E. Earley, Michael D. Walser, Robyn D. Ruzek, Josef TI Reduction of Burnout in Mental Health Care Providers Using the Provider Resilience Mobile Application SO COMMUNITY MENTAL HEALTH JOURNAL LA English DT Article DE Burnout; Employee health; Mobile applications ID COMPASSION FATIGUE; VETERANS; SUPPORT; TRAUMA; SAMPLE AB This pilot study examined the usability, acceptability, and effectiveness of a free Provider Resilience (PR) mobile application (app) designed by the National Center for Telehealth and Technology to reduce provider burnout. Outpatient mental health providers (N = 30) used the PR app for 1 month. Participants rated the PR app on the System Usability Scale with an overall score of 79.7, which is in the top quartile for usability. Results of paired sample t tests on the Professional Quality of Life Scale indicated significant decreases on the Burnout (t = 3.65, p < .001) and Compassion Fatigue (t = 4.54, p < .001) subscales. The Provider Resilience app shows promise in reducing burnout and compassion fatigue in mental health care providers. C1 [Wood, Amanda Ernst; Hsia, Jennifer F.; Bourn, Laura E.; Earley, Michael D.] VA Puget Sound Hlth Care Syst, Amer Lake Div A116R, Tacoma, WA 98493 USA. [Wood, Amanda Ernst] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Prins, Annabel; Walser, Robyn D.; Ruzek, Josef] VA Palo Alto Hlth Care Syst, Natl Ctr PTSD, Menlo Pk, CA USA. [Prins, Annabel] San Jose State Univ, Dept Psychol, San Jose, CA 95192 USA. [Bush, Nigel E.] Natl Ctr Telehlth & Technol, Tacoma, WA USA. [Walser, Robyn D.] Univ Calif Berkeley, Dept Psychol, 3210 Tolman Hall, Berkeley, CA 94720 USA. RP Wood, AE (reprint author), VA Puget Sound Hlth Care Syst, Amer Lake Div A116R, Tacoma, WA 98493 USA.; Wood, AE (reprint author), Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. EM Amanda.wood@va.gov FU National Center for PTSD FX Support for this study was provided by the National Center for PTSD. NR 22 TC 0 Z9 0 U1 3 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0010-3853 EI 1573-2789 J9 COMMUNITY MENT HLT J JI Community Ment. Health J. PD MAY PY 2017 VL 53 IS 4 BP 452 EP 459 DI 10.1007/s10597-016-0076-5 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA ES0TM UT WOS:000399239600010 PM 28070775 ER PT J AU Mridha, AR Wree, A Robertson, AAB Yeh, MM Johnson, CD Van Rooyen, DM Haczeyni, F Teoh, NCH Savard, C Ioannou, GN Masters, SL Schroder, K Cooper, MA Feldstein, AE Farrell, GC AF Mridha, Auvro R. Wree, Alexander Robertson, Avril A. B. Yeh, Matthew M. Johnson, Casey D. Van Rooyen, Derrick M. Haczeyni, Fahrettin Teoh, Narci C. -H. Savard, Christopher Ioannou, George N. Masters, Seth L. Schroder, Kate Cooper, Matthew A. Feldstein, Ariel E. Farrell, Geoffrey C. TI NLRP3 inflammasome blockade reduces liver inflammation and fibrosis in experimental NASH in mice SO JOURNAL OF HEPATOLOGY LA English DT Article DE NAFLD; NLRP3; Inflammasomes; Cholesterol crystals; Kupffer cells; Hepatocytes; Interleukin-1 beta; Fibrosis; Diet, atherogenic; Methionine; NLR proteins ID CROWN-LIKE STRUCTURES; NONALCOHOLIC STEATOHEPATITIS; CHOLESTEROL CRYSTALS; DIABETIC MICE; FATTY-ACID; DISEASE; ACTIVATION; LIPOTOXICITY; PATHOGENESIS; INJURY AB Background & Aims: NOD-like receptor protein 3 (NLRP3) inflammasome activation occurs in Non-alcoholic fatty liver disease (NAFLD). We used the first small molecule NLRP3 inhibitor, MCC950, to test whether inflammasome blockade alters inflammatory recruitment and liver fibrosis in two murine models of steatohepatitis. Methods: We fed foz/foz and wild-type mice an atherogenic diet for 16 weeks, gavaged MCC950 or vehicle until 24 weeks, then determined NAFLD phenotype. In mice fed an methionine/choline deficient (MCD) diet, we gavaged MCC950 or vehicle for 6 weeks and determined the effects on liver fibrosis. Results: In vehicle-treated foz/foz mice, hepatic expression of NLRP3, pro-IL-1 beta, active caspase-1 and IL-1 beta increased at 24 weeks, in association with cholesterol crystal formation and NASH pathology; plasma IL-1 beta, IL-6, MCP-1, ALT/AST all increased. MCC950 treatment normalized hepatic caspase 1 and IL-1b expression, plasma IL-1 beta, MCP-1 and IL-6, lowered ALT/AST, and reduced the severity of liver inflammation including designation as NASH pathology, and liver fibrosis. In vitro, cholesterol crystals activated Kupffer cells and macrophages to release IL-1 beta; MCC950 abolished this, and the associated neutrophil migration. MCD diet-fed mice developed fibrotic steatohepatitis; MCC950 suppressed the increase in hepatic caspase 1 and IL-1 beta, lowered numbers of macrophages and neutrophils in the liver, and improved liver fibrosis. Conclusion: MCC950, an NLRP3 selective inhibitor, improved NAFLD pathology and fibrosis in obese diabetic mice. This is potentially attributable to the blockade of cholesterol crystal-mediated NLRP3 activation in myeloid cells. MCC950 reduced liver fibrosis in MCD-fed mice. Targeting NLRP3 is a logical direction in pharmacotherapy of NASH. Lay summary: Fatty liver disease caused by being overweight with diabetes and a high risk of heart attack, termed nonalcoholic steatohepatitis (NASH), is the most common serious liver disease with no current treatment. There could be several causes of inflammation in NASH, but activation of a protein scaffold within cells termed the inflammasome (NLRP3) has been suggested to play a role. Here we show that cholesterol crystals could be one pathway to activate the inflammasome in NASH. We used a drug called MCC950, which has already been shown to block NLRP3 activation, in an attempt to reduce liver injury in NASH. This drug partly reversed liver inflammation, particularly in obese diabetic mice that most closely resembles the human context of NASH. In addition, such dampening of liver inflammation in NASH achieved with MCC950 partly reversed liver scarring, the process that links NASH to the development of cirrhosis. (C) 2017 European Association for the Study of the Liver. Published by Elsevier B.V. All rights reserved. C1 [Mridha, Auvro R.; Van Rooyen, Derrick M.; Haczeyni, Fahrettin; Teoh, Narci C. -H.; Farrell, Geoffrey C.] Australian Natl Univ, Canberra Hosp, ANU Med Sch, Liver Res Grp, Garran, ACT, Australia. [Wree, Alexander] RWTH Aachen Univ Hosp, Dept Internal Med 3, Aachen, Germany. [Wree, Alexander; Johnson, Casey D.; Feldstein, Ariel E.] Univ Calif San Diego, Dept Pediat, San Diego, CA 92103 USA. [Robertson, Avril A. B.; Schroder, Kate; Cooper, Matthew A.] Univ Queensland, Inst Mol Biosci, St Lucia, Qld, Australia. [Yeh, Matthew M.] Univ Washington, Dept Pathol, Seattle, WA 98195 USA. [Savard, Christopher; Ioannou, George N.] Vet Affairs Puget Sound Hlth Care Syst, Dept Gastroenterol & Hepatol, Seattle, WA USA. [Savard, Christopher; Ioannou, George N.] Univ Washington, Seattle, WA 98195 USA. [Masters, Seth L.] Walter & Eliza Hall Inst Med Res, Parkville, Vic, Australia. RP Farrell, GC (reprint author), Canberra Hosp, Gastroenterol & Hepatol Unit, POB 111, Woden, ACT 2605, Australia. EM geoff.farrell@anu.edu.au FU NIH [R2 AA023574, U01 AA022489]; Australian NHMRC [1084136, 1044288, 1086786]; Deutsche Forschungsgemeinschaft [WR 173/3-1] FX Supported by NIH Project grants R2 AA023574 and U01 AA022489 (to AEF), Australian NHMRC project grants 1084136 and 1044288 (to GCF), and 1086786 (to MAC and AABR), and Deutsche Forschungsgemeinschaft WR 173/3-1 (to AW). Matthew Cooper is an NHMRC Principle Research Fellow (1059354). NR 50 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0168-8278 EI 1600-0641 J9 J HEPATOL JI J. Hepatol. PD MAY PY 2017 VL 66 IS 5 BP 1037 EP 1046 DI 10.1016/j.jhep.2017.01.022 PG 10 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ES0DM UT WOS:000399196300021 PM 28167322 ER PT J AU Aghazadehsanai, N Chang, TI Garrett, NR Friedlander, AH AF Aghazadehsanai, Nona Chang, Tina I. Garrett, Neal R. Friedlander, Arthur H. TI Prevalence of calcified carotid artery atheromas on digital panoramic images among perimenopausal and postmenopausal African American women SO ORAL SURGERY ORAL MEDICINE ORAL PATHOLOGY ORAL RADIOLOGY LA English DT Article ID HEART; ASSOCIATION; RADIOGRAPHS; DISEASE; HEALTH; PLAQUE; RISK; ATHEROSCLEROSIS; CALCIFICATIONS; POPULATION AB Objective. Health care disparities, often of an obscure nature, result in African American women (AAw) having enhanced risk of adverse cardiovascular events. Therefore, we sought to determine the prevalence of calcified carotid artery atheromas (CCAA), a validated risk indicator of these events, on their digital panoramic images. Study Design. Comprehensive electronic medical records and digital panoramic images of self-identified AAw aged >= 45 years treated between 2007 and 2014 were retrieved from a Veterans Affairs Dental Service. Images were reviewed for CCAA in the cervical bifurcation region, and medical records were reviewed for atherogenic risk factors: hypertension, diabetes, and dyslipidemia. Results. The study sample of 171 AAw (mean age 58.2 +/- 8.0 years) evidenced a 24% CCAA positive prevalence rate. In comparison with the CCAA negative group, those with atheromas were significantly older (61.4 +/- 10.1 vs. 57.2 +/- 7.0), diabetic, and dyslipidemic. Also observed among the full study sample was significant concordant increase of CCAA prevalence with age. Among those who were CCAA positive, there was a significant increased prevalence of dyslipidemia with age. Conclusions. Panoramic images of older AAw frequently revealed carotid atheromas, a risk indicator of generalized atherosclerosis and future adverse cardiovascular events. C1 [Aghazadehsanai, Nona] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Chang, Tina I.] VA Greater Los Angeles Healthcare Syst, Res Fellowship & Inpatient Oral & Maxillofacial S, Los Angeles, CA USA. [Chang, Tina I.; Friedlander, Arthur H.] Univ Calif Los Angeles, Sch Dent, Oral & Maxillofacial Surg, Los Angeles, CA 90024 USA. [Garrett, Neal R.] Univ Calif Los Angeles, Sch Dent, Los Angeles, CA 90024 USA. [Friedlander, Arthur H.] VA Greater Los Angeles Healthcare Syst, Grad Med Educ, Los Angeles, CA USA. [Friedlander, Arthur H.] Ronald Reagan UCLA Med Ctr, Hosp Dent Serv, Qual Assurance, Los Angeles, CA USA. RP Friedlander, AH (reprint author), Hosp Dent Serv, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM arthur.friedlander@va.gov FU VA Greater Los Angeles Healthcare System FX This material is the result of work supported with resources and use of facilities at the VA Greater Los Angeles Healthcare System. Its contents do not represent the views of the U. S. Department of Veterans Affairs or the United States Government. The authors have no conflicts of interest to disclose. NR 22 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 2212-4403 EI 1528-395X J9 OR SURG OR MED OR PA JI Oral Surg. Oral Med. Oral Pathol. Oral Radiol. PD MAY PY 2017 VL 123 IS 5 BP 621 EP 625 DI 10.1016/j.oooo.2017.01.011 PG 5 WC Dentistry, Oral Surgery & Medicine SC Dentistry, Oral Surgery & Medicine GA ER6XT UT WOS:000398954000021 PM 28407989 ER PT J AU Moon, AM Green, PK Berry, K Ioannou, GN AF Moon, A. M. Green, P. K. Berry, K. Ioannou, G. N. TI Transformation of hepatitis C antiviral treatment in a national healthcare system following the introduction of direct antiviral agents SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Article ID SUSTAINED VIROLOGICAL RESPONSE; GENOTYPE 1 INFECTION; OF-VETERANS-AFFAIRS; VIRUS-INFECTION; HEPATOCELLULAR-CARCINOMA; UNITED-STATES; COST-EFFECTIVENESS; HCV; SOFOSBUVIR; DASABUVIR AB BackgroundHighly effective direct antiviral agents (DAAs) for hepatitis C virus (HCV) were introduced recently. Their utilisation has been limited by high cost and low access to care. AimTo describe the effect of DAAs on HCV treatment and cure rates in the United States Veterans Affairs (VA) national healthcare system. MethodsWe identified all HCV antiviral treatment regimens initiated from 1 January 1999 to 31 December 2015 (n = 105 369) in the VA national healthcare system, and determined if they resulted in sustained virological response (SVR). ResultsHCV antiviral treatment rates were low (1981-6679 treatments/year) in the interferon era (1999-2010). The introduction of simeprevir and sofosbuvir in 2013 and ledipasvir/sofosbuvir and paritaprevir/ombitasvir/ritonavir/dasabuvir in 2014 were followed by increases in annual treatment rates to 9180 in 2014 and 31 028 in 2015. The number of patients achieving SVR was 1313 in 2010, the last year of the interferon era, and increased 5.6-fold to 7377 in 2014 and 21-fold to 28 084 in 2015. The proportion of treated patients who achieved SVR increased from 19.2% in 1999 and 36.0% in 2010 to 90.5% in 2015. Within 2015, monthly treatment rates ranged from 727 in July to 6868 in September correlating with the availability of funds for DAAs. ConclusionsDAAs resulted in a 21-fold increase in the number of patients achieving HCV cure. Treatment rates in 2015 were limited primarily by the availability of funds. Further increases in funding and cost reductions of DAAs in 2016 suggest that the VA could cure the majority of HCV-infected Veterans in VA care within the next few years. C1 [Moon, A. M.; Ioannou, G. N.] Univ Washington, Div Gen Internal Med, Seattle, WA 98195 USA. [Green, P. K.; Berry, K.; Ioannou, G. N.] Vet Affairs Puget Sound Healthcare Syst, Hlth Serv Res, Seattle, WA USA. [Green, P. K.; Berry, K.; Ioannou, G. N.] Vet Affairs Puget Sound Healthcare Syst, Hlth Serv Dev, Seattle, WA USA. [Ioannou, G. N.] Vet Affairs Puget Sound Healthcare Syst, Gastroenterol, S-111 Gastro,1660 S Columbian Way, Seattle, WA 98108 USA. [Ioannou, G. N.] Univ Washington, Seattle, WA 98195 USA. RP Ioannou, GN (reprint author), Vet Affairs Puget Sound Healthcare Syst, Gastroenterol, S-111 Gastro,1660 S Columbian Way, Seattle, WA 98108 USA. EM georgei@medicine.washington.edu FU Merit Review grant, Clinical Science Research and Development, Office of Research and Development, Veterans Affairs [I01CX001156] FX The study was funded by a Merit Review grant (I01CX001156), Clinical Science Research and Development, Office of Research and Development, Veterans Affairs (GNI). NR 48 TC 0 Z9 0 U1 1 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-2813 EI 1365-2036 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD MAY PY 2017 VL 45 IS 9 BP 1201 EP 1212 DI 10.1111/apt.14021 PG 12 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA ER3EM UT WOS:000398678600003 PM 28271521 ER PT J AU Cook, DB Light, AR Light, KC Broderick, G Shields, MR Dougherty, RJ Meyer, JD VanRiper, S Stegner, AJ Ellingson, LD Vernon, SD AF Cook, Dane B. Light, Alan R. Light, Kathleen C. Broderick, Gordon Shields, Morgan R. Dougherty, Ryan J. Meyer, Jacob D. VanRiper, Stephanie Stegner, Aaron J. Ellingson, Laura D. Vernon, Suzanne D. TI Neural consequences of post-exertion malaise in Myalgic Encephalomyelitis/Chronic Fatigue Syndrome SO BRAIN BEHAVIOR AND IMMUNITY LA English DT Article DE Exercise; Symptoms; Brain; Cognitive performance ID ANTERIOR CINGULATE CORTEX; STATE FUNCTIONAL CONNECTIVITY; BRAIN MRI ABNORMALITIES; GULF-WAR ILLNESS; MULTIPLE-SCLEROSIS; COGNITIVE FATIGUE; WORKING-MEMORY; POSTEXERTIONAL MALAISE; PROCESSING SPEED; MENTAL FATIGUE AB Post exertion malaise is one of the most debilitating aspects of Myalgic Encephalomyelitis/Chronic Fatigue Syndrome, yet the neurobiological consequences are largely unexplored. The objective of the study was to determine the neural consequences of acute exercise using functional brain imaging. Fifteen female Myalgic Encephalomyelitis/Chronic Fatigue Syndrome patients and 15 healthy female controls completed 30 min of submaximal exercise (70% of peak heart rate) on a cycle ergometer. Symptom assessments (e.g. fatigue, pain, mood) and brain imaging data were collected one week prior to and 24 h following exercise. Functional brain images were obtained during performance of: 1) a fatiguing cognitive task - the Paced Auditory Serial Addition Task, 2) a non-fatiguing cognitive task - simple number recognition, and 3) a non fatiguing motor task - finger tapping. Symptom and exercise data were analyzed using independent samples t-tests. Cognitive performance data were analyzed using mixed-model analysis of variance with repeated measures. Brain responses to fatiguing and non-fatiguing tasks were analyzed using linear mixed effects with cluster-wise (101-voxels) alpha of 0.05. Myalgic Encephalomyelitis/Chronic Fatigue Syndrome patients reported large symptom changes compared to controls (effect size >= 0.8, p < 0.05). Patients and controls had similar physiological responses to exercise (p > 0.05). However, patients exercised at significantly lower Watts and reported greater exertion and leg muscle pain (p < 0.05). For cognitive performance, a significant Group by Time interaction (p < 0.05), demonstrated pre- to post-exercise improvements for controls and worsening for patients. Brain responses to finger tapping did not differ between groups at either time point. During number recognition, controls exhibited greater brain activity (p < 0.05) in the posterior cingulate cortex, but only for the pre-exercise scan. For the Paced Serial Auditory Addition Task, there was a significant Group by Time interaction (p < 0.05) with patients exhibiting increased brain activity from pre- to postexercise compared to controls bilaterally for inferior and superior parietal and cingulate cortices. Changes in brain activity were significantly related to symptoms for patients (p < 0.05). Acute exercise exacerbated symptoms, impaired cognitive performance and affected brain function in Myalgic Encephalomyelitis/ Chronic Fatigue Syndrome patients. These converging results, linking symptom exacerbation with brain function, provide objective evidence of the detrimental neurophysiological effects of post-exertion malaise. Published by Elsevier Inc. This is an open access article under the CC BY-NC-ND license. C1 [Cook, Dane B.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Cook, Dane B.; Shields, Morgan R.; Dougherty, Ryan J.; Meyer, Jacob D.; VanRiper, Stephanie; Stegner, Aaron J.] Univ Wisconsin, Madison, WI USA. [Light, Alan R.; Light, Kathleen C.] Univ Utah, Salt Lake City, UT USA. [Broderick, Gordon] Nova Southeastern Univ, Ft Lauderdale, FL USA. [Ellingson, Laura D.] Iowa State Univ, Ames, IA USA. [Vernon, Suzanne D.] Bateman Horne Ctr, Salt Lake City, UT USA. RP Cook, DB (reprint author), Univ Wisconsin, Dept Kinesiol, 2000 Observ Dr, Madison, WI 53706 USA. EM dane.cook@wisc.edu FU Solve ME/CFS Initiative (SMCI) United States FX Supported by a grant from the Solve ME/CFS Initiative (SMCI) United States - Dane B Cook PI NR 88 TC 0 Z9 0 U1 2 U2 2 PU ACADEMIC PRESS INC ELSEVIER SCIENCE PI SAN DIEGO PA 525 B ST, STE 1900, SAN DIEGO, CA 92101-4495 USA SN 0889-1591 EI 1090-2139 J9 BRAIN BEHAV IMMUN JI Brain Behav. Immun. PD MAY PY 2017 VL 62 BP 87 EP 99 DI 10.1016/j.bbi.2017.02.009 PG 13 WC Immunology; Neurosciences SC Immunology; Neurosciences & Neurology GA ER2TS UT WOS:000398647300012 PM 28216087 ER PT J AU Wile, DJ Agarwal, PA Schulzer, M Mak, E Dinelle, K Shahinfard, E Vafai, N Hasegawa, K Zhang, J McKenzie, J Neilson, N Strongosky, A Uitti, RJ Guttman, M Zabetian, CP Ding, YS Adam, M Aasly, J Wszolek, ZK Farrer, M Sossi, V Stoessl, AJ AF Wile, Daryl J. Agarwal, Pankaj A. Schulzer, Michael Mak, Edwin Dinelle, Katherine Shahinfard, Elham Vafai, Nasim Hasegawa, Kazuko Zhang, Jing McKenzie, Jessamyn Neilson, Nicole Strongosky, Audrey Uitti, Ryan J. Guttman, Mark Zabetian, Cyrus P. Ding, Yu-Shin Adam, Mike Aasly, Jan Wszolek, Zbigniew K. Farrer, Matthew Sossi, Vesna Stoessl, A. Jon TI Serotonin and dopamine transporter PET changes in the premotor phase of LRRK2 parkinsonism: cross-sectional studies SO LANCET NEUROLOGY LA English DT Article ID G2019S MUTATION CARRIERS; DISEASE; DYSFUNCTION; BINDING; PROGRESSION AB Background People with Parkinson's disease can show premotor neurochemical changes in the dopaminergic and non-dopaminergic systems. Using PET, we assessed whether dopaminergic and serotonin transporter changes are similar in LRRK2 mutation carriers with Parkinson's disease and individuals with sporadic Parkinson's disease, and whether LRRK2 mutation carriers without motor symptoms show PET changes. Methods We did two cross-sectional PET studies at the Pacific Parkinson's Research Centre in Vancouver, BC, Canada. We included LRRK2 mutation carriers with or without manifest Parkinson's disease, people with sporadic Parkinson's disease, and age-matched healthy controls, all aged 18 years or older. People with Parkinson's disease were diagnosed by a neurologist with movement disorder training, in accordance with the UK Parkinson's Disease Society Brain Bank criteria. LRRK2 carrier status was confirmed by bidirectional Sanger sequencing. In the first study, LRRK2 mutation carriers with or without manifest Parkinson's disease who were referred for investigation between July, 1999, and January, 2012, were scanned with PET tracers for the membrane dopamine transporter, and dopamine synthesis and storage (F-18-6-fluoro-L-dopa; F-18-FDOPA). We compared findings with those in people with sporadic Parkinson's disease and age-matched healthy controls. In the second study, distinct groups of LRRK2 mutation carriers, individuals with sporadic Parkinson's disease, and age-matched healthy controls seen from November, 2012, to May, 2016, were studied with tracers for the serotonin transporter and vesicular monoamine transporter 2 (VMAT2). Striatal dopamine transporter binding, VMAT2 binding, F-18-FDOPA uptake, and serotonin transporter binding in multiple brain regions were compared by ANCOVA, adjusted for age. Findings Between January, 1997, and January, 2012, we obtained data for our first study from 40 LRRK2 mutation carriers, 63 individuals with sporadic Parkinson's disease, and 35 healthy controls. We identified significant group differences in striatal dopamine transporter binding (all age ranges in caudate and putamen, p<0.0001) and F-18-FDOPA uptake (in caudate: age <= 50 years, p=0.0002; all other age ranges, p<0.0001; in putamen: all age ranges, p<0.0001). LRRK2 mutation carriers with manifest Parkinson's disease (n=15) had reduced striatal dopamine transporter binding and F-18-FDOPA uptake, comparable with amounts seen in individuals with sporadic Parkinson's disease of similar duration. LRRK2 mutation carriers without manifest Parkinson's disease (n=25) had greater F-18-FDOPA uptake and dopamine transporter binding than did individuals with sporadic Parkinson's disease, with F-18-FDOPA uptake comparable with controls and dopamine transporter binding lower than in controls. Between November, 2012, and May, 2016, we obtained data for our second study from 16 LRRK2 mutation carriers, 13 individuals with sporadic Parkinson's disease, and nine healthy controls. Nine LRRK2 mutation carriers without manifest Parkinson's disease had significantly elevated serotonin transporter binding in the hypothalamus (compared with controls, individuals with LRRK2 Parkinson's disease, and people with sporadic Parkinson's disease, p<0.0001), striatum (compared with people with sporadic Parkinson's disease, p=0.02), and brainstem (compared with LRRK2 mutation carriers with manifest Parkinson's disease, p=0.01), after adjustment for age. Serotonin transporter binding in the cortex did not differ significantly between groups after age adjustment. Striatal VMAT2 binding was reduced in all individuals with manifest Parkinson's disease and reduced asymmetrically in one LRRK2 mutation carrier without manifest disease. Interpretation Dopaminergic and serotonergic changes progress in a similar fashion in LRRK2 mutation carriers with manifest Parkinson's disease and individuals with sporadic Parkinson's disease, but LRRK2 mutation carriers without manifest Parkinson's disease show increased serotonin transporter binding in the striatum, brainstem, and hypothalamus, possibly reflecting compensatory changes in serotonergic innervation preceding the motor onset of Parkinson's disease. Increased serotonergic innervation might contribute to clinical differences in LRRK2 Parkinson's disease, including the emergence of non-motor symptoms and, potentially, differences in the long-term response to levodopa. C1 [Wile, Daryl J.; Stoessl, A. Jon] Univ British Columbia, Dept Med, Vancouver, BC, Canada. [Schulzer, Michael] Univ British Columbia, Dept Stat, Vancouver, BC, Canada. [Dinelle, Katherine; Shahinfard, Elham; Vafai, Nasim; Sossi, Vesna] Univ British Columbia, Dept Phys & Astron, Vancouver, BC, Canada. [Farrer, Matthew] Univ British Columbia, Dept Med Genet, Vancouver, BC, Canada. [Agarwal, Pankaj A.] Global Hosp, Bombay, Maharashtra, India. [Aasly, Jan] Norwegian Univ Sci & Technol, Trondheim, Norway. [Strongosky, Audrey; Uitti, Ryan J.; Wszolek, Zbigniew K.] Mayo Clin, Jacksonville, FL 32224 USA. [Mak, Edwin; McKenzie, Jessamyn; Neilson, Nicole; Stoessl, A. Jon] Pacific Parkinsons Res Ctr, Vancouver, BC, Canada. [Hasegawa, Kazuko] Sagamihara Natl Hosp, Sagamihara, Kanagawa, Japan. [Zhang, Jing; Zabetian, Cyrus P.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Guttman, Mark] Ctr Movement Disorders, Toronto, ON, Canada. [Ding, Yu-Shin] NYU, Sch Med, New York, NY USA. [Adam, Mike] TRIUMF, Vancouver, BC, Canada. RP Wile, DJ (reprint author), Univ British Columbia, Southern Med Program, Kelowna, BC V1W 4V5, Canada. EM dwile@mail.ubc.ca FU Canada Research Chairs; Michael J Fox Foundation; National Institutes of Health; Pacific Alzheimer Research Foundation; Pacific Parkinson's Research Institute; National Research Council of Canada FX Canada Research Chairs, Michael J Fox Foundation, National Institutes of Health, Pacific Alzheimer Research Foundation, Pacific Parkinson's Research Institute, National Research Council of Canada. NR 28 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1474-4422 EI 1474-4465 J9 LANCET NEUROL JI Lancet Neurol. PD MAY PY 2017 VL 16 IS 5 BP 351 EP 359 DI 10.1016/S1474-4422(17)30056-X PG 9 WC Clinical Neurology SC Neurosciences & Neurology GA ER4PH UT WOS:000398782100012 PM 28336296 ER PT J AU Parang, B Kaz, AM Barrett, CW Short, SP Ning, W Keating, CE Mittal, MK Naik, RD Washington, MK Revetta, FL Smith, J Chen, X Wilson, KT Brand, T Bader, DM Tansey, WP Chen, R Brentnall, TA Grady, WM Williams, CS AF Parang, Bobak Kaz, Andrew M. Barrett, Caitlyn W. Short, Sarah P. Ning, Wei Keating, Cody E. Mittal, Mukul K. Naik, Rishi D. Washington, Mary K. Revetta, Frank L. Smith, Joshua Chen, Xi Wilson, Keith T. Brand, Thomas Bader, David M. Tansey, William P. Chen, Ru Brentnall, Teresa A. Grady, William M. Williams, Christopher S. TI BVES regulates c-Myc stability via PP2A and suppresses colitis-induced tumourigenesis SO GUT LA English DT Article ID INFLAMMATORY-BOWEL-DISEASE; JUNCTIONAL ADHESION MOLECULE; DEXTRAN SODIUM-SULFATE; ULCERATIVE-COLITIS; TIGHT JUNCTION; COLORECTAL-CANCER; COLON-CARCINOMA; GASTRIC-CANCER; E-CADHERIN; EXPRESSION AB Objective Blood vessel epicardial substance (BVES) is a tight junction-associated protein that regulates epithelial-mesenchymal states and is underexpressed in epithelial malignancy. However, the functional impact of BVES loss on tumourigenesis is unknown. Here we define the in vivo role of BVES in colitis-associated cancer (CAC), its cellular function and its relevance to patients with IBD. Design We determined BVES promoter methylation status using an Infinium HumanMethylation450 array screen of patients with UC with and without CAC. We also measured BVES mRNA levels in a tissue microarray consisting of normal colons and CAC samples. Bves(-/-) and wild-type mice (controls) were administered azoxymethane (AOM) and dextran sodium sulfate (DSS) to induce tumour formation. Last, we used a yeast two-hybrid screen to identify BVES interactors and performed mechanistic studies in multiple cell lines to define how BVES reduces c-Myc levels. Results BVES mRNA was reduced in tumours from patients with CAC via promoter hypermethylation. Importantly, BVES promoter hypermethylation was concurrently present in distant non-malignant-appearing mucosa. As seen in human patients, Bves was underexpressed in experimental inflammatory carcinogenesis, and Bves(-/-) mice had increased tumour multiplicity and degree of dysplasia after AOM/DSS administration. Molecular analysis of Bves(-/-) tumours revealed Wnt activation and increased c-Myc levels. Mechanistically, we identified a new signalling pathway whereby BVES interacts with PR61 alpha, a protein phosphatase 2A regulatory subunit, to mediate c-Myc destruction. Conclusion Loss of BVES promotes inflammatory tumourigenesis through dysregulation of Wnt signalling and the oncogene c-Myc. BVES promoter methylation status may serve as a CAC biomarker. C1 [Parang, Bobak; Barrett, Caitlyn W.; Short, Sarah P.; Ning, Wei; Keating, Cody E.; Mittal, Mukul K.; Naik, Rishi D.; Wilson, Keith T.; Williams, Christopher S.] Vanderbilt Univ, Dept Med, Div Gastroenterol, Nashville, TN USA. [Parang, Bobak; Barrett, Caitlyn W.; Short, Sarah P.; Ning, Wei; Keating, Cody E.; Mittal, Mukul K.; Wilson, Keith T.; Williams, Christopher S.] Vanderbilt Univ, Dept Canc Biol, 221 Kirkland Hall, Nashville, TN 37235 USA. [Kaz, Andrew M.] VA Puget Sound Hlth Care Syst, Gastroenterol Sect, Seattle, WA USA. [Kaz, Andrew M.; Chen, Ru; Brentnall, Teresa A.; Grady, William M.] Univ Washington, Dept Med, Div Gastroenterol, Seattle, WA USA. [Washington, Mary K.; Revetta, Frank L.] Vanderbilt Univ, Dept Pathol Microbiol & Immunol, 221 Kirkland Hall, Nashville, TN 37235 USA. [Smith, Joshua] Mem Sloan Kettering Canc Ctr, Dept Surg, Colorectal Serv, 1275 York Ave, New York, NY 10021 USA. [Chen, Xi] Univ Miami, Miller Sch Med, Sylvester Comprehens Canc Ctr, Dept Publ Hlth Sci,Div Biostat, Miami, FL 33136 USA. [Wilson, Keith T.; Williams, Christopher S.] Vanderbilt Ingram Canc Ctr, Nashville, TN USA. [Wilson, Keith T.; Williams, Christopher S.] Vet Affairs Tennessee Valley Hlth Care Syst, Nashville, TN USA. [Brand, Thomas] Imperial Coll London, Heart Sci Ctr, Natl Heart & Lung Inst, London, England. [Bader, David M.; Tansey, William P.] Vanderbilt Univ, Dept Cell & Dev Biol, 221 Kirkland Hall, Nashville, TN 37235 USA. RP Williams, CS (reprint author), Vanderbilt Univ, Sch Med, Med & Canc Biol, 1065D MRB-4,B2215 Garland Ave, Nashville, TN 37232 USA.; Williams, CS (reprint author), Vanderbilt Univ, Sch Med, Phys Scientist Training Programme, 1065D MRB-4,B2215 Garland Ave, Nashville, TN 37232 USA.; Williams, CS (reprint author), Vanderbilt Univ, Sch Med, VA Hlth Syst, 1065D MRB-4,B2215 Garland Ave, Nashville, TN 37232 USA. EM christopher.williams@vanderbilt.edu FU VA Merit [1I01BX001426]; Medical Research Council [MR/J010383/J1]; Vanderbilt Institute for Clinical and Translational Research [UL1TR000445]; NIH [1F30DK096718-01A1, R01AT004821, T32 GM07347, DK080221, P50CA095103]; ACS [ACS-RSG 116552] FX VA Merit (1I01BX001426), Medical Research Council (MR/J010383/J1), Vanderbilt Institute for Clinical and Translational Research (UL1TR000445), NIH (1F30DK096718-01A1, R01AT004821, T32 GM07347), NIH (DK080221, P50CA095103) and ACS (ACS-RSG 116552). NR 46 TC 1 Z9 1 U1 3 U2 3 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0017-5749 EI 1468-3288 J9 GUT JI Gut PD MAY PY 2017 VL 66 IS 5 BP 852 EP 862 DI 10.1136/gutjnl-2015-310255 PG 11 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ER1QH UT WOS:000398566800012 PM 28389570 ER PT J AU Singh, JA AF Singh, Jasvinder A. TI Lesinurad combination therapy with allopurinol in gout: do CLEAR studies make the treatment of gout clearer? SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Editorial Material ID PREVALENCE; HYPERURICEMIA C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower B805, 510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com FU Takeda; Savient; Regeneron; Merz; Iroko; Bioiberica; Crealta; Allergan pharmaceuticals; WebMD; UBM LLC; American College of Rheumatology; Horizon pharmaceuticals; ACR's Annual Meeting Planning Committee; Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee; Veterans Affairs Rheumatology Field Advisory Committee FX JAS has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta and Allergan pharmaceuticals, WebMD, UBM LLC and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA, a 501 (c) (3) entity. JAS is a member of the executive of OMERACT, an organisation that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the ACR's Annual Meeting Planning Committee; Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee; and a member of the Veterans Affairs Rheumatology Field Advisory Committee. JAS is supported by the resources and the use of facilities at the VA Medical Center at Birmingham, Alabama, USA. NR 13 TC 0 Z9 0 U1 4 U2 4 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD MAY PY 2017 VL 76 IS 5 DI 10.1136/annrheumdis-2016-210519 PG 3 WC Rheumatology SC Rheumatology GA EQ9EM UT WOS:000398387200004 PM 28039184 ER PT J AU Kishan, AU Shaikh, T Wang, PC Reiter, RE Said, J Raghavan, G Nickols, NG Aronson, WJ Sadeghi, A Kamrava, M Demanes, DJ Steinberg, ML Horwitz, EM Kupelian, PA King, CR AF Kishan, Amar U. Shaikh, Talha Wang, Pin-Chieh Reiter, Robert E. Said, Jonathan Raghavan, Govind Nickols, Nicholas G. Aronson, William J. Sadeghi, Ahmad Kamrava, Mitchell Demanes, David Jeffrey Steinberg, Michael L. Horwitz, Eric M. Kupelian, Patrick A. King, Christopher R. TI Clinical Outcomes for Patients with Gleason Score 9-10 Prostate Adenocarcinoma Treated With Radiotherapy or Radical Prostatectomy: A Multi-institutional Comparative Analysis SO EUROPEAN UROLOGY LA English DT Article DE Gleason 9; Gleason 10; Radiotherapy; Radical prostatectomy ID ANDROGEN-DEPRIVATION THERAPY; ISUP CONSENSUS CONFERENCE; INTERNATIONAL-SOCIETY; RANDOMIZED-TRIALS; RADIATION-THERAPY; BEAM RADIOTHERAPY; HORMONAL-THERAPY; SHORT-TERM; CANCER; CARCINOMA AB Background: The long natural history of prostate cancer (CaP) limits comparisons of efficacy between radical prostatectomy (RP) and external beam radiotherapy (EBRT), since patients treated years ago received treatments considered suboptimal by modern standards (particularly with regards to androgen deprivation therapy [ADT] and radiotherapy dose-escalation]. Gleason score (GS) 9-10 CaP is particularly aggressive, and clinically-relevant endpoints occur early, facilitating meaningful comparisons. Objective: To compare outcomes of patientswithGS 9-10 CaP following EBRT, extremely-dose escalatedradiotherapy(as exemplifiedbyEBRT + brachytherapy[EBRT + BT]), andRP. Design, setting, participants: Retrospective analysis of 487 patients with biopsy GS 9-10 CaP treated between 2000 and 2013 (230 with EBRT, 87 with EBRT + BT, and 170 with RP). Most radiotherapy patients received ADT and dose-escalated radiotherapy. Outcome measurements and statistical analysis: Kaplan-Meier analysis and multivariate Cox regression estimated and compared 5-yr and 10-yr rates of distant metastasisfree survival, cancer-specific survival (CSS), and overall survival (OS). Results and limitations: The median follow-up was 4.6 yr. Local salvage and systemic salvage were performed more frequently in RP patients (49.0% and 30.1%) when compared with either EBRT patients (0.9% and 19.7%) or EBRT + BT patients (1.2% and 16.1%, p < 0.0001). Five-yr and 10-yr distant metastasis-free survival rates were significantly higher with EBRT + BT (94.6% and 89.8%) than with EBRT (78.7% and 66.7%, p = 0.0005) or RP (79.1% and 61.5%, p < 0.0001). The 5-yr and 10-yr CSS and OS rates were similar across all three cohorts. Conclusions: Radiotherapy and RP provide equivalent CSS and OS. Extremely dose-escalated radiotherapy with ADT in particular offers improved systemic control when compared with either EBRT or RP. These data suggest that extremely dose-escalated radiotherapy with ADT might be the optimal upfront treatment for patients with biopsy GS 9-10 CaP. Patient summary: While some prostate cancers are slow-growing requiring many years, sometimes decades, of follow-up in order to compare between radiation and surgery, high-risk and very aggressive cancers follow a much shorter time course allowing such comparisons to bemade and updated as treatments, especially radiation, rapidly evolve. We showed that radiation-based treatments and surgery, with contemporary standards, offer equivalent survival for patientswith very aggressive cancers (defined asGleason score 9-10). Extremely-dose escalated radiotherapy with short-course androgen deprivation therapy offered the least risk of developing metastases, and equivalent long term survival. (C) 2016 European Association of Urology. Published by Elsevier B. V. All rights reserved. C1 [Kishan, Amar U.; Wang, Pin-Chieh; Raghavan, Govind; Nickols, Nicholas G.; Kamrava, Mitchell; Demanes, David Jeffrey; Steinberg, Michael L.; Kupelian, Patrick A.; King, Christopher R.] Univ Calif Los Angeles, Dept Radiat Oncol, Los Angeles, CA 90024 USA. [Shaikh, Talha; Horwitz, Eric M.] Fox Chase Canc Ctr, Dept Radiat Oncol, 7701 Burholme Ave, Philadelphia, PA 19111 USA. [Reiter, Robert E.; Aronson, William J.] Univ Calif Los Angeles, Dept Urol, Los Angeles, CA USA. [Said, Jonathan] Univ Calif Los Angeles, Dept Pathol, Los Angeles, CA 90024 USA. [Nickols, Nicholas G.; Sadeghi, Ahmad] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Radiat Oncol, Los Angeles, CA USA. [Aronson, William J.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Urol, Los Angeles, CA USA. RP Kishan, AU (reprint author), Dept Radiat Oncol, Suite B265,200 Med Plaza, Los Angeles, CA 90095 USA. EM aukishan@mednet.ucla.edu NR 34 TC 1 Z9 1 U1 4 U2 4 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 0302-2838 EI 1873-7560 J9 EUR UROL JI Eur. Urol. PD MAY PY 2017 VL 71 IS 5 BP 766 EP 773 DI 10.1016/j.eururo.2016.06.046 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA EQ0PO UT WOS:000397773300031 PM 27452951 ER PT J AU Abdallah, CG AF Abdallah, Chadi G. TI What's the Buzz About Hydroxynorketamine? Is It the History, the Story, the Debate, or the Promise? SO BIOLOGICAL PSYCHIATRY LA English DT Editorial Material ID ANTIDEPRESSANT; KETAMINE; METABOLITES; DEPRESSION; RECEPTORS C1 [Abdallah, Chadi G.] US Dept Vet Affairs, Natl Ctr PTSD, Clin Neurosci Div, West Haven, CT USA. [Abdallah, Chadi G.] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. RP Abdallah, CG (reprint author), Yale Univ, Sch Med, VA Natl Ctr PTSD, Dept Psychiat,Clin Neurosci Div, 950 Campbell Ave,151E, West Haven, CT 06516 USA. EM chadi.abdallah@yale.edu FU U.S. Department of Veterans Affairs; National Center for PTSD; Patterson Trust Award; National Institute of Mental Health [K23MH101498] FX This work was supported by the U. S. Department of Veterans Affairs, National Center for PTSD, the Patterson Trust Award, and the National Institute of Mental Health (Grant No. K23MH101498). The views expressed in this article are those of the author and do not necessarily reflect the position or policy of the Department of Veterans Affairs or other sponsoring institutions. NR 10 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 15 PY 2017 VL 81 IS 8 BP E61 EP E63 DI 10.1016/j.biopsych.2017.01.002 PG 3 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA EP3SA UT WOS:000397300800002 PM 28317551 ER PT J AU Peralta, CA Frigaard, M Rubinsky, AD Rolon, L Lo, L Voora, S Seal, K Tuot, D Chao, S Lui, K Chiao, P Powe, N Shlipak, M AF Peralta, Carmen A. Frigaard, Martin Rubinsky, Anna D. Rolon, Leticia Lo, Lowell Voora, Santhi Seal, Karen Tuot, Delphine Chao, Shirley Lui, Kimberly Chiao, Phillip Powe, Neil Shlipak, Michael TI Implementation of a pragmatic randomized trial of screening for chronic kidney disease to improve care among non-diabetic hypertensive veterans SO BMC NEPHROLOGY LA English DT Article DE Chronic kidney disease; Blood pressure; Hypertension; Screening ID CLINICAL-PRACTICE GUIDELINE; RE-AIM FRAMEWORK; QUALITY-OF-CARE; COST-EFFECTIVENESS; CYSTATIN C; UNITED-STATES; HEALTH; RISK; INTERVENTIONS; CREATININE AB Background: Whether screening for chronic kidney disease (CKD) can improve the care of persons at high risk for complications remains uncertain. We describe the design and early implementation experience of a pilot, cluster-randomized pragmatic trial to evaluate the feasibility, implementation, and effectiveness of a "triple marker" CKD screening program (creatinine, cystatin C and albumin to creatinine ratio) for improving care among hypertensive veterans seen in primary care at one Veterans Administration Hospital. Methods/design: Non-diabetic hypertensive veterans age 18-80 without known CKD were randomized in clusters determined by primary care provider (unit of randomization) into three arms. Usual care will be compared with two incrementally intensified treatment strategies: (1) screen for CKD followed by patient and provider education or (2) screen-educate plus a clinical pharmacist-led CKD and BP management program. The primary clinical outcome is systolic blood pressure (BP) change from baseline. Secondary clinical outcome is BP control. The primary process outcomes is triple marker screening (across three arms), and secondary process outcomes include use of inhibitors of the renin-angiotensin system (ACE/ARB) overall and in persons with albuminuria, CKD recognition by PCP, use of non-steroidal anti-inflammatory drugs (NSAIDs) and NSAID education by PCP. The design uses the Veterans Health Administration electronic health record (EHR) to identify participants, deliver the interventions and ascertain study outcomes. Assessment of the program implementation will use the Reach, Effectiveness, Adoption, Implementation, and Maintenance (RE-AIM) framework. Study duration is 12 months. Results: A total of 1,819 patients have been randomized within 41 provider clusters. The median age (interquartile range) is 68 years (61-72), and 99% of participants are male. Approximately 16% are Black, and 5% Hispanic. In the first 6 months of the trial, 434 triple marker screening tests have been ordered, and 217(50%) have been tested. A total of 48 new CKD cases have been identified among those tested, for a preliminary yield of 22%. Conclusion: We have successfully implemented a pragmatic protocol that uses the EHR to identify and characterize eligible participants, deliver the intervention, and ascertain study outcomes with high rates of participation by providers and patients. Results from this study can guide design of pragmatic trials in the field of CKD. C1 [Peralta, Carmen A.; Frigaard, Martin; Rubinsky, Anna D.; Seal, Karen; Chao, Shirley; Lui, Kimberly; Chiao, Phillip; Shlipak, Michael] San Francisco VA Med Ctr, 4150 Clement St,111A1, San Francisco, CA 94121 USA. [Rolon, Leticia; Lo, Lowell] Univ Calif San Francisco, 533 Parnassus Ave, San Francisco, CA 94117 USA. [Voora, Santhi] Univ Calif San Francisco, 533 Parnassus Ave,UC Hall, San Francisco, CA 94143 USA. [Tuot, Delphine; Powe, Neil] San Francisco Gen Hosp, 1001 Potrero Ave,SFGH 100, San Francisco, CA 94110 USA. RP Peralta, CA (reprint author), San Francisco VA Med Ctr, 4150 Clement St,111A1, San Francisco, CA 94121 USA. EM carmenalicia.peralta@ucsf.edu FU National Kidney Foundation; [1R34DK102152] FX This work is supported by 1R34DK102152 (PI: Peralta) and the National Kidney Foundation. NR 26 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2369 J9 BMC NEPHROL JI BMC Nephrol. PD APR 12 PY 2017 VL 18 AR 132 DI 10.1186/s12882-017-0541-6 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA ES0AD UT WOS:000399187400001 PM 28399844 ER PT J AU Williams, JS Bishu, K Dismuke, CE Egede, LE AF Williams, Joni S. Bishu, Kinfe Dismuke, Clara E. Egede, Leonard E. TI Sex differences in healthcare expenditures among adults with diabetes: evidence from the medical expenditure panel survey, 2002-2011 SO BMC HEALTH SERVICES RESEARCH LA English DT Article DE Sex differences; Healthcare expenditures; Adults; Diabetes ID UNITED-STATES; US ADULTS; COSTS; MODELS AB Background: The evidence assessing differences in medical costs between men and women with diabetes living in the United States is sparse; however, evidence suggests women generally have higher healthcare expenditures compared to men. Since little is known about these differences, the aim of this study was to assess differences in out-of-pocket (OOP) and total healthcare expenditures among adults with diabetes. Methods: Data were used from 20,442 adults (>= 18 years of age) with diabetes from the 2002-2011 Medical Expenditure Panel Survey. Dependent variables were OOP and total direct expenditures for multiple health services (prescription, office-based, inpatient, outpatient, emergency, dental, home healthcare, and other services). The independent variable was sex. Covariates included sociodemographic characteristics, comorbid conditions, and time. Sample demographics were summarized. Mean OOP and total direct expenditures for health services by sex status were analyzed. Regression models were performed to assess incremental costs of healthcare expenditures by sex among adults with diabetes. Results: Fifty-six percent of the sample was composed of women. Unadjusted mean OOP costs were higher for women for prescriptions ($1177; 95% CI $1117-$1237 vs. $959; 95% CI $918-$1000; p < 0.001) compared to men. Unadjusted mean total direct expenditures were also higher for women for prescriptions ($3797; 95% CI $3660-$3934 vs. $3334; 95% CI $3208-$3460; p < 0.001) and home healthcare ($752; 95% CI $646-$858 vs. $397; 95% CI $332-$462; p < 0.001). When adjusting for covariates, higher OOP and total direct costs persisted for women for prescription services (OOP: $156; 95% CI $87-$ 225; p < 0.001 and total: $184; 95% CI $50-$318; p = 0.007). Women also paid > $50 OOP for office-based visits (p < 0.001) and > $55 total expenditures for home healthcare (p = 0.041) compared to men after adjustments. Conclusions: Our findings show women with diabetes have higher OOP and total direct expenditures compared to men. Additional research is needed to investigate this disparity between men and women and to understand the associated drivers and clinical implications. Policy recommendations are warranted to minimize the higher burden of costs for women with diabetes. C1 [Williams, Joni S.; Egede, Leonard E.] Med Coll Wisconsin, Ctr Patient Care & Outcomes Res, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA. [Williams, Joni S.; Egede, Leonard E.] Med Coll Wisconsin, Dept Med, Div Gen Internal Med, 9200 Wisconsin Ave, Milwaukee, WI 53226 USA. [Bishu, Kinfe; Dismuke, Clara E.] Med Univ South Carolina, Dept Med, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280,MSC 250593, Charleston, SC 29425 USA. [Bishu, Kinfe; Dismuke, Clara E.] Med Univ South Carolina, Dept Med, Div Gen Internal Med & Geriat, 171 Ashley Ave, Charleston, SC 29425 USA. [Dismuke, Clara E.] Vet Affairs Med Ctr, Ctr Innovat COIN, Hlth Equity & Rural Outreach Innovat Ctr HEROIC, Ralph H Johnson Dept, 109 Bee St,Mail Code 151, Charleston, SC 29401 USA. RP Egede, LE (reprint author), Med Coll Wisconsin, Ctr Patient Care & Outcomes Res, 8701 Watertown Plank Rd, Milwaukee, WI 53226 USA.; Egede, LE (reprint author), Med Coll Wisconsin, Dept Med, Div Gen Internal Med, 9200 Wisconsin Ave, Milwaukee, WI 53226 USA. EM legede@mcw.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [K24DK093699] FX This study was supported by the National Institute of Diabetes and Digestive and Kidney Diseases (grant K24DK093699, Principal Investigator: Leonard Egede, MD). NR 34 TC 0 Z9 0 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1472-6963 J9 BMC HEALTH SERV RES JI BMC Health Serv. Res. PD APR 11 PY 2017 AR 259 DI 10.1186/s12913-017-2178-3 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA ER8MH UT WOS:000399073100001 PM 28399859 ER PT J AU Young, MRI AF Young, M. Rita I. TI Redirecting the focus of cancer immunotherapy to premalignant conditions SO CANCER LETTERS LA English DT Review DE Cancer; Immune infiltrate; Immunotherapy; Premalignant ID SQUAMOUS-CELL CARCINOMA; ORAL LESIONS; T-CELLS; ESOPHAGEAL ADENOCARCINOMA; BARRETTS-ESOPHAGUS; INFLAMMATORY MICROENVIRONMENT; PRECANCEROUS LESIONS; COLORECTAL-CANCER; ACTINIC KERATOSES; IMMUNE REACTIVITY AB Much progress has been made in introducing immunological treatment approaches for cancer, with lessons learned from both the successes and failures of immunotherapy. Among the challenges of immunotherapeutic approaches for cancer are the multitudes of mechanisms by which cancers are known to subvert the immune defenses. This has led to the incorporation into the immunotherapeutic arsenal strategies by which to overcome the cancer's immunological blockades. What has been only superficially explored is the immunological milieu of premalignant lesions and the possibility of immunological approaches for the treatment of premalignant lesions so as to prevent secondary pre malignant lesions and their progression to cancer. This review discusses the immunological environment associated with premalignant lesions, and the possible missed opportunity of utilizing immunological treatment strategies in the less hostile environment of premalignant lesions as compared to the immune subversive cancer environment. Published by Elsevier Ireland Ltd. C1 [Young, M. Rita I.] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA. [Young, M. Rita I.] Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. RP Young, MRI (reprint author), Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC 29401 USA.; Young, MRI (reprint author), Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. EM youngmr@musc.edu FU Clinical Sciences Research and Development Program of the Department of Veterans Affairs [1 I01CX000851] FX MRI Young is funded by Clinical Sciences Research and Development Program of the Department of Veterans Affairs (1 I01CX000851). NR 76 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0304-3835 EI 1872-7980 J9 CANCER LETT JI Cancer Lett. PD APR 10 PY 2017 VL 391 BP 83 EP 88 DI 10.1016/j.canlet.2017.01.022 PG 6 WC Oncology SC Oncology GA EP4RG UT WOS:000397367000009 PM 28130162 ER PT J AU Lee, HJ Lee, DY Mariappan, MM Feliers, D Ghosh-Choudhury, G Abboud, HE Gorin, Y Kasinath, BS AF Lee, Hak Joo Lee, Doug Yoon Mariappan, Meenalakshmi M. Feliers, Denis Ghosh-Choudhury, Goutam Abboud, Hanna E. Gorin, Yves Kasinath, Balakuntalam S. TI Hydrogen sulfide inhibits high glucose-induced NADPH oxidase 4 expression and matrix increase by recruiting inducible nitric oxide synthase in kidney proximal tubular epithelial cells SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article DE AMP-activated kinase (AMPK); diabetic nephropathy; laminin; oxidative stress; reactive oxygen species (ROS) ID ACTIVATED PROTEIN-KINASE; DIABETIC-NEPHROPATHY; OXIDATIVE STRESS; FIBRONECTIN EXPRESSION; SODIUM HYDROSULFIDE; S-NITROSYLATION; ANGIOTENSIN-II; MOUSE MODEL; TGF-BETA; MICE AB High-glucose increases NADPH oxidase 4 (NOX4) expression, reactive oxygen species generation, and matrix protein synthesis by inhibiting AMP-activated protein kinase (AMPK) in renal cells. Because hydrogen sulfide (H2S) inhibits high glucose-induced matrix protein increase by activating AMPK in renal cells, we examined whether H2S inhibits high glucose-induced expression of NOX4 and matrix protein and whether H2S and NO pathways are integrated. High glucose increased NOX4 expression and activity at 24 h in renal proximal tubular epithelial cells, which was inhibited by sodium hydrosulfide (NaHS), a source of H2S. High glucose decreased AMPK phosphorylation and activity, which was restored by NaHS. Compound C, an AMPK inhibitor, prevented NaHS inhibition of high glucose-induced NOX4 expression. NaHS inhibition of high glucose-induced NOX4 expression was abrogated by N()-nitro-l-arginine methyl ester, an inhibitor of NOS. NaHS unexpectedly augmented the expression of inducible NOS (iNOS) but not endothelial NOS. iNOS siRNA and 1400W, a selective iNOS inhibitor, abolished the ameliorative effects of NaHS on high glucose-induced NOX4 expression, reactive oxygen species generation, and, matrix laminin expression. Thus, H2S recruits iNOS to generate NO to inhibit high glucose-induced NOX4 expression, oxidative stress, and matrix protein accumulation in renal epithelial cells; the two gasotransmitters H2S and NO and their interaction may serve as therapeutic targets in diabetic kidney disease. C1 [Lee, Hak Joo; Lee, Doug Yoon; Mariappan, Meenalakshmi M.; Feliers, Denis; Ghosh-Choudhury, Goutam; Abboud, Hanna E.; Gorin, Yves; Kasinath, Balakuntalam S.] Univ Texas Hlth Sci Ctr San Antonio, MC7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. [Lee, Hak Joo; Mariappan, Meenalakshmi M.; Feliers, Denis; Ghosh-Choudhury, Goutam; Abboud, Hanna E.; Kasinath, Balakuntalam S.] South Texas Vet Hlth Care Syst, San Antonio, TX 78229 USA. RP Kasinath, BS (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, MC7882,7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM Kasinath@uthscsa.edu FU University of Texas Health Science Center at San Antonio (UTHSCSA); NCI, National Institutes of Health [P30 CA54174] FX Images were generated in the Core Optical Imaging Facility, which is supported by University of Texas Health Science Center at San Antonio (UTHSCSA) and NCI, National Institutes of Health Grant P30 CA54174 (Cancer Therapy & Research Center (CTRC) at UTHSCSA). NR 55 TC 0 Z9 0 U1 2 U2 2 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD APR 7 PY 2017 VL 292 IS 14 BP 5665 EP 5675 DI 10.1074/jbc.M116.766758 PG 11 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA ER5AI UT WOS:000398813200005 PM 28188286 ER PT J AU Carcamo-Orive, I Hoffman, GE Cundiff, P Beckmann, ND D'Souza, SL Knowles, JW Patel, A Papatsenko, D Abbasi, F Reaven, GM Whalen, S Lee, P Shahbazi, M Henrion, MYR Zhu, KX Wang, S Roussos, P Schadt, EE Pandey, G Chang, R Quertermous, T Lemischka, I AF Carcamo-Orive, Ivan Hoffman, Gabriel E. Cundiff, Paige Beckmann, Noam D. D'Souza, Sunita L. Knowles, Joshua W. Patel, Achchhe Papatsenko, Dimitri Abbasi, Fahim Reaven, Gerald M. Whalen, Sean Lee, Philip Shahbazi, Mohammad Henrion, Marc Y. R. Zhu, Kuixi Wang, Sven Roussos, Panos Schadt, Eric E. Pandey, Gaurav Chang, Rui Quertermous, Thomas Lemischka, Ihor TI Analysis of Transcriptional Variability in a Large Human iPSC Library Reveals Genetic and Non-genetic Determinants of Heterogeneity SO CELL STEM CELL LA English DT Article ID PLURIPOTENT STEM-CELLS; DIFFERENTIAL EXPRESSION ANALYSIS; POLYCOMB COMPLEXES; CHROMOSOMAL-ABERRATIONS; R/BIOCONDUCTOR PACKAGE; EPIGENETIC MEMORY; NETWORK ANALYSIS; DNA METHYLATION; IDENTIFICATION; VARIANTS AB Variability in induced pluripotent stem cell (iPSC) lines remains a concern for disease modeling and regenerative medicine. We have used RNA-sequencing analysis and linear mixed models to examine the sources of gene expression variability in 317 human iPSC lines from 101 individuals. We found that similar to 50% of genome-wide expression variability is explained by variation across individuals and identified a set of expression quantitative trait loci that contribute to this variation. These analyses coupled with allele-specific expression show that iPSCs retain a donor-specific gene expression pattern. Network, pathway, and key driver analyses showed that Polycomb targets contribute significantly to the non-genetic variability seen within and across individuals, highlighting this chromatin regulator as a likely source of reprogramming-based variability. Our findings therefore shed light on variation between iPSC lines and illustrate the potential for our dataset and other similar large-scale analyses to identify underlying drivers relevant to iPSC applications. C1 [Carcamo-Orive, Ivan; Knowles, Joshua W.; Abbasi, Fahim; Reaven, Gerald M.; Lee, Philip; Shahbazi, Mohammad; Quertermous, Thomas] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA. [Carcamo-Orive, Ivan; Knowles, Joshua W.; Abbasi, Fahim; Reaven, Gerald M.; Lee, Philip; Shahbazi, Mohammad; Quertermous, Thomas] Stanford Univ, Sch Med, Cardiovasc Inst, Stanford, CA 94305 USA. [Hoffman, Gabriel E.; Beckmann, Noam D.; Henrion, Marc Y. R.; Zhu, Kuixi; Wang, Sven; Roussos, Panos; Schadt, Eric E.; Pandey, Gaurav; Chang, Rui] Icahn Sch Med Mt Sinai, Inst Genom & Multiscale Biol, Dept Genet & Genom Sci, New York, NY 10029 USA. [Cundiff, Paige; Patel, Achchhe; Papatsenko, Dimitri; Lemischka, Ihor] Icahn Sch Med Mt Sinai, Black Family Stem Cell Inst, Dept Dev & Regenerat Biol, New York, NY 10029 USA. [D'Souza, Sunita L.] Icahn Sch Med Mt Sinai, Expt Therapeut Inst, Black Family Stem Cell Inst, Dept Dev & Regenerat Biol, New York, NY 10029 USA. [Papatsenko, Dimitri] Skolkovo Inst Sci & Technol, Nobel St,Bldg 3, Moscow 143026, Russia. [Whalen, Sean] Univ Calif San Francisco, Gladstone Inst, San Francisco, CA 94148 USA. [Roussos, Panos] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Roussos, Panos] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN 3, Bronx, NY 10468 USA. [Lemischka, Ihor] Icahn Sch Med Mt Sinai, Dept Pharmacol & Syst Therapeut, New York, NY 10029 USA. RP Quertermous, T (reprint author), Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA.; Quertermous, T (reprint author), Stanford Univ, Sch Med, Cardiovasc Inst, Stanford, CA 94305 USA.; Chang, R (reprint author), Icahn Sch Med Mt Sinai, Inst Genom & Multiscale Biol, Dept Genet & Genom Sci, New York, NY 10029 USA. EM rui.r.chang@mssm.edu; tomq1@stanford.edu OI Carcamo-Orive, Ivan/0000-0001-8823-4925 FU NIH [U01HL107388, R01GM114434, 1RF1AG051504-01, R01AG043076, R01DK107437, R01MH097276]; IBM faculty award; AHA [10FTF3360005] FX This work was supported by NIH grants U01HL107388 (T.Q., E.E.S., and I.L.) and R01GM114434; an IBM faculty award (G.P.); the AHA (grant 10FTF3360005, J.W.K.); and NIH grants 1RF1AG051504-01, R01AG043076, R01DK107437 (T.Q.), and R01MH097276 (R.C.). NR 72 TC 0 Z9 0 U1 5 U2 5 PU CELL PRESS PI CAMBRIDGE PA 50 HAMPSHIRE ST, FLOOR 5, CAMBRIDGE, MA 02139 USA SN 1934-5909 EI 1875-9777 J9 CELL STEM CELL JI Cell Stem Cell PD APR 6 PY 2017 VL 20 IS 4 BP 518 EP + DI 10.1016/j.stem.2016.11.005 PG 24 WC Cell & Tissue Engineering; Cell Biology SC Cell Biology GA EQ8QO UT WOS:000398350800015 PM 28017796 ER PT J AU Lavery, K Gilden, DJ Saint, S Judson, MA Dhaliwal, G AF Lavery, Karen Gilden, Daniel J. Saint, Sanjay Judson, Marc A. Dhaliwal, Gurpreet TI A Bare-Bones Approach SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID VITAMIN-D; SARCOIDOSIS; ADALIMUMAB; THERAPY; PET/CT C1 [Lavery, Karen; Gilden, Daniel J.] Legacy Emanuel Hosp, Dept Med, Portland, OR USA. [Lavery, Karen; Gilden, Daniel J.] Legacy Good Samaritan Hosp, 1015 NW 22nd Ave, Portland, OR 97210 USA. [Saint, Sanjay] Univ Michigan Hlth Syst, Ann Arbor Vet Affairs VA Hlth Serv Res & Dev Ctr, Patient Safety Enhancement Program, Ann Arbor, MI USA. [Saint, Sanjay] Univ Michigan, Sch Med, Dept Internal Med, Ann Arbor, MI USA. [Judson, Marc A.] Albany Med Coll, Dept Med, Albany, NY 12208 USA. [Judson, Marc A.] Albany Med Coll, Div Pulm & Crit Care Med, Albany, NY 12208 USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA. [Dhaliwal, Gurpreet] Univ Calif San Francisco, Sch Med, Dept Med, San Francisco, CA USA. RP Gilden, DJ (reprint author), Legacy Good Samaritan Hosp, 1015 NW 22nd Ave, Portland, OR 97210 USA.; Gilden, DJ (reprint author), Legacy Emanuel Hosp, 1015 NW 22nd Ave, Portland, OR 97210 USA. EM dgilden@lhs.org NR 14 TC 0 Z9 0 U1 2 U2 2 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD APR 6 PY 2017 VL 376 IS 14 BP 1371 EP 1376 DI 10.1056/NEJMcps1516629 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA EQ9SJ UT WOS:000398424800014 PM 28379797 ER PT J AU Ellerbe, LS Manfredi, L Gupta, S Phelps, TE Bowe, TR Rubinsky, AD Burden, JL Harris, AHS AF Ellerbe, Laura S. Manfredi, Luisa Gupta, Shalini Phelps, Tyler E. Bowe, Thomas R. Rubinsky, Anna D. Burden, Jennifer L. Harris, Alex H. S. TI VA residential substance use disorder treatment program providers' perceptions of facilitators and barriers to performance on pre-admission processes SO ADDICTION SCIENCE & CLINICAL PRACTICE LA English DT Article DE Substance use disorders; Residential treatment; Standards of care; Quality measurement; Quality improvement ID QUALITY MEASURES AB Background: In the U.S. Department of Veterans Affairs (VA), residential treatment programs are an important part of the continuum of care for patients with a substance use disorder (SUD). However, a limited number of program-specific measures to identify quality gaps in SUD residential programs exist. This study aimed to: (1) Develop metrics for two pre-admission processes: Wait Time and Engagement While Waiting, and (2) Interview program management and staff about program structures and processes that may contribute to performance on these metrics. The first aim sought to supplement the VA's existing facility-level performance metrics with SUD program-level metrics in order to identify high-value targets for quality improvement. The second aim recognized that not all key processes are reflected in the administrative data, and even when they are, new insight may be gained from viewing these data in the context of day-to-day clinical practice. Methods: VA administrative data from fiscal year 2012 were used to calculate pre-admission metrics for 97 programs (63 SUD Residential Rehabilitation Treatment Programs (SUD RRTPs); 34 Mental Health Residential Rehabilitation Treatment Programs (MH RRTPs) with a SUD track). Interviews were then conducted with management and front-line staff to learn what factors may have contributed to high or low performance, relative to the national average for their program type. We hypothesized that speaking directly to residential program staff may reveal innovative practices, areas for improvement, and factors that may explain system-wide variability in performance. Results: Average wait time for admission was 16 days (SUD RRTPs: 17 days; MH RRTPs with a SUD track: 11 days), with 60% of Veterans waiting longer than 7 days. For these Veterans, engagement while waiting occurred in an average of 54% of the waiting weeks (range 3-100% across programs). Fifty-nine interviews representing 44 programs revealed factors perceived to potentially impact performance in these domains. Efficient screening processes, effective patient flow, and available beds were perceived to facilitate shorter wait times, while lack of beds, poor staffing levels, and lengths of stay of existing patients were thought to lengthen wait times. Accessible outpatient services, strong patient outreach, and strong encouragement of pre-admission outpatient treatment emerged as facilitators of engagement while waiting; poor staffing levels, socioeconomic barriers, and low patient motivation were viewed as barriers. Conclusions: Metrics for pre-admission processes can be helpful for monitoring residential SUD treatment programs. Interviewing program management and staff about drivers of performance metrics can play a complementary role by identifying innovative and other strong practices, as well as high-value targets for quality improvement. Key facilitators of high-performing facilities may offer programs with lower performance useful strategies to improve specific pre-admission processes. C1 [Ellerbe, Laura S.; Manfredi, Luisa; Gupta, Shalini; Phelps, Tyler E.; Bowe, Thomas R.; Harris, Alex H. S.] Dept Vet Affairs VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 795 Willow Rd MPD 152, Menlo Pk, CA 94025 USA. [Rubinsky, Anna D.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Rubinsky, Anna D.] San Francisco VA Med Ctr, San Francisco, CA USA. [Burden, Jennifer L.] Salem VA Med Ctr, Salem, VA USA. RP Manfredi, L (reprint author), Dept Vet Affairs VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, 795 Willow Rd MPD 152, Menlo Pk, CA 94025 USA. EM Luisa.Manfredi@va.gov FU Department of Veterans Affairs (VA) Quality Enhancement Research Initiative [RRP-12-468]; VA Research Career Scientist Award [RCS-14-232] FX This work was funded in part by the Department of Veterans Affairs (VA) Quality Enhancement Research Initiative (RRP-12-468) and a VA Research Career Scientist Award to Dr. Harris (RCS-14-232). The views expressed are those of the authors and do not represent the position or policy of the Department of Veterans Affairs or the United States Government. NR 11 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1940-0640 J9 ADDICT SCI CLIN PRAC JI Addict. Sci. Clin. Pract. PD APR 4 PY 2017 VL 12 BP 1 EP 11 AR 10 DI 10.1186/s13722-017-0075-z PG 11 WC Substance Abuse SC Substance Abuse GA EQ9QL UT WOS:000398419100001 PM 28372579 ER PT J AU Simmons, MM Gabrielian, S Byrne, T McCullough, MB Smith, JL Taylor, TJ O'Toole, TP Kane, V Yakovchenko, V McInnes, DK Smelson, DA AF Simmons, Molly M. Gabrielian, Sonya Byrne, Thomas McCullough, Megan B. Smith, Jeffery L. Taylor, Thom J. O'Toole, Tom P. Kane, Vincent Yakovchenko, Vera McInnes, D. Keith Smelson, David A. TI A Hybrid III stepped wedge cluster randomized trial testing an implementation strategy to facilitate the use of an evidence-based practice in VA Homeless Primary Care Treatment Programs SO IMPLEMENTATION SCIENCE LA English DT Article DE Facilitation; Step wedge design; Co-occurring disorders; Vulnerable populations ID MENTAL-ILLNESS; NATIONAL DISSEMINATION; EXTERNAL FACILITATION; SUBSTANCE-ABUSE; QUERI SERIES; HEALTH; INTERVENTION; INDIVIDUALS; VETERANS; DESIGNS AB Background: Homeless veterans often have multiple health care and psychosocial needs, including assistance with access to housing and health care, as well as support for ongoing treatment engagement. The Department of Veterans Affairs (VA) developed specialized Homeless Patient Alignment Care Teams (HPACT) with the goal of offering an integrated, " one-stop program" to address housing and health care needs of homeless veterans. However, while 70% of HPACT's veteran enrollees have co-occurring mental health and substance use disorders, HPACT does not have a uniform, embedded treatment protocol for this subpopulation. One wraparound intervention designed to address the needs of homeless veterans with co-occurring mental health and substance use disorders which is suitable to be integrated into HPACT clinic sites is the evidence-based practice called Maintaining Independence and Sobriety through Systems Integration, Outreach, and Networking-Veterans Edition, or MISSION-Vet. Despite the promise of MISSION-Vet within HPACT clinics, implementation of an evidence-based intervention within a busy program like HPACT can be difficult. The current study is being undertaken to identify an appropriate implementation strategy for MISSION-Vet within HPACT. The study will test the implementation platform called Facilitation and compared to implementation as usual (IU). The aims of this study are as follows: (1) Compare the extent to which IU or Facilitation strategies achieve fidelity to the MISSION-Vet intervention as delivered by HPACT homeless provider staff. (2) Compare the effects of Facilitation and IU strategies on the National HPACT Performance Measures. (3) Compare the effects of IU and Facilitation on the permanent housing status. (4) Identify and describe key stakeholders' (patients, providers, staff) experiences with, and perspectives on, the barriers to, and facilitators of implementing MISSION. Design: Type III Hybrid modified stepped wedge implementation comparing IU to Facilitation across seven HPACT teams in three sites in the greater Los Angeles VA system. This is a cluster randomized trial. Discussion: Integrating MISSION-Vet within HPACT has the potential to improve the health of thousands of veterans, but it is crucial to implement the intervention appropriately in order for it to succeed. The lessons learned in this protocol could assist with a larger roll-out of MISSION within HPACT. This protocol is registered with clinicaltrials. gov and was assigned the number NCT 02942979. C1 [Simmons, Molly M.; Byrne, Thomas; O'Toole, Tom P.; Smelson, David A.] VA Natl Ctr Homelessness Vet, Washington, DC 20420 USA. [Simmons, Molly M.; McCullough, Megan B.; Yakovchenko, Vera; McInnes, D. Keith; Smelson, David A.] VA Ctr Hlth Org & Implementat Res, Bedford, MA 01730 USA. [Simmons, Molly M.; McCullough, Megan B.; Yakovchenko, Vera; McInnes, D. Keith] Boston Univ, Sch Publ Hlth, Boston, MA USA. [Gabrielian, Sonya; Smith, Jeffery L.] VA Greater Los Angeles Hlth Care Syst, Los Angeles, CA USA. [Gabrielian, Sonya] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Byrne, Thomas] Boston Univ, Sch Social Work, Boston, MA 02215 USA. [Smith, Jeffery L.] Univ Arkansas Med Sci, Coll Med, Little Rock, AR 72205 USA. [Taylor, Thom J.] VA Palo Alto Hlth Care Syst, Palo Alto, CA USA. [Smith, Jeffery L.; Taylor, Thom J.] VA Qual Enhancement Res Initiat Team Based Behav, Palo Alto, CA USA. [O'Toole, Tom P.] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA. [Kane, Vincent] VA Med Ctr Wilmington, Wilmington, DE USA. [McInnes, D. Keith; Smelson, David A.] VA Bridging Care Continuum Qual Enhancement Res I, Bedford, MA USA. [Smelson, David A.] Univ Massachusetts, Med Sch, Worcester, MA 01605 USA. RP Simmons, MM (reprint author), VA Natl Ctr Homelessness Vet, Washington, DC 20420 USA.; Simmons, MM (reprint author), VA Ctr Hlth Org & Implementat Res, Bedford, MA 01730 USA. EM msimmons@post.harvard.edu FU VA Health Services Research and Development Quality Enhancement Research Initiative [QUE 15-284] FX This project was funded by a grant from the VA Health Services Research and Development Quality Enhancement Research Initiative, "Bridging the Care Continuum" (QUE 15-284). NR 57 TC 0 Z9 0 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD APR 4 PY 2017 VL 12 AR 46 DI 10.1186/s13012-017-0563-2 PG 10 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA ER0YU UT WOS:000398516200003 PM 28376839 ER PT J AU Nguyen, KL Han, F Zhou, ZW Brunengraber, DZ Ayad, I Levi, DS Satou, GM Reemtsen, BL Hu, P Finn, JP AF Kim-Lien Nguyen Han, Fei Zhou, Ziwu Brunengraber, Daniel Z. Ayad, Ihab Levi, Daniel S. Satou, Gary M. Reemtsen, Brian L. Hu, Peng Finn, J. Paul TI 4D MUSIC CMR: value-based imaging of neonates and infants with congenital heart disease SO JOURNAL OF CARDIOVASCULAR MAGNETIC RESONANCE LA English DT Article DE Congenital heart disease; Magnetic resonance angiography; Cardiovascular magnetic resonance; Ferumoxytol; 4-D imaging ID CARDIOVASCULAR MAGNETIC-RESONANCE; ENHANCED MR-ANGIOGRAPHY; CONTRAST AGENT; HIGH-RESOLUTION; THORACIC AORTA; STEADY-STATE; YOUNG-ADULTS; FERUMOXYTOL; CHILDREN; SAFETY AB Background: 4D Multiphase Steady State Imaging with Contrast (MUSIC) acquires high-resolution volumetric images of the beating heart during uninterrupted ventilation. We aim to evaluate the diagnostic performance and clinical impact of 4D MUSIC in a cohort of neonates and infants with congenital heart disease (CHD). Methods: Forty consecutive neonates and infants with CHD (age range 2 days to 2 years, weight 1 to 13 kg) underwent 3.0 T CMR with ferumoxytol enhancement (FE) at a single institution. Independently, two readers graded the diagnostic image quality of intra-cardiac structures and related vascular segments on FE-MUSIC and breath held FE-CMRA images using a four-point scale. Correlation of the CMR findings with surgery and other imaging modalities was performed in all patients. Clinical impact was evaluated in consensus with referring surgeons and cardiologists. One point was given for each of five key outcome measures: 1) change in overall management, 2) change in surgical approach, 3) reduction in the need for diagnostic catheterization, 4) improved assessment of risk-to-benefit for planned intervention and discussion with parents, 5) accurate pre-procedural roadmap. Results: All FE-CMR studies were completed successfully, safely and without adverse events. On a four-point scale, the average FE-MUSIC image quality scores were >3.5 for intra-cardiac structures and >3.0 for coronary arteries. Intra-cardiac morphology and vascular anatomy were well visualized with good interobserver agreement (r = 0.46). Correspondence between the findings on MUSIC, surgery, correlative imaging and autopsy was excellent. The average clinical impact score was 4.2 +/- 0.9. In five patients with discordant findings on echo/MUSIC (n = 5) and catheter angiography/MUSIC (n = 1), findings on FE-MUSIC were shown to be accurate at autopsy (n = 1) and surgery (n = 4). The decision to undertake biventricular vs univentricular repair was amended in 2 patients based on FE-MUSIC findings. Plans for surgical approaches which would have involved circulatory arrest were amended in two of 28 surgical cases. In all 28 cases requiring procedural intervention, FE-MUSIC provided accurate dynamic 3D roadmaps and more confident risk-to-benefit assessments for proposed interventions. Conclusions: FE-MUSIC CMR has high clinical impact by providing accurate, high quality, simple and safe dynamic 3D imaging of cardiac and vascular anatomy in neonates and infants with CHD. The findings influenced patient management in a positive manner. C1 [Kim-Lien Nguyen; Han, Fei; Zhou, Ziwu; Brunengraber, Daniel Z.; Hu, Peng; Finn, J. Paul] UCLA, Dept Radiol Sci, David Geffen Sch Med, Diag Cardiovasc Imaging Lab, Los Angeles, CA 90095 USA. [Kim-Lien Nguyen] UCLA, David Geffen Sch Med, Div Cardiol, Los Angeles, CA USA. [Kim-Lien Nguyen] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Han, Fei; Zhou, Ziwu; Hu, Peng; Finn, J. Paul] Univ Calif Los Angeles, Dept Biomed Phys, Los Angeles, CA 90095 USA. [Ayad, Ihab] UCLA, David Geffen Sch Med, Dept Anesthesiol, Los Angeles, CA USA. [Levi, Daniel S.; Satou, Gary M.] UCLA, David Geffen Sch Med, Div Pediat Cardiol, Los Angeles, CA USA. [Reemtsen, Brian L.] UCLA, David Geffen Sch Med, Div Cardiothorac Surg, Los Angeles, CA USA. [Han, Fei; Zhou, Ziwu; Brunengraber, Daniel Z.; Hu, Peng; Finn, J. Paul] Univ Calif Los Angeles, Dept Radiol Sci, Peter V Ueberroth Bldg Suite 3371, Los Angeles, CA 90095 USA. RP Finn, JP (reprint author), UCLA, Dept Radiol Sci, David Geffen Sch Med, Diag Cardiovasc Imaging Lab, Los Angeles, CA 90095 USA.; Finn, JP (reprint author), Univ Calif Los Angeles, Dept Biomed Phys, Los Angeles, CA 90095 USA.; Finn, JP (reprint author), Univ Calif Los Angeles, Dept Radiol Sci, Peter V Ueberroth Bldg Suite 3371, Los Angeles, CA 90095 USA. EM pfinn@mednet.ucla.edu FU National Heart, Lung, and Blood Institute [R01HL127153] FX This work is supported by grant R01HL127153 from the National Heart, Lung, and Blood Institute. NR 35 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1097-6647 EI 1532-429X J9 J CARDIOVASC MAGN R JI J. Cardiov. Magn. Reson. PD APR 3 PY 2017 VL 19 AR 40 DI 10.1186/s12968-017-0352-8 PG 15 WC Cardiac & Cardiovascular Systems; Radiology, Nuclear Medicine & Medical Imaging SC Cardiovascular System & Cardiology; Radiology, Nuclear Medicine & Medical Imaging GA EQ2SA UT WOS:000397919600001 PM 28366171 ER PT J AU Reid, AT Hoffstaedter, F Gong, GL Laird, AR Fox, P Evans, AC Amunts, K Eickhoff, SB AF Reid, Andrew T. Hoffstaedter, Felix Gong, Gaolang Laird, Angela R. Fox, Peter Evans, Alan C. Amunts, Katrin Eickhoff, Simon B. TI A seed-based cross-modal comparison of brain connectivity measures SO BRAIN STRUCTURE & FUNCTION LA English DT Article DE Multimodal comparison; Cortical thickness; VBM; Resting-state fMRI; MACM ID STATE FUNCTIONAL CONNECTIVITY; AUTOMATED 3-D EXTRACTION; GLOBAL SIGNAL REGRESSION; VOXEL-BASED MORPHOMETRY; HUMAN CEREBRAL-CORTEX; SMALL VESSEL DISEASE; CORTICAL THICKNESS; ALZHEIMERS-DISEASE; CORPUS-CALLOSUM; DEFAULT MODE AB Human neuroimaging methods have provided a number of means by which the connectivity structure of the human brain can be inferred. For instance, correlations in blood-oxygen-level-dependent (BOLD) signal time series are commonly used to make inferences about "functional connectivity." Correlations across samples in structural morphometric measures, such as voxel-based morphometry (VBM) or cortical thickness (CT), have also been used to estimate connectivity, putatively through mutually trophic effects on connected brain areas. In this study, we have compared seed-based connectivity estimates obtained from four common correlational approaches: resting-state functional connectivity (RS-fMRI), meta-analytic connectivity modeling (MACM), VBM correlations, and CT correlations. We found that the two functional approaches (RS-fMRI and MACM) had the best agreement. While the two structural approaches (CT and VBM) had better-than-random convergence, they were no more similar to each other than to the functional approaches. The degree of correspondence between modalities varied considerably across seed regions, and also depended on the threshold applied to the connectivity distribution. These results demonstrate some degrees of similarity between connectivity inferred from structural and functional covariances, particularly for the most robust functionally connected regions (e.g., the default mode network). However, they also caution that these measures likely capture very different aspects of brain structure and function. C1 [Reid, Andrew T.; Hoffstaedter, Felix; Amunts, Katrin; Eickhoff, Simon B.] Julich Res Ctr, Inst Neurosci & Med INM 1, Wilhelm Johnen Str, D-52428 Julich, Germany. [Hoffstaedter, Felix; Eickhoff, Simon B.] Heinrich Heine Univ, Dept Clin Neurosci & Med, Dusseldorf, Germany. [Gong, Gaolang] Sch Brain & Cognit Sci, Natl Key Lab Cognit Neurosci & Learning, Beijing, Peoples R China. [Laird, Angela R.] Florida Int Univ, Dept Phys, Miami, FL 33199 USA. [Fox, Peter] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Fox, Peter] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Evans, Alan C.] McGill Univ, Montreal Neurol Inst, McConnell Brain Imaging Ctr, Montreal, PQ, Canada. [Amunts, Katrin] Heinrich Heine Univ, C&O Vogt Inst Brain Res, Dusseldorf, Germany. [Reid, Andrew T.] Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Nijmegen, Netherlands. RP Reid, AT (reprint author), Julich Res Ctr, Inst Neurosci & Med INM 1, Wilhelm Johnen Str, D-52428 Julich, Germany.; Reid, AT (reprint author), Radboud Univ Nijmegen, Donders Inst Brain Cognit & Behav, Nijmegen, Netherlands. EM a.reid@donders.ru.nl FU Deutsche Forschungsgemeinschaft (DFG) [EI 816/4-1, EI 816/6-1, LA 3071/3-1]; National Institute of Mental Health [R01-MH074457]; European EFT program (Human Brain Project) FX This study was supported by the Deutsche Forschungsgemeinschaft (DFG, EI 816/4-1; EI 816/6-1 and LA 3071/3-1.), the National Institute of Mental Health (R01-MH074457) and the European EFT program (Human Brain Project). NR 105 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1863-2653 EI 1863-2661 J9 BRAIN STRUCT FUNCT JI Brain Struct. Funct. PD APR PY 2017 VL 222 IS 3 BP 1131 EP 1151 DI 10.1007/s00429-016-1264-3 PG 21 WC Anatomy & Morphology; Neurosciences SC Anatomy & Morphology; Neurosciences & Neurology GA ER6QH UT WOS:000398930700002 ER PT J AU Niquet, J Baldwin, R Suchomelova, L Lumley, L Eavey, R Wasterlain, CG AF Niquet, Jerome Baldwin, Roger Suchomelova, Lucie Lumley, Lucille Eavey, Roland Wasterlain, Claude G. TI Treatment of experimental status epilepticus with synergistic drug combinations SO EPILEPSIA LA English DT Article DE Refractory status epilepticus; Cholinergic seizures; Polytherapy; Diazepam; Ketamine; Valproate ID GABA(A) RECEPTORS; PILOCARPINE MODEL; KETAMINE; ACCUMULATION; INCREASES; DIAZEPAM; EPILEPSY; ADULTS AB During status epilepticus (SE), synaptic -aminobutyric acid A receptors (GABA(A)Rs) become internalized and inactive, whereas spare N-methyl-d-aspartate receptors (NMDARs) assemble, move to the membrane, and become synaptically active. When treatment of SE is delayed, the number of synaptic GABA(A)Rs is drastically reduced, and a GABA(A) agonist cannot fully restore inhibition. We used a combination of low-dose diazepam (to stimulate the remaining GABA(A)Rs), ketamine (to mitigate the effect of the NMDAR increase), and valproate (to enhance inhibition at a nonbenzodiazepine site) to treat seizures in a model of severe cholinergic SE. High doses of diazepam failed to stop electrographic SE, showing that benzodiazepine pharmacoresistance had developed. The diazepam-ketamine-valproate combination was far more effective in stopping SE than triple-dose monotherapy using the same individual drugs. Isobolograms showed that this drug combination's therapeutic actions were synergistic, with positive cooperativity between drugs, whereas drug toxicity was simply additive, without positive or negative cooperativity. As a result, the therapeutic index was improved by this drug combination compared to monotherapy. These results suggest that synergistic drug combinations that target receptor changes can control benzodiazepine-refractory SE. C1 [Niquet, Jerome; Suchomelova, Lucie; Eavey, Roland; Wasterlain, Claude G.] Univ Calif Los Angeles, Dept Neurol, David Geffen Sch Med, Los Angeles, CA 90024 USA. [Niquet, Jerome; Baldwin, Roger; Suchomelova, Lucie; Eavey, Roland; Wasterlain, Claude G.] Vet Affairs Greater Los Angeles Healthcare Syst, Epilepsy Res Lab 151, Los Angeles, CA USA. [Lumley, Lucille] US Army Med Res Inst Chem Def USAMRICD, Aberdeen Proving Ground, MD USA. [Wasterlain, Claude G.] Univ Calif Los Angeles, David Geffen Sch Med, Brain Res Inst, Los Angeles, CA 90095 USA. RP Niquet, J (reprint author), VA Greater Los Angeles Healthcare Syst, Epilepsy Res Lab, 11301 Wilshire Blvd,Bldg 114,Room 139, West Los Angeles, CA 90073 USA. EM jniquet@ucla.edu FU Department of Veterans Health Affairs [I01 BX000273-07]; NINDS (NIH Counteract Program) [UO1 NS074926]; James and Debbie Cho Foundation FX This work was supported by Merit Review Award # I01 BX000273-07 from the Department of Veterans Health Affairs, by NINDS (NIH Counteract Program; grant UO1 NS074926), and by the James and Debbie Cho Foundation NR 19 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0013-9580 EI 1528-1167 J9 EPILEPSIA JI Epilepsia PD APR PY 2017 VL 58 IS 4 BP E49 EP E53 DI 10.1111/epi.13695 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA ER5RU UT WOS:000398861000001 PM 28225161 ER PT J AU Best, SL AF Best, Sara L. TI Editorial Comment for Jones et al. SO JOURNAL OF ENDOUROLOGY LA English DT Editorial Material ID OUTCOMES C1 [Best, Sara L.] Univ Wisconsin, Dept Urol, Sch Med & Publ Hlth, 1685 Highland Ave,MFCB 3229, Madison, WI 53705 USA. [Best, Sara L.] William S Middleton Mem Vet Adm Med Ctr, Dept Urol, Madison, WI USA. RP Best, SL (reprint author), Univ Wisconsin, Dept Urol, Sch Med & Publ Hlth, 1685 Highland Ave,MFCB 3229, Madison, WI 53705 USA. EM best@urology.wisc.edu NR 2 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0892-7790 EI 1557-900X J9 J ENDOUROL JI J. Endourol. PD APR PY 2017 VL 31 IS 4 BP 341 EP 341 DI 10.1089/end.2017.0183 PG 1 WC Urology & Nephrology SC Urology & Nephrology GA ES2BJ UT WOS:000399330400003 PM 28322584 ER PT J AU Doupnik, SK Feudtner, C Marcus, SC AF Doupnik, Stephanie K. Feudtner, Chris Marcus, Steven C. TI Family Report Compared to Clinician-Documented Diagnoses for Psychiatric Conditions Among Hospitalized Children SO JOURNAL OF HOSPITAL MEDICINE LA English DT Article ID MENTAL-HEALTH DISORDERS; COLLABORATIVE CARE; UNITED-STATES; SERVICES ASSESSMENT; ANXIETY DISORDERS; PERCEIVED STIGMA; DEPRESSION; TRIAL; ILLNESS; YOUTH AB BACKGROUND: Psychiatric comorbidity is common in pediatric medical and surgical hospitalizations and is associated with worse hospital outcomes. Integrating medical or surgical and psychiatric hospital care depends on accurate estimates of which hospitalized children have psychiatric comorbidity. OBJECTIVE: We conducted a study to determine agreement of family report (FR) and clinician documentation (CD) identification of psychiatric diagnoses in hospitalized children. DESIGN AND SETTING: This was a cross-sectional study at a tertiary-care children's hospital. PATIENTS: The patients were children and adolescents (age, 4-21 years) who were hospitalized for medical or surgical indications. MEASUREMENTS: Psychiatric diagnoses were identified from structured interviews (FR) and from inpatient notes and International Classification of Diseases codes in medical records (CD). We compared estimates of point prevalence of any comorbid psychiatric diagnosis using each method, and estimated FR-CD agreement in identifying psychiatric comorbidity in hospitalized children. RESULTS: Of 119 study patients, 26 (22%; 95% confidence interval [CI], 14%-29%) had a psychiatric comorbidity identified by FR, 30 (25%; 95% CI, 17%-34%) had it identified by CD, and 37 (23%-40%) had it identified by FR or CD. Agreement between FR and CD was low overall (kappa = .46; 95% CI, .27-.66), highest for attention-deficit/hyperactivity disorder (kappa=.78; 95% CI, .59-.97), and lowest for anxiety disorders (kappa = .11; 95% CI, -.16 to.56). CONCLUSIONS: Current methods may underestimate the prevalence of psychiatric conditions in hospitalized children. Information from multiple sources may be needed to develop accurate estimates of the scope of the population in need of services so that mental health resources can be appropriately allocated. (C) 2017 Society of Hospital Medicine C1 [Doupnik, Stephanie K.; Feudtner, Chris] Childrens Hosp Philadelphia, Ctr Pediat Clin Effectiveness, Div Gen Pediat, Philadelphia, PA 19104 USA. [Doupnik, Stephanie K.; Feudtner, Chris] Childrens Hosp Philadelphia, PolicyLab, Philadelphia, PA 19104 USA. [Doupnik, Stephanie K.; Feudtner, Chris; Marcus, Steven C.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. [Feudtner, Chris] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. [Feudtner, Chris] Univ Penn, Perelman Sch Med, Dept Med Eth & Hlth Policy, Philadelphia, PA 19104 USA. [Marcus, Steven C.] Philadelphia VA Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. [Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. [Marcus, Steven C.] Univ Penn, Ctr Mental Hlth Policy & Serv Res, Philadelphia, PA 19104 USA. RP Doupnik, SK (reprint author), Childrens Hosp Philadelphia, Div Gen Pediat, Room 1451,CHOP North,3401 Civ Ctr Blvd, Philadelphia, PA 19104 USA. EM doupniks@chop.edu FU Center for Pediatric Health Disparities at Children's Hospital of Philadelphia; Ruth L. Kirschstein National Research Service Award [T32-HP010026-11]; National Institutes of Health FX The direct costs of this project were funded by an internal pilot grant from the Center for Pediatric Health Disparities at Children's Hospital of Philadelphia. Dr. Doupnik was supported by Ruth L. Kirschstein National Research Service Award T32-HP010026-11, funded by the National Institutes of Health. The sponsors had no role in study design; collection, analysis, or interpretation of data; manuscript writing; or deciding to submit this article for publication. NR 38 TC 0 Z9 0 U1 1 U2 1 PU FRONTLINE MEDICAL COMMUNICATIONS PI THE WOODLANDS PA WRIGHTS MEDIA, 2407 TIMBERLOCH PLACE, SUITE B, THE WOODLANDS, TX 77386 USA SN 1553-5592 EI 1553-5606 J9 J HOSP MED JI J. Hosp. Med. PD APR PY 2017 VL 12 IS 4 BP 245 EP 250 DI 10.12788/jhm.2698 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA ES5KQ UT WOS:000399578000006 ER PT J AU Han, S Pistole, MC Caldwell, JM AF Han, Suejung Pistole, M. Carole Caldwell, Jarred M. TI Acculturative Stress, Parental and Professor Attachment, and College Adjustment in Asian International Students SO JOURNAL OF MULTICULTURAL COUNSELING AND DEVELOPMENT LA English DT Article DE attachment; acculturative stress; Asian international students; college adjustment; apego; estres aculturativo; estudiantes internacionales asiaticos; adaptacion al entorno academico ID ADULT ATTACHMENT; PERFECTIONISM; SYMPTOMS; SCALE AB This study examined parental and professor attachment as buffers against acculturative stress and as predictors of college adjustment of 210 Asian international students (AISs). Moderated hierarchical regression analyses revealed that acculturative stress negatively and secure parental and professor attachment positively predicted academic integration. Secure professor attachment positively predicted grade point average. Mother attachment may buffer against acculturative stress on academic integration; father attachment may exacerbate it. Counselors may use these findings to enhance AISs' attachment functioning for their college adjustment. Este estudio examino el apego parental y el apego al profesor como protectores contra el estres aculturativo y como indicadores de adaptacion al entorno academico en 210 estudiantes internacionales asiaticos (AIS, por sus siglas en ingles). Los analisis de regresion jerarquica moderada revelaron que el estres aculturativo fue un indicador negativo de integracion academica, mientras que el apego parental y el apego al profesor fueron indicadores positivos. El apego seguro al profesor fue un indicador positivo de la media de las calificaciones academicas. El apego materno puede proteger contra el estres aculturativo en la integracion academica; el apego paterno puede agravarlo. Los consejeros pueden usar estos descubrimientos para enfatizar el funcionamiento del apego en los AIS para su adaptacion al entorno academico. C1 [Han, Suejung] Illinois State Univ, Dept Psychol, Normal, IL 61761 USA. [Pistole, M. Carole] Purdue Univ, Dept Educ Studies, W Lafayette, IN 47907 USA. [Caldwell, Jarred M.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Han, S (reprint author), Illinois State Univ, Dept Psychol, Normal, IL 61761 USA. EM shan3@ilstu.edu FU Purdue Research Foundation FX Suejung Han, Department of Psychology, Illinois State University; M. Carole Pistole, Department of Educational Studies, Purdue University; Jarred M. Caldwell, Ralph H. Johnson VA Medical Center, Charleston, South Carolina. This study was supported by a grant from the Purdue Research Foundation awarded to M. Carole Pistole. Correspondence concerning this article should be addressed to Suejung Han, Department of Psychology, Illinois State University, Normal, IL 61761 (e-mail: shan3@ilstu.edu). NR 35 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0883-8534 EI 2161-1912 J9 J MULTICULT COUNS D JI J. Multicult. Couns. Dev. PD APR PY 2017 VL 45 IS 2 BP 111 EP 126 DI 10.1002/jmcd.12068 PG 16 WC Psychology, Applied SC Psychology GA ER5NC UT WOS:000398847600003 ER PT J AU Zullo, AR Lee, Y Daiello, LA Mor, V Boscardin, WJ Dore, DD Miao, YH Fung, KZ Komaiko, KDR Steinman, MA AF Zullo, Andrew R. Lee, Yoojin Daiello, Lori A. Mor, Vincent Boscardin, W. John Dore, David D. Miao, Yinghui Fung, Kathy Z. Komaiko, Kiya D. R. Steinman, Michael A. TI Beta-Blocker Use in US Nursing Home Residents After Myocardial Infarction: A National Study SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE nursing homes; myocardial infarction; beta-blockers; elderly; drug utilization ID CONVERTING ENZYME-INHIBITORS; CALCIUM-CHANNEL BLOCKERS; CORONARY-ARTERY-DISEASE; MINIMUM DATA SET; OLDER PATIENTS; HEART-FAILURE; PRACTICE GUIDELINES; ELDERLY SURVIVORS; PRIMARY-CARE; THERAPY AB ObjectivesTo evaluate how often beta-blockers were started after acute myocardial infarction (AMI) in nursing home (NH) residents who previously did not use these drugs and to evaluate which factors were associated with post-AMI use of beta-blockers. DesignRetrospective cohort using linked national Minimum Data Set assessments; Online Survey, Certification and Reporting records; and Medicare claims. SettingU.S. NHs. ParticipantsNational cohort of 15,720 residents aged 65 and older who were hospitalized for AMI between May 2007 and March 2010, had not taken beta-blockers for at least 4 months before their AMI, and survived 14 days or longer after NH readmission. MeasurementsThe outcome was beta-blocker initiation within 30 days of NH readmission. ResultsFifty-seven percent (n = 8,953) of residents initiated a beta-blocker after AMI. After covariate adjustment, use of beta-blockers was less in older residents (ranging from odds ratio (OR) = 0.89, 95% confidence interval (CI) = 0.79-1.00 for aged 75-84 to OR = 0.65, 95% CI = 0.54-0.79 for 95 vs 65-74) and less in residents with higher levels of functional impairment (dependent or totally dependent vs independent to limited assistance: OR = 0.84, 95% CI = 0.75-0.94) and medication use (15 vs 10 medications: OR = 0.89, 95% CI = 0.80-0.99). A wide variety of resident and NH characteristics were not associated with beta-blocker use, including sex, cognitive function, comorbidity burden, and NH ownership. ConclusionAlmost half of older NH residents in the United States do not initiate a beta-blocker after AMI. The absence of observed factors that strongly predict beta-blocker use may indicate a lack of consensus on how to manage older NH residents, suggesting the need to develop and disseminate thoughtful practice standards. C1 [Zullo, Andrew R.; Lee, Yoojin; Daiello, Lori A.; Mor, Vincent; Dore, David D.] Brown Univ, Sch Publ Hlth, Dept Hlth Serv Policy & Practice, 121 South Main St,Box G-S121-8, Providence, RI 02912 USA. [Mor, Vincent] Providence Vet Affairs Med Ctr, Ctr Innovat, Providence, RI USA. [Boscardin, W. John; Miao, Yinghui; Fung, Kathy Z.; Komaiko, Kiya D. R.; Steinman, Michael A.] Univ Calif San Francisco, Div Geriatr, San Francisco, CA 94143 USA. [Boscardin, W. John; Miao, Yinghui; Fung, Kathy Z.; Komaiko, Kiya D. R.; Steinman, Michael A.] San Francisco VA Med Ctr, San Francisco, CA USA. [Boscardin, W. John] Univ Calif San Francisco, Div Biostat, San Francisco, CA 94143 USA. [Dore, David D.] Optum Epidemiol, Boston, MA USA. RP Zullo, AR (reprint author), Brown Univ, Sch Publ Hlth, Dept Hlth Serv Policy & Practice, 121 South Main St,Box G-S121-8, Providence, RI 02912 USA. EM andrew_zullo@brown.edu FU National Heart, Lung, and Blood Institute [5R01HL111032]; National Institute on Aging [K24AG049057]; Agency for Healthcare Research and Quality Award [5K12HS022998]; HCR Manor Care, Inc., a NH chain; NaviHealth, a postacute care service organization; iodine.com FX Financial support for this study was provided by the National Heart, Lung, and Blood Institute (5R01HL111032) and National Institute on Aging (K24AG049057). Dr. Zullo is supported by Agency for Healthcare Research and Quality Award 5K12HS022998.; V.M.'s research is in a related area to that of several different paid activities. V.M. also periodically serves as a paid speaker at national conferences, where he discusses trends and research findings in long-term and postacute care. V.M. holds stock of unknown value in PointRight, Inc., an information services company providing advice and consultation to various components of the LTC and postacute care industry, including suppliers and insurers. PointRight sells information on the measurement of NH quality to NHs and liability insurers. V.M. was a founder of the company but has subsequently divested much of his equity in the company and relinquished his seat on board. In addition, V.M. chairs the Independent Quality Committee for HCR Manor Care, Inc., a NH chain, for which he receives compensation in the range of $ 20,000 to $ 40,000. V.M. also serves as chair of a Scientific Advisory Committee for NaviHealth, a postacute care service organization, for which he also receives compensation in the range of $ 20,000 to $ 40,000 per year. V.M. serves as a technical expert panel member on several Centers for Medicare and Medicaid Services quality measurement panels. V.M. is a member of the board of directors of Tufts Health Plan Foundation; Hospice Care of Rhode Island; and Jewish Alliance of Rhode Island. D.D.D. is an employee of Optum and stockholder in UnitedHealth Group, Optum's parent company. M.A.S. is a paid consultant for iodine.com. NR 48 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD APR PY 2017 VL 65 IS 4 BP 754 EP 762 DI 10.1111/jgs.14671 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA ES7CL UT WOS:000399707100016 PM 27861719 ER PT J AU Nitzburg, GC Cuesta-Diaz, A Ospina, LH Russo, M Shanahan, M Perez-Rodriguez, M Larsen, E Mulaimovic, S Burdick, KE AF Nitzburg, George C. Cuesta-Diaz, Armando Ospina, Luz H. Russo, Manuela Shanahan, Megan Perez-Rodriguez, Mercedes Larsen, Emmett Mulaimovic, Sandra Burdick, Katherine E. TI Organizational Learning Strategies and Verbal Memory Deficits in Bipolar Disorder SO JOURNAL OF THE INTERNATIONAL NEUROPSYCHOLOGICAL SOCIETY LA English DT Article DE Cognitive deficits; Cognitive remediation; Functional remediation; Mood disorder; Semantic clustering; Serial clustering ID COGNITIVE IMPAIRMENT; I DISORDER; NEUROCOGNITIVE IMPAIRMENT; 1ST-DEGREE RELATIVES; EXECUTIVE CONTROL; EUTHYMIC PATIENTS; RATING-SCALE; FOLLOW-UP; METAANALYSIS; SCHIZOPHRENIA AB Background: Verbal memory (VM) impairment is prominent in bipolar disorder (BD) and is linked to functional outcomes. However, the intricacies of VM impairment have not yet been studied in a large sample of BD patients. Moreover, some have proposed VM deficits that may be mediated by organizational strategies, such as semantic or serial clustering. Thus, the exact nature of VM break-down in BD patients is not well understood, limiting remediation efforts. We investigated the intricacies of VM deficits in BD patients versus healthy controls (HCs) and examined whether verbal learning differences were mediated by use of clustering strategies. Methods: The California Verbal Learning Test (CVLT) was administered to 113 affectively stable BD patients and 106 HCs. We compared diagnostic groups on all CVLT indices and investigated whether group differences in verbal learning were mediated by clustering strategies. Results: Although BD patients showed significantly poorer attention, learning, and memory, these indices were only mildly impaired. However, BD patients evidenced poorer use of effective learning strategies and lower recall consistency, with these indices falling in the moderately impaired range. Moreover, relative reliance on semantic clustering fully mediated the relationship between diagnostic category and verbal learning, while reliance on serial clustering partially mediated this relationship. Conclusions: VM deficits in affectively stable bipolar patients were widespread but were generally mildly impaired. However, patients displayed inadequate use of organizational strategies with clear separation from HCs on semantic and serial clustering. Remediation efforts may benefit from education about mnemonic devices or chunking" techniques to attenuate VM deficits in BD. C1 [Nitzburg, George C.; Cuesta-Diaz, Armando; Ospina, Luz H.; Russo, Manuela; Shanahan, Megan; Perez-Rodriguez, Mercedes; Larsen, Emmett; Mulaimovic, Sandra; Burdick, Katherine E.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Nitzburg, George C.; Cuesta-Diaz, Armando; Ospina, Luz H.; Russo, Manuela; Shanahan, Megan; Perez-Rodriguez, Mercedes; Larsen, Emmett; Mulaimovic, Sandra; Burdick, Katherine E.] Icahn Sch Med Mt Sinai, Dept Neurosci, New York, NY 10029 USA. [Burdick, Katherine E.] James J Peters VA Hosp, Bronx, NY USA. RP Nitzburg, GC (reprint author), Icahn Sch Med Mt Sinai, One Gustave L Levy Pl,Box 1230, New York, NY 10029 USA. EM george.nitzburg@gmail.com FU National Institute of Mental Health (NIMH) [K23MH077807, R01MH100125] FX Dr. Burdick has served as an advisory board member for Dainippon Sumitomo Pharmaceutical and for Takeda Lundbeck, which had no impact upon the work presented in this manuscript. Dr. Nitzburg has received research funding from Talkspace Incorporated, which had no impact upon the work presented in this manuscript. All other authors report no competing interests regarding the present study. This study was funded by grants from the National Institute of Mental Health (NIMH) to Dr. Burdick (K23MH077807; R01MH100125). NR 57 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 1355-6177 EI 1469-7661 J9 J INT NEUROPSYCH SOC JI J. Int. Neuropsychol. Soc. PD APR PY 2017 VL 23 IS 4 BP 358 EP 366 DI 10.1017/S1355617717000133 PG 9 WC Clinical Neurology; Neurosciences; Psychiatry; Psychology SC Neurosciences & Neurology; Psychiatry; Psychology GA ES2YO UT WOS:000399394000008 PM 28382899 ER PT J AU Nelson, HN Borrero, S Lehman, E Velott, DL Chuang, CH AF Nelson, Hallie N. Borrero, Sonya Lehman, Erik Velott, Diana L. Chuang, Cynthia H. TI MEASURING ORAL CONTRACEPTIVE ADHERENCE USING SELF-REPORT VERSUS PHARMACY CLAIMS DATA SO JOURNAL OF WOMENS HEALTH LA English DT Meeting Abstract C1 [Nelson, Hallie N.] Penn State Coll Med, Hershey, PA USA. [Borrero, Sonya] Univ Pittsburgh, Div Gen Internal Med, Ctr Hlth Equ Res & Promot, VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Lehman, Erik; Velott, Diana L.; Chuang, Cynthia H.] Penn State Coll Med, Dept Publ Hlth Sci, Hershey, PA USA. [Chuang, Cynthia H.] Penn State Coll Med, Div Gen Internal Med, Hershey, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1540-9996 EI 1931-843X J9 J WOMENS HEALTH JI J. Womens Health PD APR PY 2017 VL 26 IS 4 MA 105 BP A42 EP A42 PG 1 WC Public, Environmental & Occupational Health; Medicine, General & Internal; Obstetrics & Gynecology; Women's Studies SC Public, Environmental & Occupational Health; General & Internal Medicine; Obstetrics & Gynecology; Women's Studies GA ES4HB UT WOS:000399492100106 ER PT J AU Bush, NE Smolenski, DJ Denneson, LM Williams, HB Thomas, EK Dobscha, SK AF Bush, Nigel E. Smolenski, Derek J. Denneson, Lauren M. Williams, Holly B. Thomas, Elissa K. Dobscha, Steven K. TI A Virtual Hope Box: Randomized Controlled Trial of a Smartphone App for Emotional Regulation and Coping With Distress SO PSYCHIATRIC SERVICES LA English DT Article ID COGNITIVE THERAPY; SUICIDE ATTEMPTS; LIVING INVENTORY; KILLING YOURSELF; STAYING ALIVE; SCALE; INTERVENTION; MILITARY; VALIDITY; BEHAVIOR AB Objective: The purpose of this study was to assess the impact of the Virtual Hope Box (VHB), a smartphone app to improve stress coping skills, suicidal ideation, and perceived reasons for living among patients at elevated risk of suicide and self-harm. Methods: The authors conducted a parallel-group randomized controlled trial with two groups of U.S. service veterans in active mental health treatment who had recently expressed suicidal ideation. Between March 2014 and April 2015, 118 patients were enrolled in the study. Participants were assigned to use the VHB (N=58) or to a control group that received printed materials about coping with suicidality (N=60) to supplement treatment as usual over a 12-week period. Three measures-the Coping Self-Efficacy Scale, Beck Scale for Suicidal Ideation, and Brief Reasons for Living Inventory-were collected at baseline (before randomization) and three, six, and 12 weeks. Secondary measures-the Interpersonal Needs Questionnaire, Perceived Stress Scale, and Columbia-Suicide Severity Rating Scale-were collected at baseline and 12 weeks. Results: VHB users reported significantly greater ability to cope with unpleasant emotions and thoughts (Coping Self-Efficacy Scale) at three (b=2.41, 95% confidence interval [CI]=.29-4.55) and 12 weeks (b=2.99, 95% CI=.08-5.90) compared with the control group. No significant advantage was found on other outcome measures for treatment augmented by the VHB. Conclusions: The VHB is a demonstrably useful accessory to treatment-an easily accessible tool that can increase stress coping skills. Because the app is easily disseminated across a large population, it is likely to have broad, positive utility in behavioral health care. C1 [Bush, Nigel E.; Smolenski, Derek J.; Thomas, Elissa K.] US Dept Def, Natl Ctr Telehlth & Technol, Joint Base Lewis McChord, Tacoma, WA 98409 USA. [Denneson, Lauren M.; Williams, Holly B.] US Dept Vet Affairs, Ctr Improve Veteran Involvement Carc, Portland Hlth Care Syst, Portland, OR USA. [Dobscha, Steven K.] Oregon Hlth & Sci Univ, Mental Hlth Div, Portland, OR 97201 USA. [Dobscha, Steven K.] Oregon Hlth & Sci Univ, Dept Psychiat, Portland, OR 97201 USA. RP Bush, NE (reprint author), US Dept Def, Natl Ctr Telehlth & Technol, Joint Base Lewis McChord, Tacoma, WA 98409 USA. EM nigele.bush.civ@mail.mil FU Military Suicide Research Consortium [W81XWH-10-2-0178] FX This randomized controlled trial of the Virtual Hope Box was supported by grant W81XWH-10-2-0178 from the Military Suicide Research Consortium, with oversight by the Military Operational Medicine Research Program. NR 37 TC 0 Z9 0 U1 1 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD APR 1 PY 2017 VL 68 IS 4 BP 330 EP 336 DI 10.1176/appi.ps.201600283 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA ER5DV UT WOS:000398822600006 PM 27842473 ER PT J AU Lagomasino, IT Dwight-Johnson, M Green, JM Tang, LQ Zhang, LL Duan, NH Miranda, J AF Lagomasino, Isabel T. Dwight-Johnson, Megan Green, Jennifer M. Tang, Lingqi Zhang, Lily Duan, Naihua Miranda, Jeanne TI Effectiveness of Collaborative Care for Depression in Public-Sector Primary Care Clinics Serving Latinos SO PSYCHIATRIC SERVICES LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; LOW-INCOME LATINOS; TREATMENT PREFERENCES; QUALITY IMPROVEMENT; MAJOR DEPRESSION; UNITED-STATES; MANAGEMENT; DISPARITIES; VALIDATION; DISORDERS AB Objective: Quality improvement interventions for depression care have been shown to be effective for improving quality of care and depression outcomes in settings with primarily insured patients. The aim of this study was to determine the impact of a collaborative care intervention for depression that was tailored for low-income Latino patients seen in public-sector clinics. Methods: A total of 400 depressed patients from three public-sector primary care clinics were enrolled in a randomized controlled trial of a tailored collaborative care intervention versus enhanced usual care. Social workers without previous mental health experience served as depression care specialists for the intervention patients (N=196). Depending on patient preference, they delivered a cognitive-behavioral therapy (CBT) intervention or facilitated antidepressant medication given by primary care providers or both. In enhanced usual care, patients (N=204) received a pamphlet about depression, a letter for their primary care provider stating that they had a positive depression screen, and a list of local mental health resources. Intent-to-treat analyses examined clinical and process-of-care outcomes at 16 weeks. Results: Compared with patients in the enhanced usual care group, patients in the intervention group had significantly improved depression, quality of life, and satisfaction outcomes (p<.001 for all). Intervention patients also had significantly improved quality-of-care indicators, including the proportion of patients receiving either psychotherapy or antidepressant medication (77% versus 21%, p<.001). Conclusions: Collaborative care for depression can greatly improve care and outcomes in public-sector clinics. Social workers without prior mental health experience can effectively provide CBT and manage depression care. C1 [Lagomasino, Isabel T.; Green, Jennifer M.] Univ Southern Calif, Keck Sch Med, Dept Psychiat & Behav Sci, Los Angeles, CA 90033 USA. [Dwight-Johnson, Megan] US Dept Vet Affairs, Greater Los Angeles Healthcare Syst, Dept Psychiat, Los Angeles, CA USA. [Tang, Lingqi; Zhang, Lily; Miranda, Jeanne] Univ Calif Los Angeles, Dept Psychiat, Ctr Hlth Serv & Soc, Los Angeles, CA 90095 USA. [Duan, Naihua] Columbia Univ, Div Biostat, New York, NY USA. [Duan, Naihua] New York State Psychiat Inst & Hosp, New York, NY 10032 USA. RP Miranda, J (reprint author), Univ Calif Los Angeles, Dept Psychiat, Ctr Hlth Serv & Soc, Los Angeles, CA 90095 USA. EM jmmiranda@mednet.ucla.edu FU National Institute of Mental Health [5R01MH067949] FX This work was sponsored by grant 5R01MH067949 from the National Institute of Mental Health. The authors acknowledge Maribel Avila, Jeannette Hilgert, Gustavo Rodriguez, Ricardo Romero, Melissa Van Dyk, and Maribel Vega for their contributions to this project and Kenneth Wells, M.D, M.P.H, for his invaluable consultation and mentorship. NR 33 TC 0 Z9 0 U1 1 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD APR 1 PY 2017 VL 68 IS 4 BP 353 EP 359 DI 10.1176/appi.ps.201600187 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA ER5DV UT WOS:000398822600009 PM 27842470 ER PT J AU Lucksted, A Drapalski, AL Brown, CH Wilson, C Charlotte, M Mullane, A Fang, LJ AF Lucksted, Alicia Drapalski, Amy L. Brown, Clayton H. Wilson, Camille Charlotte, Melanie Mullane, Audrina Fang, Li Juan TI Outcomes of a Psychoeducational Intervention to Reduce Internalized Stigma Among Psychosocial Rehabilitation Clients SO PSYCHIATRIC SERVICES LA English DT Article ID RANDOMIZED CONTROLLED-TRIAL; SEVERE MENTAL-ILLNESS; SCHIZOPHRENIA SPECTRUM DISORDERS; MEASURING COGNITIVE INSIGHT; SELF-STIGMA; NEUROPSYCHOLOGICAL STATUS; NARRATIVE ENHANCEMENT; REPEATABLE BATTERY; PERCEIVED STIGMA; HEALTH PROBLEMS AB Objective: This community-based randomized controlled trial was carried out to test the Ending SelfStigma (ESS) psychoeducational intervention, which is designed to help adults with serious mental illnesses reduce internalization of mental illness stigma and its effects. Methods: A total of 268 adults from five different mental health programs in Maryland took part. After baseline interview, consenting participants were randomly assigned to the nine-week ESS intervention or a minimally enhanced treatment-as-usual control condition. Participants were assessed by using symptom, psychosocial functioning, and self-stigma measures at baseline, postintervention, and sixmonth follow-up. Demographic characteristics were assessed at baseline. Results: Compared with participants in the control condition, ESS group participants showed significant decreases on the stereotype agreement and self-concurrence subscales of the Self Stigma of Mental Illness Scale, significant improvement on the alienation and stigma resistance subscales of the Internalized Stigma Mental Illness measure, and a significant increase in recovery orientation from baseline to postintervention. None of these differences were sustained at six-month follow-up. Conclusions: Results indicate that ESS was useful in helping to reduce key aspects of internalized stigma among individuals with mental illnesses and that advances in the delivery, targeting, and content of the intervention in the field may be warranted to increase its potency. C1 [Lucksted, Alicia; Charlotte, Melanie; Fang, Li Juan] Univ Maryland, Sch Med, Dept Psychiat, Div Psychiat Serv Res, Baltimore, MD 21201 USA. [Brown, Clayton H.] Univ Maryland, Sch Med, Dept Epidemiol & Publ Hlth, Baltimore, MD 21201 USA. [Drapalski, Amy L.] US Dept Vet Affairs, Maryland Hlth Care Syst, Mental Illness Res Educ & Clin Ctr, Baltimore, MD USA. [Wilson, Camille] Univ Maryland Baltimore Cty, Dept Psychol, Baltimore, MD 21228 USA. [Mullane, Audrina] Cleveland Clin, Dept Psychiat & Psychol, Cleveland, OH 44106 USA. RP Lucksted, A (reprint author), Univ Maryland, Sch Med, Dept Psychiat, Div Psychiat Serv Res, Baltimore, MD 21201 USA. EM aluckste@psych.umaryland.edu FU National Institutes of Health [1R01MH090036-01A1] FX This project was supported by National Institutes of Health grant 1R01MH090036-01A1. NR 73 TC 0 Z9 0 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD APR 1 PY 2017 VL 68 IS 4 BP 360 EP 367 DI 10.1176/appi.ps.201600037 PG 8 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA ER5DV UT WOS:000398822600010 PM 27903136 ER PT J AU Tsai, J Flatley, B Kasprow, WJ Clark, S Finlay, A AF Tsai, Jack Flatley, Bessie Kasprow, Wesley J. Clark, Sean Finlay, Andrea TI Diversion of Veterans With Criminal Justice Involvement to Treatment Courts: Participant Characteristics and Outcomes SO PSYCHIATRIC SERVICES LA English DT Article ID PEER-SUPPORT; ERA VETERANS; AFGHANISTAN; IRAQ; INCARCERATION AB Objective: This study compared characteristics and outcomes between veterans who participated in veterans treatment courts (VTCs) and veterans involved in criminal justice who participated in other treatment courts (TCs) or who participated in neither VTCs or TCs. Methods: Data from 22,708 veterans (N=8,083 VTC participants, 680 participants in other TCs [other-TC participants], and 13,945 participants in neither VTCs nor TCs [non-TC participants]) in the Veterans Justice Outreach (VJO) program were analyzed by using multilevel regression models. Results: VTC participants were more likely than other VJO participants to have served in Iraq or Afghanistan, but there were no sociodemographic disparities in access to VTCs. VTC participants were more likely than non-TC participants to have drug or public-order offenses, and they were more likely than other-TC participants to have DUI offenses. VTC participants had better independent housing outcomes than other VJO participants, and they had better employment outcomes than non-TC participants. However, VTC and other-TC participants were also more likely to have jail sanctions and new incarcerations compared with non-TC participants. Conclusions: VTCs are a growing service model that serves a broad group of veterans with a range of criminal offenses. Although VTCs show moderate benefits in housing and employment, specialized services are needed to reduce recidivism and maximize these benefits. C1 [Tsai, Jack] US Dept Vet Affairs, Connecticut Healthcare Syst, New England Mental Illness Res Educ & Clin Ctr, West Haven, CT USA. [Kasprow, Wesley J.] US Dept Vet Affairs, Connecticut Healthcare Syst, Northeast Program Evaluat Ctr, W Haven, NH USA. [Tsai, Jack] Yale Sch Med, Dept Psychiat, New Haven, CT 06510 USA. [Flatley, Bessie] US Dept Vet Affairs, Vet Justice Programs, Philadelphia, PA USA. [Flatley, Bessie] US Dept Vet Affairs, Natl Ctr Homelessness Vet, Philadelphia, PA USA. [Clark, Sean] Vet Hlth Adm, Vet Justice Program Off, Lexington, KY USA. [Finlay, Andrea] VA Palo Alto Hlth Care Syst, Ctr Innovat Implementat, Palo Alto, CA USA. [Finlay, Andrea] Stanford Univ, Sch Med, Dept Med, Stanford, CA 94305 USA. [Finlay, Andrea] Stanford Univ, Sch Med, Div Gen Med Disciplines, Stanford, CA 94305 USA. RP Tsai, J (reprint author), US Dept Vet Affairs, Connecticut Healthcare Syst, New England Mental Illness Res Educ & Clin Ctr, West Haven, CT USA.; Tsai, J (reprint author), Yale Sch Med, Dept Psychiat, New Haven, CT 06510 USA. EM jack.tsai@yale.edu NR 28 TC 0 Z9 0 U1 1 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD APR 1 PY 2017 VL 68 IS 4 BP 375 EP 383 DI 10.1176/appi.ps.201600233 PG 9 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA ER5DV UT WOS:000398822600012 PM 27903139 ER PT J AU Meshberg-Cohen, S DeViva, JC Rosen, MI AF Meshberg-Cohen, Sarah DeViva, Jason C. Rosen, Marc I. TI Counseling Veterans Applying for Service Connection Status for Mental Health Conditions SO PSYCHIATRIC SERVICES LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; DISABILITY; STIGMA; PTSD; CARE; COMPENSATION; ATTITUDES; CLINICIAN AB Veterans with mental health conditions that were either caused or aggravated by their military service are eligible to receive service-connected disability benefits from the Department of Veterans Affairs. The process of applying for service connection status is complex, and it is not surprising that veterans frequently develop beliefs about service connection that may not be accurate and that could interfere with treatment. The authors describe some of these beliefs and offer suggestions to clinicians for addressing them. Veterans may believe that their clinician is directly involved in service connection determination or that therapy notes will determine the outcome of the claim. Veterans may not understand the basis for award of service connection and may interpret rejection of their claim as reflecting disrespect for their service or degree of distress. The authors argue that discussing these beliefs with veterans might enhance therapy by demonstrating familiarity with an important aspect of veterans' experience and by helping veterans address a significant and distressing issue. C1 [Meshberg-Cohen, Sarah; DeViva, Jason C.; Rosen, Marc I.] Yale Sch Med, Dept Psychiat, New Haven, CT 06510 USA. [Meshberg-Cohen, Sarah; DeViva, Jason C.; Rosen, Marc I.] US Dept Vet Affairs, Connecticut Healthcare Syst, Dept Psychiat, West Haven, CT USA. RP Meshberg-Cohen, S (reprint author), Yale Sch Med, Dept Psychiat, New Haven, CT 06510 USA.; Meshberg-Cohen, S (reprint author), US Dept Vet Affairs, Connecticut Healthcare Syst, Dept Psychiat, West Haven, CT USA. EM sarah.meshberg-cohen@yale.edu NR 15 TC 0 Z9 0 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD APR 1 PY 2017 VL 68 IS 4 BP 396 EP 399 DI 10.1176/appi.ps.201500533 PG 4 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA ER5DV UT WOS:000398822600015 PM 27629795 ER PT J AU Quinn, AE Rubinsky, AD Fernandez, AC Hahm, HC Samet, JH AF Quinn, Amity E. Rubinsky, Anna D. Fernandez, Anne C. Hahm, Hyeouk Chris Samet, Jeffrey H. TI A Research Agenda to Advance the Coordination of Care for General Medical and Substance Use Disorders SO PSYCHIATRIC SERVICES LA English DT Article ID ADDICTION TREATMENT; RANDOMIZED-TRIAL; UNITED-STATES; ALCOHOL; BURDEN; MANAGEMENT; DISEASE; HEALTH AB The separation of addiction care from the general medical care system has a negative impact on patients' receipt of high-quality medical care. Clinical and policy-level strategies to improve the coordination of addiction care and general medical care include identifying and engaging patients with unhealthy substance use in general medical settings, providing effective chronic disease management of substance use disorders in primary care, including patient and family perspectives in care coordination, and implementing pragmatic models to pay for the coordination of addiction and general medical care. This Open Forum discusses practice and research recommendations to advance the coordination of general medical and addiction care. The discussion is based on the proceedings of a national meeting of experts in 2014. C1 [Quinn, Amity E.] Brandeis Univ, Heller Sch Social Policy & Management, Inst Behav Hlth, Waltham, MA 02453 USA. [Rubinsky, Anna D.] Vet Affairs Puget Sound Hlth Care Syst, Hlth Serv Res & Dev Ctr Innovat, Seattle, WA USA. [Rubinsky, Anna D.] Univ Calif San Francisco, Kidney Hlth Res Collaborat, San Francisco, CA 94143 USA. [Rubinsky, Anna D.] VA Med Ctr, San Francisco, CA USA. [Fernandez, Anne C.] Brown Univ, Ctr Alcohol & Addict Studies, Providence, RI 02912 USA. [Hahm, Hyeouk Chris] Boston Univ, Sch Social Work, Boston, MA 02215 USA. [Samet, Jeffrey H.] Boston Univ, Sch Med, Boston, MA 02215 USA. [Samet, Jeffrey H.] Boston Univ, Sch Publ Hlth, Boston, MA 02215 USA. [Samet, Jeffrey H.] Boston Med Ctr, Boston, MA USA. RP Quinn, AE (reprint author), Brandeis Univ, Heller Sch Social Policy & Management, Inst Behav Hlth, Waltham, MA 02453 USA. EM amity@brandeis.edu FU [F31 AA023711]; [T32 AA007459]; [R25-DA13582]; [P30DA040500] FX The contributions of Dr. Quinn and Dr. Fernandez were funded in part by grants F31 AA023711 and T32 AA007459, respectively. The contribution of Dr. Samet was funded in part by grants R25-DA13582 and P30DA040500. The results presented are from a preconference session, which was part of the Addiction Health Services Research conference, held in Boston, October 15-17, 2014. The preconference and report were supported by the Blending Initiative of the National Institute on Drug Abuse under the leadership of the Center for the National Drug Abuse Treatment Clinical Trials Network. The authors thank preconference presenters Katharine Bradley, M.D., M.P.H., Constance Horgan, Sc.D., Richard Saitz, M.D., M.P.H., and Constance Weisner, Dr.P.H., M.S.W., and commentators JudyAnn Bigby, M.D., and Mary Jane England, M.D. The views expressed arc those of the authors and do not necessarily represent the position or policy of the Department of Veterans Affairs, the United States Government, or the authors' institutions. NR 17 TC 0 Z9 0 U1 1 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD APR 1 PY 2017 VL 68 IS 4 BP 400 EP 404 DI 10.1176/appi.ps.201600070 PG 5 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA ER5DV UT WOS:000398822600017 PM 27629798 ER PT J AU Herbst, E Zaman, T Rife, T AF Herbst, Ellen Zaman, Tauheed Rife, Tessa TI Prescriptions Filled Following an Opioid-Related Hospitalization SO PSYCHIATRIC SERVICES LA English DT Letter C1 [Herbst, Ellen; Zaman, Tauheed; Rife, Tessa] San Francisco VA Med Ctr, Addict Recovery Treatment Serv, San Francisco, CA 94121 USA. [Herbst, Ellen; Zaman, Tauheed] Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA 94143 USA. [Rife, Tessa] Univ Calif San Francisco, Sch Pharm, San Francisco, CA 94143 USA. RP Herbst, E (reprint author), San Francisco VA Med Ctr, Addict Recovery Treatment Serv, San Francisco, CA 94121 USA.; Herbst, E (reprint author), Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA 94143 USA. EM ellen.herbst@va.gov NR 3 TC 0 Z9 0 U1 0 U2 0 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD APR 1 PY 2017 VL 68 IS 4 BP 422 EP 423 DI 10.1176/appi.ps.68304 PG 2 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA ER5DV UT WOS:000398822600028 PM 28366126 ER PT J AU Krejsgaard, T Lindahl, LM Mongan, NP Wasik, MA Litvinov, IV Iversen, L Langhoff, E Woetmann, A Odum, N AF Krejsgaard, Thorbjorn Lindahl, Lise M. Mongan, Nigel P. Wasik, Mariusz A. Litvinov, Ivan V. Iversen, Lars Langhoff, Erik Woetmann, Anders Odum, Niels TI Malignant inflammation in cutaneous TaEurocell lymphoma-a hostile takeover SO SEMINARS IN IMMUNOPATHOLOGY LA English DT Review DE Cutaneous T-cell lymphoma; Malignant T cells; Inflammation; Pathogenesis; Cancer; Infection; Mycosis fungoides; Sezary syndrome ID T-CELL LYMPHOMA; ENDOTHELIAL GROWTH-FACTOR; STAPHYLOCOCCUS-AUREUS COLONIZATION; LIGAND-MEDIATED APOPTOSIS; MESSENGER-RNA EXPRESSION; EARLY MYCOSIS-FUNGOIDES; NF-KAPPA-B; SEZARY-SYNDROME; INTERFERON-GAMMA; TUMOR MICROENVIRONMENT AB Cutaneous T-cell lymphomas (CTCL) are characterized by the presence of chronically inflamed skin lesions containing malignant T cells. Early disease presents as limited skin patches or plaques and exhibits an indolent behavior. For many patients, the disease never progresses beyond this stage, but in approximately one third of patients, the disease becomes progressive, and the skin lesions start to expand and evolve. Eventually, overt tumors develop and the malignant T cells may disseminate to the blood, lymph nodes, bone marrow, and visceral organs, often with a fatal outcome. The transition from early indolent to progressive and advanced disease is accompanied by a significant shift in the nature of the tumor-associated inflammation. This shift does not appear to be an epiphenomenon but rather a critical step in disease progression. Emerging evidence supports that the malignant T cells take control of the inflammatory environment, suppressing cellular immunity and anti-tumor responses while promoting a chronic inflammatory milieu that fuels their own expansion. Here, we review the inflammatory changes associated with disease progression in CTCL and point to their wider relevance in other cancer contexts. We further define the term "malignant inflammation" as a pro-tumorigenic inflammatory environment orchestrated by the tumor cells and discuss some of the mechanisms driving the development of malignant inflammation in CTCL. C1 [Krejsgaard, Thorbjorn; Woetmann, Anders; Odum, Niels] Univ Copenhagen, Dept Immunol & Microbiol, Blegdamsvej 3c, DK-2200 Copenhagen N, Denmark. [Lindahl, Lise M.; Iversen, Lars] Aarhus Univ Hosp, Dept Dermatol, Aarhus, Denmark. [Mongan, Nigel P.] Univ Nottingham, Sch Vet Med & Sci, Loughborough, Leics, England. [Wasik, Mariusz A.] Univ Penn, Dept Pathol & Lab Med, Philadelphia, PA USA. [Litvinov, Ivan V.] Univ Ottawa, Div Dermatol, Ottawa, ON, Canada. [Langhoff, Erik] James J Peters VA Med Ctr, Vet Affairs, Bronx, NY USA. RP Krejsgaard, T; Odum, N (reprint author), Univ Copenhagen, Dept Immunol & Microbiol, Blegdamsvej 3c, DK-2200 Copenhagen N, Denmark. EM thorkr@sund.ku.dk; ndum@sund.ku.dk FU Danish Research Council; Novo Nordic Foundation; Novo Nordic Foundation Tandem program; Lundbeck Foundation; Danish Cancer Society (Kraeftens Bekaempelse); Danish Cancer Society; TV2 "Knaek-Cancer-Program"; Sapera Aude Talent Grant from Danish Council for Independent Research [DFF-4092-00122] FX This work was supported by research funding from the Danish Research Council, the Novo Nordic Foundation, the Novo Nordic Foundation Tandem program, the Lundbeck Foundation, the Danish Cancer Society (Kraeftens Bekaempelse), and the Danish Cancer Society and TV2 "Knaek-Cancer-Program". TK was further supported by a Sapera Aude Talent Grant (DFF-4092-00122) from the Danish Council for Independent Research. NR 165 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1863-2297 EI 1863-2300 J9 SEMIN IMMUNOPATHOL JI Semin. Immunopathol. PD APR PY 2017 VL 39 IS 3 BP 269 EP 282 DI 10.1007/s00281-016-0594-9 PG 14 WC Immunology; Pathology SC Immunology; Pathology GA ER6PR UT WOS:000398928500004 PM 27717961 ER PT J AU Jia, H Pan, YL Guo, XG Zhao, LN Wang, XP Zhang, LH Dong, T Luo, H Ge, ZZ Liu, J Hao, JY Yao, P Zhang, Y Ren, HY Zhou, WZ Guo, YJ Zhang, W Chen, XL Sun, DY Yang, XQ Kang, XY Liu, N Liu, ZG Leung, F Wu, KC Fan, DM AF Jia, Hui Pan, Yanglin Guo, Xuegang Zhao, Lina Wang, Xiangping Zhang, Linhui Dong, Tao Luo, Hui Ge, Zhizheng Liu, Jun Hao, Jianyu Yao, Ping Zhang, Yao Ren, Hongyu Zhou, Weizhen Guo, Yujie Zhang, Wei Chen, Xiaolin Sun, Dayong Yang, Xiaoqiang Kang, Xiaoyu Liu, Na Liu, Zhiguo Leung, Felix Wu, Kaichun Fan, Daiming TI Water Exchange Method Significantly Improves Adenoma Detection Rate: A Multicenter, Randomized Controlled Trial SO AMERICAN JOURNAL OF GASTROENTEROLOGY LA English DT Article ID LONGER WITHDRAWAL TIME; SCREENING COLONOSCOPY; QUALITY INDICATORS; COLORECTAL-CANCER; AIDED COLONOSCOPY; AIR INSUFFLATION; CECAL INTUBATION; INTERVAL CANCER; IMMERSION; RISK AB OBJECTIVES: Adenoma detection rate (ADR) is a key colonoscopy quality indicator in Western clinical literature. Our low ADR prompted us to assess novel methods to improve performance. Western retrospective reports suggested that water exchange (WE) could increase ADR. However, most of these studies used pain score or intubation rate as the primary outcome. Here we test the hypothesis that WE significantly increases ADR among Chinese colonoscopists and design a prospective randomized controlled trial using ADR as our primary outcome. METHODS: This prospective, randomized controlled trial was performed at six centers in China. Screening, surveillance, and diagnostic cases were randomized to be examined by WE or traditional air insufflation (AI) method. The primary outcome was ADR. RESULTS: From April 2014 to July 2015, 3,303 patients were randomized to WE (n = 1,653) and AI (n = 1,650). The baseline characteristics were comparable. Overall ADR was 18.3% (WE) and 13.4% (AI) (relative risk 1.45, 95% confidential interval: 1.20-1.75, P < 0.001). ADR in screening patients using AI was 25.8% (male) and 15.7% (female). ADR in screening patients aged > 50 years old was 29.4% (WE) and 22.9% (AI) (relative risk 1.09, 95% confidential interval: 1.00-1.19, P = 0.040). The increase by WE was reproducibly observed in all indication categories, and significant in screening and diagnostic cases. The limitation imposed by the unblinded investigators was mitigated by comparable inspection times in cases without polyps, similar adenoma per positive colonoscopy, and reproducible enhancement of ADR and adenoma per colonoscopy by WE across all eight investigators. CONCLUSIONS: This prospective study confirms Western retrospective data that WE significantly improves ADR among Chinese colonoscopists. WE may be superior to AI for screening colonoscopy in China. Colonoscopists elsewhere with low ADR might consider evaluating WE for performance improvement. C1 [Jia, Hui; Pan, Yanglin; Guo, Xuegang; Wang, Xiangping; Zhang, Linhui; Dong, Tao; Luo, Hui; Kang, Xiaoyu; Liu, Na; Liu, Zhiguo; Wu, Kaichun; Fan, Daiming] Fourth Mil Med Univ, Xijing Hosp Digest Dis, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China. [Jia, Hui] Weinan Cent Hosp, Dept Gastroenterol, Weinan, Peoples R China. [Zhao, Lina] Fourth Mil Med Univ, Xijing Hosp, Dept Radiotherapy, Xian, Peoples R China. [Ge, Zhizheng; Zhang, Yao; Zhang, Wei] Shanghai Jiao Tong Univ, Div Gastroenterol, Shanghai Renji Hosp, Sch Med, Shanghai, Peoples R China. [Liu, Jun; Ren, Hongyu; Chen, Xiaolin] Huazhong Sci Technol Univ, Tongji Med Union Hosp, Dept Gastroenterol, Wuhan, Peoples R China. [Hao, Jianyu; Zhou, Weizhen] Capital Med Univ, Beijing Chao Yang Hosp, Dept Gastroenterol, Beijing, Peoples R China. [Guo, Yujie] Xinjiang Med Univ, Dept Gastroenterol, Affiliated Hosp 1, Urumqi, Peoples R China. [Sun, Dayong; Yang, Xiaoqiang] Guangzhou Gen Hosp Guangzhou Mil Command Peoples, Dept Gastroenterol, Guangzhou, Guangdong, Peoples R China. [Leung, Felix] Vet Affairs Greater Los Angeles Healthcare Syst, Div Gastroenterol, Dept Med, Sepulveda Ambulatory Care Ctr, North Hills, CA USA. [Leung, Felix] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP Pan, YL; Wu, KC (reprint author), Fourth Mil Med Univ, Xijing Hosp Digest Dis, 127 Changle West Rd, Xian 710032, Shaanxi, Peoples R China.; Leung, F (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Sepulveda Ambulatory Care Ctr, 111G,16111 Plummer St, North Hills, CA 91343 USA. EM yanglinpan@hotmail.com; felix.leung@va.gov; kaicwu@fmmu.edu.cn FU National Natural Science Foundation of China [81172288, 81370585]; National Key Technology RD Program [2015BAI13B07] FX National Natural Science Foundation of China (81172288 and 81370585) and National Key Technology R&D Program (2015BAI13B07). NR 38 TC 1 Z9 1 U1 1 U2 1 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 0002-9270 EI 1572-0241 J9 AM J GASTROENTEROL JI Am. J. Gastroenterol. PD APR PY 2017 VL 112 IS 4 BP 568 EP 576 DI 10.1038/ajg.2016.501 PG 9 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA ES2MG UT WOS:000399362000013 PM 27922025 ER PT J AU Cui, CW Basen, T Philipp, AT Yusin, J Krishnaswamy, G AF Cui, Chongwei Basen, Tyler Philipp, Ami Thakor Yusin, Joseph Krishnaswamy, Guha TI Celiac disease and nonceliac gluten sensitivity SO ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY LA English DT Article C1 [Cui, Chongwei; Basen, Tyler; Philipp, Ami Thakor; Yusin, Joseph] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Allergy & Immunol, Los Angeles, CA USA. [Krishnaswamy, Guha] Wake Forest Sch Med, Med Ctr Blvd,Watlington Tower,Second Floor, Winston Salem, NC 27157 USA. [Krishnaswamy, Guha] Wake Baptist Hosp, Med Ctr Blvd,Watlington Tower,Second Floor, Winston Salem, NC 27157 USA. [Krishnaswamy, Guha] WG Bill Hefner Vet Affairs Med Ctr & Affiliated C, Salisbury, NC USA. RP Krishnaswamy, G (reprint author), Wake Forest Sch Med, Med Ctr Blvd,Watlington Tower,Second Floor, Winston Salem, NC 27157 USA.; Krishnaswamy, G (reprint author), Wake Baptist Hosp, Med Ctr Blvd,Watlington Tower,Second Floor, Winston Salem, NC 27157 USA. EM gkrishna@wakehealth.edu NR 16 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1081-1206 EI 1534-4436 J9 ANN ALLERG ASTHMA IM JI Ann. Allergy Asthma Immunol. PD APR PY 2017 VL 118 IS 4 BP 389 EP 393 DI 10.1016/j.anai.2017.01.008 PG 5 WC Allergy; Immunology SC Allergy; Immunology GA ER6SE UT WOS:000398936900002 PM 28390579 ER PT J AU Weinstock, MA Lott, JP Wang, Q Titus, LJ Onega, T Nelson, HD Pearson, L Piepkorn, M Barnhill, RL Elmore, JG Tosteson, ANA AF Weinstock, M. A. Lott, J. P. Wang, Q. Titus, L. J. Onega, T. Nelson, H. D. Pearson, L. Piepkorn, M. Barnhill, R. L. Elmore, J. G. Tosteson, A. N. A. TI Skin biopsy utilization and melanoma incidence among Medicare beneficiaries SO BRITISH JOURNAL OF DERMATOLOGY LA English DT Article ID UNITED-STATES; CANCER; OVERDIAGNOSIS; POPULATION AB Background Melanoma incidence has increased in recent decades in the U.S.A. Uncertainty remains regarding how much of this increase is attributable to greater melanoma screening activities, potential detection bias and overdiagnosis. Objectives To use a cross-sectional ecological analysis to evaluate the relationship between skin biopsy and melanoma incidence rates over a more recent time period than prior reports. Methods Examination of the association of biopsy rates and melanoma incidence (invasive and in situ) in SEER-Medicare data (including 10 states) for 2002-2009. Results The skin biopsy rate increased by approximately 50% (6% per year) throughout this 8-year period, from 7012 biopsies per 100 000 persons in 2002 to 10 528 biopsies per 100 000 persons in 2009. The overall melanoma incidence rate increased approximately 4% (< 1% per year) over the same time period. The incidence of melanoma in situ increased approximately 10% (1% per year), while the incidence of invasive melanoma increased from 2002 to 2005 then decreased from 2006 to 2009. Regression models estimated that, on average, for every 1000 skin biopsies performed, an additional 5.2 (95% confidence interval 4.1-6.3) cases of melanoma in situ were diagnosed and 8.1 (95% confidence interval 6.7-9.5) cases of invasive melanoma were diagnosed. When considering individual states, some demonstrated a positive association between biopsy rate and invasive melanoma incidence, others an inverse association, and still others a more complex pattern. Conclusions Increased skin biopsies over time are associated with increased diagnosis of in situ melanoma, but the association with invasive melanoma is more complex. C1 [Weinstock, M. A.] US Dept Vet Affairs, Ctr Dermatoepidemiol, Med Ctr, Providence, RI USA. [Weinstock, M. A.] Rhode Isl Hosp, Dept Dermatol, Providence, RI USA. [Weinstock, M. A.] Brown Univ, Dept Dermatol, Providence, RI 02912 USA. [Weinstock, M. A.] Brown Univ, Dept Epidemiol, Providence, RI 02912 USA. [Lott, J. P.] Cornell Scott Hill Hlth Ctr, New Haven, CT USA. [Wang, Q.; Pearson, L.; Tosteson, A. N. A.] Geisel Sch Med Dartmouth, Dartmouth Inst Hlth Policy & Clin Practice, Lebanon, NH USA. [Titus, L. J.; Onega, T.] Geisel Sch Med Dartmouth, Dept Epidemiol, Lebanon, NH USA. [Onega, T.] Geisel Sch Med Dartmouth, Dept Biomed Data Sci, Lebanon, NH USA. [Tosteson, A. N. A.] Geisel Sch Med Dartmouth, Dept Med, Lebanon, NH USA. [Titus, L. J.; Onega, T.; Tosteson, A. N. A.] Norris Cotton Canc Ctr, Lebanon, NH USA. [Nelson, H. D.] Oregon Hlth & Sci Univ, Dept Med Informat, Portland, OR 97201 USA. [Nelson, H. D.] Oregon Hlth & Sci Univ, Dept Clin Epidemiol, Portland, OR 97201 USA. [Nelson, H. D.] Oregon Hlth & Sci Univ, Dept Med, Portland, OR 97201 USA. [Nelson, H. D.] Providence Hlth & Serv, Providence Canc Ctr, Providence, OR USA. [Piepkorn, M.] Univ Washington, Sch Med, Dept Med, Div Dermatol, Seattle, WA 98195 USA. [Elmore, J. G.] Univ Washington, Sch Med, Dept Internal Med, Seattle, WA 98105 USA. [Piepkorn, M.] Dermatopathol Northwest, Bellevue, WA USA. [Barnhill, R. L.] Univ Paris 05, Dept Pathol, Inst Curie, Paris, France. [Barnhill, R. L.] Univ Paris 05, Fac Med, Paris, France. RP Elmore, JG (reprint author), Univ Washington, Sch Med, Dept Internal Med, Seattle, WA 98105 USA. EM jelmore@u.washington.edu FU National Cancer Institute [R01 CA151306, K05 CA104699] FX This work was supported by the National Cancer Institute (R01 CA151306 and K05 CA104699). The funder was not involved in the design and conduct of the study; the collection, management, analysis and interpretation of data; the preparation, review and approval of the manuscript; or the decision to submit the manuscript for publication. NR 13 TC 1 Z9 1 U1 1 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0007-0963 EI 1365-2133 J9 BRIT J DERMATOL JI Br. J. Dermatol. PD APR PY 2017 VL 176 IS 4 BP 949 EP 954 DI 10.1111/bjd.15077 PG 6 WC Dermatology SC Dermatology GA ES2MR UT WOS:000399363100039 PM 27639256 ER PT J AU Dasgupta, SK Le, A Vijayan, KV Thiagarajan, P AF Dasgupta, Swapan K. Le, Anhquyen Vijayan, K. Vinod Thiagarajan, Perumal TI Dasatinib inhibits actin fiber reorganization and promotes endothelial cell permeability through RhoA-ROCK pathway SO CANCER MEDICINE LA English DT Article DE Actin fibers; dasatinib; endothelial permeability; tyrosine phosphorylation ID FOCAL ADHESION FORMATION; CHRONIC MYELOID-LEUKEMIA; TYROSINE PHOSPHORYLATION; VASCULAR-PERMEABILITY; KINASE; PAXILLIN; HYPERPERMEABILITY; SRC; ACTIVATION; MECHANISM AB Treatment with dasatinib, a tyrosine kinase inhibitor, is associated with edema, pleural effusion, and pulmonary edema. We investigated the effect of dasatinib on the barrier function of human microvascular endothelial cells-1 (HMEC-1) in vitro and in vivo. The permeability of HMEC-1 to fluorescein isothiocyante (FITC)-dextran increased in Transwell chambers within 5min following the addition of therapeutic concentrations of dasatinib. The change in permeability was associated with increased activation of RhoA GTPase and its effector Rho-associated coiled-coil kinase 1(ROCK1). RhoA inhibitor C3 transferase almost completely inhibited dasatinib-induced increase in permeability. Under similar conditions, imatinib had no effect on permeability or activation of RhoA. Since integrin-induced cell spreading suppresses RhoA activation, we examined the effect of dasatinib on cell spreading on fibronectin substrate. Dasatinib impaired endothelial cell spreading in a concentration-dependent manner and induced disorganization of actin fibers. Tyrosine kinases play an essential role in transmitting signals from integrins to RhoA and we examined tyrosine phosphorylation of several cytoskeletal proteins. Dasatinib markedly inhibited tyrosine phosphorylation of p130 Crk-associated substrate (p130cas), paxillin and vinculin. These results suggest that the inhibition of tyrosine phosphorylation of the focal adhesion plaque components by dasatinib may alter the assembly of actin fibers resulting in the activation of RhoA/ROCK pathway. Consistent with these findings, dasatinib-induced increase in the permeability was blocked by ROCK inhibitor y27632. In vivo administration of y27632, significantly inhibited the dasatinib-induced extravasation of Evans blue in mice and dasatinib-induced increase in microvascular permeability was attenuated in ROCK1-deficient mice. These findings suggest that ROCK inhibitors could serve as therapeutic modalities to ameliorate the dasatinib-induced pulmonary changes. C1 [Dasgupta, Swapan K.; Le, Anhquyen; Thiagarajan, Perumal] Baylor Coll Med, Dept Pathol, Michael E DeBakey Vet Affairs Med Ctr, CTRID, Houston, TX 77030 USA. [Vijayan, K. Vinod; Thiagarajan, Perumal] Baylor Coll Med, Dept Med, Michael E DeBakey Vet Affairs Med Ctr, CTRID, Houston, TX 77030 USA. RP Dasgupta, SK; Thiagarajan, P (reprint author), Michael E DeBakey VA Med Ctr, Mail Stop 113, Houston, TX 77030 USA. EM swapand@bcm.edu; perumalt@bcm.edu FU Department of Veterans Affairs, Veterans Health Administration; Office of Research and Development, Biomedical Laboratory Research and Development; American Heart Association; Gulf Coast Blood Center; National Institutes of Health [HL08163, GM112806] FX This study was supported in part by grants from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Biomedical Laboratory Research and Development, American Heart Association, a grant from Gulf Coast Blood Center, and National Institutes of Health HL08163 and GM112806. NR 39 TC 0 Z9 0 U1 1 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2045-7634 J9 CANCER MED-US JI Cancer Med. PD APR PY 2017 VL 6 IS 4 BP 809 EP 818 DI 10.1002/cam4.1019 PG 10 WC Oncology SC Oncology GA ER5ND UT WOS:000398847700010 PM 28316141 ER PT J AU El-Sherief, AH Lau, CT Obuchowski, NA Mehta, AC Rice, TW Blackstone, EH AF El-Sherief, Ahmed H. Lau, Charles T. Obuchowski, Nancy A. Mehta, Atul C. Rice, Thomas W. Blackstone, Eugene H. TI Cross-Disciplinary Analysis of Lymph Node Classification in Lung Cancer on CT Scanning SO CHEST LA English DT Article DE lung cancer; lymph nodes; staging ID INTERNATIONAL ASSOCIATION AB BACKGROUND: Accurate and consistent regional lymph node classification is an important element in the staging and multidisciplinary management of lung cancer. Regional lymph node definition sets-lymph node maps-have been created to standardize regional lymph node classification. In 2009, the International Association for the Study of Lung Cancer (IASLC) introduced a lymph node map to supersede all preexisting lymph node maps. Our aim was to study if and how lung cancer specialists apply the IASLC lymph node map when classifying thoracic lymph nodes encountered on CT scans during lung cancer staging. METHODS: From April 2013 through July 2013, invitations were distributed to all members of the Fleischner Society, Society of Thoracic Radiology, General Thoracic Surgical Club, and the American Association of Bronchology and Interventional Pulmonology to participate in an anonymous online image-based and text-based 20-question survey regarding lymph node classification for lung cancer staging on CT imaging. RESULTS: Three hundred thirty-seven people responded (approximately 25% participation). Respondents consisted of self-reported thoracic radiologists (n = 158), thoracic surgeons (n = 102), and pulmonologists who perform endobronchial ultrasonography (n = 77). Half of the respondents (50%; 95% CI, 44%-55%) reported using the IASLC lymph node map in daily practice, with no significant differences between subspecialties. A disparity was observed between the IASLC definition sets and their interpretation and application on CT scans, in particular for lymph nodes near the thoracic inlet, anterior to the trachea, anterior to the tracheal bifurcation, near the ligamentum arteriosum, between the bronchus intermedius and esophagus, in the internal mammary space, and adjacent to the heart. CONCLUSIONS: Use of older lymph node maps and inconsistencies in interpretation and application of definitions in the IASLC lymph node map may potentially lead to misclassification of stage and suboptimal management of lung cancer in some patients. C1 [El-Sherief, Ahmed H.; Lau, Charles T.] Cleveland Clin, Sect Thorac Imaging, Heart & Vasc Inst, Cleveland, OH 44106 USA. [Obuchowski, Nancy A.; Blackstone, Eugene H.] Cleveland Clin, Imaging Inst, Dept Qualitat Hlth Sci, Heart & Vasc Inst, Cleveland, OH 44106 USA. [Mehta, Atul C.] Cleveland Clin, Sect Pulm Med, Heart & Vasc Inst, Cleveland, OH 44106 USA. [Rice, Thomas W.; Blackstone, Eugene H.] Cleveland Clin, Resp Inst, Heart & Vasc Inst, Cleveland, OH 44106 USA. [Rice, Thomas W.; Blackstone, Eugene H.] Cleveland Clin, Sect Thorac & Cardiovasc Surg, Heart & Vasc Inst, Cleveland, OH 44106 USA. [El-Sherief, Ahmed H.] Vet Affairs Greater Angeles Healthcare Syst, Dept Diagnost Radiol, Sect Thorac Imaging, Los Angeles, CA USA. [El-Sherief, Ahmed H.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. RP El-Sherief, AH (reprint author), Greater Los Angeles Vet Adm Healthcare Syst, Sect Thorac Imaging, Dept Diagnost Radiol, 11301 Wilshire Blvd,Bldg 500, Los Angeles, CA 90073 USA. EM ahelsherief@gmail.com NR 10 TC 1 Z9 1 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD APR PY 2017 VL 151 IS 4 BP 776 EP 785 DI 10.1016/j.chest.2016.09.016 PG 10 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA ER3WV UT WOS:000398731500019 PM 27713056 ER PT J AU Meyer, S Teerlink, JR Metra, M Ponikowski, P Cotter, G Davison, BA Felker, GM Filippatos, G Greenberg, BH Hua, TA Severin, T Qian, M Voors, AA AF Meyer, Sven Teerlink, John R. Metra, Marco Ponikowski, Piotr Cotter, Gad Davison, Beth A. Felker, G. Michael Filippatos, Gerasimos Greenberg, Barry H. Hua, Tsushung A. Severin, Thomas Qian, Min Voors, Adriaan A. TI Sex differences in early dyspnea relief between men and women hospitalized for acute heart failure: insights from the RELAX-AHF study SO CLINICAL RESEARCH IN CARDIOLOGY LA English DT Article DE Serelaxin; Acute heart failure; Sex; Gender; Dyspnea ID RENAL IMPAIRMENT; OUTCOMES; SERELAXIN; ASSOCIATION; PROTECT; GENDER; DETERMINANTS; REGISTRY AB Women with heart failure are typically older, and more often have hypertension and a preserved left ventricular ejection fraction as compared with men. We sought to analyze if these sex differences influence the course and outcome of acute heart failure. We analyzed sex differences in acute heart failure in 1161 patients enrolled in the RELAX-AHF study. The pre-specified study endpoints were used. At baseline, women (436/1161 patients) were older, had a higher left ventricular ejection fraction, a higher rate of hypertension, and were treated differently from men. Early dyspnea improvement (moderate or marked dyspnea improvement measured by Likert scale during the first 24 h) was greater in women. However, dyspnea improvement over the first 5 days (change from baseline in the visual analog scale area under the curve (VAS AUC) to day 5) was similar between men and women. Women reported greater improvements in general wellbeing by Likert, but no such benefits were evident with the VAS score. Multi-variable predictors of moderate or marked dyspnea improvement were female sex (p = 0.0011), lower age (p = 0.0026) and lower diuretic dose (p = 0.0067). The additional efficacy endpoints of RELAX-AHF were similar between men and women and serelaxin was equally effective in men and women. Women exhibit better earlier dyspnea relief and improvement in general wellbeing compared with men, even adjusted for age and left ventricular ejection fraction. However, in-hospital and post-discharge clinical outcomes were similar between men and women. This trial is registered at ClinicalTrials.gov, NCT00520806. C1 [Meyer, Sven; Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands. [Meyer, Sven] Carl von Ossietzky Univ Oldenburg, European Med Sch Oldenburg Groningen, Heart Ctr Oldenburg, Dept Cardiol, Oldenburg, Germany. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Metra, Marco] Univ Brescia, Cardiol, Dept Med & Surg Specialties, Radiol Sci & Publ Hlth, Brescia, Italy. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Cotter, Gad; Davison, Beth A.] Momentum Res Inc, Durham, NC USA. [Felker, G. Michael] Duke Univ, Sch Med, Duke Heart Ctr, Durham, NC USA. [Filippatos, Gerasimos] Athens Univ Hosp, Athens, Greece. [Greenberg, Barry H.] Univ Calif San Diego, La Jolla, CA 92093 USA. [Hua, Tsushung A.] Novartis Pharmaceut, E Hanover, NJ USA. [Severin, Thomas] Novartis Pharma AG, Basel, Switzerland. [Qian, Min] Columbia Univ, Med Ctr, New York, NY USA. RP Voors, AA (reprint author), Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands. EM a.a.voors@umcg.nl FU Servier; Novartis; Amgen; Bayer; Cardio3 Bioscience; Cytokinetics; Mast Therapeutics; Medtronic; St. Jude; Trevena; Abbott Vascular; Corthera; Abbott; Merck; PDL BioPharma; Otsuka; Roche Diagnostics; Bristol Myers Squibb; NHLBI; European Union; Alere; Boehringer Ingelheim; Cardio3Biosciences; Celladon; GSK; Merck/MSD; Stealth Peptides; Singulex; Sphingotec; Vifor; ZS Pharma FX SM received consulting fees, travel support and honoraria from Servier and Novartis. JRT has received research grants or consulting fees from Amgen, Bayer, Cardio3 Bioscience, Cytokinetics, Mast Therapeutics, Medtronic, Novartis, St. Jude and Trevena. MM has received consulting income from Abbott Vascular, Bayer, Corthera, and Novartis, as well as travel support and honoraria from Servier and Novartis. PP was a consultant for Astellas, Bayer, EKR Therapeutics, J&J, the Medicines Company, Medtronic, Novartis, Otsuka, Palatin Technologies, PDL BioPharma, Pericor Therapeutics, SigmaTau, Solvay Pharmaceuticals, and Trevena; has received honoraria from Alere, Beckman-Coulter, BiogenIdec, Corthera, Ikaria, Nile Therapeutics, Momentum Research, and Overcome; has received research support from Abbott, Merck and PDL BioPharma; and has received travel support from MyLife and equipment support from Sonosite. PSP, in the last one year is or has been a Consultant for: Intersection Medical, INSYS, Janssen, Medtronic, Novartis, Trevena, scPharmaceuticals, Cardioxyl, Roche Diagnostics, Relypsa, Honoraria: Palatin Technologies. GC and BAD are employees of Momentum Research, which has provided consulting and trial management services to NovaCardia, Merck, Corthera, Novartis, Nile Therapeutics, Bioheart, Cardio3 Biosciences, Amgen, Celadon, Targegen, Trevena, Sorbent Therapeutics, and NIH. GMF reports consulting income from Novartis, Amgen, Otsuka, Trevena, Roche Diagnostics, Merck, Medtronic, Bristol Myers Squibb and grant fundings from Novartis, Amgen, Otsuka, Roche Diagnostics, and NHLBI. GF is an executive committee member and consultant to Corthera (a Novartis company), Bayer, Cardiorentis, and has received research grants from Amgen, European Union. BHG served as a consultant for Novartis, Teva, Celladon, Janssen, Zensun, Relypsa, MAST and ZS Pharma. MQ receives partial salary support from Novartis for statistical analysis of the data for this trial. TS and TAH are employees and receive salary, benefits, and stocks options from Novartis Pharma. AAV reports consultancy fees and/or research grants from: Alere, Amgen, Bayer, Boehringer Ingelheim, Cardio3Biosciences, Celladon, GSK, Merck/MSD, Novartis, Servier, Stealth Peptides, Singulex, Sphingotec, Trevena, Vifor, ZS Pharma. NR 22 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER HEIDELBERG PI HEIDELBERG PA TIERGARTENSTRASSE 17, D-69121 HEIDELBERG, GERMANY SN 1861-0684 EI 1861-0692 J9 CLIN RES CARDIOL JI Clin. Res. Cardiol. PD APR PY 2017 VL 106 IS 4 BP 280 EP 292 DI 10.1007/s00392-016-1051-4 PG 13 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA ER3VG UT WOS:000398727100005 PM 27838739 ER PT J AU Flores, LE Berenbaum, H AF Flores, Luis E., Jr. Berenbaum, Howard TI The Effect of the Social Regulation of Emotion on Emotional Long-Term Memory SO EMOTION LA English DT Article DE emotional memory; social regulation of emotion; interpersonal ID HUMAN AMYGDALA; OXYTOCIN; PERSONALITY; INVOLVEMENT; PERFORMANCE; MECHANISMS; REACTIVITY; CLOSENESS; EXPLICIT; SUPPORT AB Memories for emotional events tend to be stronger than for neutral events, and weakening negative memories can be helpful to promote well-being. The present study examined whether the social regulation of emotion (in the form of handholding) altered the strength of emotional long-term memory. A sample of 219 undergraduate students viewed sets of negative, neutral, and positive images. Each participant held a stress ball while viewing half of the images and held someone's hand while viewing the other half. Participants returned 1 week later to complete a recognition task. Performance on the recognition task demonstrated that participants had lower memory accuracy for negative but not for positive pictures that were shown while they were holding someone's hand compared with when they were holding a stress ball. Although handholding altered the strength of negative emotional long-term memory, it did not down-regulate negative affective response as measured by self-report or facial expressivity. The present findings provide evidence that the social regulation of emotion can help weaken memory for negative information. Given the role of strong negative memories in different forms of psychopathology (e.g., depression, posttraumatic stress disorder), these findings may help better understand how close relationships protect against psychopathology. C1 [Flores, Luis E., Jr.] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res Educ & Clin Ctr MIRECC 4, Pittsburgh, PA USA. [Flores, Luis E., Jr.] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA 15260 USA. [Berenbaum, Howard] Univ Illinois, Dept Psychol, Champaign, IL USA. RP Flores, LE (reprint author), VA Pittsburgh Healthcare Syst, MIRECC Res Off Bldg 151R,Univ Dr Campus, Pittsburgh, PA 15240 USA. EM floresle@pitt.edu NR 50 TC 0 Z9 0 U1 5 U2 5 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 1528-3542 EI 1931-1516 J9 EMOTION JI Emotion PD APR PY 2017 VL 17 IS 3 BP 547 EP 556 DI 10.1037/emo0000259 PG 10 WC Psychology, Experimental SC Psychology GA ER6JE UT WOS:000398910600014 PM 27936815 ER PT J AU Snowden, MB Steinman, LE Bryant, LL Cherrier, MM Greenlund, KJ Leith, KH Levy, C Logsdon, RG Copeland, C Vogel, M Anderson, LA Atkins, DC Bell, JF Fitzpatrick, AL AF Snowden, Mark B. Steinman, Lesley E. Bryant, Lucinda L. Cherrier, Monique M. Greenlund, Kurt J. Leith, Katherine H. Levy, Cari Logsdon, Rebecca G. Copeland, Catherine Vogel, Mia Anderson, Lynda A. Atkins, David C. Bell, Janice F. Fitzpatrick, Annette L. TI Dementia and co-occurring chronic conditions: a systematic literature review to identify what is known and where are the gaps in the evidence? SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Review DE dementia; cognitive impairment; multiple chronic conditions; systematic literature review; public health; aging ID NURSING-HOME RESIDENTS; COMMUNITY-BASED COHORT; AFRICAN-AMERICAN PATIENTS; CONGESTIVE-HEART-FAILURE; COGNITIVE IMPAIRMENT; ALZHEIMERS-DISEASE; OLDER-ADULTS; PARKINSONS-DISEASE; VASCULAR DEMENTIA; INCIDENT DEMENTIA AB ObjectiveThe challenges posed by people living with multiple chronic conditions are unique for people with dementia and other significant cognitive impairment. There have been recent calls to action to review the existing literature on co-occurring chronic conditions and dementia in order to better understand the effect of cognitive impairment on disease management, mobility, and mortality. MethodsThis systematic literature review searched PubMed databases through 2011 (updated in 2016) using key constructs of older adults, moderate-to-severe cognitive impairment (both diagnosed and undiagnosed dementia), and chronic conditions. Reviewers assessed papers for eligibility and extracted key data from each included manuscript. An independent expert panel rated the strength and quality of evidence and prioritized gaps for future study. ResultsFour thousand thirty-three articles were identified, of which 147 met criteria for review. We found that moderate-to-severe cognitive impairment increased risks of mortality, was associated with prolonged institutional stays, and decreased function in persons with multiple chronic conditions. There was no relationship between significant cognitive impairment and use of cardiovascular or hypertensive medications for persons with these comorbidities. Prioritized areas for future research include hospitalizations, disease-specific outcomes, diabetes, chronic pain, cardiovascular disease, depression, falls, stroke, and multiple chronic conditions. ConclusionsThis review summarizes that living with significant cognitive impairment or dementia negatively impacts mortality, institutionalization, and functional outcomes for people living with multiple chronic conditions. Our findings suggest that chronic-disease management interventions will need to address co-occurring cognitive impairment. Copyright (c) 2017 John Wiley & Sons, Ltd. C1 [Snowden, Mark B.; Cherrier, Monique M.; Atkins, David C.] Univ Washington, Sch Med, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Steinman, Lesley E.; Copeland, Catherine; Vogel, Mia] Univ Washington, Hlth Promot Res Ctr, Seattle, WA 98195 USA. [Bryant, Lucinda L.] Univ Colorado, Dept Community & Behav Hlth, Colorado Sch Publ Hlth, Anschutz Med Campus, Aurora, CO USA. [Greenlund, Kurt J.; Anderson, Lynda A.] Ctr Dis Control & Prevent, Natl Ctr Chron Dis Prevent & Hlth Promot, Atlanta, GA USA. [Leith, Katherine H.] Univ South Carolina, Coll Social Work, Hamilton Coll, Columbia, SC USA. [Levy, Cari] Univ Colorado, Sch Med, Div Hlth Care Policy & Res, Denver, CO USA. [Levy, Cari] Denver Vet Affairs Med Ctr, Denver, CO USA. [Logsdon, Rebecca G.] UW Sch Nursing, Northwest Res Grp Aging, Seattle, WA USA. [Anderson, Lynda A.] Emory Univ, Rollins Sch Publ Hlth, Atlanta, GA 30322 USA. [Bell, Janice F.] Univ Calif Davis, Betty Irene Moore Sch Nursing, Davis, CA 95616 USA. [Fitzpatrick, Annette L.] Univ Washington, Sch Med, Dept Family Med, Seattle, WA 98195 USA. [Fitzpatrick, Annette L.] Univ Washington, Dept Epidemiol, Sch Med, Seattle, WA 98195 USA. [Fitzpatrick, Annette L.] Univ Washington, Sch Med, Dept Global Hlth, Seattle, WA USA. [Fitzpatrick, Annette L.] Univ Washington, Sch Publ Hlth, Seattle, WA 98195 USA. RP Steinman, LE (reprint author), Univ Washington, Hlth Promot Res Ctr, Seattle, WA 98195 USA. EM lesles@uw.edu FU Centers for Disease Control and Prevention's (CDC) Healthy Aging Program through the CDC Prevention Research Centers Program, Special Interest Project [U48-DP000050] FX This research was funded by the Centers for Disease Control and Prevention's (CDC) Healthy Aging Program through the CDC Prevention Research Centers Program, Special Interest Project grant (U48-DP000050) to the University of Washington Health Promotion Research Center. Special thanks to Lucinda L. Bryant, PhD, MSHA, and Catherine Copeland, MPA for their contributions to the literature search and data abstraction, to Angie Deokar for grant management, and to Oejin Shin for her work preparing the manuscript. Please contact the corresponding author for further information about categories not presented or for detailed summary data tables. The findings and conclusions in this article are those of the authors and do not necessarily represent the official position of the CDC. Please contact the corresponding author for copies of the underlying research materials related to our paper (e.g., detailed summary data tables, article abstraction instruments). NR 165 TC 0 Z9 0 U1 5 U2 5 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-6230 EI 1099-1166 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD APR PY 2017 VL 32 IS 4 BP 357 EP 371 DI 10.1002/gps.4652 PG 15 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA ES1PV UT WOS:000399300400001 PM 28146334 ER PT J AU Harrington, KD Gould, E Lim, YY Ames, D Pietrzak, RH Rembach, A Rainey-Smith, S Martins, RN Salvado, O Villemagne, VL Rowe, CC Masters, CL Maruff, P AF Harrington, Karra D. Gould, Emma Lim, Yen Ying Ames, David Pietrzak, Robert H. Rembach, Alan Rainey-Smith, Stephanie Martins, Ralph N. Salvado, Olivier Villemagne, Victor L. Rowe, Christopher C. Masters, Colin L. Maruff, Paul CA AIBL Res Grp TI Amyloid burden and incident depressive symptoms in cognitively normal older adults SO INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE amyloid; depression; Alzheimer's disease; cognitively normal ID LATE-LIFE DEPRESSION; ALZHEIMERS ASSOCIATION WORKGROUPS; BETA PROTEIN; DIAGNOSTIC GUIDELINES; ELDERLY DEPRESSION; NATIONAL INSTITUTE; MAJOR DEPRESSION; A-BETA; DISEASE; IMPAIRMENT AB ObjectiveSeveral studies have reported that non-demented older adults with clinical depression show changes in amyloid- (A) levels in blood, cerebrospinal fluid and on neuroimaging that are consistent with those observed in patients with Alzheimer's disease. These findings suggest that A may be one of the mechanisms underlying the relation between the two conditions. We sought to determine the relation between elevated cerebral A and the presence of depression across a 54-month prospective observation period. MethodsCognitively normal older adults from the Australian Imaging Biomarkers and Lifestyle study who were not depressed and had undergone a positron emission tomography scan to classify them as either high A (n=81) or low A (n=278) participated. Depressive symptoms were assessed using the Geriatric Depression Scale Short Form at 18-month intervals over 54months. ResultsWhilst there was no difference in probable depression between groups at baseline, incidence was 4.5 (95% confidence interval [CI] 1.3-16.4) times greater within the high A group (9%) than the low A group (2%) by the 54-month assessment. ConclusionsResults of this study suggest that elevated A levels are associated with a 4.5-fold increased likelihood of developing clinically significant depressive symptoms on follow-up in preclinical Alzheimer's disease. This underscores the importance of assessing, monitoring and treating depressive symptoms in older adults with elevated A. Copyright (c) 2016 John Wiley & Sons, Ltd. C1 [Harrington, Karra D.; Gould, Emma] Deakin Univ, Sch Psychol, Geelong, Vic, Australia. [Harrington, Karra D.; Lim, Yen Ying; Rembach, Alan; Villemagne, Victor L.; Masters, Colin L.; Maruff, Paul] Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Parkville, Vic, Australia. [Harrington, Karra D.; Ames, David] Univ Melbourne, Acad Unit Psychiat Old Age, Dept Psychiat, Parkville, Vic, Australia. [Ames, David] Natl Ageing Res Inst, Parkville, Vic, Australia. [Pietrzak, Robert H.] VA Connecticut Healthcare Syst, Clin Neurosci Div, Natl Ctr Posttraumat Stress Disorder, US Dept Vet Affairs, West Haven, CT USA. [Pietrzak, Robert H.] Yale Sch Med, Dept Psychiat, New Haven, CT USA. [Rainey-Smith, Stephanie; Martins, Ralph N.] Edith Cowan Univ, Sch Exercise Biomed & Hlth Sci, Ctr Excellence Alzheimers Dis Res & Care, Perth, WA, Australia. [Rainey-Smith, Stephanie; Martins, Ralph N.] Hollywood Private Hosp, Sir James McCusker Alzheimers Dis Res Unit, Nedlands, WA, Australia. [Salvado, Olivier] Australian E Hlth Res Ctr BioMedIA, CSIRO Preventat Hlth Natl Res Flagship, Herston, Qld, Australia. [Villemagne, Victor L.; Rowe, Christopher C.] Austin Hlth, Ctr PET, Dept Nucl Med, Heidelberg, Vic, Australia. [Villemagne, Victor L.; Rowe, Christopher C.] Univ Melbourne, Dept Med, Austin Hlth, Heidelberg, Vic, Australia. [Maruff, Paul] CogState Ltd, Melbourne, Vic, Australia. RP Harrington, KD (reprint author), Deakin Univ, Sch Psychol, Geelong, Vic, Australia.; Harrington, KD (reprint author), Univ Melbourne, Florey Inst Neurosci & Mental Hlth, Parkville, Vic, Australia.; Harrington, KD (reprint author), Univ Melbourne, Acad Unit Psychiat Old Age, Dept Psychiat, Parkville, Vic, Australia. EM karra.harrington@florey.edu.au FU Australian Commonwealth Scientific Industrial and Research Organization [CSIRO]; Edith Cowan University [ECU]; Mental Health Research Institute [MHRI]; Alzheimer's Australia [AA]; National Ageing Research Institute [NARI]; Austin Health; CogState Ltd.; Hollywood Private Hospital; Sir Charles Gardner Hospital; National Health and Medical Research Council (NHMRC); Dementia Collaborative Research Centres program (DCRC2); Science and Industry Endowment Fund (SIEF); Cooperative Research Centre (CRC) for Mental Health from the Australian Government FX Funding for the study was provided in part by the study partners (Australian Commonwealth Scientific Industrial and Research Organization [CSIRO], Edith Cowan University [ECU], Mental Health Research Institute [MHRI], Alzheimer's Australia [AA], National Ageing Research Institute [NARI], Austin Health, CogState Ltd., Hollywood Private Hospital, Sir Charles Gardner Hospital). The study also received support from the National Health and Medical Research Council (NHMRC) and the Dementia Collaborative Research Centres program (DCRC2), as well as ongoing funding from the Science and Industry Endowment Fund (SIEF). The authors also acknowledge the financial support of the Cooperative Research Centre (CRC) for Mental Health, from the Australian Government. NR 52 TC 1 Z9 1 U1 1 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0885-6230 EI 1099-1166 J9 INT J GERIATR PSYCH JI Int. J. Geriatr. Psychiatr. PD APR PY 2017 VL 32 IS 4 BP 455 EP 463 DI 10.1002/gps.4489 PG 9 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA ES1PV UT WOS:000399300400011 PM 27114112 ER PT J AU Horan, WP Johnson, MW Green, MF AF Horan, William P. Johnson, Matthew W. Green, Michael F. TI Altered Experiential, But Not Hypothetical, Delay Discounting in Schizophrenia SO JOURNAL OF ABNORMAL PSYCHOLOGY LA English DT Article DE cost-benefit decision making; prospection; psychosis; reward valuation; reliability ID TEST-RETEST RELIABILITY; CIGARETTE-SMOKING STATUS; DECISION-MAKING; INTERTEMPORAL CHOICE; QUALITY-ASSURANCE; REWARDS; TASK; IMPULSIVITY; REAL; DEFICITS AB Delay discounting (DD) is a future-oriented decision-making process that refers to whether one is willing to forego a smaller, sooner reward for the sake of a larger, later reward. It can be assessed using hypothetical tasks, which involve choices between hypothetical rewards of varying amounts over delay periods of days to years, or experiential tasks, which involve receiving actual rewards in real time over delay periods of seconds to minutes. Initial studies in schizophrenia have only used hypothetical tasks and have been mixed in finding either elevated or normal levels of DD. One hundred thirty-one outpatients with schizophrenia and 70 healthy controls completed hypothetical and experiential DD tasks involving monetary rewards, and the schizophrenia group was retested after 4 weeks. Although both groups showed qualitatively similar hyperbolic discounting functions on both tasks, they showed a quantitative DD difference. The schizophrenia showed higher DD than controls on the experiential task but normal DD on the hypothetical task. This pattern was not attributable to a range of potential confounds, including smoking status, substance use disorder status, or neurocognition. It was also not attributable to differences in the test-retest reliability, which was good for both tasks. The schizophrenia group's robust pattern of altered experiential but normal hypothetical task performance points to key factors that may contribute to impaired DD in this disorder. These may include increased valuation of small (but not large) monetary rewards, or a hypersensitivity to costs associated with waiting inactively for those rewards. C1 [Horan, William P.; Green, Michael F.] VISN 22 Mental Illness Res Educ & Clin Ctr, Dept Vet Affairs, Los Angeles, CA USA. [Horan, William P.; Green, Michael F.] Univ Calif Los Angeles, David Geffen Sch Med, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. [Johnson, Matthew W.] Johns Hopkins Univ, Sch Med, Dept Psychiat & Behav Sci, Baltimore, MD 21218 USA. RP Horan, WP (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, MIRECC 210A,Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM horan@ucla.edu FU VA Merit Award; [R01DA035277] FX This project was funded by a VA Merit Award (to William P. Horan). Support of Matthew W. Johnson's time was provided by Grants R01DA035277 and R01DA035277. NR 73 TC 0 Z9 0 U1 0 U2 0 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0021-843X EI 1939-1846 J9 J ABNORM PSYCHOL JI J. Abnorm. Psychol. PD APR PY 2017 VL 126 IS 3 BP 301 EP 311 DI 10.1037/abn0000249 PG 11 WC Psychology, Clinical; Psychology, Multidisciplinary SC Psychology GA ER4AD UT WOS:000398740500004 PM 28165261 ER PT J AU Walker, RJ Neelon, B Egede, LE AF Walker, Rebekah J. Neelon, Brian Egede, Leonard E. TI Advancing the Understanding of Social Determinants of Health Through Geospatial Analysis SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material ID EMERGENCY-DEPARTMENT EXPENDITURES; MODEL C1 [Walker, Rebekah J.; Neelon, Brian; Egede, Leonard E.] Ralph H Johnson Vet Affairs Med Ctr, HEROIC, Charleston, SC USA. [Walker, Rebekah J.; Egede, Leonard E.] Med Univ South Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280G, Charleston, SC 29425 USA. [Walker, Rebekah J.; Egede, Leonard E.] Med Univ South Carolina, Div Gen Internal Med & Geriatr, Dept Med, Charleston, SC USA. [Neelon, Brian] Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC USA. RP Egede, LE (reprint author), Med Univ South Carolina, Ctr Hlth Dispar Res, 135 Rutledge Ave,Room 280G, Charleston, SC 29425 USA. EM egedel@musc.edu NR 10 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2017 VL 32 IS 4 BP 371 EP 372 DI 10.1007/s11606-016-3942-5 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA ER5NH UT WOS:000398848100002 PM 27957663 ER PT J AU Nelson, K Schwartz, G Hernandez, S Simonetti, J Curtis, I Fihn, SD AF Nelson, Karin Schwartz, Greg Hernandez, Susan Simonetti, Joseph Curtis, Idamay Fihn, Stephan D. TI The Association Between Neighborhood Environment and Mortality: Results from a National Study of Veterans SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE risk adjustment; veteran; socioeconomic factors; public health; clinical epidemiology ID SOCIOECONOMIC-STATUS; UNITED-STATES; POPULATION HEALTH; OLDER-ADULTS; US ADULTS; MULTILEVEL; DETERMINANTS; MODELS; SAMPLE; CARE AB As the largest integrated US health system, the Veterans Health Administration (VHA) provides unique national data to expand knowledge about the association between neighborhood socioeconomic status (NSES) and health. Although living in areas of lower NSES has been associated with higher mortality, previous studies have been limited to higher-income, less diverse populations than those who receive VHA care. To describe the association between NSES and all-cause mortality in a national sample of veterans enrolled in VHA primary care. One-year observational cohort of veterans who were alive on December 31, 2011. Data on individual veterans (vital status, and clinical and demographic characteristics) were abstracted from the VHA Corporate Data Warehouse. Census tract information was obtained from the US Census Bureau American Community Survey. Logistic regression was used to model the association between NSES deciles and all-cause mortality during 2012, adjusting for individual-level income and demographics, and accounting for spatial autocorrelation. Veterans who had vital status, demographic, and NSES data, and who were both assigned a primary care physician and alive on December 31, 2011 (n = 4,814,631). Census tracts were used as proxies for neighborhoods. A summary score based on census tract data characterized NSES. Veteran addresses were geocoded and linked to census tract NSES scores. Census tracts were divided into NSES deciles. In adjusted analysis, veterans living in the lowest-decile NSES tract were 10 % (OR 1.10, 95 % CI 1.07, 1.14) more likely to die than those living in the highest-decile NSES tract. Lower neighborhood SES is associated with all-cause mortality among veterans after adjusting for individual-level socioeconomic characteristics. NSES should be considered in risk adjustment models for veteran mortality, and may need to be incorporated into strategies aimed at improving veteran health. C1 [Nelson, Karin; Simonetti, Joseph] VA Puget Sound Healthcare Syst, Hlth Serv Res & Dev Seattle Denver COIN, Seattle, WA 98108 USA. [Nelson, Karin; Fihn, Stephan D.] VA Puget Sound Healthcare Syst, Gen Internal Med Serv, Seattle, WA USA. [Nelson, Karin; Simonetti, Joseph; Fihn, Stephan D.] Univ Washington, Sch Med, Dept Med, Seattle, WA 98195 USA. [Nelson, Karin; Hernandez, Susan; Fihn, Stephan D.] Univ Washington, Sch Publ Hlth, Dept Hlth Serv, Seattle, WA 98195 USA. [Schwartz, Greg; Curtis, Idamay; Fihn, Stephan D.] VHA Off Analyt & Business Intelligence, Seattle, WA USA. RP Nelson, K (reprint author), VA Puget Sound Healthcare Syst, Hlth Serv Res & Dev Seattle Denver COIN, Seattle, WA 98108 USA. EM Karin.Nelson@va.gov FU US Department of Veterans Affairs, VHA Office of Analytics and Business Intelligence FX This material is based upon work supported by the US Department of Veterans Affairs, VHA Office of Analytics and Business Intelligence. This work was presented at the Society for General Internal Medicine National Meeting (May, 2015) and at Academy Health (June, 2015). The views expressed in this article are those of the authors and do not necessarily represent the views of the Department of Veterans Affairs. NR 40 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2017 VL 32 IS 4 BP 416 EP 422 DI 10.1007/s11606-016-3905-x PG 7 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA ER5NH UT WOS:000398848100013 PM 27815763 ER PT J AU Haas, JS Barlow, WE Schapira, MM MacLean, CD Klabunde, CN Sprague, BL Beaber, EF Chen, JS Bitton, A Onega, T Harris, K Tosteson, ANA AF Haas, Jennifer S. Barlow, William E. Schapira, Marilyn M. MacLean, Charles D. Klabunde, Carrie N. Sprague, Brian L. Beaber, Elisabeth F. Chen, Jane S. Bitton, Asaf Onega, Tracy Harris, Kimberly Tosteson, Anna N. A. CA PROSPR Population-Based Res TI Primary Care Providers' Beliefs and Recommendations and Use of Screening Mammography by their Patients SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE mammography; variation in care; provider beliefs ID SERVICES TASK-FORCE; BREAST-CANCER; PREVENTIVE CARE; WOMEN; ATTITUDES; GUIDELINES; UPDATE; TRENDS; OLDER AB Revised breast cancer screening guidelines have fueled debate about the effectiveness and frequency of screening mammography, encouraging discussion between women and their providers. To examine whether primary care providers' (PCPs') beliefs about the effectiveness and frequency of screening mammography are associated with utilization by their patients. Cross-sectional survey data from PCPs (2014) from three primary care networks affiliated with the Population-based Research Optimizing Screening through Personalized Regimens (PROSPR) consortium, linked with data about their patients' mammography use (2011-2014). PCPs (n = 209) and their female patients age 40-89 years without breast cancer (n = 30,233). Outcomes included whether (1) women received a screening mammogram during a 2-year period; and (2) screened women had > 1 mammogram during that period, reflecting annual screening. Principal independent variables were PCP beliefs about the effectiveness of mammography and their recommendations for screening frequency. Overall 65.2% of women received > 1 screening mammogram. For women 40-48 years, mammography use was modestly lower for those cared for by PCPs who believed that screening was ineffective compared with those who believed it was somewhat or very effective (59.1%, 62.3%, and 64.7%; p = 0.019 after controlling for patient characteristics). Of women with PCPs who reported they did not recommend screening before age 50, 48.1% were nonetheless screened. For women age 49-74 years, the vast majority were cared for by providers who believed that screening was effective. Provider recommendations were not associated with screening frequency. For women >= 75 years, those cared for by providers who were uncertain about effectiveness had higher screening use (50.7%) than those cared for by providers who believed it was somewhat effective (42.8%). Patients of providers who did not recommend screening were less likely to be screened than were those whose providers recommended annual screening, yet 37.1% of patients whose providers recommended against screening still received screening. PCP beliefs about mammography effectiveness and screening recommendations are only modestly associated with use, suggesting other likely influences on patient participation in mammography. C1 [Haas, Jennifer S.; Chen, Jane S.; Bitton, Asaf; Harris, Kimberly] Brigham & Womens Hosp, Div Gen Med & Primary Care, 1620 Tremont St, Boston, MA 02120 USA. [Haas, Jennifer S.; Bitton, Asaf] Harvard Med Sch, Boston, MA USA. [Haas, Jennifer S.] Harvard TH Chan Sch Publ Hlth, Boston, MA USA. [Barlow, William E.; Beaber, Elisabeth F.] Fred Hutchinson Canc Res Ctr, 1124 Columbia St, Seattle, WA 98104 USA. [Schapira, Marilyn M.] Univ Penn, Philadelphia, PA 19104 USA. [Schapira, Marilyn M.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Klabunde, Carrie N.] NIH, Off Dis Prevent, Off Director, Bldg 10, Bethesda, MD 20892 USA. [MacLean, Charles D.; Sprague, Brian L.] Univ Vermont, Burlington, VT USA. [Onega, Tracy; Tosteson, Anna N. A.] Geisel Sch Med Dartmouth, Lebanon, NH USA. [Onega, Tracy; Tosteson, Anna N. A.] Norris Cotton Canc Ctr, Lebanon, NH USA. RP Haas, JS (reprint author), Brigham & Womens Hosp, Div Gen Med & Primary Care, 1620 Tremont St, Boston, MA 02120 USA. EM jhaas@partners.org FU National Cancer Institute-funded consortium, Population-Based Research Optimizing Screening through Personalized Regimens (PROSPR) [U54 CA163307, U54 CA163313, U54 CA163303, U01 CA163304] FX This study was conducted as part of the National Cancer Institute-funded consortium, Population-Based Research Optimizing Screening through Personalized Regimens (PROSPR) (Grant numbers U54 CA163307, U54 CA163313, U54 CA163303, U01 CA163304). NR 28 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD APR PY 2017 VL 32 IS 4 BP 449 EP 457 DI 10.1007/s11606-016-3973-y PG 9 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA ER5NH UT WOS:000398848100017 PM 28070772 ER PT J AU Anderson, E Stevenson, K Johnson, D Ebert, J Blair, T AF Anderson, E. Stevenson, K. Johnson, D. Ebert, J. Blair, T. TI Controlled Substance Advisory: A review of patient outcomes in the year following a prohibition of opioids for chronic conditions due to safety concerns SO JOURNAL OF PAIN LA English DT Meeting Abstract C1 [Anderson, E.; Stevenson, K.; Johnson, D.; Ebert, J.; Blair, T.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD APR PY 2017 VL 18 IS 4 SU 1 MA 235 BP S34 EP S34 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA ER4FV UT WOS:000398755400140 ER PT J AU Domanski, A Bair, M Balk, R Brandt, C Brody, A Dismore, R Gaetano, V Garrido, M Gittleman, D Kerns, R Krebs, E Linden, E Morrison, R Natividad, D Penrod, J Rinaldi, A Stefanis, L Sun, D Hwang, U AF Domanski, A. Bair, M. Balk, R. Brandt, C. Brody, A. Dismore, R. Gaetano, V. Garrido, M. Gittleman, D. Kerns, R. Krebs, E. Linden, E. Morrison, R. Natividad, D. Penrod, J. Rinaldi, A. Stefanis, L. Sun, D. Hwang, U. TI Evaluating the agreement between self-reported and documented analgesic use in older veterans with osteoarthritis SO JOURNAL OF PAIN LA English DT Meeting Abstract C1 [Domanski, A.; Bair, M.; Balk, R.; Brandt, C.; Brody, A.; Dismore, R.; Gaetano, V.; Garrido, M.; Gittleman, D.; Kerns, R.; Krebs, E.; Linden, E.; Morrison, R.; Natividad, D.; Penrod, J.; Rinaldi, A.; Stefanis, L.; Sun, D.; Hwang, U.] James J Peters VAMC, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. FU VA HSRD; Icahn School of Medicine's Summer Student Investigator Program Award FX This project was supported by VA HSR&D as well as the Icahn School of Medicine's Summer Student Investigator Program Award. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD APR PY 2017 VL 18 IS 4 SU 1 MA 233 BP S34 EP S34 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA ER4FV UT WOS:000398755400138 ER PT J AU Hausmann, L Hanlon, J Sileanu, F Zhao, X Thorpe, C Thorpe, J Cashy, J Mor, M Hale, J Radomski, T Fine, M Good, C Gellad, W AF Hausmann, L. Hanlon, J. Sileanu, F. Zhao, X. Thorpe, C. Thorpe, J. Cashy, J. Mor, M. Hale, J. Radomski, T. Fine, M. Good, C. Gellad, W. TI Use of potentially unsafe high opioid dosage varies by demographic characteristics among Veterans dually-enrolled in Veterans Affairs and Medicare SO JOURNAL OF PAIN LA English DT Meeting Abstract C1 [Hausmann, L.; Hanlon, J.; Sileanu, F.; Zhao, X.; Thorpe, C.; Thorpe, J.; Cashy, J.; Mor, M.; Hale, J.; Radomski, T.; Fine, M.; Good, C.; Gellad, W.] Vet Affairs Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA USA. FU VA HSRD IIR [14-297] FX Funded by VA HSR&D IIR 14-297. NR 0 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE PI EDINBURGH PA JOURNAL PRODUCTION DEPT, ROBERT STEVENSON HOUSE, 1-3 BAXTERS PLACE, LEITH WALK, EDINBURGH EH1 3AF, MIDLOTHIAN, SCOTLAND SN 1526-5900 J9 J PAIN JI J. Pain PD APR PY 2017 VL 18 IS 4 SU 1 MA 229 BP S33 EP S33 PG 1 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA ER4FV UT WOS:000398755400134 ER PT J AU Kaji, I Akiba, Y Kato, I Maruta, K Kuwahara, A Kaunitz, JD AF Kaji, Izumi Akiba, Yasutada Kato, Ikuo Maruta, Koji Kuwahara, Atsukazu Kaunitz, Jonathan D. TI Xenin Augments Duodenal Anion Secretion via Activation of Afferent Neural Pathways SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID RAT GASTROINTESTINAL-TRACT; BICARBONATE SECRETION; NEUROTENSIN RECEPTOR; 5-HT3 RECEPTORS; NONPEPTIDE ANTAGONIST; ENTEROENDOCRINE CELLS; DEFENSE-MECHANISMS; CL-SECRETION; DISTAL COLON; IN-VITRO AB Xenin-25, a neurotensin (NT)-related anorexigenic gut hormone generated mostly in the duodenal mucosa, is believed to increase the rate of duodenal ion secretion, because xenin-induced diarrhea is not present after Roux-en-Y gastric bypass surgery. Because the local effects of xenin on duodenal ion secretion have remained uninvestigated, we thus examined the neural pathways underlying xenin-induced duodenal anion secretion. Intravenous infusion of xenin-8, a bioactive C-terminal fragment of xenin-25, dose dependently increased the rate of duodenal HCO (3) (-) secretion in perfused duodenal loops of anesthetized rats. Xenin was immunolocalized to a subset of enteroendocrine cells in the rat duodenum. The mRNA of the xenin/NT receptor 1 (NTS1) was predominantly expressed in the enteric plexus, nodose and dorsal root ganglia, and in the lamina propria rather than in the epithelium. The serosal application of xenin-8 or xenin-25 rapidly and transiently increased short-circuit current in Ussing-chambered mucosa-submucosa preparations in a concentration-dependent manner in the duodenum and jejunum, but less so in the ileum and colon. The selective antagonist for NTS1, substance P (SP) receptor (NK1), or 5-hydroxytryptamine (5-HT) (3), but not NTS2, inhibited the responses to xenin. Xenin-evoked Cl-secretion was reduced by tetrodotoxin (TTX) or capsaicin-pretreatment, and abolished by the inhibitor of TTX-resistant sodiumchannel Nav1.8 in combination with TTX, suggesting that peripheral xenin augments duodenal HCO3- and Cl- secretion through NTS1 activation on intrinsic and extrinsic afferent nerves, followed by release of SP and 5-HT. Afferent nerve activation by postprandial, peripherally released xeninmay account for its secretory effects in the duodenum. C1 [Kaji, Izumi; Akiba, Yasutada; Kaunitz, Jonathan D.] Greater Los Angeles Vet Affairs Healthcare Syst, Los Angeles, CA USA. [Kaji, Izumi; Akiba, Yasutada; Maruta, Koji; Kaunitz, Jonathan D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Kaunitz, Jonathan D.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Surg, Los Angeles, CA 90095 USA. [Kato, Ikuo] Kobe Pharmaceut Univ, Dept Med Biochem, Kobe, Hyogo, Japan. [Kuwahara, Atsukazu] Univ Shizuoka, Grad Sch Integrated Pharmaceut & Nutr Sci, Shizuoka, Japan. RP Kaunitz, JD (reprint author), Greater LA VAHS, Bldg 114,Rm 217,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM jake@ucla.edu FU VA Merit Review; National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [R01-DK54221]; American Gastroenterology Association-Rome Foundation Functional Gastroenterology and Motility Disorders Pilot Research Award FX This study was supported by VA Merit Review (J.D.K.); the National Institutes of Health National Institute of Diabetes and Digestive and Kidney Diseases [Grant R01-DK54221] (J.D.K.); and American Gastroenterology Association-Rome Foundation Functional Gastroenterology and Motility Disorders Pilot Research Award (I.K.). NR 54 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 EI 1521-0103 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD APR 1 PY 2017 VL 361 IS 1 BP 151 EP 161 DI 10.1124/jpet.116.238485 PG 11 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA ER5EF UT WOS:000398823700016 PM 28115552 ER PT J AU Gannon, BM Galindo, KI Rice, KC Collins, GT AF Gannon, Brenda M. Galindo, Kayla I. Rice, Kenner C. Collins, Gregory T. TI Individual Differences in the Relative Reinforcing Effects of 3,4-Methylenedioxypyrovalerone under Fixed and Progressive Ratio Schedules of Reinforcement in Rats SO JOURNAL OF PHARMACOLOGY AND EXPERIMENTAL THERAPEUTICS LA English DT Article ID SALT CONSTITUENT 3,4-METHYLENEDIOXYPYROVALERONE; MICE DRUG DISCRIMINATION; BATH SALTS; LOCOMOTOR-ACTIVITY; SYNTHETIC CATHINONES; WHEEL ACTIVITY; UNITED-STATES; LEGAL HIGHS; MDPV; COCAINE AB The recreational use of designer drugs, including synthetic cathinones (bath salts), is associated with high levels of abuse and toxicity, and represents a growing threat to public health. 3,4-Methylenedioxypyrovalerone (MDPV) is a cocaine-like monoamine uptake inhibitor, and one of the most widely available and abused synthetic cathinones. The present study used male Sprague-Dawley rats to directly compare: (1) the acquisition of responding for MDPV and cocaine under a fixed ratio (FR) 1 schedule of reinforcement; (2) full dose-response curves for MDPV and cocaine under a FR5 schedule; and (3) progressive ratio (PR) schedules of reinforcement. Selfadministration of MDPV and cocaine was acquired at comparable rates, and by a similar percentage of rats. Compared with cocaine, MDPV was similar to 10-fold more potent and similar to 3-fold more effective at maintaining responding (PR; final ratio completed). Unlike cocaine, for which little variability was observed among rats, the FR5 dose-response curve for MDPV was shifted similar to 3-fold upward for a subset of rats (high-responders) relative to other rats with identical histories (low-responders). Compared with low-responding rats, high responders also self-administered more cocaine under the FR5 schedule, and earned significantly more MDPV, cocaine, and methamphetamine under a PR schedule of reinforcement. In addition to functioning as a significantly more effective reinforcer than either cocaine or methamphetamine, MDPV also appears to be unique in its capacity to establish an enduring phenotype in rats, characterized by unusually high levels of drug intake. Although the factors underlying this high-responder phenotype are unclear, they might be related to individual differences in human drug-taking behavior. C1 [Gannon, Brenda M.; Galindo, Kayla I.; Collins, Gregory T.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr,MC 7764, San Antonio, TX 78229 USA. [Collins, Gregory T.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Rice, Kenner C.] NIDA, Chem Biol Res Branch, NIH, Bethesda, MD 20892 USA. [Rice, Kenner C.] NIAAA, NIH, Bethesda, MD USA. RP Collins, GT (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, 7703 Floyd Curl Dr,MC 7764, San Antonio, TX 78229 USA. EM CollinsG@uthscsa.edu FU National Institutes of Health National Institute on Drug Abuse [R01DA039146, T32DA031115]; Intramural Research Programs of the National Institutes of Health National Institute on Drug Abuse; National Institutes of Health National Institute of Alcohol Abuse and Alcoholism FX This research was supported by the National Institutes of Health National Institute on Drug Abuse [Grants R01DA039146 and T32DA031115]. The work of the Drug Design and Synthesis Section was supported by the Intramural Research Programs of the National Institutes of Health National Institute on Drug Abuse and the National Institutes of Health National Institute of Alcohol Abuse and Alcoholism. NR 31 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC PHARMACOLOGY EXPERIMENTAL THERAPEUTICS PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3995 USA SN 0022-3565 EI 1521-0103 J9 J PHARMACOL EXP THER JI J. Pharmacol. Exp. Ther. PD APR 1 PY 2017 VL 361 IS 1 BP 181 EP 189 DI 10.1124/jpet.116.239376 PG 9 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA ER5EF UT WOS:000398823700019 PM 28179474 ER PT J AU Strand, V Singh, JA AF Strand, Vibeke Singh, Jasvinder A. TI Evaluation and Management of the Patient With Suspected Inflammatory Spine Disease SO MAYO CLINIC PROCEEDINGS LA English DT Article ID NONRADIOGRAPHIC AXIAL SPONDYLOARTHRITIS; CHRONIC BACK-PAIN; ANKYLOSING-SPONDYLITIS; PRIMARY-CARE; REFERRAL RECOMMENDATIONS; DIAGNOSTIC-CRITERIA; PREVALENCE; UVEITIS; DELAY; CLASSIFICATION AB Axial spondyloarthritis (AxSpA) is a chronic inflammatory rheumatic disease characterized by inflammatory back pain (IBP) that manifests in childhood, late adolescence, or early adulthood. Ankylosing spondylitis (AS) and nonradiographic AxSpA represent 2 ends of the AxSpA spectrum. Diagnosis can be challenging because patients develop IBP that may not be associated with radiographic changes in the sacroiliac joints. Patients early in the course of disease are estimated to have at least the same level of disease activity and pain as patients with established disease; thus, they could benefit substantially from earlier diagnosis. Although the recent use of magnetic resonance imaging and its inclusion in diagnostic criteria has enhanced the identification of early AxSpA, improvement in early diagnosis has not been consistently reported across all studies. Limited knowledge of the continuum of AxSpA disease manifestations and lack of recognition of IBP in primary practice may contribute to this. Implementing a referral strategy that identifies patients with IBP for additional testing and assessment may lead to better recognition of early signs and symptoms of AxSpA, thereby offering the potential for improved patient outcomes. This review presents an overview of the epidemiology, clinical characteristics, and burdens of AxSpA, followed by a case presentation outlining approaches to the evaluation and management of a patient with suspected inflammatory spine disease. (C) 2016 Mayo Foundation for Medical Education and Research. Published by Elsevier Inc. C1 [Strand, Vibeke] Stanford Univ, Sch Med, Div Immunol Rheumatol, Palo Alto, CA 94304 USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Div Clin Immunol & Rheumatol, Birmingham, AL USA. [Singh, Jasvinder A.] Birmingham Vet Affairs Med Ctr, Med Serv, Birmingham, AL USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. RP Strand, V (reprint author), 306 Ramona Rd, Portola Valley, CA 94028 USA. EM vstrand@stanford.edu FU Novartis Pharmaceuticals Corporation FX Technical assistance with editing, figure preparation, and styling of the manuscript for submission was provided by Oxford PharmaGenesis Inc and was funded by Novartis Pharmaceuticals Corporation. The authors are fully responsible for all content and editorial decisions and received no financial support or other form of compensation related to the development of this manuscript. NR 59 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0025-6196 EI 1942-5546 J9 MAYO CLIN PROC JI Mayo Clin. Proc. PD APR PY 2017 VL 92 IS 4 BP 555 EP 564 DI 10.1016/j.mayocp.2016.12.008 PG 10 WC Medicine, General & Internal SC General & Internal Medicine GA ER6WF UT WOS:000398949300012 PM 28233529 ER PT J AU Mayl, P Morrison, RS Murtagh, FEM AF Mayl, Peter Morrison, R. Sean Murtagh, Fliss E. M. TI Current state of the economics of palliative and end-of-life care: A clinical view SO PALLIATIVE MEDICINE LA English DT Editorial Material ID CANCER C1 [Mayl, Peter] Trinity Coll Dublin, Ctr Hlth Policy & Management, 3-4 Foster Pl, Dublin 2, Ireland. [Murtagh, Fliss E. M.] Kings Coll London, Cicely Saunders Inst, Dept Palliat Care Policy & Rehabil, London, England. [Morrison, R. Sean] Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Morrison, R. Sean] James J Peters VA Med Ctr, Dept Geriatr & Palliat Med, Bronx, NY USA. RP Mayl, P (reprint author), Trinity Coll Dublin, Ctr Hlth Policy & Management, 3-4 Foster Pl, Dublin 2, Ireland. EM peter.may@tcd.ie NR 13 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0269-2163 EI 1477-030X J9 PALLIATIVE MED JI Palliat. Med. PD APR PY 2017 VL 31 IS 4 SI SI BP 293 EP 295 DI 10.1177/0269216317695680 PG 3 WC Health Care Sciences & Services; Public, Environmental & Occupational Health; Medicine, General & Internal SC Health Care Sciences & Services; Public, Environmental & Occupational Health; General & Internal Medicine GA ER5UO UT WOS:000398869300002 ER PT J AU May, P Garrido, MM Cassel, JB Kelley, AS Meier, DE Normand, C Smith, TJ Morrison, RS AF May, Peter Garrido, Melissa M. Cassel, J. Brian Kelley, Amy S. Meier, Diane E. Normand, Charles Smith, Thomas J. Morrison, R. Sean TI Cost analysis of a prospective multi-site cohort study of palliative care consultation teams for adults with advanced cancer: Where do cost-savings come from? SO PALLIATIVE MEDICINE LA English DT Article DE Palliative care; economics; cancer; hospital costs; length of stay ID LENGTH-OF-STAY; ECONOMIC-IMPACT; GUIDANCE; LARGER AB Background: Studies report cost-savings from hospital-based palliative care consultation teams compared to usual care only, but drivers of observed differences are unclear. Aim: To analyse cost-differences associated with palliative care consultation teams using two research questions: (Q1) What is the association between early palliative care consultation team intervention, and intensity of services and length of stay, compared to usual care only? (Q2) What is the association between early palliative care consultation team intervention and day-to-day hospital costs, compared to a later intervention? Design: Prospective multi-site cohort study (2007-2011). Patients who received a consultation were placed in the intervention group, those who did not in the comparison group. Intervention group was stratified by timing, and groups were matched using propensity scores. Setting/participants: Adults admitted to three US hospitals with advanced cancer. Principle analytic sample contains 863 patients (n(UC) = 637; n(PC EARLY) = 177; n(PC LATE)=49) discharged alive. Results: Cost-savings from early palliative care accrue due to both reduced length of stay and reduced intensity of treatment, with an estimated 63% of savings associated with shorter length of stay. A reduction in day-to-day costs is observable in the days immediately following initial consult but does not persist indefinitely. A comparison of early and late palliative care consultation team cost-effects shows negligible difference once the intervention is administered. Conclusion: Reduced length of stay is the biggest driver of cost-saving from early consultation for patients with advanced cancer. Patient- and family-centred discussions on goals of care and transition planning initiated by palliative care consultation teams may be at least as important in driving cost-savings as the reduction of unnecessary tests and pharmaceuticals identified by previous studies. C1 [May, Peter; Normand, Charles] Trinity Coll Dublin, Ctr Hlth Policy & Management, 3-4 Foster Pl, Dublin 2, Ireland. [Garrido, Melissa M.; Morrison, R. Sean] James J Peters VA Med Ctr, Dept Geriatr & Palliat Med, Bronx, NY USA. [Garrido, Melissa M.; Kelley, Amy S.; Meier, Diane E.; Morrison, R. Sean] Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Cassel, J. Brian] Virginia Commonwealth Univ, Massey Canc Ctr, Div Hematol Oncol & Palliat Care, Richmond, VA USA. [Smith, Thomas J.] Johns Hopkins Med Inst, Palliat Med, Baltimore, MD 21205 USA. RP May, P (reprint author), Trinity Coll Dublin, Ctr Hlth Policy & Management, 3-4 Foster Pl, Dublin 2, Ireland. EM peter.may@tcd.ie FU National Cancer Institute [R01 CA116227]; HRB/NCI Health Economics Fellowship; Veterans Affairs HSRD [CDA 11-201/CDP 12-255]; National Institute on Aging [1K23AG040774-01A1]; American Federation for Aging; NCI [P 30 006973, 1-R01 CA177562-01A1, 1-R01 NR014050 01]; Harry J. Duffey Family Endowment for Palliative Care; Midcareer Investigator Award in Patient-Oriented Research [5K24AG022345]; NIA; Claude D. Pepper Older Americans Independence Center at the Icahn School of Medicine at Mount Sinai [5P30AG028741]; National Palliative Care Research Center FX The author(s) disclosed receipt of the following financial support for the research, authorship and/or publication of this article: This work was supported by the National Cancer Institute (Grant/ Award Number: '# R01 CA116227'). Dr May was supported by a HRB/NCI Health Economics Fellowship during this work. Dr Garrido is supported by a Veterans Affairs HSR&D career development award (CDA 11-201/CDP 12-255); the views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of VA or the United States government. Dr Kelley's time was funded by the National Institute on Aging (1K23AG040774-01A1) and the American Federation for Aging. Dr Smith is funded by the NCI Core Grant P 30 006973, 1-R01 CA177562-01A1, 1-R01 NR014050 01, and the Harry J. Duffey Family Endowment for Palliative Care. Dr Morrison was the recipient of a Midcareer Investigator Award in Patient-Oriented Research (5K24AG022345) during the course of this work. This work was supported by the NIA, Claude D. Pepper Older Americans Independence Center at the Icahn School of Medicine at Mount Sinai [5P30AG028741], and the National Palliative Care Research Center. NR 34 TC 0 Z9 0 U1 1 U2 1 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 0269-2163 EI 1477-030X J9 PALLIATIVE MED JI Palliat. Med. PD APR PY 2017 VL 31 IS 4 SI SI BP 378 EP 386 DI 10.1177/0269216317690098 PG 9 WC Health Care Sciences & Services; Public, Environmental & Occupational Health; Medicine, General & Internal SC Health Care Sciences & Services; Public, Environmental & Occupational Health; General & Internal Medicine GA ER5UO UT WOS:000398869300010 PM 28156192 ER PT J AU Hanson, ER Finley, EP Petershack, JA AF Hanson, Elizabeth R. Finley, Erin P. Petershack, Jean A. TI What Do Pediatric Residents Gain From an Experience in Juvenile Justice? A Qualitative Analysis of Community-Based Learning SO ACADEMIC PEDIATRICS LA English DT Article DE advocacy training; community pediatrics; juvenile justice; qualitative analysis; resident education ID MEDICAL-EDUCATION; HIDDEN CURRICULUM; REFLECTIVE CAPACITY; CHILD ADVOCACY; SERVICE; ROTATION; HEALTH; PROGRAM; PROFESSIONALISM; COMPETENCE AB BACKGROUND: Training in advocacy and community pediatrics often involves the use of community site visits. However, data on the specific knowledge, skills, and attitudes gained from these experiences are limited. In this study we used qualitative analysis of written narratives to explore the response of residents to a juvenile justice experience. METHODS: Pediatric residents participated in a week-long experience in the juvenile probation department and completed a written narrative. Narratives were analyzed using grounded theory to explore the effects of this experience on residents' views of youth in the juvenile justice system. RESULTS: Analysis of 29 narratives revealed 13 themes relating to 5 core concepts: social determinants of behavior, role of professionals and institutions, achieving future potential, resolving discrepancies, and distancing. A conceptual model was developed to explore the interactions of these concepts in the resident view of youth in the juvenile justice system. Of the themes only 3 (23%) were related to content explicitly covered in the assigned reading materials. CONCLUSIONS: Several important concepts emerged as elements of this experience, many of which were not covered in the explicit curriculum. Variability in attitudinal response to the experience raised important questions about the influence of the ideological framework of the learner and the hidden curriculum on the learning that occurs in community settings. We propose a theoretical model that delineates the factors that influence learning in community settings to guide educators in planning these types of experiences. C1 [Hanson, Elizabeth R.; Petershack, Jean A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat, 7703 Floyd Curl Dr,MSC 7808, San Antonio, TX 78229 USA. [Finley, Erin P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Finley, Erin P.] Univ Texas Hlth Sci Ctr San Antonio, Dept Psychiat, San Antonio, TX 78229 USA. [Finley, Erin P.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Hanson, ER (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Pediat, 7703 Floyd Curl Dr,MSC 7808, San Antonio, TX 78229 USA. EM Hansone3@uthscsa.edu NR 35 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1876-2859 EI 1876-2867 J9 ACAD PEDIATR JI Acad. Pediatr. PD APR PY 2017 VL 17 IS 3 BP 296 EP 302 PG 7 WC Pediatrics SC Pediatrics GA ER2UF UT WOS:000398648600013 PM 27988206 ER PT J AU Williams, NR Bentzley, BS Sahlem, GL Pannu, J Korte, JE Revuelta, G Short, EB George, MS AF Williams, N. R. Bentzley, B. S. Sahlem, G. L. Pannu, J. Korte, J. E. Revuelta, G. Short, E. B. George, M. S. TI Unilateral ultra-brief pulse electroconvulsive therapy for depression in Parkinson's disease SO ACTA NEUROLOGICA SCANDINAVICA LA English DT Article DE depression; electroconvulsive therapy; Parkinson's disease; ultra-brief pulse ID RATING-SCALE; ELECTRODE PLACEMENT; RECEPTOR-BINDING; DISORDERS; PSYCHOSIS; RECOMMENDATIONS; PERFORMANCE; CRITIQUE; NUCLEUS; ECT AB Objectives: Electroconvulsive therapy (ECT) has demonstrated efficacy in treating core symptoms of Parkinson's disease (PD); however, widespread use of ECT in PD has been limited due to concern over cognitive burden. We investigated the use of a newer ECT technology known to have fewer cognitive side effects (right unilateral [RUL] ultra-brief pulse [UBP]) for the treatment of medically refractory psychiatric dysfunction in PD. Materials and methods: This open-label pilot study included 6 patients who were assessed in the motoric, cognitive, and neuropsychiatric domains prior to and after RUL UBP ECT. Primary endpoints were changes in total score on the HAM-D-17 and GDS-30 rating scales. Results: Patients were found to improve in motoric and psychiatric domains following RUL UBP ECT without cognitive side effects, both immediately following ECT and at 1-month follow- up. Conclusions: This study demonstrates that RUL UBP ECT is safe, feasible, and potentially efficacious in treating multiple domains of PD, including motor and mood, without clear cognitive side effects. C1 [Williams, N. R.; Bentzley, B. S.; Pannu, J.] Stanford Univ, Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. [Revuelta, G.; George, M. S.] Med Univ South Carolina, Dept Neurol, Charleston, SC USA. [Sahlem, G. L.; Short, E. B.; George, M. S.] Med Univ South Carolina, Dept Psychiat, Charleston, SC USA. [Korte, J. E.] Med Univ South Carolina, Dept Publ Hlth Sci, Charleston, SC USA. [George, M. S.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. RP Williams, NR (reprint author), Dept Psychiat & Behav Sci, Stanford, CA 94305 USA. EM nolanw@stanford.edu OI Williams, Nolan/0000-0003-4368-3203; Bentzley, Brandon/0000-0001-6014-4514 FU NIH [F30 DA035065, T32 GM008716, R25 DA020537, 1K23NS091391-01A1, UL1TR000062] FX This work was supported by NIH grants F30 DA035065,T32 GM008716,R25 DA020537,1K23NS091391- -01A1, UL1TR000062. NR 33 TC 1 Z9 1 U1 1 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0001-6314 EI 1600-0404 J9 ACTA NEUROL SCAND JI Acta Neurol. Scand. PD APR PY 2017 VL 135 IS 4 BP 407 EP 411 DI 10.1111/ane.12614 PG 5 WC Clinical Neurology SC Neurosciences & Neurology GA EQ4HE UT WOS:000398035900004 PM 27241213 ER PT J AU Wimberly, AS Ivey, M Rennert, L McKay, JR AF Wimberly, Alexandra S. Ivey, Megan Rennert, Lior McKay, James R. TI Effect of Continuing Care for Cocaine Dependence on HIV Sex-Risk Behaviors SO AIDS AND BEHAVIOR LA English DT Article DE HIV; Sex-risk; Continuing care; Cocaine ID SEXUALLY-TRANSMITTED-DISEASES; RANDOMIZED CONTROLLED-TRIAL; ADDICTION SEVERITY INDEX; INJECTION-DRUG USERS; METAANALYTIC EVIDENCE; SMOKE CRACK; REDUCTION; INTERVENTIONS; RELIABILITY; EFFICACY AB Evaluate the effect of continuing care interventions for cocaine use with HIV risk-reduction components on HIV sex-risk. Explore whether cocaine use at treatment initiation interacts with the type of continuing care intervention to affect HIV sex-risk. Cocaine dependent participants (N = 321) were randomized to: (1) Treatment as usual (TAU): intensive outpatient treatment, (2) TAU and telephone monitoring and counseling (TMC), and (3) TAU and TMC plus incentives for participation in telephone contacts (TMC+). Participants in TMC and TMC+ received a brief HIV intervention, with booster sessions as needed. Generalized estimating equations analysis compared TAU, TMC and TMC+ at 6, 12, 18, 24 months post-baseline on the following outcomes: overall HIV sex-risk, number of sexual partners, condom usage, exchange of drugs for sex, exchange of sex for drugs, exchange of money for sex, exchange of sex for money, and crack house visits. Overall sex-risk decreased for all treatment conditions at follow-up, with no treatment main effects. For people with no cocaine use at baseline, TAU experienced greater sex-risk reductions than TMC (p < .01) and TMC+ (p < .001). The three treatment conditions are effective in reducing HIV sex-risk. TMC with HIV risk-reduction components is unnecessary for cocaine-dependent clients who stop using cocaine early in treatment. C1 [Wimberly, Alexandra S.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. [Ivey, Megan; McKay, James R.] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Rennert, Lior] Univ Penn, Biomed Grad Studies, Philadelphia, PA 19104 USA. [McKay, James R.] Philadelphia Vet Affairs Med Ctr, Dept Behav Hlth, Philadelphia, PA USA. RP Wimberly, AS (reprint author), Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. EM schepa@sp2.upenn.edu FU National Institute on Drug Abuse [F31 DA038429, R01 DA020623, K02 DA000361, K24 DA029062] FX This study was funded by National Institute on Drug Abuse Grants F31 DA038429, R01 DA020623, K02 DA000361, and K24 DA029062. Additional support was provided by the Center of Excellence in Substance Abuse Treatment and Education of the Department of Veterans Affairs. NR 33 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD APR PY 2017 VL 21 IS 4 BP 1082 EP 1090 DI 10.1007/s10461-016-1434-6 PG 9 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA EN6QM UT WOS:000396128500014 PM 27224980 ER PT J AU Becker, WC Gordon, K Edelman, EJ Kerns, RD Crystal, S Dziura, JD Fiellin, LE Gordon, AJ Goulet, JL Justice, AC Fiellin, DA AF Becker, William C. Gordon, Kirsha Edelman, E. Jennifer Kerns, Robert D. Crystal, Stephen Dziura, James D. Fiellin, Lynn E. Gordon, Adam J. Goulet, Joseph L. Justice, Amy C. Fiellin, David A. TI Trends in Any and High-Dose Opioid Analgesic Receipt Among Aging Patients With and Without HIV (vol 20, pg 679, 2016) SO AIDS AND BEHAVIOR LA English DT Correction C1 [Becker, William C.; Gordon, Kirsha; Justice, Amy C.] VA Connecticut Healthcare Syst, West Haven VA Med Ctr, Internal Med, Mail Stop 151B,950 Campbell Ave, West Haven, CT 06516 USA. [Kerns, Robert D.; Goulet, Joseph L.] VA Connecticut Healthcare Syst, Psychol, West Haven, CT USA. [Becker, William C.; Edelman, E. Jennifer; Dziura, James D.; Fiellin, Lynn E.; Justice, Amy C.; Fiellin, David A.] Yale Univ, Sch Med, Internal Med, New Haven, CT USA. [Kerns, Robert D.; Goulet, Joseph L.] Yale Univ, Sch Med, Psychol, New Haven, CT USA. [Crystal, Stephen] Rutgers State Univ, Ctr Hlth Serv Res, New Brunswick, NJ USA. [Gordon, Adam J.] Univ Pittsburgh, Pittsburgh, PA USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. RP Becker, WC (reprint author), VA Connecticut Healthcare Syst, West Haven VA Med Ctr, Internal Med, Mail Stop 151B,950 Campbell Ave, West Haven, CT 06516 USA.; Becker, WC (reprint author), Yale Univ, Sch Med, Internal Med, New Haven, CT USA. EM william.becker@yale.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER/PLENUM PUBLISHERS PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1090-7165 EI 1573-3254 J9 AIDS BEHAV JI AIDS Behav. PD APR PY 2017 VL 21 IS 4 BP 1228 EP 1228 DI 10.1007/s10461-017-1725-6 PG 1 WC Public, Environmental & Occupational Health; Social Sciences, Biomedical SC Public, Environmental & Occupational Health; Biomedical Social Sciences GA EN6QM UT WOS:000396128500026 PM 28188459 ER PT J AU Simpson, TL Lehavot, K Petrakis, IL AF Simpson, Tracy L. Lehavot, Keren Petrakis, Ismene L. TI No Wrong Doors: Findings from a Critical Review of Behavioral Randomized Clinical Trials for Individuals with Co-Occurring Alcohol/Drug Problems and Posttraumatic Stress Disorder SO ALCOHOLISM-CLINICAL AND EXPERIMENTAL RESEARCH LA English DT Review DE Posttraumatic Stress Disorder; Substance Use Disorders; Behavioral Intervention; Psychotherapy; Critical Review ID SUBSTANCE USE DISORDERS; CONTINGENCY MANAGEMENT PROCEDURES; NATIONAL EPIDEMIOLOGIC SURVEY; CHRONIC CARE MANAGEMENT; DEPENDENT PATIENTS; EXPOSURE THERAPY; PTSD; TRAUMA; INTERVENTIONS; METAANALYSIS AB Prior reviews of behavioral treatments for individuals with comorbid alcohol and drug use disorders (substance use disorder SUD) and posttraumatic stress disorder (PTSD) have not systematically considered whether comparison conditions are matched to target treatments on time and attention. A systematic literature search using PubMed MESH terms for alcohol and substance use disorders, PTSD, and treatment identified relevant behavioral randomized clinical trials (RCTs) that evaluated PTSD-oriented exposure-based treatments, addiction-focused treatments, and coping-based treatments that do not involve exposure to trauma memories. Information pertaining to within-subject changes over time and between-subject differences, quality of control condition, recruitment efficiency, and assessment and treatment retention was synthesized. Alcohol and drug outcomes were described separately when possible. Twenty-four behavioral RCTs were identified: 7 exposure based, 6 addiction focused, and 11 coping based. Seven studies included SUD intervention comparison conditions matched to the target intervention on time and attention. Most of the 24 studies found that participants in both the experimental and control conditions improved significantly over time on SUD and PTSD outcomes. No study found significant between-group differences in both SUD and PTSD outcomes favoring the experimental treatment. Despite greater treatment dropout, there was greater improvement in some PTSD outcomes for exposure-based interventions than the control conditions, including when the control conditions were matched for time and attention. Addiction-focused and coping-based interventions did not generally show an advantage over comparably robust controls, although some coping-based interventions yielded better drug use outcomes than control conditions. When available, interventions that integrate exposure-based PTSD treatment and behavioral SUD treatment are recommended as they are associated with better PTSD outcomes than SUD care matched for time and attention. However, the results of this critical review also suggest that people with SUD/PTSD can benefit from a variety of treatment options, including standard SUD care. C1 [Simpson, Tracy L.] VA Puget Sound Hlth Care, CESATE, Seattle, WA USA. [Simpson, Tracy L.; Lehavot, Keren] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Lehavot, Keren] VA Puget Sound Hlth Care, Ctr Innovat Vet Ctr & Value Driven Care, HSR&D, Seattle, WA USA. [Lehavot, Keren] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Petrakis, Ismene L.] Mental Illness Res Educ & Clin Ctr MIRECC VA Conn, West Haven, CT USA. [Petrakis, Ismene L.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA. RP Petrakis, IL (reprint author), Yale Univ, West Haven VA Med Ctr, 116A,950 Campbell Ave 116-A, West Haven, CT 06516 USA. EM Ismene.Petrakis@Yale.Edu FU CSRD VA [IK2 CX000867] NR 52 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0145-6008 EI 1530-0277 J9 ALCOHOL CLIN EXP RES JI Alcoholism (NY) PD APR PY 2017 VL 41 IS 4 BP 681 EP 702 DI 10.1111/acer.13325 PG 22 WC Substance Abuse SC Substance Abuse GA ER2KF UT WOS:000398622200002 PM 28055143 ER PT J AU George, JF Lever, JM Agarwal, A AF George, James F. Lever, Jeremie M. Agarwal, Anupam TI Mononuclear phagocyte subpopulations in the mouse kidney SO AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY LA English DT Review DE acute kidney injury; inflammation; ischemia-reperfusion; macrophages; renal fibrosis ID ISCHEMIA-REPERFUSION INJURY; RENAL ISCHEMIA/REPERFUSION INJURY; TUBULAR EPITHELIAL-CELLS; REGULATORY T-CELLS; DENDRITIC CELLS; RESIDENT MACROPHAGES; ALTERNATIVE ACTIVATION; ADRIAMYCIN NEPHROPATHY; TISSUE MACROPHAGES; STEADY-STATE AB Mononuclear phagocytes are the most common cells in the kidney associated with immunity and inflammation. Although the presence of these cells in the kidney has been known for decades, the study of mononuclear phagocytes in the context of kidney function and dysfunction is still at an early stage. The purpose of this review is to summarize the present knowledge regarding classification of these cells in the mouse kidney and to identify relevant questions that would further advance the field and potentially lead to new opportunities for treatment of acute kidney injury and other kidney diseases. C1 [George, James F.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA. [Lever, Jeremie M.; Agarwal, Anupam] Univ Alabama Birmingham, Dept Med, Birmingham, AL 35294 USA. [George, James F.; Lever, Jeremie M.; Agarwal, Anupam] Univ Alabama Birmingham, Dept Nephrol, Birmingham, AL USA. [George, James F.; Lever, Jeremie M.; Agarwal, Anupam] Univ Alabama Birmingham, Res & Training Ctr, Birmingham, AL USA. [Agarwal, Anupam] US Dept Vet Affairs, Birmingham, AL USA. RP Agarwal, A (reprint author), Univ Alabama Birmingham, Dept Med, Div Nephrol, Rm 647 THT,1720 2nd Ave South, Birmingham, AL 35294 USA. EM agarwal@uab.edu FU University of Alabama at Birmingham-University of California San Diego O'Brien Center [P30 DK079337, R01 DK059600]; NIGMS MSTP [T32GM008361]; AHA [17PRE33370121, 16GRNT31180023] FX The authors acknowledge grant support from the University of Alabama at Birmingham-University of California San Diego O'Brien Center (P30 DK079337) and R01 DK059600 (to A. Agarwal and J. F. George), NIGMS MSTP T32GM008361 to Dr. Robin Lorenz for J. M. Lever; AHA 17PRE33370121 to J. M. Lever; and 16GRNT31180023 to J. F. George. NR 63 TC 0 Z9 0 U1 1 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 1931-857X EI 1522-1466 J9 AM J PHYSIOL-RENAL JI Am. J. Physiol.-Renal Physiol. PD APR PY 2017 VL 312 IS 4 BP F640 EP F646 DI 10.1152/ajprenal.00369.2016 PG 7 WC Physiology; Urology & Nephrology SC Physiology; Urology & Nephrology GA EQ2AS UT WOS:000397871300010 PM 28100500 ER PT J AU Sunshine, JE Dagal, A Burns, SP Bransford, RJ Zhang, F Newman, SF Nair, BG Sharar, SR AF Sunshine, Jacob E. Dagal, Armagan Burns, Stephen P. Bransford, Richard J. Zhang, Fangyi Newman, Shu-Fang Nair, Bala G. Sharar, Sam R. TI Methylprednisolone Therapy in Acute Traumatic Spinal Cord Injury: Analysis of a Regional Spinal Cord Model Systems Database SO ANESTHESIA AND ANALGESIA LA English DT Article ID CONTROLLED-TRIAL; STEROIDS; EPIDEMIOLOGY AB BACKGROUND: The objective of this study was to assess the relationship between exposure to methylprednisolone (MO) and improvements in motor function among patients with acute traumatic spinal cord injury (TSCI). MP therapy for patients with TSCI is controversial because of the current conflicting evidence documenting its benefits and risks. METHODS: We conducted a retrospective cohort study from September 2007 to November 2014 of 311 patients with acute TSCI who were enrolled into a model systems database of a regional, level I trauma center. We linked outcomes and covariate data from the model systems database with MP exposure data from the electronic medical record. The primary outcomes were rehabilitation discharge in American Spinal Injury Association (ASIA) motor scores (sum of 10 key muscles bilaterally as per International Standards for Neurological Classification of Spinal Cord Injury, range, 0-100) and Functional Independence Measure (FIM) motor scores (range, 13-91). Secondary outcomes measured infection risk and gastrointestinal (GI) complications among MP recipients. For the primary outcomes, multivariable linear regression was used. RESULTS: There were 160 MP recipients and 151 nonrecipients. Adjusting for age, sex, weight, race, respective baseline motor score, surgical intervention, injury level, ASIA Impairment Scale (AIS) grade, education, and insurance status, there was no association with improvement in discharge ASIA motor function or FIM motor score among MP recipients: -0.34 (95% CI, -2.8, 2.1) and 0.75 (95% CI, -2.8, 4.3), respectively. Adjusting for age, sex, race, weight, injury level, and receipt of surgery, no association with increased risk of infection or GI complications was observed. CONCLUSIONS: This retrospective cohort study involving patients with acute TSCI observed no short-term improvements in motor function among MP recipients compared with nonrecipients. Our findings support current recommendations that MP use in this population should be limited. C1 [Sunshine, Jacob E.; Dagal, Armagan; Newman, Shu-Fang; Nair, Bala G.; Sharar, Sam R.] Univ Washington, Dept Anesthesiol & Pain Med, 1959 NE Pacific St,Box 356540, Seattle, WA 98195 USA. [Dagal, Armagan; Bransford, Richard J.] Univ Washington, Harborview Med Ctr, Orthopaed & Sports Med, 1959 NE Pacific St,Box 356540, Seattle, WA 98195 USA. [Burns, Stephen P.] Vet Affairs Puget Sound Hlth Care Syst, Spinal Cord Injury Serv, Seattle, WA USA. [Burns, Stephen P.] Univ Washington, Harborview Med Ctr, Dept Rehabil, Seattle, WA USA. [Zhang, Fangyi] Univ Washington, Harborview Med Ctr, Dept Neurosurg, 1959 NE Pacific St,Box 356540, Seattle, WA 98195 USA. RP Dagal, A (reprint author), Univ Washington, Sch Med, Dept Anesthesiol & Pain Med, 1959 NE Pacific St,Box 356540, Seattle, WA 98195 USA. EM dagal@uw.edu FU National Institute on Disability, Independent Living and Rehabilitation Research Grant [90SI5006-01-00] FX This study was supported in part by a National Institute on Disability, Independent Living and Rehabilitation Research Grant (90SI5006-01-00). NR 25 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-2999 J9 ANESTH ANALG JI Anesth. Analg. PD APR PY 2017 VL 124 IS 4 BP 1200 EP 1205 DI 10.1213/ANE.0000000000001906 PG 6 WC Anesthesiology SC Anesthesiology GA EP4MH UT WOS:000397354100025 PM 28319547 ER PT J AU Larson, J AF Larson, James TI An Alternate Take on Airside Economizing SO ASHRAE JOURNAL LA English DT Article AB In a dry, desert climate such as in Phoenix, we must still design for occasional freezing temperatures. For a Veterans Affairs medical center and campus in that climate, we found that using advanced direct digital control (DDC) strategies with airside economizers worked well, contributing to an approximate 45% reduction in air-conditioning electricity consumption between 2008 and 2013. C1 [Larson, James] US Dept Vet Affairs, Washington, DC 20571 USA. RP Larson, J (reprint author), US Dept Vet Affairs, Washington, DC 20571 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC HEATING REFRIGERATING AIR-CONDITIONING ENG, INC, PI ATLANTA PA 1791 TULLIE CIRCLE NE, ATLANTA, GA 30329 USA SN 0001-2491 EI 1943-6637 J9 ASHRAE J JI ASHRAE J. PD APR PY 2017 VL 59 IS 4 BP 36 EP 41 PG 6 WC Thermodynamics; Construction & Building Technology; Engineering, Mechanical SC Thermodynamics; Construction & Building Technology; Engineering GA EQ9UK UT WOS:000398430500007 ER PT J AU Goldzweig, CL AF Goldzweig, Caroline Lubick TI Opening up to Open Notes and adding the patient to the team SO BMJ QUALITY & SAFETY LA English DT Editorial Material ID DECISION-MAKING; HEALTH RECORDS; CLINICAL NOTES; OUTCOMES; PORTALS; EXPERIENCES; ACCESS C1 [Goldzweig, Caroline Lubick] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Goldzweig, Caroline Lubick] Univ Calif Los Angeles, David Geffen Sch Med, Hlth Sci Clin Prof Med, Los Angeles, CA 90095 USA. RP Goldzweig, CL (reprint author), 11301 Wilshire Blvd,Mail Code 11, Los Angeles, CA 90073 USA. EM Caroline.Goldzweig@va.gov NR 12 TC 0 Z9 0 U1 0 U2 0 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 2044-5415 EI 2044-5423 J9 BMJ QUAL SAF JI BMJ Qual. Saf. PD APR PY 2017 VL 26 IS 4 BP 257 EP 258 DI 10.1136/bmjqs-2016-005641 PG 2 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA EP7UR UT WOS:000397583200002 PM 27343275 ER PT J AU Bowe, B Xie, Y Xian, H Li, TT Al-Aly, Z AF Bowe, Benjamin Xie, Yan Xian, Hong Li, Tingting Al-Aly, Ziyad TI Association between Monocyte Count and Risk of Incident CKD and Progression to ESRD SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID DENSITY-LIPOPROTEIN CHOLESTEROL; CHRONIC KIDNEY-DISEASE; RENAL INJURY; MORTALITY; ATHEROSCLEROSIS; PREDICTOR; FIBROSIS; OUTCOMES; MICE AB Background and objectives Experimental evidence suggests a role for monocytes in the biology of kidney disease progression; however, whether monocyte count is associated with risk of incident CKD, CKD progression, and ESRD has not been examined in large epidemiologic studies. Design, settings, participants, & measurements We built a longitudinal observational cohort of 1,594,700 United States veterans with at least one eGFR during fiscal year 2004 (date of last eGFR during this period designated time zero) and no prior history of ESRD, dialysis, or kidney transplant. Cohort participants were followed until September 30, 2013 or death. Monocyte count closest to and before time zero was categorized in quartiles: quartile 1, >0.00 to <= 0.40 thousand cells per cubic millimeter (k/cmm); quartile 2, >0.40 to <= 0.55 k/cmm; quartile 3, >0.55 to <= 0.70 k/cmm; and quartile 4, >0.70 k/cmm. Survival models were built to examine the association between monocyte count and risk of incident eGFR<60 ml/min per 1.73 m(2), risk of incident CKD, and risk of CKD progression defined as doubling of serum creatinine, eGFR decline or the composite outcome of ESRD, dialysis, or renal transplantation. Results Over a median follow-up of 9.2 years (interquartile range, 8.3-9.4); in adjusted survival models, there was a graded association between monocyte counts and risk of renal outcomes. Compared with quartile 1, quartile 4 was associated with higher risk of incident eGFR<60 ml/min per 1.73 m(2) (hazard ratio, 1.13; 95% confidence interval, 1.12 to 1.14) and risk of incident CKD (hazard ratio, 1.15; 95% confidence interval, 1.13 to 1.16). Quartile 4 was associated with higher risk of doubling of serum creatinine (hazard ratio, 1.22; 95% confidence interval, 1.20 to 1.24), >= 30% eGFR decline (hazard ratio, 1.18; 95% confidence interval, 1.17 to 1.19), and the composite renal end point (hazard ratio, 1.19; 95% confidence interval, 1.16 to 1.22). Cubic spline analyses of the relationship between monocyte count levels and renal outcomes showed a linear relationship, in which risk was higher with higher monocyte count. Results were robust to changes in sensitivity analyses. Conclusions Our results show a significant association between higher monocyte count and risks of incident CKD and CKD progression to ESRD. C1 [Bowe, Benjamin; Xie, Yan; Xian, Hong; Li, Tingting; Al-Aly, Ziyad] US Dept Vet Affairs, Clin Epidemiol Ctr, Res & Educ Serv, St Louis Hlth Care Syst, St Louis, MO USA. [Al-Aly, Ziyad] US Dept Vet Affairs, Div Nephrol, Dept Med, St Louis Hlth Care Syst, St Louis, MO USA. [Xian, Hong] St Louis Univ, Coll Publ Hlth & Social Justice, Dept Biostat, St Louis, MO 63103 USA. [Li, Tingting; Al-Aly, Ziyad] Washington Univ, Sch Med, Dept Med, St Louis, MO 63110 USA. [Al-Aly, Ziyad] Washington Univ, Sch Med, Inst Publ Hlth, St Louis, MO USA. RP Al-Aly, Z (reprint author), US Dept Vet Affairs, Clin Epidemiol Ctr, St Louis Hlth Care Syst, 915 North Grand Blvd,151-JC, St Louis, MO 63106 USA. EM zalaly@gmail.com FU US Department of Veterans Affairs (VA); VA, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, VA Information Resource Center Project/Data Use Agreement [Al-Aly-01] FX This work was funded by a grant from the US Department of Veterans Affairs (VA; to Z.A.-A.). Support for the VA/Centers for USRDS Data is provided by VA, Veterans Health Administration, Office of Research and Development, Health Services Research and Development, VA Information Resource Center Project/Data Use Agreement Al-Aly-01. NR 42 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD APR PY 2017 VL 12 IS 4 BP 603 EP 613 DI 10.2215/CJN.09710916 PG 11 WC Urology & Nephrology SC Urology & Nephrology GA ER2TN UT WOS:000398646800010 PM 28348030 ER PT J AU Miller, MJ Stevens-Lapsley, J Fields, TT Coons, D Bray-Hall, S Sullivan, W Christiansen, CL AF Miller, Matthew J. Stevens-Lapsley, Jennifer Fields, Thomas T. Coons, David Bray-Hall, Susan Sullivan, William Christiansen, Cory L. TI Physical activity behavior change for older veterans after dysvascular amputation SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Dysvascular amputation; Physical activity; Behavior change; Veteran; Telerehabilitation; Feasibility ID LOWER-LIMB AMPUTATION; RANDOMIZED CONTROLLED-TRIAL; QUALITY-OF-LIFE; PROSTHESIS EVALUATION QUESTIONNAIRE; UNILATERAL TRANSTIBIAL AMPUTATION; PERIPHERAL ARTERIAL-DISEASE; IMPAIRED GLUCOSE-TOLERANCE; GERIATRIC DEPRESSION SCALE; TOTAL KNEE ARTHROPLASTY; HEART-RATE RESPONSE AB Objective: Determine the feasibility of using a physical-activity behavior-change (PABC) intervention for increasing physical activity and reducing disability in Veterans 1-5 years following dysvascular lower-limb amputation (LLA). Design: Cross-over, feasibility trial Setting: VA Geriatric Research Education and Clinical Center and Veterans Homes Participants: 32 Veterans with dysvascular LLA (1-5 years after major LLA) Intervention: The home-based study, using telerehabilitation technology, is intended to reduce participant burden by removing transportation and time bafflers. Participants will be randomized into two participation periods of three months (Months 1-3 and 4-6). PABC intervention will occur Months 1-3 for GROUP1 and Months 4-6 for GROUP2. During PABC Intervention, participants engage in weekly video interaction with a physical therapist, who uses a collaborative approach to develop self-monitoring, barrier identification, problem solving and action planning skills to improve physical activity. GROUP2 will participate in a no physical activity intervention, attention control in Months 1-3. GROUP1 will have a no contact, intervention "wash-out" period in Months 4-6. Main outcome measures: Feasibility will be determined using measures of 1) participant retention, 2) dose goal attainment, 3) participant acceptability, 4) safety, and 5) initial effect size. Effect size will be based on accelerometer-based physical activity and self-report disability using the Late-Life Function and Disability Index. Conclusions: This study focuses on a prevalent and understudied population with low physical activity and high levels of disability due to dysvascular LLA. The results of this study will guide future development of targeted rehabilitation research to improve long term physical activity and disability outcomes. Published by Elsevier Inc. C1 [Miller, Matthew J.; Stevens-Lapsley, Jennifer; Coons, David; Bray-Hall, Susan; Sullivan, William; Christiansen, Cory L.] Univ Colorado Denver, Sch Med, Dept Phys Med & Rehabil, 13121 East 17th Ave, Aurora, CO 80045 USA. [Stevens-Lapsley, Jennifer; Bray-Hall, Susan; Sullivan, William; Christiansen, Cory L.] VA Eastern Colorado Healthcare Syst, Geriatr Res Educ & Clin Ctr, 1055 Clermont St, Denver, CO 80220 USA. [Miller, Matthew J.; Fields, Thomas T.; Coons, David; Bray-Hall, Susan; Sullivan, William] VA Eastern Colorado Healthcare Syst, Denver Vet Affairs Med Ctr, 1055 Clermont St, Denver, CO 80220 USA. RP Miller, MJ (reprint author), 13121 East 17th Ave,Mail Stop C244, Aurora, CO 80045 USA. EM matthew.j4.miller@ucdenver.edu OI Miller, Matthew/0000-0002-1301-7149 FU Small Projects in Rehabilitation Research (SPiRE) [RX002054-01A1]; NIH [K12 HD055931] FX We would like to thank Veterans and staff devoting time and effort to the success of the study. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. Additionally, we would like to acknowledge Pam Wolfe for her assistance in the statistical methods design. This study is funded by a grant from Small Projects in Rehabilitation Research (SPiRE; RX002054-01A1) and Dr. Christiansen's time supported in part by NIH grant (K12 HD055931). NR 71 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 EI 1559-2030 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD APR PY 2017 VL 55 BP 10 EP 15 DI 10.1016/j.cct.2017.01.008 PG 6 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA EP9KI UT WOS:000397692100002 PM 28153768 ER PT J AU Middlebrooks, EH Ver Hoef, L Szaflarski, JP AF Middlebrooks, Erik H. Ver Hoef, Lawrence Szaflarski, Jerzy P. TI Neuroimaging in Epilepsy SO CURRENT NEUROLOGY AND NEUROSCIENCE REPORTS LA English DT Review DE Epilepsy; Seizure; Neuroimaging; fMRI; DiffusionMRI; EEG ID TEMPORAL-LOBE EPILEPSY; IDIOPATHIC GENERALIZED EPILEPSY; VERBAL MEMORY DECLINE; INTERICTAL EPILEPTIFORM DISCHARGES; GUIDELINE DEVELOPMENT SUBCOMMITTEE; FOCAL CORTICAL DYSPLASIA; UNPROVOKED 1ST SEIZURE; EEG-FMRI; FUNCTIONAL MRI; AMERICAN-ACADEMY AB In recent years, the field of neuroimaging has undergone dramatic development. Specifically, of importance for clinicians and researchers managing patients with epilepsies, new methods of brain imaging in search of the seizure-producing abnormalities have been implemented, and older methods have undergone additional refinement. Methodology to predict seizure freedom and cognitive outcome has also rapidly progressed. In general, the image data processing methods are very different and more complicated than even a decade ago. In this review, we identify the recent developments in neuroimaging that are aimed at improved management of epilepsy patients. Advances in structural imaging, diffusion imaging, fMRI, structural and functional connectivity, hybrid imaging methods, quantitative neuroimaging, and machine-learning are discussed. We also briefly summarize the potential new developments that may shape the field of neuroimaging in the near future and may advance not only our understanding of epileptic networks as the source of treatment-resistant seizures but also better define the areas that need to be treated in order to provide the patients with better long-term outcomes. C1 [Middlebrooks, Erik H.] UAB, Dept Radiol, Birmingham, AL USA. [Ver Hoef, Lawrence; Szaflarski, Jerzy P.] UAB, Dept Neurol, UAB Epilepsy Ctr, 1719 6th Ave South,CIRC 312, Birmingham, AL 35294 USA. [Ver Hoef, Lawrence] UAB, Birmingham VA Med Ctr, Birmingham, AL USA. RP Szaflarski, JP (reprint author), UAB, Dept Neurol, UAB Epilepsy Ctr, 1719 6th Ave South,CIRC 312, Birmingham, AL 35294 USA. EM jszaflarski@uabmc.edu OI Middlebrooks, Erik/0000-0002-4418-9605 FU National Institutes of Health [K23EB008452, R01NS094743] FX No funding was provided for this study. Data for Fig. 1 were obtained via grants K23EB008452 and R01NS094743 from the National Institutes of Health to LVH. NR 113 TC 0 Z9 0 U1 4 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1528-4042 EI 1534-6293 J9 CURR NEUROL NEUROSCI JI Curr. Neurol. Neurosci. Rep. PD APR PY 2017 VL 17 IS 4 AR 32 DI 10.1007/s11910-017-0746-x PG 11 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA EQ3VH UT WOS:000398000900007 PM 28324301 ER PT J AU Willard, JR Barrow, BM Zraika, S AF Willard, Joshua R. Barrow, Breanne M. Zraika, Sakeneh TI Improved glycaemia in high-fat-fed neprilysin-deficient mice is associated with reduced DPP-4 activity and increased active GLP-1 levels SO DIABETOLOGIA LA English DT Article DE DPP-4; GLP-1; Glucose tolerance; High fat diet; Insulin secretion; Mme; Mouse; Nep; Neprilysin ID ANGIOTENSIN-CONVERTING ENZYME; DIPEPTIDYL-PEPTIDASE-IV; NEUTRAL ENDOPEPTIDASE ACTIVITY; GLUCAGON-LIKE PEPTIDE-1; INSULIN SENSITIVITY; METABOLIC SYNDROME; HUMAN SERUM; INHIBITION; CELLS; DEGRADATION AB Aim/hypothesis Neprilysin, a widely expressed peptidase, is upregulated in metabolically altered states such as obesity and type 2 diabetes. Like dipeptidyl peptidase-4 (DPP-4), neprilysin can degrade and inactivate the insulinotropic peptide glucagon-like peptide-1 (GLP-1). Thus, we investigated whether neprilysin deficiency enhances active GLP-1 levels and improves glycaemia in a mouse model of high fat feeding. Methods Nep(+/+) and Nep(-/-) mice were fed a 60% fat diet for 16 weeks, after which active GLP-1 and DPP-4 activity levels were measured, as were glucose, insulin and C-peptide levels during an OGTT. Insulin sensitivity was assessed using an insulin tolerance test. Results High-fat-fed Nep-/-mice exhibited elevated active GLP-1 levels (5.8 +/- 1.1 vs 3.5 +/- 0.8 pmol/l, p<0.05) in association with improved glucose tolerance, insulin sensitivity and beta cell function compared with high-fat-fed Nep+/+ mice. In addition, plasma DPP-4 activity was lower in high-fat-fed Nep-/-mice (7.4 +/- 1.0 vs 10.7 +/- 1.3 nmol ml(-1) min(-1), p<0.05). No difference in insulin: C-peptide ratio was observed between Nep(-/-) and Nep+/+ mice, suggesting that improved glycaemia does not result from changes in insulin clearance. Conclusions/interpretation Under conditions of increased dietary fat, an improved glycaemic status in neprilysin-deficient mice is associated with elevated active GLP-1 levels, reduced plasma DPP-4 activity and improved beta cell function. Thus, neprilysin inhibition may be a novel treatment strategy for type 2 diabetes. C1 [Willard, Joshua R.; Barrow, Breanne M.; Zraika, Sakeneh] Vet Affairs Puget Sound Hlth Care Syst, 1660 South Columbian Way 151, Seattle, WA 98108 USA. [Zraika, Sakeneh] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. RP Zraika, S (reprint author), Vet Affairs Puget Sound Hlth Care Syst, 1660 South Columbian Way 151, Seattle, WA 98108 USA.; Zraika, S (reprint author), Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA 98195 USA. EM zraikas@uw.edu FU National Institutes of Health [DK-098506, DK-080945, P30 DK-017047]; United States Department of Veterans Affairs FX This work was supported by the National Institutes of Health (grants DK-098506 and DK-080945 to SZ; P30 DK-017047 to the Cell Function Analysis Core, University of Washington Diabetes Research Center) and the United States Department of Veterans Affairs. NR 27 TC 1 Z9 1 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0012-186X EI 1432-0428 J9 DIABETOLOGIA JI Diabetologia PD APR PY 2017 VL 60 IS 4 BP 701 EP 708 DI 10.1007/s00125-016-4172-4 PG 8 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EQ4KS UT WOS:000398046400011 PM 27933334 ER PT J AU Sonnenberg, A Turner, KO Genta, RM AF Sonnenberg, Amnon Turner, Kevin O. Genta, Robert M. TI Interaction of Ethnicity and H-pylori Infection in the Occurrence of Microscopic Colitis SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Collagenous colitis; Environmental risk factors; Epidemiology; Lymphocytic colitis; Helicobacter ID INFLAMMATORY-BOWEL-DISEASE; UNITED-STATES; METAANALYSIS; ASSOCIATION; CLASSIFICATION; GASTRITIS; NEOPLASIA; RECORDS; CANCER AB Previous studies found that microscopic colitis is inversely associated with Helicobacter pylori infection and that microscopic colitis is characterized by a marked ethnic variation. The aim of the present study was to test whether an underlying ethnic variation of H. pylori infection is responsible for the ethnic variation of microscopic colitis. The Miraca Life Sciences Database is a large national electronic repository of histopathologic records of patients distributed throughout the entire USA. A cross-sectional study evaluated the influence of age, gender, ethnicity, and histologic diagnosis of H. pylori on the occurrence of microscopic colitis among subjects who underwent esophago-gastro-duodenoscopies plus colonoscopy. The total study population comprised 228,506 subjects, of whom 28,890 carried a diagnosis of H. pylori gastritis and 3460 microscopic colitis. Female sex, old age, and H. pylori infection exerted the strongest influence on the occurrence of microscopic colitis. In comparison with the population comprising Caucasians and African-Americans, microscopic colitis was less common among subjects of Hispanic (0.34, 0.27-0.47), East Asian (0.13, 0.06-0.22), Indian (0.31, 0.10-0.73), or Middle Eastern descent (0.28, 0.07-0.74). All these ethnic subgroups were also characterized by a higher prevalence of H. pylori than the comparison group. A low prevalence of H. pylori was significantly associated with a high prevalence of microscopic colitis (R (2) = 0.91, p < 0.001). Ethnic variations in the gastric infection with H. pylori may be partly responsible for the observed ethnic distribution of microscopic colitis. C1 [Sonnenberg, Amnon; Turner, Kevin O.; Genta, Robert M.] Miraca Life Sci, Irving, TX 75039 USA. [Sonnenberg, Amnon] Oregon Hlth & Sci Univ, Portland VA Med Ctr, P3-GI, Portland, OR 97239 USA. [Genta, Robert M.] Baylor Coll Med, Houston, TX 77030 USA. RP Sonnenberg, A (reprint author), Miraca Life Sci, Irving, TX 75039 USA.; Sonnenberg, A (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, P3-GI, Portland, OR 97239 USA. EM sonnenbe@ohsu.edu NR 26 TC 0 Z9 0 U1 3 U2 3 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD APR PY 2017 VL 62 IS 4 BP 1009 EP 1015 DI 10.1007/s10620-016-4441-6 PG 7 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EN9UA UT WOS:000396343900025 PM 28070826 ER PT J AU Gulati, S Wells, JM AF Gulati, Swati Wells, J. Michael TI Bringing Stability to the Chronic Obstructive Pulmonary Disease Patient: Clinical and Pharmacological Considerations for Frequent Exacerbators SO DRUGS LA English DT Review ID PLACEBO-CONTROLLED TRIAL; TO-SEVERE COPD; RANDOMIZED CONTROLLED-TRIAL; PDE4 INHIBITOR ROFLUMILAST; DAILY ACLIDINIUM BROMIDE; CHRONIC LUNG-DISEASE; DOUBLE-BLIND; INHALED CORTICOSTEROIDS; INFLAMMATORY MARKERS; N-ACETYLCYSTEINE AB Acute exacerbations of chronic obstructive pulmonary disease (AECOPD) are critical events associated with an accelerated loss of lung function, increased morbidity, and excess mortality. AECOPD are heterogeneous in nature and this may directly impact clinical decision making, specifically in patients with frequent exacerbations. A 'frequent exacerbator' is a sub-phenotype of chronic obstructive pulmonary disease (COPD) and is defined as an individual who experiences two or more moderate-to-severe exacerbations per year. This distinct subgroup has higher mortality and accounts for more than half of COPD-related hospitalizations annually. Thus, it is imperative to identify individuals at risk for frequent exacerbations and choose optimal strategies to minimize risk for these events. New paradigms for using combination inhalers and the introduction of novel oral compounds provide expanded treatment options to reduce the risk and frequency of exacerbations. The goals of managing frequent exacerbators or patients at risk for AECOPD are: (1) maximizing bronchodilation; (2) reducing inflammation; and (3) targeting specific molecular pathways implicated in COPD and AECOPD pathogenesis. Novel inhaler therapies including combination long-acting muscarinic agents plus long-acting beta agonists show promising results compared with monotherapy or a long-acting beta agonist inhaled corticosteroid combination in reducing exacerbation risk among individuals at risk for exacerbations and among frequent exacerbators. Likewise, oral medications including macrolides and phosphodiesterase-4 inhibitors reduce the risk for AECOPD in select groups of individuals at high risk for exacerbation. Future direction in COPD management is based on the identification of various subtypes or ` endotypes' and targeting therapies based on their pathophysiology. This review describes the impact of AECOPD and the challenges posed by frequent exacerbators, and explores the rationale for different pharmacologic approaches to preventing AECOPD in these individuals. C1 [Gulati, Swati; Wells, J. Michael] Univ Alabama Birmingham, Div Pulm Allergy & Crit Care, Lung Hlth Ctr, Birmingham, AL 35294 USA. [Wells, J. Michael] Birmingham VA Med Ctr, Birmingham, AL 35233 USA. RP Wells, JM (reprint author), Univ Alabama Birmingham, Div Pulm Allergy & Crit Care, Lung Hlth Ctr, Birmingham, AL 35294 USA.; Wells, JM (reprint author), Birmingham VA Med Ctr, Birmingham, AL 35233 USA. EM jmwells@uabmc.edu FU National Institutes of Health/National Heart, Lung, and Blood Institute [K08 123940]; Cystic Fibrosis Foundation FX S.G. has no conflict of interest to disclose. J.M.W. receives grant funding from the National Institutes of Health/National Heart, Lung, and Blood Institute (K08 123940) and the Cystic Fibrosis Foundation; has contracts to conduct clinical trials from GlaxoSmithKline, AstraZeneca, and Gilead; and is a consultant for Mylan and Quintiles. NR 140 TC 0 Z9 0 U1 1 U2 1 PU ADIS INT LTD PI NORTHCOTE PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND SN 0012-6667 EI 1179-1950 J9 DRUGS JI Drugs PD APR PY 2017 VL 77 IS 6 BP 651 EP 670 DI 10.1007/s40265-017-0713-5 PG 20 WC Pharmacology & Pharmacy; Toxicology SC Pharmacology & Pharmacy; Toxicology GA EQ4HG UT WOS:000398036100005 PM 28255962 ER PT J AU Lee, JH Kang, M Wang, H Naik, G Mobley, JA Sonpavde, G Garvey, WT Darley-Usmar, VM Ponnazhagan, S AF Lee, Joo Hyoung Kang, Minsung Wang, Hong Naik, Gurudatta Mobley, James A. Sonpavde, Guru Garvey, W. Timothy Darley-Usmar, Victor M. Ponnazhagan, Selvarangan TI Endostatin inhibits androgen-independent prostate cancer growth by suppressing nuclear receptor-mediated oxidative stress SO FASEB JOURNAL LA English DT Article DE androgen-deprivation therapy; reactive oxygen species; androgen receptor; glucocorticoid receptor; castration resistance ID GLUCOCORTICOID-RECEPTOR; RESISTANCE; THERAPY; CELLS; MODEL; DIFFERENTIATION; ENZALUTAMIDE; CHEMOTHERAPY; DEPRIVATION; ABIRATERONE AB Androgen-deprivation therapy has been identified to induce oxidative stress in prostate cancer (PCa), leading to reactivation of androgen receptor (AR) signaling in a hormone-refractory manner. Thus, antioxidant therapies have gained attention as adjuvants for castration-resistant PCa. Here, we report for the first time that human endostatin (ES) prevents androgen-independent growth phenotype in PCa cells through its molecular targeting of AR and glucocorticoid receptor (GR) and downstream pro-oxidant signaling. This reversal after ES treatment significantly decreased PCa cell proliferation through down-regulation of GR and up-regulation of manganese superoxide dismutase and reduced glutathione levels. Proteome and biochemical analyses of ES-treated PCa cells further indicated a significant up-regulation of enzymes in the major reactive oxygen species (ROS) scavenging machinery, including catalase, glutathione synthetase, glutathione reductase, NADPH-cytochrome P450 reductase, biliverdin reductase, and thioredoxin reductase, resulting in a concomitant reduction of intracellular ROS. ES further augmented the antioxidant system through up-regulation of glucose influx, the pentose phosphate pathway, and NAD salvaging pathways. This shift in cancer cell redox homeostasis by ES significantly decreased the effect of protumorigenic oxidative machinery on androgen-independent PCa growth, suggesting that ES can suppress GR-induced resistant phenotype upon AR antagonism and that the dual targeting action of ES on AR and GR can be further translated to PCa therapy.-Lee, J. H., Kang, M., Wang, H., Naik, G., Mobley, J. A., Sonpavde, G., Garvey, W. T., Darley-Usmar, V. M., Ponnazhagan, S. Endostatin inhibits androgen-independent prostate cancer growth by suppressing nuclear receptor-mediated oxidative stress. C1 [Lee, Joo Hyoung; Wang, Hong; Darley-Usmar, Victor M.; Ponnazhagan, Selvarangan] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL 35294 USA. [Kang, Minsung; Garvey, W. Timothy] Univ Alabama Birmingham, Dept Nutr Sci, Birmingham, AL 35294 USA. [Naik, Gurudatta; Sonpavde, Guru] Univ Alabama Birmingham, Comprehens Canc Ctr, Birmingham, AL USA. [Mobley, James A.] Univ Alabama Birmingham, Dept Surg, Birmingham, AL 35294 USA. [Garvey, W. Timothy] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. RP Ponnazhagan, S (reprint author), Univ Alabama Birmingham, Dept Pathol, 1825 Univ Blvd,SHEL 814, Birmingham, AL 35294 USA. EM pons@uab.edu FU U.S. National Institutes of Health, National Cancer Institute [R01CA184770, P30CA013148] FX This work was supported by U.S. National Institutes of Health, National Cancer Institute Grants R01CA184770 (to S.P.) and P30CA013148 (to J.A.M.). The authors thank UAB Mass Spectrometry/Proteomics Shared Facility for proteome analysis. The authors declare no conflicts of interest. NR 42 TC 0 Z9 0 U1 3 U2 3 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD APR PY 2017 VL 31 IS 4 BP 1608 EP 1619 DI 10.1096/fj.201601178R PG 12 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA ER0UR UT WOS:000398504300027 PM 28069826 ER PT J AU Hoffman, BL Shensa, A Wessel, C Hoffman, R Primack, BA AF Hoffman, Beth L. Shensa, Ariel Wessel, Charles Hoffman, Robert Primack, Brian A. TI Exposure to fictional medical television and health: a systematic review SO HEALTH EDUCATION RESEARCH LA English DT Review ID ENTERTAINMENT TELEVISION; GRAYS-ANATOMY; CARDIOPULMONARY-RESUSCITATION; DRAMAS; STORYLINES; PERCEPTIONS; KNOWLEDGE; ATTITUDES; EDUCATION; MESSAGES AB Fictional medical television programs have long been a staple of television programming, and they remain popular today. We aimed to examine published literature assessing the influence of medical television programs on health outcomes. We conducted systematic literature searches in PubMed, PsychINFO and CINAHL. Selected studies had to be scholarly research, to involve exposure to fictionalized medical television programming, and to assess associations between exposures and outcomes. Of 3541 unique studies identified, nineteen met selection criteria. The most commonly studied programs were ER (73%), Grey's Anatomy (58%) and House M.D. (37%). Outcomes included knowledge, perceptions and behaviors related to topics as diverse as organ donation, cancer screening, sexually transmitted infections, and heart disease. Viewing fictional medical television programs had a negative influence on viewers' healthrelated knowledge, perceptions and/or behavior in 11% of studies, a positive influence in 32% of studies, and mixed influence in 58%. While most studies (58%) were characterized as having fair quality in terms of rigor of study design, 21% were classified as good and 21% were classified as poor. As such, medical television can affect health education and outcomes. Future work should utilize randomization, more longitudinal assessments, and more direct assessments of health education and behavioral outcomes. C1 [Hoffman, Beth L.; Shensa, Ariel; Primack, Brian A.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Hoffman, Beth L.; Shensa, Ariel; Primack, Brian A.] Univ Pittsburgh, Sch Med, Ctr Res Media Technol & Hlth, Pittsburgh, PA 15213 USA. [Wessel, Charles] Univ Pittsburgh, Hlth Sci Lib Syst, Pittsburgh, PA 15213 USA. [Hoffman, Robert] VA Pittsburgh Healthcare Syst, Dept Med, Pittsburgh, PA 15213 USA. RP Primack, BA (reprint author), Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA.; Primack, BA (reprint author), Univ Pittsburgh, Sch Med, Ctr Res Media Technol & Hlth, Pittsburgh, PA 15213 USA. EM bprimack@pitt.edu RI Wessel, Charles/B-2318-2013 OI Wessel, Charles/0000-0002-5018-0156 NR 37 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0268-1153 EI 1465-3648 J9 HEALTH EDUC RES JI Health Educ. Res. PD APR PY 2017 VL 32 IS 2 BP 107 EP 123 DI 10.1093/her/cyx034 PG 17 WC Education & Educational Research; Public, Environmental & Occupational Health SC Education & Educational Research; Public, Environmental & Occupational Health GA EQ3AZ UT WOS:000397944600001 PM 28334962 ER PT J AU Hebert, PL Howell, EA Wong, ES Hernandez, SE Rinne, ST Sulc, CA Neely, EL Liu, CF AF Hebert, Paul L. Howell, Elizabeth A. Wong, Edwin S. Hernandez, Susan E. Rinne, Seppo T. Sulc, Christine A. Neely, Emily L. Liu, Chuan-Fen TI Methods for Measuring Racial Differences in Hospitals Outcomes Attributable to Disparities in Use of High-Quality Hospital Care SO HEALTH SERVICES RESEARCH LA English DT Article DE Race; disparities; hospital readmissions ID ACUTE MYOCARDIAL-INFARCTION; MEDICARE BENEFICIARIES; BLACK PATIENTS; SERVING HOSPITALS; UNITED-STATES; MORTALITY; WHITES; RACE; HEALTH; CANCER AB ObjectiveTo compare two approaches to measuring racial/ethnic disparities in the use of high-quality hospitals. Data SourcesSimulated data. Study DesignThrough simulations, we compared the minority-serving approach of assessing differences in risk-adjusted outcomes at minority-serving and non-minority-serving hospitals with a fixed-effect approach that estimated the reduction in adverse outcomes if the distribution of minority and white patients across hospitals was the same. We evaluated each method's ability to detect and measure a disparity in outcomes caused by minority patients receiving care at poor-quality hospitals, which we label a between-hospital disparity, and to reject it when the disparity in outcomes was caused by factors other than hospital quality. Principal FindingsThe minority-serving and fixed-effect approaches correctly identified between-hospital disparities in quality when they existed and rejected them when racial differences in outcomes were caused by other disparities; however, the fixed-effect approach has many advantages. It does not require an ad hoc definition of a minority-serving hospital, and it estimated the magnitude of the disparity accurately, while the minority-serving approach underestimated the disparity by 35-46 percent. ConclusionsResearchers should consider using the fixed-effect approach for measuring disparities in use of high-quality hospital care by vulnerable populations. C1 [Hebert, Paul L.; Wong, Edwin S.; Hernandez, Susan E.; Sulc, Christine A.; Neely, Emily L.; Liu, Chuan-Fen] VA Puget Sound Hlth Care Syst, VA HSR&D Ctr Innovat Patient Ctr & Value Drive Hl, 1660 S Columbian Way HSR&D MS-152, Seattle, WA 98108 USA. [Howell, Elizabeth A.] Mt Sinai Sch Med, Dept Populat Hlth Sci & Policy, New York, NY USA. [Rinne, Seppo T.] Yale Pulm & Crit Care Med, New Haven, CT USA. RP Hebert, PL (reprint author), VA Puget Sound Hlth Care Syst, VA HSR&D Ctr Innovat Patient Ctr & Value Drive Hl, 1660 S Columbian Way HSR&D MS-152, Seattle, WA 98108 USA. EM paul.hebert2@va.gov FU Health Services Research and Development (HSRD) Service; Office of Research and Development; Department of Veterans Affairs [IIR 09-354]; National Institute on Minority Health and Health Disparities [R01MD007651]; VA HSR&D Career Development Award [CDA 13-024] FX We acknowledge the helpful suggestions of the external reviewers. The study was supported by a grants from the Health Services Research and Development (HSR&D) Service, the Office of Research and Development, the Department of Veterans Affairs (IIR 09-354), and the National Institute on Minority Health and Health Disparities R01MD007651 (Howell). Dr. Wong is supported by a VA HSR&D Career Development Award (CDA 13-024). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs, the United States Government, the University of Washington, the Yale School of Medicine, or the Mount Sinai School of Medicine. Dr. Wong reports ownership of common stock in Community Health Systems Inc. and UnitedHealth Group Inc. NR 30 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0017-9124 EI 1475-6773 J9 HEALTH SERV RES JI Health Serv. Res. PD APR PY 2017 VL 52 IS 2 BP 826 EP 848 DI 10.1111/1475-6773.12514 PG 23 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA EP8AT UT WOS:000397599000015 PM 27256878 ER PT J AU Shirley, D Scholtz, H Osterby, K Musuuza, J Fox, B Safdar, N AF Shirley, Daniel Scholtz, Harry Osterby, Kurt Musuuza, Jackson Fox, Barry Safdar, Nasia TI Optimizing Inpatient Urine Culture Ordering Practices Using the Electronic Medical Record: A Pilot Study SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Article ID HOSPITALIZED-PATIENTS; TRACT-INFECTION; CARE AB A prospective quasi-experimental before-and-after study of an electronic medical record anchored intervention of embedded education on appropriate urine culture indications and indication selection reduced the number of urine cultures ordered for catheterized patients at an academic medical center. This intervention could be a component of CAUTI-reduction bundles. C1 [Shirley, Daniel; Scholtz, Harry; Fox, Barry; Safdar, Nasia] Univ Wisconsin, Dept Med, Div Infect Dis, Sch Med & Publ Hlth, Madison, WI USA. [Scholtz, Harry; Osterby, Kurt] UW Hlth, Madison, WI USA. [Musuuza, Jackson] Univ Wisconsin, Inst Clin & Translat Res, Madison, WI USA. [Musuuza, Jackson; Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Shirley, D (reprint author), Univ Wisconsin, Div Infect Dis, Sch Med & Publ Hlth, Med Fdn Centennial Bldg 5th Floor, Madison, WI 53706 USA. EM dshirley@medicine.wisc.edu FU Veterans' Affairs Patient Safety Center; Agency for Healthcare Research and Quality FX Nasia Safdar is supported by a grant from the Veterans' Affairs Patient Safety Center and by an R18 grant from the Agency for Healthcare Research and Quality. NR 9 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD APR PY 2017 VL 38 IS 4 BP 486 EP 488 DI 10.1017/ice.2016.301 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA EP4LP UT WOS:000397352300017 PM 28025951 ER PT J AU Mehrotra, P Gupta, K Strymish, J Kramer, DB Lambert-Kerzner, A Ho, PM -Elliman, WB AF Mehrotra, Preeti Gupta, Kalpana Strymish, Judith Kramer, Daniel B. Lambert-Kerzner, Anne Ho, P. Michael -Elliman, Westyn Branch TI Implementation of Infection Prevention and Antimicrobial Stewardship in Cardiac Electrophysiology Laboratories: Results from the SHEA Research Network SO INFECTION CONTROL AND HOSPITAL EPIDEMIOLOGY LA English DT Editorial Material ID RISK-FACTORS; METAANALYSIS; MORTALITY AB Infection prevention in electrophysiology (EP) laboratories is poorly characterized; thus, we conducted a cross-sectional survey using the SHEA Research Network. We found limited uptake of basic interventions, such as surveillance and appropriate peri-procedural antimicrobial use. Further study is needed to identify ways to improve infection prevention in this setting. C1 [Mehrotra, Preeti; Kramer, Daniel B.; -Elliman, Westyn Branch] Beth Israel Deaconess Med Ctr, Dept Med, Div Infect Dis & Cardiol, Boston, MA 02215 USA. [Mehrotra, Preeti; Strymish, Judith; Kramer, Daniel B.; -Elliman, Westyn Branch] Harvard Med Sch, Boston, MA USA. [Gupta, Kalpana; Strymish, Judith; -Elliman, Westyn Branch] Vet Affairs Boston Healthcare Syst, Dept Med, Div Infect Dis, W Roxbury, MA USA. [Gupta, Kalpana] Boston Univ, Sch Med, Boston, MA 02118 USA. [Lambert-Kerzner, Anne; Ho, P. Michael] Seattle Denver Ctr Veteran Centr & Value Driven C, Denver, CO USA. [Lambert-Kerzner, Anne; Ho, P. Michael] Univ Colorado, Sch Med, Denver, CO USA. [Ho, P. Michael] Denver VA Med Ctr, Dept Med, Div Cardiol, Denver, CO USA. RP Mehrotra, P (reprint author), 110 Francis St, Boston, MA USA. FU NIA NIH HHS [K23 AG045963] NR 7 TC 0 Z9 0 U1 0 U2 0 PU CAMBRIDGE UNIV PRESS PI NEW YORK PA 32 AVENUE OF THE AMERICAS, NEW YORK, NY 10013-2473 USA SN 0899-823X EI 1559-6834 J9 INFECT CONT HOSP EP JI Infect. Control Hosp. Epidemiol. PD APR PY 2017 VL 38 IS 4 BP 496 EP 498 DI 10.1017/ice.2016.309 PG 3 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA EP4LP UT WOS:000397352300021 PM 28103958 ER PT J AU Patz, MD Sa, RC Darquenne, C Elliott, AR Asadi, AK Theilmann, RJ Dubowitz, DJ Swenson, ER Prisk, GK Hopkins, SR AF Patz, Michael D. Sa, Rui C. Darquenne, Chantal Elliott, Ann R. Asadi, Amran K. Theilmann, Rebecca J. Dubowitz, David J. Swenson, Erik R. Prisk, G. Kim Hopkins, Susan R. TI Susceptibility to high-altitude pulmonary edema is associated with a more uniform distribution of regional specific ventilation SO JOURNAL OF APPLIED PHYSIOLOGY LA English DT Article DE high-altitude illness; high-altitude pulmonary edema; multiple-breath washout; proton magnetic resonance imaging; specific ventilation imaging ID EXHALED NITRIC-OXIDE; COLLATERAL VENTILATION; BLOOD-FLOW; SUSTAINED MICROGRAVITY; SODIUM-TRANSPORT; ACUTE-HYPOXIA; GAS-EXCHANGE; PROTON MRI; LUNG; HETEROGENEITY AB High-altitude pulmonary edema (HAPE) is a potentially fatal condition affecting high-altitude sojourners. The biggest predictor of HAPE development is a history of prior HAPE. Magnetic resonance imaging (MRI) shows that HAPE-susceptible (with a history of HAPE), but not HAPE-resistant (with a history of repeated ascents without illness) individuals develop greater heterogeneity of regional pulmonary perfusion breathing hypoxic gas (O-2 = 12.5%), consistent with uneven hypoxic pulmonary vasoconstriction (HPV). Why HPV is uneven in HAPE-susceptible individuals is unknown but may arise from regionally heterogeneous ventilation resulting in an uneven stimulus to HPV. We tested the hypothesis that ventilation is more heterogeneous in HAPE-susceptible subjects (n = 6) compared with HAPE-resistant controls (n = 7). MRI specific ventilation imaging (SVI) was used to measure regional specific ventilation and the relative dispersion (SD/mean) of SVI used to quantify baseline heterogeneity. Ventilation heterogeneity from conductive and respiratory airways was measured in normoxia and hypoxia (O-2 = 12.5%) using multiple-breath washout and heterogeneity quantified from the indexes S-cond and S-acin, respectively. Contrary to our hypothesis, HAPE-susceptible subjects had significantly lower relative dispersion of specific ventilation than the HAPEresistant controls [susceptible = 1.33 +/- 0.67 (SD), resistant = 2.36 +/- 0.98, P = 0.05], and Sacin tended to be more uniform (susceptible = 0.085 +/- 0.009, resistant = 0.113 +/- 0.030, P = 0.07). Scond was not significantly different between groups (susceptible = 0.019 +/- 0.007, resistant = 0.020 +/- 0.004, P = 0.67). S-acin and S-cond did not change significantly in hypoxia (P = 0.56 and 0.19, respectively). In conclusion, ventilation heterogeneity does not change with short-term hypoxia irrespective of HAPE susceptibility, and lesser rather than greater ventilation heterogeneity is observed in HAPE-susceptible subjects. This suggests that the basis for uneven HPV in HAPE involves vascular phenomena. NEW & NOTEWORTHY Uneven hypoxic pulmonary vasoconstriction (HPV) is thought to incite high-altitude pulmonary edema (HAPE). We evaluated whether greater heterogeneity of ventilation is also a feature of HAPE-susceptible subjects compared with HAPEresistant subjects. Contrary to our hypothesis, ventilation heterogene-ity was less in HAPE-susceptible subjects and unaffected by hypoxia, suggesting a vascular basis for uneven HPV. C1 [Patz, Michael D.] Univ Washington, Dept Anesthesiol, Seattle, WA 98195 USA. [Sa, Rui C.; Darquenne, Chantal; Elliott, Ann R.; Asadi, Amran K.; Prisk, G. Kim; Hopkins, Susan R.] Univ Calif San Diego, Dept Med, La Jolla, CA 92093 USA. [Theilmann, Rebecca J.; Dubowitz, David J.; Prisk, G. Kim] Univ Calif San Diego, Dept Radiol, La Jolla, CA 92093 USA. [Swenson, Erik R.] Univ Washington, Vet Affairs Puget Sound Hlth Care Syst, Med Serv, Seattle, WA 98195 USA. RP Hopkins, SR (reprint author), Univ Calif San Diego, Div Physiol 0623A, 9500 Gilman Dr, La Jolla, CA 92093 USA. EM shopkins@ucsd.edu FU National Heart, Lung, and Blood Institute [118539, 104118, 122753]; Seattle Foundation FX This study was supported by National Heart, Lung, and Blood Institute Grants 118539, 104118, and 122753 and the Seattle Foundation. NR 48 TC 1 Z9 1 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 8750-7587 EI 1522-1601 J9 J APPL PHYSIOL JI J. Appl. Physiol. PD APR PY 2017 VL 122 IS 4 BP 844 EP 852 DI 10.1152/japplphysiol.00494.2016 PG 9 WC Physiology; Sport Sciences SC Physiology; Sport Sciences GA EQ7PK UT WOS:000398275900011 PM 28057815 ER PT J AU Andorko, JI Pineault, KG Jewell, CM AF Andorko, James I. Pineault, Kevin G. Jewell, Christopher M. TI Impact of molecular weight on the intrinsic immunogenic activity of poly(beta amino esters) SO JOURNAL OF BIOMEDICAL MATERIALS RESEARCH PART A LA English DT Article DE poly(beta amino ester); dendritic cell and lymphocyte; nanoparticle and microparticle; degradable biomaterial; immunology and vaccine ID PARTICULATE VACCINE ADJUVANTS; DENDRITIC CELL MATURATION; POLYELECTROLYTE MULTILAYERS; IMMUNE-RESPONSE; IN-VIVO; POLYMERIC NANOPARTICLES; GENE DELIVERY; SHAPE; ACTIVATION; DNA AB Polymeric carriers are ubiquitously studied in vaccine and drug delivery to control the encapsulation, kinetics, and targeting of cargo. Recent research reveals many polymers can cause immunostimulatory and inflammatory responses, even in the absence of other immune signals. However, the extent to which this intrinsic immunogenicity evolves during degradation is understudied. Here we synthesized a small library of poly(beta amino esters) (PBAEs) that exhibit different starting molecular weights (MWs), but with similar and rapid degradation rates. Primary dendritic cells (DCs) treated with free PBAEs, either intact or degraded to form low MW fragments, were not activated. In contrast particles formed from PBAEs at different extents of degradation caused differential expression of classical DC activation markers (for example, CD40, CD80, CD86, MHCII), as well as antigen presentation. During degradation, activation levels changed with changing physicochemical properties (for example, MW, concentration, size, charge). Of note, irrespective of starting MW, immunogenicity peaked when the MW of degrading PBAEs decreased to a range of similar to 1500-3000 Da. These findings could help inform design of future carriers that exploit the dynamic interactions with the immune system as materials degrade, leading to carriers that deliver cargo but also help direct the immune responses to vaccine or immunotherapy cargo. (C) 2017 Wiley Periodicals, Inc. C1 [Andorko, James I.; Pineault, Kevin G.; Jewell, Christopher M.] Univ Maryland, Fischell Dept Bioengn, College Pk, MD USA. [Jewell, Christopher M.] Univ Maryland Med Sch, Dept Microbiol & Immunol, Baltimore, MD USA. [Jewell, Christopher M.] Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD USA. [Jewell, Christopher M.] US Dept Vet Affairs, Biomed Lab Res & Dev, Baltimore, MD USA. RP Jewell, CM (reprint author), Univ Maryland, Fischell Dept Bioengn, College Pk, MD USA.; Jewell, CM (reprint author), Univ Maryland Med Sch, Dept Microbiol & Immunol, Baltimore, MD USA.; Jewell, CM (reprint author), Marlene & Stewart Greenebaum Canc Ctr, Baltimore, MD USA.; Jewell, CM (reprint author), US Dept Vet Affairs, Biomed Lab Res & Dev, Baltimore, MD USA. EM cmjewell@umd.edu FU American Association of Pharmaceutical Scientists; National Science Foundation CAREER Award [CAREER 1351688]; Alliance for Cancer Gene Therapy [15051543]; Damon Runyon Foundation [DRR3415]; Melanoma Research Alliance [348963]; Alex's Lemonade Stand Foundation for Childhood Cancer [27120]; National Multiple Sclerosis Society [RG-1501-02968] FX Contract grant sponsors: American Association of Pharmaceutical Scientists; Contract grant sponsor: National Science Foundation CAREER Award; contract grant number: CAREER 1351688; Contract grant sponsor: Alliance for Cancer Gene Therapy; contract grant number: 15051543; Contract grant sponsor: Damon Runyon Foundation; contract grant number: DRR3415; Contract grant sponsor: Melanoma Research Alliance; contract grant number: 348963; Contract grant sponsor: Alex's Lemonade Stand Foundation for Childhood Cancer; contract grant number: 27120; Contract grant sponsor: National Multiple Sclerosis Society; contract grant number: RG-1501-02968 NR 58 TC 1 Z9 1 U1 6 U2 6 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1549-3296 EI 1552-4965 J9 J BIOMED MATER RES A JI J. Biomed. Mater. Res. Part A PD APR PY 2017 VL 105 IS 4 BP 1219 EP 1229 DI 10.1002/jbm.a.35970 PG 11 WC Engineering, Biomedical; Materials Science, Biomaterials SC Engineering; Materials Science GA EM0KX UT WOS:000395008300027 PM 27977902 ER PT J AU Zhao, KW Murray, EJB Murray, SS AF Zhao, Ke-Wei Murray, Elsa J. Brochmann Murray, Samuel S. TI HK2 Proximal Tubule Epithelial Cells Synthesize and Secrete Plasma Proteins Predominantly Through the Apical Surface SO JOURNAL OF CELLULAR BIOCHEMISTRY LA English DT Article DE alpha(2)-MACROGLOBULIN (A2M); CHAPERONE; COMPLEMENT C3; CYTOKINES; HK2; HepG2; TGF beta ID GROWTH-FACTOR-BETA; ACUTE KIDNEY INJURY; TGF-BETA; TRANSFORMING GROWTH-FACTOR-BETA-1; COMPLEMENT C3; FETUIN-A; ALPHA; ACTIVATION; PRECURSOR; BINDING AB Renal proximal tubule epithelial cells (PTECs) are known to reabsorb salts and small plasma proteins filtered through Bowman's capsule. Following acute kidney injury, PTECs assume some characteristics of hepatocytes in producing various plasma proteins. We now demonstrate that even at a resting state, a PTEC cell line, HK2 expresses mRNAs for and synthesizes and secretes plasma proteins in a complex with complement C3, an alpha 2-macroglobulin family chaperone, including albumin, transferrin, alpha 1-antitrypsin, alpha 1-antichymotrypsin, alpha 2-HS-glycoprotein, ceruloplasmin, haptoglobin, C1-inhibitor, secreted phosphoprotein-24, and insulin-like growth factor-1. When grown on transwell inserts, HK2 cells predominantly secrete (similar to 90%) plasma proteins into the apical side and a smaller fraction into the basolateral side as determined by ELISA assays. When cultured in the presence of exogenous cytokines such as IL1 beta, IL6, TNF alpha, BMP2, or TGF beta 1, HK2 cell mRNA expressions for plasma proteins were variably affected whereas basolateral secretions were elevated to or in excess of those of the apical level. In addition, HK2 cells produce proTGF beta 1 with its intact N-terminal latency associated peptide and latent-TGF-beta-binding proteins. The complex cannot be dissociated under conditions of SDS, heating, and electrophoresis. Moreover, HK2 cells maintain their ability to quickly uptake exogenously added serum proteins from the culture medium, as if they are recognized differently by the endocytic receptors. These results provide new insight into the hepatization of PTECs. In addition to their unique uptake of plasma proteins and salts from the filtrate, they are a source of urinary proteins under normal conditions as wells as in chronic and acute kidney diseases. (C) 2016 Wiley Periodicals, Inc. C1 [Zhao, Ke-Wei; Murray, Elsa J. Brochmann; Murray, Samuel S.] Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr 11E, Sepulveda, CA 91343 USA. [Murray, Elsa J. Brochmann; Murray, Samuel S.] Univ Calif Los Angeles, Dept Med, Los Angeles, CA 90095 USA. [Murray, Samuel S.] Univ Calif Los Angeles, Interdept tmental Program Biomed Engn, Los Angeles, CA 90095 USA. RP Zhao, KW; Murray, EJB; Murray, SS (reprint author), Vet Affairs Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr 11E, Sepulveda, CA 91343 USA. EM keweizhao@gmail.com; elsa.murray@va.gov; samuel.murray@va.gov FU Department of Veterans Affairs [1IPBX000511, 1IORX000383] FX Grant sponsor: Department of Veterans Affairs; Grant numbers: 1IPBX000511, 1IORX000383. NR 50 TC 0 Z9 0 U1 2 U2 2 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0730-2312 EI 1097-4644 J9 J CELL BIOCHEM JI J. Cell. Biochem. PD APR PY 2017 VL 118 IS 4 BP 924 EP 933 DI 10.1002/jcb.25786 PG 10 WC Biochemistry & Molecular Biology; Cell Biology SC Biochemistry & Molecular Biology; Cell Biology GA EP5LO UT WOS:000397420300027 PM 27862254 ER PT J AU Hull, RL Willard, JR Struck, MD Barrow, BM Brar, GS Andrikopoulos, S Zraika, S AF hull, Rebecca L. Willard, Joshua R. Struck, Matthias D. Barrow, Breanne M. Brar, Gurkirat S. Andrikopoulos, Sofianos Zraika, Sakeneh TI High fat feeding unmasks variable insulin responses in male C57BL/6 mouse substrains SO JOURNAL OF ENDOCRINOLOGY LA English DT Article DE insulin secretion; C57BU6 substrains; islet; high-fat diet ID NICOTINAMIDE NUCLEOTIDE TRANSHYDROGENASE; DIET-INDUCED OBESITY; INTRAVENOUS GLUCOSE; SECRETORY FUNCTION; INBRED STRAINS; MICE; SENSITIVITY; SUSCEPTIBILITY; INTOLERANCE; MECHANISMS AB Mouse models are widely used for elucidating mechanisms underlying type 2 diabetes. Genetic background profoundly affects metabolic phenotype; therefore, selecting the appropriate model is critical. Although variability in metabolic responses between mouse strains is now well recognized, it also occurs within C57BL/6 mice, of which several substrains exist. This within-strain variability is poorly understood and could emanate from genetic and/or environmental differences. To better define the within strain variability, we performed the first comprehensive comparison of insulin secretion from C57BL/6 substrains 61, 6JWehi, 6NJ, 6NHsd, 6NTac and 6NCrl. in vitro, glucose stimulated insulin secretion correlated with Nnt mutation status, wherein responses were uniformly lower in islets from C57BL/61 vs C57BL/6N mice. In contrast, in vivo insulin responses after 18 weeks of low fat feeding showed no differences among any of the six substrains. When challenged with a high-fat diet for 18 weeks, C57BL/6J substrains responded with a similar increase in insulin release. However, variability was evident among C57BL/6N substrains. Strikingly, 6NJ mice showed no increase in insulin release after high fat feeding, contributing to the ensuing hyperglycemia. The variability in insulin responses among high-fat-fed C57BL/6N mice could not be explained by differences in insulin sensitivity, body weight, food intake or beta-cell area. Rather, as yet unidentified genetic and/or environmental factor(s) are likely contributors. Together, our findings emphasize that caution should be exercised in extrapolating data from in vitro studies to the in vivo situation and inform on selecting the appropriate C57BL/6 substrain for metabolic studies. C1 [hull, Rebecca L.; Willard, Joshua R.; Barrow, Breanne M.; Brar, Gurkirat S.; Zraika, Sakeneh] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. [hull, Rebecca L.; Struck, Matthias D.; Zraika, Sakeneh] Univ Washington, Dept Med, Dept Med Endocrinol & Nutr, Seattle, WA USA. [Andrikopoulos, Sofianos] Univ Melbourne, Austin Hosp, Dept Med, Heidelberg, Vic, Australia. RP Zraika, S (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA.; Zraika, S (reprint author), Univ Washington, Dept Med, Dept Med Endocrinol & Nutr, Seattle, WA USA. EM zraikas@uw.edu FU NIH [DK-080945, DK-098506, DK-088082]; University of Washington Diabetes Research Center [DK-017047]; Department of Veterans Affairs, VA Puget Sound Health Care System; Seattle Institute for Biomedical and Clinical Research; NHMRC Senior Research Fellowship FX This work was supported by: NIH grants DK-080945 and DK-098506 to S Z, DK-088082 to R L H, and DK-017047 (University of Washington Diabetes Research Center); the Department of Veterans Affairs, VA Puget Sound Health Care System; Seattle Institute for Biomedical and Clinical Research; and a NHMRC Senior Research Fellowship to S A. NR 31 TC 0 Z9 0 U1 0 U2 0 PU BIOSCIENTIFICA LTD PI BRISTOL PA EURO HOUSE, 22 APEX COURT WOODLANDS, BRADLEY STOKE, BRISTOL BS32 4JT, ENGLAND SN 0022-0795 EI 1479-6805 J9 J ENDOCRINOL JI J. Endocrinol. PD APR PY 2017 VL 233 IS 1 BP 53 EP 64 DI 10.1530/10E-16-0377 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EP2VS UT WOS:000397242300009 PM 28138002 ER PT J AU Ffytche, DH Pereira, JB Ballard, C Chaudhuri, KR Weintraub, D Aarsland, D AF Ffytche, Dominic H. Pereira, Joana B. Ballard, Clive Chaudhuri, K. Ray Weintraub, Daniel Aarsland, Dag TI Risk factors for early psychosis in PD: insights from the Parkinson's Progression Markers Initiative SO JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY LA English DT Article ID NURSING-HOME PLACEMENT; VISUAL HALLUCINATIONS; COGNITIVE IMPAIRMENT; MINOR HALLUCINATIONS; DIAGNOSTIC-CRITERIA; DISEASE PATIENTS; DEMENTIA; SYMPTOMS; PREVALENCE; BRAIN AB Background Parkinson's Disease (PD) psychosis refers to the spectrum of illusions, formed hallucinations and delusions that occur in PD. Visual hallucinations and illusions are thought to be caused by specific cognitive and higher visual function deficits and patients who develop such symptoms early in the disease course have greater rates of cognitive decline and progression to dementia. To date, no studies have investigated whether such deficits are found prior to the onset of PD psychosis. Method Here we compare baseline cognitive, biomarker (structural imaging and cerebrospinal fluid) and other PD psychosis risk factor data in patients who go on to develop illusions or hallucinations within 3-4 years of follow-up in the Parkinson's Progression Markers Initiative cohort of newly diagnosed PD. Results Of n=423 patients with PD, n=115 (27%) reported predominantly illusions with the median time of onset at 19.5 months follow-up. At study entry these patients had reduced CSF amyloid A beta(1-42), lower olfaction scores, higher depression scores and increased REM sleep behaviour disorder symptoms compared to patients without early onset PD psychosis but no differences in cognitive, higher visual or structural imaging measures. A subset of patients with early onset formed hallucinations (n=21) had reduced higher visual function at baseline, cortical thinning in parietal, occipital and frontal cortex and reduced hippocampal volume. Conclusions The findings suggest early onset illusions and formed hallucinations are linked to amyloid pathology in PD and point to a difference in the underlying pathophysiological mechanism of illusions and formed hallucinations, with implications for their respective links to future cognitive decline. C1 [Ffytche, Dominic H.; Ballard, Clive; Chaudhuri, K. Ray; Weintraub, Daniel; Aarsland, Dag] Kings Coll London, KCL PARCOG Grp, Inst Psychiat Psychol & Neurosci, PO70,de Crespigny Pk, London SE5 8AF, England. [Ffytche, Dominic H.; Aarsland, Dag] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Old Age Psychiat, London, England. [Pereira, Joana B.] Karolinska Inst, Dept Neurobiol Care Sci & Soc, Stockholm, Sweden. [Ballard, Clive] Univ Exeter, Sch Med, Exeter, Devon, England. [Chaudhuri, K. Ray] Kings Coll London, Maurice Wohl Clin Neurosci Inst, Dept Basic & Clin Neurosci, London, England. [Weintraub, Daniel] Univ Penn, Dept Psychiat, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Dept Neurol, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Res Educ & Clin Ctr, Philadelphia, PA USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr PADRECC & MIRE, Philadelphia, PA USA. [Aarsland, Dag] Stavanger Univ Hosp, Ctr Age Related Med, Stavanger, Norway. RP Ffytche, DH (reprint author), Kings Coll London, KCL PARCOG Grp, Inst Psychiat Psychol & Neurosci, PO70,de Crespigny Pk, London SE5 8AF, England. EM dominic.ffytche@kcl.ac.uk FU NIHR Maudsley Biomedical Research Centre and Dementia Unit; NIHR Programme Grants for Applied Research [RP-PG-0610-10100 SHAPED]; Wolfson Foundation; Royal Society FX Data used in the preparation of this article were obtained from the Parkinson's Progression Markers Initiative database (http://www.ppmi-info.org/). The authors thank Dr Fabrizia D'Antonio for help with R programming, the NIHR Maudsley Biomedical Research Centre and Dementia Unit and NIHR Programme Grants for Applied Research (RP-PG-0610-10100 SHAPED) for supporting involvement in this work. Dag Aarsland is a Royal Society Wolfson Research Merit Award Holder and thanks the Wolfson Foundation and the Royal Society for their support. NR 41 TC 0 Z9 0 U1 1 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0022-3050 EI 1468-330X J9 J NEUROL NEUROSUR PS JI J. Neurol. Neurosurg. Psychiatry PD APR PY 2017 VL 88 IS 4 BP 325 EP 331 DI 10.1136/jnnp-2016-314832 PG 7 WC Clinical Neurology; Psychiatry; Surgery SC Neurosciences & Neurology; Psychiatry; Surgery GA EP8JO UT WOS:000397621900010 PM 28315846 ER PT J AU Rule, ME Vargas-Irwin, CE Donoghue, JP Truccolo, W AF Rule, Michael E. Vargas-Irwin, Carlos E. Donoghue, John P. Truccolo, Wilson TI Dissociation between sustained single-neuron spiking and transient beta-LFP oscillations in primate motor cortex SO JOURNAL OF NEUROPHYSIOLOGY LA English DT Article DE beta oscillations; collective dynamics; motor cortex; neural dynamics; spike-field coupling ID LOCAL-FIELD POTENTIALS; RECORDED IN-VIVO; TASK-DEPENDENT MODULATION; FAST NETWORK OSCILLATIONS; PRECISION GRIP TASK; SENSORIMOTOR CORTEX; VISUAL-CORTEX; ELECTROPHYSIOLOGICAL CHARACTERIZATION; FUNCTIONAL CONNECTIVITY; PARKINSONS-DISEASE AB Determining the relationship between single-neuron spiking and transient (20 Hz) beta-local field potential (beta-LFP) oscillations is an important step for understanding the role of these oscillations in motor cortex. We show that whereas motor cortex firing rates and beta spiking rhythmicity remain sustained during steady-state movement preparation periods,beta-LFP oscillations emerge, in contrast, as short transient events. Single-neuron mean firing rates within and outside transient beta-LFP events showed no differences, and no consistent correlation was found between the beta oscillation amplitude and firing rates, as was the case for movement- and visual cue-related beta-LFP suppression. Importantly, well-isolated single units featuring beta-rhythmic spiking (43%, 125/292) showed no apparent or only weak phase coupling with the transient beta-LFP oscillations. Similar results were obtained for the population spiking. These findings were common in triple microelectrode array recordings from primary motor (M1), ventral (PMv), and dorsal premotor (PMd) cortices in nonhuman primates during movement preparation. Although beta spiking rhythmicity indicates strong membrane potential fluctuations in the beta band, it does not imply strong phase coupling with beta-LFP oscillations. The observed dissociation points to two different sources of variation in motor cortex beta-LFPs: one that impacts single- neuron spiking dynamics and another related to the generation of mesoscopic beta-LFP signals. Furthermore, our findings indicate that rhythmic spiking and diverse neuronal firing rates, which encode planned actions during movement preparation, may naturally limit the ability of different neuronal populations to strongly phase-couple to a single dominant oscillation frequency, leading to the observed spiking and beta-LFP dissociation. NEW & NOTEWORTHY We show that whereas motor cortex spiking rates and beta (similar to 20 Hz) spiking rhythmicity remain sustained during steady-state movement preparation periods, beta-local field potential (beta-LFP) oscillations emerge, in contrast, as transient events. Furthermore, the beta-LFP phase at which neurons spike drifts: phase coupling is typically weak or absent. This dissociation points to two sources of variation in the level of motor cortex beta: one that impacts single- neuron spiking and and another related to the generation of measured mesoscopic beta-LFPs. C1 [Rule, Michael E.; Vargas-Irwin, Carlos E.; Donoghue, John P.; Truccolo, Wilson] Brown Univ, Dept Neurosci, Providence, RI 02912 USA. [Donoghue, John P.; Truccolo, Wilson] Brown Univ, Inst Brain Sci, Providence, RI 02912 USA. [Donoghue, John P.; Truccolo, Wilson] US Dept Vet Affairs, Ctr Neurorestorat & Neurotechnol, Providence, RI USA. RP Truccolo, W (reprint author), Brown Univ, Dept Neurosci, Providence, RI 02912 USA. EM wilson_truccolo@brown.edu FU National Institutes of Neurological Disorders and Stroke (NINDS) [R01 NS25074]; K01 Career Award [NS057389]; Defense Advanced Research Projects Agency (DARPA) REPAIR [N66001-10-C-2010]; National Science Foundation predoctoral fellowship; Pablo J. Salame '88 Goldman Sachs Endowed Assistant Professorship of Computational Neuroscience FX This research is supported by National Institutes of Neurological Disorders and Stroke (NINDS) Grants R01 NS25074 (to J.P. Donoghue) and K01 Career Award NS057389 (to W. Truccolo), Defense Advanced Research Projects Agency (DARPA) REPAIR Grant N66001-10-C-2010 (to J.P. Donoghue and W. Truccolo), a National Science Foundation predoctoral fellowship (to M.E. Rule), and the Pablo J. Salame '88 Goldman Sachs Endowed Assistant Professorship of Computational Neuroscience (to W. Truccolo). NR 70 TC 0 Z9 0 U1 1 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0022-3077 EI 1522-1598 J9 J NEUROPHYSIOL JI J. Neurophysiol. PD APR PY 2017 VL 117 IS 4 BP 1524 EP 1543 DI 10.1152/jn.00651.2016 PG 20 WC Neurosciences; Physiology SC Neurosciences & Neurology; Physiology GA EQ7WU UT WOS:000398296400010 PM 28100654 ER PT J AU Robertson, CS McCarthy, JJ Miller, ER Levin, H McCauley, SR Swank, PR AF Robertson, Claudia S. McCarthy, James J. Miller, Emmy R. Levin, Harvey McCauley, Stephen R. Swank, Paul R. CA Mission Connect Mild TBI TI Phase II Clinical Trial of Atorvastatin in Mild Traumatic Brain Injury SO JOURNAL OF NEUROTRAUMA LA English DT Article DE clinical trial; cognitive function; traumatic brain injury ID INTRACEREBRAL HEMORRHAGE; NEURONAL SURVIVAL; SIMVASTATIN; RATS; INCREASE; STATINS; NEUROGENESIS; ANGIOGENESIS; THROMBOSIS; REDUCTION AB Statins constitute a class of medications commonly used in the treatment of elevated cholesterol. However, in experimental studies, statins also have other non-cholesterol-mediated mechanisms of action, which may have neuroprotective effects. The aim of this study was to determine whether administration of atorvastatin for 7 days post-injury would improve neurological recovery in patients with mild traumatic brain injury (mTBI). The hypothesis was that atorvastatin administration would reduce post-concussion symptoms and also that atorvastatin administration for 1 week post-injury would be safe. One hundred forty patients with mTBI were planned to be enrolled and randomly assigned to receive atorvastatin 1 mg/kg (up to 80 mg/kg) per day or placebo for 7 days starting within 24 h of injury. Assessments of post-concussion syndrome, post-traumatic stress and depressive symptoms, cognition, memory, verbal fluency, functional, and work status were performed at baseline, 1 week, and 1 and 3 months. The result on the Rivermead Post-Concussion Symptoms Questionnaire at 3 months was the primary outcome. Enrollment in the trial was stopped early because of difficulty in recruiting sufficient numbers of subjects. Fifty-two patients with mTBI were enrolled; 28 patients received atorvastatin and 24 received placebo. The median Rivermead score was 2 for the atorvastatin group, compared to 3.5 for the placebo group, at 3 months post-injury (chi(2) (1) = 0.0976; p = 0.7547). The change in the Rivermead score between baseline and 3 months was also analyzed. The median decrease in score was 4 for the atorvastatin group and 10.5 for the placebo group (chi(2) (1) = 0.8750; p = 0.3496). No serious adverse events occurred, and there was no significant difference in the incidence of adverse events in the two treatment groups. Atorvastatin administration for 7 days post-injury was safe, but there were no significant differences in neurological recovery post-mTBI with atorvastatin. C1 [Robertson, Claudia S.; Miller, Emmy R.; Levin, Harvey; McCauley, Stephen R.] Baylor Coll Med, One Baylor Plaza, Houston, TX 77030 USA. [McCarthy, James J.] Univ Texas Hlth Sci Ctr Houston, Houston, TX 77030 USA. [Levin, Harvey] Michael E De Bakey Vet Affairs Med Ctr, Houston, TX USA. [Swank, Paul R.] Univ Texas Hlth Sci Ctr Houston, Sch Publ Hlth, Houston, TX 77030 USA. [Miller, Emmy R.] Virginia Commonwealth Univ, Richmond, VA USA. RP Robertson, CS (reprint author), Baylor Coll Med, One Baylor Plaza, Houston, TX 77030 USA. EM claudiar@bcm.edu FU Department of Defense [W81XWH-08-2-0132, W81XWH-08-2-0131, W81XWH-08-2-0133, W81XWH-08-2-0142] FX This study was supported by the Department of Defense (grant nos. W81XWH-08-2-0132 [Robertson], W81XWH-08-2-0131 [McCarthy], W81XWH-08-2-0133 [Levin], and W81XWH-08-2-0142 [Swank]). NR 32 TC 0 Z9 0 U1 2 U2 2 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD APR PY 2017 VL 34 IS 7 BP 1394 EP 1401 DI 10.1089/neu.2016.4717 PG 8 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA ER0FB UT WOS:000398461600009 ER PT J AU Watkins, LE Sippel, LM Pietrzak, RH Hoff, R Harpaz-Rotem, I AF Watkins, Laura E. Sippel, Lauren M. Pietrzak, Robert H. Hoff, Rani Harpaz-Rotem, Ilan TI Co-occurring aggression and suicide attempt among veterans entering residential treatment for PTSD: The role of PTSD symptom clusters and alcohol misuse SO JOURNAL OF PSYCHIATRIC RESEARCH LA English DT Article DE Posttraumatic stress disorder; Aggression; Suicide; Veterans; Alcohol; Dysphoric arousal ID POSTTRAUMATIC-STRESS-DISORDER; DIMENSIONAL STRUCTURE; AFGHANISTAN VETERANS; MILITARY VETERANS; VIOLENT BEHAVIOR; US VETERANS; ANGER; IRAQ; CARE; PERPETRATION AB Aggression and suicidality are two serious public health concerns among U.S. veterans that can co-occur and share many overlapping risk factors. The current study aims to elucidate the contribution of post traumatic stress disorder (PTSD) symptom clusters defined by a five-factor model and alcohol misuse in predicting aggression and suicide attempts among veterans entering residential treatment for PTSD. Participants were 2570 U.S. veterans across 35 Veterans Health Administration sites. Multinomial logistic regression models were used to identify correlates of aggression only (n = 1471; 57.2%), suicide attempts only (n = 41; 1.6%), co-occurring aggression and suicide attempts (n = 202; 7.9%), and neither behavior (n = 856; 33.3%) over the past four months. When compared to veterans endorsing neither behavior, greater PTSD re-experiencing symptoms were related to suicide attempts (odds ratio [OR] = 1.58, 95% confidence interval [CI] = 1.09-2.30), aggression (OR = 1.13, 95% CI = 1.02-1.26), and co-occurring aggression and suicide (OR = 1.38, 95% CI = 1.13-1.68), and higher PTSD dysphoric arousal symptoms and alcohol misuse symptoms were related to aggression (OR = 1.54, 95% CI = 1.38-1.71; OR = 130, 95% CI = 1.18-1.44, respectively) and co-occurring aggression and suicide (OR = 1.66, 95% CI = 1.35-2.04; OR = 1.50, 95% CI = 1.28-1.75, respectively). Our findings suggest that assessment of PTSD symptom clusters and alcohol misuse can potentially help to identify veterans who endorse suicide attempts, aggression, or both concurrently. These results have important implications for risk assessment and treatment planning with U.S. veterans seeking care for PTSD. Published by Elsevier Ltd. C1 [Watkins, Laura E.; Sippel, Lauren M.; Pietrzak, Robert H.; Hoff, Rani; Harpaz-Rotem, Ilan] US Dept Vet Affairs, Natl Ctr Posttraumat Stress Disorder, VA Connecticut Healthcare Syst, West Haven, CT USA. [Watkins, Laura E.; Sippel, Lauren M.; Pietrzak, Robert H.; Hoff, Rani; Harpaz-Rotem, Ilan] Yale Univ, Sch Med, Dept Psychiat, New Haven, CT USA. [Hoff, Rani; Harpaz-Rotem, Ilan] Northeast Program Evaluat Ctr, VA Connecticut Healthcare Syst, West Haven, CT USA. RP Watkins, LE (reprint author), VA Connecticut Healthcare Syst, 950 Campbell Ave 151D, West Haven, CT 06516 USA. EM laura.watkins@yale.edu FU Department of Veterans Affairs Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment; Department of Veterans Affairs National Center for Posttraumatic Stress Disorder Clinical Neurosciences Division; VA Connecticut Healthcare System FX Preparation of this manuscript was supported in part by the Department of Veterans Affairs Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, the Department of Veterans Affairs National Center for Posttraumatic Stress Disorder Clinical Neurosciences Division, and VA Connecticut Healthcare System. NR 38 TC 0 Z9 0 U1 1 U2 1 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0022-3956 EI 1879-1379 J9 J PSYCHIATR RES JI J. Psychiatr. Res. PD APR PY 2017 VL 87 BP 8 EP 14 DI 10.1016/j.jpsychires.2016.12.009 PG 7 WC Psychiatry SC Psychiatry GA EO8WK UT WOS:000396971000002 PM 27984702 ER PT J AU Kumar, G Albright, KC Donnelly, JP Shapshak, AH Harrigan, MR AF Kumar, Gyanendra Albright, Karen C. Donnelly, John P. Shapshak, Angela Hays Harrigan, Mark R. TI Trends in Transcranial Doppler Monitoring in Aneurysmal Subarachnoid Hemorrhage: A 10-Year Analysis of the Nationwide Inpatient Sample SO JOURNAL OF STROKE & CEREBROVASCULAR DISEASES LA English DT Article DE Aneurysmal subarachnoid hemorrhage; transcranial Doppler; cerebral vasospasm; Nationwide Inpatient Sample ID DELAYED CEREBRAL-ISCHEMIA; ANGIOGRAPHIC VASOSPASM; NEUROCRITICAL CARE; CT PERFUSION; DOUBLE-BLIND; METAANALYSIS; INFARCTION; ULTRASONOGRAPHY; RECOMMENDATIONS; MANAGEMENT AB Background: Transcranial Doppler (TCD) is endorsed by national guidelines for use in aneurysmal subarachnoid hemorrhage (aSAH) for surveillance of cerebral vasospasm (CV). However, nationwide data on utilization of TCD for CV detection and monitoring in aSAH are lacking. Methods: Analysis of nationwide trends in TCD prevalence was performed using Nationwide Inpatient Sample (NIS) data from 2002 to 2011. Raw counts were converted into weighted counts, which were used to generate national estimates. Teaching hospitals were examined separately for TCD utilization rates. All analyses accounted for the complex sampling design and sample discharge weights of the NIS, following Healthcare Cost and Utilization Project-NIS recommendations. The objective was to estimate the proportion of patients with aSAH receiving TCD monitoring using the NIS. Results: Between 2002 and 2011, a total of 256,089 patients were discharged with a diagnosis of aSAH, of which 3850 underwent TCD monitoring. aSAH accounted for an average of 67.1 discharges per 100,000 annually (95% confidence interval [CI] 61.3-72.8). Of these, 1.5% (95% CI 0.4-2.6) underwent TCD examination. In teaching hospitals, aSAH accounted for an average of 108.5 discharges per 100,000 biennially (95% CI, 96.2-120.8), of which 2% (95% CI 1.0-4.0) underwent TCD examination. TCD utilization increased from < 1% during the 2002-2005 period to = 1.5% during the 2006-2011 period (odds ratio 2.3, 95% CI 1.0-5.7), an increase also seen in teaching hospitals. Conclusions: TCD is underused nationally in the care of aSAH. Whereas the prevalence of TCD is low in teaching hospitals, it is nearly nonexistent in nonteaching hospitals. C1 [Kumar, Gyanendra] Mayo Clin, Dept Neurol, Phoenix, AZ USA. [Albright, Karen C.; Shapshak, Angela Hays] Univ Alabama Birmingham, Dept Neurol, Comprehens Stroke Ctr, UAB Stn, Birmingham, AL 35294 USA. [Albright, Karen C.] Birmingham VA Med Ctr, GRECC, Birmingham, AL USA. [Donnelly, John P.] Univ Alabama Birmingham, COERE, Birmingham, AL USA. [Donnelly, John P.] Univ Alabama Birmingham, Dept Prevent Med, Birmingham, AL USA. [Harrigan, Mark R.] Univ Alabama Birmingham, Dept Neurosurg, Birmingham, AL USA. RP Kumar, G (reprint author), 5777 E Mayo Blvd, Phoenix, AZ 85054 USA. EM kumar.gyanendra@mayo.edu FU [AHA14CRP20380256] FX This study was supported by the following grant: AHA14CRP20380256. NR 31 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 1052-3057 EI 1532-8511 J9 J STROKE CEREBROVASC JI J. Stroke Cerebrovasc. Dis. PD APR PY 2017 VL 26 IS 4 BP 851 EP 857 DI 10.1016/j.jstrokecerebrovasdis.2016.10.033 PG 7 WC Neurosciences; Peripheral Vascular Disease SC Neurosciences & Neurology; Cardiovascular System & Cardiology GA EP3AF UT WOS:000397254200029 PM 27866915 ER PT J AU Porter, AL Margolis, AR Schoen, RR Staresinic, CE Ray, CA Fletcher, CD AF Porter, Andrea L. Margolis, Amanda R. Schoen, Rebecca R. Staresinic, Carla E. Ray, Cheryl A. Fletcher, Christopher D. TI Use of an extended INR follow-up interval for Veteran patients in an anticoagulation clinic SO JOURNAL OF THROMBOSIS AND THROMBOLYSIS LA English DT Article DE Anticoagulation; Warfarin; Interval; Monitoring; International normalized ratio (INR); Management ID ATRIAL-FIBRILLATION; PREDICTING STROKE; WARFARIN; VALIDATION; OUTCOMES; RISK AB A prospective, single-arm study of 50 participants evaluated an extended INR follow-up interval to determine the implementation feasibility and safety of an extended interval in Veterans on a stable dose of warfarin. A protocol was designed to allow for a rigorous, yet pragmatic evaluation of a 12-week INR follow-up interval. Feasibility was determined by study enrollment, retention, and participant achievement rates for the extended INR interval. Safety was determined by bleeding and thromboembolism rates. Participants were monitored for 6 months. Despite the long-term stability of participants prior to enrollment, only 56% achieved a 12-week follow-up interval and only 34% of enrolled participants maintained a 12-week interval. Sixteen percent of participants were never eligible for an extension of their INR follow-up interval despite meeting initial enrollment criteria. There were two major bleeding events and one participant who experienced a thromboembolic event. Implementation of an extended interval of INR follow-up appears feasible as participant enrollment goals were met and pharmacists were able to follow the study protocol. However, a lower than expected proportion of participants were able to achieve and maintain an extended INR follow-up interval. Future evaluations are needed to confirm the safety of an extended INR interval. C1 [Porter, Andrea L.; Margolis, Amanda R.] Univ Wisconsin, Madison Sch Pharm, 777 Highland Ave, Madison, WI 53705 USA. [Porter, Andrea L.; Margolis, Amanda R.; Schoen, Rebecca R.; Staresinic, Carla E.; Ray, Cheryl A.; Fletcher, Christopher D.] William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace 119, Madison, WI 53705 USA. [Schoen, Rebecca R.] Texas Tech Univ, Hlth Sci Ctr, 4500 S Lancaster Rd,Bldg 7, Dallas, TX 75216 USA. [Fletcher, Christopher D.] Univ Wisconsin, Sch Med & Publ Hlth, Div Hematol, 750 Highland Ave, Madison, WI 53726 USA. RP Porter, AL (reprint author), Univ Wisconsin, Madison Sch Pharm, 777 Highland Ave, Madison, WI 53705 USA.; Porter, AL (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace 119, Madison, WI 53705 USA. EM andrea.porter@wisc.edu FU Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS) [UL1TR000427] FX The project described was supported by the Clinical and Translational Science Award (CTSA) program, through the NIH National Center for Advancing Translational Sciences (NCATS), Grant UL1TR000427. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH. This material is the result of work supported with resources and the use of facilities at the William S. Middleton Memorial Veterans Hospital in Madison, Wisconsin. The contents do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. Clinicaltrials.gov: NCT02392104. NR 18 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0929-5305 EI 1573-742X J9 J THROMB THROMBOLYS JI J. Thromb. Thrombolysis PD APR PY 2017 VL 43 IS 3 BP 318 EP 325 DI 10.1007/s11239-016-1448-y PG 8 WC Hematology; Peripheral Vascular Disease SC Hematology; Cardiovascular System & Cardiology GA EN2GX UT WOS:000395829100005 PM 27803999 ER PT J AU Kutney-Lee, A Smith, D Thorpe, J del Rosario, C Ibrahim, S Ersek, M AF Kutney-Lee, Ann Smith, Dawn Thorpe, Joshua del Rosario, Cindy Ibrahim, Said Ersek, Mary TI Race/Ethnicity and End-of-Life Care Among Veterans SO MEDICAL CARE LA English DT Article DE disparities; end-of-life care; veterans ID FAMILY-MEMBERS PERCEPTIONS; HOSPICE CARE; HEALTH-CARE; AFRICAN-AMERICAN; PALLIATIVE CARE; RACIAL DISPARITIES; ETHNIC DISPARITIES; MEDICAL-CARE; QUALITY; OUTCOMES AB Background: Few studies have examined comprehensively racial/ ethnic variations in quality of end-of-life care. Objective: Examine end-of-life care quality received by Veterans and their families, comparing racial/ethnic minorities to non-minorities. Research Design: This is a retrospective, cross-sectional analysis of chart review and survey data. Subjects: Nearly all deaths in 145 Veterans Affairs Medical Centers nationally (n = 94,697) in addition to Bereaved Family Survey (BFS) data (n = 51,859) from October 2009 to September 2014. Measures: Outcomes included 15 BFS items and 4 indicators of high-quality end-of-life care, including receipt of a palliative care consult, chaplain visit, bereavement contact, and death in hospice/ palliative care unit. Veteran race/ethnicity was measured via chart review and defined as non-Hispanic white, non-Hispanic black, Hispanic, or other. Results: In adjusted models, no differences were observed by race/ ethnicity in receipt of a palliative care consult or death in a hospice unit. Although black Veterans were less likely than white Veterans to receive a chaplain visit, Hispanic Veterans were more likely than white Veterans to receive a chaplain visit and to receive a bereavement contact. Less favorable outcomes for racial/ethnic minorities were noted on several BFS items. In comparison with family members of white Veterans, families of minority Veterans were less likely to report excellent overall care, and this difference was largest for black Veterans (48% vs. 62%). Conclusions: Bereaved family members of minority Veterans generally rate the quality of end-of-life care less favorably than those of white Veterans. Family perceptions are critical to the evaluation of equity and quality of end-of-life care. C1 [Kutney-Lee, Ann; del Rosario, Cindy; Ersek, Mary] Univ Penn, Sch Nursing, Philadelphia, PA 19104 USA. [Kutney-Lee, Ann; Smith, Dawn; Ibrahim, Said; Ersek, Mary] Corporal Michael J Crescenz VA Med Ctr, Philadelphia, PA USA. [Thorpe, Joshua] Vet Affairs Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Thorpe, Joshua] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA USA. [Ibrahim, Said] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. RP Kutney-Lee, A (reprint author), Univ Penn, Sch Nursing, Corporal Michael J Crescenz VA Med Ctr, 418 Curie Blvd,Claire M Fagin Hall,Room 385, Philadelphia, PA 19104 USA. EM akutney@nursing.upenn.edu NR 44 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD APR PY 2017 VL 55 IS 4 BP 342 EP 351 PG 10 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA EP8AO UT WOS:000397598500007 PM 27579913 ER PT J AU Hempel, S Graham, GD Fu, N Estrada, E Chen, AY Miake-Lye, I Miles, JNV Shanman, R Shekelle, PG Beroes, JM Wallin, MT AF Hempel, Susanne Graham, Glenn D. Fu, Ning Estrada, Elena Chen, Annie Y. Miake-Lye, Isomi Miles, Jeremy N. V. Shanman, Roberta Shekelle, Paul G. Beroes, Jessica M. Wallin, Mitchell T. TI A systematic review of the effects of modifiable risk factor interventions on the progression of multiple sclerosis SO MULTIPLE SCLEROSIS JOURNAL LA English DT Review DE Multiple sclerosis; MS progression; risk factors; randomized controlled trial; systematic review ID POLYUNSATURATED FATTY-ACIDS; TRIAL; EXERCISE AB Background: Several risk factors are associated with multiple sclerosis (MS) progression and may be amenable to intervention. Objective: To systematically review the evidence for interventions targeting risk factors for MS progression. Methods: We searched six databases and existing reviews till March 2015 and consulted with experts to identify randomized controlled trials (RCTs) of interventions targeting MS risk factors (PROSPERO 2015: CRD42015016461). Results: In total, 37 RCTs met inclusion criteria. Expanded Disability Status Scale (EDSS) scores after exercise interventions did not differ compared with untreated controls (standardized mean differences (SMDs): 0.02; confidence interval (CI): -0.40, 0.44; I-2: 0%; seven RCTs; very low quality of evidence (QoE)). Dietary interventions did not show a statistically significant effect on the relative risk (RR) of progression (RR: 0.86; CI: 0.67, 1.05; I-2: 0%; four RCTs; moderate QoE) compared to placebo. EDSS scores after vitamin D supplementation were not significantly different from placebo (SMD: -0.15; CI: -0.33, 0.02; I-2: 0%; five RCTs; very low QoE). Conclusion: We did not identify any risk factor interventions with significant effects on MS progression, but the overall QoE was limited. More adequately powered trials are needed on vitamin D supplementation, long-term exercise, and smoking cessation. C1 [Hempel, Susanne; Fu, Ning; Miles, Jeremy N. V.; Shanman, Roberta; Shekelle, Paul G.] RAND Corp, Southern Calif Evidence Based Practice Ctr, 1776 Main St, Santa Monica, CA 90407 USA. [Graham, Glenn D.] US Dept Vet Affairs, Specialty Care Serv, Washington, DC USA. [Graham, Glenn D.] Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA USA. [Estrada, Elena; Chen, Annie Y.; Miake-Lye, Isomi; Shekelle, Paul G.; Beroes, Jessica M.] West Los Angeles VA Med Ctr, Evidence Based Synth Program ESP Ctr, Los Angeles, CA USA. [Wallin, Mitchell T.] US Dept Vet Affairs, Multiple Sclerosis Ctr Excellence East, Washington, DC USA. [Wallin, Mitchell T.] Georgetown Univ, Sch Med, Dept Neurol, Washington, DC USA. RP Hempel, S (reprint author), RAND Corp, Southern Calif Evidence Based Practice Ctr, 1776 Main St, Santa Monica, CA 90407 USA. EM susanne_hempel@rand.org FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Quality Enhancement Research Initiative FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Quality Enhancement Research Initiative. The findings and conclusions in this document are those of the author(s), and the findings and conclusions do not necessarily represent the views of the Department of Veterans Affairs or the US government. NR 15 TC 0 Z9 0 U1 2 U2 2 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 EI 1477-0970 J9 MULT SCLER J JI Mult. Scler. J. PD APR PY 2017 VL 23 IS 4 BP 513 EP 524 DI 10.1177/1352458517690271 PG 12 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA EQ3DD UT WOS:000397950400007 PM 28151074 ER PT J AU Hempel, S Graham, GD Fu, N Estrada, E Chen, AY Miake-Lye, I Miles, JNV Shanman, R Shekelle, PG Beroes, JM Wallin, MT AF Hempel, Susanne Graham, Glenn D. Fu, Ning Estrada, Elena Chen, Annie Y. Miake-Lye, Isomi Miles, Jeremy N. V. Shanman, Roberta Shekelle, Paul G. Beroes, Jessica M. Wallin, Mitchell T. TI A systematic review of modifiable risk factors in the progression of multiple sclerosis SO MULTIPLE SCLEROSIS JOURNAL LA English DT Review DE Multiple sclerosis; multiple sclerosis progression; risk factors; prognostic study; systematic review ID VITAMIN-D STATUS; PUBLICATION BIAS; DISABILITY; METAANALYSIS; EXERCISE; PREDICTOR; SMOKING AB Background: The presenting symptoms and rate of progression of multiple sclerosis (MS) are very heterogeneous. The diverse clinical manifestations and the clinical course of the disease may vary with modifiable risk factors. Objective: To systematically review modifiable risk factors and exposures associated with MS progression. Methods: We searched six databases till March 2015, reference-mined reviews, and consulted with experts (PROSPERO 2015: CRD42015016461). Two reviewers screened and extracted data. We used random meta-analysis models and Grading of Recommendations Assessment, Development, and Evaluation (GRADE) to assess the quality of evidence. Results: In total, 59 studies met inclusion criteria. Lower vitamin D levels were associated with higher Expanded Disability Status Scale (EDSS) scores (r = -0.22; confidence interval (CI) = -0.32, -0.12; 11 studies; I-2 = 66%), smokers had an increased risk of MS progression (hazard ratio (HR) = 1.55; CI = 1.10, 2.19; I-2 = 72%; seven studies), and there was no association of MS progression with the use of epidural analgesics during childbirth delivery (three studies). There was insufficient evidence to draw conclusions for 11 risk factors due to conflicting results or use of different predictor and outcome measures. Conclusion: MS progression was consistently associated with low vitamin D levels, and smoking was associated with a more rapid decline in MS disability. Studies used a variety of methods, predictors, and outcomes making it difficult to draw conclusions. Future studies should focus on prospective assessments. C1 [Hempel, Susanne; Fu, Ning; Miles, Jeremy N. V.; Shanman, Roberta; Shekelle, Paul G.] RAND Corp, Southern Calif Evidence Based Practice Ctr, 1776 Main St, Santa Monica, CA 90407 USA. [Graham, Glenn D.] US Dept Vet Affairs, Specialty Care Serv, Washington, DC USA. [Graham, Glenn D.] Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA USA. [Estrada, Elena; Chen, Annie Y.; Miake-Lye, Isomi; Shekelle, Paul G.; Beroes, Jessica M.] West Los Angeles VA Med Ctr, Evidence Based Synth Program ESP Ctr, Los Angeles, CA USA. [Wallin, Mitchell T.] US Dept Vet Affairs, Multiple Sclerosis Ctr Excellence East, Washington, DC USA. [Wallin, Mitchell T.] Georgetown Univ, Sch Med, Dept Neurol, Washington, DC USA. RP Hempel, S (reprint author), RAND Corp, Southern Calif Evidence Based Practice Ctr, 1776 Main St, Santa Monica, CA 90407 USA. EM susanne_hempel@rand.org FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Quality Enhancement Research Initiative FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was funded by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Quality Enhancement Research Initiative. The findings and conclusions in this document are those of the author(s) who are responsible for its contents; the findings and conclusions do not necessarily represent the views of the Department of Veterans Affairs or the US Government. NR 33 TC 0 Z9 0 U1 1 U2 1 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1352-4585 EI 1477-0970 J9 MULT SCLER J JI Mult. Scler. J. PD APR PY 2017 VL 23 IS 4 BP 525 EP 533 DI 10.1177/1352458517690270 PG 9 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA EQ3DD UT WOS:000397950400008 PM 28151053 ER PT J AU Hawkins, T Berman, BD AF Hawkins, Trevor Berman, Brian D. TI Pimavanserin: A novel therapeutic option for Parkinson disease psychosis SO NEUROLOGY-CLINICAL PRACTICE LA English DT Review ID VISUAL HALLUCINATIONS; CLOZAPINE; QUETIAPINE; RECEPTORS; AGONIST AB Purpose of review:In April 2016, the Food and Drug Administration (FDA) approved a first-in-class atypical antipsychotic medication called pimavanserin for the treatment of Parkinson disease psychosis (PDP). We aim to inform readers about its indications, effectiveness, and safety profile. Recent findings:Pimavanserin acts as an inverse agonist at serotonin 5-HT2A receptors and has negligible effects on other receptors, thereby avoiding the D2 receptor antagonism that can potentially worsen motor symptoms. Its FDA approval was based primarily on the results of a single randomized, placebo-controlled phase 3 trial. Summary:While pimavanserin appears to be a safe, effective, and well-tolerated therapeutic option for PDP, additional clinical trials and open-label extension studies are needed to determine the long-term safety and efficacy of this promising therapy. In the meantime, prescribers need to be aware of the possible adverse effects of pimavanserin including QT interval prolongation and a potential to cause a paradoxical worsening of symptoms. C1 [Hawkins, Trevor; Berman, Brian D.] Univ Colorado, Dept Neurol, Anschutz Med Campus, Aurora, CO 80045 USA. [Berman, Brian D.] Denver VA Med Ctr, Neurol Sect, Denver, CO 80220 USA. RP Berman, BD (reprint author), Univ Colorado, Dept Neurol, Anschutz Med Campus, Aurora, CO 80045 USA.; Berman, BD (reprint author), Denver VA Med Ctr, Neurol Sect, Denver, CO 80220 USA. EM brian.berman@ucdenver.edu NR 25 TC 1 Z9 1 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2163-0402 EI 2163-0933 J9 NEUROL-CLIN PRACT JI Neurol.-Clin. Pract. PD APR PY 2017 VL 7 IS 2 BP 157 EP 162 DI 10.1212/CPJ.0000000000000342 PG 6 WC Clinical Neurology SC Neurosciences & Neurology GA ER5QL UT WOS:000398856700012 ER PT J AU Busch, RA Curtis, CS Kight, CE Leverson, GE Ma, Y Maursetter, L Kudsk, KA AF Busch, Rebecca A. Curtis, Caitlin S. Kight, Cassandra E. Leverson, Glen E. Ma, Yue Maursetter, Laura Kudsk, Kenneth A. TI An Institutional Change in Continuous Renal Replacement Therapy: Nutrition Support Team Resolves Resultant Severe Hypophosphatemia SO NUTRITION IN CLINICAL PRACTICE LA English DT Article DE parenteral nutrition; renal replacement therapy; phosphate; hypophosphatemia; renal replacement fluids ID ACUTE KIDNEY INJURY; DRUG SHORTAGES; FAILURE; IMPACT AB Background: Critically ill patients with acute kidney injury may require parenteral nutrition (PN) and continuous renal replacement therapy (CRRT). Introduction of a phosphate-free premixed renal replacement fluid without system-wide education in May 2011 resulted in increased incidence of hypophosphatemia, necessitating change in practice. Changes included (1) maximizing phosphate in PN, (2) modifying the CRRT order set, and (3) developing a CRRT competency evaluation for nutrition support team members. This study evaluates the effect of these changes on the incidence of hypophosphatemia. Methods: Phosphate levels and predicated probability of hypophosphatemia were evaluated for patients receiving PN and CRRT over 3 time periods: prior to implementing the changes (preimplementation), during change implementation (intermediate), and following implementation (postimplementation). Hypophosphatemia was defined as a serum phosphate level <2.5 mg/dL. Generalized linear mixed models were applied for statistical analysis. Results: The retrospective study includes 336 measures from 49 patients. Patients in the intermediate and postimplementation periods were not significantly different from each other and had significantly higher mean phosphate levels than patients in the preimplementation period (P <.0001). They were also less likely to develop hypophosphatemia compared with preimplementation patients (intermediate: odds ratio [OR], 0.07; 95% confidence interval [CI], 0.03-0.18, P <.0001; postimplementation: OR, 0.09; 95% CI, 0.03-0.27, P <.0001). Conclusions: Modifications in phosphate dosing together with CRRT education reduced the incidence of hypophosphatemia in PN patients receiving CRRT. Communication of significant changes in clinical care should be shared with all services prior to implementation. Communication and planning between services caring for complex patients are necessary to prevent systems-based problems. C1 [Busch, Rebecca A.; Leverson, Glen E.; Ma, Yue; Kudsk, Kenneth A.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, G5-341 Clinical Sci Ctr,600 Highland Ave, Madison, WI 53792 USA. [Curtis, Caitlin S.] Univ Wisconsin, Hosp & Clin, Dept Pharm, Madison, WI 53792 USA. [Kight, Cassandra E.] Univ Wisconsin, Hosp & Clin, Clin Nutr Serv, Madison, WI 53792 USA. [Maursetter, Laura] Univ Wisconsin, Sch Med & Publ Hlth, Dept Internal Med, Nephrol Sect, Madison, WI USA. [Kudsk, Kenneth A.] William S Middleton Mem Vet Adm Med Ctr, Veteran Adm Surg Serv, Madison, WI USA. RP Kudsk, KA (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, G5-341 Clinical Sci Ctr,600 Highland Ave, Madison, WI 53792 USA. EM kudsk@surgery.wisc.edu FU Surgical Oncology Research Training Program [T32CA090217] FX The project described was supported in part (to R.A.B.) by the Surgical Oncology Research Training Program (grant number T32CA090217). NR 14 TC 0 Z9 0 U1 0 U2 0 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0884-5336 EI 1941-2452 J9 NUTR CLIN PRACT JI Nutr. Clin. Pract. PD APR PY 2017 VL 32 IS 2 BP 245 EP 251 DI 10.1177/0884533616662987 PG 7 WC Nutrition & Dietetics SC Nutrition & Dietetics GA EQ5DO UT WOS:000398102200015 PM 27589256 ER PT J AU Auerbach, BJ Wolf, FM Hikida, A Vallila-Buchman, P Littman, A Thompson, D Louden, D Taber, DR Krieger, J AF Auerbach, Brandon J. Wolf, Fred M. Hikida, Abigail Vallila-Buchman, Petra Littman, Alyson Thompson, Douglas Louden, Diana Taber, Daniel R. Krieger, James TI Fruit Juice and Change in BMI: A Meta-analysis SO PEDIATRICS LA English DT Review ID BODY-MASS INDEX; BEVERAGE CONSUMPTION; WEIGHT STATUS; VEGETABLE INTAKE; UNITED-STATES; CHILDREN; ADOLESCENTS; GAIN; RISK; ASSOCIATION AB CONTEXT: Whether 100% fruit juice consumption causes weight gain in children remains abstract controversial. OBJECTIVE: To determine the association between 100% fruit juice consumption and change in BMI or BMI z score in children. DATA SOURCES: PubMed, Embase, CINAHL, and Cochrane databases. STUDY SELECTION: Longitudinal studies examining the association of 100% fruit juice and change in BMI measures were included. DATA EXTRACTION: Two independent reviewers extracted data using a predesigned data collection form. RESULTS: Of the 4657 articles screened, 8 prospective cohort studies (n = 34 470 individual children) met the inclusion criteria. Controlling for total energy intake, 1 daily 6-to 8-oz serving increment of 100% fruit juice was associated with a 0.003 (95% CI: 0.001 to 0.004) unit increase in BMI z score over 1 year in children of all ages (0% increase in BMI percentile). In children ages 1 to 6 years, 1 serving increment was associated with a 0.087 (95% confidence interval: 0.008 to 0.167) unit increase in BMI z score (4% increase in BMI percentile). 100% fruit juice consumption was not associated with BMI z score increase in children ages 7 to 18 years. LIMITATIONS: All observational studies; studies differed in exposure assessment and covariate adjustment. CONCLUSIONS: Consumption of 100% fruit juice is associated with a small amount of weight gain in children ages 1 to 6 years that is not clinically significant, and is not associated with weight gain in children ages 7 to 18 years. More studies are needed in children ages 1 to 6 years. C1 [Auerbach, Brandon J.; Krieger, James] Univ Washington, Dept Med, Seattle, WA USA. [Auerbach, Brandon J.; Wolf, Fred M.; Littman, Alyson] Univ Washington, Dept Epidemiol, Seattle, WA 98195 USA. [Wolf, Fred M.] Univ Washington, Dept Biomed Informat & Med Educ, Seattle, WA 98195 USA. [Wolf, Fred M.; Hikida, Abigail; Krieger, James] Univ Washington, Dept Hlth Serv, Seattle, WA 98195 USA. [Louden, Diana] Univ Washington, Univ Lib, Seattle, WA 98195 USA. [Hikida, Abigail; Littman, Alyson] VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Hikida, Abigail; Littman, Alyson] Northwest VA Hlth Serv, Res & Dev Ctr Excellence, Seattle, WA USA. [Vallila-Buchman, Petra; Taber, Daniel R.; Krieger, James] Hlth Food Amer, Seattle, WA USA. [Thompson, Douglas] Thompson Res Consulting, Chicago, IL USA. RP Auerbach, BJ (reprint author), Univ Washington, Harborview Med Ctr, Div Gen Internal Med, Box 359780,325 Ninth Ave, Seattle, WA 98104 USA. EM auerbach@post.harvard.edu OI Louden, Diana/0000-0002-6161-5557 FU Ruth L. Kirschstein National Research Service of the National Institutes of Health through the University of Washington [T32HP10002] FX Dr Auerbach is funded by the Ruth L. Kirschstein National Research Service of the National Institutes of Health through the University of Washington (grant T32HP10002). The funding sources had no role in the design, conduct, or analysis of the study, or the decision to submit the manuscript for publication. Funded by the National Institutes of Health (NIH). NR 46 TC 1 Z9 1 U1 0 U2 0 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD APR PY 2017 VL 139 IS 4 AR UNSP e20162454 DI 10.1542/peds.2016-2454 PG 12 WC Pediatrics SC Pediatrics GA ER2CU UT WOS:000398602400017 ER PT J AU Raz, M AF Raz, Mical TI Unintended Consequences of Expanded Mandatory Reporting Laws SO PEDIATRICS LA English DT Editorial Material ID ABUSE C1 [Raz, Mical] Univ Penn, Perelman Sch Med, Philadelphia Vet Affairs Med Ctr, Robert Wood Johnson Clin Scholars Program, Philadelphia, PA 19104 USA. RP Raz, M (reprint author), Univ Penn, Perelman Sch Med, Philadelphia VA Med Ctr, Robert Wood Johnson Clin Scholars Program, 1310 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM micalraz@mail.med.upenn.edu NR 10 TC 0 Z9 0 U1 0 U2 0 PU AMER ACAD PEDIATRICS PI ELK GROVE VILLAGE PA 141 NORTH-WEST POINT BLVD,, ELK GROVE VILLAGE, IL 60007-1098 USA SN 0031-4005 EI 1098-4275 J9 PEDIATRICS JI Pediatrics PD APR PY 2017 VL 139 IS 4 AR e0163511 DI 10.1542/peds.2016-3511 PG 3 WC Pediatrics SC Pediatrics GA ER2CU UT WOS:000398602400042 ER PT J AU Zhang, YQ Unnikrishnan, A Deepa, SS Liu, YH Li, Y Ikeno, Y Sosnowska, D Van Remmen, H Richardson, A AF Zhang, Yiqiang Unnikrishnan, Archana Deepa, Sathyaseelan S. Liu, Yuhong Li, Yan Ikeno, Yuji Sosnowska, Danuta Van Remmen, Holly Richardson, Arlan TI A new role for oxidative stress in aging: The accelerated aging phenotype in Sod1(-/-) mice is correlated to increased cellular senescence SO REDOX BIOLOGY LA English DT Article DE Cellular senescence; Superoxide dismutase; Aging; Inflammation; DNA damage; Dietary restriction; Oxidative stress ID LOW-GRADE INFLAMMATION; SECRETORY PHENOTYPE; NLRP3 INFLAMMASOME; HUMAN-CELLS; DNA-DAMAGE; LIFE-SPAN; IN-VIVO; NECROPTOSIS; BIOMARKER; DISEASES AB In contrast to other mouse models that are deficient in antioxidant enzymes, mice null for Cu/Zn-superoxide dismutase (Sod1(-/-) mice) show a major decrease in lifespan and several accelerated aging phenotypes. The goal of this study was to determine if cell senescence might be a contributing factor in the accelerated aging phenotype observed in the Sod1(-/-) mice. We focused on kidney because it is a tissue that has been shown to a significant increase in senescent cells with age. The Sod1(-/-) mice are characterized by high levels of DNA oxidation in the kidney, which is attenuated by DR. The kidney of the Sod1(-/-) mice also have higher levels of double strand DNA breaks than wild type (WT) mice. Expression (mRNA and protein) of p16 and p21, two of the markers of cellular senescence, which increased with age, are increased significantly in the kidney of Sod1(-/-)mice as is beta-gal staining cells. In addition, the senescence associated secretory phenotype was also increased significantly in the kidney of Sod1(-/-) mice compared to WT mice as measured by the expression of transcripts for IL-6 and IL-1 beta. Dietary restriction of the Sod1(-/-) mice attenuated the increase in DNA damage, cellular senescence, and expression of IL-6 and IL-1 beta. Interestingly, the Sod1-/- mice showed higher levels of circulating cytokines than WT mice, suggesting that the accelerated aging phenotype shown by the Sod1(-/-) mice could result from increased inflammation arising from an accelerated accumulation of senescent cells. Based on our data with Sod1(-/-) mice, we propose that various bouts of increased oxidative stress over the lifespan of an animal leads to the accumulation of senescent cells. The accumulation of senescent cells in turn leads to increased inflammation, which plays a major role in the loss of function and increased pathology that are hallmark features of aging. C1 [Zhang, Yiqiang] Univ Texas Hlth Sci Ctr San Antonio, Greehy Childrens Canc Inst, San Antonio, TX 78229 USA. [Liu, Yuhong; Li, Yan] Univ Texas Hlth Sci Ctr San Antonio, Dept Cellular Biol, San Antonio, TX 78229 USA. [Liu, Yuhong; Li, Yan] Univ Texas Hlth Sci Ctr San Antonio, Dept Biol Struct, San Antonio, TX 78229 USA. [Ikeno, Yuji] Univ Texas Hlth Sci Ctr San Antonio, Dept Pathol, San Antonio, TX 78229 USA. [Ikeno, Yuji] South Texas Vet Hlth Care Syst, GRECC, San Antonio, TX USA. [Unnikrishnan, Archana; Deepa, Sathyaseelan S.; Sosnowska, Danuta; Richardson, Arlan] Univ Oklahoma, Hlth Sci Ctr, Dept Geriatr Med, Oklahoma City, OK 73104 USA. [Unnikrishnan, Archana; Deepa, Sathyaseelan S.; Sosnowska, Danuta; Richardson, Arlan] Univ Oklahoma, Hlth Sci Ctr, Reynolds Oklahoma Ctr Aging, Oklahoma City, OK 73104 USA. [Van Remmen, Holly] Oklahoma Med Res Fdn, 825 NE 13th St, Oklahoma City, OK 73104 USA. [Van Remmen, Holly; Richardson, Arlan] Oklahoma City VA Med Ctr, Oklahoma City, OK USA. RP Richardson, A (reprint author), Univ Oklahoma, Hlth Sci Ctr, Dept Geriatr Med, Oklahoma City, OK 73104 USA.; Richardson, A (reprint author), Univ Oklahoma, Hlth Sci Ctr, Reynolds Oklahoma Ctr Aging, Oklahoma City, OK 73104 USA. EM Arlan-richardson@ouhsc.edu FU NIH [P01AG020591, P01AG051442, R01 AG045693]; Senior Research Career Scientist awards from the Department of Veteran Affairs FX This study was supported by NIH grants to HVR and AR (P01AG020591 and P01AG051442) and an NIH grant to AR and AU (R01 AG045693). AR and HVR are supported by the Senior Research Career Scientist awards from the Department of Veteran Affairs. NR 49 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2213-2317 J9 REDOX BIOL JI Redox Biol. PD APR PY 2017 VL 11 BP 30 EP 37 DI 10.1016/j.redox.2016.10.014 PG 8 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA EQ6RY UT WOS:000398212000004 PM 27846439 ER PT J AU Redmann, M Wani, WY Volpicelli-Daley, L Darley-Usmar, V Zhang, JH AF Redmann, Matthew Wani, Willayat Y. Volpicelli-Daley, Laura Darley-Usmar, Victor Zhang, Jianhua TI Trehalose does not improve neuronal survival on exposure to alpha-synuclein pre-formed fibrils SO REDOX BIOLOGY LA English DT Article DE Parkinson's disease; Alpha-synuclein fibrils; P-alpha-synuclein trehalose; Autophagy; LC3-II ID PARKINSONS-DISEASE; LYSOSOMAL BIOGENESIS; LEWY BODIES; AGGREGATION; AUTOPHAGY; NEURODEGENERATION; DEGRADATION; TOLERANCE; PATHOLOGY; CHAPERONE AB Parkinson's disease is a debilitating neurodegenerative disorder that is pathologically characterized by intracellular inclusions comprised primarily of alpha-synuclein (alpha Syn) that can also be transmitted from neuron to neuron. Several lines of evidence suggest that these inclusions cause neurodegeneration. Thus exploring strategies to improve neuronal survival in neurons with alpha Syn aggregates is critical. Previously, exposure to alpha Syn pre-formed fibrils (PFFs) has been shown to induce aggregation of endogenous alpha Syn resulting in cell death that is exacerbated by either starvation or inhibition of mTOR by rapamycin, both of which are able to induce autophagy, an intracellular protein degradation pathway. Since mTOR inhibition may also inhibit protein synthesis and starvation itself can be detrimental to neuronal survival, we investigated the effects of autophagy induction on neurons with alpha Syn inclusions by a starvation and mTOR-independent autophagy induction mechanism. We exposed mouse primary cortical neurons to PFFs to induce inclusion formation in the presence and absence of the disaccharide trehalose, which has been proposed to induce autophagy and stimulate lysosomal biogenesis. As expected, we observed that on exposure to PFFs, there was increased abundance of pS129-alpha Syn aggregates and cell death. Trehalose alone increased LC3-II levels, consistent with increased autophagosome levels that remained elevated with PFF exposure. Interestingly, trehalose alone increased cell viability over a 14-d time course. Trehalose was also able to restore cell viability to control levels, but PFFs still exhibited toxic effects on the cells. These data provide essential information regarding effects of trehalose on aSyn accumulation and neuronal survival on exposure to PFF. C1 [Redmann, Matthew; Wani, Willayat Y.; Darley-Usmar, Victor; Zhang, Jianhua] Univ Alabama Birmingham, Dept Pathol, Birmingham, AL USA. [Redmann, Matthew; Wani, Willayat Y.; Darley-Usmar, Victor; Zhang, Jianhua] Univ Alabama Birmingham, Ctr Free Rad Biol, Birmingham, AL USA. [Volpicelli-Daley, Laura; Zhang, Jianhua] Univ Alabama Birmingham, Ctr Neurodegenerat Expt Therapeut, Birmingham, AL USA. [Volpicelli-Daley, Laura] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35294 USA. [Zhang, Jianhua] Birmingham VA Med Ctr, Dept Vet Affairs, Birmingham, AL USA. RP Zhang, JH (reprint author), Univ Alabama Birmingham, Dept Pathol, BMRII 534, 901 19th St S, Birmingham, AL 35294 USA. EM zhanja@uab.edu FU [NIHR01-NS064090] FX We would like to thank Dr. Laura Volpicelli-Daley and members of the Zhang and Darley-Usmar laboratories for discussion and technical assistance. This work was supported by NIHR01-NS064090 (to JZ). NR 34 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE BV PI AMSTERDAM PA PO BOX 211, 1000 AE AMSTERDAM, NETHERLANDS SN 2213-2317 J9 REDOX BIOL JI Redox Biol. PD APR PY 2017 VL 11 BP 429 EP 437 DI 10.1016/j.redox.2016.12.032 PG 9 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA EQ6RY UT WOS:000398212000043 PM 28068606 ER PT J AU Vogelmeier, CF Criner, GJ Martinez, FJ Anzueto, A Barnes, PJ Bourbeau, J Celli, BR Chen, RC Decramer, M Fabbri, LM Frith, P Halpin, DMG Lopez Varela, MV Nishimura, M Roche, N Rodriguez-Roisin, R Sin, DD Singh, D Stockley, R Vestbo, J Wedzicha, JA Agusti, A AF Vogelmeier, Claus F. Criner, Gerard J. Martinez, Fernando J. Anzueto, Antonio Barnes, Peter J. Bourbeau, Jean Celli, Bartolome R. Chen, Rongchang Decramer, Marc Fabbri, Leonardo M. Frith, Peter Halpin, David M. G. Lopez Varela, M. Victorina Nishimura, Masaharu Roche, Nicolas Rodriguez-Roisin, Roberto Sin, Don D. Singh, Dave Stockley, Robert Vestbo, Jorgen Wedzicha, Jadwiga A. Agusti, Alvar TI Global Strategy for the Diagnosis, Management and Prevention of Chronic Obstructive Lung Disease 2017 Report GOLD Executive Summary SO RESPIROLOGY LA English DT Article DE chronic obstructive pulmonary disease; COPD diagnosis; COPD management; COPD prevention ID RANDOMIZED CONTROLLED-TRIAL; AIR-FLOW OBSTRUCTION; POSITIVE-PRESSURE VENTILATION; PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; INHALED FLUTICASONE FUROATE; CHRONIC RESPIRATORY-DISEASE; VOLUME-REDUCTION SURGERY; BONE-MINERAL DENSITY; REQUIRING MECHANICAL VENTILATION AB This Executive Summary of the Global Strategy for the Diagnosis, Management and Prevention of COPD, Global Initiative for Chronic Obstructive Lung Disease (GOLD) 2017 Report focuses primarily on the revised and novel parts of the document. The most significant changes include: (i) the assessment of chronic obstructive pulmonary disease has been refined to separate the spirometric assessment from symptom evaluation. ABCD groups are now proposed to be derived exclusively from patient symptoms and their history of exacerbations; (ii) for each of the groups A to D, escalation strategies for pharmacological treatments are proposed; (iii) the concept of deescalation of therapy is introduced in the treatment assessment scheme; (iv) non-pharmacological therapies are comprehensively presented and (v) the importance of co-morbid conditions in managing COPD is reviewed. C1 [Vogelmeier, Claus F.] Univ Marburg, German Ctr Lung Res DZL, Marburg, Germany. [Criner, Gerard J.] Temple Univ, Lewis Katz Sch Med, Philadelphia, PA 19122 USA. [Martinez, Fernando J.] New York Presbyterian Hosp, Weill Cornell Med Ctr, New York, NY USA. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Anzueto, Antonio] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Barnes, Peter J.; Wedzicha, Jadwiga A.] Imperial Coll, Natl Heart & Lung Inst, London, England. [Bourbeau, Jean] McGill Univ, Ctr Hlth, Montreal, PQ, Canada. [Celli, Bartolome R.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Chen, Rongchang] Guangzhou Med Univ, Affiliated Hosp 1, Guangzhou Inst Resp Dis, State Key Lab Resp Dis, Guangzhou, Guangdong, Peoples R China. [Decramer, Marc] Univ Leuven, Leuven, Belgium. [Fabbri, Leonardo M.] Univ Modena & Reggio Emilia, Modena, Italy. [Frith, Peter] Flinders Univ S Australia, Fac Med, Bedford Pk, SA, Australia. [Halpin, David M. G.] Royal Devon & Exeter Hosp, Exeter, Devon, England. [Lopez Varela, M. Victorina] Univ Republica, Hosp Maciel, Montevideo, Uruguay. [Nishimura, Masaharu] Hokkaido Univ, Sch Med, Sapporo, Hokkaido, Japan. [Roche, Nicolas] Univ Paris 05, Hop Cochin, AP HP, Paris, France. [Rodriguez-Roisin, Roberto] Hosp Clin Univ Barcelona, Thorax Inst, Barcelona, Spain. [Sin, Don D.] Univ British Columbia, St Pauls Hosp, Vancouver, BC, Canada. [Singh, Dave; Vestbo, Jorgen] Univ Manchester, Manchester, Lancs, England. [Stockley, Robert] Univ Hosp, Birmingham, W Midlands, England. [Agusti, Alvar] Univ Barcelona, Hosp Clin, Ctr Invest Biomed Red Enfermedade Resp, Barcelona, Spain. RP Vogelmeier, CF (reprint author), Univ Marburg, Dept Med Pulm & Crit Care Med, Baldingerstr 1, D-35043 Marburg, Germany. EM Claus.Vogelmeier@med.uni-marburg.de NR 339 TC 1 Z9 1 U1 7 U2 7 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1323-7799 EI 1440-1843 J9 RESPIROLOGY JI Respirology PD APR PY 2017 VL 22 IS 3 BP 575 EP 601 DI 10.1111/resp.13012 PG 27 WC Respiratory System SC Respiratory System GA EQ3BY UT WOS:000397947200023 PM 28150362 ER PT J AU Restrepo, MI Chalmers, JD Song, YL Mallow, C Hewlett, J Maldonado, F Yarmus, L AF Restrepo, Marcos I. Chalmers, James D. Song, Yuanlin Mallow, Christopher Hewlett, Justin Maldonado, Fabien Yarmus, Lonny TI Year in review 2016: Respiratory infections, acute respiratory distress syndrome, pleural diseases, lung cancer and interventional pulmonology SO RESPIROLOGY LA English DT Review DE acute respiratory distress syndrome; bronchoscopy and interventional techniques; lung cancer; pleural disease; respiratory infections (non-tuberculous) ID COMMUNITY-ACQUIRED PNEUMONIA; RESISTANT STAPHYLOCOCCUS-AUREUS; CARE-ASSOCIATED PNEUMONIA; TUBERCULOSIS INFECTION; FLEXIBLE BRONCHOSCOPY; PROGNOSTIC-FACTORS; METAANALYSIS; INJURY; BRONCHIECTASIS; MANAGEMENT C1 [Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Restrepo, Marcos I.] Univ Texas Hlth, San Antonio, TX USA. [Mallow, Christopher; Yarmus, Lonny] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Hewlett, Justin; Maldonado, Fabien] Vanderbilt Univ, Sch Med, Nashville, TN 37212 USA. [Chalmers, James D.] Univ Dundee, Ninewells Hosp & Med Sch, Scottish Ctr Resp Res, Dundee, Scotland. [Chalmers, James D.] Univ Dundee, Ninewells Hosp & Med Sch, Sch Med, Dundee, Scotland. [Song, Yuanlin] Fudan Univ, Zhongshan Hosp, Dept Pulm Med, Shanghai, Peoples R China. RP Chalmers, JD (reprint author), Ninewells Hosp & Med Sch, Scottish Ctr Resp Res, Ninewells Ave, Dundee DD1 9SY, Scotland. EM j.chalmers@dundee.ac.uk FU AstraZeneca; Bayer Healthcare; Pfizer Ltd; GlaxoSmithKline; Centurion, Inc; Department of Defense, USA FX J.D.C. reports grant support from AstraZeneca, Bayer Healthcare, Pfizer Ltd and GlaxoSmithKline. F.M. has consulted for Boston Scientific and Intuitive, Inc; and received grant support from Centurion, Inc and from the Department of Defense, USA. NR 66 TC 0 Z9 0 U1 1 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1323-7799 EI 1440-1843 J9 RESPIROLOGY JI Respirology PD APR PY 2017 VL 22 IS 3 BP 602 EP 611 DI 10.1111/resp.13016 PG 10 WC Respiratory System SC Respiratory System GA EQ3BY UT WOS:000397947200024 PM 28244617 ER PT J AU Giordano, S Zhao, XM Chen, YF Litovsky, SH Hage, FG Townes, TM Sun, CW Wu, LC Oparil, S Xing, DQ AF Giordano, Samantha Zhao, Xiangmin Chen, Yiu-Fai Litovsky, Silvio H. Hage, Fadi G. Townes, Tim M. Sun, Chiao-Wang Wu, Li-Chen Oparil, Suzanne Xing, Dongqi TI Induced Pluripotent Stem Cell-Derived Endothelial Cells Overexpressing Interleukin-8 Receptors A/B and/or C-C Chemokine Receptors 2/5 Inhibit Vascular Injury Response SO STEM CELLS TRANSLATIONAL MEDICINE LA English DT Article DE iPS-endothelial cells; Targeted cell therapy; Vascular injury; Interleukin 8 receptor; C-C chemokine receptor 2/5 ID MONOCYTE CHEMOATTRACTANT PROTEIN-1; SMOOTH-MUSCLE-CELLS; ADVENTITIAL FIBROBLAST MIGRATION; CHANGES NEOINTIMAL HYPERPLASIA; ATHEROSCLEROSIS-PRONE MICE; RAT CAROTID ARTERIES; E-DEFICIENT MICE; KNOCKOUT MICE; IN-VITRO; HYPERCHOLESTEROLEMIC RABBITS AB Recruitment of neutrophils and monocytes/macrophages to the site of vascular injury is mediated by binding of chemoattractants to interleukin (IL) 8 receptors RA and RB (IL8RA/B) C-C chemokine receptors (CCR) 2 and 5 expressed on neutrophil and monocyte/macrophage membranes. Endothelial cells (ECs) derived from rat-induced pluripotent stem cells (RiPS) were transduced with adenovirus containing cDNA of IL8RA/B and/or CCR2/5. We hypothesized that RiPS-ECs overexpressing IL8RA/B (RiPS-IL8RA/B-ECs), CCR2/5 (RiPS-CCR2/5-ECs), or both receptors (RiPS-IL8RA/B+CCR2/5-ECs) will inhibit inflammatory responses and neointima formation in balloon-injured rat carotid artery. Twelve-week-old male Sprague-Dawley rats underwent balloon injury of the right carotid artery and intravenous infusion of (a) saline vehicle, (b) control RiPS-Null-ECs (ECs transduced with empty virus), (c) RiPS-IL8RA/B-ECs, (d) RiPS-CCR2/5-ECs, or (e) RiPS-IL8RA/B+CCR2/5-ECs. Inflammatory mediator expression and leukocyte infiltration were measured in injured and uninjured arteries at 24 hours postinjury by enzyme-linked immunosorbent assay (ELISA) and immunohistochemistry, respectively. Neointima formation was assessed at 14 days postinjury. RiPS-ECs expressing the IL8RA/B or CCR2/5 homing device targeted the injured arteries and decreased injury-induced inflammatory cytokine expression, neutrophil/macrophage infiltration, and neointima formation. Transfused RiPS-ECs overexpressing IL8RA/B and/or CCR2/5 prevented inflammatory responses and neointima formation after vascular injury. Targeted delivery of iPS-ECs with a homing device to inflammatory mediators in injured arteries provides a novel strategy for the treatment of cardiovascular diseases. C1 [Giordano, Samantha; Zhao, Xiangmin; Chen, Yiu-Fai; Hage, Fadi G.; Oparil, Suzanne; Xing, Dongqi] Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Vascu Biol & Hypertens Program, 1010 Zeigler Res Bldg,703 19th St South, Birmingham, AL 35294 USA. [Litovsky, Silvio H.] Univ Alabama Birmingham, Dept Pathol, Div Anat Pathol, Birmingham, AL 35294 USA. [Hage, Fadi G.] Birmingham Vet Affairs Med Ctr, Cardiol Sect, Birmingham, AL USA. [Townes, Tim M.; Sun, Chiao-Wang; Wu, Li-Chen] Univ Alabama Birmingham, Dept Biochem & Mol Genet, Birmingham, AL USA. RP Xing, DQ (reprint author), Univ Alabama Birmingham, Dept Med, Div Cardiovasc Dis, Vascu Biol & Hypertens Program, 1010 Zeigler Res Bldg,703 19th St South, Birmingham, AL 35294 USA. EM dqxing@uab.edu FU National Institutes of Health (NIH) [RO1 HL116727, RO1 HL087980, R56 HL128285-01A1, T32 HL07457]; American Heart Association (AHA) [SDG 0930098N]; Veterans Affairs Biomedical Laboratory Research & Development Service Merit Award [OMB 4040-0001]; CCVC William W. Featheringill Innovative Award of the University of Alabama at Birmingham FX This study was supported by National Institutes of Health (NIH) grants: RO1 HL116727 (Y.-F. Chen), RO1 HL087980 (S. Oparil), R56 HL128285-01A1 (D. Xing), and T32 HL07457 (S. Oparil, S. Giordano); an American Heart Association (AHA) grant SDG 0930098N (F. G. Hage); a Veterans Affairs Biomedical Laboratory Research & Development Service Merit Award OMB 4040-0001 (F. G. Hage); and a CCVC William W. Featheringill Innovative Award of the University of Alabama at Birmingham (Y.-F. Chen). NR 67 TC 0 Z9 0 U1 1 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2157-6564 EI 2157-6580 J9 STEM CELL TRANSL MED JI Stem Cells Transl. Med. PD APR PY 2017 VL 6 IS 4 BP 1168 EP 1177 DI 10.1002/sctm.16-0316 PG 10 WC Cell & Tissue Engineering SC Cell Biology GA EQ6QB UT WOS:000398206500012 PM 28233474 ER PT J AU Jay, CL Washburn, K Dean, PG Helmick, RA Pugh, JA Stegall, MD AF Jay, Colleen L. Washburn, Kenneth Dean, Patrick G. Helmick, Ryan A. Pugh, Jacqueline A. Stegall, Mark D. TI Survival Benefit in Older Patients Associated With Earlier Transplant With High KDPI Kidneys SO TRANSPLANTATION LA English DT Article ID EUROTRANSPLANT SENIOR PROGRAM; RENAL-TRANSPLANTATION; RECIPIENTS; DIALYSIS; OUTCOMES; RISK; AGE; THROMBOSIS; VOLUME AB Background. Given high dialysis mortality rates for patients older than 60 years, accepting a kidney with a high Kidney Donor Profile Index (KDPI) score could enable earlier and potentially preemptive transplantation (preKT). However, evidence regarding the risks of high KDPI allografts in older patients is limited. Our objective was to determine the relative benefit for older patients of KDPI greater than 85% transplant either preemptively or not compared with remaining on the waitlist. Methods. United Network of Organ Sharing data from 2003 to 2012 for adult deceased donor kidney transplant candidates was analyzed to evaluate patient survival in patients older than 60 years for preKT and non-preKT KDPI greater than 85% transplants compared with candidates remaining on the waitlist including patients who received KDPI 0% to 85% transplants according to multivariate Cox regression models. Results. In the first year posttransplant for KDPI greater than 85% of transplants in recipients older than 60 years, preKT had a reduced mortality hazard (hazards ratio [HR], 0.61; 95% confidence interval [95% CI], 0.41-0.90) and non-preKT an increased mortality hazard (HR, 1.15; 95% CI, 1.03-1.27) compared with the waitlist including KDPI 0% to 85% transplant recipients. At 1 to 2 years and after 2 years, both KDPI greater than 85% groups had significant reductions in mortality (1-2 years: preKT HR, 0.38; 95% CI, [0.23-0.60] and non-preKT HR, 0.52; 95% CI, 0.45-0.61; and 2+ years: preKT HR, 0.50; 95% CI, 0.38-0.66 and non-preKT HR, 0.64; 95% CI, 0.58-0.70, respectively). Conclusions. PreKT and non-preKT KDPI greater than 85% transplant was associated with lower mortality hazard after the first year compared with the waitlist including KDPI 0% to 85% transplants in patients older than 60 years. Further consideration should be given to increased utilization of high KDPI grafts in older patients with the goal of avoiding or limiting time on dialysis. C1 [Jay, Colleen L.; Washburn, Kenneth] Univ Texas Hlth Sci Ctr San Antonio, Transplant Ctr, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. [Dean, Patrick G.; Stegall, Mark D.] Mayo Clin, Div Transplant Surg, Rochester, MN USA. [Helmick, Ryan A.] Univ Tennessee, Ctr Hlth Sci, Methodist Univ Hosp, Transplant Inst, Memphis, TN 38163 USA. [Pugh, Jacqueline A.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Pugh, Jacqueline A.] Univ Texas Hlth Sci Ctr San Antonio, Div Hosp Med, San Antonio, TX 78229 USA. RP Jay, CL (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Transplant Ctr, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. EM jay@uthscsa.edu FU National Center for Advancing Translational Sciences, National Institutes of Health [KL2 TR001118]; Department of Veterans Affairs FX The project described was supported by the National Center for Advancing Translational Sciences, National Institutes of Health, through Grant KL2 TR001118. J.A.P.'s salary is supported by the Department of Veterans Affairs. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health or the Department of Veterans Affairs. NR 24 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD APR PY 2017 VL 101 IS 4 BP 867 EP 872 DI 10.1097/TP.0000000000001405 PG 6 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA EQ5XU UT WOS:000398157200044 PM 27495758 ER PT J AU Zhu, P Bailey, SR Lei, BA Paulos, CM Atkinson, C Tomlinson, S AF Zhu, Peng Bailey, Stefanie R. Lei, Biao Paulos, Chrystal M. Atkinson, Carl Tomlinson, Stephen TI Targeted Complement Inhibition Protects Vascularized Composite Allografts From Acute Graft Injury and Prolongs Graft Survival When Combined With Subtherapeutic Cyclosporine A Therapy SO TRANSPLANTATION LA English DT Article ID ISCHEMIA-REPERFUSION INJURY; MEMBRANE ATTACK COMPLEX; ALTERNATIVE PATHWAY; ACUTE REJECTION; T-CELLS; ALLOTRANSPLANTATION; TRANSPLANTATION; SYSTEM; HAND; REGENERATION AB Background. Recipients of vascularized composite allografts require aggressive and lifelong immunosuppression, and because the surgery is usually performed in nonlife-threatening situations, the development of strategies to minimize immunosuppression is especially pertinent for this procedure. We investigated how complement affects acute graft injury, alloimmunity, and immunosuppressive therapy. Methods. Vascularized composite allografts were transplanted from Balb/C to C57BL/6 mice that were complement deficient (C3 or double C3a Receptor (R)/C5aR), or treated with a targeted complement inhibitor (CR2-Crry). Allografts were analyzed for acute inflammation and injury, subacute T cell response, and survival in the absence and presence of cyclosporine A (CsA) therapy. Results. Allografts in C3-deficient or CR2-Crry-treated recipients were protected from skin and muscle ischemia-reperfusion injury (IRI). C3aR/C5aR-deficient recipients were more modestly protected. IgM and C3d colocalized within allografts from wild type and C3aR/C5aR-deficient recipients indicating IgM-mediated complement activation, and C3d deposition was almost absent in allografts from C3-deficient and CR2-Crry-treated recipients. Inflammatory cell infiltration and P-selectin expression was also significantly reduced in C3-deficient and CR2-Crry-treated recipients. Acute treatment with CR2-Crry or with 3 mg/kg per day CsA modestly, but significantly increased median allograft survival from 5.8 to 7.4 and 7.2 days, respectively. However, combined acute CR2-Crry treatment and CsA therapy increased mean graft survival to 17.2 days. Protection was associated with significantly reduced T cell infiltration of allografts and Tc1 cells in recipient spleens. Conclusions. Complement-mediated IRI augments graft allogenicity, and appropriate complement inhibition ameliorates IRI, decreases alloimmune priming and allows more immune-sparing CsA dosing. C1 [Zhu, Peng] Huazhong Univ Sci & Technol, Tongji Hosp, Dept Surg, Wuhan, Peoples R China. [Zhu, Peng; Bailey, Stefanie R.; Lei, Biao; Paulos, Chrystal M.; Atkinson, Carl; Tomlinson, Stephen] Med Univ South Carolina, Dept Microbiol & Immunol, 173 Ashley Ave, Charleston, SC 29425 USA. [Atkinson, Carl] Med Univ South Carolina, Lee Patterson Allen Transplant Immunobiol Lab, Div Transplantat, Dept Surg, Charleston, SC USA. [Atkinson, Carl; Tomlinson, Stephen] Med Univ South Carolina, SCIT, Charleston, SC USA. [Tomlinson, Stephen] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Tomlinson, S (reprint author), Med Univ South Carolina, Dept Microbiol & Immunol, 173 Ashley Ave, Charleston, SC 29425 USA.; Atkinson, C (reprint author), Med Univ South Carolina, Dept Microbiol & Immunol & Surg, 173 Ashley Ave, Charleston, SC 29425 USA. EM atkinsoc@musc.edu; tomlinss@musc.edu FU NIH [R56AI119026, R01DK102912]; Department of Veterans Affairs [1I01RX001141, 1BX001218]; Department of Defense [W81XWH-16-1-0783] FX This work was supported by grants from the NIH (R56AI119026 and R01DK102912), Department of Veterans Affairs (Merit Award 1I01RX001141 and 1BX001218) and the Department of Defense (W81XWH-16-1-0783). NR 43 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0041-1337 EI 1534-6080 J9 TRANSPLANTATION JI Transplantation PD APR PY 2017 VL 101 IS 4 BP E75 EP E85 DI 10.1097/TP.0000000000001625 PG 11 WC Immunology; Surgery; Transplantation SC Immunology; Surgery; Transplantation GA EQ5XU UT WOS:000398157200001 PM 28045880 ER PT J AU Ho, N Lieberman, D AF Ho, N. Lieberman, D. TI Editorial: smoking status and 5-year survival in patients with colorectal cancer SO ALIMENTARY PHARMACOLOGY & THERAPEUTICS LA English DT Editorial Material C1 [Ho, N.] Portland VA Med Ctr, & Oregon Hlth & Sci Univ, Portland, OR 97239 USA. Oregon Hlth & Sci Univ, Portland, OR 97201 USA. RP Ho, N (reprint author), Portland VA Med Ctr, & Oregon Hlth & Sci Univ, Portland, OR 97239 USA. EM nho4383@gmail.com; lieberma@ohsu.edu NR 4 TC 0 Z9 0 U1 1 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-2813 EI 1365-2036 J9 ALIMENT PHARM THER JI Aliment. Pharmacol. Ther. PD APR PY 2017 VL 45 IS 8 BP 1162 EP 1163 DI 10.1111/apt.13979 PG 2 WC Gastroenterology & Hepatology; Pharmacology & Pharmacy SC Gastroenterology & Hepatology; Pharmacology & Pharmacy GA EQ1CW UT WOS:000397807900014 PM 28326580 ER PT J AU Banerjee, G Edelman, EJ Barry, DT Becker, WC Cerda, M Crystal, S Gaither, JR Gordon, AJ Gordon, KS Kerns, RD Martins, SS Fiellin, DA Marshall, BDL AF Banerjee, Geetanjoli Edelman, E. Jennifer Barry, Declan T. Becker, William C. Cerda, Magdalena Crystal, Stephen Gaither, Julie R. Gordon, Adam J. Gordon, Kirsha S. Kerns, Robert D. Martins, Silvia S. Fiellin, David A. Marshall, Brandon D. L. TI Reply to Ruan et al. (2017): Non-medical use of prescription opioids is associated with heroin initiation among US veterans SO ADDICTION LA English DT Letter DE Epidemiology; heroin; longitudinal study; NMUPO; non-medical use of prescription opioids; veterans ID UNITED-STATES; MORTALITY; TRENDS; ABUSE C1 [Banerjee, Geetanjoli; Marshall, Brandon D. L.] Brown Sch Publ Hlth, Dept Epidemiol, Providence, RI 02903 USA. [Edelman, E. Jennifer; Fiellin, David A.] Yale Univ, Dept Internal Med, Yale Sch Med, New Haven, CT USA. [Edelman, E. Jennifer; Gaither, Julie R.; Fiellin, David A.] Yale Univ, Yale Sch Publ Hlth, Yale Ctr Interdisciplinary Res AIDS, New Haven, CT USA. [Barry, Declan T.] Yale Univ, New Haven, CT USA. [Barry, Declan T.] APT Fdn Pain Treatment Serv, New Haven, CT USA. [Becker, William C.; Kerns, Robert D.] Connecticut Healthcare Syst, VA, Pain Res Informat Multimorbid & Educ PRIME Ctr, West Haven, CT USA. [Cerda, Magdalena] Univ Calif Davis, Dept Emergency Med, Sacramento, CA 95817 USA. [Crystal, Stephen] Rutgers State Univ, Inst Hlth Hlth Cure Policy & Aging Res, New Brunswick, NJ USA. [Gaither, Julie R.] Yale Sch Med, Yale Ctr Med Informat, New Haven, CT USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, CHERP, Pittsburgh, PA USA. [Gordon, Adam J.] VA Pittsburgh Healthcare Syst, MIRECC, Pittsburgh, PA USA. [Gordon, Adam J.] Univ Pittsburgh, Pittsburgh, PA USA. [Gordon, Kirsha S.] VA Connecticut Healthcare Syst, West Haven, CT USA. [Kerns, Robert D.] Yale Univ, Dept Psychiat, New Haven, CT 06520 USA. [Kerns, Robert D.] Yale Univ, Dept Neurol, New Haven, CT USA. [Kerns, Robert D.] Yale Univ, Dept Psychol, New Haven, CT USA. [Martins, Silvia S.] Columbia Univ, Mailman Sch Publ Hlth, Dept Epidemiol, New York, NY USA. RP Marshall, BDL (reprint author), Brown Sch Publ Hlth, Dept Epidemiol, Providence, RI 02903 USA. EM brandon_marshall@brown.edu NR 10 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0965-2140 EI 1360-0443 J9 ADDICTION JI Addiction PD APR PY 2017 VL 112 IS 4 BP 728 EP 729 DI 10.1111/add.13710 PG 2 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA EM7DJ UT WOS:000395471400034 PM 28120531 ER PT J AU Borazanci, E Dang, CV Robey, RW Bates, SE Chabot, JA Von Hoff, DD AF Borazanci, Erkut Dang, Chi V. Robey, Robert W. Bates, Susan E. Chabot, John A. Von Hoff, Daniel D. TI Pancreatic Cancer: "A Riddle Wrapped in a Mystery inside an Enigma" SO CLINICAL CANCER RESEARCH LA English DT Article ID ABO BLOOD-GROUP; CONTROL CONSORTIUM PANC4; DUCTAL ADENOCARCINOMA; STELLATE CELLS; COMBINATION THERAPY; RANDOMIZED-TRIALS; PLUS GEMCITABINE; POOLED ANALYSIS; PD-1 BLOCKADE; UNITED-STATES AB Pancreatic ductal adenocarcinoma (PDAC) is one of the most difficult-to-treat cancers. With an increasing incidence and inability to make major progress, it represents the very definition of unmet medical need. Progress has been made in understanding the basic biology-systematic genomic sequencing has led to the recognition that PDAC is not typically a heavily mutated tumor, although there are exceptions. The most consistently mutated genes are KRAS, CDKN2A, TP53, and SMAD4/DPC4. Study of familial PDAChas led to the recognition that a variety of defects in DNA repair genes can be associated with the emergence of pancreatic cancer. Recent studies suggest that epigenetics may play a larger role than previously recognized. A major new understanding is the recognition that PDAC should be considered a composite of tumor cells, as well as pancreatic stellate cells, immune cells, and extracellular matrix. The individual components contribute to metabolic aberration, immune dysfunction, and chemotherapy resistance, and therapeutic innovationsmaybe needed to address them individually. It has also been recognized that metastatic seeding from PDAC occurs very early in the disease course-in an estimated 73% of cases, once the tumor reaches 2 cm. The implication of this is that therapies directed toward micrometastatic disease and increasing fractional cell kill are most needed. Neoadjuvant approaches have been taken to increase resectability and improve outcome. So much work remains, and most critical is the need to understand how this tumor originates and develops. C1 [Borazanci, Erkut; Von Hoff, Daniel D.] Arizona & TGen, HonorHealth, Phoenix, AZ USA. [Dang, Chi V.] Univ Penn, Abramson Canc Ctr, Philadelphia, PA 19104 USA. [Robey, Robert W.] NIH, Bethesda, MD 20892 USA. [Bates, Susan E.; Chabot, John A.] Columbia Univ, Med Ctr, New York, NY USA. [Bates, Susan E.] James J Peters Bronx VA Med Ctr, Bronx, NY USA. RP Borazanci, E (reprint author), HonorHlth Res Inst, 10510 N 92nd St,Suite 200, Scottsdale, AZ 85258 USA. EM Erkut.Borazanci@HonorHealth.com FU Stand Up To Cancer-Cancer Research UK-Lustgarten Foundation Pancreatic Cancer Dream Team Research Grant [SU2C-AACR-DT-20-16]; Seena Magowitz Foundation; Mattress Firm FX Research supported by a Stand Up To Cancer-Cancer Research UK-Lustgarten Foundation Pancreatic Cancer Dream Team Research Grant (E. Borazanci and D.D. Von Hoff; Grant Number: SU2C-AACR-DT-20-16). Stand Up To Cancer is a program of the Entertainment Industry Foundation. Research grants are administered by the American Association for Cancer Research, the scientific partner of SU2C. E. Borazanci and D.D. Von Hoff also received clinical research support from Seena Magowitz Foundation and Mattress Firm. NR 95 TC 1 Z9 1 U1 3 U2 3 PU AMER ASSOC CANCER RESEARCH PI PHILADELPHIA PA 615 CHESTNUT ST, 17TH FLOOR, PHILADELPHIA, PA 19106-4404 USA SN 1078-0432 EI 1557-3265 J9 CLIN CANCER RES JI Clin. Cancer Res. PD APR 1 PY 2017 VL 23 IS 7 BP 1629 EP 1637 DI 10.1158/1078-0432.CCR-16-2070 PG 9 WC Oncology SC Oncology GA EQ7KK UT WOS:000398262700003 PM 28373361 ER PT J AU Montgomery, AE Cusack, M Szymkowiak, D Fargo, J O'Toole, T AF Montgomery, Ann Elizabeth Cusack, Meagan Szymkowiak, Dorota Fargo, Jamison O'Toole, Thomas TI Factors contributing to eviction from permanent supportive housing: Lessons from HUD-VASH SO EVALUATION AND PROGRAM PLANNING LA English DT Article DE Eviction; Permanent supportive housing; Substance use disorder; Acute care; Veterans ID CHRONICALLY HOMELESS INDIVIDUALS; INDEPENDENT LIVING PROGRAMS; SEVERE ALCOHOL-PROBLEMS; SERIOUS MENTAL-ILLNESS; 1ST; PROJECT; EXPANSION; OUTCOMES; PEOPLE; CARE AB Introduction: Eviction from housing is associated with several negative outcomes, further exacerbated among high-need populations requiring financial and supportive services to maintain housing stability. This study investigated risk and protective factors both characteristics and precipitating events of tenant eviction informing permanent supportive housing (PSH) programs' efforts to identify tenants at risk and intervene. Methods: Using administrative data for a cohort of 20,146 Veterans participating in PSH, this study assessed differences in Veterans who exited the program due to eviction and Veterans Who exited because they accomplished their goals. A series of logistic regressions identified patterns of health services use that may signal imminent eviction. Results: Veterans with a drug use disorder and those who received inpatient, emergency, or outpatient care related to mental/behavioral health and substance use conditions proximal to program exit had greater risk for eviction. Receipt of outpatient primary medical care and supportive services was generally protective against eviction. The likelihood of eviction was greatest for Veterans with acute care use within 30 days of exit. Discussion: PSH providers may use these correlates of eviction to identify Veterans in need of an intervention to prevent eviction. Future work should focus on operationalizing these findings and identifying appropriate interventions. Published by Elsevier Ltd. C1 [Montgomery, Ann Elizabeth; Cusack, Meagan; Szymkowiak, Dorota; Fargo, Jamison; O'Toole, Thomas] US Dept Vet Affairs, Natl Ctr Homelessness Vet, Philadelphia, PA USA. [Montgomery, Ann Elizabeth] Birmingham VA Med Ctr, Hlth Serv Res, Birmingham, AL USA. [Montgomery, Ann Elizabeth] Univ Alabama Birmingham, Sch Publ Hlth, Birmingham, AL 35294 USA. [Fargo, Jamison] Utah State Univ, Coll Educ & Human Serv, Logan, UT 84322 USA. [O'Toole, Thomas] Brown Univ, Alpert Med Sch, Providence, RI 02912 USA. [Cusack, Meagan] 4100 Chester Ave,Suite 202, Philadelphia, PA 19104 USA. [Szymkowiak, Dorota] 4100 Chester Ave,Suite 201, Philadelphia, PA 19104 USA. [Fargo, Jamison] 2810 Old Main Hill, Logan, UT 84322 USA. [O'Toole, Thomas] 830 Chalkstone Ave, Providence, RI 02908 USA. RP Montgomery, AE (reprint author), RPHB 227M,1720 2nd Ave South, Birmingham, AL 35294 USA. EM ann.montgomery2@va.gov; meagan.cusack@va.gov; dorota.szymkowiak@va.gov; jamison.fargo@usu.edu; thomas.o'toole@va.gov FU U.S. Department of Veterans Affairs (VA); National Center on Homelessness Among Veterans; U.S. Department of Housing and Urban Development (HUD); Office of Policy Development and Research FX Research for this paper was supported by the U.S. Department of Veterans Affairs (VA), National Center on Homelessness Among Veterans and the U.S. Department of Housing and Urban Development (HUD), Office of Policy Development and Research. The authors wish to express their gratitude to Brent Roberts of the VA Center on Health Equity Research and Promotion and Todd Manning of the Veterans Health Administration Support Service Center for their assistance with data management. The contents of this paper do not represent the views of the U.S. Department of Veterans Affairs or the United States Government. NR 44 TC 0 Z9 0 U1 5 U2 5 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0149-7189 EI 1873-7870 J9 EVAL PROGRAM PLANN JI Eval. Program Plan. PD APR PY 2017 VL 61 BP 55 EP 63 DI 10.1016/j.evalprogplan.2016.11.014 PG 9 WC Social Sciences, Interdisciplinary SC Social Sciences - Other Topics GA EM3MZ UT WOS:000395220600006 PM 27940343 ER PT J AU Levingston, CA Young, MRI AF Levingston, Corinne A. Young, M. Rita I. TI Transient immunological and clinical effectiveness of treating mice bearing premalignant oral lesions with PD-1 antibodies SO INTERNATIONAL JOURNAL OF CANCER LA English DT Article DE cytokines; head and neck cancer; HNSCC; immunotherapy; PD-1; premalignant oral lesions; T cell ID SQUAMOUS-CELL CARCINOMA; REGULATORY T-CELLS; ADVANCED MELANOMA; IMMUNE REACTIVITY; ENDOTHELIAL-CELLS; OVARIAN-CANCER; NEGATIVE HEAD; LUNG-CANCER; NECK-CANCER; OPEN-LABEL AB A carcinogen-induced premalignant oral lesion model that progresses to oral cancer was used to examine the impact of blocking PD-1 on cytokine expression and on progression of lesions to cancer. The results of this study show increased production of IL-2 and the inflammatory cytokines IL-6, IL-17 and TNF-a by spleen cells of lesion-bearing mice that were treated with PD-1 antibody for 1 week compared to cytokine production by spleen cells of lesion-bearing mice treated with control antibody. Production of IFN-c increased at 3 weeks of PD-1 antibody treatment, although production of the other Th1 and inflammatory mediators declined. By 5 weeks, levels of these cytokines declined for both control and PD-1 antibody-treated mice. Flow cytometric analysis for IFN-c-expressing cells showed shifts in CD4(+) 1 cells expressing IFN-c consistent with the changes in cytokine secretion. Whether or not treatment generated reactivity to lesions or HNSCC was determined. Spleen cells from PD-1 antibody- treated mice were stimulated by lysates of premalignant lesion and HNSCC tongue tissues to produce increased levels of Th1 and select inflammatory cytokines early in the course of PD-1 antibody treatment. However, with continued treatment, reactivity to lesion and HNSCC lysates declined. Analysis of clinical response to treatment suggested an early delay in lesion progression but, with continued treatment, lesions in PD-1 antibody-treated mice progressed to the same degree as in control antibody-treated mice. Overall, these results show an early beneficial response to PD-1 antibody treatment, which then fails with continued treatment and lesion progression. C1 [Levingston, Corinne A.; Young, M. Rita I.] Ralph H Johnson VA Med Ctr, Res Serv, Charleston, SC USA. [Young, M. Rita I.] Med Univ South Carolina, Dept Otolaryngol Head & Neck Surg, Charleston, SC 29425 USA. RP Young, MRI (reprint author), Med Univ South Carolina, Dept Otolaryngol, 114 Doughty St, Charleston, SC 29425 USA. EM Youngmr@musc.edu FU Merck Investigator Studies Program [52353]; The Clinical Sciences Research and Development Program of the Department of Veterans Affairs [I01-CX000851] FX Grant sponsors: Merck Investigator Studies Program; Grant sponsors: ID#52353; Grant sponsors: The Clinical Sciences Research and Development Program of the Department of Veterans Affairs; Grant number: Grant number: NR 46 TC 0 Z9 0 U1 2 U2 2 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0020-7136 EI 1097-0215 J9 INT J CANCER JI Int. J. Cancer PD APR PY 2017 VL 140 IS 7 BP 1609 EP 1619 DI 10.1002/ijc.30543 PG 11 WC Oncology SC Oncology GA EM2WT UT WOS:000395177200015 PM 27914100 ER PT J AU Lo, B Grady, D AF Lo, Bernard Grady, Deborah TI Addressing Ethical Lapses in Research SO JAMA INTERNAL MEDICINE LA English DT Editorial Material C1 [Lo, Bernard] Greenwal Fdn, One Penn Plaza,Suite 4726, New York, NY 10119 USA. [Grady, Deborah] Univ Calif San Francisco, San Francisco, CA USA. [Grady, Deborah] San Francisco VA Med Ctr, San Francisco, CA USA. RP Lo, B (reprint author), Greenwal Fdn, One Penn Plaza,Suite 4726, New York, NY 10119 USA. EM bernardlo@greenwall.org NR 8 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD APR 1 PY 2017 VL 177 IS 4 BP 461 EP 462 DI 10.1001/jamainternmed.2016.9579 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA EQ9SM UT WOS:000398425200003 PM 28241241 ER PT J AU Stevens, VW Nelson, RE Schwab-Daugherty, EM Khader, K Jones, MM Brown, KA Greene, T Croft, LD Neuhauser, M Glassman, P Goetz, MB Samore, MH Rubin, MA AF Stevens, Vanessa W. Nelson, Richard E. Schwab-Daugherty, Elyse M. Khader, Karim Jones, Makoto M. Brown, Kevin A. Greene, Tom Croft, Lindsay D. Neuhauser, Melinda Glassman, Peter Goetz, Matthew Bidwell Samore, Matthew H. Rubin, Michael A. TI Comparative Effectiveness of Vancomycin and Metronidazole for the Prevention of Recurrence and Death in Patients With Clostridium difficile Infection SO JAMA INTERNAL MEDICINE LA English DT Article ID PSEUDOMEMBRANOUS COLITIS; STEWARDSHIP PROGRAMS; CARE FACILITIES; DIARRHEA; DISEASE; RISK; EPIDEMIOLOGY; GUIDELINES; SEVERITY; RATIOS AB IMPORTANCE Metronidazole hydrochloride has historically been considered first-line therapy for patients with mild to moderate Clostridium difficile infection (CDI) but is inferior to vancomycin hydrochloride for clinical cure. The choice of therapy may likewise have substantial consequences on other downstream outcomes, such as recurrence and mortality, although these secondary outcomes have been less studied. OBJECTIVE To evaluate the risk of recurrence and all-cause 30-day mortality among patients receiving metronidazole or vancomycin for the treatment of mild to moderate and severe CDI. DESIGN, SETTING, AND PARTICIPANTS This retrospective, propensity-matched cohort study evaluated patients treated for CDI, defined as a positive laboratory test result for the presence of C difficile toxins or toxin genes in a stool sample, in the US Department of Veterans Affairs health care system from January 1, 2005, through December 31, 2012. Data analysis was performed from February 7, 2015, through November 22, 2016. EXPOSURES Treatment with vancomycin or metronidazole. MAIN OUTCOMES AND MEASURES The outcomes of interest in this study were CDI recurrence and all-cause 30-day mortality. Recurrence was defined as a second positive laboratory test result within 8 weeks of the initial CDI diagnosis. All-cause 30-day mortality was defined as death from any cause within 30 days of the initial CDI diagnosis. RESULTS A total of 47 471 patients (mean [SD] age, 68.8 [13.3] years; 1947 women [4.1%] and 45 524 men [95.9%]) developed CDI, were treated with vancomycin or metronidazole, and met criteria for entry into the study. Of 47 147 eligible first treatment episodes, 2068 (4.4%) were with vancomycin. Those 2068 patients were matched to 8069 patients in the metronidazole group for a total of 10 137 included patients. Subcohorts were constructed that comprised 5452 patients with mild to moderate disease and 3130 patients with severe disease. There were no differences in the risk of recurrence between patients treated with vancomycin vs those treated with metronidazole in any of the disease severity cohorts. Among patients in the any severity cohort, those who were treated with vancomycin were less likely to die (adjusted relative risk, 0.86; 95% CI, 0.74 to 0.98; adjusted risk difference, -0.02; 95% CI, -0.03 to -0.01). No significant difference was found in the risk of mortality between treatment groups among patients with mild to moderate CDI, but vancomycin significantly reduced the risk of all-cause 30-day mortality among patients with severe CDI (adjusted relative risk, 0.79; 95% CI, 0.65 to 0.97; adjusted risk difference, -0.04; 95% CI, -0.07 to -0.01). CONCLUSIONS AND RELEVANCE Recurrence rates were similar among patients treated with vancomycin and metronidazole. However, the risk of 30-day mortality was significantly reduced among patients who received vancomycin. Our findings may further justify the use of vancomycin as initial therapy for severe CDI. C1 [Stevens, Vanessa W.; Nelson, Richard E.; Khader, Karim; Jones, Makoto M.; Brown, Kevin A.; Croft, Lindsay D.; Samore, Matthew H.; Rubin, Michael A.] Vet Affairs VA Salt Lake City Hlth Care Syst, IDEAS Ctr 2 0, Salt Lake City, UT USA. [Stevens, Vanessa W.; Nelson, Richard E.; Khader, Karim; Jones, Makoto M.; Greene, Tom; Croft, Lindsay D.; Samore, Matthew H.; Rubin, Michael A.] Univ Utah, Sch Med, Dept Internal Med, Div Epidemiol, Salt Lake City, UT USA. [Schwab-Daugherty, Elyse M.] Univ Utah, Coll Pharm, Dept Pharmacotherapy, Salt Lake City, UT 84112 USA. [Brown, Kevin A.] Publ Hlth Ontario, Toronto, ON, Canada. [Neuhauser, Melinda; Glassman, Peter] VA Pharm Benefits Management Serv, Hines, IL USA. [Glassman, Peter; Goetz, Matthew Bidwell] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Stevens, VW (reprint author), Vet Affairs Salt Lake City Hlth Care Syst, IDEAS Ctr 2 0, 500 Foothill Dr, Salt Lake City, UT 84148 USA. EM vanessa.stevens@hsc.utah.edu FU Center of Innovation [13-414]; US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development [11-210] FX This material is based on work supported in part by Center of Innovation grant 13-414 (Dr Samore, principal investigator) and Career Development Award 11-210 (Dr Nelson, principal investigator) from the US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development. NR 38 TC 0 Z9 0 U1 3 U2 3 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6106 EI 2168-6114 J9 JAMA INTERN MED JI JAMA Intern. Med. PD APR 1 PY 2017 VL 177 IS 4 BP 546 EP 553 DI 10.1001/jamainternmed.2016.9045 PG 8 WC Medicine, General & Internal SC General & Internal Medicine GA EQ9SM UT WOS:000398425200019 PM 28166328 ER PT J AU Hanlon, JT Perera, S Newman, AB Thorpe, JM Donohue, JM Simonsick, EM Shorr, RI Bauer, DC Marcum, ZA AF Hanlon, J. T. Perera, S. Newman, A. B. Thorpe, J. M. Donohue, J. M. Simonsick, E. M. Shorr, R. I. Bauer, D. C. Marcum, Z. A. CA Hlth ABC Study TI Potential drug-drug and drug-disease interactions in well-functioning community-dwelling older adults SO JOURNAL OF CLINICAL PHARMACY AND THERAPEUTICS LA English DT Article DE aged; drug interaction; drug utilization ID INAPPROPRIATE MEDICATION USE; ELDERLY-PEOPLE; RISK; HEALTH; OUTPATIENTS AB What is known and objective: There are few studies examining both drug-drug and drug-disease interactions in older adults. Therefore, the objective of this study was to describe the prevalence of potential drug-drug and drug-disease interactions and associated factors in community-dwelling older adults. Methods: This cross-sectional study included 3055 adults aged 70-79 without mobility limitations at their baseline visit in the Health Aging and Body Composition Study conducted in the communities of Pittsburgh PA and Memphis TN, USA. The outcome factors were potential drug-drug and drug-disease interactions as per the application of explicit criteria drawn from a number of sources to self-reported prescription and non-prescription medication use. Results: Over one-third of participants had at least one type of interaction. Approximately one quarter (25.1%) had evidence of had one or more drug-drug interactions. Nearly 10.7% of the participants had a drug-drug interaction that involved a non-prescription medication. % The most common drug-drug interaction was non-steroidal anti-inflammatory drugs (NSAIDs) affecting antihypertensives. Additionally, 16.0% had a potential drug-disease interaction with 3.7% participants having one involving non-prescription medications. The most common drug-disease interaction was aspirin/NSAID use in those with history of peptic ulcer disease without gastroprotection. Over one-third (34.0%) had at least one type of drug interaction. Each prescription medication increased the odds of having at least one type of drug interaction by 35-40% [drug-drug interaction adjusted odds ratio (AOR) = 1.35, 95% confidence interval (CI) = 1.27-1.42; drug-disease interaction AOR = 1.30; CI = 1.21-1.40; and both AOR = 1.45; CI = 1.34-1.57]. A prior hospitalization increased the odds of having at least one type of drug interaction by 49-84% compared with those not hospitalized (drug-drug interaction AOR = 1.49, 95% CI = 1.11-2.01; drug-disease interaction AOR = 1.69, CI = 1.15-2.49; and both AOR = 1.84, CI = 1.20-2.84). What is new and conclusionDrug interactions are common among community-dwelling older adults and are associated with the number of medications and hospitalization in the previous year. Longitudinal studies are needed to evaluate the impact of drug interactions on health-related outcomes. C1 [Hanlon, J. T.; Perera, S.; Newman, A. B.; Marcum, Z. A.] Univ Pittsburgh, Sch Med, Dept Med, Div Geriatr, Pittsburgh, PA 15213 USA. [Hanlon, J. T.; Thorpe, J. M.] Univ Pittsburgh, Sch Pharm, Dept Pharm & Therapeut, Pittsburgh, PA 15261 USA. [Hanlon, J. T.; Newman, A. B.] Univ Pittsburgh, Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Hanlon, J. T.; Thorpe, J. M.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res, Pittsburgh, PA USA. [Hanlon, J. T.; Thorpe, J. M.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Perera, S.] Univ Pittsburgh, Dept Biostat, Sch Publ Hlth, Pittsburgh, PA 15261 USA. [Donohue, J. M.] Univ Pittsburgh, Sch Publ Hlth, Dept Hlth Policy & Management, Pittsburgh, PA 15260 USA. [Simonsick, E. M.] NIA, Intramural Res Program, Baltimore, MD 21224 USA. [Shorr, R. I.] Malcolm Randall Vet Affairs Med Ctr, Geriatr Res Educ & Clin Ctr, Gainesville, FL USA. [Bauer, D. C.] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Hanlon, JT (reprint author), Univ Pittsburgh, Dept Geriatr Med, Kaufman Med Bldg Suite 514,3471 5th Ave, Pittsburgh, PA 15213 USA. EM jth14@pitt.edu FU National Institute on Aging (NIA) [P30-AG024827, T32-AG021885]; NIH, NIA [N01-AG-6-2101, N01-AG-6-2103, N01-AG-6-2106]; NIA [R01-AG028050]; National Institute of Nursing Research grant [R01-NR012459] FX The research reported in this manuscript was primarily supported by National Institute on Aging (NIA) grants and contracts (P30-AG024827, T32-AG021885). This research was also supported in part by the Intramural Research program of the NIH, NIA (N01-AG-6-2101, N01-AG-6-2103, and N01-AG-6-2106), NIA grant (R01-AG028050), and a National Institute of Nursing Research grant (R01-NR012459). NR 27 TC 0 Z9 0 U1 2 U2 2 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0269-4727 EI 1365-2710 J9 J CLIN PHARM THER JI J. Clin. Pharm. Ther. PD APR PY 2017 VL 42 IS 2 BP 228 EP 233 DI 10.1111/jcpt.12502 PG 6 WC Pharmacology & Pharmacy SC Pharmacology & Pharmacy GA EM5TN UT WOS:000395376300017 PM 28111765 ER PT J AU Miller, TR Weiss, JJ Brau, N Dieterich, DT Stivala, A Rivera-Mindt, M AF Miller, Theodore R. Weiss, Jeffrey J. Brau, Norbert Dieterich, Douglas T. Stivala, Alicia Rivera-Mindt, Monica TI Greater decline in memory and global neurocognitive function in HIV/hepatitis C co-infected than in hepatitis C mono-infected patients treated with pegylated interferon and ribavirin SO JOURNAL OF NEUROVIROLOGY LA English DT Article DE Hepatitis C; HIV; Pegylated interferon; Ribavirin; Neurocognitive; Side effects ID ANTIRETROVIRAL THERAPY; HUMAN-PAPILLOMAVIRUS; ALPHA; HIV; VIRUS; ERA; INDIVIDUALS; IMPAIRMENT; CHARTER; ADULTS AB The human immunodeficiency virus (HIV), hepatitis C virus (HCV), and the treatment of HCV with pegylated interferon and ribavirin (IFN/RBV) have been associated with neurocognitive and psychiatric abnormalities. The goal of this research was to prospectively evaluate neurocognitive functioning among a group of HCV mono-infected and HIV/HCV co-infected patients during the first 24 weeks of IFN/RBV treatment while accounting for practice effects, normal variations in change over time, and variations in IFN/RBV treatment exposure. Forty-four HCV mono-infected and 30 HIV/HCV co-infected patients were enrolled in a prospective study of patients beginning on IFN/RBV for chronic HCV infection. Patients were administered a depression inventory, a measure of fatigue, a structured psychiatric interview, and a neurocognitive battery at baseline and 24 weeks after initiation of treatment. Analyses were conducted to explore possible associations between neurocognitive functioning and the following: HIV/HCV co-infection vs. HCV mono-infection, IFN and RBV treatment exposure, psychiatric status, liver disease stage, and other medical characteristics. At baseline, there were no significant differences between the two groups' neuropsychiatric or neurocognitive function other than the mono-infected group had significantly higher reports of fatigue (p = 0.033). Over the course of 24 weeks of treatment after controlling for practice effects, the HIV/HCV co-infected patients experienced significantly greater declines in memory (t(56) = 2.14, p = 0.037) and global neurocognitive functioning (t(53) = 2.28, p = 0.027). In a well-characterized sample of mono-infected and co-infected patients, it appears that persons with HIV/HCV co-infection are potentially more vulnerable to neurocognitive sequalae during HCV treatment. C1 [Miller, Theodore R.; Weiss, Jeffrey J.; Brau, Norbert; Dieterich, Douglas T.; Stivala, Alicia] Icahn Sch Med Mt Sinai, Dept Med, One Gustave L Levy Pl,POB 1087, New York, NY 10029 USA. [Miller, Theodore R.] Yale Sch Nursing, 400 West Campus Dr, Orange, CT 06477 USA. [Weiss, Jeffrey J.; Rivera-Mindt, Monica] Icahn Sch Med Mt Sinai, Dept Psychiat, One Gustave L Levy Pl, New York, NY 10029 USA. [Brau, Norbert] Bronx Vet Affairs Med Ctr, Infect Dis Sect, 130 W Kingsbridge Rd, New York, NY 10468 USA. [Rivera-Mindt, Monica] Fordham Univ, Dept Psychol, 340,441 E Fordham Rd, Bronx, NY 10458 USA. [Rivera-Mindt, Monica] Icahn Sch Med Mt Sinai, Dept Neurol, One Gustave L Levy Pl, New York, NY 10029 USA. RP Weiss, JJ (reprint author), Icahn Sch Med Mt Sinai, Dept Med, One Gustave L Levy Pl,POB 1087, New York, NY 10029 USA.; Weiss, JJ (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, One Gustave L Levy Pl, New York, NY 10029 USA. EM Jeffrey.Weiss@mountsinai.org OI Miller, Theodore/0000-0002-3286-8176 FU National Institute of Mental Health of the National Institutes of Health [K23MH071177] FX This work was supported by the National Institute of Mental Health of the National Institutes of Health (K23MH071177). The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institute of Mental Health or the National Institutes of Health. NR 66 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1355-0284 EI 1538-2443 J9 J NEUROVIROL JI J. Neurovirol. PD APR PY 2017 VL 23 IS 2 BP 260 EP 272 DI 10.1007/s13365-016-0494-8 PG 13 WC Neurosciences; Virology SC Neurosciences & Neurology; Virology GA EN7XG UT WOS:000396214900008 PM 27896573 ER PT J AU Patel, AN Lee, S Andrews, HF Pelton, GH Schultz, SK Sultzer, DL Mintzer, J de la Pena, D Gupta, S Colon, S Schimming, C Levin, B Devanand, DP AF Patel, Anjali N. Lee, Seonjoo Andrews, Howard F. Pelton, Gregory H. Schultz, Susan K. Sultzer, David L. Mintzer, Jacobo de la Pena, Danilo Gupta, Sanjay Colon, Sylvia Schimming, Corbett Levin, Bruce Devanand, D. P. TI Prediction of Relapse After Discontinuation of Antipsychotic Treatment in Alzheimer's Disease: The Role of Hallucinations SO AMERICAN JOURNAL OF PSYCHIATRY LA English DT Article ID NEUROPSYCHIATRIC INVENTORY; DEMENTIA; DRUGS AB Objective: In Alzheimer's disease, antipsychotic medications are often used for a period, with relief of symptoms, and then discontinued, after which relapse may occur. The authors sought to determine which neuropsychiatric symptoms predict relapse. Method: In the Antipsychotic Discontinuation in Alzheimer's Disease trial, 180 patients with Alzheimer's disease and symptoms of agitation or psychosis were treated with risperidone for 16 weeks, after which patients who responded (N=110) were randomly assigned to continue risperidone for 32 weeks, to continue risperidone for 16 weeks followed by switch to placebo for 16 weeks, or to receive placebo for 32 weeks. As reported previously, discontinuation of risperidone was associated with a two-to fourfold increased risk of relapse over 16-32 weeks. In planned post hoc analyses, the authors examined associations between the 12 symptom domains in the Neuropsychiatric Inventory (NPI) and relapse in the first 16-week phase after randomization. Results: Compared with patients with mild hallucinations or no hallucinations, patients with severe hallucinations as a presenting symptom at baseline had a higher likelihood of relapse (hazard ratio=2.96, 95% CI=1.52, 5.76). This effect was present for the subgroup with auditory hallucinations, but not the subgroup with visual hallucinations. Among patients with baseline hallucinations, 13 of 17 (76.5%) who discontinued risperidone relapsed, compared with 10 of 26 (38.5%) who continued risperidone (p<0.02). This group difference remained significant for severe (77.8%) compared with mild (36%) hallucinations. NPI domain scores after the initial open-treatment phase were not associated with relapse. Conclusions: Patients with severe baseline hallucinations were more likely to relapse after randomization, and the presence of baseline hallucinations was associated with a higher risk of relapse after discontinuation of risperidone compared with continued risperidone treatment. For patients with hallucinations, particularly auditory hallucinations, antipsychotic discontinuation should be approached cautiously because of high relapse risk. C1 [Devanand, D. P.] Columbia Univ, Coll Physicians & Surg, New York State Psychiat Inst, Div Geriatr Psychiat, New York, NY 10027 USA. Columbia Univ, Coll Physicians & Surg, Gertrude H Sergievsky Ctr, New York, NY USA. Columbia Univ, Coll Physicians & Surg, Dept Neurol, New York, NY USA. Columbia Univ, Taub Inst Res Alzheimers Dis & Aging Brain, New York, NY USA. Columbia Univ, Mailman Sch Publ Hlth, Dept Biostat, New York, NY USA. Med Univ South Carolina, Dept Neurosci, Div Translat Res, Charleston, SC USA. Ralph H Johnson VA Med Ctr, Charleston, SC USA. Univ Iowa Carver, Coll Med, Dept Psychiat, Iowa City, IA USA. Clin Biotechnol Res Inst, Roper St Francis Healthcare, Charleston, SC USA. Res Ctr Clin Studies, Norwalk, CT USA. SUNY Buffalo, Sch Med & Biomed Sci, Dept Psychiat, Buffalo, NY USA. VA Med Ctr, Dept Psychiat, Tuscaloosa, AL USA. Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY USA. RP Devanand, DP (reprint author), Columbia Univ, Coll Physicians & Surg, New York State Psychiat Inst, Div Geriatr Psychiat, New York, NY 10027 USA. EM dpd3@cumc.columbia.edu FU NIH [R01 AG021488, R01 AG17761]; Department of Veterans Affairs; NIMH; National Institute on Aging; Alzheimer's Association; Alzheimer's Disease Cooperative Study; Eli Lilly; Toyama Chemical Company; Avanir; Transition Therapeutics; Biogen; Elan; EnVivo; Genentech; Hoffmann-La Roche; Lundbeck; Merck Sharp Dohme; Neurim; Novartis; Otsuka; Pfizer; Reckitt-Benckiser; Takeda; TauRx Therapeutics; Toyama Chemical; Transition Therapeutics Ireland; UCSD; Wyeth; Department of Defense FX Supported by NIH grants R01 AG021488 and R01 AG17761 and by the Department of Veterans Affairs. Risperidone tablets and matching placebo were donated by Janssen, a division of Johnson & Johnson. ClinicalTrials.gov identifier: NCT00417482.; Dr. Pelton has received grants from NIMH, the National Institute on Aging, and the Alzheimer's Association. Dr. Schultz has received research support from the Alzheimer's Disease Cooperative Study in partnership with Eli Lilly and Toyama Chemical Company. Dr. Sultzer has received support from the Department of Veterans Affairs and research support from Avanir, Eli Lilly, and Transition Therapeutics, and he has served as a consultant for Astellas, AbbVie, Insys, Lundbeck, and Otsuka. Dr. Mintzer is employed by Roper St. Francis Healthcare, Medical University of South Carolina, Ralph H. Johnson VA Medical Center, and NeuroQuest, and he is the founder of BioPharma Connex. Dr. de la Pena has received research support from Avanir, Biogen, Elan, Eli Lilly, EnVivo, Genentech, Hoffmann-La Roche, Lundbeck, Merck Sharp & Dohme, Neurim, Novartis, Otsuka, Pfizer, Reckitt-Benckiser, Takeda, TauRx Therapeutics, Toyama Chemical, Transition Therapeutics Ireland, UCSD, and Wyeth. Dr. Gupta has served as a speaker for Alkermes, Allergan, Avanir, Global Medical Education, Lundbeck, Merck, Otsuka, Sunovion, and Takeda. Dr. Devanand has received research support from Avanir, the Department of Defense, and the National Institute on Aging, has served on scientific advisory boards for AbbVie and Astellas, and has served as a consultant for Intra-Cellular Therapies. The other authors report no financial relationships with commercial interests. NR 16 TC 1 Z9 1 U1 1 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 0002-953X EI 1535-7228 J9 AM J PSYCHIAT JI Am. J. Psychiat. PD APR PY 2017 VL 174 IS 4 BP 362 EP 369 DI 10.1176/appi.ajp.2016.16020226 PG 8 WC Psychiatry SC Psychiatry GA EQ2SU UT WOS:000397921800012 PM 27855483 ER PT J AU Waterer, G Restrepo, MI AF Waterer, Grant Restrepo, Marcos I. TI Maladaptive Suppression of Bacterial Clearance in Early Sepsis Setting the Scene for Failure SO AMERICAN JOURNAL OF RESPIRATORY AND CRITICAL CARE MEDICINE LA English DT Editorial Material C1 [Waterer, Grant] Univ Western Australia, Perth, WA, Australia. [Waterer, Grant] Northwestern Univ, Chicago, IL 60611 USA. [Restrepo, Marcos I.] South Texas Vet Hlth Care Syst, Dept Med, San Antonio, TX USA. [Restrepo, Marcos I.] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. RP Waterer, G (reprint author), Univ Western Australia, Perth, WA, Australia.; Waterer, G (reprint author), Northwestern Univ, Chicago, IL 60611 USA. NR 7 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1073-449X EI 1535-4970 J9 AM J RESP CRIT CARE JI Am. J. Respir. Crit. Care Med. PD APR 1 PY 2017 VL 195 IS 7 BP 846 EP 847 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EQ4BH UT WOS:000398017200003 PM 28362200 ER PT J AU Robertson, DJ Lee, JK Boland, CR Dominitz, JA Giardiello, FM Johnson, DA Kaltenbach, T Lieberman, D Levin, TR Rex, DK AF Robertson, Douglas J. Lee, Jeffrey K. Boland, C. Richard Dominitz, Jason A. Giardiello, Francis M. Johnson, David A. Kaltenbach, Tonya Lieberman, David Levin, Theodore R. Rex, Douglas K. TI Recommendations on Fecal Immunochemical Testing to Screen for Colorectal Neoplasia: A Consensus Statement by the US Multi-Society Task Force on Colorectal Cancer SO GASTROENTEROLOGY LA English DT Article ID OCCULT-BLOOD-TEST; RANDOMIZED CONTROLLED-TRIAL; LOW-DOSE ASPIRIN; AVERAGE-RISK POPULATION; SAMPLE RETURN TIME; ADENOMA DETECTION; ASYMPTOMATIC ADULTS; COLONOSCOPY SURVEILLANCE; AMBIENT-TEMPERATURE; SEASONAL-VARIATIONS AB The use of the fecal occult blood test ( FOBT) for colorectal cancer ( CRC) screening is supported by randomized trials demonstrating effectiveness in cancer prevention and widely recommended by guidelines for this purpose. The fecal immunochemical test ( FIT), as a direct measure of human hemoglobin in stool has a number of advantages relative to conventional FOBT and is increasingly used relative to that test. This review summarizes current evidence for FIT in colorectal neoplasia detection and the comparative effectiveness of FIT relative to other commonly used CRC screening modalities. Based on evidence, guidance statements on FIT application were developed and quality metrics for program implementation proposed. C1 [Robertson, Douglas J.] VA Med Ctr, White River Jct, VT USA. [Robertson, Douglas J.] Geisel Sch Med Dartmouth, Hanover, NH USA. [Lee, Jeffrey K.] Univ Calif San Francisco, Med Ctr, San Francisco, CA USA. [Boland, C. Richard] Baylor Univ, Med Ctr, Dallas, TX USA. [Dominitz, Jason A.] Univ Washington, Sch Med, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Giardiello, Francis M.] Johns Hopkins Univ, Sch Med, Baltimore, MD USA. [Johnson, David A.] Eastern VA Med Sch, Norfolk, VA USA. [Kaltenbach, Tonya] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Lieberman, David] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Levin, Theodore R.] Kaiser Permanente Med Ctr, Walnut Creek, CA USA. [Rex, Douglas K.] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. RP Robertson, DJ (reprint author), VA Med Ctr, Gastroenterol 111E, 215 N Main St, White River Jct, VT 05009 USA. EM douglas.robertson@va.gov FU Olympus; Endochoice FX This authors discloses the following: David A. Johnson is a clinical investigator for Exact Sciences and Epigenomics. David Lieberman served on scientific advisory Board for Exact Sciences. Douglas K. Rex received consulting fees from Olympus and research support from Endochoice. Douglas J. Robertson is on the scientific advisory board for Medtronic. Tonya Kaltenback served as Consultant for Olympus America. The remaining authors disclose no conflicts. NR 118 TC 1 Z9 1 U1 2 U2 2 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0016-5085 EI 1528-0012 J9 GASTROENTEROLOGY JI Gastroenterology PD APR PY 2017 VL 152 IS 5 BP 1217 EP + DI 10.1053/j.gastro.2016.08.053 PG 24 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EP3QV UT WOS:000397297700046 PM 27769517 ER PT J AU Chen, HI Wolf, JA Smith, DH AF Chen, H. Isaac Wolf, John A. Smith, Douglas H. TI Multichannel activity propagation across an engineered axon network SO JOURNAL OF NEURAL ENGINEERING LA English DT Article DE activity propagation; connectome; neural code; neural interfaces; neural networks; optogenetics; tissue engineering ID CORTICAL-NEURONS; IN-VIVO; LONG-RANGE; NEURAL REPRESENTATION; SYNAPTIC INPUT; VISUAL-CORTEX; CONNECTOME; PLASTICITY; SPIKING; BRAIN AB Objective. Although substantial progress has been made in mapping the connections of the brain, less is known about how this organization translates into brain function. In particular, the massive interconnectivity of the brain has made it difficult to specifically examine data transmission between two nodes of the connectome, a central component of the 'neural code.' Here, we investigated the propagation of multiple streams of asynchronous neuronal activity across an isolated in vitro 'connectome unit.' Approach. We used the novel technique of axon stretch growth to create a model of a long-range cortico-cortical network, a modular system consisting of paired nodes of cortical neurons connected by axon tracts. Using optical stimulation and multi-electrode array recording techniques, we explored how input patterns are represented by cortical networks, how these representations shift as they are transmitted between cortical nodes and perturbed by external conditions, and how well the downstream node distinguishes different patterns. Main results. Stimulus representations included direct, synaptic, and multiplexed responses that grew in complexity as the distance between the stimulation source and recorded neuron increased. These representations collapsed into patterns with lower information content at higher stimulation frequencies. With internodal activity propagation, a hierarchy of network pathways, including latent circuits, was revealed using glutamatergic blockade. As stimulus channels were added, divergent, non-linear effects were observed in local versus distant network layers. Pairwise difference analysis of neuronal responses suggested that neuronal ensembles generally outperformed individual cells in discriminating input patterns. Significance. Our data illuminate the complexity of spiking activity propagation in cortical networks in vitro, which is characterized by the transformation of an input into myriad outputs over several network layers. These results provide insight into how the brain potentially processes information and generates the neural code and could guide the development of clinical therapies based on multichannel brain stimulation. C1 [Chen, H. Isaac; Wolf, John A.; Smith, Douglas H.] Univ Penn, Perelman Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA. [Chen, H. Isaac; Wolf, John A.] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Chen, H. Isaac] 3rd Floor,Silverstein Pavil,3400 Spruce St, Philadelphia, PA 19104 USA. RP Chen, HI (reprint author), Univ Penn, Perelman Sch Med, Dept Neurosurg, Philadelphia, PA 19104 USA.; Chen, HI (reprint author), Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA.; Chen, HI (reprint author), 3rd Floor,Silverstein Pavil,3400 Spruce St, Philadelphia, PA 19104 USA. EM Isaac.Chen@uphs.upenn.edu OI Chen, Han-Chiao/0000-0002-7431-6046 FU Department of Defense [PT110785]; National Institutes of Health [F32NS073267, R01NS056202]; Department of Veterans Affairs [IK2-RX002013, IK2-RX001479] FX We would like to thank Diego Contreras and Dave Meaney for editorial input and Andrew Jaye, J P Dolle, Mindy Ezra, and Kevin Truskowski for technical assistance. This work was supported by the Department of Defense (PT110785 to DHS), the National Institutes of Health (F32NS073267 to HIC and R01NS056202 to DHS), and the Department of Veterans Affairs (IK2-RX002013 to HIC and IK2-RX001479 to JAW). The authors have no conflicts of interest to report. NR 56 TC 0 Z9 0 U1 7 U2 7 PU IOP PUBLISHING LTD PI BRISTOL PA TEMPLE CIRCUS, TEMPLE WAY, BRISTOL BS1 6BE, ENGLAND SN 1741-2560 EI 1741-2552 J9 J NEURAL ENG JI J. Neural Eng. PD APR PY 2017 VL 14 IS 2 AR 026016 DI 10.1088/1741-2552/aa5ccd PG 12 WC Engineering, Biomedical; Neurosciences SC Engineering; Neurosciences & Neurology GA EN3LL UT WOS:000395909900003 PM 28140365 ER PT J AU Nowak, KL Bartz, TM Dalrymple, L de Boer, IH Kestenbaum, B Shlipak, MG Garimella, PS Ix, JH Chonchol, M AF Nowak, Kristen L. Bartz, Traci M. Dalrymple, Lorien de Boer, Ian H. Kestenbaum, Bryan Shlipak, Michael G. Garimella, Pranav S. Ix, Joachim H. Chonchol, Michel TI Fibroblast Growth Factor 23 and the Risk of Infection-Related Hospitalization in Older Adults SO JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID CHRONIC KIDNEY-DISEASE; VITAMIN-D STATUS; CARDIOVASCULAR EVENTS; 24,25-DIHYDROXYVITAMIN D-3; MINERAL METABOLISM; UNITED-STATES; CYSTATIN-C; FIBROBLAST-GROWTH-FACTOR-23; HEALTH; DEATH AB Within monocytes, 1,25-dihydroxyvitamin D [1,25(OH)(2)D] is important for production of cathelicidins, which in turn, are critical for antibacterial action. Fibroblast growth factor 23 (FGF23) decreases 1,25(OH)(2)D production and thus, could increase infection risk. We examined this possibility in 3141 community-dwelling adults ages >= 65 years old at baseline in the Cardiovascular Health Study using Cox proportional hazards models to examine the association between FGF23 concentrations and first infection-related hospitalizations and determine whether associations differed by the presence of CKD (eGFR<60 ml/min per 1.73 m(2) [n=832] or urine albumin-to-creatinine ratio >30 mg/g [n=577]). Mean +/- SD age of participants was 78 5 years old, 60% of participants were women, and the median plasma FGF23 concentration was 70 (interquartile range, 53-99) relative units per milliliter. In fully adjusted models, higher FGF23 concentrations associated with higher risk of first infection related hospitalization (hazard ratio [HR], 1.11; 95% confidence interval [95% CI], 1.03 to 1.20 per doubling of FGF23) during a median follow-up of 8.6 years. In participants with or without CKD (defined by eGFR), FGF23 concentration associated with first infection-related hospitalization with HRs of 1.24 (95% CI, 1.08 to 1.42) and 1.06 (95% CI, 0.97 to 1.17) per doubling of FGF23, respectively (P=0.13 for interaction). Associations did not differ between groups when stratified by urine albumin-to-creatinine ratio. In sensitivity analyses, the addition of serum calcium, phosphorus, 25-hydroxyvitamin D, intact parathyroid hormone, and 24,25-dihydroxyvitamin D did not meaningfully change the estimates. In conclusion, in community-dwelling older adults, higher plasma FGF23 concentrations independently associated with the risk of first infection-related hospitalization. C1 [Nowak, Kristen L.; Chonchol, Michel] Univ Colorado, Div Renal Dis & Hypertens, Anschutz Med Campus, Aurora, CO USA. [Bartz, Traci M.] Univ Washington, Dept Biostat, Seattle, WA 98195 USA. [de Boer, Ian H.] Univ Washington, Div Nephrol, Seattle, WA 98195 USA. [de Boer, Ian H.; Kestenbaum, Bryan] Univ Washington, Kidney Res Inst, Seattle, WA 98195 USA. [Dalrymple, Lorien] Univ Calif Davis, Dept Med, Sacramento, CA 95817 USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Shlipak, Michael G.] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Shlipak, Michael G.] San Francisco VA Med Ctr, Gen Internal Med Sect, San Francisco, CA USA. [Garimella, Pranav S.] Tufts Med Ctr, Div Nephrol, Boston, MA USA. [Ix, Joachim H.] Univ Calif San Diego, Div Nephrol, San Diego, CA 92103 USA. [Ix, Joachim H.] Univ Calif San Diego, Div Prevent Med, San Diego, CA 92103 USA. [Ix, Joachim H.] Vet Affairs San Diego Healthcare Syst, Nephrol Sect, San Diego, CA USA. RP Nowak, KL (reprint author), Univ Colorado Denver, Div Renal Dis & Hypertens, Anschutz Med Campus,12700 East 19th Ave C281, Aurora, CO 80045 USA. EM Kristen.Nowak@ucdenver.edu FU National Heart, Lung, and Blood Institute [HHSN268201200036C, HSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, N01HC85086, HL080295]; National Institute on Aging; National Institute of Diabetes and Digestive and Kidney Diseases [K01DK103678]; American Heart Association [0575021N] FX This research was supported by contracts HHSN268201200036C, HSN268200800007C, N01HC55222, N01HC85079, N01HC85080, N01HC85081, N01HC85082, N01HC85083, and N01HC85086 and grant HL080295 from the National Heart, Lung, and Blood Institute, with additional contribution from the National Institute of Neurological Disorders and Stroke. Additional support was provided by grants AG023629 and R01HL094555 from the National Institute on Aging and grant K01DK103678 from the National Institute of Diabetes and Digestive and Kidney Diseases. J.H.I. was supported by American Heart Association award 0575021N, which supported fibroblast growth factor 23 and the other mineral metabolism measurements in this study. NR 30 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1046-6673 EI 1533-3450 J9 J AM SOC NEPHROL JI J. Am. Soc. Nephrol. PD APR PY 2017 VL 28 IS 4 BP 1239 EP 1246 DI 10.1681/ASN.2016040401 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA EQ1LZ UT WOS:000397832900025 PM 28122946 ER PT J AU Robinson, TN Berian, JR AF Robinson, Thomas N. Berian, Julia R. TI Incorporating Patient-centered Outcomes Into Surgical Care SO ANNALS OF SURGERY LA English DT Editorial Material ID DELIRIUM C1 [Robinson, Thomas N.] Denver VA Med Ctr, Dept Surg, Denver, CO USA. [Berian, Julia R.] Amer Coll Surg, Div Res & Optimal Patient Care, Chicago, IL USA. RP Robinson, TN (reprint author), 1055 Clermont St 112, Denver, CO 80220 USA. EM thomas.robinson@ucdenver.edu FU John A. Hartford Foundation; University of Chicago; American College of Surgeons FX Dr Berian's position as the James C. Thompson Geriatric Surgery Clinical Scholar in Residence at the American College of Surgeons is supported by a grant from the John A. Hartford Foundation. Additional support for Dr Berian's position as the American College of Surgeons Clinical Scholar in Residence was provided by the University of Chicago and the American College of Surgeons. NR 6 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-4932 EI 1528-1140 J9 ANN SURG JI Ann. Surg. PD APR PY 2017 VL 265 IS 4 BP 654 EP 655 DI 10.1097/SLA.0000000000002038 PG 2 WC Surgery SC Surgery GA EN4PQ UT WOS:000395989800004 PM 27735822 ER PT J AU Kim, SJ Chen, ZL Essani, AB Elshabrawy, HA Volin, MV Fantuzzi, G McInnes, IB Baker, JF Finn, P Kondos, G Volkov, S Swedler, W Arami, S Sweiss, N Shahrara, S AF Kim, Seung-jae Chen, Zhenlong Essani, Abdul B. Elshabrawy, Hatem A. Volin, Michael V. Fantuzzi, Giamila McInnes, Iain B. Baker, Joshua F. Finn, Patricia Kondos, George Volkov, Suncica Swedler, William Arami, Shiva Sweiss, Nadera Shahrara, Shiva TI Differential impact of obesity on the pathogenesis of RA or preclinical models is contingent on the disease status SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Article ID BODY-MASS INDEX; COLLAGEN-INDUCED ARTHRITIS; OF-RHEUMATOLOGY CRITERIA; ADIPOSE-TISSUE; INTERLEUKIN-8 PRODUCTION; INSULIN-RESISTANCE; INNATE IMMUNITY; IN-VITRO; CLASSIFICATION; OSTEOARTHRITIS AB Objective Studies were performed to uncover the significance of obesity in rheumatoid arthritis (RA) and preclinical models. Methods Preclinical arthritis models were used to examine the impact of obesity on disease onset and remission. Conditioned media from RA adipose tissues were used to investigate the mechanism contributing to joint neutrophil influx and M1 macrophage differentiation observed in early and remission phases of arthritis. Results We report that mice fed with high fat diet (HFD) have an earlier onset of collagen-induced arthritis (CIA) compared with mice on regular diet. However, the differences in CIA joint swelling between the two diet groups are lost once disease is established. We found that early arthritis triggered by obesity is due to elevated joint MIP2/interleukin-8 levels detected in CIA as well as in the RA and mouse adipose tissues and the effect of this chemokine on neutrophil recruitment. Although active disease progression is similarly affected in both diet groups, arthritis resolution is accelerated in lean mice while joint inflammation is sustained in obese mice. We document that HFD can prolong toll-like receptor (TLR) 4-induced arthritis by increasing joint monocyte migration and further remodelling the recruited cells into M1 macrophages. Consistently, we show that adipose condition media can transform RA and wild-type naive myeloid cells into M1 macrophages; however, this function is impaired by TLR4 blockade or deficiency. Conclusions We conclude that despite established disease being unaffected by obesity, the early and the resolution phases of RA are impacted by obesity through different mechanisms. C1 [Volin, Michael V.] Univ Illinois, Dept Med, Div Rheumatol, 840 S Woods St,Bldg CSB,Room 1113-1114, Chicago, IL 60612 USA. [Kim, Seung-jae; Chen, Zhenlong; Essani, Abdul B.; Elshabrawy, Hatem A.; Swedler, William; Arami, Shiva; Sweiss, Nadera; Shahrara, Shiva] Jesse Brown VA Med Ctr, Div Rheumatol, Chicago, IL USA. [Kim, Seung-jae; Chen, Zhenlong; Essani, Abdul B.; Elshabrawy, Hatem A.; Volkov, Suncica; Swedler, William; Arami, Shiva; Shahrara, Shiva] Midwestern Univ, Dept Microbiol & Immunol, Downers Grove, IL 60515 USA. [Fantuzzi, Giamila] Univ Illinois, Dept Kinesiol & Nutr, Chicago, IL USA. [McInnes, Iain B.] Univ Glasgow, Inst Infect Immun & Inflammat, Glasgow, Lanark, Scotland. [Baker, Joshua F.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Baker, Joshua F.] Hosp Univ Penn, Dept Med, Div Rheumatol, Philadelphia, PA 19104 USA. [Finn, Patricia] Univ Illinois, Div Med, Div Pulm, Chicago, IL USA. [Kondos, George] Univ Illinois, Div Med, Div Cardiol, Chicago, IL USA. RP Shahrara, S (reprint author), Univ Illinois, Dept Med, Div Rheumatol, 840 S Woods St,Bldg CSB,Room 1113-1114, Chicago, IL 60612 USA. EM shahrara@uic.edu FU Department of Veteran's Affairs MERIT Award [1I01BX002286]; National Institutes of Health [AR055240, AR065778]; Within Our Reach from the ACR; Department of Defense [PR093477]; Arthritis Foundation Innovative award; VA clinical science research and development; VA Career Development Award [IK2 CX000955] FX This work was supported in part by awards from Department of Veteran's Affairs MERIT Award 1I01BX002286, the National Institutes of Health AR055240 and AR065778, grant from Within Our Reach from the ACR, funding provided by Department of Defense PR093477 and Arthritis Foundation Innovative award. JFB efforts were funded by VA clinical science research and development as well as VA Career Development Award IK2 CX000955. NR 54 TC 0 Z9 0 U1 1 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD APR PY 2017 VL 76 IS 4 AR UNSP 731 DI 10.1136/annrheumdis-2016-209206 PG 9 WC Rheumatology SC Rheumatology GA EO7FH UT WOS:000396856100019 ER PT J AU Singh, JA Uhlig, T AF Singh, Jasvinder A. Uhlig, Till TI Chasing crystals out of the body: will treat to serum urate target for gout help us get there? SO ANNALS OF THE RHEUMATIC DISEASES LA English DT Editorial Material ID QUALITY-OF-LIFE; LOWERING THERAPY; ALLOPURINOL; CARE; HYPERURICEMIA; FEBUXOSTAT; ADHERENCE; RECOMMENDATIONS; PRODUCTIVITY; MANAGEMENT C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Med, Dept Med, Birmingham, AL USA. [Singh, Jasvinder A.] Univ Alabama Birmingham, Sch Publ Hlth, Div Epidemiol, Birmingham, AL 35294 USA. [Uhlig, Till] Diakonhjemmet Hosp, Dept Rheumatol, Natl Advisory Unit Rehabil Rheumatol, Oslo, Norway. [Uhlig, Till] Univ Oslo, Fac Med, Oslo, Norway. RP Singh, JA (reprint author), Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. EM Jasvinder.md@gmail.com FU Takeda; Savient; Regeneron; Merz; Iroko; Bioiberica; Crealta; Allergan pharmaceuticals; WebMD; UBM LLC; American College of Rheumatology; Horizon pharmaceuticals; AstraZeneca; Novartis; Sobi FX JAS has received research grants from Takeda and Savient and consultant fees from Savient, Takeda, Regeneron, Merz, Iroko, Bioiberica, Crealta and Allergan pharmaceuticals, WebMD, UBM LLC and the American College of Rheumatology. JAS serves as the principal investigator for an investigator-initiated study funded by Horizon pharmaceuticals through a grant to DINORA, a 501 (c) (3) entity. JAS is a member of the executive of OMERACT, an organisation that develops outcome measures in rheumatology and receives arms-length funding from 36 companies; a member of the American College of Rheumatology's (ACR) Annual Meeting Planning Committee (AMPC); Chair of the ACR Meet-the-Professor, Workshop and Study Group Subcommittee and a member of the Veterans Affairs Rheumatology Field Advisory Committee. TU has received honorarium or consultant fees from AstraZeneca, Novartis and Sobi. NR 34 TC 0 Z9 0 U1 1 U2 1 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 0003-4967 EI 1468-2060 J9 ANN RHEUM DIS JI Ann. Rheum. Dis. PD APR PY 2017 VL 76 IS 4 DI 10.1136/annrheumdis-2016-210436 PG 3 WC Rheumatology SC Rheumatology GA EO7FH UT WOS:000396856100003 ER PT J AU Chawla, LS Bellomo, R Bihorac, A Goldstein, SL Siew, ED Bagshaw, SM Bittleman, D Cruz, D Endre, Z Fitzgerald, RL Forni, L Kane-Gill, SL Hoste, E Koyner, J Liu, KD Macedo, E Mehta, R Murray, P Nadim, M Ostermann, M Palevsky, PM Pannu, N Rosner, M Wald, R Zarbock, A Ronco, C Kellum, JA AF Chawla, Lakhmir S. Bellomo, Rinaldo Bihorac, Azra Goldstein, Stuart L. Siew, Edward D. Bagshaw, Sean M. Bittleman, David Cruz, Dinna Endre, Zoltan Fitzgerald, Robert L. Forni, Lui Kane-Gill, Sandra L. Hoste, Eric Koyner, Jay Liu, Kathleen D. Macedo, Etienne Mehta, Ravindra Murray, Patrick Nadim, Mitra Ostermann, Marlies Palevsky, Paul M. Pannu, Neesh Rosner, Mitchell Wald, Ron Zarbock, Alexander Ronco, Claudio Kellum, John A. TI Acute kidney disease and renal recovery: consensus report of the Acute Disease Quality Initiative (ADQI) 16 Workgroup SO NATURE REVIEWS NEPHROLOGY LA English DT Article ID CRITICALLY-ILL PATIENTS; GLOMERULAR-FILTRATION-RATE; ACUTE TUBULAR-NECROSIS; GELATINASE-ASSOCIATED LIPOCALIN; ANGIOTENSIN RECEPTOR BLOCKERS; REPLACEMENT THERAPY MODALITY; INJURY REQUIRING DIALYSIS; SERUM CREATININE LEVEL; LONG-TERM SURVIVAL; CARDIAC-SURGERY AB Consensus definitions have been reached for both acute kidney injury (AKI) and chronic kidney disease (CKD) and these definitions are now routinely used in research and clinical practice. The KDIGO guideline defines AKI as an abrupt decrease in kidney function occurring over 7 days or less, whereas CKD is defined by the persistence of kidney disease for a period of > 90 days. AKI and CKD are increasingly recognized as related entities and in some instances probably represent a continuum of the disease process. For patients in whom pathophysiologic processes are ongoing, the term acute kidney disease (AKD) has been proposed to define the course of disease after AKI; however, definitions of AKD and strategies for the management of patients with AKD are not currently available. In this consensus statement, the Acute Disease Quality Initiative (ADQI) proposes definitions, staging criteria for AKD, and strategies for the management of affected patients. We also make recommendations for areas of future research, which aim to improve understanding of the underlying processes and improve outcomes for patients with AKD. C1 [Chawla, Lakhmir S.] Vet Affairs Med Ctr, Dept Med, 50 Irving St, Washington, DC 20310 USA. [Bellomo, Rinaldo] Monash Univ, Australian & New Zealand Intens Care Res Ctr, Clayton, Vic 3800, Australia. [Bihorac, Azra] Univ Florida, Dept Med, Gainesville, FL 32611 USA. [Goldstein, Stuart L.] Cincinnati Childrens Hosp Med Ctr, Div Nephrol & Hypertens, Cincinnati, OH 45229 USA. [Siew, Edward D.] Vanderbilt Univ, Sch Med, Div Nephrol & Hypertens, Nashville, TN USA. [Bagshaw, Sean M.] Univ Alberta, Fac Med & Dent, Div Crit Care Med, Edmonton, AB T6G 2M7, Canada. [Bittleman, David] Univ Calif San Diego, Dept Med, San Diego, CA USA. [Cruz, Dinna] Univ Calif San Diego, UCSD Med Ctr, San Diego, CA USA. [Endre, Zoltan] Univ New South Wales, Prince Wales Hosp, Dept Nephrol, Kensington, NSW, Australia. [Endre, Zoltan] Univ New South Wales, Sch Clin, Kensington, NSW, Australia. [Forni, Lui] Surrey Cty Hosp, Surrey, England. [Kane-Gill, Sandra L.] Univ Pittsburgh, Sch Pharm, Pittsburgh, PA 15260 USA. [Hoste, Eric] Univ Ghent, Ghent Univ Hosp, Intens Care Unit, Ghent, Belgium. [Koyner, Jay] Univ Chicago, Dept Med, Chicago, IL USA. [Liu, Kathleen D.] Univ Calif San Francisco, Dept Med & Anesthesia, Divi Nephrol & Crit Care, San Francisco, CA 94143 USA. [Murray, Patrick] Uni Coll Dublin, UCD Hlth Sci Ctr, Dublin, Ireland. [Nadim, Mitra] Univ Southern California, Keck Sch Med, Dept Med, Div Nephrol, Los Angeles, CA USA. [Ostermann, Marlies] Guys & St Thomas NHS Fdn Hosp, Dept Intens Care, Westminster, England. [Palevsky, Paul M.] VA Pittsburgh Healthcare Syst, Renal Sect, Pittsburgh, PA USA. [Palevsky, Paul M.] Univ Pittsburgh, Renal Electrolyte Div, Pittsburgh, PA USA. [Pannu, Neesh] Univ Alberta, Fac Med & Dent, Div Crit Care Med, Edmonton, AB T6G 2M7, Canada. [Rosner, Mitchell] Univ Virginia, Div Nephrol, Charlottesville, VA 22903 USA. [Wald, Ron] St Michaels Hosp, Div Nephrol, Toronto, ON, Canada. [Wald, Ron] Univ Toronto, Toronto, ON, Canada. [Zarbock, Alexander] Univ Hosp Munster, Munster, Germany. [Ronco, Claudio] San Bortolo Hosp, Int Renal Res Inst Vicenza, Dept Nephrol, Dept Dialysis & Transplantat, Vicenza, Italy. [Kellum, John A.] Univ Pittsburgh, Ctr Crit Care Nephrol, Dept Crit Care Med, Pittsburgh, PA USA. RP Chawla, LS (reprint author), Vet Affairs Med Ctr, Dept Med, 50 Irving St, Washington, DC 20310 USA. EM minkchawla@gmail.com FU Baxter Medical; Astute Medical; INC; Society of Critical Care Medicine; Gambro Renal Products; VitaFlo; Mallinckrodt; Baxter Healthcare; Bellco; AM Pharma; La Jolla Pharmaceuticals; Relypsa; Fresenius-Kabi; iSAEC; Fresenius Medical Care; Baxter; Fresenius FX L.S.C. has received consulting fees from Astute Medical, Nxstage Medical and Bard Medical. R.B has received research support from Baxter Medical. A.B. has received research support from Astute Medical, INC and the Society of Critical Care Medicine. S.L.G. has received grants from Gambro Renal Products, VitaFlo, Mallinckrodt, and Alexion; grants and personal fees from Baxter Healthcare, Astute Medical, Bellco, AM Pharma, and La Jolla Pharmaceuticals; and personal fees from Bioporto, Akebia, Otsuka, Kaneka, and MediBeacon, all outside the submitted work. S.M.B. has received consulting fees from Baxter and La Jolla Pharmaceuticals. L.F. has received receiving consulting fees from Fresenius, Astute Medical, Eras Pharma, Baxter, and Ortho Clinical. E.H. has received speaker's fees from Alexion and a research grant from Bellco. J.K. has received consulting fees from Nxstage Medical, Astute Medical, Sphingotec and Pfizer. E.M. has received research funding from Relypsa and Fresenius-Kabi. R.M. has received consulting fees from Eli Lilly, Spectral, Keryx, Baxter, Ardea, AM Pharma, GSK, CSL Behring, Grifols, Astute Inc. Fresenius-Kabi, Quark, Ferring Research, Ionis Pharmaceuticals, Johnsons and Johnson and DURECT, and has received research support from iSAEC, Relypsa, Fresenius-Kabi and Fresenius. M.O. has received speaker honoraria and research funding from Fresenius Medical Care, and payment for advisory services from Baxter/Gambro. P.M.P has received consulting fees from Durect and Baxter. R.W. has received consulting fees from Durect and MedBeacon and unrestricted research support from Baxter. A.Z. has received unrestricted research grants from Fresenius and Astute Medical and lecture fees from Fresenius, Braun, Astute Medical, and Astellas. C.R. has received consulting fees from Astute, Asahi, GE and Baxter. J.A.K. has received consulting fees from Astute Medical, Atoc Bio, Astellas, Bard Medical, Baxter Medical, Bioporto, Grifols, Medibeacon and Nxstage Medical. E.D.S., D.B., D.C., Z.E., R.L.F., S.L.K.-G., K.D.L., P.M, M.N., N.P. and M.R. declare no competing interests. NR 152 TC 0 Z9 0 U1 4 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-5061 EI 1759-507X J9 NAT REV NEPHROL JI Nat. Rev. Nephrol. PD APR PY 2017 VL 13 IS 4 BP 241 EP 257 DI 10.1038/nrneph.2017.2 PG 17 WC Urology & Nephrology SC Urology & Nephrology GA EP3QN UT WOS:000397296900007 PM 28239173 ER PT J AU Aarsland, D Creese, B Politis, M Chaudhuri, KR Ffytche, DH Weintraub, D Ballard, C AF Aarsland, Dag Creese, Byron Politis, Marios Chaudhuri, K. Ray Ffytche, Dominic H. Weintraub, Daniel Ballard, Clive TI Cognitive decline in Parkinson disease SO NATURE REVIEWS NEUROLOGY LA English DT Review ID POSITRON-EMISSION-TOMOGRAPHY; DEEP BRAIN-STIMULATION; LEWY BODY DEMENTIA; CEREBROSPINAL-FLUID BIOMARKERS; CLINICAL DIAGNOSTIC-CRITERIA; FACTOR G196A POLYMORPHISM; 5-YEAR FOLLOW-UP; ALPHA-SYNUCLEIN; ALZHEIMERS-DISEASE; AMYLOID-BETA AB Dementia is a frequent problem encountered in advanced stages of Parkinson disease (PD). In recent years, research has focused on the pre-dementia stages of cognitive impairment in PD, including mild cognitive impairment (MCI). Several longitudinal studies have shown that MCI is a harbinger of dementia in PD, although the course is variable, and stabilization of cognition-or even reversal to normal cognition - is not uncommon. In addition to limbic and cortical spread of Lewy pathology, several other mechanisms are likely to contribute to cognitive decline in PD, and a variety of biomarker studies, some using novel structural and functional imaging techniques, have documented in vivo brain changes associated with cognitive impairment. The evidence consistently suggests that low cerebrospinal fluid levels of amyloid-beta(42), a marker of comorbid Alzheimer disease (AD), predict future cognitive decline and dementia in PD. Emerging genetic evidence indicates that in addition to the APOE*epsilon 4 allele (an established risk factor for AD), GBA mutations and SCNA mutations and triplications are associated with cognitive decline in PD, whereas the findings are mixed for MAPT polymorphisms. Cognitive enhancing medications have some effect in PD dementia, but no convincing evidence that progression from MCI to dementia can be delayed or prevented is available, although cognitive training has shown promising results. C1 [Aarsland, Dag; Creese, Byron; Politis, Marios; Chaudhuri, K. Ray; Ffytche, Dominic H.; Weintraub, Daniel; Ballard, Clive] Kings Coll London, Inst Psychiat Psychol & Neurosci, KCL PARCOG Grp, De Crespigny Pk, London SE5 8AF, England. [Aarsland, Dag; Ffytche, Dominic H.] Kings Coll London, Inst Psychiat Psychol & Neurosci, Dept Old Age Psychiat, De Crespigny Pk, London SE5 8AF, England. [Creese, Byron; Ballard, Clive] Univ Exeter, Sch Med, Exeter EX1 2LU, Devon, England. [Politis, Marios] Kings Coll London, Neurodegenerat Imaging Grp, Maurice Wohl Clin Neurosci Inst, Inst Psychiat Psychol & Neurosci, 125 Coldharbour Lane, London SE5 9NU, England. [Chaudhuri, K. Ray] Kings Coll London, Dept Basic & Clin Neurosci, Maurice Wohl Clin Neurosci Inst, Natl Parkinson Fdn Ctr Excellence,Kings Coll Hosp, 5 Cutcombe Rd, London SE5 9RT, England. [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Dept Psychiat, 3615 Chestnut St,330, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Dept Neurol, 3615 Chestnut St,330, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Parkinsons Dis Ctr, PADRECC & MIRECC, 3900 Woodland Ave, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Mental Illness Res Educ & Clin Ctr, PADRECC & MIRECC, 3900 Woodland Ave, Philadelphia, PA 19104 USA. RP Aarsland, D (reprint author), Kings Coll London, Inst Psychiat Psychol & Neurosci, KCL PARCOG Grp, De Crespigny Pk, London SE5 8AF, England. EM daarsland@gmail.com OI Aarsland, Dag/0000-0001-6314-216X FU National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust; Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK; Wolfson Foundation; Royal Society FX The authors thank Dr Michael Haworth for help in preparing the final manuscript. The authors would like to thank the National Institute for Health Research (NIHR) Mental Health Biomedical Research Centre and Dementia Unit at South London and Maudsley NHS Foundation Trust and Institute of Psychiatry, Psychology and Neuroscience, King's College London, UK. D.A. is a Royal Society Wolfson Research Merit Award Holder and would like to thank the Wolfson Foundation and the Royal Society for their support. The views expressed are those of the authors and not necessarily those of the NHS, the NIHR or the Department of Health. NR 215 TC 0 Z9 0 U1 5 U2 5 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1759-4758 EI 1759-4766 J9 NAT REV NEUROL JI Nat. Rev. Neurol. PD APR PY 2017 VL 13 IS 4 BP 217 EP 231 DI 10.1038/nrneurol.2017.27 PG 15 WC Clinical Neurology SC Neurosciences & Neurology GA EP7KU UT WOS:000397557500005 PM 28257128 ER PT J AU Egervari, G Landry, J Callens, J Fullard, JF Roussos, P Keller, E Hurd, YL AF Egervari, Gabor Landry, Joseph Callens, James Fullard, John F. Roussos, Panos Keller, Eva Hurd, Yasmin L. TI Striatal H3K27 Acetylation Linked to Glutamatergic Gene Dysregulation in Human Heroin Abusers Holds Promise as Therapeutic Target SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Addiction; Epigenetics; Glutamate; Heroin; Histone acetylation; JQ1 ID BROMODOMAIN INHIBITOR OTX015; GLOBAL HISTONE ACETYLATION; COCAINE-INDUCED PLASTICITY; ACTIVATES TRANSCRIPTION; EPIGENETIC MECHANISMS; DOSE-ESCALATION; DRUG-ADDICTION; EXPRESSION; CHROMATIN; METHYLATION AB BACKGROUND: Opiate abuse and overdose reached epidemic levels in the United States. However, despite significant advances in animal and in vitro models, little knowledge has been directly accrued regarding the neurobiology of the opiate-addicted human brain. METHODS: We used postmortem human brain specimens from a homogeneous European Caucasian population of heroin users for transcriptional and epigenetic profiling, as well as direct assessment of chromatin accessibility in the striatum, a brain region central to reward and emotion. A rat heroin self-administration model was used to obtain translational molecular and behavioral insights. RESULTS: Our transcriptome approach revealed marked impairments related to glutamatergic neurotransmission and chromatin remodeling in the human striatum. A series of biochemical experiments tracked the specific location of the epigenetic disturbances to hyperacetylation of lysine 27 of histone H3, showing dynamic correlations with heroin use history and acute opiate toxicology. Targeted investigation of GRIA1, a glutamatergic gene implicated in drug-seeking behavior, verified the increased enrichment of lysine-27 acetylated histone H3 at discrete loci, accompanied by enhanced chromatin accessibility at hyperacetylated regions in the gene body. Analogous epigenetic impairments were detected in the striatum of heroin self-administering rats. Using this translational model, we showed that bromodomain inhibitor JQ1, which blocks the functional readout of acetylated lysines, reduced heroin self-administration and cue-induced drug-seeking behavior. CONCLUSIONS: Overall, our data suggest that heroin-related histone H3 hyperacetylation contributes to glutamatergic transcriptional changes that underlie addiction behavior and identify JQ1 as a promising candidate for targeted clinical interventions in heroin use disorder. C1 [Egervari, Gabor; Landry, Joseph; Callens, James; Fullard, John F.; Roussos, Panos; Hurd, Yasmin L.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, Dept Psychiat, 1470 Madison Ave, New York, NY 10029 USA. [Egervari, Gabor; Landry, Joseph; Callens, James; Hurd, Yasmin L.] Icahn Sch Med Mt Sinai, Friedman Brain Inst, Dept Neurosci, New York, NY USA. [Fullard, John F.; Roussos, Panos] Icahn Sch Med Mt Sinai, Dept Genet & Genom Sci, New York, NY USA. [Fullard, John F.; Roussos, Panos] Icahn Sch Med Mt Sinai, Inst Multiscale Biol, New York, NY USA. [Roussos, Panos] James J Peters VA Med Ctr, Mental Illness Res Educ & Clin Ctr VISN 3, Bronx, NY USA. [Keller, Eva] Semmelweis Univ, Dept Forens Med, Budapest, Hungary. RP Hurd, YL (reprint author), Icahn Sch Med Mt Sinai, Friedman Brain Inst, Dept Psychiat, 1470 Madison Ave, New York, NY 10029 USA. EM Yasmin.Hurd@mssm.edu FU National Institutes of Health [DA15446, DA008227, AG050986]; Veterans Affairs [BX002395] FX This work was supported by grants from the National Institutes of Health (Grant Nos. DA15446 to YLH and EK, DA008227 to YLH, AG050986 to PR) and the Veterans Affairs (Merit Grant No. BX002395 to PR). NR 62 TC 1 Z9 1 U1 6 U2 6 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD APR 1 PY 2017 VL 81 IS 7 BP 585 EP 594 DI 10.1016/j.biopsych.2016.09.015 PG 10 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA EP3RX UT WOS:000397300500013 PM 27863698 ER PT J AU Morton, GJ Muta, K Kaiyala, KJ Rojas, JM Scarlett, JM Matsen, ME Nelson, JT Acharya, NK Piccinini, F Stefanovski, D Bergman, RN Taborsky, GJ Kahn, SE Schwartz, MW AF Morton, Gregory J. Muta, Kenjiro Kaiyala, Karl J. Rojas, Jennifer M. Scarlett, Jarrad M. Matsen, Miles E. Nelson, Jarrell T. Acharya, Nikhil K. Piccinini, Francesca Stefanovski, Darko Bergman, Richard N. Taborsky, Gerald J., Jr. Kahn, Steven E. Schwartz, Michael W. TI Evidence That the Sympathetic Nervous System Elicits Rapid, Coordinated, and Reciprocal Adjustments of Insulin Secretion and Insulin Sensitivity During Cold Exposure SO DIABETES LA English DT Article ID GLUCOSE-TOLERANCE; INTRAVENOUS GLUCOSE; PERIPHERAL-TISSUES; DISPOSITION INDEX; B-CELL; RESISTANCE; RATS; DIET; DOGS; QUANTIFICATION AB Dynamic adjustment of insulin secretion to compensate for changes of insulin sensitivity that result from alteration of nutritional or metabolic status is a fundamental aspect of glucose homeostasis. To investigate the role of the brain in this coupling process, we used cold exposure as an experimental paradigm because the sympathetic nervous system (SNS) helps to coordinate the major shifts of tissue glucose utilization needed to ensure that increased thermogenic needs are met. We found that glucose-induced insulin secretion declined by 50% in rats housed at 5 degrees C for 28 h, and yet, glucose tolerance did not change, owing to a doubling of insulin sensitivity. These potent effects on insulin secretion and sensitivity were fully reversed by returning animals to room temperature (22 degrees C) for 4 h or by intravenous infusion of the alpha-adrenergic receptor antagonist phentolamine for only 30 min. By comparison, insulin clearance was not affected by cold exposure or phentolamine infusion. These findings offer direct evidence of a key role for the brain, acting via the SNS, in the rapid, highly coordinated, and reciprocal changes of insulin secretion and insulin sensitivity that preserve glucose homeostasis in the setting of cold exposure. C1 [Morton, Gregory J.; Muta, Kenjiro; Rojas, Jennifer M.; Scarlett, Jarrad M.; Matsen, Miles E.; Nelson, Jarrell T.; Acharya, Nikhil K.; Schwartz, Michael W.] Univ Washington, Dept Med, Inst Diabet, Seattle, WA 98105 USA. [Kaiyala, Karl J.] Univ Washington, Sch Dent, Dept Oral Hlth Sci, Seattle, WA 98195 USA. [Scarlett, Jarrad M.] Seattle Childrens Hosp, Dept Pediat Gastroenterol & Hepatol, Seattle, WA USA. [Piccinini, Francesca; Bergman, Richard N.] Cedars Sinai Med Ctr, Diabet & Obes Res Inst, Los Angeles, CA 90048 USA. [Stefanovski, Darko] Univ Penn, Sch Vet Med, New Bolton Ctr, Philadelphia, PA 19104 USA. [Taborsky, Gerald J., Jr.; Kahn, Steven E.] Vet Affairs Puget Sound Hlth Care Syst, Dept Vet Affairs Med Ctr, Seattle, WA USA. RP Schwartz, MW (reprint author), Univ Washington, Dept Med, Inst Diabet, Seattle, WA 98105 USA. EM mschwart@u.washington.edu FU National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases [DK-089056, DK-27619, DK-29867, DK-50154, DK-083042, DK-090320, DK-101997]; National Institute of Diabetes and Digestive Kidney Diseases-funded Nutrition Obesity Research Center [DK-035816]; Diabetes Research Center [DK-017047]; Nutrition, Obesity and Atherosclerosis Training Grant from the National Heart, Lung, and Blood Institute [T32-HL007028]; Diabetes and Metabolism Training Grant at the University of Washington [T32-DK-0007247]; Department of Veterans Affairs [BX001060] FX This work was supported by National Institutes of Health, National Institute of Diabetes and Digestive and Kidney Diseases grants DK-089056 (G.J.M.), DK-27619 and DK-29867 (R.N.B.), DK-50154 (G.J.T.), DK-083042, DK-090320, and DK-101997 (M.W.S.); the National Institute of Diabetes and Digestive Kidney Diseases-funded Nutrition Obesity Research Center (DK-035816) and Diabetes Research Center (DK-017047); the Nutrition, Obesity and Atherosclerosis Training Grant from the National Heart, Lung, and Blood Institute (T32-HL007028) and the Diabetes and Metabolism Training Grant (T32-DK-0007247) at the University of Washington; and the Department of Veterans Affairs grant BX001060 (S.E.K.). NR 39 TC 0 Z9 0 U1 2 U2 2 PU AMER DIABETES ASSOC PI ALEXANDRIA PA 1701 N BEAUREGARD ST, ALEXANDRIA, VA 22311-1717 USA SN 0012-1797 EI 1939-327X J9 DIABETES JI Diabetes PD APR PY 2017 VL 66 IS 4 BP 823 EP 834 DI 10.2337/db16-1351 PG 12 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EP0ZJ UT WOS:000397114900007 PM 28115396 ER PT J AU Schrag, A Weintraub, D Schott, JM AF Schrag, Anette Weintraub, Daniel Schott, Jonathan M. TI Cognitive decline before diagnosis of Parkinson's disease Reply SO LANCET NEUROLOGY LA English DT Letter C1 [Schrag, Anette; Schott, Jonathan M.] UCL, UCL Inst Neurol, London, England. [Weintraub, Daniel] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Weintraub, Daniel] Philadelphia Vet Affairs Med Ctr, Philadelphia, PA USA. RP Schrag, A (reprint author), UCL, UCL Inst Neurol, London, England. EM a.schrag@ucl.ac.uk FU Economic and Social Research Council; GE Healthcare; Parkinson's UK; EU FP7; Movement Disorders Society; Medtronic; AstraZeneca; Roche; Eli Lilly; AVID Radiopharmaceuticals FX AS reports grants from Economic and Social Research Council, GE Healthcare, Parkinson's UK, EU FP7, and the Movement Disorders Society; and personal fees from Medtronic and AstraZeneca. JMS reports personal fees from Roche and Eli Lilly, grants and non-financial support from AVID Radiopharmaceuticals, and serves on a data safety management board for Axon Neuroscience. DW declares no competing interests. NR 5 TC 0 Z9 0 U1 4 U2 4 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1474-4422 EI 1474-4465 J9 LANCET NEUROL JI Lancet Neurol. PD APR PY 2017 VL 16 IS 4 BP 262 EP 262 PG 1 WC Clinical Neurology SC Neurosciences & Neurology GA EN9RF UT WOS:000396336600012 PM 28327332 ER PT J AU Jimenez, AM Lee, J Green, MF Wynn, JK AF Jimenez, Amy M. Lee, Junghee Green, Michael F. Wynn, Jonathan K. TI Functional connectivity when detecting rare visual targets in schizophrenia SO PSYCHIATRY RESEARCH-NEUROIMAGING LA English DT Article DE fMRI; Psychophysiological interaction; Attention; Salience; Oddball; Target detection ID EVENT-RELATED FMRI; VENTRAL ATTENTION SYSTEMS; NEGATIVE SYMPTOMS; BRAIN NETWORKS; HEMODYNAMIC-RESPONSES; ODDBALL FMRI; SEARCH; DORSAL; P300; TASK AB Individuals with schizophrenia demonstrate difficulties in attending to important stimuli (e.g., targets) and ignoring distractors (e.g., non-targets). We used a visual oddball task during fMRI to examine functional connectivity within and between the ventral and dorsal attention networks to determine the relative contribution of each network to detection of rare visual targets in schizophrenia. The sample comprised 25 schizophrenia patients and 27 healthy controls. Psychophysiological interaction analysis was used to examine whole-brain functional connectivity in response to targets. We used the right temporo parietal junction (TPJ) as the seed region for the ventral network and the right medial intraparietal sulcus (IPS) as the seed region for the dorsal network. We found that connectivity between right IPS and right anterior insula (AI; a component of the ventral network) was significantly greater in controls than patients. Expected patterns of within-and between network connectivity for right TPJ were observed in controls, and not significantly different in patients. These findings indicate functional connectivity deficits between the dorsal and ventral attention networks in schizophrenia that may create problems in processing relevant versus irrelevant stimuli. Understanding the nature of network disruptions underlying cognitive deficits of schizophrenia may help shed light on the pathophysiology of this disorder. C1 [Jimenez, Amy M.; Lee, Junghee; Green, Michael F.; Wynn, Jonathan K.] VA Greater Los Angeles Healthcare Syst, Desert Pacific MIRECC, Los Angeles, CA USA. [Jimenez, Amy M.; Lee, Junghee; Green, Michael F.; Wynn, Jonathan K.] Univ Calif Los Angeles, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90024 USA. RP Jimenez, AM (reprint author), VA Greater Los Angeles Healthcare Syst, MIRECC, Bldg 210,11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM amjimenez@ucla.edu FU VA Career Development Award; NIMH [MH43292, MH065707] FX This research was supported by a VA Career Development Award to Jonathan K. Wynn, Ph.D. and NIMH Grants MH43292 and MH065707 (PI: Michael F. Green, Ph.D.). Writing of this manuscript was supported by the Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment, Department of Veterans Affairs. For generous support, we also thank the Brain Mapping Medical Research Organization, Brain Mapping Support Foundation, Pierson -Lovelace Foundation, The Ahmanson Foundation, William M. and Linda R. Dietel Philanthropic Fund at the Northern Piedmont Community Foundation, Tamkin Foundation, Jennifer Jones-Simon Foundation, Capital Group Companies Charitable Foundation, Robson Family, and Northstar Fund. The authors thank Poorang Nori and Crystal Gibson for assistance in data collection. The funders had no role in the study design, data collection and analysis, decision to publish, or preparation of the manuscript. These data were presented, in part, as a poster at the 2015 Annual Meeting of the Society for Research in Psychopathology. NR 77 TC 0 Z9 0 U1 5 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0925-4927 EI 1872-7506 J9 PSYCHIAT RES-NEUROIM JI Psychiatry Res. Neuroimaging PD MAR 30 PY 2017 VL 261 BP 35 EP 43 DI 10.1016/j.pscychresns.2017.01.007 PG 9 WC Clinical Neurology; Neuroimaging; Psychiatry SC Neurosciences & Neurology; Psychiatry GA EN4DT UT WOS:000395958900005 PM 28126618 ER PT J AU AuYoung, M Damschroder, LJ Kinsinger, L Moin, T Richardson, CR AF AuYoung, Mona Damschroder, Laura J. Kinsinger, Linda Moin, Tannaz Richardson, Caroline R. TI Practical partnered research to improve weight loss among overweight/obese veterans: lessons from the trenches SO BMC MEDICAL RESEARCH METHODOLOGY LA English DT Article DE Partnered research; Weight loss; Implementation; Pragmatic clinical trials; Veterans ID MANAGEMENT PROGRAM; DECISION-MAKING; IMPLEMENTATION; VA; TRANSLATION; RELEVANCE; TRIALS AB Background: Obesity and obesity-related conditions, such as type 2 diabetes, are a major issue for Veteran health. Veterans Health Administration (VA) researchers and health systems leaders have worked separately and together to provide more effective weight management programs for Veterans. Although randomized clinical trials are often considered the gold standard for establishing efficacy of interventions in controlled circumstances, pragmatic clinical trials (PCTs) provide agility for translation. Main text: VA researchers and health system leaders collaboratively designed a PCT to compare the Diabetes Prevention Program (VA-DPP) to usual care (MOVE (R)) in promoting weight loss and glycemic control among overweight/obese Veterans with prediabetes. Together, they navigated the tensions that exist between quality improvement and research activities, facing challenges but reaping significant rewards. Early findings led to updated national guidance for delivering obesity treatment in VA. Short conclusion: Partnered research and the use of PCTs can be powerful strategies for accelerating evidence-based findings into practice. Collaborative partnerships between researchers and health systems leaders can help enhance and sustain translation in real-world settings. C1 [AuYoung, Mona; Richardson, Caroline R.] Ann Arbor VA Ctr Clin Management Res, CCMR, HSR&D, Mail Stop 152,P Box 130170, Ann Arbor, MI 48113 USA. [Damschroder, Laura J.; Richardson, Caroline R.] VA Diabet QUERI, CCMR, HSR, Mail Stop 152,P Box 130170, Ann Arbor, MI 48113 USA. [Kinsinger, Linda] Natl Ctr Hlth Promot & Dis Prevent, 3022 Croasdaile Dr 200, Durham, NC 27705 USA. [Moin, Tannaz] VA Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Moin, Tannaz] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA USA. [Moin, Tannaz] Greater Angeles CA Hlth Serv Res & Dev HSR & D, Ctr Healthcare Innovat Implementat & Policy, 11301 Wilshire Blvd,Mail Code 111D, Los Angeles, CA 90073 USA. [Richardson, Caroline R.] Univ Michigan, Dept Family Med, 1018 Fuller St, Ann Arbor, MI 48104 USA. RP AuYoung, M (reprint author), Ann Arbor VA Ctr Clin Management Res, CCMR, HSR&D, Mail Stop 152,P Box 130170, Ann Arbor, MI 48113 USA. EM mona.auyoung@va.gov FU Veteran Affairs (VA) Quality Enhancement Research Initiative (QUERI) program [RRP 12-440, SDP 12-549]; clinical quality improvement funding [XVA 41-048]; VA Office of Academic Affiliations through the VA Health Services Research and Development Advanced Fellowship Program, VA Greater Los Angeles [TPM65-010]; VA Health Services Research and Development Advanced Postdoctoral Fellowship Program, VA Ann Arbor FX This work was funded by the Veteran Affairs (VA) Quality Enhancement Research Initiative (QUERI) program through two research grants (RRP 12-440 and SDP 12-549) and clinical quality improvement funding (XVA 41-048). Dr. Moin received support from the VA Office of Academic Affiliations through the VA Health Services Research and Development Advanced Fellowship Program (TPM65-010), VA Greater Los Angeles, from 2011 to 2014. Dr. AuYoung received support through the VA Health Services Research and Development Advanced Postdoctoral Fellowship Program, VA Ann Arbor. This quality improvement project was partially funded by operational partners. Our partners helped to inform feasibility of study design alternatives. However, they had no role in final decisions regarding study design nor were they involved in data collection or analysis, decision to publish, or preparation of this manuscript. NR 40 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2288 J9 BMC MED RES METHODOL JI BMC Med. Res. Methodol. PD MAR 29 PY 2017 VL 17 AR 50 DI 10.1186/s12874-017-0321-9 PG 8 WC Health Care Sciences & Services SC Health Care Sciences & Services GA EP7AT UT WOS:000397530700001 PM 28356073 ER PT J AU Srinivasainagendra, V Sandel, MW Singh, B Sundaresan, A Mooga, VP Bajpai, P Tiwari, HK Singh, KK AF Srinivasainagendra, Vinodh Sandel, Michael W. Singh, Bhupendra Sundaresan, Aishwarya Mooga, Ved P. Bajpai, Prachi Tiwari, Hemant K. Singh, Keshav K. TI Migration of mitochondrial DNA in the nuclear genome of colorectal adenocarcinoma SO GENOME MEDICINE LA English DT Article DE Cancer; Tumor; Colorectal cancer; Mitochondria; Mitochondrial DNA; YME1L1; NUMT; Numtogenesis; mtDNA transfer; Genetic instability ID HUMAN MYOCARDIAL-CELLS; HUMAN GENETIC-DISEASE; SACCHAROMYCES-CEREVISIAE; INTRANUCLEAR MITOCHONDRIA; CANCER-CELLS; COPY NUMBER; DYSFUNCTION; MUTATIONS; TRANSFORMATION; PSEUDOGENES AB Background: Colorectal adenocarcinomas are characterized by abnormal mitochondrial DNA (mtDNA) copy number and genomic instability, but a molecular interaction between mitochondrial and nuclear genome remains unknown. Here we report the discovery of increased copies of nuclear mtDNA (NUMT) in colorectal adenocarcinomas, which supports link between mtDNA and genomic instability in the nucleus. We name this phenomenon of nuclear occurrence of mitochondrial component as numtogenesis. We provide a description of NUMT abundance and distribution in tumor versus matched blood-derived normal genomes. Methods: Whole-genome sequence data were obtained for colon adenocarcinoma and rectum adenocarcinoma patients participating in The Cancer Genome Atlas, via the Cancer Genomics Hub, using the GeneTorrent file acquisition tool. Data were analyzed to determine NUMT proportion and distribution on a genome-wide scale. A NUMT suppressor gene was identified by comparing numtogenesis in other organisms. Results: Our study reveals that colorectal adenocarcinoma genomes, on average, contains up to 4.2-fold more somatic NUMTs than matched normal genomes. Women colorectal tumors contained more NUMT than men. NUMT abundance in tumor predicted parallel abundance in blood. NUMT abundance positively correlated with GC content and gene density. Increased numtogenesis was observed with higher mortality. We identified YME1L1, a human homolog of yeast YME1 (yeast mitochondrial DNA escape 1) to be frequently mutated in colorectal tumors. YME1L1 was also mutated in tumors derived from other tissues. We show that inactivation of YME1L1 results in increased transfer of mtDNA in the nuclear genome. Conclusions: Our study demonstrates increased somatic transfer of mtDNA in colorectal tumors. Our study also reveals sex-based differences in frequency of NUMT occurrence and that NUMT in blood reflects NUMT in tumors, suggesting NUMT may be used as a biomarker for tumorigenesis. We identify YME1L1 as the first NUMT suppressor gene in human and demonstrate that inactivation of YME1L1 induces migration of mtDNA to the nuclear genome. Our study reveals that numtogenesis plays an important role in the development of cancer. C1 [Srinivasainagendra, Vinodh; Sandel, Michael W.; Sundaresan, Aishwarya; Tiwari, Hemant K.] Univ Alabama Birmingham, Sch Publ Hlth, Dept Biostatist, Birmingham, AL 35294 USA. [Singh, Bhupendra; Mooga, Ved P.; Bajpai, Prachi] Univ Alabama Birmingham, Dept Genet, Birmingham, AL 35294 USA. [Singh, Keshav K.] Univ Alabama Birmingham, Ctr Aging & UAB Comprehens Canc Ctr, Ctr Free Radical Biol, Dept Genet, Birmingham, AL 35294 USA. [Singh, Keshav K.] Univ Alabama Birmingham, Ctr Aging & UAB Comprehens Canc Ctr, Ctr Free Radical Biol, Dept Pathol, Birmingham, AL 35294 USA. [Singh, Keshav K.] Univ Alabama Birmingham, Ctr Aging & UAB Comprehens Canc Ctr, Ctr Free Radical Biol, Dept Environm Hlth, Birmingham, AL 35294 USA. [Singh, Keshav K.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA. [Singh, Keshav K.] Univ Alabama Birmingham, Sch Med, Dept Genet, Kaul Genet Bldg,Suite 620,720 20th St South, Birmingham, AL 35294 USA. [Sandel, Michael W.] Univ West Alabama, Sch Nat Sci & Math, Dept Biol & Environm Sci, Livingston, NJ USA. RP Tiwari, HK (reprint author), Univ Alabama Birmingham, Sch Publ Hlth, Dept Biostatist, Birmingham, AL 35294 USA.; Singh, KK (reprint author), Univ Alabama Birmingham, Ctr Aging & UAB Comprehens Canc Ctr, Ctr Free Radical Biol, Dept Genet, Birmingham, AL 35294 USA.; Singh, KK (reprint author), Univ Alabama Birmingham, Ctr Aging & UAB Comprehens Canc Ctr, Ctr Free Radical Biol, Dept Pathol, Birmingham, AL 35294 USA.; Singh, KK (reprint author), Univ Alabama Birmingham, Ctr Aging & UAB Comprehens Canc Ctr, Ctr Free Radical Biol, Dept Environm Hlth, Birmingham, AL 35294 USA.; Singh, KK (reprint author), Birmingham Vet Affairs Med Ctr, Birmingham, AL 35294 USA.; Singh, KK (reprint author), Univ Alabama Birmingham, Sch Med, Dept Genet, Kaul Genet Bldg,Suite 620,720 20th St South, Birmingham, AL 35294 USA. EM htiwari@uab.edu; kksingh@uab.edu FU Veterans Administration [1I01BX001716]; NCTN-LAPS Program Translational Research Award; [T32HL072757] FX This study was supported by grants from the Veterans Administration 1I01BX001716 and a NCTN-LAPS Program Translational Research Award to KKS and T32HL072757 (PI: HKT) to MWS. NR 88 TC 0 Z9 0 U1 10 U2 10 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1756-994X J9 GENOME MED JI Genome Med. PD MAR 29 PY 2017 VL 9 AR 31 DI 10.1186/s13073-017-0420-6 PG 15 WC Genetics & Heredity SC Genetics & Heredity GA EP9ZA UT WOS:000397730300001 PM 28356157 ER PT J AU La Fountaine, MF Cirnigliaro, CM Kirshblum, SC McKenna, C Bauman, WA AF La Fountaine, Michael F. Cirnigliaro, Christopher M. Kirshblum, Steven C. McKenna, Cristin Bauman, William A. TI Effect of functional sympathetic nervous system impairment of the liver and abdominal visceral adipose tissue on circulating triglyceride-rich lipoproteins SO PLOS ONE LA English DT Article ID SPINAL-CORD-INJURY; HOMEOSTASIS MODEL ASSESSMENT; ISOLATED RAT HEPATOCYTES; BODY-FAT DISTRIBUTION; INSULIN-RESISTANCE; LIPID-METABOLISM; TRIACYLGLYCEROL SECRETION; INTERNATIONAL STANDARDS; MOLECULAR-MECHANISMS; DIABETES-MELLITUS AB Background Interruption of sympathetic innervation to the liver and visceral adipose tissue (VAT) in animal models has been reported to reduce VAT lipolysis and hepatic secretion of very low density lipoprotein (VLDL) and concentrations of triglyceride-rich lipoprotein particles. Whether functional impairment of sympathetic nervous system (SNS) innervation to tissues of the abdominal cavity reduce circulating concentrations of triglyceride (TG) and VLDL particles (VLDL-P) was tested in men with spinal cord injury (SCI). Methods One hundred-three non-ambulatory men with SCI [55 subjects with neurologic injury at or proximal to the 4th thoracic vertebrae (T up arrow 4); 48 subjects with SCI at or distal to the 5th thoracic vertebrae (down arrow T5)] and 53 able-bodied (AB) subjects were studied. Fasting blood samples were obtained for determination of TG, VLDL-P concentration by NMR spectroscopy, serum glucose by autoanalyzer, and plasma insulin by radioimmunoassay. VAT volume was determined by dual energy x-ray absorptiometry imaging with calculation by a validated proprietary software package. Results Significant group main effects for TG and VLDL-P were present; post-hoc tests revealed that serum TG concentrations were significantly higher in down arrow T5 group compared to AB and up arrow T4 groups [150 +/- 9 vs. 101 +/- 8 (p<0.01) and 112 +/- 8 mg/dl (p<0.05), respectively]. VLDL-P concentration was significantly elevated in down arrow T5 group compared to AB and up arrow T4 groups [74 +/- 4 vs. 58 4 (p<0.05) and 55 +/- 4 mu mol/l(p<0.05)]. VAT volume was significantly higher in both SCI groups than in the AB group, and HOMA-IR was higher and approached significance in the SCI groups compared to the AB group. A linear relationship between triglyceride rich lipoproteins (i.e., TG or Large VLDL-P) and VAT volume or HOMA-IR was significant only in the down arrow T5 group. Conclusions Despite a similar VAT volume and insulin resistance in both SCI groups, the down arrow T5 group had significantly higher serum TG and VLDL-P values than that observed in the up arrow T4 and the AB control groups. Thus, level of injury is an important determinate of the concentration of circulating triglyceride rich lipoproteins, which may play a role in the genesis of cardiometabolic dysfunction. C1 [La Fountaine, Michael F.; Cirnigliaro, Christopher M.; Bauman, William A.] James J Peters Vet Affairs Med Ctr, Dept Vet Affairs, Rehabil Res & Dev Serv, Natl Ctr Med Consequences Spinal Cord Injury, Bronx, NY 10468 USA. [La Fountaine, Michael F.; Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [La Fountaine, Michael F.] Seton Hall Univ, Sch Hlth & Med Sci, S Orange, NJ 07079 USA. [La Fountaine, Michael F.] Seton Hall Univ, Inst Adv Study Rehabil & Sports Sci, Sch Hlth & Med Sci, S Orange, NJ 07079 USA. [Kirshblum, Steven C.; McKenna, Cristin] Kessler Inst Rehabil, W Orange, NJ USA. [Kirshblum, Steven C.; McKenna, Cristin] Rutgers New Jersey Med Sch, Dept Phys Med & Rehabil, Newark, NJ USA. [Bauman, William A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. RP La Fountaine, MF (reprint author), James J Peters Vet Affairs Med Ctr, Dept Vet Affairs, Rehabil Res & Dev Serv, Natl Ctr Med Consequences Spinal Cord Injury, Bronx, NY 10468 USA.; La Fountaine, MF (reprint author), Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA.; La Fountaine, MF (reprint author), Seton Hall Univ, Sch Hlth & Med Sci, S Orange, NJ 07079 USA.; La Fountaine, MF (reprint author), Seton Hall Univ, Inst Adv Study Rehabil & Sports Sci, Sch Hlth & Med Sci, S Orange, NJ 07079 USA. EM michael.lafountaine@va.gov FU Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service National Center of Excellence for the Medical Consequences of Spinal Cord Injury [139212-C, B2020-C] FX This work was supported by the Department of Veterans Affairs, Veterans Health Administration, Rehabilitation Research and Development Service National Center of Excellence for the Medical Consequences of Spinal Cord Injury (#139212-C and #B2020-C). The funders had no role in study design, data collection and analysis, NR 65 TC 0 Z9 0 U1 0 U2 0 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 27 PY 2017 VL 12 IS 3 AR e0173934 DI 10.1371/joumal.pone.0173934 PG 15 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA ER9VD UT WOS:000399174300015 PM 28346471 ER PT J AU Patra, A Chen, XD Sadowska, GB Zhang, JY Lim, YP Padbury, JF Banks, WA Stonestreet, BS AF Patra, Aparna Chen, Xiaodi Sadowska, Grazyna B. Zhang, Jiyong Lim, Yow-Pin Padbury, James F. Banks, William A. Stonestreet, Barbara S. TI NEUTRALIZING ANTI-INTERLEUKIN-1 beta ANTIBODIES REDUCE ISCHEMIA-RELATED INTERLEUKIN-1 beta TRANSPORT ACROSS THE BLOOD-BRAIN BARRIER IN FETAL SHEEP SO NEUROSCIENCE LA English DT Article DE blood-brain barrier; cytokines; interleukin-1 beta; fetus; hypoxia-ischemia; sheep ID EXTREMELY PRETERM INFANTS; NECROSIS-FACTOR-ALPHA; WHITE-MATTER INJURY; IN-OVINE FETUSES; NEONATAL ENCEPHALOPATHY; INFLAMMATORY CYTOKINES; PROTEIN EXPRESSION; CEREBRAL-ISCHEMIA; ENDOTHELIAL-CELLS; TNF-ALPHA AB Hypoxic ischemic insults predispose to perinatal brain injury. Pro-inflammatory cytokines are important in the evolution of this injury. Interleukin-1 beta (IL-1 beta) is a key mediator of inflammatory responses and elevated IL-1b levels in brain correlate with adverse neuro developmental outcomes after brain injury. Impaired blood-brain barrier (BBB) function represents an important component of hypoxic-ischemic brain injury in the fetus. In addition, ischemia-reperfusion increases cytokine transport across the BBB of the ovine fetus. Reducing pro-inflammatory cytokine entry into brain could represent a novel approach to attenuate ischemia-related brain injury. We hypothesized that infusions of neutralizing IL-1 beta monoclonal antibody (mAb) reduce IL-1 beta transport across the BBB after ischemia in the fetus. Fetal sheep were studied 24-h after 30-min of carotid artery occlusion. Fetuses were treated with placebo-or anti-IL-1 beta mAb intravenously 15-min and 4-h after ischemia. Ovine IL-1 beta protein expressed from IL-1 beta pGEX-2T vectors in Escherichia coli (E.coli) BL-21 cells was produced, purified, and radiolabeled with (125) I. BBB permeability was quantified using the blood-to-brain transfer constant (K-i) with I-125-radiolabeled-IL-1 beta. Increases in antiIL-1 beta mAb were observed in the brain of the mAb-treated group (P < 0.001). Blood-to-brain transport of I-125-IL-1 beta was lower (P < 0.04) across brain regions in the anti-IL-1 beta mAb-treated than placebo-treated ischemic fetuses. Plasma I-125-IL-1 beta counts were higher (P < 0.001) in the anti-IL-1 beta mAb-than placebo-treated ischemic fetuses. Systemic infusions of anti-IL-1 beta mAb reduce IL-1 beta transport across the BBB after ischemia in the ovine fetus. Our findings suggest that conditions associated with increases in systemic proinflammatory cytokines and neurodevelopmental impairment could benefit from an anti-cytokine therapeutic strategy. (C) 2017 IBRO. Published by Elsevier Ltd. All rights reserved. C1 [Patra, Aparna; Chen, Xiaodi; Sadowska, Grazyna B.; Zhang, Jiyong; Padbury, James F.; Stonestreet, Barbara S.] Brown Univ, Women & Infants Hosp Rhode Isl, Alpert Med Sch, Pediat, Providence, RI 02905 USA. [Lim, Yow-Pin] ProThera Biol, Providence, RI 02903 USA. [Banks, William A.] Univ Washington, Dept Med, Div Gerontol & Geriatr Med, Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98104 USA. [Patra, Aparna] Univ Kentucky, Dept Pediat, 138 Leader Ave,Room 10C, Lexington, KY 40508 USA. RP Stonestreet, BS (reprint author), Brown Univ, Women & Infants Hosp Rhode Isl, Alpert Med Sch, Dept Pediat, 101 Dudley St, Providence, RI 02905 USA. EM aparna.patra@uky.edu; bstonestreet@wihri.org FU National Institute of General Medical Sciences of the National Institutes of Health [1R01-HD-057100, P20 RR018728, P20GM103537]; American Heart Association [13POST16860015] FX Research summarized in this publication was supported by the National Institute of General Medical Sciences of the National Institutes of Health under award number 1R01-HD-057100, by an Institutional Development Award (IDeA) from the National Institute of General Medical Sciences of the National Institutes of Health under grant number P20 RR018728 and P20GM103537, and by a postdoctoral fellowship award (J.Z.) from the American Heart Association under grant number 13POST16860015. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 65 TC 0 Z9 0 U1 3 U2 3 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0306-4522 EI 1873-7544 J9 NEUROSCIENCE JI Neuroscience PD MAR 27 PY 2017 VL 346 BP 113 EP 125 DI 10.1016/j.neuroscience.2016.12.051 PG 13 WC Neurosciences SC Neurosciences & Neurology GA EN1SK UT WOS:000395790100011 PM 28089577 ER PT J AU Morris, BJ Krieger, JN Klausner, JD AF Morris, Brian J. Krieger, John N. Klausner, Jeffrey D. TI CDC's Male Circumcision Recommendations Represent a Key Public Health Measure SO GLOBAL HEALTH-SCIENCE AND PRACTICE LA English DT Editorial Material ID SIMPLEX-VIRUS TYPE-2; HUMAN-PAPILLOMAVIRUS INFECTION; RANDOMIZED CONTROLLED-TRIAL; AUSTRALIAN HOMOSEXUAL-MEN; TOUCH PRESSURE THRESHOLDS; INFANT MALE CIRCUMCISION; SUB-SAHARAN AFRICA; NEWBORN CIRCUMCISION; SEXUAL FUNCTION; HIV-INFECTION C1 [Morris, Brian J.] Univ Sydney, Sch Med Sci, Sydney, NSW, Australia. [Morris, Brian J.] Univ Sydney, Bosch Inst, Sydney, NSW, Australia. [Krieger, John N.] Univ Washington, Sch Med, Seattle, WA 98195 USA. [Krieger, John N.] VA Puget Sound Hlth Care Syst, Urol Sect, Seattle, WA USA. [Klausner, Jeffrey D.] Univ Calif Los Angeles, Jonathan & Karin Fielding Sch Publ Hlth, Dept Epidemiol, Los Angeles, CA USA. RP Morris, BJ (reprint author), Univ Sydney, Sch Med Sci, Sydney, NSW, Australia.; Morris, BJ (reprint author), Univ Sydney, Bosch Inst, Sydney, NSW, Australia. EM brian.morris@sydney.edu.au NR 132 TC 0 Z9 0 U1 0 U2 0 PU US AGENCY INT DEVELOPMENT-USAID PI BALTIMORE PA US AGENCY INT DEVELOPMENT-USAID, BALTIMORE, MD 00000 USA SN 2169-575X J9 GLOB HEALTH-SCI PRAC JI Glob. Health PD MAR 24 PY 2017 VL 5 IS 1 BP 15 EP 27 DI 10.9745/GHSP-D-16-00390 PG 13 WC Public, Environmental & Occupational Health SC Public, Environmental & Occupational Health GA ER7DK UT WOS:000398970200004 PM 28351877 ER PT J AU Jadhav, S Russo, S Cowart, LA Greenberg, ML AF Jadhav, Shyamalagauri Russo, Sarah Cowart, L. Ashley Greenberg, Miriam L. TI Inositol Depletion Induced by Acute Treatment of the Bipolar Disorder Drug Valproate Increases Levels of Phytosphingosine SO JOURNAL OF BIOLOGICAL CHEMISTRY LA English DT Article ID SACCHAROMYCES-CEREVISIAE; SPHINGOLIPID HOMEOSTASIS; PROTEIN; BIOSYNTHESIS; YEAST; GENES; ORM2; PHOSPHORYLATION; MODULATION; LITHIUM AB Bipolar disorder (BD) is a severe psychiatric illness affecting similar to 1% of the world population. Valproate (VPA) and lithium, widely used for the treatment of BD, are not universally effec-tive. These drugs have been shown to cause inositol depletion, but translating this observation to a specific therapeutic mech-anism has been difficult, hampering the development of more effective therapies. We have shown previously in yeast that chronic VPA treatment induces the unfolded protein response due to increasing ceramide levels. To gain insight into the mechanisms activated during acute VPA treatment, we performed a genome-wide expression study in yeast treated with VPA for 30 min. We observed increased mRNA and protein levels of RSB1, which encodes an exporter of long chain bases dihydrosphingosine (DHS) and phytosphingosine (PHS), and further saw that VPA increased sensitivity of an rsb1 Delta mutant to PHS, suggesting that VPA increases long chain base levels. Consistent with this, PHS levels were elevated in wild type and, to a greater extent, in rsb1 Delta cells. Expression of ORM genes (negative regulators of PHS synthesis) and of fatty acid elongase genes FEN1 and SUR4 were decreased, and expression of YOR1 (exporter of PHS-1P) and DPL1 (lyase that degrades DHS-1P and PHS-1P) was increased. These effects were more pronounced in medium lacking inositol, and were mirrored by inositol starvation of an ino1 Delta mutant. These findings provide a metabolic explanation as to how VPA-mediated inositol depletion causes increased synthesis of PHS and further support the therapeutic relevance of inositol depletion as a bipolar disorder treatment. C1 [Jadhav, Shyamalagauri; Greenberg, Miriam L.] Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA. [Russo, Sarah; Cowart, L. Ashley] Med Univ South Carolina, Dept Biochem & Mol Biol, Charleston, SC 29425 USA. [Russo, Sarah; Cowart, L. Ashley] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC 29425 USA. [Jadhav, Shyamalagauri] NIDDK, NIH, Bethesda, MD 20892 USA. RP Greenberg, ML (reprint author), Wayne State Univ, Dept Biol Sci, Detroit, MI 48202 USA. EM mgreenberg@wayne.edu FU National Institutes of Health [DK081367]; Graduate School of Wayne State University FX This work was supported, in whole or in part, by National Institutes of Health Grant DK081367 (to M. L. G.), and support from the Graduate School of Wayne State University (to S. J.). The authors declare that they have no conflicts of interest with the contents of this article. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 25 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC BIOCHEMISTRY MOLECULAR BIOLOGY INC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3996 USA SN 0021-9258 EI 1083-351X J9 J BIOL CHEM JI J. Biol. Chem. PD MAR 24 PY 2017 VL 292 IS 12 BP 4953 EP 4959 DI 10.1074/jbc.M117.775460 PG 7 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA EP7XL UT WOS:000397590400017 PM 28100786 ER PT J AU Kang, SL Li, QJ Chen, Q Zhou, YG Park, S Lee, G Grimes, B Krysan, K Yu, M Wang, W Alber, F Sun, FZ Dubinett, SM Li, WY Zhou, XHJ AF Kang, Shuli Li, Qingjiao Chen, Quan Zhou, Yonggang Park, Stacy Lee, Gina Grimes, Brandon Krysan, Kostyantyn Yu, Min Wang, Wei Alber, Frank Sun, Fengzhu Dubinett, Steven M. Li, Wenyuan Zhou, Xianghong Jasmine TI CancerLocator: non-invasive cancer diagnosis and tissue-of-origin prediction using methylation profiles of cell-free DNA SO GENOME BIOLOGY LA English DT Article DE Cell-free DNA; Liquid biopsy; DNA methylation; Next-generation sequencing; Cancer diagnosis ID COPY NUMBER ABERRATIONS; PLASMA DNA; COLORECTAL-CANCER; HYPOMETHYLATION; CLASSIFIERS; BIOMARKERS; CARCINOMA; PATTERNS AB We propose a probabilistic method, CancerLocator, which exploits the diagnostic potential of cell-free DNA by determining not only the presence but also the location of tumors. CancerLocator simultaneously infers the proportions and the tissue-of-origin of tumor-derived cell-free DNA in a blood sample using genome-wide DNA methylation data. CancerLocator outperforms two established multi-class classification methods on simulations and real data, even with the low proportion of tumor-derived DNA in the cell-free DNA scenarios. CancerLocator also achieves promising results on patient plasma samples with low DNA methylation sequencing coverage. C1 [Kang, Shuli; Li, Qingjiao; Chen, Quan; Alber, Frank; Sun, Fengzhu] Univ Southern Calif, Mol & Computat Biol, Los Angeles, CA 90089 USA. [Zhou, Yonggang; Dubinett, Steven M.; Li, Wenyuan; Zhou, Xianghong Jasmine] Univ Calif Los Angeles, Dept Pathol & Lab Med, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Zhou, Yonggang; Zhou, Xianghong Jasmine] Univ Calif Los Angeles, Inst Quantitat & Computat Biosci, Los Angeles, CA 90095 USA. [Park, Stacy; Grimes, Brandon; Krysan, Kostyantyn] Univ Calif Los Angeles, David Geffen Sch Med, Div Pulm Crit Care Med Clin Immunol & Allergy, Los Angeles, CA 90095 USA. [Lee, Gina] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Yu, Min] Univ Southern Calif, Dept Stem Cell Biol & Regenerat Med, Los Angeles, CA 90033 USA. [Yu, Min] Univ Southern Calif, Norris Comprehens Canc Ctr, Los Angeles, CA 90033 USA. [Wang, Wei] Zhejiang Prov Tongde Hosp, Clin Lab, Hangzhou, Zhejiang, Peoples R China. [Dubinett, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA. [Dubinett, Steven M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Dubinett, Steven M.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. RP Dubinett, SM; Li, WY; Zhou, XHJ (reprint author), Univ Calif Los Angeles, Dept Pathol & Lab Med, David Geffen Sch Med, Los Angeles, CA 90095 USA.; Zhou, XHJ (reprint author), Univ Calif Los Angeles, Inst Quantitat & Computat Biosci, Los Angeles, CA 90095 USA.; Dubinett, SM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Mol & Med Pharmacol, Los Angeles, CA 90095 USA.; Dubinett, SM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA.; Dubinett, SM (reprint author), Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90095 USA. EM sdubinett@mednet.ucla.edu; WenyuanLi@mednet.ucla.edu; XJZhou@mednet.ucla.edu RI Sun, Fengzhu /G-4373-2010 FU NHLBI MAPGEN [U01HL108634]; NIH/NCI [1U01CA214182-01, 1U01CA196408-01]; National Institutes of Health (NIH) [NHLBI MAPGEN] [U01HL108634] FX This work was supported by the NHLBI MAPGEN U01HL108634 grant to X.J.Z., the NIH/NCI 1U01CA214182-01 and the NIH/NCI 1U01CA196408-01 to S.M.D. Funding for open access charge: National Institutes of Health (NIH) [NHLBI MAPGEN U01HL108634 to X.J.Z.]. The authors greatly acknowledge Dr. Yuk Ming Dennis Lo and his circulating nucleic acids research group in the Chinese University of Hong Kong for his cfDNA data [19, 21]. We also thank Wing Hung Wong for his constructive input for the manuscript. NR 29 TC 0 Z9 0 U1 4 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1474-760X J9 GENOME BIOL JI Genome Biol. PD MAR 24 PY 2017 VL 18 AR 53 DI 10.1186/s13059-017-1191-5 PG 12 WC Biotechnology & Applied Microbiology; Genetics & Heredity SC Biotechnology & Applied Microbiology; Genetics & Heredity GA EP0ZI UT WOS:000397114800001 PM 28335812 ER PT J AU Poewe, W Seppi, K Tanner, CM Halliday, GM Brundin, P Volkmann, J Schrag, AE Lang, AE AF Poewe, Werner Seppi, Klaus Tanner, Caroline M. Halliday, Glenda M. Brundin, Patrik Volkmann, Jens Schrag, Anette-Eleonore Lang, Anthony E. TI Parkinson disease SO NATURE REVIEWS DISEASE PRIMERS LA English DT Article ID DEEP-BRAIN-STIMULATION; CHAPERONE-MEDIATED AUTOPHAGY; QUALITY-OF-LIFE; RANDOMIZED CONTROLLED-TRIAL; SLEEP BEHAVIOR DISORDER; MDS RESEARCH CRITERIA; INCIDENTAL LEWY BODY; CELL-BASED THERAPIES; ALPHA-SYNUCLEIN; DOPAMINE NEURONS AB Parkinson disease is the second-most common neurodegenerative disorder that affects 2-3% of the population >= 65 years of age. Neuronal loss in the substantia nigra, which causes striatal dopamine deficiency, and intracellular inclusions containing aggregates of a-synuclein are the neuropathological hallmarks of Parkinson disease. Multiple other cell types throughout the central and peripheral autonomic nervous system are also involved, probably from early disease onwards. Although clinical diagnosis relies on the presence of bradykinesia and other cardinal motor features, Parkinson disease is associated with many non-motor symptoms that add to overall disability. The underlying molecular pathogenesis involves multiple pathways and mechanisms: a-synuclein proteostasis, mitochondrial function, oxidative stress, calcium homeostasis, axonal transport and neuroinflammation. Recent research into diagnostic biomarkers has taken advantage of neuroimaging in which several modalities, including PET, single-photon emission CT (SPECT) and novel MRI techniques, have been shown to aid early and differential diagnosis. Treatment of Parkinson disease is anchored on pharmacological substitution of striatal dopamine, in addition to non-dopaminergic approaches to address both motor and non-motor symptoms and deep brain stimulation for those developing intractable l-DOPA-related motor complications. Experimental therapies have tried to restore striatal dopamine by gene-based and cell-based approaches, and most recently, aggregation and cellular transport of a-synuclein have become therapeutic targets. One of the greatest current challenges is to identify markers for prodromal disease stages, which would allow novel disease-modifying therapies to be started earlier. C1 [Poewe, Werner; Seppi, Klaus] Med Univ Innsbruck, Dept Neurol, Anichstr 35, A-6020 Innsbruck, Austria. [Tanner, Caroline M.] San Francisco VA Med Ctr, Parkinsons Dis Res Educ & Clin, San Francisco, CA USA. [Tanner, Caroline M.] Univ Calif San Francisco, Dept Neurol, San Francisco, CA USA. [Halliday, Glenda M.] Univ Sydney, Sydney Med Sch, Brain & Mind Ctr, Sydney, NSW, Australia. [Halliday, Glenda M.] Univ New South Wales, Fac Med, Sydney, NSW, Australia. [Halliday, Glenda M.] Neurosci Res Australia, Sydney, NSW, Australia. [Brundin, Patrik] Van Andel Res Inst, Ctr Neurodegenerat Sci, Grand Rapids, MI USA. [Volkmann, Jens] Univ Hosp Wurzburg, Dept Neurol, Wurzburg, Germany. [Schrag, Anette-Eleonore] UCL Inst Neurol, Dept Clin Neurosci, London, England. [Lang, Anthony E.] Univ Toronto, Dept Med, Div Neurol, Toronto, ON, Canada. RP Poewe, W (reprint author), Med Univ Innsbruck, Dept Neurol, Anichstr 35, A-6020 Innsbruck, Austria. EM werner.poewe@i-med.ac.at FU AbbVie; Allergan; AstraZeneca; BIAL; Boehringer-Ingelheim; Boston Scientific; GlaxoSmithKline; Ipsen; Lundbeck; Medtronic; MSD; Merck-Serono; Merz Pharmaceuticals; Neuroderm; Novartis; Orion Pharma; Teva; UCB; Zambon; Roche; AOP Orphan Pharmaceuticals AG; Ultragenyx Pharmaceuticals; Neurocrine Biosciences; Cynapsus; Therapeutics; Sage Bionetworks; Adamas; American Academy of Neurology; Bionomics; Renovo Neural; Versant Ventures/Apollo; IOS Press Partners; Parkinson's UK; GE Healthcare; International Parkinson and Movement Disorder Society; Grunenthal; Oxford University Press; Acorda; Avanir Pharmaceuticals; Bristol-Myers Squibb; Cipla; Intekrin; Sun Pharma; Medichem; Merck FX W.P. reports personal fees from AbbVie, Allergan, AstraZeneca, BIAL, Boehringer-Ingelheim, Boston Scientific, GlaxoSmithKline, Ipsen, Lundbeck, Medtronic, MSD, Merck-Serono, Merz Pharmaceuticals, Neuroderm, Novartis, Orion Pharma, Teva, UCB and Zambon (consultancy and lecture fees in relation to clinical drug development programmes for Parkinson disease) and publishing royalties from Thieme, Wiley-Blackwell, Oxford University Press and Cambridge University Press. K.S. reports personal fees from Boehringer-Ingelheim, UCB, Lundbeck, AbbVie, Roche, Teva and AOP Orphan Pharmaceuticals AG. C.M.T. has received compensation for serving on Data Monitoring Committees from Biotie Therapeutics, Voyager Therapeutics and Intec Pharma and personal fees for consulting services from Ultragenyx Pharmaceuticals, Neurocrine Biosciences, Cynapsus, Therapeutics, Sage Bionetworks and Adamas. G.M.H. has received compensation for serving on data monitoring committees from Biotie Therapeutics, Voyager Therapeutics and Intec Pharma, and personal fees from the American Academy of Neurology, Bionomics and Lundbeck. P.B. has received commercial support as a consultant from Renovo Neural, Roche, Teva, Lundbeck, AbbVie, Neuroderm, Versant Ventures/Apollo and IOS Press Partners. J.V. reports personal fees from Boston Scientific, Medtronic, Bial, Allergan, Zambon (consultancy and lecture fees in relation to clinical therapeutic development programmes for Parkinson disease) and grants from Boston Scientific and Medtronic. A.-E.S. reports grants from, Parkinson's UK, GE Healthcare, International Parkinson and Movement Disorder Society, shares from AstraZeneca, and personal fees from Grunenthal, Medtronic and Oxford University Press. A.E.L. reports personal fees from AbbVie, Acorda, Avanir Pharmaceuticals, Bristol-Myers Squibb, Cipla, Intekrin, Sun Pharma, Medichem, Medtronic, Teva, UCB and Merck, and publishing royalties from Saunders, Wiley-Blackwell, Johns Hopkins Press and Cambridge University Press. NR 241 TC 0 Z9 0 U1 19 U2 19 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2056-676X J9 NAT REV DIS PRIMERS JI Nat. Rev. Dis. Primers PD MAR 23 PY 2017 VL 3 AR 17013 DI 10.1038/nrdp.2017.13 PG 21 WC Medicine, General & Internal SC General & Internal Medicine GA EQ2JS UT WOS:000397895800001 PM 28332488 ER PT J AU Singh, JA Cleveland, J AF Singh, Jasvinder A. Cleveland, John TI Allopurinol and the risk of ventricular arrhythmias in the elderly: a study using US Medicare data SO BMC MEDICINE LA English DT Article DE Allopurinol; Ventricular arrhythmias; Risk factor; Elderly; Medicare ID XANTHINE-OXIDASE INHIBITION; SUDDEN CARDIAC DEATH; REPERFUSION-INDUCED ARRHYTHMIAS; ACUTE MYOCARDIAL-INFARCTION; CORONARY-ARTERY-DISEASE; ATRIAL-FIBRILLATION; CARDIOVASCULAR-DISEASE; HEART-DISEASE; RACIAL-DIFFERENCES; BLOOD-PRESSURE AB Background: There are no published human studies investigating whether the use of allopurinol, the most commonly used medication for the treatment of hyperuricemia in gout, the most common type of inflammatory arthritis in adults, has any beneficial effects on ventricular electrophysiology. The objective of our study was to assess whether allopurinol use is associated with a reduction in the risk of ventricular arrhythmias (VA). Methods: We used the 5% random sample of Medicare beneficiaries from 2006-2012 to examine new allopurinol use and the risk of incident VA. Multivariable Cox regression analyses were adjusted for demographics (age, race, sex), comorbidity, cardiac medications, and conditions associated with VA. We calculated hazard ratios (HR) and 95% confidence intervals (CI). Results: Of the 28,755 episodes of new allopurinol use, 2538 were associated with incident VA (8.8%). Among patients with incident VA, 54% were male, 78% were White, 75% had gout as the underlying diagnosis, and the mean Charlson-Romano comorbidity score was 4.8. The crude incidence of VA per 1,000,000 person-days declined as the duration of allopurinol use increased: 1-180 days, 151; 181 days to 2 years, 105; and > 2 years, 85. In multivariableadjusted analyses, compared to non-use, allopurinol use was associated with lower HR of VA of 0.82 (95% CI, 0.76-0.90). Compared to allopurinol non-use, longer allopurinol use durations were significantly associated with lower multivariable-adjusted HR for VA: 1-180 days, 0.96 (95% CI, 0.85-1.08); 181 days to 2 years, 0.76 (95% CI, 0.68-0.85); and > 2 years, 0.72 (95% CI, 0.60-0.87). Multiple sensitivity analyses adjusting for cardiac conditions, anti-arrhythmic drugs and alternate definitions confirmed our findings with minimal/no attenuation of estimates. Conclusion: Allopurinol use and use duration of more than 6 months were independently associated with a lower risk of VA. Future studies need to assess the pathophysiology of this potential benefit. C1 [Singh, Jasvinder A.] Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA. [Singh, Jasvinder A.; Cleveland, John] UAB, Sch Med, Dept Med, Birmingham, AL 35294 USA. [Singh, Jasvinder A.; Cleveland, John] UAB, Div Epidemiol, Sch Publ Hlth, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Mayo Clin, Coll Med, Dept Orthoped Surg, Rochester, MN USA. [Singh, Jasvinder A.; Cleveland, John] Univ Alabama Birmingham, Fac Off Tower 805B,510 20th St S, Birmingham, AL 35294 USA. RP Singh, JA (reprint author), Birmingham VA Med Ctr, Med Serv, Birmingham, AL 35233 USA.; Singh, JA (reprint author), UAB, Sch Med, Dept Med, Birmingham, AL 35294 USA.; Singh, JA (reprint author), UAB, Div Epidemiol, Sch Publ Hlth, Birmingham, AL 35294 USA. EM jasvinder.md@gmail.com FU UAB Division of Rheumatology FX This material is the result of work supported by research funds from the UAB Division of Rheumatology and the resources and use of facilities at the Birmingham VA Medical Center. Role of Funding Agencies: The funding agencies played no role in study design, collection, analysis, interpretation of data, writing of the manuscript, or in the decision to submit the paper for publication. They accept no responsibility for the contents. NR 54 TC 0 Z9 0 U1 0 U2 0 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1741-7015 J9 BMC MED JI BMC Med. PD MAR 22 PY 2017 VL 15 AR 59 DI 10.1186/s12916-017-0816-6 PG 11 WC Medicine, General & Internal SC General & Internal Medicine GA EP9FA UT WOS:000397678300001 PM 28327188 ER PT J AU Rymer, J Kaltenbach, L Doll, J Messenger, J Peterson, E Wang, T AF Rymer, Jennifer Kaltenbach, Lisa Doll, Jacob Messenger, John Peterson, Eric Wang, Tracy TI BLEEDING AND PREMATURE ANTIPLATELET THERAPY DISCONTINUATION AFTER MYOCARDIAL INFARCTION AMONG PATIENTS WITH CHRONIC KIDNEY DISEASE SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 66th Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC) CY MAR 17-19, 2017 CL Washington, DC SP Amer Coll Cardiol C1 Duke Univ, Durham, NC USA. VA Puget Sound Hlth Care Syst, Seattle, WA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 21 PY 2017 VL 69 IS 11 SU S MA 1296-308 BP 262 EP 262 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EP4HT UT WOS:000397342300263 ER PT J AU Warner, AL Ghaznavi, Z Lu, LY Jackevicius, C AF Warner, Alberta L. Ghaznavi, Zunera Lu, Lingyun Jackevicius, Cynthia TI SAFETY OF ALPHA BLOCKERS IN PATIENTS WITH HEART FAILURE SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 66th Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC) CY MAR 17-19, 2017 CL Washington, DC SP Amer Coll Cardiol C1 VA Greater Los Angeles, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 21 PY 2017 VL 69 IS 11 SU S MA 1216M-05 BP 683 EP 683 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EP4HT UT WOS:000397342301205 ER PT J AU Chirinos, JA Zamani, P Hashmath, Z Reddy, M Syed, KAA Bhattacharya, P Chahwala, J Oldland, HG Miller, R Kewan, U Varakantam, S Tariq, A Phan, TS Akers, S AF Chirinos, Julio A. Zamani, Payman Hashmath, Zeba Reddy, Maheshwara Syed, Koppula Amer Ahmed Bhattacharya, Priyanka Chahwala, Jugal Oldland, Harry G. Miller, Rachana Kewan, Uzma Varakantam, Swapna Tariq, Ali Phan, Timothy S. Akers, Scott TI EFFECT OF DIABETES MELLITUS ON PULSATILE ARTERIAL LOAD AND HEMODYNAMICS IN HFPEF SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 66th Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC) CY MAR 17-19, 2017 CL Washington, DC SP Amer Coll Cardiol C1 Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. Philadelphia VA Med Ctr, Philadelphia, PA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 21 PY 2017 VL 69 IS 11 SU S MA 1250-275 BP 888 EP 888 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EP4HT UT WOS:000397342301410 ER PT J AU Lu, LY Warner, A Ghaznavi, Z Chang, D Tubert, N Jackevicius, C AF Lu, Lingyun Warner, Alberta Ghaznavi, Zunera Chang, Donald Tubert, Nikolas Jackevicius, Cynthia TI BLEEDING RISK OF DIRECT ORAL ANTICOAGULANTS COMPARED WITH WARFARIN IN PATIENTS WITH ATRIAL FIBRILLATION AND HEART FAILURE SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 66th Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC) CY MAR 17-19, 2017 CL Washington, DC SP Amer Coll Cardiol C1 Calif Northstate Univ, Coll Pharm, Elk Grove, CA USA. VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 21 PY 2017 VL 69 IS 11 SU S MA 1250-287 BP 900 EP 900 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EP4HT UT WOS:000397342301422 ER PT J AU Armstrong, EJ Stanislawski, M Plomondon, M Banerjee, S Waldo, S AF Armstrong, Ehrin J. Stanislawski, Maggie Plomondon, Meg Banerjee, Subhash Waldo, Stephen TI CORONARY ATHERECTOMY FOR TREATMENT OF CALCIFIED CORONARY ARTERY LESIONS IS ASSOCIATED WITH INCREASED PROCEDURAL SUCCESS AND LOWER PROCEDURAL COMPLICATION RATES: INSIGHTS FROM A NATIONAL VETERAN COHORT SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 66th Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC) CY MAR 17-19, 2017 CL Washington, DC SP Amer Coll Cardiol C1 [Armstrong, Ehrin J.; Stanislawski, Maggie; Plomondon, Meg; Banerjee, Subhash; Waldo, Stephen] Denver VA Med Ctr, Denver, CO USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 21 PY 2017 VL 69 IS 11 SU S MA 1155-153 BP 1112 EP 1112 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EP4HT UT WOS:000397342301634 ER PT J AU Garg, V Rezvani, B Bersohn, M Benharash, P Han, J AF Garg, Vinisha Rezvani, Brian Bersohn, Malcolm Benharash, Peyman Han, Janet TI MYOCARDIAL FRAGILITY IN EHLERS DANLOS SYNDROME SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Meeting Abstract CT 66th Annual Scientific Session and Expo of the American-College-of-Cardiology (ACC) CY MAR 17-19, 2017 CL Washington, DC SP Amer Coll Cardiol C1 VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. Univ Calif Los Angeles, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 21 PY 2017 VL 69 IS 11 SU S MA 1206-420 BP 2332 EP 2332 PG 1 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EP4HT UT WOS:000397342303254 ER PT J AU Galatzer-Levy, IR Ma, S Statnikov, A Yehuda, R Shalev, AY AF Galatzer-Levy, I. R. Ma, S. Statnikov, A. Yehuda, R. Shalev, A. Y. TI Utilization of machine learning for prediction of post-traumatic stress: a re-examination of cortisol in the prediction and pathways to non-remitting PTSD SO TRANSLATIONAL PSYCHIATRY LA English DT Article ID MARKOV BLANKET INDUCTION; CIVILIAN TRAUMA VICTIMS; FEATURE-SELECTION; CAUSAL DISCOVERY; LOCAL CAUSAL; PART II; DISORDER; TRAJECTORIES; FKBP5; RESILIENCE AB To date, studies of biological risk factors have revealed inconsistent relationships with subsequent post-traumatic stress disorder (PTSD). The inconsistent signal may reflect the use of data analytic tools that are ill equipped for modeling the complex interactions between biological and environmental factors that underlay post-traumatic psychopathology. Further, using symptom-based diagnostic status as the group outcome overlooks the inherent heterogeneity of PTSD, potentially contributing to failures to replicate. To examine the potential yield of novel analytic tools, we reanalyzed data from a large longitudinal study of individuals identified following trauma in the general emergency room (ER) that failed to find a linear association between cortisol response to traumatic events and subsequent PTSD. First, latent growth mixture modeling empirically identified trajectories of post-traumatic symptoms, which then were used as the study outcome. Next, support vector machines with feature selection identified sets of features with stable predictive accuracy and built robust classifiers of trajectory membership (area under the receiver operator characteristic curve (AUC) = 0.82 (95% confidence interval (CI) = 0.80-0.85)) that combined clinical, neuroendocrine, psychophysiological and demographic information. Finally, graph induction algorithms revealed a unique path from childhood trauma via lower cortisol during ER admission, to non-remitting PTSD. Traditional general linear modeling methods then confirmed the newly revealed association, thereby delineating a specific target population for early endocrine interventions. Advanced computational approaches offer innovative ways for uncovering clinically significant, non-shared biological signals in heterogeneous samples. C1 [Galatzer-Levy, I. R.; Shalev, A. Y.] NYU, Sch Med, Dept Psychiat, 1 Pk Ave, New York, NY 10016 USA. [Galatzer-Levy, I. R.; Shalev, A. Y.] Steven & Alexandra Cohen Ctr Study Posttraumat St, New York, NY USA. [Ma, S.] Univ Minnesota, Dept Med, Minneapolis, MN USA. [Statnikov, A.] New York Univ, Sch Med, Dept Med, New York, NY USA. [Yehuda, R.] James J Peters VA Med Ctr, Mt Sinai Sch Med, Traumat Stress Studies Div, Bronx, NY USA. RP Galatzer-Levy, IR (reprint author), NYU, Sch Med, Dept Psychiat, 1 Pk Ave, New York, NY 10016 USA. EM Isaac.Galatzer-Levy@nyumc.org OI Galatzer-Levy, Isaac/0000-0003-1864-064X FU PHS Research [MH 50379]; NIMH [K01MH102415] FX The study was supported by PHS Research grant no. MH 50379 to Dr Shalev and an NIMH K01MH102415 to Dr Galatzer-Levy. NR 47 TC 0 Z9 0 U1 5 U2 5 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 2158-3188 J9 TRANSL PSYCHIAT JI Transl. Psychiatr. PD MAR 21 PY 2017 VL 7 AR e1070 DI 10.1038/tp.2017.38 PG 8 WC Psychiatry SC Psychiatry GA EP2RB UT WOS:000397229800007 ER PT J AU Konstam, MA Kiernan, M Chandler, A Dhingra, R Mody, FV Eisen, H Haught, WH Wagoner, L Gupta, D Patten, R Gordon, P Korr, K Fileccia, R Pressler, SJ Gregory, D Wedge, P Dowling, D Romeling, M Konstam, JM Massaro, JM Udelson, JE AF Konstam, Marvin A. Kiernan, Michael Chandler, Arthur Dhingra, Ravi Mody, Freny Vaghaiwalla Eisen, Howard Haught, W. Herbert Wagoner, Lynne Gupta, Divya Patten, Richard Gordon, Paul Korr, Kenneth Fileccia, Russell Pressler, Susan J. Gregory, Douglas Wedge, Patricia Dowling, Douglas Romeling, Matthew Konstam, Jeremy M. Massaro, Joseph M. Udelson, James E. CA SECRET CHF Investigators TI Short-Term Effects of Tolvaptan in Patients With Acute Heart Failure and Volume Overload SO JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY LA English DT Article DE clinical trials; diuresis; dyspnea; jugular venous pressure; vasopressin antagonism ID WORSENING RENAL-FUNCTION; VASOPRESSIN ANTAGONIST; CONTROLLED-TRIAL; CLINICAL-COURSE; ORAL TOLVAPTAN; OUTCOMES; DECONGESTION; DYSFUNCTION; CHF AB BACKGROUND In patients with acute heart failure (AHF), dyspnea relief is the most immediate goal. Renal dysfunction, diuretic resistance, and hyponatremia represent treatment impediments. OBJECTIVES It was hypothesized that the addition of tolvaptan to a background diuretic improved dyspnea early in patients selected for an enhanced vasopressin antagonism response. METHODS In a double-blind trial, patients were randomized to tolvaptan 30 mg/day or placebo. Study entry required hospitalization within the previous 36 h, active dyspnea, and any of the following: 1) estimated glomerular filtration rate <60 ml/min/1.73 m(2); 2) hyponatremia; or 3) diuretic resistance (urine output <= 125 ml/h following intravenous furosemide >= 40 mg). The primary endpoint was a 7-point change in self-assessed dyspnea at 8 and 16 h, using a novel standardized approach. RESULTS We randomized 250 patients. There was no difference in the primary endpoint of day 1 dyspnea reduction, despite significantly greater weight reduction with tolvaptan (-2.4 +/- 2.1 kg vs. -0.9 +/- 1.8 kg; p < 0.001). At day 3, dyspnea reduction was greater with tolvaptan (p = 0.01). There were 2 significant treatment-by-subgroup interactions: patients without elevated jugular venous pressure and those without ascites showed directional favorability of tolvaptan over placebo for the primary endpoint compared with patients with these findings. CONCLUSIONS Despite rapid and persistent weight loss with tolvaptan compared with placebo, in patients with AHF who were selected for greater potential benefit from vasopressin receptor inhibition, tolvaptan was not associated with greater early improvement in dyspnea. Apparent subsequent differences in dyspnea warrant further exploration of the temporal relationship between diuresis and dyspnea relief and a possible clinical role for tolvaptan. (Randomized, Double-Blind, Placebo Controlled Study of the Short Term Clinical Effects of Tolvaptan in Patients Hospitalized for Worsening Heart Failure With Challenging Volume Management [ SECRET of CHF]; NCT01584557) (J Am Coll Cardiol 2017; 69: 1409-19) (C) 2017 by the American College of Cardiology Foundation. C1 [Konstam, Marvin A.; Kiernan, Michael; Udelson, James E.] Tufts Med Ctr, Cardiovasc Ctr, Box 108,800 Washington St, Boston, MA 02111 USA. [Chandler, Arthur] Univ Cardiol Associates, Augusta, GA USA. [Dhingra, Ravi] Univ Wisconsin, Cardiovasc Div, Madison, WI USA. [Mody, Freny Vaghaiwalla] VA Greater Los Angeles, Div Cardiol, Los Angeles, CA USA. [Eisen, Howard] Drexel Univ, Div Cardiol, Philadelphia, PA 19104 USA. [Haught, W. Herbert] Heart Ctr Res, Huntsville, AL USA. [Wagoner, Lynne] Mercy Hosp, Inst Heart, Fairfield, OH USA. [Gupta, Divya] Emory Univ, Div Cardiol, Atlanta, GA 30322 USA. [Patten, Richard] Lahey Med Ctr, Cardiovasc Med, Burlington, MA USA. [Gordon, Paul; Korr, Kenneth] Miriam Hosp, Cardiovasc Inst, Providence, RI 02906 USA. [Fileccia, Russell] Adv Cardiovasc Specialists, Shreveport, LA USA. [Pressler, Susan J.] Indiana Univ, Sch Nursing, Ctr Enhancing Qual Life Chron Dis, Indianapolis, IN 46204 USA. [Gregory, Douglas; Wedge, Patricia; Dowling, Douglas; Romeling, Matthew; Konstam, Jeremy M.] Cardiovasc Clin Sci Fdn, Boston, MA USA. [Massaro, Joseph M.] Boston Univ, Sch Publ Hlth, Boston, MA USA. RP Konstam, MA (reprint author), Tufts Med Ctr, Cardiovasc Ctr, Box 108,800 Washington St, Boston, MA 02111 USA. EM mkonstam@tuftsmedicalcenter.org FU Otsuka Pharmaceuticals Co., Rockville, Maryland; Otsuka Pharmaceuticals; Otsuka FX This investigation was an investigator-initiated study funded by Otsuka Pharmaceuticals Co., Rockville, Maryland. Each of the authors and/or their organizations received support originating from Otsuka Pharmaceuticals to support this research. Dr. Gupta has received additional research support from Otsuka. Drs. M.A. Konstam and Wagoner have received honoraria from Otsuka. Randall Starling, MD, served as Guest Editor for this paper. NR 22 TC 1 Z9 1 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0735-1097 EI 1558-3597 J9 J AM COLL CARDIOL JI J. Am. Coll. Cardiol. PD MAR 21 PY 2017 VL 69 IS 11 BP 1409 EP 1419 DI 10.1016/j.jacc.2016.12.035 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EO0AU UT WOS:000396361500009 PM 28302292 ER PT J AU Low, CM Akthar, S Patel, DF Loser, S Wong, CT Jackson, PL Blalock, JE Hare, SA Lloyd, CM Snelgrove, RJ AF Low, Caroline M. Akthar, Samia Patel, Dhiren F. Loeser, Stephan Wong, Chi-Tung Jackson, Patricia L. Blalock, J. Edwin Hare, Stephen A. Lloyd, Clare M. Snelgrove, Robert J. TI The development of novel LTA(4)H modulators to selectively target LTB4 generation SO SCIENTIFIC REPORTS LA English DT Article ID LEUKOTRIENE A(4) HYDROLASE; OBSTRUCTIVE PULMONARY-DISEASE; PROLINE-GLYCINE-PROLINE; NEUTROPHILIC INFLAMMATION; AIRWAY INFLAMMATION; INHIBITOR; ENZYME; AMINOPEPTIDASE; DISCOVERY; EMPHYSEMA AB The pro-inflammatory mediator leukotriene B-4 (LTB4) is implicated in the pathologies of an array of diseases and thus represents an attractive therapeutic target. The enzyme leukotriene A(4) hydrolase (LTA(4)H) catalyses the distal step in LTB4 synthesis and hence inhibitors of this enzyme have been actively pursued. Despite potent LTA(4)H inhibitors entering clinical trials all have failed to show efficacy. We recently identified a secondary anti-inflammatory role for LTA(4)H in degrading the neutrophil chemoattractant Pro-Gly-Pro (PGP) and rationalized that the failure of conventional LTA(4)H inhibitors may be that they inadvertently prevented PGP degradation. We demonstrate that these inhibitors do indeed fail to discriminate between the dual activities of LTA(4)H, and enable PGP accumulation in mice. Accordingly, we have developed novel compounds that potently inhibit LTB4 generation whilst leaving PGP degradation unperturbed. These novel compounds could represent a safer and superior class of LTA(4)H inhibitors for translation into the clinic. C1 [Low, Caroline M.] Computat Drug Design Consultant, London SE21 8LS, England. [Akthar, Samia; Patel, Dhiren F.; Loeser, Stephan; Lloyd, Clare M.; Snelgrove, Robert J.] Imperial Coll London, Natl Heart & Lung Inst, Inflammat Repair & Dev, London SW7 2AZ, England. [Wong, Chi-Tung; Hare, Stephen A.] Imperial Coll London, Dept Life Sci, London SW7 2AZ, England. [Jackson, Patricia L.; Blalock, J. Edwin] Univ Alabama Birmingham, Dept Med, Div Pulm Allergy & Crit Care Med, Birmingham, AL 35294 USA. [Jackson, Patricia L.] Birmingham VA Med Ctr, Birmingham, AL 35294 USA. RP Snelgrove, RJ (reprint author), Imperial Coll London, Natl Heart & Lung Inst, Inflammat Repair & Dev, London SW7 2AZ, England. EM robert.snelgrove@imperial.ac.uk FU Wellcome Trust Career Development Fellow [095707/Z/11/Z]; Asthma UK Innovations award [AUK-IG-2014-286]; Imperial College Biomedical Research Centre (BRC) Therapeutic Primer fund and MRC/Imperial College Confidence in Concept schemes; Wellcome Trust Senior Fellow in Basic Biomedical Sciences [086718/Z/08/Z]; MRC Career Development Fellow [G1100332]; National Heart, Lung and Blood Institute funds [HL077783, HL110950, HL114439, HL126596]; UAB Lung Health Center Pulmonary Proteomics Laboratory is funded through the UAB Health Service Foundation General Endowment Fund FX R.J.S. is a Wellcome Trust Career Development Fellow (095707/Z/11/Z) and is also funded through an Asthma UK Innovations award (AUK-IG-2014-286). Aspects of this work have been funded (through R.J.S.) by the Imperial College Biomedical Research Centre (BRC) Therapeutic Primer fund and MRC/Imperial College Confidence in Concept schemes. C.M.L. is a Wellcome Trust Senior Fellow in Basic Biomedical Sciences (086718/Z/08/Z). S.H. is an MRC Career Development Fellow (G1100332). The National Heart, Lung and Blood Institute funds J.E.B. (HL077783, HL110950, HL114439 and HL126596). The UAB Lung Health Center Pulmonary Proteomics Laboratory is funded through the UAB Health Service Foundation General Endowment Fund. We would like to thank Dr. Anna Caldwell and the Centre of Excellence for Mass Spectrometry at King's College London for the use of equipment and technical assistance, and the staff of beamline I02 at Diamond Light Source for facilitating X-ray crystallography studies. We would like to thank Jen Morton, Matt Tozer, David Leese, Stuart Cameron, Seb Hallworth and David Fengas (all Peakdale Molecular) for compound synthesis and ADMET studies. NR 47 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 2045-2322 J9 SCI REP-UK JI Sci Rep PD MAR 17 PY 2017 VL 7 AR 44449 DI 10.1038/srep44449 PG 13 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EO2PB UT WOS:000396537300001 PM 28303931 ER PT J AU Bramlet, M Olivieri, L Farooqi, K Ripley, B Coakley, M AF Bramlet, Matthew Olivieri, Laura Farooqi, Kanwal Ripley, Beth Coakley, Meghan TI Impact of Three-Dimensional Printing on the Study and Treatment of Congenital Heart Disease SO CIRCULATION RESEARCH LA English DT Article DE 3D printing; cardiac models; congenital heart disease; database; peer review; segmentation ID SIMULATION; MODELS AB Three-dimensional (3D) printing technology allows for the translation of a 2-dimensional medical imaging study into a physical replica of a patient's individual anatomy. 3D printed models can facilitate a deeper understanding of complex patient anatomy and can aid in presurgical decision-making.(1) Although there are 3D printing case reports in almost every subspecialty of medicine to date, the rate of adoption in the field of congenital heart disease (CHD) is particularly advanced.(2,3) This is due, in no small part, to the fact that the heart is a hollow organ, which makes it a perfect substrate for 3D printing. More importantly, medical decision-making in CHD is informed by assessment of the anatomic morphology of the heart because cardiac pathology is a direct manifestation of the underlying 3D structure. C1 [Bramlet, Matthew] Univ Illinois, Coll Med, Pediat Cardiol, 1306 N Berkeley Ave, Peoria, IL 61603 USA. [Bramlet, Matthew] Jump Trading Simulat & Educ Ctr, Adv Imaging & Modeling Initiat, 1306 N Berkeley Ave, Peoria, IL 61603 USA. [Olivieri, Laura] Childrens Natl Med Ctr, Div Cardiol, Washington, DC USA. [Farooqi, Kanwal] Univ Med & Dent New Jersey, Dept Pediat, Rutgers Div Pediat Cardiol, Newark, NJ USA. [Farooqi, Kanwal] Icahn Sch Med Mt Sinai, Dept Pediat, Div Pediat Cardiol, New York, NY USA. [Ripley, Beth] VA Puget Sound Hlth Care Syst, Radiol, Seattle, WA USA. [Ripley, Beth] Univ Washington, Sch Med, Seattle, WA USA. [Coakley, Meghan] NIAID, Bioinformat & Computat Biosci Branch, Off Cyber Infrastruct & Computat Biol, NIH, Bethesda, MD USA. RP Bramlet, M (reprint author), Univ Illinois, Coll Med, Pediat Cardiol, 1306 N Berkeley Ave, Peoria, IL 61603 USA.; Bramlet, M (reprint author), Jump Trading Simulat & Educ Ctr, Adv Imaging & Modeling Initiat, 1306 N Berkeley Ave, Peoria, IL 61603 USA. EM Matthew.T.Bramlet@osfhealthcare.org FU National Institutes of Allergy and Infectious Diseases [GS35F0373X]; US Department of Health and Human Services through HHS Ignite program; US Department of Health and Human Services through HHS Ventures program FX The National Institutes of Health (NIH) 3D Print Exchange is operated by the Office of Cyber Infrastructure and Computational Biology, National Institute of Allergy and Infectious Diseases, National Institutes of Health. Resources are provided in part through BCBB Support Services Contract [GS35F0373X], funded by the National Institutes of Allergy and Infectious Diseases. Initial funding for the 3D Print Exchange was supplemented by the US Department of Health and Human Services through the HHS Ignite and HHS Ventures programs. NR 16 TC 0 Z9 0 U1 2 U2 2 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0009-7330 EI 1524-4571 J9 CIRC RES JI Circ.Res. PD MAR 17 PY 2017 VL 120 IS 6 BP 904 EP 907 DI 10.1161/CIRCRESAHA.116.310546 PG 4 WC Cardiac & Cardiovascular Systems; Hematology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Hematology GA EP4DL UT WOS:000397330700004 PM 28302738 ER PT J AU Wu, MD Atkinson, TM Lindner, JR AF Wu, Melinda D. Atkinson, Tamara M. Lindner, Jonathan R. TI Platelets and von Willebrand factor in atherogenesis SO BLOOD LA English DT Article ID PROTEIN DISULFIDE-ISOMERASE; HIGH-DENSITY-LIPOPROTEIN; ENDOTHELIAL-CELLS; GLYCOPROTEIN IB; P-SELECTIN; CORONARY ATHEROSCLEROSIS; VASCULAR INFLAMMATION; THROMBUS FORMATION; YOUNG-PATIENTS; IX COMPLEX AB The role of platelet adhesion, activation, and aggregation in acute atherothrombotic events such as myocardial infarction and strokeis wellestablished. Thereis increasing evidence that platelet-endothelial interactions also contribute to early atherosclerotic plaque initiation and growth. Through these interactions, platelet-derived factors can contribute to the proinflammatory and mitogenic status of resident mural cells. Among the many putative mechanisms for platelet-endothelial interactions, increased endothelial-associated von Willebrand factor, particularly in a multimerized form, which interacts with platelet glycoproteins and integrins, is a major factor and represents a therapeutic target in early atherogenesis. C1 [Wu, Melinda D.; Atkinson, Tamara M.; Lindner, Jonathan R.] Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. [Wu, Melinda D.; Atkinson, Tamara M.; Lindner, Jonathan R.] Oregon Hlth & Sci Univ, Dept Pediat, 3181 Sw Sam Jackson Pk Rd, Portland, OR 97201 USA. [Atkinson, Tamara M.] Portland VA Med Ctr, Portland, OR USA. [Lindner, Jonathan R.] Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Portland, OR 97201 USA. RP Lindner, JR (reprint author), Oregon Hlth & Sci Univ, Knight Cardiovasc Inst, 3181 SW Sam Jackson Pk Rd, Portland, OR 97239 USA. EM lindnerj@ohsu.edu FU National Heart, Lung, and Blood Institute of the National Institutes of Health [R01-HL078610, R01-HL111969, R01-HL120046, T32-HL094294, K08-HL133493]; National Space Biomedical Research Institute [14-14NSBRI10025] FX This work was supported by grants R01-HL078610, R01-HL111969, and R01-HL120046 (J.R.L.), T32-HL094294 (M.D.W. and T.M.A.), and K08-HL133493 (M.D.W.) from the National Heart, Lung, and Blood Institute of the National Institutes of Health, and 14-14NSBRI10025 from the National Space Biomedical Research Institute (J.R.L.). NR 84 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC HEMATOLOGY PI WASHINGTON PA 2021 L ST NW, SUITE 900, WASHINGTON, DC 20036 USA SN 0006-4971 EI 1528-0020 J9 BLOOD JI Blood PD MAR 16 PY 2017 VL 129 IS 11 BP 1415 EP 1419 DI 10.1182/blood-2016-07-692673 PG 5 WC Hematology SC Hematology GA EP3PR UT WOS:000397294700009 PM 28174163 ER PT J AU Tan, Y Richards, D Coyle, RC Yao, JN Xu, RY Gou, WY Wang, HJ Menick, DR Tian, BZ Mei, Y AF Tan, Yu Richards, Dylan Coyle, Robert C. Yao, Jenny Xu, Ruoyu Gou, Wenyu Wang, Hongjun Menick, Donald R. Tian, Bozhi Mei, Ying TI Cell number per spheroid and electrical conductivity of nanowires influence the function of silicon nanowired human cardiac spheroids SO ACTA BIOMATERIALIA LA English DT Article DE Human induced pluripotent stem cell-; derived cardiomyocytes; Spheroids; Silicon nanowires; Oxygen transport ID PLURIPOTENT STEM-CELLS; MYOCARDIAL-INFARCTION; OXYGEN-CONSUMPTION; RAT HEARTS; CARDIOMYOCYTES; TISSUE; TRANSPLANTATION; VIABILITY; BIOCOMPATIBILITY; VASCULARIZATION AB Human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) provide an unlimited cell source to treat cardiovascular diseases, the leading cause of death worldwide. However, current hiPSCCMs retain an immature phenotype that leads to difficulties for integration with adult myocardium after transplantation. To address this, we recently utilized electrically conductive silicon nanowires (e-SiNWs) to facilitate self-assembly of hiPSC-CMs to form nanowired hiPSC cardiac spheroids. Our previous results showed addition of e-SiNWs effectively enhanced the functions of the cardiac spheroids and improved the cellular maturation of hiPSC-CMs. Here, we examined two important factors that can affect functions of the nanowired hiPSC cardiac spheroids: (1) cell number per spheroid (i.e., size of the spheroids), and (2) the electrical conductivity of the e-SiNWs. To examine the first factor, we prepared hiPSC cardiac spheroids with four different sizes by varying cell number per spheroid (similar to-0.5k, similar to 1k, similar to 3k, similar to 7k cells/ spheroid). Spheroids with similar to 3k cells/spheroid was found to maximize the beneficial effects of the 3D spheroid microenvironment. This result was explained with a semi-quantitative theory that considers two competing factors: 1) the improved 3D cell-cell adhesion, and 2) the reduced oxygen supply to the center of spheroids with the increase of cell number. Also, the critical role of electrical conductivity of silicon nanowires has been confirmed in improving tissue function of hiPSC cardiac spheroids. These results lay down a solid foundation to develop suitable nanowired hiPSC cardiac spheroids as an innovative cell delivery system to treat cardiovascular diseases. Statement of Significance Cardiovascular disease is the leading cause of death and disability worldwide. Due to the limited regenerative capacity of adult human hearts, human induced pluripotent stem cell-derived cardiomyocytes (hiPSC-CMs) have received significant attention because they provide a patient specific cell source to regenerate damaged hearts. Despite the progress, current human hiPSC-CMs retain an immature phenotype that leads to difficulties for integration with adult myocardium after transplantation. To address this, we recently utilized electrically conductive silicon nanowires (e-SiNWs) to facilitate self-assembly of hiPSC-CMs to form nanowired hiPSC cardiac spheroids. Our previous results showed addition of eSiNWs effectively enhanced the functions of the cardiac spheroids and improved the cellular maturation of hiPSC-CMs. In this manuscript, we examined the effects of two important factors on the functions of nanowired hiPSC cardiac spheroids: (1) cell number per spheroid (i.e., size of the spheroids), and (2) the electrical conductivity of the e-SiNWs. The results from these studies will allow for the development of suitable nanowired hiPSC cardiac spheroids to effectively deliver hiPSC-CMs for heart repair. (c) 2017 Acta Materialia Inc. Published by Elsevier Ltd. All rights reserved. C1 [Tan, Yu; Richards, Dylan; Coyle, Robert C.; Mei, Ying] Clemson Univ, Bioengn Dept, Clemson, SC 29634 USA. [Yao, Jenny] Acad Magnet High Sch, N Charleston, SC 29405 USA. [Xu, Ruoyu; Tian, Bozhi] Univ Chicago, James Franck Inst, Dept Chem, Chicago, IL 60637 USA. [Xu, Ruoyu; Tian, Bozhi] Univ Chicago, Inst Biophys Dynam, Chicago, IL 60637 USA. [Gou, Wenyu; Wang, Hongjun] Med Univ South Carolina, Dept Surg, Charleston, SC 29425 USA. [Menick, Donald R.] Med Univ South Carolina, Ralph H Johnson Vet Affairs Med Ctr, Gazes Cardiac Res Inst, Dept Med,Div Cardiol, Charleston, SC 29425 USA. [Mei, Ying] Med Univ South Carolina, Dept Regenerat Med & Cell Biol, Charleston, SC 29425 USA. RP Mei, Y (reprint author), Clemson Univ, Bioengn Dept, Clemson, SC 29634 USA. EM mei@clemson.edu FU National Institutes of Health [8P20 GM103444, U54 GM104941]; Clemson University; National Science Foundation [NSF - EPS-0903795]; NIH [T32 HL007260]; US Department of Veterans Affairs Merit Review [I01 BX002327]; NIH-NIGMS [P30 GM103342] FX The work is supported by the National Institutes of Health (8P20 GM103444, U54 GM104941), the startup funds from Clemson University, the National Science Foundation (NSF - EPS-0903795), the NIH Cardiovascular Training Grant (T32 HL007260), and US Department of Veterans Affairs Merit Review (I01 BX002327). This study used the services of the Morphology, Imaging, and Instrumentation Core, which is supported by NIH-NIGMS P30 GM103342 to the South Carolina COBRE for Developmentally Based Cardiovascular Diseases. NR 49 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 1742-7061 EI 1878-7568 J9 ACTA BIOMATER JI Acta Biomater. PD MAR 15 PY 2017 VL 51 BP 495 EP 504 DI 10.1016/j.actbio.2017.01.029 PG 10 WC Engineering, Biomedical; Materials Science, Biomaterials SC Engineering; Materials Science GA EQ4AB UT WOS:000398014000039 PM 28087483 ER PT J AU Kallianos, K Henry, TS Yeghiazarians, Y Zimmet, J Shunk, KA Tseng, EE Mahadevan, V Hope, MD AF Kallianos, Kimberly Henry, Travis S. Yeghiazarians, Yerem Zimmet, Jeffrey Shunk, Kendrick A. Tseng, Elaine E. Mahadevan, Vaikom Hope, Michael D. TI Ferumoxytol MRA for transcatheter aortic valve replacement planning with renal insufficiency SO INTERNATIONAL JOURNAL OF CARDIOLOGY LA English DT Article ID CARDIOVASCULAR MAGNETIC-RESONANCE; ANGIOGRAPHY; ECHOCARDIOGRAPHY; REGURGITATION; IMPLANTATION; ACCURACY; CT AB Background: Computed tomography angiography (CTA) is the test of choice for pre-procedure imaging of trans-catheter aortic valve replacement (TAVR) candidates. The iodinated contrast required, however, increases the risk of renal dysfunction in patients with pre-existing renal failure. Ferumoxytol is a magnetic resonance imaging (MRI) contrast agent that can be used with renal failure. Its long vascular resonance time allows gated MRA sequences that approach CTA in image quality. We present respiratory and cardiac gated MRA enabled by ferumoxytol that can be post-processed in an analogous fashion to CTA. Methods: Seven patients with renal failure presenting for TAVR were imaged with respiratory and cardiac gated MRA at 3T using ferumoxtyol for contrast. Aortic annulus, root and peripheral access dimensions were calculated in a fashion identical to that used for CTA. Of these, 6 patients underwent a TAVR procedure and 5 had intraoperative valve assessment with transesophageal echocardiograph (TEE) using standard clinical protocols that employed both two-and three-dimensional techniques. Results: Good correlation between MRA aortic annulus measurements and those from TEE were shown in 5 patients with mean annulus area of 392.4 mm(2) (290-470 range) versus 374.1 mm(2) (285-440 range), with a pairwise correlation coefficient of 0.92, p = 0.029. All patients received Sapien valve implants (one 20 mm, three 23 mm, and two 26 mm valves). Access decisions were guided by MRA with no complications. Annulus sizing resulted in no greater than trace/mild aortic regurgitation in all patients. Conclusions: Ferumoxytol MRA is a safe alternative to CTA in patients with renal failure for pre-TAVR analysis of the aortic root and peripheral access. (C) 2016 Elsevier Ireland Ltd. All rights reserved. C1 [Kallianos, Kimberly; Henry, Travis S.; Hope, Michael D.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, 505 Parnassus Ave,Box 0628, San Francisco, CA 94143 USA. [Yeghiazarians, Yerem; Mahadevan, Vaikom] Univ Calif San Francisco, Dept Cardiol, San Francisco, CA 94143 USA. [Zimmet, Jeffrey; Shunk, Kendrick A.] San Francisco VA Med Ctr, Dept Cardiol, San Francisco, CA USA. [Tseng, Elaine E.] San Francisco VA Med Ctr, Dept Surg, San Francisco, CA USA. RP Hope, MD (reprint author), Univ Calif San Francisco, Dept Radiol & Biomed Imaging, 505 Parnassus Ave,Box 0628, San Francisco, CA 94143 USA. EM michael.hope@ucsf.edu FU NIH/NHLBI [R01 HL123759] FX This work was supported by NIH/NHLBI R01 HL123759. NR 11 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0167-5273 EI 1874-1754 J9 INT J CARDIOL JI Int. J. Cardiol. PD MAR 15 PY 2017 VL 231 BP 255 EP 257 DI 10.1016/j.ijcard.2016.12.147 PG 3 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EQ2NE UT WOS:000397905600046 PM 28100426 ER PT J AU Singh, JA Dowsey, M Choong, PF AF Singh, Jasvinder A. Dowsey, Michelle Choong, Peter F. TI Patient Endorsement of the Outcome Measures in Rheumatology (OMERACT) Total Joint Replacement (TJR) clinical trial draft core domain set SO BMC MUSCULOSKELETAL DISORDERS LA English DT Article ID TOTAL KNEE ARTHROPLASTY; TOTAL SHOULDER ARTHROPLASTY; TOTAL ELBOW ARTHROPLASTY; QUALITY-OF-LIFE; PAIN OUTCOMES; INPATIENT SAMPLE; FILTER 2.0; TOTAL HIP; ARTHRITIS; TRENDS AB Background: A patient- and surgeon-Delphi-derived Outcome Measures in Rheumatology (OMERACT) draft core domain set for total joint arthroplasty (TJR) trials was recently developed. Our objective was to obtain further patient stakeholder endorsement of draft core domain set for TJR clinical trials. Methods: We surveyed two patient groups: (1) OMERACT patient partners; and (2) patients who had undergone hip or knee TJR. Patients received an introductory email with explanations about the core domain set and instructions to rate the core domains, i.e., important aspects, of OMERACT TJR clinical trial draft core domain set. Rating was on a nominal scale, where 1-3 indicated a domain of limited importance, 4-6 an important, but not critical domain, and 7-9 a critical domain. We used Mann-Whitney test (a non-parametric test) to compare the distribution of ratings between the two groups. Results: Thirty one survey participants from the OMERACT patient partner group and 118 knee/hip TJR patients responded with response rates of 66 and 80%, respectively. Majority of the survey respondents were female, 87 vs. 53%, and were 55 years or older, 57 vs. 94%. Median (interquartile range [IQR]) scores for six core domains by OMERACT and knee/hip TJR patient groups were, respectively: pain, 8 [8, 9] and 9 [8, 9]; function, 9 [8, 9] and 9 [8, 9]; patient satisfaction, 8 [8, 9] and 8 [7, 9]; revision surgery, 7 [7, 8] and 7 [5, 9]; adverse events, 8 [7, 9] and 8 [6, 9]; and death, 9 [6, 9] and 9 [4, 9]. No statistically significant differences in rating were noted for any of the six core domains between the two groups (p >= 0.31). Among the additional domains, ratings for patient participation did not differ by group (p = 0.98), but ratings for cost were significantly different (p = 0.005). Patients provided qualitative feedback regarding core domains, and did not propose any modifications to the draft core domain set. Conclusions: Two separate patient stakeholder groups endorsed the OMERACT TJR draft core domain set for TJR trials. C1 [Singh, Jasvinder A.] Univ Alabama Birmingham, 510 20th St S,Fac Off Tower 805B, Birmingham, AL 35294 USA. [Singh, Jasvinder A.] Birmingham Vet Affairs Med Ctr, 700 19th St S, Birmingham, AL 35233 USA. [Dowsey, Michelle; Choong, Peter F.] Univ Melbourne, St Vincents Hosp, Dept Surg, Melbourne, Vic, Australia. RP Singh, JA (reprint author), Univ Alabama Birmingham, 510 20th St S,Fac Off Tower 805B, Birmingham, AL 35294 USA.; Singh, JA (reprint author), Birmingham Vet Affairs Med Ctr, 700 19th St S, Birmingham, AL 35233 USA. EM Jasvinder.md@gmail.com FU National Health & Medical Research Council Career Development Fellowship [APP1122526] FX A/Prof Dowsey holds a National Health & Medical Research Council Career Development Fellowship (APP1122526). We thank the patients for participating in this study. NR 31 TC 0 Z9 0 U1 1 U2 1 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2474 J9 BMC MUSCULOSKEL DIS JI BMC Musculoskelet. Disord. PD MAR 15 PY 2017 VL 18 AR 111 DI 10.1186/s12891-017-1464-x PG 6 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA EQ0LE UT WOS:000397761900001 PM 28298194 ER PT J AU Kyle, JE Casey, CP Stratton, KG Zink, EM Kim, YM Zheng, XY Monroe, ME Weitz, KK Bloodsworth, KJ Orton, DJ Ibrahim, YM Moore, RJ Lee, CG Pedersen, C Orwoll, E Smith, RD Burnum-Johnson, KE Baker, ES AF Kyle, Jennifer E. Casey, Cameron P. Stratton, Kelly G. Zink, Erika M. Kim, Young-Mo Zheng, Xueyun Monroe, Matthew E. Weitz, Karl K. Bloodsworth, Kent J. Orton, Daniel J. Ibrahim, Yehia M. Moore, Ronald J. Lee, Christine G. Pedersen, Catherine Orwoll, Eric Smith, Richard D. Burnum-Johnson, Kristin E. Baker, Erin S. TI Comparing identified and statistically significant lipids and polar metabolites in 15-year old serum and dried blood spot samples for longitudinal studies SO RAPID COMMUNICATIONS IN MASS SPECTROMETRY LA English DT Article ID MASS-SPECTROMETRY; FATTY-ACIDS; PROTEOMICS DATA; FILTER-PAPER; TERM STABILITY; ION MOBILITY; DEGREES-C; FRAGMENTATION; LIPOPROTEINS; METABOLOMICS AB RATIONALE: The use of dried blood spots (DBS) has many advantages over traditional plasma and serum samples such as the smaller blood volume required, storage at room temperature, and ability to sample in remote locations. However, understanding the robustness of different analytes in DBS samples is essential, especially in older samples collected for longitudinal studies. METHODS: Here we analyzed the stability of polar metabolites and lipids in DBS samples collected in 2000-2001 and stored at room temperature. The identified and statistically significant molecules were then compared to matched serum samples stored at-80 degrees C to determine if the DBS samples could be effectively used in a longitudinal study following metabolic disease. RESULTS: A total of 400 polar metabolites and lipids were identified in the serum and DBS samples using gas chromatograph/mass spectrometry (GC/MS), liquid chromatography (LC)/MS, and LC/ion mobility spectrometry-MS (LC/IMS-MS). The identified polar metabolites overlapped well between the sample types, though only one statistically significant metabolite was conserved in a case-control study of older diabetic males with low amounts of high-density lipoproteins and high body mass indices, triacylglycerides and glucose levels when compared to non-diabetic patients with normal levels, indicating that degradation in the DBS samples affects polar metabolite quantitation. Differences in the lipid identifications indicated that some oxidation occurs in the DBS samples. However, 36 statistically significant lipids correlated in both sample types. CONCLUSIONS: The difference in the number of statistically significant polar metabolites and lipids indicated that the lipids did not degrade to as great of a degree as the polar metabolites in the DBS samples and lipid quantitation was still possible. Copyright (c) 2016 John Wiley & Sons, Ltd. C1 [Kyle, Jennifer E.; Casey, Cameron P.; Zink, Erika M.; Kim, Young-Mo; Zheng, Xueyun; Monroe, Matthew E.; Weitz, Karl K.; Bloodsworth, Kent J.; Orton, Daniel J.; Ibrahim, Yehia M.; Moore, Ronald J.; Smith, Richard D.; Burnum-Johnson, Kristin E.; Baker, Erin S.] Pacific Northwest Natl Lab, Earth & Biol Sci Directorate, Richland, WA 99352 USA. [Stratton, Kelly G.] Pacific Northwest Natl Lab, Nat Secur Directorate, Richland, WA 99352 USA. [Lee, Christine G.; Pedersen, Catherine; Orwoll, Eric] Oregon Hlth & Sci Univ, Dept Med, Bone & Mineral Unit, Portland, OR 97201 USA. [Lee, Christine G.] Portland VA Med Ctr, Res Serv, Portland, OR USA. RP Burnum-Johnson, KE; Baker, ES (reprint author), 902 Battelle Blvd,POB 999,MSIN K8-98, Richland, WA 99352 USA. EM kristin.burnum-johnson@pnnl.gov; erin.baker@pnnl.gov RI Kim, Young-Mo/D-3282-2009; Smith, Richard/J-3664-2012 OI Kim, Young-Mo/0000-0002-8972-7593; Smith, Richard/0000-0002-2381-2349; Zheng, Xueyun/0000-0001-9782-4521; Casey, Cameron/0000-0001-6790-2170 FU National Institute of Environmental Health Sciences of the NIH [R01 ES022190]; NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development [R21 HD084788]; National Institute of General Medical Sciences [P41 GM103493]; Laboratory Directed Research and Development Program at Pacific Northwest National Laboratory; U.S. Department of Energy Office of Biological and Environmental Research Genome Sciences Program; National Institute of Allergy and Infectious Diseases [U19 AI106772]; National Institute on Aging (NIA); National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS); National Center for Advancing Translational Sciences (NCATS); NIH Roadmap for Medical Research [U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, UL1 TR000128]; DOE [DE-AC05-76RL0 1830] FX The authors would like to thank Nathan Johnson for assistance in preparing the figures. Portions of this research were supported by grants from the National Institute of Environmental Health Sciences of the NIH (R01 ES022190), NIH Eunice Kennedy Shriver National Institute of Child Health and Human Development (R21 HD084788), National Institute of General Medical Sciences (P41 GM103493), and the Laboratory Directed Research and Development Program at Pacific Northwest National Laboratory. This research utilized capabilities developed by the Pan-omics program (funded by the U.S. Department of Energy Office of Biological and Environmental Research Genome Sciences Program) and by the National Institute of Allergy and Infectious Diseases under grant U19 AI106772. The Osteoporotic Fractures in Men (MrOS) Study in the US was supported by the National Institute on Aging (NIA), the National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), the National Center for Advancing Translational Sciences (NCATS), and NIH Roadmap for Medical Research under the following grant numbers: U01 AG027810, U01 AG042124, U01 AG042139, U01 AG042140, U01 AG042143, U01 AG042145, U01 AG042168, U01 AR066160, and UL1 TR000128. This work was performed in the W. R. Wiley Environmental Molecular Sciences Laboratory (EMSL), a DOE national scientific user facility at the Pacific Northwest National Laboratory (PNNL). PNNL is operated by Battelle for the DOE under contract DE-AC05-76RL0 1830. NR 56 TC 0 Z9 0 U1 8 U2 8 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0951-4198 EI 1097-0231 J9 RAPID COMMUN MASS SP JI Rapid Commun. Mass Spectrom. PD MAR 15 PY 2017 VL 31 IS 5 BP 447 EP 456 DI 10.1002/rcm.7808 PG 10 WC Biochemical Research Methods; Chemistry, Analytical; Spectroscopy SC Biochemistry & Molecular Biology; Chemistry; Spectroscopy GA EL3IK UT WOS:000394512600006 PM 27958645 ER PT J AU Kort, NS Ford, JM Roach, BJ Gunduz-Bruce, H Krystal, JH Jaeger, J Reinhart, RMG Mathalon, DH AF Kort, Naomi S. Ford, Judith M. Roach, Brian J. Gunduz-Bruce, Handan Krystal, John H. Jaeger, Judith Reinhart, Robert M. G. Mathalon, Daniel H. TI Role of N-Methyl-D-Aspartate Receptors in Action-Based Predictive Coding Deficits in Schizophrenia SO BIOLOGICAL PSYCHIATRY LA English DT Article DE Electroencephalography; Ketamine; N-methyl-D-aspartate glutamate receptor; Predictive coding; Schizophrenia; Speech motor control ID COROLLARY DISCHARGE DYSFUNCTION; AUDITORY SENSORY MEMORY; MISMATCH NEGATIVITY GENERATION; SUBUNIT GENE GRIN2B; HEALTHY-VOLUNTEERS; SPEECH PRODUCTION; SYNAPTIC PLASTICITY; NEUROPHYSIOLOGICAL EVIDENCE; COGNITIVE DEFICITS; PSYCHOTIC SYMPTOMS AB BACKGROUND: Recent theoretical models of schizophrenia posit that dysfunction of the neural mechanisms subserving predictive coding contributes to symptoms and cognitive deficits, and this dysfunction is further posited to result from N-methyl-D-aspartate glutamate receptor (NMDAR) hypofunction. Previously, by examining auditory cortical responses to self-generated speech sounds, we demonstrated that predictive coding during vocalization is disrupted in schizophrenia. To test the hypothesized contribution of NMDAR hypofunction to this disruption, we examined the effects of the NMDAR antagonist, ketamine, on predictive coding during vocalization in healthy volunteers and compared them with the effects of schizophrenia. METHODS: In two separate studies, the N1 component of the event-related potential elicited by speech sounds during vocalization (talk) and passive playback(listen) were compared to assess the degree of N1 suppression during vocalization, a putative measure of auditory predictive coding. In the crossover study, 31 healthy volunteers completed two randomly ordered test days, a saline day and a ketamine day. Event- related potentials during the talk/ listen task were obtained before infusion and during infusion on both days, and N1 amplitudes were compared across days. In the case- control study, N1 amplitudes from 34 schizophrenia patients and 33 healthy control volunteers were compared. RESULTS: N1 suppression to self produced vocalizations was significantly and similarly diminished by ketamine (Cohen's d= 1.14) and schizophrenia(Cohen's d=.85). CONCLUSIONS: Disruption of NMDARs causes dysfunction in predictive coding during vocalization in a manner similar to the dysfunction observed in schizophrenia patients, consistent with the theorized contribution of NMDAR hypofunction to predictive coding deficits in schizophrenia. C1 [Kort, Naomi S.; Ford, Judith M.; Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco, CA USA. [Ford, Judith M.; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA. [Roach, Brian J.] Northern California Inst Res & Educ, San Francisco, CA USA. [Gunduz-Bruce, Handan; Krystal, John H.; Reinhart, Robert M. G.] Yale Univ, Sch Med, New Haven, CT USA. [Gunduz-Bruce, Handan; Krystal, John H.] Vet Affairs Connecticut Healthcare Syst, West Haven, CT USA. [Jaeger, Judith] Clin Dev AstraZeneca Pharmaceut, Wilmington, DE USA. [Jaeger, Judith] Albert Einstein Coll York, Yorktown Hts, NY USA. [Jaeger, Judith] LLC, CognitionMetr, Wilmington, DC USA. [Reinhart, Robert M. G.] Boston Univ, Boston, MA USA. [Mathalon, Daniel H.] Mental Hlth Serv 116D, SFVAMC, 4150 Clement St, San Francisco, CA 94121 USA. RP Mathalon, DH (reprint author), Mental Hlth Serv 116D, SFVAMC, 4150 Clement St, San Francisco, CA 94121 USA. EM daniel.mathalon@ucsf.edu FU AstraZeneca for an investigator-initiated study (DHM); National Institute of Mental Health [R01 MH-58262, T32 MH089920]; Yale Center for Clinical Investigation [UL1RR024139]; US National Institute on Alcohol Abuse and Alcoholism [P50AA012879] FX This work was supported by AstraZeneca for an investigator-initiated study (DHM) and the National Institute of Mental Health Grant Nos. R01 MH-58262 (to JMF) and T32 MH089920 (to NSK). JHK was supported by the Yale Center for Clinical Investigation Grant No. UL1RR024139 and the US National Institute on Alcohol Abuse and Alcoholism Grant No. P50AA012879. NR 109 TC 1 Z9 1 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0006-3223 EI 1873-2402 J9 BIOL PSYCHIAT JI Biol. Psychiatry PD MAR 15 PY 2017 VL 81 IS 6 BP 514 EP 524 DI 10.1016/j.biopsych.2016.06.019 PG 11 WC Neurosciences; Psychiatry SC Neurosciences & Neurology; Psychiatry GA EP3RS UT WOS:000397300000010 PM 27647218 ER PT J AU Reusch, JEB Manson, JE AF Reusch, Jane E. B. Manson, JoAnn E. TI Management of Type 2 Diabetes in 2017 Getting to Goal SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Editorial Material ID ASSOCIATION; STATEMENT C1 [Reusch, Jane E. B.] Univ Colorado, Anschutz Med Ctr, Ctr Womens Hlth Res, Denver, CO 80202 USA. [Reusch, Jane E. B.] Denver VA Med Ctr, Denver, CO USA. [Manson, JoAnn E.] Brigham & Womens Hosp, Dept Med, 75 Francis St, Boston, MA 02115 USA. [Manson, JoAnn E.] Harvard Med Sch, Boston, MA USA. [Manson, JoAnn E.] Harvard TH Chan Sch Publ Hlth, Dept Epidemiol, Boston, MA USA. RP Manson, JE (reprint author), Harvard Med Sch, Brigham & Womens Hosp, 900 Commonwealth Ave,Third Floor, Boston, MA 02215 USA. EM jmanson@rics.bwh.harvard.edu FU AstraZeneca; Merck FX The authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Dr Reusch reported receiving grant funding from AstraZeneca and Merck; and serving on the board of directors for the American Diabetes Association. No other disclosures were reported. NR 7 TC 0 Z9 0 U1 5 U2 5 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 14 PY 2017 VL 317 IS 10 BP 1015 EP 1016 DI 10.1001/jama.2017.0241 PG 2 WC Medicine, General & Internal SC General & Internal Medicine GA EO5DO UT WOS:000396713400009 PM 28249081 ER PT J AU Hoy, AR Ly, M Carlsson, CM Okonkwo, OC Zetterberg, H Blennow, K Sager, MA Asthana, S Johnson, SC Alexander, AL Bendlin, BB AF Hoy, Andrew R. Ly, Martina Carlsson, Cynthia M. Okonkwo, Ozioma C. Zetterberg, Henrik Blennow, Kaj Sager, Mark A. Asthana, Sanjay Johnson, Sterling C. Alexander, Andrew L. Bendlin, Barbara B. TI Microstructural white matter alterations in preclinical Alzheimer's disease detected using free water elimination diffusion tensor imaging SO PLOS ONE LA English DT Article ID MILD COGNITIVE IMPAIRMENT; FIBER TRACTOGRAPHY; CORPUS-CALLOSUM; HEALTHY-ADULTS; CSF; BRAIN; DEMENTIA; MRI; SCHIZOPHRENIA; DEGENERATION AB Brain changes associated with Alzheimer's disease (AD) begin decades before disease diagnosis. While beta-amyloid plaques and neurofibrillary tangles are defining features of AD, neuronal loss and synaptic pathology are closely related to the cognitive dysfunction. Brain imaging methods that are tuned to assess degeneration of myelinated nerve fibers in the brain (collectively called white matter) include diffusion tensor imaging (DTI) and related techniques, and are expected to shed light on disease-related loss of structural connectivity. Participants (N = 70, ages 47-76 years) from the Wisconsin Registry for Alzheimer's Prevention study underwent DTI and hybrid diffusion imaging to determine a free-water elimination (FWE-DTI) model. The study assessed the extent to which preclinical AD pathology affects brain white matter. Preclinical AD pathology was determined using cerebrospinal fluid (CSF) biomarkers. The sample was enriched for AD risk (APOE epsilon 4 and parental history of AD). AD pathology assessed by CSF analyses was significantly associated with altered microstructure on both DTI and FWE-DTI. Affected regions included frontal, parietal, and especially temporal white matter. The f-value derived from the FWE-DTI model appeared to be the most sensitive to the relationship between the CSF AD biomarkers and microstructural alterations in white matter. These findings suggest that white matter degeneration is an early pathological feature of AD that may have utility both for early disease detection and as outcome measures for clinical trials. More complex models of microstructural diffusion properties including FWE-DTI may provide increased sensitivity to early brain changes associated with AD over standard DTI. C1 [Hoy, Andrew R.] US Navy, Med Serv Corp, Falls Church, VA 22042 USA. [Hoy, Andrew R.; Alexander, Andrew L.] Univ Wisconsin, Dept Med Phys, Sch Med & Publ Hlth, 1530 Med Sci Ctr, Madison, WI 53706 USA. [Hoy, Andrew R.; Alexander, Andrew L.] Univ Wisconsin, Waisman Lab Brain Imaging & Behav, Madison, WI 53706 USA. [Hoy, Andrew R.] Uniformed Serv Univ Hlth Sci, Dept Radiol & Radiol Sci, Bethesda, MD 20814 USA. [Ly, Martina; Carlsson, Cynthia M.; Okonkwo, Ozioma C.; Asthana, Sanjay; Johnson, Sterling C.; Bendlin, Barbara B.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Ly, Martina; Carlsson, Cynthia M.; Okonkwo, Ozioma C.; Sager, Mark A.; Asthana, Sanjay; Johnson, Sterling C.; Bendlin, Barbara B.] Univ Wisconsin, Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA. [Ly, Martina] Univ Wisconsin, Neurosci Training Program, Madison, WI USA. [Carlsson, Cynthia M.; Okonkwo, Ozioma C.; Sager, Mark A.; Asthana, Sanjay; Johnson, Sterling C.; Bendlin, Barbara B.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Inst, Madison, WI USA. [Zetterberg, Henrik; Blennow, Kaj] Univ Gothenburg, Sahlgrenska Acad, Inst Neurosci & Physiol, Clin Neurochem Lab,Dept Psychiat & Neurochem, Gothenburg, Sweden. [Zetterberg, Henrik] UCL Inst Neurol, Queen Sq, London WC1N 3BG, England. [Alexander, Andrew L.] Univ Wisconsin, Dept Psychiat, Madison, WI 53706 USA. RP Hoy, AR (reprint author), US Navy, Med Serv Corp, Falls Church, VA 22042 USA.; Hoy, AR (reprint author), Univ Wisconsin, Dept Med Phys, Sch Med & Publ Hlth, 1530 Med Sci Ctr, Madison, WI 53706 USA.; Hoy, AR (reprint author), Univ Wisconsin, Waisman Lab Brain Imaging & Behav, Madison, WI 53706 USA.; Hoy, AR (reprint author), Uniformed Serv Univ Hlth Sci, Dept Radiol & Radiol Sci, Bethesda, MD 20814 USA. EM Andrew.Hoy@usuhs.edu FU National Institutes of Health [P50AG033514, R01AG027161, P30HD003352, P50MH100031, R01AG037639]; Torsten Soderberg Foundation at the Royal Swedish Academy of Sciences FX Research reported in this publication was supported in part by the National Institutes of Health under Grant Award Numbers P50AG033514, R01AG027161, P30HD003352, P50MH100031, and R01AG037639. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. Biomarker analyses in this project was supported by the Torsten Soderberg Foundation at the Royal Swedish Academy of Sciences. NR 88 TC 0 Z9 0 U1 2 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 14 PY 2017 VL 12 IS 3 AR e0173982 DI 10.1371/journal.pone.0173982 PG 21 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EN6DM UT WOS:000396094700053 PM 28291839 ER PT J AU Debnath, S Velagapudi, C Redus, L Thameem, F Kasinath, B Hura, CE Lorenzo, C Abboud, HE O'Connor, JC AF Debnath, Subrata Velagapudi, Chakradhar Redus, Laney Thameem, Farook Kasinath, Balakuntalam Hura, Claudia E. Lorenzo, Carlos Abboud, Hanna E. O'Connor, Jason C. TI Tryptophan Metabolism in Patients With Chronic Kidney Disease Secondary to Type 2 Diabetes: Relationship to Inflammatory Markers SO INTERNATIONAL JOURNAL OF TRYPTOPHAN RESEARCH LA English DT Article DE Chronic kidney disease; indoleamine 2,3-dioxygenase 1; inflammatory cytokines; kynurenine; tryptophan; type 2 diabetes ID KYNURENINE PATHWAY ENZYMES; STAGE RENAL-DISEASE; INDOLEAMINE 2,3-DIOXYGENASE; AMINO-ACID; QUINOLINIC ACID; NEPHROPATHY; PROGRESSION; PREDICTION; PLASMA; IDO2 AB OBJECTIVE : Type 2 diabetes (T2D) is the primary case of chronic kidney disease (CKD). Inflammation is associated with metabolic dysregulation in patients with T2D and CKD. Tryptophan (TRP) metabolism may have relevance to the CKD outcomes and associated symptoms. We investigated the relationships of TRP metabolism with inflammatory markers in patients with T2D and CKD. METHODS: Data were collected from a well-characterized cohort of type 2 diabetic individuals with all stages of CKD, including patients on hemodialysis. Key TRP metabolites (kynurenine [KYN], kynurenic acid [KYNA], and quinolinic acid [QA]), proinflammatory cytokines (tumor necrosis factor-alpha [TNF-alpha] and interleukin-6 [IL-6]), and C-reactive protein were measured in plasma. The KYN/TRP ratio was utilized as a surrogate marker for indoleamine 2,3-dioxygenase 1 (IDO1) enzyme activity. RESULTS : There was a significant inverse association between circulating TRP level and stages of CKD (P < 0.0001). Downstream bioactive TRP metabolites KYN, KYNA, and QA were positively and robustly correlated with the severity of kidney disease (P < 0.0001). In multiple linear regression, neither TNF-alpha nor IL-6 was independently related to KYN/TRP ratio after adjusting for estimated glomerular filtration rate (eGFR). Only TNF-alpha was independently related to KYN after taking into account the effect of eGFR. CONCLUSIONS: Chronic kidney disease secondary to T2D may be associated with accumulation of toxic TRP metabolites due to both inflammation and impaired kidney function. Future longitudinal studies to determine whether the accumulation of KYN directly contributes to CKD progression and associated symptoms in patients with T2D are warranted. C1 [Debnath, Subrata; Velagapudi, Chakradhar; Thameem, Farook; Kasinath, Balakuntalam; Hura, Claudia E.; Abboud, Hanna E.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. [Redus, Laney; O'Connor, Jason C.] Univ Texas Hlth Sci Ctr San Antonio, Dept Pharmacol, San Antonio, TX 78229 USA. [Lorenzo, Carlos] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Rheumatol & Clin Immunol, San Antonio, TX 78229 USA. [O'Connor, Jason C.] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Debnath, S (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Med, Div Nephrol, San Antonio, TX 78229 USA. EM nath@uthscsa.edu; oconnorj@uthscsa.edu FU San Antonio Area Foundation; National Institute of Diabetes and Digestive and Kidney Diseases; National Institutes of Health (NIH) [U01DK57292-05]; NIH [1S10OD016417-01] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was partially supported by the San Antonio Area Foundation. The Family Investigation of Nephropathy in Diabetes study was supported by the National Institute of Diabetes and Digestive and Kidney Diseases, and the National Institutes of Health (NIH) (U01DK57292-05). Mass spectrometry analyses were conducted at the Mass Spectrometry Core Facilities, University of Texas Health Science Center at San Antonio, on instrumentation obtained with funding from the NIH (1S10OD016417-01). Funding sources had no role in data analyses and interpretations. NR 51 TC 0 Z9 0 U1 1 U2 1 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1178-6469 J9 INT J TRYPTOPHAN RES JI Int. J. Trypotophan Res. PD MAR 10 PY 2017 VL 10 BP 1 EP 9 DI 10.1177/1178646917694600 PG 9 WC Neurosciences SC Neurosciences & Neurology GA EP8TZ UT WOS:000397649000001 ER PT J AU Chinman, M McCarthy, S Hannah, G Byrne, TH Smelson, DA AF Chinman, Matthew McCarthy, Sharon Hannah, Gordon Byrne, Thomas Hugh Smelson, David A. TI Using Getting To Outcomes to facilitate the use of an evidence-based practice in VA homeless programs: a cluster-randomized trial of an implementation support strategy SO IMPLEMENTATION SCIENCE LA English DT Article DE Implementation support; Co-occurring disorders; Fidelity; Training; Technical assistance ID TREATMENT ENGAGEMENT INTERVENTION; SUBSTANCE USE DISORDERS; HEALTH-PROMOTION; CONSOLIDATED FRAMEWORK; MENTAL ILLNESSES; HOUSING 1ST; INDIVIDUALS; SERVICES; ELEMENTS; IMPROVE AB Background: Incorporating evidence-based integrated treatment for dual disorders into typical care settings has been challenging, especially among those serving Veterans who are homeless. This paper presents an evaluation of an effort to incorporate an evidence-based, dual disorder treatment called Maintaining Independence and Sobriety Through Systems Integration, Outreach, and Networking-Veterans Edition (MISSION-Vet) into case management teams serving Veterans who are homeless, using an implementation strategy called Getting To Outcomes (GTO). Methods: This Hybrid Type III, cluster-randomized controlled trial assessed the impact of GTO over and above MISSION-Vet Implementation as Usual (IU). Both conditions received standard MISSION-Vet training and manuals. The GTO group received an implementation manual, training, technical assistance, and data feedback. The study occurred in teams at three large VA Medical Centers over 2 years. Within each team, existing sub-teams (case managers and Veterans they serve) were the clusters randomly assigned. The trial assessed MISSION-Vet services delivered and collected via administrative data and implementation barriers and facilitators, via semi-structured interview. Results: No case managers in the IU group initiated MISSION-Vet while 68% in the GTO group did. Seven percent of Veterans with case managers in the GTO group received at least one MISSION-Vet session. Most case managers appreciated the MISSION-Vet materials and felt the GTO planning meetings supported using MISSION-Vet. Case manager interviews also showed that MISSION-Vet could be confusing; there was little involvement from leadership after their initial agreement to participate; the data feedback system had a number of difficulties; and case managers did not have the resources to implement all aspects of MISSION-Vet. Conclusions: This project shows that GTO-like support can help launch new practices but that multiple implementation facilitators are needed for successful execution of a complex evidence-based program like MISSION-Vet. C1 [Chinman, Matthew; McCarthy, Sharon; Hannah, Gordon] VA Pittsburgh Healthcare Syst, VISN Mental Illness Res & Clin Ctr 4, Pittsburgh, PA 15240 USA. [Chinman, Matthew; McCarthy, Sharon; Hannah, Gordon] VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15240 USA. [Chinman, Matthew] RAND Corp, Pittsburgh, PA 15213 USA. [Chinman, Matthew; Byrne, Thomas Hugh; Smelson, David A.] VA Natl Ctr Homelessness Vet, Philadelphia, PA 19120 USA. [Byrne, Thomas Hugh] Boston Univ, Sch Social Work, Boston, MA 02215 USA. [Byrne, Thomas Hugh; Smelson, David A.] VA Ctr Healthcare Org & Implementat Res, Boston, MA USA. [Smelson, David A.] Univ Massachusetts, Sch Med, Dept Psychiat, Worcester, MA 01605 USA. RP Chinman, M (reprint author), VA Pittsburgh Healthcare Syst, VISN Mental Illness Res & Clin Ctr 4, Pittsburgh, PA 15240 USA.; Chinman, M (reprint author), VA Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA 15240 USA.; Chinman, M (reprint author), RAND Corp, Pittsburgh, PA 15213 USA.; Chinman, M (reprint author), VA Natl Ctr Homelessness Vet, Philadelphia, PA 19120 USA. EM Chinman@rand.org FU Health Services Research and Development Quality Enhancement Research Initiative, "MISSION-Vet HUD-VASH Implementation Study" [SDP 11-240] FX All the authors are funded by a grant from the Health Services Research and Development Quality Enhancement Research Initiative, "MISSION-Vet HUD-VASH Implementation Study" (SDP 11-240). NR 43 TC 0 Z9 0 U1 2 U2 2 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1748-5908 J9 IMPLEMENT SCI JI Implement. Sci. PD MAR 9 PY 2017 VL 12 AR 34 DI 10.1186/s13012-017-0565-0 PG 12 WC Health Care Sciences & Services; Health Policy & Services SC Health Care Sciences & Services GA EO3RB UT WOS:000396610800001 PM 28279207 ER PT J AU Bowers, JS Nelson, MH Majchrzak, K Bailey, SR Rohrer, B Kaiser, ADM Atkinson, C Gattinoni, L Paulos, CM AF Bowers, Jacob S. Nelson, Michelle H. Majchrzak, Kinga Bailey, Stefanie R. Rohrer, Baerbel Kaiser, Andrew D. M. Atkinson, Carl Gattinoni, Luca Paulos, Chrystal M. TI Th17 cells are refractory to senescence and retain robust antitumor activity after long-term ex vivo expansion SO JCI INSIGHT LA English DT Article ID CD8(+) T-CELLS; TUMOR-INFILTRATING LYMPHOCYTES; ADOPTIVE IMMUNOTHERAPY; METASTATIC MELANOMA; ESTABLISHED MELANOMA; CANCER-IMMUNOTHERAPY; TRANSFER THERAPY; TELOMERE LENGTH; HUMAN EFFECTOR; MEMORY CELLS AB Adoptive immunotherapy for solid tumors relies on infusing large numbers of T cells to mediate successful antitumor responses in patients. While long-term rapid-expansion protocols (REPs) produce sufficient numbers of CD8(+) T cells for treatment, they also cause decline in the cell's therapeutic fitness. In contrast, we discovered that IL-17-producing CD4(+) T cells (Th17 cells) do not require REPs to expand 5,000-fold over 3 weeks. Also, unlike Th1 cells, Th17 cells do not exhibit hallmarks of senescence or apoptosis, retaining robust antitumor efficacy in vivo. Three-week-expanded Th17 cells eliminated melanoma as effectively as Th17 cells expanded for 1 week when infused in equal numbers into mice. However, treating mice with large recalcitrant tumors required the infusion of all cells generated after 2 or 3 weeks of expansion, while the cell yield obtained after 1-week expansion was insufficient. Long-term-expanded Th17 cells also protected mice from tumor rechallenge including lung metastasis. Importantly, 2-week-expanded human chimeric antigen receptor-positive (CAR(+)) Th17 cells also retained their ability to regress human mesothelioma, while CAR(+) Th1 cells did not. Our results indicate that tumor-reactive Th17 cells are an effective cell therapy for cancer, remaining uncompromised when expanded for a long duration owing to their resistance to senescence. C1 [Bowers, Jacob S.; Nelson, Michelle H.; Majchrzak, Kinga; Bailey, Stefanie R.; Atkinson, Carl; Paulos, Chrystal M.] Med Univ South Carolina, Dept Microbiol & Immunol, Charleston, SC 29425 USA. [Bowers, Jacob S.; Nelson, Michelle H.; Majchrzak, Kinga; Bailey, Stefanie R.; Paulos, Chrystal M.] Med Univ South Carolina, Dept Dermatol, Charleston, SC 29425 USA. [Bowers, Jacob S.; Nelson, Michelle H.; Majchrzak, Kinga; Bailey, Stefanie R.; Paulos, Chrystal M.] Med Univ South Carolina, Dept Surg, Charleston, SC 29425 USA. [Majchrzak, Kinga] Warsaw Univ Life Sci, Dept Physiol Sci, Fac Vet Med, Warsaw, Poland. [Rohrer, Baerbel] Med Univ South Carolina, Dept Ophthalmol, Charleston, SC 29425 USA. [Rohrer, Baerbel] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Kaiser, Andrew D. M.] NCI, Ctr Canc Res, NIH, Bethesda, MD 20892 USA. [Gattinoni, Luca] NCI, Expt Transplantat & Immunol Branch, NIH, Bethesda, MD 20892 USA. [Kaiser, Andrew D. M.] Miltenyi Biotec, Bergisch Gladbach, Germany. RP Bowers, JS; Paulos, CM (reprint author), Med Univ South Carolina, Hollings Canc Ctr, 86 Jonathan Lucas St,Room 606B MSC509, Charleston, SC 29425 USA. EM bowersjs@musc.edu; paulos@musc.edu FU Hollings Cell Evaluation Therapy; Hollings Cell Evaluation & Therapy, and Hollings Biostatistics Shared Resources, Hollings Cancer Center, MUSC [P30 CA138313]; NIH [F30 CA200272, T32 GM008716, F31 CA192787]; Jeane B. Kempner Foundation; ACS [122704-PF-13-084-01-LIB]; NCI [R01 CA175061, R01 CA208514]; KL2 South Carolina Clinical & Translational Research grant [UL1 TR000062]; ACS-IRG grant [016623-004]; MUSC start-up funds FX We thank Logan Huff and Hannah Knochelmann for experimental support and Kent Armeson for help in statistical analysis of this work. This research was supported in part by the Hollings Cell Evaluation & Therapy, and Hollings Biostatistics Shared Resources, Hollings Cancer Center, MUSC (P30 CA138313).; This work was supported by NIH fellowship grant F30 CA200272 and NIH training grant T32 GM008716 to J.S. Bowers, a Jeane B. Kempner Foundation grant and ACS Postdoctoral fellowship (122704-PF-13-084-01-LIB) grant to M.H. Nelson, an NIH fellowship grant F31 CA192787 to S.R. Bailey, and NCI grants R01 CA175061 and R01 CA208514, KL2 South Carolina Clinical & Translational Research grant UL1 TR000062, ACS-IRG grant 016623-004, and MUSC start-up funds to C.M. Paulos. NR 57 TC 0 Z9 0 U1 1 U2 1 PU AMER SOC CLINICAL INVESTIGATION INC PI ANN ARBOR PA 2015 MANCHESTER RD, ANN ARBOR, MI 48104 USA SN 2379-3708 J9 JCI INSIGHT JI JCI Insight PD MAR 9 PY 2017 VL 2 IS 5 AR e90772 DI 10.1172/jci.insight.90772 PG 16 WC Medicine, Research & Experimental SC Research & Experimental Medicine GA EN5FA UT WOS:000396029800010 PM 28289713 ER PT J AU Riad, FS Razak, E Saba, S Shalaby, A Nemec, J AF Riad, Fady S. Razak, Eathar Saba, Samir Shalaby, Alaa Nemec, Jan TI Recent heart rate history affects QT interval duration in atrial fibrillation SO PLOS ONE LA English DT Article ID ACTION-POTENTIAL DURATION; TORSADE-DE-POINTES; RATE DEPENDENCE; MORTALITY; PROLONGATION; DYNAMICS; FORMULAS AB QT interval prolongation is associated with a risk of polymorphic ventricular tachycardia. QT interval shortens with increasing heart rate and correction for this effect is necessary for meaningful QT interval assessment. We aim to improve current methods of correcting the QT interval during atrial fibrillation (AF). Digitized Holter recordings were analyzed from patients with AF. Models of QT interval dependence on RR intervals were tested by sorting the beats into 20 bins based on corrected RR interval and assessing ST-T variability within the bins. Signal-averaging within bins was performed to determine QT/RR dependence. Data from 30 patients (29 men, 69.3 7.3 years) were evaluated. QT behavior in AF is well described by a linear function (slope-0.19) of steady-state corrected RR interval. Corrected RR is calculated as a combination of an exponential weight function with time-constant of 2 minutes and a smaller "immediate response" component (weight- 0.18). This model performs significantly (p<0.0001) better than models based on instantaneous RR interval only including Bazett and Fridericia. It also outperforms models based on shorter time-constants and other previously proposed models. This model may improve detection of repolarization delay in AF. QT response to heart rate changes in AF is similar to previously published QT dynamics during atrial pacing and in sinus rhythm. C1 [Riad, Fady S.] Univ Pittsburgh, Med Ctr, Dept Internal Med, Pittsburgh, PA USA. [Razak, Eathar; Shalaby, Alaa] VA Pittsburgh Healthcare Syst, Dept Cardiol, Pittsburgh, PA USA. [Saba, Samir; Nemec, Jan] Univ Pittsburgh, Med Ctr, Inst Heart & Vasc, Pittsburgh, PA 15260 USA. [Razak, Eathar] CHI Franciscan Hlth, Franciscan Heart & Vasc Associates St Joseph, Tacoma, WA USA. RP Nemec, J (reprint author), Univ Pittsburgh, Med Ctr, Inst Heart & Vasc, Pittsburgh, PA 15260 USA. EM limidus@hotmail.com NR 29 TC 0 Z9 0 U1 1 U2 1 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 8 PY 2017 VL 12 IS 3 AR e0172962 DI 10.1371/journal.pone.0172962 PG 14 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EN5VL UT WOS:000396073700033 PM 28273109 ER PT J AU Bibbins-Domingo, K Grossman, DC Curry, SJ Barry, MJ Davidson, KW Doubeni, CA Epling, J Garcia, FAR Kemper, AR Krist, AH Kurth, AE Landefeld, CS Mangione, CM Phillips, WR Phipps, MG Silverstein, M Simon, M Siu, AL Tseng, CW AF Bibbins-Domingo, Kirsten Grossman, David C. Curry, Susan J. Barry, Michael J. Davidson, Karina W. Doubeni, Chyke A. Epling, Johnw., Jr. Garcia, Francisco A. R. Kemper, Alex R. Krist, Alex H. Kurth, Ann E. Landefeld, C. Seth Mangione, Carol M. Phillips, William R. Phipps, Maureen G. Silverstein, Michael Simon, Melissa Siu, Albert L. Tseng, Chien-Wen CA US Preventive Serv Task Force TI Screening for Gynecologic Conditions With Pelvic Examination US Preventive Services Task Force Recommendation Statement SO JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION LA English DT Article ID OVARIAN-CANCER; CLINICAL MANIFESTATIONS; BACTERIAL VAGINOSIS; ASYMPTOMATIC WOMEN AB IMPORTANCE Many conditions that can affect women's health are often evaluated through pelvic examination. Although the pelvic examination is a common part of the physical examination, it is unclear whether performing screening pelvic examinations in asymptomatic women has a significant effect on disease morbidity and mortality. OBJECTIVE To issue a new US Preventive Services Task Force(USPSTF) recommendation on screening for gynecologic conditions with pelvic examination for conditions other than cervical cancer, gonorrhea, and chlamydia, for which the USPSTF has already made specific recommendations. EVIDENCE REVIEW The USPSTF reviewed the evidence on the accuracy, benefits, and potential harms of performing screening pelvic examinations in asymptomatic, nonpregnant adult women 18 years and older who are not at increased risk for any specific gynecologic condition. FINDINGS Overall, the USPSTF found inadequate evidence on screening pelvic examinations for the early detection and treatment of a range of gynecologic conditions in asymptomatic, nonpregnant adult women. CONCLUSIONS AND RECOMMENDATION The USPSTF concludes that the current evidence is insufficient to assess the balance of benefits and harms of performing screening pelvic examinations in asymptomatic, nonpregnant adult women. (I statement) This statement does not apply to specific disorders for which the USPSTF already recommends screening (ie, screening for cervical cancer with a Papanicolaou smear, screening for gonorrhea and chlamydia). C1 [Bibbins-Domingo, Kirsten] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Grossman, David C.] Grp Hlth Res Inst, Seattle, WA USA. [Curry, Susan J.] Univ Iowa, Iowa City, IA USA. [Barry, Michael J.] Harvard Med Sch, Boston, MA USA. [Davidson, Karina W.] Columbia Univ, New York, NY USA. [Doubeni, Chyke A.] Univ Penn, Philadelphia, PA 19104 USA. [Epling, Johnw., Jr.] SUNY Upstate Med Univ, Syracuse, NY 13210 USA. [Garcia, Francisco A. R.] Pima Cty Dept Hlth, Tucson, AZ USA. [Kemper, Alex R.] Duke Univ, Durham, NC USA. [Krist, Alex H.] Fairfax Family Practice Residency, Fairfax, VA USA. [Krist, Alex H.] Virginia Commonwealth Univ, Richmond, VA 23284 USA. [Kurth, Ann E.] Yale Univ, New Haven, CT USA. [Landefeld, C. Seth] Univ Alabama Birmingham, Birmingham, AL USA. [Mangione, Carol M.] Univ Calif Los Angeles, Los Angeles, CA USA. [Phillips, William R.] Univ Washington, Seattle, WA 98195 USA. [Phipps, Maureen G.] Brown Univ, Providence, RI 02912 USA. [Silverstein, Michael] Boston Univ, Boston, MA 02215 USA. [Simon, Melissa] Northwestern Univ, Evanston, IL USA. [Siu, Albert L.] Mt Sinai Hosp, New York, NY 10029 USA. [Siu, Albert L.] James J Peters Vet Affairs Med Ctr, Bronx, NY USA. [Tseng, Chien-Wen] Univ Hawaii Manoa, Honolulu, HI 96822 USA. RP Bibbins-Domingo, K (reprint author), Univ Calif San Francisco, San Francisco, CA 94143 USA. EM chair@uspstf.net FU USPSTF FX The USPSTF is an independent, voluntary body. The US Congress mandates that the Agency for Healthcare Research and Quality (AHRQ) support the operations of the USPSTF. NR 23 TC 0 Z9 0 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 0098-7484 EI 1538-3598 J9 JAMA-J AM MED ASSOC JI JAMA-J. Am. Med. Assoc. PD MAR 7 PY 2017 VL 317 IS 9 BP 947 EP 953 DI 10.1001/jama.2017.0807 PG 7 WC Medicine, General & Internal SC General & Internal Medicine GA EM8DM UT WOS:000395541500014 ER PT J AU Balasubramanian, P Kumar, R Williams, C Itri, V Wang, SX Lu, S Hessell, AJ Haigwood, NL Sinangil, F Higgins, KW Liu, L Li, LZ Nyambi, P Gorny, MK Totrov, M Nadas, A Kong, XP Zolla-Pazner, S Hioe, CE AF Balasubramanian, Preetha Kumar, Rajnish Williams, Constance Itri, Vincenza Wang, Shixia Lu, Shan Hessell, Ann J. Haigwood, Nancy L. Sinangil, Faruk Higgins, Keith W. Liu, Lily Li, Liuzhe Nyambi, Phillipe Gorny, Miroslaw K. Totrov, Maxim Nadas, Arthur Kong, Xiang-Peng Zolla-Pazner, Susan Hioe, Catarina E. TI Differential induction of anti-V3 crown antibodies with cradle- and ladle-binding modes in response to HIV-1 envelope vaccination SO VACCINE LA English DT Article DE HIV; HIV envelope; V3; Mimotopes; Antibodies ID V3 LOOP; TYPE-1 GP120; NEUTRALIZING ANTIBODIES; V3-SPECIFIC ANTIBODIES; HIV-1-INFECTED HUMANS; MONOCLONAL-ANTIBODIES; BROAD NEUTRALIZATION; IMMUNE-RESPONSE; INFECTION; EPITOPES AB The V3 loop in the HIV envelope gp120 is one of the immunogenic sites targeted by Abs. The V3 crown in particular has conserved structural elements recognized by cross-reactive neutralizing Abs, indicating its potential contribution in protection against HIV. Crystallographic analyses of anti-V3 crown mAbs in complex with the V3 peptides have revealed that these mAbs recognize the conserved sites on the V3 crown via two distinct strategies: a cradle-binding mode (V3C) and a ladle-binding (V3L) mode. However, almost all of the anti-V3 crown mAbs studied in the past were isolated from chronically HIV-infected individuals. The extents to which the two types of anti-V3 crown Abs are generated by vaccination are unknown. This study analyzed the prevalence of V3C-type and V3L-type Ab responses in HIV-infected individuals and in HIV envelope-immunized humans and animals using peptide mimotopes that distinguish the two Ab types. The results show that both V3L-type and V3C-type Abs were generated by the vast majority of chronically HIV-infected humans, although the V3L-type were more prevalent. In contrast, only one of the two V3 Ab types was elicited in vaccinated humans or animal models, irrespective of HIV-1 envelope clades, envelope constructs (oligomeric or monomeric), and protocols (DNA plus protein or protein alone) used for vaccinations. The V3C-type Abs were produced by vaccinated humans. macaques, and rabbits, whereas the V3L-type Abs were made by mice. The V3C-type and V3L-type Abs generated by the vaccinations were able to mediate virus neutralization. These data indicate the restricted repertoires and the species-specific differences in the functional V3-specific Ab responses induced by the HIV envelope vaccines. The study implies the need for improving immunogen designs and vaccination strategies to broaden the diversity of Abs in order to target the different conserved epitopes in the V3 loop and, by extension, in the entire HIV envelope. Published by Elsevier Ltd. C1 [Balasubramanian, Preetha] NYU, Sch Med, Sackler Inst Grad Biomed Sci, New York, NY 10016 USA. [Balasubramanian, Preetha; Kumar, Rajnish; Itri, Vincenza; Zolla-Pazner, Susan; Hioe, Catarina E.] Icahn Sch Med Mt Sinai, Dept Med, Div Infect Dis, New York, NY 10029 USA. [Kumar, Rajnish; Hioe, Catarina E.] James J Peters VA Med Ctr, Bronx, NY 10468 USA. [Williams, Constance; Liu, Lily; Li, Liuzhe; Nyambi, Phillipe; Gorny, Miroslaw K.] NYU, Sch Med, Dept Pathol, New York, NY 10016 USA. [Wang, Shixia; Lu, Shan] Univ Massachusetts, Sch Med, Worcester, MA 01605 USA. [Hessell, Ann J.; Haigwood, Nancy L.] Oregon Hlth & Sci Univ, Oregon Natl Primate Res Ctr, Beaverton, OR 97006 USA. [Haigwood, Nancy L.] Oregon Hlth & Sci Univ, Dept Mol Microbiol & Immunol, Portland, OR 97239 USA. [Sinangil, Faruk; Higgins, Keith W.] Global Solut Infect Dis, San Francisco, CA USA. [Totrov, Maxim] Molsoft LLC, 3366 N Torrey Pines Ct, La Jolla, CA 92037 USA. [Nadas, Arthur] NYU, Sch Med, Dept Environm Med, New York, NY 10016 USA. [Kong, Xiang-Peng] NYU, Sch Med, Dept Biochem & Mol Pharmacol, New York, NY 10016 USA. RP Hioe, CE (reprint author), Dept Med, Div Infect Dis, One Gustave L Levy Pl,Box 1090, New York, NY 10029 USA. EM catarina.hioe@mssm.edu OI Kong, Xiang-Peng/0000-0001-5773-2681; Gorny, Miroslaw/0000-0002-2714-8780 FU Henry M. Jackson Foundation for the Advancement of Military Medicine - USA; NIH [R21 AI114520, HIVRAD P01 AI100151]; Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development FX This work was supported in part by the Henry M. Jackson Foundation for the Advancement of Military Medicine - USA (SZP, CEH), NIH grants R21 AI114520 (CEH) and HIVRAD P01 AI100151 (XPK, SZP) and by research funds from the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development (VA Merit Review and Research Career Scientist - CEH). NR 49 TC 0 Z9 0 U1 3 U2 3 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0264-410X EI 1873-2518 J9 VACCINE JI Vaccine PD MAR 7 PY 2017 VL 35 IS 10 BP 1464 EP 1473 DI 10.1016/j.vaccine.2016.11.107 PG 10 WC Immunology; Medicine, Research & Experimental SC Immunology; Research & Experimental Medicine GA EM9DK UT WOS:000395611300015 PM 28185743 ER PT J AU Bauer, EM Ben-Artzi, A Duffy, EL Elashoff, DA Vangala, SS Fitzgerald, J Ranganath, VK AF Bauer, Erin M. Ben-Artzi, Ami Duffy, Erin L. Elashoff, David A. Vangala, Sitaram S. Fitzgerald, John Ranganath, Veena K. TI Joint-specific assessment of swelling and power Doppler in obese rheumatoid arthritis patients SO BMC MUSCULOSKELETAL DISORDERS LA English DT Article DE Ultrasound; Obesity; Outcome measures; Rheumatoid arthritis ID BODY-MASS INDEX; ANTITUMOR NECROSIS FACTOR; DISEASE-ACTIVITY; TREATMENT RESPONSE; AMERICAN-COLLEGE; CONTROLLED-TRIAL; ASSOCIATION; ULTRASOUND; THERAPY; PROGRESSION AB Background: Clinical swollen joint examination of the obese rheumatoid arthritis (RA) patient can be difficult. Musculoskeletal Ultrasound (MSUS) has higher sensitivity than physical examination for swollen joints (SJ). The purpose of this study was to determine the joint-specific association between power Doppler (PDUS) and clinical SJ in RA across body mass index (BMI) categories. Methods: Cross-sectional clinical and laboratory data were collected on 43 RA patients. PDUS was performed on 9 joints (wrist, metacarpalphalangeal 2-5, proximal interphalgeal 2/3 and metatarsalphalangeal 2/5). DAS28 and clinical disease activity index (CDAI) were calculated. Patients were categorized by BMI: <25, 25-30, and >30. Demographic and clinical characteristics were compared across BMI groups with Kruskal-Wallis test and chi-square tests. Joint-level associations between PDUS and clinically SJ were evaluated with mixed effects logistic regression models. Results: While demographics and clinically-determined disease activity were similar among BMI groups, PDUS scores significantly differed (p = 0.02). Using PDUS activity as the reference standard for synovitis and clinically SJ as the test, the positive predictive value of SJ was significantly lower in higher BMI groups (0.71 in BMI < 25, 0.58 in BMI 25-30 and 0.44 in BMI < 30) (p = 0.02). The logistic model demonstrated that increased BMI category resulted in decreased likelihood of PDUS positivity (OR 0.52, p = 0.03). Conclusions: This study suggests that in an obese RA patient, a clinically assessed SJ is less likely to represent true synovitis (as measured by PDUS). Disease activity in obese RA patients may be overestimated by CDAI/DAS28 calculations and clinicians when considering change in therapy. C1 [Bauer, Erin M.; Duffy, Erin L.; Elashoff, David A.; Vangala, Sitaram S.; Fitzgerald, John; Ranganath, Veena K.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Bauer, Erin M.] US Dept Vet Affairs, Los Angeles, CA USA. [Ben-Artzi, Ami] Cedars Sinai Med Ctr, Los Angeles, CA 90048 USA. RP Ranganath, VK (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. EM vranganath@mednet.ucla.edu FU National Institutes of Health [NIAMS K23 AR057818-02]; National Center for Advancing Translational Sciences through UCLA CTSI [UL1TR000124] FX This work was supported by Grant and National Institutes of Health Award (NIAMS K23 AR057818-02) to Veena K. Ranganath and supported by the National Center for Advancing Translational Sciences through UCLA CTSI Grant UL1TR000124. NR 39 TC 0 Z9 0 U1 4 U2 4 PU BIOMED CENTRAL LTD PI LONDON PA 236 GRAYS INN RD, FLOOR 6, LONDON WC1X 8HL, ENGLAND SN 1471-2474 J9 BMC MUSCULOSKEL DIS JI BMC Musculoskelet. Disord. PD MAR 4 PY 2017 VL 18 AR 99 DI 10.1186/s12891-017-1406-7 PG 8 WC Orthopedics; Rheumatology SC Orthopedics; Rheumatology GA EM7AZ UT WOS:000395465100002 PM 28259162 ER PT J AU Nielson, JL Cooper, SR Yue, JK Sorani, MD Inoue, T Yuh, EL Mukherjee, P Petrossian, TC Paquette, J Lum, PY Carlsson, GE Vassar, MJ Lingsma, HF Gordon, WA Valadka, AB Okonkwo, DO Manley, GT Ferguson, AR AF Nielson, Jessica L. Cooper, Shelly R. Yue, John K. Sorani, Marco D. Inoue, Tomoo Yuh, Esther L. Mukherjee, Pratik Petrossian, Tanya C. Paquette, Jesse Lum, Pek Y. Carlsson, Gunnar E. Vassar, Mary J. Lingsma, Hester F. Gordon, Wayne A. Valadka, Alex B. Okonkwo, David O. Manley, Geoffrey T. Ferguson, Adam R. CA TRACK-TBI Investigators TI Uncovering precision phenotype-biomarker associations in traumatic brain injury using topological data analysis SO PLOS ONE LA English DT Article ID COMMON DATA ELEMENTS; TRANSFORMING RESEARCH; CLINICAL KNOWLEDGE; POLYMORPHISM; COMT; CLASSIFICATION; PREDICTION; PROTEIN AB Background Traumatic brain injury (TBI) is a complex disorder that is traditionally stratified based on clinical signs and symptoms. Recent imaging and molecular biomarker innovations provide unprecedented opportunities for improved TBI precision medicine, incorporating patho-ana-tomical and molecular mechanisms. Complete integration of these diverse data for TBI diag-nosis and patient stratification remains an unmet challenge. Methods and findings The Transforming Research and Clinical Knowledge in Traumatic Brain Injury (TRACK-TBI) Pilot multicenter study enrolled 586 acute TBI patients and collected diverse common data elements (TBI-CDEs) across the study population, including imaging, genetics, and clinical outcomes. We then applied topology-based data-driven discovery to identify natural sub-groups of patients, based on the TBI-CDEs collected. Our hypothesis was two-fold: 1) A machine learning tool known as topological data analysis (TDA) would reveal data-driven patterns in patient outcomes to identify candidate biomarkers of recovery, and 2) TDA-iden-tified biomarkers would significantly predict patient outcome recovery after TBI using more traditional methods of univariate statistical tests. TDA algorithms organized and mapped the data of TBI patients in multidimensional space, identifying a subset of mild TBI patients with a specific multivariate phenotype associated with unfavorable outcome at 3 and 6 months after injury. Further analyses revealed that this patient subset had high rates of post-trau-matic stress disorder (PTSD), and enrichment in several distinct genetic polymorphisms associated with cellular responses to stress and DNA damage (PARP1), and in striatal dopamine processing (ANKK1, COMT, DRD2). Conclusions TDA identified a unique diagnostic subgroup of patients with unfavorable outcome after mild TBI that were significantly predicted by the presence of specific genetic polymorphisms. Machine learning methods such as TDA may provide a robust method for patient stratifica-tion and treatment planning targeting identified biomarkers in future clinical trials in TBI patients. C1 [Nielson, Jessica L.; Cooper, Shelly R.; Yue, John K.; Inoue, Tomoo; Vassar, Mary J.; Manley, Geoffrey T.; Ferguson, Adam R.] Zuckerberg San Francisco Gen Hosp, Brain & Spinal Injury Ctr BASIC, San Francisco, CA 94110 USA. [Nielson, Jessica L.; Cooper, Shelly R.; Yue, John K.; Sorani, Marco D.; Inoue, Tomoo; Vassar, Mary J.; Manley, Geoffrey T.; Ferguson, Adam R.] Univ Calif San Francisco, Dept Neurol Surg, Weill Inst Neurosci, San Francisco, CA 94143 USA. [Cooper, Shelly R.; Yuh, Esther L.; Mukherjee, Pratik] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Petrossian, Tanya C.; Paquette, Jesse; Lum, Pek Y.; Carlsson, Gunnar E.] Ayasdi Inc, Palo Alto, CA USA. [Lingsma, Hester F.] Erasmus MC, Publ Hlth, Rotterdam, Netherlands. [Gordon, Wayne A.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. [Valadka, Alex B.] Virginia Commonwealth Univ, Dept Neurosurg, Richmond, VA USA. [Okonkwo, David O.] Univ Pittsburgh, Dept Neurosurg, Pittsburgh, PA USA. [Ferguson, Adam R.] San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA 94121 USA. RP Manley, GT; Ferguson, AR (reprint author), Zuckerberg San Francisco Gen Hosp, Brain & Spinal Injury Ctr BASIC, San Francisco, CA 94110 USA.; Manley, GT; Ferguson, AR (reprint author), Univ Calif San Francisco, Dept Neurol Surg, Weill Inst Neurosci, San Francisco, CA 94143 USA.; Ferguson, AR (reprint author), San Francisco VA Med Ctr, Dept Vet Affairs, San Francisco, CA 94121 USA. EM manleyg@neurosurg.ucsf.edu; adam.ferguson@ucsf.edu OI Yue, John/0000-0001-9694-7722 FU Department of Defense (DoD) [W81XWH-131-0441]; National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) [NS067092, NS069409, NS069409-0251]; Craig H. Neilsen Foundation (ARF); Wings for Life Foundation (ARF) FX This work was funded by the following: Department of Defense (DoD) grant W81XWH-131-0441 (GTM): http://cdmrp.army.mil/funding/phtbi.shtml; National Institutes of Health/National Institute of Neurological Disorders and Stroke (NIH/NINDS) grants NS067092 (ARF), NS069409 (GTM) and NS069409-0251 (GTM): http://www.runds.nih.govt/; Craig H. Neilsen Foundation (ARF): http://chnfoundation.org/; and Wings for Life Foundation (ARF): http://www.wingsforlrie.com/en/. NR 41 TC 0 Z9 0 U1 5 U2 5 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1932-6203 J9 PLOS ONE JI PLoS One PD MAR 3 PY 2017 VL 12 IS 3 AR e0169490 DI 10.1371/journal.pone.0169490 PG 19 WC Multidisciplinary Sciences SC Science & Technology - Other Topics GA EN5BR UT WOS:000396021100002 PM 28257413 ER PT J AU He, K Palen, BN Mattox, EA Parsons, EC AF He, Ken Palen, Brian N. Mattox, Elizabeth A. Parsons, Elizabeth C. TI Veteran Preferences Regarding Wireless Management of Positive Airway Pressure for Obstructive Sleep Apnea at a Tertiary Health-Care System SO RESPIRATORY CARE LA English DT Article DE sleep apnea syndrome; CPAP; patient preference; telehealth; telemedicine; e-health; home health monitoring; technology ID RANDOMIZED CONTROLLED-TRIAL; CARDIOVASCULAR-DISEASE; HIGH-RISK; ADHERENCE; PROGRAM; POPULATION; ADULTS; DIAGNOSIS; MEDICINE; ACCESS AB BACKGROUND: Timely monitoring of obstructive sleep apnea (OSA) therapy can be a challenge amid conflicting pressures of rising patient volume and shortage of sleep medicine providers. Positive airway pressure (PAP) devices with wireless modem technology have the potential to improve patient access to care and streamline work load, yet little is known about patient attitudes toward telehealth integration among veterans with sleep apnea. As part of a larger quality improvement initiative at the Veterans Affairs (VA) Puget Sound Health Care System, we elicited veterans' preferences toward modem versus traditional PAP data download, including patient attitudes and factors affecting those preferences. METHODS: We conducted an anonymous survey of veterans without previous CPAP experience presenting for initial device setup and training at VA Puget Sound PAP clinics. Surveys assessed subject demographics, PAP download preferences (modem vs mail), and Likert- type scale ratings of importance placed on factors including convenience and information privacy. Using multinomial logistic regression, we examined the association between convenience rating and download preference, adjusting for information privacy rating, age, and commute time. RESULTS: Of 444 surveys analyzed, respondents were primarily male with a mean age of 52 y. Most respondents reported taking >= 30 min to commute to the PAP clinic. Convenience was rated as the most important factor affecting download preferences. Veteran preferences regarding PAP download method were mixed, with 47% preferring modem, 38% preferring memory card mail- in, and 15% undecided. A higher rating of convenience was significantly associated with modem preference, both before and after adjustment for information privacy rating, commute time, and veteran age (adjusted relative risk ratio 1.67, P <.001, 95% CI 1.40-1.99). CONCLUSIONS: PAP data download preferences were mixed among new veteran users. Veterans placed a high value on the potentially competing concerns of convenience and information privacy. Veterans preferring modem factored convenience as important in their decision making, independent of privacy concerns. C1 [Palen, Brian N.; Parsons, Elizabeth C.] Univ Washington, Div Pulm & Crit Care Med, Seattle, WA 98195 USA. [He, Ken; Palen, Brian N.; Mattox, Elizabeth A.; Parsons, Elizabeth C.] Vet Affairs Puget Sound Hlth Care Syst, 1600 S Columbian Way,S-111 Pulm, Seattle, WA 98108 USA. RP Parsons, EC (reprint author), Vet Affairs Puget Sound Hlth Care Syst, 1600 S Columbian Way,S-111 Pulm, Seattle, WA 98108 USA. EM Elizabeth.parsons@va.gov NR 43 TC 0 Z9 0 U1 1 U2 1 PU DAEDALUS ENTERPRISES INC PI IRVING PA 9425 N MAC ARTHUR BLVD, STE 100, IRVING, TX 75063-4706 USA SN 0020-1324 EI 1943-3654 J9 RESP CARE JI Respir. Care PD MAR 2 PY 2017 VL 62 IS 3 BP 357 EP 362 DI 10.4187/respcare.05002 PG 6 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EL9WT UT WOS:000394971500013 PM 27879382 ER PT J AU Geha, R Peters, M Gill, RM Dhaliwal, G AF Geha, Rabih Peters, Marion Gill, Ryan M. Dhaliwal, Gurpreet TI Histology Rings True SO NEW ENGLAND JOURNAL OF MEDICINE LA English DT Editorial Material ID Q-FEVER; HEPATIC GRANULOMAS; DIAGNOSIS; DISEASE C1 [Peters, Marion] Univ Calif San Francisco, Div Gastroenterol, San Francisco, CA 94143 USA. [Geha, Rabih; Peters, Marion; Dhaliwal, Gurpreet] Univ Calif San Francisco, Dept Med, San Francisco, CA USA. [Gill, Ryan M.] Univ Calif San Francisco, Dept Pathol, San Francisco, CA 94140 USA. [Dhaliwal, Gurpreet] San Francisco VA Med Ctr, Med Serv, San Francisco, CA USA. RP Geha, R (reprint author), 505 Parnassus Ave,Rm 987, San Francisco, CA 94143 USA. EM rabih.geha@ucsf.edu FU Philips Healthcare FX Dr. Peters reports receiving honoraria from Merck, Roche, Johnson & Johnson, Gilead Sciences, Abbott, and Genentech; Dr. Gill, receiving consulting fees from Philips Healthcare; and Dr. Dhaliwal, receiving honoraria from the ISMIE Mutual Insurance and Physicians' Reciprocal Insurers. No other potential conflict of interest relevant to this article was reported. NR 13 TC 0 Z9 0 U1 1 U2 1 PU MASSACHUSETTS MEDICAL SOC PI WALTHAM PA WALTHAM WOODS CENTER, 860 WINTER ST,, WALTHAM, MA 02451-1413 USA SN 0028-4793 EI 1533-4406 J9 NEW ENGL J MED JI N. Engl. J. Med. PD MAR 2 PY 2017 VL 376 IS 9 BP 870 EP 875 DI 10.1056/NEJMcps1609391 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA EM9JK UT WOS:000395627500012 ER PT J AU Sheshadri, A Johansen, KL AF Sheshadri, Anoop Johansen, Kirsten L. TI Prehabilitation for the Frail Patient Approaching ESRD SO SEMINARS IN NEPHROLOGY LA English DT Review DE Frailty; CKD; ESRD; prehabilitation; physical function; exercise ID CHRONIC KIDNEY-DISEASE; STAGE RENAL-DISEASE; QUALITY-OF-LIFE; RECEIVING MAINTENANCE HEMODIALYSIS; PHYSICAL-ACTIVITY; DIALYSIS PATIENTS; EXERCISE PROGRAM; CONTROLLED-TRIAL; MUSCLE STRENGTH; PREDIALYSIS PATIENTS AB Frailty is a distinct phenotype that is highly prevalent in chronic kidney disease (CKD) and appears to be more prevalent with decreasing glomerular filtration rate. Exercise training or intervention to increase physical activity may ameliorate poor physical functioning and frailty, and even may improve survival in patients with CKD. Although exercise interventions improve outcomes across the spectrum of CKD, including patients treated with dialysis, patients treated with dialysis face barriers to exercise that patients with predialysis CKD do not. Rehabilitation at earlier stages of CKD (or prehabilitation before dialysis) might be more beneficial than not addressing the decreasing physical functioning and low physical activity until patients are receiving dialysis. This review summarizes available literature on frailty in the CKD and end-stage renal disease population, including exercise interventions and the limited evidence for prehabilitation as a strategy. Published by Elsevier Inc. C1 [Johansen, Kirsten L.] San Francisco VA Med Ctr, Nephrol Sect, 111J,4150 Clement St, San Francisco, CA 94121 USA. Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Johansen, KL (reprint author), San Francisco VA Med Ctr, Nephrol Sect, 111J,4150 Clement St, San Francisco, CA 94121 USA. EM Kirsten.johansen@ucsf.edu FU NIDDK NIH HHS [K24 DK085153] NR 102 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0270-9295 EI 1558-4488 J9 SEMIN NEPHROL JI Semin. Nephrol. PD MAR PY 2017 VL 37 IS 2 BP 159 EP 172 DI 10.1016/j.semnephrol.2016.12.006 PG 14 WC Urology & Nephrology SC Urology & Nephrology GA ES9CF UT WOS:000399852900007 PM 28410650 ER PT J AU Brennan, MB Hess, TM Bartle, B Cooper, JM Kang, J Huang, ES Smith, M Sohn, MW Crnich, C AF Brennan, Meghan B. Hess, Timothy M. Bartle, Brian Cooper, Jennifer M. Kang, Jonathan Huang, Elbert S. Smith, Maureen Sohn, Min-Woong Crnich, Christopher TI Diabetic foot ulcer severity predicts mortality among veterans with type 2 diabetes SO JOURNAL OF DIABETES AND ITS COMPLICATIONS LA English DT Article DE Diabetes; Foot ulcer; Gangrene; Mortality; Vascular disease ID EURODIALE; RISK; DISEASE AB Aim: Diabetic foot ulcers are associated with an increased risk of death. We evaluated whether ulcer severity at presentation predicts mortality. Methods: Patients from a national, retrospective, cohort of veterans with type 2 diabetes who developed incident diabetic foot ulcers between January 1, 2006 and September 1, 2010, were followed until death or the end of the study period, January 1, 2012. Ulcers were characterized as early stage, osteomyelitis, or gangrene at presentation. Cox proportional hazard regression identified independent predictors of death, controlling for comorbidities, laboratory parameters, and healthcare utilization. Results: 66,323 veterans were included in the cohort and followed for a mean of 27.7 months: 1-, 2-, and 5-year survival rates were 80.80%, 69.01% and 28.64%, respectively. Compared to early stage ulcers, gangrene was associated with an increased risk of mortality (HR 1.70, 95% C11.57-1.83, p < 0.001). The magnitude of this effect was greater than diagnosed vascular disease, i.e., coronary artery disease, peripheral arterial disease, or stroke. Conclusion: Initial diabetic foot ulcer severity is a more significant predictor of subsequent mortality than coronary artery disease, peripheral arterial disease, or stroke. Unrecognized or under-estimated vascular disease and/or sepsis secondary to gangrene should be explored as possible causal explanations. (C) 2017 Elsevier Inc. All rights reserved. C1 [Brennan, Meghan B.; Hess, Timothy M.; Smith, Maureen; Crnich, Christopher] Univ Wisconsin, Sch Med & Publ Hlth, 1685 Highland Ave, Madison, WI 53705 USA. [Brennan, Meghan B.; Hess, Timothy M.; Kang, Jonathan; Crnich, Christopher] William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace, Madison, WI 53705 USA. [Brennan, Meghan B.; Bartle, Brian; Huang, Elbert S.; Sohn, Min-Woong] Edward Hines Jr Vet Hosp, 5000 S 5th Ave, Hines, IL 60141 USA. [Cooper, Jennifer M.; Huang, Elbert S.] Univ Chicago, Med Ctr, 5841 S Maryland Ave, Chicago, IL 60637 USA. [Sohn, Min-Woong] Univ Virginia, Sch Med, 1215 Lee St, Charlottesville, VA 22908 USA. RP Brennan, MB (reprint author), 1685 Highland Ave, Madison, WI 53705 USA. EM mbbrennan@medicine.wisc.edu FU Clinical and Translational Science Award (CSTA) program, through NIH National Center for Advancing Translational Science (NCATS) [UL1TR000427]; NIH [KL2TR000428, K24DK105340, P30DK092949]; AHRQ [R01 HS018542, R01 HS018368] FX The project described was supported by the Clinical and Translational Science Award (CSTA) program, through the NIH National Center for Advancing Translational Science (NCATS), grant UL1TR000427. Additional funding was through the NIH grant numbers KL2TR000428, K24DK105340, and P30DK092949 and AHRQ grants R01 HS018542 and R01 HS018368. The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH, AHRQ or VA. NR 11 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1056-8727 EI 1873-460X J9 J DIABETES COMPLICAT JI J. Diabetes Complications PD MAR PY 2017 VL 31 IS 3 BP 556 EP 561 DI 10.1016/j.jdiacomp.2016.11.020 PG 6 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA ES3NC UT WOS:000399435300007 PM 27993523 ER PT J AU Patel, AM Wang, V Philipp, A Yusin, JS AF Patel, Anil M. Wang, Vivian Philipp, Ami Yusin, Joseph S. TI Underuse of allergy services for patients having systemic reactions to Hymenoptera venom stings SO ANNALS OF ALLERGY ASTHMA & IMMUNOLOGY LA English DT Letter ID EMERGENCY-DEPARTMENT VISITS; ANAPHYLAXIS; EPIDEMIOLOGY C1 [Patel, Anil M.; Wang, Vivian; Philipp, Ami; Yusin, Joseph S.] VA Greater Los Angeles Healthcare Syst, Dept Allergy & Immunol, Los Angeles, CA 90073 USA. RP Yusin, JS (reprint author), VA Greater Los Angeles Healthcare Syst, Dept Allergy & Immunol, Los Angeles, CA 90073 USA. EM jsyusin@yahoo.com NR 10 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1081-1206 EI 1534-4436 J9 ANN ALLERG ASTHMA IM JI Ann. Allergy Asthma Immunol. PD MAR PY 2017 VL 118 IS 3 BP 366 EP 367 PG 3 WC Allergy; Immunology SC Allergy; Immunology GA ER6RT UT WOS:000398935500023 PM 28073614 ER PT J AU Burge, SK Ferrer, RL Foster, EL Becho, J Talamantes, M Wood, RC Katerndahl, DA AF Burge, Sandra K. Ferrer, Robert L. Foster, Erin L. Becho, Johanna Talamantes, Melissa Wood, Robert C. Katerndahl, David A. TI Research or Intervention or Both? Women's Changes After Participation in a Longitudinal Study About Intimate Partner Violence SO FAMILIES SYSTEMS & HEALTH LA English DT Article DE spouse abuse; battered women; domestic violence; longitudinal studies; qualitative research ID SURVIVORS; DYNAMICS AB Introduction: The tensions between risk and benefit in research are particularly evident in studies about intimate partner violence. Recalling and relating traumatic experiences may deepen posttraumatic stress or relieve the burden of terrible events long borne in secret. In this article, we examine the effects of study participation in a longitudinal investigation of intimate partner violence using both qualitative and quantitative data. Method: Researchers enrolled 200 women in moderately violent intimate relationships and asked them to report about their relationships every day for 12 weeks. Daily, participants telephoned an automated survey and responded to 34 survey questions. They also completed baseline and end-of-study surveys and maintained telephone contact with 1 researcher weekly. Forty-2 participants completed qualitative end-of-study interviews to describe their relationships and their experiences in the study. Results: Over 12 weeks, participants showed improvements in coping strategies, hope, and mental health, and increased readiness to leave their partners. In qualitative interviews, women reported gaining insight, feeling better emotionally, making behavioral changes, finding comfort in daily surveys, learning resources for help, and taking action to improve their lives. Fourteen percent left their partners by end-of-study; 35% sought counseling. Discussion: The study's daily survey invited the participant to become more reflective about her relationship, which changed how she saw herself and her situation. The study methods also included weekly conversations with a compassionate researcher, allowing women to tell their stories. These 2 strategies may be incorporated into brief interventions for intimate partner violence in primary care settings. C1 [Burge, Sandra K.; Ferrer, Robert L.; Wood, Robert C.; Katerndahl, David A.] Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, 7703 Floyd Curl Dr,Mail Code 7795, San Antonio, TX 78229 USA. [Foster, Erin L.] Univ Texas Hlth Sci Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Talamantes, Melissa] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Burge, SK (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Family & Community Med, 7703 Floyd Curl Dr,Mail Code 7795, San Antonio, TX 78229 USA. EM burge@uthscsa.edu FU "Dynamics of Human Behavior" program, National Science Foundation [0525026] FX This study was funded with a grant from the "Dynamics of Human Behavior" program, National Science Foundation, Award 0525026. Automated data collection was provided by the University of Colorado, Department of Family Medicine Information Services group. We thank Stephanie Mitchell, Kelli Giacomini, and Wilson Pace for their invaluable assistance with the Interactive Voice Response system. We also express appreciation to Norma Cantu and Diandrea Garza for their commitment to screening and enrolling women for this study. NR 26 TC 0 Z9 0 U1 1 U2 1 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1091-7527 EI 1939-0602 J9 FAM SYST HEALTH JI Fam. Syst. Health PD MAR PY 2017 VL 35 IS 1 BP 25 EP 35 DI 10.1037/fsh0000246 PG 11 WC Health Care Sciences & Services; Family Studies; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Family Studies; Public, Environmental & Occupational Health GA ER4OR UT WOS:000398780300005 PM 28068119 ER PT J AU Vig, EK Taylor, JS O'Hare, AM AF Vig, Elizabeth K. Taylor, Janelle S. O'Hare, Ann M. TI Considering a Family Systems Approach to Surrogate Decision-Making SO FAMILIES SYSTEMS & HEALTH LA English DT Editorial Material C1 [Vig, Elizabeth K.] Vet Affairs Puget Sound Hlth Care Syst, Dept Geriatr & Extended Care, Seattle, WA 98108 USA. [Vig, Elizabeth K.] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Taylor, Janelle S.] Univ Washington, Dept Anthropol, Seattle, WA 98195 USA. [O'Hare, Ann M.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA 98108 USA. [O'Hare, Ann M.] Univ Washington, Ctr Innovat Vet Ctr & Value Driven Care, Hosp & Specialty Med Serv, Seattle, WA 98195 USA. [O'Hare, Ann M.] Univ Washington, Dept Med, Seattle, WA 98195 USA. RP Vig, EK (reprint author), Vet Affairs Puget Sound Hlth Care Syst, Dept Geriatr & Extended Care, Seattle, WA 98108 USA. EM vigster@uw.edu NR 8 TC 0 Z9 0 U1 0 U2 0 PU EDUCATIONAL PUBLISHING FOUNDATION-AMERICAN PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST, NE, WASHINGTON, DC 20002-4242 USA SN 1091-7527 EI 1939-0602 J9 FAM SYST HEALTH JI Fam. Syst. Health PD MAR PY 2017 VL 35 IS 1 BP 85 EP 87 DI 10.1037/fsh0000255 PG 3 WC Health Care Sciences & Services; Family Studies; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Family Studies; Public, Environmental & Occupational Health GA ER4OR UT WOS:000398780300011 PM 28333517 ER PT J AU Kontos, AP Van Cott, AC Roberts, J Pan, JW Kelly, MB McAllister-Deitrick, J Hetherington, HP AF Kontos, Anthony P. Van Cott, Anne C. Roberts, Jodilyn Pan, Jullie W. Kelly, Monique B. McAllister-Deitrick, Jamie Hetherington, Hoby P. TI Clinical and Magnetic Resonance Spectroscopic Imaging Findings in Veterans With Blast Mild Traumatic Brain Injury and Post-Traumatic Stress Disorder SO MILITARY MEDICINE LA English DT Article; Proceedings Paper CT 5th Military Health System Research Symposium CY AUG 17-21, 2015 CL Fort Lauderdale, FL ID EXPLOSIVE BLAST; 7 T; AFGHANISTAN; HISTORY; ARRAYS; IRAQ; CARE AB Objectives: To compare magnetic resonance spectroscopic imaging (MRSI) findings from the hippocampal regions of military veterans with blast-related mild traumatic brain injury (blast mTBI) and post-traumatic stress disorder (PTSD) to those with PTSD only; and to examine the relationship of MRSI findings to cognitive and neuromotor impairment. Methods: 35 military veterans-23 with blast mTBI and PTSD (blast mTBI/PTSD) and 12 with PTSD only participated in the study. Whole plane MRSI data including N-acetyl aspartate (NAA) and choline (Ch) were acquired at 7T for the hippocampus. Concurrent cognitive and neuromotor data were collected using established assessments. General linear models (GLMs) with Bonferroni correction were used to compare the two groups on NAA/Ch ratios across regions of the hippocampus. Spearman's correlations were used to examine correlations between NAA/Ch and cognitive and neuromotor impairment. Results: The NAA/Ch results for the left hippocampus were lower in the blast mTBI/PTSD group than the PTSD-only group. The blast mTBI/PTSD group also scored worse on the WAIS-IV-vocabulary. Significant correlations between NAA/Ch and neuromotor outcomes-including vestibular impairment-were supported. Conclusions: Combined MRSI and cognitive and neuromotor data may help inform more objective and accurate diagnoses and effective treatments for patients with blast mTBI and PTSD. C1 [Kontos, Anthony P.; McAllister-Deitrick, Jamie] Univ Pittsburgh, Dept Orthopaed Surg, 3471 Fifth Ave,1010, Pittsburgh, PA 15213 USA. [Van Cott, Anne C.; Roberts, Jodilyn; Kelly, Monique B.] VA Pittsburgh Healthcare Syst, Univ Dr C, Pittsburgh, PA 15240 USA. [Van Cott, Anne C.; Pan, Jullie W.] Univ Pittsburgh, Dept Neurol, 811 Kaufmann Med Bldg,3471 Fifth Ave 810, Pittsburgh, PA 15213 USA. [Hetherington, Hoby P.] Univ Pittsburgh, Magnet Resonance Res Ctr, 200 Lothrop St, Pittsburgh, PA 15213 USA. RP Kontos, AP (reprint author), Univ Pittsburgh, Dept Orthopaed Surg, 3471 Fifth Ave,1010, Pittsburgh, PA 15213 USA. FU National Institutes of Health/National Institute of Neurological Disorders [Stroke-NIH-R01NS081772]; National Institute on Deafness and Other Communication Disorders [1K01DC012332-01A1]; National Institutes of Health/National Institute of Biomedical Imaging and Bioengineering NIH [R01EB011639] FX This research was supported in part by a grant to the University of Pittsburgh to Dr. Hetherington and Dr. VanCott from the National Institutes of Health/National Institute of Neurological Disorders and Stroke-NIH-R01NS081772; and by a grant to the University of Pittsburgh to Dr. Kontos from the National Institute on Deafness and Other Communication Disorders (1K01DC012332-01A1); and a grant to Dr Jullie W. Pan from the National Institutes of Health/National Institute of Biomedical Imaging and Bioengineering NIH R01EB011639. NR 27 TC 0 Z9 0 U1 0 U2 0 PU ASSOC MILITARY SURG US PI BETHESDA PA 9320 OLD GEORGETOWN RD, BETHESDA, MD 20814 USA SN 0026-4075 EI 1930-613X J9 MIL MED JI Milit. Med. PD MAR PY 2017 VL 182 SU 1 BP 99 EP 104 DI 10.7205/MILMED-D-16-00177 PG 6 WC Medicine, General & Internal SC General & Internal Medicine GA ER6VN UT WOS:000398947100017 PM 28291459 ER PT J AU Fung, CH Martin, JL Hays, RD Patterson, ES Aysola, R Col, N Mitchell, MN Truong, C Dzierzewski, JM Jouldjian, S Song, Y Rodriguez, JC Josephson, K Alessi, C AF Fung, Constance H. Martin, Jennifer L. Hays, Ron D. Patterson, Emily S. Aysola, Ravi Col, Nananda Mitchell, Michael N. Truong, Cindy Dzierzewski, Joseph M. Jouldjian, Stella Song, Yeonsu Carlos Rodriguez, Juan Josephson, Karen Alessi, Cathy TI Patient-Reported Usability of Positive Airway Pressure Equipment Is Associated With Adherence in Older Adults SO SLEEP LA English DT Article DE sleep apnea; adherence; usability; predictive modeling. ID SLEEP-APNEA; INTERNET; THERAPY; USERS; CARE AB Study objectives: To examine the usability of positive airway pressure (PAP) devices and its association with PAP adherence among older adults with sleep-disordered breathing. Methods: We mailed questionnaires to patients aged >= 65 years prescribed PAP therapy during the prior 36 months from two large healthcare systems. Survey participants completed the Usability of Sleep Apnea Equipment-Positive Airway Pressure (USE-PAP) questionnaire, which assessed the usability of their PAP device. Other questionnaire items included demographics and self-rated health. We also abstracted adherence data (mean nightly hours of PAP use available from one site) and interface type from the electronic health record. Results: Five hundred sixty-four patients completed the survey (response rate = 33%). The mean USE-PAP score (0 = best to 100 = worst) was 20 (SD +/- 20). Mean duration of PAP use (available in 189 respondents) was 5.2 hours per night (SD +/- 2.0). In a nested regression model predicting nightly hours of PAP use, a 10-point (0.5 SD) increase in USE-PAP score corresponded to a 0.37 hour/night reduction in PAP use. The model including the USE-PAP score explained a significant proportion (R-2 = 15%) of the variation in nightly hours of PAP use above and beyond demographics, self-reported health, and interface type (R-2 = 12%). Conclusions: Our results demonstrate that PAP usability varies among older patients and is associated with PAP adherence, above and beyond other predictors of adherence. These results support measuring and improving PAP usability to further improve PAP adherence for older patients. C1 [Fung, Constance H.; Martin, Jennifer L.; Mitchell, Michael N.; Truong, Cindy; Dzierzewski, Joseph M.; Jouldjian, Stella; Song, Yeonsu; Josephson, Karen; Alessi, Cathy] VA Greater Los Angeles Healthcare Syst, Geriatr Res Educ & Clin Ctr, Los Angeles, CA USA. [Fung, Constance H.; Martin, Jennifer L.; Hays, Ron D.; Aysola, Ravi; Song, Yeonsu; Carlos Rodriguez, Juan; Alessi, Cathy] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Patterson, Emily S.] Ohio State Univ, Sch Hlth & Rehabil Sci, Columbus, OH 43210 USA. [Col, Nananda] Univ New England, Biddeford, ME USA. [Dzierzewski, Joseph M.] Virginia Commonwealth Univ, Dept Psychol, Box 2018, Richmond, VA 23284 USA. [Carlos Rodriguez, Juan] Pontificia Univ Catolica Chile, Santiago, Chile. RP Fung, CH (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Geriatr Res Educ & Clin Ctr,VA Greater Los Angele, 16111 Plummer St,11E, North Hills, CA 91343 USA. EM constance.fung@va.gov FU VA Greater Los Angeles Healthcare System Sleep Center FX We thank Michelle Zeidler, MD, MS and Silverio Santiago, MD from the VA Greater Los Angeles Healthcare System Sleep Center for their support of our study, and Sergio Martinez and Simone Vukelich for their help abstracting data and preparing the survey mailings. We also thank the UCLA Pulmonary/Sleep Clinic administrative staff for their support of our project. NR 22 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS INC PI CARY PA JOURNALS DEPT, 2001 EVANS RD, CARY, NC 27513 USA SN 0161-8105 EI 1550-9109 J9 SLEEP JI Sleep PD MAR 1 PY 2017 VL 40 IS 3 DI 10.1093/sleep/zsx007 PG 7 WC Clinical Neurology; Neurosciences SC Neurosciences & Neurology GA ER6ND UT WOS:000398921100024 ER PT J AU Katsiougiannis, S Chia, D Kim, Y Singh, RP Wong, DTW AF Katsiougiannis, Stergios Chia, David Kim, Yong Singh, Ram P. Wong, David T. W. TI Saliva exosomes from pancreatic tumor-bearing mice modulate NK cell phenotype and antitumor cytotoxicity SO FASEB JOURNAL LA English DT Article DE extracellular vesicles; immune surveillance; cancer ID NATURAL-KILLER-CELLS; EXTRACELLULAR VESICLES; CANCER EXOSOMES; EMERGING ROLE; MARKERS; DIAGNOSTICS; METASTASIS; BIOMARKERS; INNATE AB Tumor exosomes are emerging as antitumor immunity regulators; however, their effects on secondary exosome secretion by distal organs have not been explored. We have previously demonstrated that suppression of exosomes at the distal tumor site of pancreatic ductal adenocarcinoma (PDAC) ablated the development of salivary biomarker profile. Here, we explore the function of salivary exosomes from tumor-bearing mice in immune surveillance. We provide evidence that salivary exosomes from mice with PDA Cexhibit a suppressive effect that results in reduced tumor-killing capacity by NK cells. Salivary exosomes from mice with PDAC where pancreatic tumors were engineered to suppress exosome biogenesis failed to suppress NK cell cytotoxic potential against tumor cells, as opposed to salivary exosomes from mice with PDAC with normal tumor exosome biogenesis. These results reveal an important and previously unknown mechanism of antitumor immune regulation and provide new in sights into our understanding of the alterations of this biofluid during tumor development. C1 [Katsiougiannis, Stergios; Kim, Yong; Wong, David T. W.] Univ Calif Los Angeles, Sch Dent, Ctr Oral Head & Neck Oncol Res, 10833 Le Conte Ave,Box 951668, Los Angeles, CA 90024 USA. [Chia, David; Kim, Yong; Wong, David T. W.] Univ Calif Los Angeles, Jonsson Comprehens Canc Ctr, Los Angeles, CA 90024 USA. [Kim, Yong] Univ Calif Los Angeles, Lab Stem Cell & Canc Epigenet Res, Los Angeles, CA USA. [Chia, David] Univ Calif Los Angeles, Dept Pathol & Lab Med, Los Angeles, CA USA. [Singh, Ram P.] Univ Calif Los Angeles, David Geffen Sch Med, Div Rheumatol, Los Angeles, CA 90095 USA. [Singh, Ram P.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Wong, DTW (reprint author), Univ Calif Los Angeles, Sch Dent, Ctr Oral Head & Neck Oncol Res, 10833 Le Conte Ave,Box 951668, Los Angeles, CA 90024 USA. EM dwong@dentistry.ucla.edu FU NCATS NIH HHS [UH2 TR000923] NR 29 TC 0 Z9 0 U1 5 U2 5 PU FEDERATION AMER SOC EXP BIOL PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814-3998 USA SN 0892-6638 EI 1530-6860 J9 FASEB J JI Faseb J. PD MAR PY 2017 VL 31 IS 3 BP 998 EP + DI 10.1096/fj.201600984R PG 16 WC Biochemistry & Molecular Biology; Biology; Cell Biology SC Biochemistry & Molecular Biology; Life Sciences & Biomedicine - Other Topics; Cell Biology GA EM9ZX UT WOS:000395671200016 PM 27895106 ER PT J AU Marcuccilli, M Chonchol, M Jovanovich, A AF Marcuccilli, Morgan Chonchol, Michel Jovanovich, Anna TI Phosphate Binders and Targets Over Decades: Do We have it Right Now? SO SEMINARS IN DIALYSIS LA English DT Article ID CHRONIC KIDNEY-DISEASE; CORONARY-ARTERY CALCIFICATION; STAGE RENAL-DISEASE; CHRONIC-HEMODIALYSIS PATIENTS; LEFT-VENTRICULAR HYPERTROPHY; MINERAL BONE DISORDER; CARDIOVASCULAR-DISEASE; LANTHANUM CARBONATE; PARATHYROID-HORMONE; CALCIUM-CARBONATE AB In advanced renal disease, the kidney is unable to maintain phosphate balance due to decreased urinary excretion as well as the imbalance of the bone metabolic axis. It is well established that hyperphosphatemia is associated with increased cardiovascular events and mortality in patients with chronic kidney disease (CKD). However, there are no randomized controlled trials that demonstrate a clear benefit on hard outcomes in lowering serum phosphate levels to recommended targets in the CKD or dialysis population. In addition, while calcium-based phosphate binders have traditionally been the standard of care in the treatment of hyperphosphatemia, data regarding the increased risk of vascular mineralization continues to emerge. Clinicians continue to search for new phosphate-lowering therapies as well as investigate novel nutritional perspectives. The Kidney Disease: Improving Global Outcomes is currently revising the guidelines on phosphate goals in CKD. This review will outline the history of phosphate targets and phosphate binders, and explore innovative phosphate-lowering therapies. Based on current data, clinicians moving forward should continue to treat end-stage renal disease patients with hyperphosphatemia based on individual risk factors for vascular mineralization. C1 [Marcuccilli, Morgan; Chonchol, Michel; Jovanovich, Anna] Hypertens Univ Colorado, Div Renal Dis, Denver, CO USA. [Jovanovich, Anna] Denver VA Med Ctr, Denver, CO USA. RP Chonchol, M (reprint author), Div Renal Dis & Hypertens, 12700,East 19th Ave C281, Aurora, CO 80045 USA. EM michel.chonchol@ucdenver.edu NR 60 TC 0 Z9 0 U1 2 U2 2 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0894-0959 EI 1525-139X J9 SEMIN DIALYSIS JI Semin. Dial. PD MAR-APR PY 2017 VL 30 IS 2 SI SI BP 134 EP 141 DI 10.1111/sdi.12568 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA EM5HK UT WOS:000395342400008 PM 28064444 ER PT J AU Baciewicz, AM Lee, C Ben-Ari, A Kim, H Lee, AT AF Baciewicz, Anne M. Lee, Calvin Ben-Ari, Alon Kim, Hojoong Lee, Alex T. TI Intravenous Tissue Plasminogen Activator Administration for Ischemic Stroke 1 Hour After Epidural Catheter Removal: A Case Report SO A & A CASE REPORTS LA English DT Article ID ASSOCIATION; GUIDELINES; MEDICINE; SOCIETY AB Anticoagulation after a recent neuraxial procedure poses risk for development of spinal hematoma. Clinical evidence supports prompt IV tissue plasminogen activator administration after onset of ischemic stroke. There is an absence of data regarding emergency fibrinolytic therapy for patients experiencing a stroke with recent neuraxial procedures, resulting in highly disparate, nonevidence-based guidelines. This report describes a patient who developed ischemic stroke when receiving postoperative epidural analgesia. Tissue plasminogen activator was emergently administered 1 hour after epidural catheter removal with a favorable recovery. The patient and his family reviewed the manuscript, and written consent to publish this case report was obtained from the patient. C1 [Baciewicz, Anne M.] Univ Washington, Dept Pharm, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. [Lee, Calvin] Univ Washington, Dept Anesthesiol & Pain Med, Seattle, WA 98195 USA. [Ben-Ari, Alon; Lee, Alex T.] Univ Washington, Dept Anesthesiol & Pain Med, VA Puget Sound Hlth Care Syst, 1660 Columbian Way S-112-Anes, Seattle, WA 98108 USA. [Kim, Hojoong] Univ Washington, Dept Neurol, VA Puget Sound Hlth Care Syst, Seattle, WA 98195 USA. RP Lee, AT (reprint author), Univ Washington, Dept Anesthesiol & Pain Med, VA Puget Sound Hlth Care Syst, 1660 Columbian Way S-112-Anes, Seattle, WA 98108 USA. EM alex.lee@va.gov NR 9 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2325-7237 J9 A A CASE REP JI A A Case Rep. PD MAR 1 PY 2017 VL 8 IS 5 BP 113 EP 115 DI 10.1213/XAA.0000000000000443 PG 3 WC Anesthesiology SC Anesthesiology GA EN3HQ UT WOS:000395900000006 PM 28079666 ER PT J AU Katolik, A Clark, NE Tago, N Montemayor, EJ Hart, PJ Damha, MJ AF Katolik, Adam Clark, Nathaniel E. Tago, Nobuhiro Montemayor, Eric J. Hart, P. John Damha, Masad J. TI Fluorescent Branched RNAs for High-Throughput Analysis of Dbr1 Enzyme Kinetics and Inhibition SO ACS CHEMICAL BIOLOGY LA English DT Article ID LARIAT-DEBRANCHING ENZYME; SOLID-PHASE SYNTHESIS; MANGANESE-DEPENDENT PHOSPHODIESTERASE; TY1; OLIGORIBONUCLEOTIDES; RETROTRANSPOSITION; MECHANISMS; LINKAGES; SEQUENCE; DESIGN AB We have developed fluorescent 2',S' branched RNAs (bRNA) that permit real time monitoring of RNA lariat (intron) debranching enzyme (Dbrl) kinetics. These compounds contain fluorescein (FAM) on the 5' arm of the bRNA that is quenched by a dabcyl moiety on the 2 arm. Dbrl-mediated hydrolysis of the 2',S' linkage induces a large increase in fluorescence, providing a convenient assay for Dbrl hydrolysis. We show that unlabeled bRNAs with non-native 2',5'- phosphodiester linkages, such as phosphoramidate or phosphorothioate, can inhibit Dbrl-mediated debranching with IC50 values in the low nanomolar range. In addition to measuring kinetic parameters of the debranching enzyme, these probes can be used for high throughput screening (HTS) of chemical libraries with the aim of identifying Dbrl inhibitors, compounds that may be useful in treating neurodegenerative diseases and retroviral infections. C1 [Katolik, Adam; Tago, Nobuhiro; Damha, Masad J.] McGill Univ, Dept Chem, 801 Sherbrooke St West, Montreal, PQ H3A 0B8, Canada. [Clark, Nathaniel E.; Hart, P. John] Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA. [Montemayor, Eric J.] Univ Wisconsin, Dept Biochem, 433 Babcock Dr, Madison, WI 53706 USA. [Montemayor, Eric J.] Univ Wisconsin, Dept Biomol Chem, 433 Babcock Dr, Madison, WI 53706 USA. [Hart, P. John] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA. RP Damha, MJ (reprint author), McGill Univ, Dept Chem, 801 Sherbrooke St West, Montreal, PQ H3A 0B8, Canada.; Clark, NE; Hart, PJ (reprint author), Univ Texas Hlth Sci Ctr San Antonio, Dept Biochem & Struct Biol, 7703 Floyd Curl Dr, San Antonio, TX 78229 USA.; Hart, PJ (reprint author), South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA. EM clarkn@uthscsa.edu; pjh@biochem.uthscsa.edu; masad.damha@mcgill.ca FU National Sciences and Engineering Research Council of Canada; Department of Veterans Affairs [1 I01 BX002580]; Robert A. Welch Foundation [AQ-1399]; Judith and Jean Pape Adams Charitable Foundation; National Science Foundation [DBI-0905865]; National Institutes of Health [T32 AG021890]; Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation from a Japan Society for the Promotion of Science (JSPS) FX This work was supported in part by grants from the National Sciences and Engineering Research Council of Canada (to M.J.D.), Department of Veterans Affairs (1 I01 BX002580, to PJ.H.), the Robert A. Welch Foundation (AQ-1399, to PJ.H.), the Judith and Jean Pape Adams Charitable Foundation (to PJ.H.), the National Science Foundation (DBI-0905865, to E.J.M.), the National Institutes of Health (T32 AG021890, to N.E.C. and EJ.M.), and a Strategic Young Researcher Overseas Visits Program for Accelerating Brain Circulation from a Japan Society for the Promotion of Science (JSPS to N.T.). NR 33 TC 0 Z9 0 U1 3 U2 3 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1554-8929 EI 1554-8937 J9 ACS CHEM BIOL JI ACS Chem. Biol. PD MAR PY 2017 VL 12 IS 3 BP 622 EP 627 DI 10.1021/acschembio.6b00971 PG 6 WC Biochemistry & Molecular Biology SC Biochemistry & Molecular Biology GA EP0LB UT WOS:000397077700005 PM 28055181 ER PT J AU Lin, A Brook, J Grill, JD Teng, E AF Lin, Amy Brook, Jenny Grill, Joshua D. Teng, Edmond TI Participant-Informant Relationships Affect Quality of Life Ratings in Incipient and Clinical Alzheimer Disease SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Article DE Informant; study partner; quality of life; mild cognitive impairment; Alzheimer disease ID MILD COGNITIVE IMPAIRMENT; QOL-AD SCALE; CAREGIVER BURDEN; OLDER ADULTS; DEMENTIA; PERSPECTIVES; PROGRESSION; DIAGNOSIS; VALIDITY; PEOPLE AB Objective: Clinical trials in incipient and clinical Alzheimer disease (AD) often include informant-reported outcomes. Whereas informant reports in AD dementia may be modulated by the nature of participant-informant relationships, whether informant type affects reporting at earlier disease stages is less certain. We sought to determine the effects of participant-informant relationships on informant assessments of quality of life (QOL), functional abilities, and behavioral symptoms in individuals with normal cognition (NC), mild cognitive impairment (MCI), and mild-to-moderate AD dementia. Design: Cross-sectional. Setting: Easton Center for Alzheimer Disease Research at the University of California, Los Angeles. Participants: A total of 399 individuals who met criteria for NC (N = 100), MCI [amnestic (N = 125) and nonamnestic (N = 61)], and AD (N = 113). Participants were subdivided into groups based on informantparticipant relationships (spouse versus other). Measurements: We examined informant effects on the Quality of Life-Alzheimer's Disease (QOL-AD) scale, the Functional Activities Questionnaire (FAQ), and the Neuropsychiatric Inventory (NPI). Results: After adjustments for demographic and cognitive factors, spouse informants reported higher participant QOL in the amnestic MCI and AD groups than did other informants. No informant effects were seen on QOL-AD ratings in the nonamnestic MCI or NC groups or on the FAQ or NPI in the MCI andAD groups. Conclusions: Participant-informant relationships may modulate informant responses on subjective measures such as the QOL-AD in both incipient and clinical AD. Clinical trials that use informant measures may need to address these effects. C1 [Lin, Amy] Univ Southern Calif, Keck Sch Med, Los Angeles, CA USA. [Brook, Jenny] Univ Calif Los Angeles, David Geffen Sch Med, Dept Med, Los Angeles, CA 90095 USA. [Teng, Edmond] Univ Calif Los Angeles, David Geffen Sch Med, Dept Neurol, Los Angeles, CA 90095 USA. [Grill, Joshua D.] Univ Calif Irvine, Dept Psychiat & Human Behav, Inst Memory Impairments & Neurol Disorders, Irvine, CA 92717 USA. [Teng, Edmond] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. RP Teng, E (reprint author), West Los Angeles VA Healthcare Ctr, Neurobehav Serv 116AF, 11301 Wilshire Blvd, Los Angeles, CA 90073 USA. EM eteng@mednet.ucla.edu FU National Institute on Aging [T35 AG026736, P50 AG16570]; California Alzheimer's Disease Centers; Sidell-Kagan Foundation FX This research was supported by the National Institute on Aging (T35 AG026736 [UCLA Medical Student Training in Aging Research Program] and P50 AG16570 [UCLA Alzheimer's Disease Research Center]), the California Alzheimer's Disease Centers, and the Sidell-Kagan Foundation. NR 39 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2017 VL 25 IS 3 BP 297 EP 307 DI 10.1016/j.jagp.2016.10.007 PG 11 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA EP1FZ UT WOS:000397132100015 PM 27818119 ER PT J AU Reese, PP Bloom, RD Trofe-Clark, J Mussell, A Leidy, D Levsky, S Zhu, JS Yang, L Wang, WL Troxel, A Feldman, HI Volpp, K AF Reese, Peter P. Bloom, Roy D. Trofe-Clark, Jennifer Mussell, Adam Leidy, Daniel Levsky, Simona Zhu, Jingsan Yang, Lin Wang, Wenli Troxel, Andrea Feldman, Harold I. Volpp, Kevin TI Automated Reminders and Physician Notification to Promote Immunosuppression Adherence Among Kidney Transplant Recipients: A Randomized Trial SO AMERICAN JOURNAL OF KIDNEY DISEASES LA English DT Article DE Kidney transplantation; kidney transplant recipient (KTR); immunosuppression; tacrolimus; behavior change; adherence; compliance; automated reminder; medication reminder; wireless pill bottle; polypharmacy; end-stage renal disease (ESRD); tacrolimus trough level; allograft loss; randomized controlled trial ID PERCEIVED SOCIAL SUPPORT; MEDICATION ADHERENCE; ANTIRETROVIRAL THERAPY; RENAL-TRANSPLANTATION; MULTIDIMENSIONAL SCALE; FINANCIAL INCENTIVES; BLOOD-LEVELS; RISK-FACTOR; NONADHERENCE; REJECTION AB Background: Immunosuppression nonadherence increases the risk for kidney transplant loss after transplantation. Wireless-enabled pill bottles have created the opportunity to monitor medication adherence in real time. Reminders may help patients with poor memory or organization. Provision of adherence data to providers may motivate patients to improve adherence and help providers identify adherence barriers. Study Design: Randomized controlled trial. Setting & Participants: Kidney transplant recipients (n = 120) at a single center. Intervention: Participants were provided wireless pill bottles to store tacrolimus and record bottle openings. Participants were randomly assigned 1:1:1 to adherence monitoring with customized reminders (including alarms, texts, telephone calls, and/or e-mails), monitoring with customized reminders plus provider notification (every 2 weeks, providers received notification if adherence decreased to <90% during that period), or wireless pill bottle use alone (control). Outcomes: The main outcome was bottle-measured tacrolimus adherence during the last 90 days of the 180-day trial. A secondary outcome was tacrolimus whole-blood concentrations at routine clinical visits. Measurements: Adherence for the primary outcome was assessed via wireless pill bottle openings. Results: Mean participant age was 50 years; 60% were men,. and 40% were black. Mean adherence was 78%, 88%, and 55% in the reminders, reminders-plus-notification, and control arms (P < 0.001 for comparison of each intervention to control). Mean tacrolimus levels were not significantly different between groups. Limitations: The study did not assess clinical end points. Participants and study coordinators were not blinded to intervention arm. Conclusions: Provider notification and customized reminders appear promising in helping patients achieve better medication adherence, but these strategies require evaluation in trials powered to detect differences in clinical outcomes. (C) 2016 by the National Kidney Foundation, Inc. C1 [Reese, Peter P.; Bloom, Roy D.; Trofe-Clark, Jennifer; Feldman, Harold I.] Univ Penn, Renal Electrolyte & Hypertens Div, 917 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. [Reese, Peter P.; Troxel, Andrea; Feldman, Harold I.] Univ Penn, Dept Biostat & Epidemiol, 917 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. [Reese, Peter P.; Mussell, Adam; Leidy, Daniel; Troxel, Andrea; Feldman, Harold I.] Univ Penn, Perelman Sch Med, Ctr Clin Epidemiol & Biostat, 917 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. [Reese, Peter P.; Zhu, Jingsan; Yang, Lin; Wang, Wenli; Troxel, Andrea; Volpp, Kevin] Univ Penn, Leonard Davis Inst Ctr Hlth Incent & Behav Econ, 917 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. [Trofe-Clark, Jennifer] Hosp Univ Penn, Dept Pharm Serv, 3400 Spruce St, Philadelphia, PA 19104 USA. [Levsky, Simona] Univ Penn, Sch Arts & Sci, 917 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. [Volpp, Kevin] Perelman Sch Med, Dept Med, Philadelphia, PA USA. [Volpp, Kevin] Perelman Sch Med, Med Eth & Hlth Policy, Philadelphia, PA USA. [Volpp, Kevin] Univ Penn, Wharton Sch, Dept Hlth Care Management, 917 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. [Volpp, Kevin] Cresencz Philadelphia Vet Affairs Med Ctr, Ctr Hlth Equ Res & Promot, Philadelphia, PA USA. RP Reese, PP (reprint author), Univ Penn, Ctr Clin Epidemiol & Biostat, 917 Blockley Hall,423 Guardian Dr, Philadelphia, PA 19104 USA. EM peter.reese@uphs.upenn.edu FU CVS Caremark; Merck, Sharpe, and Dohme; CVS Health; Humana; Weight Watchers; Hawaii Medical Services Association; Vitality Institute; Veloxis Pharma FX The University of Pennsylvania has received research support from CVS Caremark and Merck, Sharpe, and Dohme for other studies of medication adherence, which provided salary support to Drs Reese and Volpp. Dr Volpp is a principal at the behavioral economics consulting firm VAL Health and has received consulting income and research support from CVS Health and research support from Humana, Weight Watchers, the Hawaii Medical Services Association, and the Vitality Institute (not related to Vitality Inc, the manufacturer of the GlowCaps pill bottle). Dr Troxel has received consulting income from VAL Health and research support from the Vitality Institute, the Hawaii Medical Services Association, and Weight Watchers. After the trial interventions were completed, the University of Pennsylvania received research support from Veloxis Pharma, which provided salary support for Dr Trofe-Clark; she also received honorarium from Veloxis Pharma after this study was conducted. The other authors declare that they have no other relevant financial interests. NR 58 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0272-6386 EI 1523-6838 J9 AM J KIDNEY DIS JI Am. J. Kidney Dis. PD MAR PY 2017 VL 69 IS 3 BP 400 EP 409 DI 10.1053/j.ajkd.2016.10.017 PG 10 WC Urology & Nephrology SC Urology & Nephrology GA EM0ZV UT WOS:000395047900013 PM 27940063 ER PT J AU Leung, LB Escarce, JJ AF Leung, Lucinda B. Escarce, Jose J. TI Consumer-Directed Health Plans: Do Doctors and Nurses Buy In? SO AMERICAN JOURNAL OF MANAGED CARE LA English DT Article ID CARE; SERVICES; COST C1 [Leung, Lucinda B.] Vet Affairs Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Leung, Lucinda B.; Escarce, Jose J.] Univ Calif Los Angeles, Div Gen Internal Med & Hlth Serv Res, Los Angeles, CA USA. RP Leung, LB (reprint author), UCLA Robert Wood Johnson Fdn, VA Clin Scholars Program, 10940 Wilshire Blvd,Ste 710, Los Angeles, CA 90024 USA. EM lleung@mednet.ucla.edu FU Robert Wood Johnson Foundation Clinical Scholars program; US Department of Veterans Affairs FX Support for this article was provided by the Robert Wood Johnson Foundation Clinical Scholars program and the US Department of Veterans Affairs. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the US government. NR 16 TC 0 Z9 0 U1 0 U2 0 PU MANAGED CARE & HEALTHCARE COMMUNICATIONS LLC PI PLAINSBORO PA 666 PLAINSBORO RD, STE 300, PLAINSBORO, NJ 08536 USA SN 1088-0224 J9 AM J MANAG CARE JI Am. J. Manag. Care PD MAR PY 2017 VL 23 IS 3 PG 3 WC Health Care Sciences & Services; Health Policy & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EO0OP UT WOS:000396398000004 ER PT J AU Govetto, A Lalane, RA Sarraf, D Figueroa, MS Hubschman, JP AF Govetto, Andrea Lalane, Robert A., III Sarraf, David Figueroa, Marta S. Hubschman, Jean Pierre TI Insights Into Epiretinal Membranes: Presence of Ectopic Inner Foveal Layers and a New Optical Coherence Tomography. Staging Scheme SO AMERICAN JOURNAL OF OPHTHALMOLOGY LA English DT Article ID OUTER SEGMENT TIPS; PROGNOSTIC-FACTOR; VITREOMACULAR TRACTION; VISUAL FUNCTION; SURGERY; METAMORPHOPSIA; ASSOCIATIONS; PREVALENCE; THICKNESS; EYES AB PURPOSE: To describe the presence of continuous ectopic inner foveal layers associated with epiretinal membranes (ERMs) and to present a new optical coherence tomography (OCT) staging system of ERMs. DESIGN: Retrospective multicenter observational case series. METHODS: Clinical charts and spectral-domain OCT images of 194 eyes of 172 consecutive patients diagnosed with ERMs were reviewed and analyzed. RESULTS: The presence of continuous ectopic inner foveal layers was identified in 63 out of 194 eyes (32.5%) and this morphology was significantly associated with lower visual acuity. ERMs were divided into 4 stages. Stage 1 (43 out of 194 eyes, 22.1%) ERMs were mild and thin and a fovea! depression was present. Stage 2 (88 out of 194 eyes, 45.4%) ERMs were associated with widening of the outer nuclear layer and loss of the foveal depression. Stage 3 (51 out of 194 eyes, 26.3%) ERMs were associated with continuous ectopic inner foveal layers crossing the entire foveal area. In stages 1, 2, and 3 all retinal layers were clearly defined on OCT. Stage 4 ERMs (12 out of 194 eyes, 6.2%) were thick and associated with continuous ectopic inner foveal layers. In addition, retinal layers were disrupted. Visual acuity progressively declined from stage 1 through stage 4 (P < .001). CONCLUSIONS: The presence of continuous ectopic inner foveal layers in ERMs is a newly described OCT finding associated with significant vision loss and is an essential element of a novel OCT-based grading scheme of ERMs that may influence visual prognosis. (C) 2016 Elsevier Inc. All rights reserved. C1 [Govetto, Andrea; Lalane, Robert A., III; Hubschman, Jean Pierre] Univ Calif Los Angeles, Stein Eye Inst, Retina Div, 100 Stein Plaza, Los Angeles, CA 90095 USA. [Sarraf, David] Univ Calif Los Angeles, Stein Eye Inst, Retinal Disorders & Ophthalm Genet Div, Los Angeles, CA USA. [Sarraf, David] Greater Los Angeles VA Healthcare Ctr, Los Angeles, CA USA. [Figueroa, Marta S.] Ramon y Cajal Univ Hosp, Dept Ophthalmol, Retina Div, Madrid, Spain. RP Govetto, A (reprint author), Univ Calif Los Angeles, Stein Eye Inst, Retina Div, 100 Stein Plaza, Los Angeles, CA 90095 USA. EM a.govetto@gmail.com OI Govetto, Andrea/0000-0003-2192-810X FU RESEARCH TO PRE vent Blindness (RPB), New York, New York, USA FX THIS WORK WAS SUPPORTED BY AN UNRESTRICTED INSTITUTIONAL GRANT FROM RESEARCH TO PRE vent Blindness (RPB), New York, New York, USA. NR 39 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 0002-9394 EI 1879-1891 J9 AM J OPHTHALMOL JI Am. J. Ophthalmol. PD MAR PY 2017 VL 175 BP 99 EP 113 DI 10.1016/j.ajo.2016.12.006 PG 15 WC Ophthalmology SC Ophthalmology GA EN4IK UT WOS:000395971000014 PM 27993592 ER PT J AU Feinstein, AJ Shay, SG Chang, E Lewis, MS Wang, MB AF Feinstein, Aaron J. Shay, Sophie G. Chang, Elena Lewis, Michael S. Wang, Marilene B. TI Treatment outcomes in veterans with HPV-positive head and neck cancer SO AMERICAN JOURNAL OF OTOLARYNGOLOGY LA English DT Article DE Squamous cell carcinoma; Human papilloma virus; Military veterans; Surgery; Chemoradiation ID SQUAMOUS-CELL CARCINOMAS; HUMAN-PAPILLOMAVIRUS INFECTION; QUALITY-OF-LIFE; OROPHARYNGEAL CANCER; HEALTH-STATUS; SURVIVAL; TOBACCO; POPULATION; ALCOHOL; SMOKING AB Objectives: Head and neck squamous cell carcinoma (HNSCC) caused by the human papilloma virus (HPV) has an improved prognosis relative to HPV-negative tumors. Patients with HPV-positive disease may benefit from different treatment modalities in order to optimize survival and quality of life. We sought to investigate HPV-positive HNSCC within the military veteran population, and analyze the role of treatment modality in outcomes of patients with HPV-positive and HPV-negative tumors. Methods: Patients diagnosed with HNSCC between January 1, 2010 and December 31, 2014 at one regional veterans health center were retrospectively examined. Pathologic specimens underwent testing for HPV subtype and p16 expression. Demographic and clinical factors, including treatment modality, were analyzed for their impact on the primary outcome of overall survival. Results: There were 209 patients with primary tumor sites including larynx (25.4%), oral tongue (19.6%), oral cavity (13.4%), oropharynx (17.2%), tonsil (17.2%), unknown primary (2.9%), nasopharynx (1.9%), and multiple sites (2.4%). Patients had HPV-positive (n = 82, 392%), HPV-negative (ri = 89, 42.6%) or unknown HPV status (n = 38, 18.2%). Primary treatment modalities were chemoradiation (n = 124, 59.3%), surgery (n = 39, 18.7%), radiation therapy (n = 37, 17.7%), or no treatment (n = 9, 4.3%). Survival analysis with Cox proportional hazards model demonstrated significant associations with T classification (T4 3.61, P = 0.005), N classification (N3 3.52, P = 0.0159), M classification (Ml 2.8, P = 0.0209), and HPV status (HPV-positive 0.43, P = 0.0185), but no relation with primary treatment modality (primary surgery vs. primary chemoradiation 1.01, P = 0.9718). Conclusion: HPV-positive HNSCC in the veteran population has a significantly improved prognosis relative to similarly staged patients with HPV-negative disease. This study demonstrates that the primary treatment modality- chemoradiation, radiation therapy, or surgery- does not impact overall survival among veterans with HPVpositive HNSCC. C1 [Feinstein, Aaron J.; Shay, Sophie G.; Wang, Marilene B.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Head & Neck Surg, Los Angeles, CA 90095 USA. [Feinstein, Aaron J.; Shay, Sophie G.; Wang, Marilene B.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Surg, Los Angeles, CA USA. [Chang, Elena; Lewis, Michael S.] Vet Affairs Greater Los Angeles Healthcare Syst, Dept Pathol, Los Angeles, CA USA. RP Wang, MB (reprint author), 200 UCLA Med Plaza Ste 550, Los Angeles, CA 90095 USA. EM mbwang@ucla.edu NR 27 TC 0 Z9 0 U1 0 U2 0 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0196-0709 EI 1532-818X J9 AM J OTOLARYNG JI Am. J. Otolaryngol. PD MAR-APR PY 2017 VL 38 IS 2 BP 188 EP 192 DI 10.1016/j.amjoto.2017.01.005 PG 5 WC Otorhinolaryngology SC Otorhinolaryngology GA EQ8KH UT WOS:000398333800016 PM 28342482 ER PT J AU Matioc, AA AF Matioc, Adrian A. TI An Anesthesiologist's Perspective on the History of Basic Airway Management The "Artisanal Anesthetic" Era: 1846 to 1904 SO ANESTHESIOLOGY LA English DT Article ID INTUBATION; MEDICINE; SURGERY AB This second installment of the history of basic airway management covers the early-artisanal-years of anesthesia from 1846 to 1904. Anesthesia was invented and practiced as a supporting specialty in the context of great surgical and medical advances. The current-day anesthesia provider tends to equate the history of airway management with the history of intubation, but for the first 58 yr after the introduction of ether anesthesia, airway management was provided by basic airway techniques with or without the use of a face mask. The jaw thrust and chin lift were described in the artisanal years and used primarily with inhalation anesthesia in the spontaneously breathing patient and less often with negative-pressure ventilation in the apneic victim. Positive-pressure ventilation and intubation stayed at the fringes of medical practice, and airway techniques and devices were developed by trial and error. At the beginning of the 20th century, airway management and anesthetic techniques lagged behind surgical requirements. C1 [Matioc, Adrian A.] Univ Wisconsin Sch Med & Publ Hlth, Dept Anesthesiol, Madison, WI USA. RP Matioc, AA (reprint author), William S Middleton Mem Vet Adm Med Ctr, 2500 Overlook Terrace,Room,A8030, Madison, WI 53705 USA. EM aamatioc@wisc.edu FU Paul M. Wood Fellowship at the Wood Library-Museum of Anesthesiology, Schaumburg, Illinois FX Support was provided by departmental sources and by a 2013 Paul M. Wood Fellowship at the Wood Library-Museum of Anesthesiology, Schaumburg, Illinois, awarded in my name for this topic. NR 119 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0003-3022 EI 1528-1175 J9 ANESTHESIOLOGY JI Anesthesiology PD MAR PY 2017 VL 126 IS 3 BP 394 EP 408 DI 10.1097/ALN.0000000000001508 PG 15 WC Anesthesiology SC Anesthesiology GA EO8DW UT WOS:000396920200007 PM 28079564 ER PT J AU Myaskovsky, L Gao, SS Hausmann, LRM Bornemann, KR Burkitt, KH Switzer, GE Fine, MJ Phillips, SL Gater, D Spungen, AM Worobey, L Boninger, ML AF Myaskovsky, Larissa Gao, Shasha Hausmann, Leslie R. M. Bornemann, Kellee R. Burkitt, Kelly H. Switzer, Galen E. Fine, Michael J. Phillips, Samuel. L. Gater, David Spungen, Ann M. Worobey, Lynn Boninger, Michael. L. TI Quality and Equity in Wheelchairs Used by Veterans SO ARCHIVES OF PHYSICAL MEDICINE AND REHABILITATION LA English DT Article DE Healthcare disparities; Rehabilitation; Spinal cord injuries; Wheelchairs ID SPINAL-CORD-INJURY; HEALTH-CARE; PERCEIVED DISCRIMINATION; OF-LIFE; ASSISTIVE TECHNOLOGY; MANUAL WHEELCHAIRS; AFRICAN-AMERICAN; PARTICIPATION; ASSOCIATION; DISPARITIES AB Objectives: To assess in Veterans with spinal cord injury (SCI) or amputated limb (AL) the following: (1) patient demographics, medical factors, cultural and psychosocial characteristic by race; (2) wheelchair quality by race; and (3) the independent associations of patient race and the other factors with wheelchair quality. Design: Cross-sectional cohort study. Setting: Three Department of Veterans Affairs (VA) medical centers affiliated with academic medical centers. Participants: Eligible participants were Veterans with SCI or ALs (N=516); 482 of them completed the interview. Analyses were restricted to white and African American participants. Because there was no variation in wheelchair quality among AL patients (n=42), they were excluded from all but descriptive analyses, leading to a final sample size of 421. Interventions: Not applicable. Main Outcome Measure: Wheelchair quality as defined by the Medicare Healthcare Common Procedure Coding System. Results: We found race differences in many of our variables, but not in quality for manual (odds ratio [OR] = .67; 95% confidence interval [CI], .33-1.36) or power (OR=.82; 95% CI,.51-1.34) wheelchairs. Several factors including age (OR= .96; 95% CI, .93-.99) and income (OR=3.78; 95% CI, 1.43-9.97) were associated with wheelchair quality. There were no significant associations of cultural or psychosocial factors with wheelchair quality. Conclusions: Although there were no racial differences in wheelchair quality, we found a significant association of older age and lower income with poorer wheelchair quality among Veterans. Efforts are needed to raise awareness of such disparities among VA wheelchair providers and to take steps to eliminate these disparities in prescription practice across VA sites. Published by Elsevier Inc. on behalf of the American Congress of Rehabilitation Medicine C1 [Myaskovsky, Larissa; Gao, Shasha; Hausmann, Leslie R. M.; Bornemann, Kellee R.; Burkitt, Kelly H.; Switzer, Galen E.; Fine, Michael J.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Univ Dr 151C,Bldg 30, Pittsburgh, PA 15240 USA. [Myaskovsky, Larissa; Hausmann, Leslie R. M.; Bornemann, Kellee R.; Switzer, Galen E.; Fine, Michael J.] Univ Pittsburgh, Sch Med, Dept Med, Div Gen Internal Med, Pittsburgh, PA 15213 USA. [Phillips, Samuel. L.] James A Haley Vet Hosp, Tampa, FL 33612 USA. [Gater, David] Hunter Holmes McGuire Vet Affairs Med Ctr, Richmond, VA USA. [Gater, David] Penn State Univ, Med Ctr, Hershey, PA USA. [Spungen, Ann M.] James J Peters Vet Affairs Med Ctr, Natl Ctr Med Consequences Spinal Cord Injury, Bronx, NY USA. [Spungen, Ann M.] Icahn Sch Med Mt Sinai, Dept Med, New York, NY 10029 USA. [Spungen, Ann M.] Icahn Sch Med Mt Sinai, Dept Rehabil Med, New York, NY 10029 USA. [Worobey, Lynn; Boninger, Michael. L.] Univ Pittsburgh, Sch Med, Dept Phys Med & Rehabil, Pittsburgh, PA USA. [Worobey, Lynn; Boninger, Michael. L.] Vet Affairs Pittsburgh Healthcare Syst, Human Engn & Res Labs, Pittsburgh, PA USA. RP Myaskovsky, L (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Univ Dr 151C,Bldg 30, Pittsburgh, PA 15240 USA. EM larissa.myaskovsky@va.gov FU Rehabilitation Research and Development Department of the Veterans Affairs [871481] FX Supported by the Rehabilitation Research and Development Department of the Veterans Affairs (grant no. 871481). NR 69 TC 0 Z9 0 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0003-9993 EI 1532-821X J9 ARCH PHYS MED REHAB JI Arch. Phys. Med. Rehabil. PD MAR PY 2017 VL 98 IS 3 BP 442 EP 449 DI 10.1016/j.apmr.2016.09.116 PG 8 WC Rehabilitation; Sport Sciences SC Rehabilitation; Sport Sciences GA EN9CD UT WOS:000396297400004 PM 27713075 ER PT J AU Vogelmeier, CF Criner, GJ Martinez, FJ Anzueto, A Barnes, PJ Bourbeau, J Celli, BR Chen, RC Decramer, M Fabbri, LM Frith, P Halpin, DMG Varela, MVL Nishimura, M Roche, N Rodriuez-Roisin, R Sin, DD Singh, D Stockley, R Vestbo, J Wedzicha, JA Agusti, YA AF Vogelmeier, Claus F. Criner, Gerard J. Martinez, Fernando J. Anzueto, Antonio Barnes, Peter J. Bourbeau, Jean Celli, Bartotome R. Chen, Rongchang Decramer, Marc Fabbri, Leonardo M. Frith, Peter Halpin, David M. G. Varela, M. Victorina Lopez Nishimura, Masaharu Roche, Nicolas Rodriguez-Roisin, Roberto Sin, Don D. Singh, Dave Stockley, Robert Vestbo, Jorgen Wedzicha, Jadwiga A. Agusti, Y. Alvar TI Global Strategy for the Diagnosis, Management, and Prevention of Chronic Obstructive Lung Disease 2017 Report: GOLD Executive Summary SO ARCHIVOS DE BRONCONEUMOLOGIA LA Spanish DT Article DE Chronic obstructive pulmonary disease; COPD; diagnosis; COPD management; COPD prevention ID RANDOMIZED CONTROLLED-TRIAL; AIR-FLOW OBSTRUCTION; POSITIVE-PRESSURE VENTILATION; PLACEBO-CONTROLLED TRIAL; QUALITY-OF-LIFE; INHALED FLUTICASONE FUROATE; CHRONIC RESPIRATORY-DISEASE; VOLUME-REDUCTION SURGERY; BONE-MINERAL DENSITY; REQUIRING MECHANICAL VENTILATION AB This Executive Summary of the Global Strategy for the Diagnosis, Management, and Prevention of COPD (GOLD) 2017 Report focuses primarily on the revised and novel parts of the document. The most significant changes include; I) the assessment of COPD has been refined to separate the spirometric assessment from symptom evaluation. ABCD groups are now proposed to be derived exclusively from patient symptoms and their history of exacerbations; 2) for each of the groups A to D, escalation strategies for pharmacological treatments are proposed; 3) the concept of de-escalation of therapy is introduced in the treatment assessment scheme; 4) nonpharmacologic therapies are comprehensively presented and; 5) the importance of comorbid conditions in managing COPD is reviewed. (C) 2017 SEPAR. Published by Elsevier Espana, S.L.U. All rights reserved. C1 [Vogelmeier, Claus F.] Univ Marburg, Miembro Ctr Aleman Invest Pulmonar DZL, Marburg, Germany. [Agusti, Y. Alvar] Univ Barcelona, Hosp Clin, Ciberes, Barcelona, Spain. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr, South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Barnes, Peter J.] Univ London Imperial Coll Sci Technol & Med, Natl Heart & Lung Inst, London, England. [Bourbeau, Jean] McGill Univ, McGill Univ Hlth Ctr, Montreal, PQ, Canada. [Celli, Bartotome R.] Brigham & Womens Hosp, Boston, MA USA. [Chen, Rongchang] Primer Hosp Afiliado Univ Med Guangzhou, Inst Enfermedades Respiratorias Guangzhou, Lab Cent Estatal Enfermedades Respiratorias, Guangzhou, Peoples R China. [Criner, Gerard J.] Temple Univ, Lewis Katz Sch Med, Philadelphia, PA USA. [Decramer, Marc] Univ Louvain, Louvain, Belgium. [Fabbri, Leonardo M.] Univ Modena & Reggio Emilia, Modena, Italy. [Frith, Peter] Flinders Univ Fac Med, Bedford Pk, SA, Australia. [Halpin, David M. G.] Royal Devon & Exeter Hosp, Exeter, Devon, England. [Varela, M. Victorina Lopez] Univ Republ Montevideo, Montevideo, Uruguay. [Martinez, Fernando J.] New York Presbyterian Hosp, Weil Cornell Med Ctr, New York, NY USA. [Nishimura, Masaharu] Hokkaido Univ, Fac Med, Sapporo, Hokkaido, Japan. [Roche, Nicolas] Univ Paris 05, Hop Cochin APHP, Paris, France. [Rodriguez-Roisin, Roberto] Univ Barcelona, Hosp Clin, Inst Torax, Barcelona, Spain. [Sin, Don D.] Univ British Columbia, St Pauls Hosp, Vancouver, BC, Canada. [Singh, Dave; Vestbo, Jorgen] Univ Manchester, Manchester, Lancs, England. [Stockley, Robert] Univ Hosp, Birmingham, W Midlands, England. [Wedzicha, Jadwiga A.] Univ London Imperial Coll Sci Technol & Med, London, England. RP Vogelmeier, CF (reprint author), Univ Marburg, Miembro Ctr Aleman Invest Pulmonar DZL, Marburg, Germany. EM claus.vogelmeier@med.uni-marburg.de FU Medical Research Council [G0800570, G1001365, G1001372] NR 339 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER DOYMA SL PI BARCELONA PA TRAVESERA DE GARCIA, 17-21, BARCELONA, 08021, SPAIN SN 0300-2896 EI 1579-2129 J9 ARCH BRONCONEUMOL JI Arch. Bronconeumol. PD MAR PY 2017 VL 53 IS 3 BP 128 EP 149 DI 10.1016/j.arbres.2017.02.001 PG 22 WC Respiratory System SC Respiratory System GA EQ8KT UT WOS:000398335000011 PM 28274597 ER PT J AU Wahl, E Gross, A Chernitskiy, V Trupin, L Gensler, L Chaganti, K Michaud, K Katz, P Yazdany, J AF Wahl, Elizabeth Gross, Andrew Chernitskiy, Vladimir Trupin, Laura Gensler, Lianne Chaganti, Krishna Michaud, Kaleb Katz, Patricia Yazdany, Jinoos TI Validity and Responsiveness of a 10-Item Patient-Reported Measure of Physical Function in a Rheumatoid Arthritis Clinic Population SO ARTHRITIS CARE & RESEARCH LA English DT Article ID QUALITY-OF-LIFE; MINIMALLY IMPORTANT DIFFERENCE; ITEM RESPONSE THEORY; DISEASE-ACTIVITY; SHORT-FORM; FUNCTION SCALES; HEALTH-STATUS; RELIABILITY; OUTCOMES; VALIDATION AB Objective: We assessed implementation of the 10-item Patient-Reported Outcomes Measurement Information System (PROMIS) physical function form (PF-10a) in routine practice in a racially and ethnically diverse population with rheumatoid arthritis (RA). Objectives were to determine feasibility of implementing PF-10a in the electronic health record (EHR) and PF-10a validity and longitudinal responsiveness. Methods: Clinical and demographic data were abstracted from EHRs for all RA patients seen at a university-based rheumatology clinic between February 2013 and February 2015. We evaluated floor and ceiling (edge) effects and construct validity of PF-10a in a subgroup of patients with Health Assessment Questionnaire (HAQ) scores (n=189). We used linear mixed-effects models to assess responsiveness of PF-10a to longitudinal changes in the Clinical Disease Activity Index (CDAI) for patients in the entire clinical cohort, with both scores recorded on at least 2 encounters (n=326). Results: Half of the patients were nonwhite, and 15% were non-English speakers. Over a 2-year period, PF10a was successfully implemented; 97% of patients and 89% of encounters had at least 1 measurement performed. PF-10a had fewer ceiling (defined as best) effects than the HAQ (8% versus 22%), and convergent validity was high (r=-0.85). PF-10a was sensitive to expected differences (older versus younger patients, more versus less active disease). Longitudinal changes in PF-10a were highly associated with changes in the CDAI score (P<0.0001). Conclusion: PF-10a was feasible to implement in a diverse RA population. It strongly correlates with the HAQ but has fewer ceiling effects and is responsive to changes in RA disease activity, suggesting its validity for use in routine clinical practice. C1 [Wahl, Elizabeth] Div Rheumatol, Dept Inter nal Med, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,Bldg 1,Room 219-D, Seattle, WA 98108 USA. RP Wahl, E (reprint author), Div Rheumatol, Dept Inter nal Med, VA Puget Sound Hlth Care Syst, 1660 S Columbian Way,Bldg 1,Room 219-D, Seattle, WA 98108 USA. EM elizabeth.wahl@va.gov FU Veterans Affairs Quality Scholars Fellowship through the Veterans Affairs Office of Academic Affiliations; NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases [P60-AR-053308-01, K23-AR-060259]; Rheumatology Research Foundation Investigator Award; Innovative Research Grant; Russell/Engleman Rheumatology Research Center; Robert L. Kroc Endowed Chair in Rheumatic and Connective Tissue Diseases at the University of California, San Francisco FX Dr. Wahl's work was supported by a Veterans Affairs Quality Scholars Fellowship through the Veterans Affairs Office of Academic Affiliations. Ms Trupin's and Dr. Katz's work was supported by the NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant P60-AR-053308-01). Dr. Michaud's work was supported by a Rheumatology Research Foundation Investigator Award and Innovative Research Grant. Dr. Yazdany's work was supported by NIH/National Institute of Arthritis and Musculoskeletal and Skin Diseases (grant K23-AR-060259), the Russell/Engleman Rheumatology Research Center, and the Robert L. Kroc Endowed Chair in Rheumatic and Connective Tissue Diseases at the University of California, San Francisco. NR 34 TC 0 Z9 0 U1 2 U2 2 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 2151-464X EI 2151-4658 J9 ARTHRIT CARE RES JI Arthritis Care Res. PD MAR PY 2017 VL 69 IS 3 BP 338 EP 346 DI 10.1002/acr.22956 PG 9 WC Rheumatology SC Rheumatology GA EM0DK UT WOS:000394988800004 PM 27332620 ER PT J AU Ravenel, JG Tanner, NT Silvestri, GA AF Ravenel, James G. Tanner, Nichole T. Silvestri, Gerard A. TI Viewing All the Trees in the Forest The Importance of Reporting Abnormal Findings on CT Scan When Screening for Lung Cancer SO CHEST LA English DT Editorial Material ID PULMONARY NODULES; CHEST PHYSICIANS; POLICY STATEMENT; PERFORMANCE; COLLEGE; TRIAL C1 [Ravenel, James G.] Ralph H Johnson Vet Affairs Hosp, Dept Radiol & Radiol Sci, Charleston, SC USA. [Tanner, Nichole T.; Silvestri, Gerard A.] Ralph H Johnson Vet Affairs Hosp, Thorac Oncol Res Grp, Charleston, SC USA. [Tanner, Nichole T.] Ralph H Johnson Vet Affairs Hosp, Hlth Equ & Rural Outreach Innovat Ctr, Charleston, SC USA. RP Ravenel, JG (reprint author), Med Univ South Carolina, Dept Radiol & Radiol Sci, 96 Jonathan Lucas St,MSC 323, Charleston, SC 29425 USA. EM ravenejg@musc.edu NR 14 TC 0 Z9 0 U1 0 U2 0 PU AMER COLL CHEST PHYSICIANS PI GLENVIEW PA 2595 PATRIOT BLVD, GLENVIEW, IL 60026 USA SN 0012-3692 J9 CHEST JI Chest PD MAR PY 2017 VL 151 IS 3 BP 525 EP 526 DI 10.1016/j.chest.2016.10.053 PG 2 WC Critical Care Medicine; Respiratory System SC General & Internal Medicine; Respiratory System GA EP1TE UT WOS:000397166400006 PM 28279269 ER PT J AU Jimenez-Torres, GJ Weinstein, BL Walker, CR Fowler, JC Ashford, P Borckardt, JJ Madan, A AF Jimenez-Torres, G. Janice Weinstein, Benjamin L. Walker, Cory R. Fowler, J. Christopher Ashford, Philippa Borckardt, Jeffrey J. Madan, Alok TI A study protocol for a single-blind, randomized controlled trial of adjunctive transcranial direct current stimulation (tDCS) for chronic pain among patients receiving specialized, inpatient multimodal pain management SO CONTEMPORARY CLINICAL TRIALS LA English DT Article DE Chronic pain; Pain management; Transcranial direct current stimulation; Somatic symptoms; Serious mental illness ID DORSOLATERAL PREFRONTAL CORTEX; COGNITIVE-BEHAVIORAL THERAPY; COLD PRESSOR TASK; COMMITMENT THERAPY; CLINICAL-TRIAL; PRIMARY-CARE; EFFICACY; PERCEPTION; MINDFULNESS; ACCEPTANCE AB Background: Available treatments for chronic pain (CP) are modestly effective or associated with iatrogenic harm. Transcranial direct current stimulation (tDCS) is a non-invasive brain stimulation technique that may be an effective, adjunctive treatment to non-opioid therapies. In this randomized contrortrial (RCI), we compare adjunctive active versus sham tDCS among patients in a multimodal inpatient pain management program. The primary objectives of the RCT are to improve pain tolerance and subjective pain experience. Methods and design: Patients admitted to the Pain Management Program at The Menninger Clinic in Houston, Texas are eligible for this trial. Eighty-four participants will be randomized (1:1) into a single-blind, 2 x 12 (group x time) controlled trial. A battery-powered direct and constant current stimulator (Soterix Medical Inc. 2014) delivers anodal stimulation over the left dorsolateral prefrontal cortex (DLPFC) and cathodal stimulation over the right DLPFC. Active tDCS is applied by supplying a 2 mA current for 20 min/session over 10 sessions. Participants complete self-report and performance-based assessments on a weekly basis just prior to brain stimulation. Self-report assessMents are collected via Chronic Pain Tracker version 3.6, an iPad interfaced application. The performance-based pain tolerance task is completed through the cold presser task. Discussion: Interventions with cross-symptomatic therapeutic potential are absolutely essential in the context of CP, in which psychiatric comorbidity is the norm. Modalities that can be used in tandem with evidence-based, non-opioid therapies have the potential to have a synergistic effect, resulting in increased effectiveness of what have been modestly effective treatments to date. (C) 2017 Elsevier Inc All rights reserved. C1 [Jimenez-Torres, G. Janice; Weinstein, Benjamin L.; Walker, Cory R.; Fowler, J. Christopher; Ashford, Philippa; Madan, Alok] Menninger Clin, Houston, TX USA. [Jimenez-Torres, G. Janice; Weinstein, Benjamin L.; Walker, Cory R.; Fowler, J. Christopher; Madan, Alok] Baylor Coll Med, Psychiat & Behav Sci, Houston, TX 77030 USA. [Borckardt, Jeffrey J.] Med Univ South Carolina, Anesthesia & Perioperat Med, Charleston, SC USA. [Borckardt, Jeffrey J.] Med Univ South Carolina, Psychiat & Behav Sci, Charleston, SC USA. [Borckardt, Jeffrey J.] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. RP Madan, A (reprint author), 12301 South Main St, Houston, TX 77035 USA. EM amadan@menninger.edu FU Menninger Clinic Foundation, McNair Medical Institute; William and Ella Owens Medical Research Foundation FX This research was partially supported by the Menninger Clinic Foundation, McNair Medical Institute, and the William and Ella Owens Medical Research Foundation. Dr. Madan is a McNair Scholar. The study follows the guidelines on good publication practices. The study sponsors were not involved in any aspect of the research activities. Thus, the authors were independent from study sponsors in the context of the research. The authors have no other potential conflicts of interest to disclose. NR 82 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1551-7144 EI 1559-2030 J9 CONTEMP CLIN TRIALS JI Contemp. Clin. Trials PD MAR PY 2017 VL 54 BP 36 EP 47 DI 10.1016/j.cct.2016.12.024 PG 12 WC Medicine, Research & Experimental; Pharmacology & Pharmacy SC Research & Experimental Medicine; Pharmacology & Pharmacy GA EL3YV UT WOS:000394557500005 ER PT J AU Fan, Y Lee, K Wang, NS He, JC AF Fan, Ying Lee, Kyung Wang, Niansong He, John Cijiang TI The Role of Endoplasmic Reticulum Stress in Diabetic Nephropathy SO CURRENT DIABETES REPORTS LA English DT Review DE Diabetic nephropathy; Endoplasmic reticulum stress; Unfolded protein response. Apoptosis; Reticulon-1 (RTN-1) ID UNFOLDED PROTEIN RESPONSE; GLOMERULAR ENDOTHELIAL-CELLS; INDUCED PODOCYTE APOPTOSIS; TUBULAR EPITHELIAL-CELLS; ACID-BINDING PROTEIN; ER-STRESS; KIDNEY-DISEASE; MESENCHYMAL TRANSITION; PREMATURE SENESCENCE; ASTRAGALOSIDE IV AB Purpose of Review Diabetic nephropathy (DN) has become the leading cause of end-stage renal disease (ESRD) worldwide. Accumulating evidence suggests that endoplasmic reticulum (ER) stress plays a major role in the development and progression of DN. Recent findings suggested that many attributes of DN, such as hyperglycemia, proteinuria, and increased advanced glycation end products and free fatty acids, can all trigger unfolded protein response (UPR) in kidney cells. Herein, we review the current knowledge on the role of ER stress in the setting of kidney injury with a specific emphasis on DN. Recent Findings As maladaptive ER stress response caused by excessively prolonged UPR will eventually cause cell death and increase kidney injury, several ER stress inhibitors have been shown to improve DN in animal models, albeit blocking both adaptive and maladaptive UPR. More recently, reticulon-1A (RTN1A), an ER-associated protein, was shown to be increased in both human and mouse diabetic kidneys. Its expression correlates with the progression of DN, and its polymorphisms are associated with kidney disease in people with diabetes. Increased RTN1A expression heightened the ER stress response and renal cell apoptosis, and conversely reduced RTN1A in renal cells decreased apoptosis and ameliorated kidney injury and DN progression, suggesting that RTN1A may be a novel target to specifically restrain the maladaptive UPR. Summary These findings suggest that ER stress response in renal cells is a key driver of progression of DN and that the inhibition of the unchecked ER stress response in DN, such as by inhibition of RTN1A function, may be a promising therapeutic approach against DN. C1 [Fan, Ying; Wang, Niansong] Shanghai Jiao Tong Univ, Affiliated Peoples Hosp 6, Shanghai, Peoples R China. [Lee, Kyung; He, John Cijiang] Icahn Sch Med Mt Sinai, Div Nephrol, Dept Med, 1 Gustave L Levy Pl,Box 1243, New York, NY 10029 USA. [He, John Cijiang] James J Peters VAMC, Renal Sect, Bronx, NY USA. RP He, JC (reprint author), Icahn Sch Med Mt Sinai, Div Nephrol, Dept Med, 1 Gustave L Levy Pl,Box 1243, New York, NY 10029 USA.; He, JC (reprint author), James J Peters VAMC, Renal Sect, Bronx, NY USA. EM cijiang.he@mssm.edu FU National Natural Science Foundation of China [81400735, 81270824, 81670657]; Chinese Medical Association Funding [15020140602]; NIH [P30 DK079307, 1R01DK098126, 1R01DK109683, 1R01DK078897, 1R01DK088541, P01-DK-56492] FX Y.F. is supported by National Natural Science Foundation of China (81400735) and Chinese Medical Association Funding (15020140602). K.L. is supported by NIH P30 DK079307 and 1R01DK098126. N.W. is supported by National Natural Science Foundation of China (81270824, 81670657). J.C.H. is supported by NIH 1R01DK109683, 1R01DK078897, 1R01DK088541, and P01-DK-56492. NR 69 TC 0 Z9 0 U1 3 U2 3 PU CURRENT MEDICINE GROUP PI PHILADELPHIA PA 400 MARKET STREET, STE 700, PHILADELPHIA, PA 19106 USA SN 1534-4827 EI 1539-0829 J9 CURR DIABETES REP JI Curr. Diabetes Rep. PD MAR PY 2017 VL 17 IS 3 AR 17 DI 10.1007/s11892-017-0842-y PG 7 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EO7KU UT WOS:000396870400004 PM 28271468 ER PT J AU Correa, M Fathi, R Benoit, A Dellavalle, R AF Correa, Mark Fathi, Ramin Benoit, Anastasia Dellavalle, Robert TI Scalp Cyst Excision in an Unknown Previous Site of Neurosurgery: Issues in Patient Safety in Dermatologic Surgery SO DERMATOLOGIC SURGERY LA English DT Letter C1 [Correa, Mark] Univ Florida, Coll Med, Gainesville, FL 32611 USA. [Fathi, Ramin; Benoit, Anastasia] Univ Colorado, Sch Med, Dept Dermatol, Denver, CO 80202 USA. [Dellavalle, Robert] Univ Colorado, Sch Med, Dept Dermatol, Denver VA Med Ctr, Denver, CO 80202 USA. RP Correa, M (reprint author), Univ Florida, Coll Med, Gainesville, FL 32611 USA. NR 5 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1076-0512 EI 1524-4725 J9 DERMATOL SURG JI Dermatol. Surg. PD MAR PY 2017 VL 43 IS 3 BP 452 EP 454 PG 4 WC Dermatology; Surgery SC Dermatology; Surgery GA EQ4KZ UT WOS:000398047200021 PM 27673489 ER PT J AU Sosenko, JM Yu, L Skyler, JS Krischer, JP Gottlieb, PA Boulware, D Miao, D Palmer, JP Steck, AK AF Sosenko, Jay M. Yu, Liping Skyler, Jay S. Krischer, Jeffrey P. Gottlieb, Peter A. Boulware, David Miao, Dongmei Palmer, Jerry P. Steck, Andrea K. TI The Use of Electrochemiluminescence Assays to Predict Autoantibody and Glycemic Progression Toward Type 1 Diabetes in Individuals with Single Autoantibodies SO DIABETES TECHNOLOGY & THERAPEUTICS LA English DT Article DE Type 1 diabetes; Autoantibodies; Hyperglycemia; Pediatrics ID GLUTAMIC-ACID DECARBOXYLASE; IDENTIFY HIGH-RISK; RELATIVES; INSULIN; CHILDREN AB Background: Electrochemiluminescence (ECL) assays have shown promise for enhancing the prediction of type 1 diabetes (T1D) with autoantibodies. We thus studied relatives of T1D patients to determine whether ECL assays can be used to refine risk assessments for T1D among individuals either positive for single GADA or single mIAA autoantibodies. Subjects and Methods: TrialNet Pathway to Prevention (PTP) study participants with either GADA or mIAA single autoantibodies were tested for ECL positivity during their participation in the TrialNet PTP study. Those ECL positive (ECL+) were compared with those ECL negative (ECL-) for conversion to multiple autoantibodies, 6-month glycemic progression (PS6M), and the progression to T1D. Results: The progression to multiple autoantibodies was significantly higher for those GADA/ECL+ (n = 107) than those GADA/ECL-(n = 78) (P = 0.001) and for those mIAA/ECL+ (n = 24) than those mIAA/ECL-(n = 63) (P < 0.001). The hazard ratios with 95% confidence intervals were 3.42 (1.58-7.39; P < 0.01) for GADA and 8.15 (3.02-22.00; P < 0.001) for mIAA. GADA/ECL+ and mIAA/ECL+ participants had significantly higher PS6M values than their ECL-counterparts (P = 0.001 for GADA and P = 0.009 for mIAA). Of those GADA/ECL+, 14% progressed to T1D; of those mIAA/ECL+, 17% progressed to T1D. Only 1 individual (positive for GADA) of the 141 who was ECL-progressed to T1D (median follow-up: 5 years). Conclusion: ECL measurements appear to have utility for natural history studies and prevention trials of individuals with single autoantibodies. Those ECL+ are at appreciable risk for developing multiple autoantibodies and for glycemic progression toward T1D, whereas those ECL-are at very low risk. C1 [Sosenko, Jay M.; Skyler, Jay S.] Univ Miami, Miller Sch Med, Div Endocrinol, POB 016960 D1110, Miami, FL 33101 USA. [Yu, Liping; Gottlieb, Peter A.; Miao, Dongmei; Steck, Andrea K.] Univ Colorado, Barbara Davis Ctr Childhood Diabet, Sch Med, Aurora, CO USA. [Krischer, Jeffrey P.; Boulware, David] Univ S Florida, Div Informat & Biostat, Tampa, FL USA. Univ Washington, VA Puget Sound Hlth Care Syst, Div Endocrinol Metab & Nutr, Seattle, WA USA. RP Sosenko, JM (reprint author), Univ Miami, Miller Sch Med, Div Endocrinol, POB 016960 D1110, Miami, FL 33101 USA. EM jsosenko@med.miami.edu FU Type 1 Diabetes TrialNet Pathway to Prevention Study Group; National Institutes of Health (NIH) through the National Institute of Diabetes and Digestive and Kidney Diseases; National Institute of Allergy and Infectious Diseases; Eunice Kennedy Shriver National Institute of Child Health and Human Development; NIH [U01 DK061010, U01 DK061034, U01 DK061042, U01 DK061058, U01 DK085465, U01DK085453, U01DK085461, U01DK085463, U01 DK085466, U01 DK085499, U01 DK085504, U01 DK085505, U01DK085509, U01 DK103180, U01-DK103153, U01-DK085476, U01-DK103266]; Juvenile Diabetes Research Foundation International (JDRF) FX The sponsor of the study was the Type 1 Diabetes TrialNet Pathway to Prevention Study Group. Type 1 Diabetes TrialNet Pathway to Prevention Study Group is a clinical trials network funded by the National Institutes of Health (NIH) through the National Institute of Diabetes and Digestive and Kidney Diseases, the National Institute of Allergy and Infectious Diseases, and The Eunice Kennedy Shriver National Institute of Child Health and Human Development through the cooperative agreements. TrialNet is funded by NIH grants U01 DK061010, U01 DK061034, U01 DK061042, U01 DK061058, U01 DK085465, U01DK085453, U01DK085461, U01DK085463, U01 DK085466, U01 DK085499, U01 DK085504, U01 DK085505, U01DK085509, U01 DK103180, U01-DK103153, U01-DK085476, U01-DK103266, and the Juvenile Diabetes Research Foundation International (JDRF). NR 14 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1520-9156 EI 1557-8593 J9 DIABETES TECHNOL THE JI Diabetes Technol. Ther. PD MAR PY 2017 VL 19 IS 3 BP 183 EP 187 DI 10.1089/dia.2016.0243 PG 5 WC Endocrinology & Metabolism SC Endocrinology & Metabolism GA EN8AP UT WOS:000396223600008 PM 28177779 ER PT J AU Moyers, TB Houck, J Glynn, LH Hallgren, KA Manuel, JK AF Moyers, Theresa B. Houck, Jon Glynn, Lisa H. Hallgren, Kevin A. Manuel, Jennifer K. TI A randomized controlled trial to influence client language in substance use disorder treatment SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Motivational interviewing; Counselor training; Client language; Randomized controlled trial; Active mechanism; Technical component ID BRIEF MOTIVATIONAL INTERVENTION; COMMITMENT LANGUAGE; DRINKING OUTCOMES; SELF-PERSUASION; CHANGE TALK; METAANALYSIS; DISSONANCE; STRENGTH; ALCOHOL; MATTERS AB Background: Client language is hypothesized to be a mechanism of action in motivational interviewing (MI). Despite the association of change and sustain talk with substance treatment outcomes, it not known whether providers can intentionally influence this language as hypothesized. Objective: This is a randomized controlled trial to investigate whether substance use providers can be trained to influence client language. Methods: Treatment providers specializing in substance use disorders (n = 190) were randomly assigned to standard training in MI (MI-AU) or training emphasizing an influence of client language (MI-LEAF). Treatment sessions with actual clients were evaluated 3, 6 and 12 months after training by masked raters. Frequencies of client change and sustain talk were the outcome variables. Results: Sustain talk, but not change talk, was significantly lower in clients whose providers had received the specialized training (b = -0.175, SE = 0.087, p=0.046, CI[-0.348 to 0.0021, d = -0.325). Mediation analyses supported a causal chain between a) training, b) providers' attempts to minimize sustain talk in treatment sessions via directive reflective listening and c) client sustain talk in the treatment session (kappa(2) = 0.0833, bootstrap SE = 0.0394, 95% CI [0.0148, 0.1691]). Conclusions: With specialized training, providers can reduce the amount of opposition language their clients offer when considering a change in their substance use. Demonstrating that client language is under partial control of the provider supports the feasibility of clinical trials to investigate the impact of shaping client language on treatment outcomes. (C) 2017 Elsevier B.V. All rights reserved. C1 [Moyers, Theresa B.; Houck, Jon] Univ New Mexico, Ctr Alcoholism Subst Abuse & Addict, MSC11 6280 1, Albuquerque, NM 87131 USA. [Glynn, Lisa H.] VA Puget Sound Hlth Care Syst, Dept Anesthesiol, 1660 S Columbian Way, Seattle, WA 98108 USA. [Hallgren, Kevin A.] Univ Washington, Dept Psychiat & Behav Sci, 1959 NE Pacific St, Seattle, WA 98195 USA. [Manuel, Jennifer K.] San Francisco VA Med Ctr, San Francisco, CA USA. [Manuel, Jennifer K.] Univ Calif San Francisco, San Francisco, CA USA. RP Moyers, TB (reprint author), Univ New Mexico, Ctr Alcoholism Subst Abuse & Addict, Dept Psychol, Albuquerque, NM 87106 USA. EM tmoyers@unm.edu; jhouck@unm.edu; Lisa.glynn2@va.gov; khallgre@uw.edu; jennifer.manuel@va.gov FU National Institute on Drug Abuse [R01 DA 021227-01] FX This research was funded by grant R01 DA 021227-01 from the National Institute on Drug Abuse. No other contributions were made to this project. NR 34 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD MAR 1 PY 2017 VL 172 BP 43 EP 50 DI 10.1016/j.drugalcdep.2016.11.036 PG 8 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA EM3LV UT WOS:000395217500006 PM 28122270 ER PT J AU Riley, ED Hsue, PY Vittinghoff, E Wu, AHB Coffin, PO Moore, PK Lynch, KL AF Riley, Elise D. Hsue, Priscilla Y. Vittinghoff, Eric Wu, Alan H. B. Coffin, Phillip O. Moore, Peter K. Lynch, Kara L. TI Higher prevalence of detectable troponin I among cocaine-users without known cardiovascular disease SO DRUG AND ALCOHOL DEPENDENCE LA English DT Article DE Cocaine; Benzoylecgonine; Cardiac injury; Troponin; cTnI ID ACUTE MYOCARDIAL-INFARCTION; MORGAM BIOMARKER PROJECT; CRACK-COCAINE; GENERAL-POPULATION; CORONARY-ARTERIES; RISK PREDICTION; HUMAN PLATELETS; UNITED-STATES; SUBSTANCE USE; MORTALITY AB Background: While cocaine use is an established risk factor for acute cardiovascular complications, associations between cocaine use and markers of cardiac injury outside of acute hospital presentation remain poorly characterized. We leveraged advances in cardiac troponin (cTnI) testing to assess low but clinically meaningful levels of cardiac injury among cocaine users and non-users. Methods: We conducted a case control study comparing cTnI levels by the presence of cocaine among patients presenting for non-cardiac care in an urban safety net hospital. Samples were chosen sequentially among those for which urine drug screens were ordered by providers hospital-wide. Results: During 2015, 14% of all hospital drug screens ordered were cocaine-positive. Among unique persons providing cocaine-positive (N = 100) and cocaine-negative (N = 100) samples, 37% were female, 45% were African-American and the median age was 51. Detectable cTnI (> 0.02 ng/mL) was observed in 21 samples (11%). It was more common in subjects using cocaine (Adjusted OR = 2.81; 95% CI = 1.03-7.65), but not other drugs. Moreover, there was a significant correlation between concentrations of cTnI and the cocaine metabolite, benzoylecgonine (Spearman Correlation = 0.34, p < 0.01). Conclusions: Among urban safety net hospital patients, 11% had detectable cTnI, and cTnI concentration was significantly correlated with benzoylecgonine concentration. While these preliminary results require additional confirmation, they suggest the potential utility of considering cocaine use as more than just an episodic exposure leading to acute cardiac events. The consideration of cocaine use as an ongoing chronic exposure leading to subclinical cardiac injury may improve risk-stratification and patient outcomes in populations where cocaine use is high. (C) 2017 Elsevier B.V. All rights reserved. C1 [Riley, Elise D.; Coffin, Phillip O.] Univ Calif San Francisco, Infect Dis & Global Hlth, Dept Med, Div HIV, San Francisco, CA 94143 USA. [Hsue, Priscilla Y.] Univ Calif San Francisco, Dept Med, Div Cardiol, San Francisco, CA 94143 USA. [Vittinghoff, Eric] Univ Calif San Francisco, Dept Epidemiol & Biostatist, San Francisco, CA 94143 USA. [Wu, Alan H. B.; Lynch, Kara L.] Univ Calif San Francisco, San Francisco Gen Hosp, Dept Lab Med, San Francisco, CA 94143 USA. [Coffin, Phillip O.] San Francisco Dept Publ Hlth, San Francisco, CA 94143 USA. [Moore, Peter K.] Univ Calif San Francisco, Dept Med, Div Gen Internal Med, San Francisco, CA 94143 USA. [Moore, Peter K.] San Francisco VA Med Ctr, Dept Med, Div Hosp Med, San Francisco, CA USA. RP Riley, ED (reprint author), 1001 Potrero Ave,UCSF Mailbox 0874, San Francisco, CA 94143 USA. EM elise.riley@ucsf.edu FU National Institutes of Health [R01 DA037012, K24 DA039780] FX This study was funded by the National Institutes of Health (R01 DA037012 and K24 DA039780). The National Institutes of Health and the National Institute on Drug Abuse had no role in the design or conduct of the study; the collection, management, analysis or interpretation of the data; or the preparation, review or approval of the manuscript. NR 56 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0376-8716 EI 1879-0046 J9 DRUG ALCOHOL DEPEN JI Drug Alcohol Depend. PD MAR 1 PY 2017 VL 172 BP 88 EP 93 DI 10.1016/j.drugalcdep.2016.11.039 PG 6 WC Substance Abuse; Psychiatry SC Substance Abuse; Psychiatry GA EM3LV UT WOS:000395217500012 PM 28157591 ER PT J AU Marcum, ZA Hanlon, JT Murray, MD AF Marcum, Zachary A. Hanlon, Joseph T. Murray, Michael D. TI Improving Medication Adherence and Health Outcomes in Older Adults: An Evidence-Based Review of Randomized Controlled Trials SO DRUGS & AGING LA English DT Review ID PHARMACIST INTERVENTION; ELDERLY-PATIENTS; PHARMACEUTICAL CARE; BLOOD-PRESSURE; IMPACT; THERAPY; HOSPITALIZATIONS; HYPERTENSION; POLYPHARMACY; METAANALYSIS AB Background Poor medication adherence is a major public health problem in older adults often resulting in negative health outcomes. Objective The objective of this review was to provide an updated summary of evidence from randomized controlled studies to determine whether interventions aimed at improving medication adherence also improve the health outcomes of older adults residing in community-based settings. Methods Articles that assessed medication adherence interventions and related health outcomes in elderly individuals were identified through searches of MEDLINE (1970-June 2016), the Cochrane Database of Systematic Reviews (through to June 2016), and Google Scholar. Across the 12 included studies, interventions were grouped into three main categories: behavioral/educational (n = 3), pharmacist-led (n = 7), and reminder/simplification (n = 2). Results Among the behavioral/educational intervention studies, two showed improvements in both adherence and related health outcomes, whereas one found no changes in adherence or health outcomes. Among the pharmacist-led studies, three showed improvements in both adherence and related health outcomes, while three reported no changes in adherence or health outcomes. One found an improvement in adherence but not health outcomes. Among the reminder/simplification studies, both studies reported improvements in adherence without a significant impact on related health outcomes. Conclusion This evidence-based review of medication adherence interventions in older adults revealed promising strategies in the larger context of a largely mixed body of literature. Future patient-centered and multidisciplinary interventions should be developed and tested using evidence-based principles to improve medication adherence and health outcomes in older adults. C1 [Marcum, Zachary A.] Univ Washington, Sch Pharm, Seattle, WA 98195 USA. [Hanlon, Joseph T.] Univ Pittsburgh, Sch Med Geriatr Pharm & Publ Hlth, 3471 Fifth Ave,Suite 500, Pittsburgh, PA 15213 USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA. [Hanlon, Joseph T.] Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15240 USA. [Murray, Michael D.] Purdue Univ, Coll Pharm, Indianapolis, IN USA. [Murray, Michael D.] Regenstrief Inst Hlth Care, Indianapolis, IN USA. RP Hanlon, JT (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA 15240 USA.; Hanlon, JT (reprint author), Vet Affairs Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA 15240 USA. EM jth14@pitt.edu FU Agency for Healthcare Research and Quality (AHRQ) [K12HS022982]; National Institutes of Health (NIH)/National Institute on Aging (NIA) [P30AG024827, T32AG021885, U13AG047008]; AHRQ [R18HS023779]; Purdue University (Indianapolis, IN, USA); Regenstrief Foundation FX Dr. Marcum is supported by funding from the Agency for Healthcare Research and Quality (AHRQ) (K12HS022982). Dr. Hanlon is supported by funding from National Institutes of Health (NIH)/National Institute on Aging (NIA) (P30AG024827, T32AG021885, U13AG047008) and AHRQ (R18HS023779). Dr. Murray is supported by funding from an endowment on medication safety from Purdue University (Indianapolis, IN, USA) and the Regenstrief Foundation. NR 37 TC 0 Z9 0 U1 3 U2 3 PU ADIS INT LTD PI NORTHCOTE PA 5 THE WAREHOUSE WAY, NORTHCOTE 0627, AUCKLAND, NEW ZEALAND SN 1170-229X EI 1179-1969 J9 DRUG AGING JI Drugs Aging PD MAR PY 2017 VL 34 IS 3 BP 191 EP 201 DI 10.1007/s40266-016-0433-7 PG 11 WC Geriatrics & Gerontology; Pharmacology & Pharmacy SC Geriatrics & Gerontology; Pharmacology & Pharmacy GA EQ4KN UT WOS:000398045900004 PM 28074410 ER PT J AU Brostow, DP Petrik, ML Starosta, AJ Waldo, SW AF Brostow, Diana P. Petrik, Megan L. Starosta, Amy J. Waldo, Stephen W. TI Depression in patients with peripheral arterial disease: A systematic review SO EUROPEAN JOURNAL OF CARDIOVASCULAR NURSING LA English DT Review DE Depression; review; peripheral arterial disease; peripheral vascular diseases ID CORONARY-HEART-DISEASE; QUALITY-OF-LIFE; ANKLE-BRACHIAL INDEX; LOWER-EXTREMITY REVASCULARIZATION; LEG SYMPTOMS; CARDIOVASCULAR-DISEASE; FUNCTIONAL DECLINE; RISK-FACTORS; SMOKING-CESSATION; ANXIETY DISORDERS AB Objectives: The association between cardiovascular disease and depression is well-established. Peripheral arterial disease arises from atherosclerosis like other cardiovascular disease, but unlike other cardiovascular disease, it impairs ambulation and lower extremity function. Given peripheral arterial disease's unique characteristics and underrepresentation in mental health research, we aimed to: (a) assess the prevalence of depression or depressive symptoms among peripheral arterial disease patients compared to coronary artery disease rates, (b) assess whether an independent association between peripheral arterial disease and depression exists, and (c) identify associated factors that may be targeted for intervention. Design: This study was based on a systematic review. Materials and methods: Electronic databases were searched to identify studies that examined peripheral arterial disease and depression or depressive symptoms. Methodological quality was assessed using the Newcastle-Ottawa Scale. Results: We identified 28 studies. Prevalence of depression or depressive symptoms ranged from 11-48% in 12 cross-sectional studies, and from 3-36% in 16 longitudinal studies, which is comparable to reported coronary artery disease rates. Depressed peripheral arterial disease patients were more likely to be female, African American, and have more severe peripheral arterial disease symptoms and more compromised physical function compared to non-depressed patients. There is evidence to suggest that depression exerts a negative influence on walking ability and physical function independently of peripheral arterial disease. Conclusions: There is a critical need to address depression in peripheral arterial disease patients, particularly those with characteristics that place them at increased risk. Vascular care providers appear to be the primary contact for assessing depressive symptoms, and once identified, integrated mental health providers may intervene to prevent the worsening of both depression and peripheral arterial disease. C1 [Brostow, Diana P.; Waldo, Stephen W.] VA Eastern Colorado Healthcare Syst, 1055 Clermont St, Denver, CO 80220 USA. [Petrik, Megan L.; Starosta, Amy J.] Denver VA Med Ctr, Rocky Mt Mental Illness Res Educ & Clin Ctr MIREC, Denver, CO USA. [Petrik, Megan L.] Univ Minnesota, Sch Med, Dept Med, Minneapolis, MN 55455 USA. [Starosta, Amy J.] Univ Colorado, Dept Psychiat, Boulder, CO 80309 USA. RP Brostow, DP (reprint author), VA Eastern Colorado Healthcare Syst, 1055 Clermont St, Denver, CO 80220 USA. EM Diana.Brostow@ucdenver.edu FU Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development FX This material is based upon work supported by the Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development. NR 77 TC 0 Z9 0 U1 5 U2 5 PU SAGE PUBLICATIONS LTD PI LONDON PA 1 OLIVERS YARD, 55 CITY ROAD, LONDON EC1Y 1SP, ENGLAND SN 1474-5151 EI 1873-1953 J9 EUR J CARDIOVASC NUR JI Eur. J. Cardiovasc. Nurs. PD MAR PY 2017 VL 16 IS 3 BP 181 EP 193 DI 10.1177/1474515116687222 PG 13 WC Cardiac & Cardiovascular Systems; Nursing SC Cardiovascular System & Cardiology; Nursing GA EQ6GD UT WOS:000398178900002 PM 28051339 ER PT J AU Mounessa, JS Caravaglio, JV Dellavalle, RP AF Mounessa, Jessica S. Caravaglio, Joseph Vincent Dellavalle, Robert P. TI Comparison of Regional and State Differences in Melanoma Rates in the United States: 2003 vs 2013 SO JAMA DERMATOLOGY LA English DT Letter C1 [Mounessa, Jessica S.; Dellavalle, Robert P.] Denver Vet Affairs Med Ctr, Dermatol Serv, 1055 Clermont St,POB 165, Denver, CO 80220 USA. [Mounessa, Jessica S.; Dellavalle, Robert P.] Univ Colorado, Sch Med, Dept Dermatol, Aurora, CO USA. [Caravaglio, Joseph Vincent] Univ Cent Florida, Coll Med, Dept Dermatol, Orlando, FL 32816 USA. RP Dellavalle, RP (reprint author), Denver Vet Affairs Med Ctr, Dermatol Serv, 1055 Clermont St,POB 165, Denver, CO 80220 USA. EM robert.dellavalle@ucdenver.edu NR 4 TC 1 Z9 1 U1 0 U2 0 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6068 EI 2168-6084 J9 JAMA DERMATOL JI JAMA Dermatol. PD MAR 1 PY 2017 VL 153 IS 3 BP 345 EP 347 DI 10.1001/jamadermatol.2016.4625 PG 4 WC Dermatology SC Dermatology GA EN8JQ UT WOS:000396247100029 PM 28030665 ER PT J AU Hall, DE Arya, S Schmid, KK Carlson, MA Lavedan, P Bailey, TL Purviance, G Bockman, T Lynch, TG Johanning, JM AF Hall, Daniel E. Arya, Shipra Schmid, Kendra K. Carlson, Mark A. Lavedan, Pierre Bailey, Travis L. Purviance, Georgia Bockman, Tammy Lynch, Thomas G. Johanning, Jason M. TI Association of a Frailty Screening Initiative With Postoperative Survival at 30, 180, and 365 Days SO JAMA SURGERY LA English DT Article ID 30-DAY MORTALITY; DECISION-MAKING; SURGICAL CARE; QUALITY; RISK; MORBIDITY; INDEX; PREDICTOR; OUTCOMES; SURGERY AB IMPORTANCE As the US population ages, the number of operations performed on elderly patients will likely increase. Frailty predicts postoperative mortality and morbidity more than age alone, thus presenting opportunities to identify the highest-risk surgical patients and improve their outcomes. OBJECTIVE To examine the effect of the Frailty Screening Initiative (FSI) on mortality and complications by comparing the surgical outcomes of a cohort of surgical patients treated before and after implementation of the FSI. DESIGN, SETTING, AND PARTICIPANTS This single-site, facility-wide, prospective cohort quality improvement project studied all 9153 patients from a level 1b Veterans Affairs medical center who presented for major, elective, noncardiac surgery from October 1, 2007, to July 1, 2014. INTERVENTIONS Assessment of preoperative frailty in all patients scheduled for elective surgery began in July 2011. Frailty was assessed with the Risk Analysis Index (RAI), and the records of all frail patients (RAI score, >= 21) were flagged for administrative review by the chief of surgery (or designee) before the scheduled operation. On the basis of this review, clinicians from surgery, anesthesia, critical care, and palliative care were notified of the patient's frailty and associated surgical risks; if indicated, perioperative plans were modified based on team input. MAIN OUTCOMES AND MEASURES Postoperative mortality at 30, 180, and 365 days. RESULTS From October 1, 2007, to July 1, 2014, a total of 9153 patients underwent surgery (mean [SD] age, 60.3 [13.5] years; female, 653 [7.1%]; and white, 7096 [79.8%]). Overall 30-day mortality decreased from 1.6%(84 of 5275 patients) to 0.7%(26 of 3878 patients, P <.001) after FSI implementation. Improvement was greatest among frail patients (12.2% [24 of 197 patients] to 3.8% [16 of 424 patients], P <.001), although mortality rates also decreased among the robust patients (1.2%[60 of 5078 patients] to 0.3%[10 of 3454 patients], P <.001). Themagnitude of improvement among frail patients increased at 180 (23.9%[47 of 197 patients] to 7.7%[30 of 389 patients], P <.001) and 365 days (34.5%[68 of 197 patients] to 11.7%[36 of 309 patients], P <.001). Multivariable models revealed improved survival after FSI implementation, controlling for age, frailty, and predicted mortality (adjusted odds ratio for 180-day survival, 2.87; 95% CI, 1.98-4.16). CONCLUSIONS AND RELEVANCE Implementation of the FSI was associated with reduced mortality, suggesting the feasibility of widespread screening of patients preoperatively to identify frailty and the efficacy of system-level initiatives aimed at improving their surgical outcomes. Additional investigation is required to establish a causal connection. C1 [Hall, Daniel E.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. [Hall, Daniel E.] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. [Arya, Shipra] Atlanta Vet Affairs Med Ctr, Atlanta, GA USA. [Arya, Shipra] Emory Univ, Dept Surg, Div Vasc & Endovasc, Atlanta, GA 30322 USA. [Schmid, Kendra K.] Univ Nebraska, Med Ctr, Dept Biostat, Omaha, NE USA. [Carlson, Mark A.] Univ Nebraska, Med Ctr, Dept Genet Cell Biol & Anat, Omaha, NE USA. [Carlson, Mark A.; Johanning, Jason M.] Univ Nebraska, Med Ctr, Dept Surg, Omaha, NE USA. [Carlson, Mark A.; Bailey, Travis L.] VA Nebraska Western Iowa Hlth Care Syst, Omaha, NE USA. [Lavedan, Pierre] VA Nebraska Western Iowa Hlth Care Syst, Dept Extended Care & Rehabil, Omaha, NE USA. [Bailey, Travis L.] Univ Utah, Dept Orthopaed Surg, Salt Lake City, UT USA. [Lynch, Thomas G.] Dept Vet Affairs Vet Hlth Adm, Off Hlth Operat & Management, Washington, DC USA. [Lynch, Thomas G.] George Washington Univ, Dept Surg, Sch Med, Washington, DC USA. RP Hall, DE (reprint author), UPMC Presbyterian, Ste 1264,200 Lothrop St, Pittsburgh, PA 15213 USA. EM hallde@upmc.edu FU US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development [CDA 08-281] FX This investigation was supported by grant CDA 08-281 from the US Department of Veterans Affairs, Veterans Health Administration, Office of Research and Development, Health Services Research and Development (Dr Hall). NR 29 TC 2 Z9 2 U1 1 U2 1 PU AMER MEDICAL ASSOC PI CHICAGO PA 330 N WABASH AVE, STE 39300, CHICAGO, IL 60611-5885 USA SN 2168-6254 EI 2168-6262 J9 JAMA SURG JI JAMA Surg. PD MAR PY 2017 VL 152 IS 3 DI 10.1001/jamasurg.2016.4219 PG 8 WC Surgery SC Surgery GA EQ5DI UT WOS:000398101400007 PM 27902826 ER PT J AU Gros, DF Szafranski, DD Shead, SD AF Gros, Daniel F. Szafranski, Derek D. Shead, Sarah D. TI A real world dissemination and implementation of Transdiagnostic Behavior Therapy (TBT) for veterans with affective disorders SO JOURNAL OF ANXIETY DISORDERS LA English DT Article DE Transdiagnostic Behavior Therapy; TBT; Dissemination; Implementation; Veterans; Veterans Affairs Medical Center ID SOMATIC ANXIETY STICSA; STATE-TRAIT INVENTORY; PRIMARY-CARE; PREVALENCE; FEATURES; TRIAL AB Dissemination and implementation of evidence-based psychotherapies is challenging in real world clinical settings. Transdiagnostic Behavior Therapy (TBT) for affective disorders was developed with dissemination and implementation in clinical settings in mind. The present study investigated a voluntary local dissemination and implementation effort, involving 28 providers participating in a four-hour training on TBT. Providers completed immediate (n = 22) and six-month follow-up (n = 12) training assessments and were encouraged to collect data on their TBT patients (delivery fidelity was not investigated). Findings demonstrated that providers endorsed learning of and interest in using TBT after the training. At six-months, 50% of providers reported using TBT with their patients and their perceived effectiveness of TBT to be very good to excellent. Submitted patient outcome data evidenced medium to large effect sizes. Together, these findings provide preliminary support for the effectiveness of a real world dissemination and implementation of TBT. Published by Elsevier Ltd. C1 [Gros, Daniel F.; Szafranski, Derek D.; Shead, Sarah D.] Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC USA. [Gros, Daniel F.; Szafranski, Derek D.] Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. RP Gros, DF (reprint author), Ralph H Johnson VAMC, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM grosd@musc.edu FU Department of Veteran Affairs Clinical Sciences Research and Development [CX000845] FX This study is supported by Department of Veteran Affairs Clinical Sciences Research and Development Career Development Award CX000845 (PI: Gros). The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs or the United States government. There are no conflicts of interest to disclose. I would like to thank the providers within the Ralph H. Johnson Veterans Affairs Medical Center for their participation in this project. NR 26 TC 2 Z9 2 U1 2 U2 2 PU PERGAMON-ELSEVIER SCIENCE LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, ENGLAND SN 0887-6185 EI 1873-7897 J9 J ANXIETY DISORD JI J. Anxiety Disord. PD MAR PY 2017 VL 46 BP 72 EP 77 DI 10.1016/j.janxdis.2016.04.010 PG 6 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA EO8VE UT WOS:000396967800009 PM 27158076 ER PT J AU Marcum, ZA Gellad, WF AF Marcum, Zachary A. Gellad, Walid F. TI Improving Medication Adherence: Keep Your Eyes on the Prize SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material C1 [Marcum, Zachary A.] Univ Washington, Sch Pharm, Seattle, WA 98195 USA. [Gellad, Walid F.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. [Gellad, Walid F.] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Pittsburgh, PA USA. [Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Univ Dr 151C, Pittsburgh, PA 15240 USA. RP Gellad, WF (reprint author), VA Pittsburgh Healthcare Syst, Univ Dr 151C, Pittsburgh, PA 15240 USA. EM Walid.gellad@pitt.edu FU Agency for Healthcare Research and Quality (AHRQ) [K12HS022982] FX Dr. Marcum is supported by funding from the Agency for Healthcare Research and Quality (AHRQ; K12HS022982). NR 10 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2017 VL 32 IS 3 BP 236 EP 237 DI 10.1007/s11606-016-3927-4 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EM2YI UT WOS:000395181300003 PM 27848188 ER PT J AU Rollman, BL Belnap, BH Mazumdar, S Abebe, KZ Karp, JF Lenze, EJ Schulberg, HC AF Rollman, Bruce L. Belnap, Bea Herbeck Mazumdar, Sati Abebe, Kaleab Z. Karp, Jordan F. Lenze, Eric J. Schulberg, Herbert C. TI Telephone-Delivered Stepped Collaborative Care for Treating Anxiety in Primary Care: A Randomized Controlled Trial SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE primary care; clinical trial; collaborative care; anxiety; depression; mental health ID COGNITIVE-BEHAVIORAL THERAPY; DISORDER SEVERITY SCALE; QUALITY-OF-CARE; PANIC DISORDER; DEPRESSION; HEALTH; MANAGEMENT; VALIDITY; PROTOCOL; IMPROVE AB Collaborative care for depression is more effective in improving treatment outcomes than primary care physicians' (PCPs) usual care (UC). However, few trials of collaborative care have targeted anxiety. To examine the impact and 12-month durability of a centralized, telephone-delivered, stepped collaborative care intervention (CC) for treating anxiety disorders across a network of primary care practices. Randomized controlled trial with blinded outcome assessments. A total of 329 patients aged 18-64 referred by their PCPs in response to an electronic medical record (EMR) prompt. They include 250 highly anxious patients randomized to either CC or to UC, and 79 moderately anxious patients who were triaged to a watchful waiting (WW) cohort and later randomized if their conditions clinically deteriorated. Twelve months of telephone-delivered CC involving non-mental health professionals who provided patients with basic psycho-education, assessed preferences for guideline-based pharmacotherapy, monitored treatment responses, and informed PCPs of their patients' care preferences and progress via the EMR. Mental health-related quality of life ([HRQoL]; SF-36 MCS); secondary outcomes: anxiety (Hamilton Anxiety Rating Scale [SIGH-A], Panic Disorder Severity Scale) and mood (PHQ-9). At 12-month follow-up, highly anxious patients randomized to CC reported improved mental HRQoL (effect size [ES]: 0.38 [95 % CI: 0.13-0.63]; P = 0.003), anxiety (SIGH-A ES: 0.30 [0.05-0.55]; P = 0.02), and mood (ES: 0.45 [0.19-0.71] P = 0.001) versus UC. These improvements were sustained for 12 months among African-Americans (ES: 0.70-1.14) and men (ES: 0.43-0.93). Of the 79 WW patients, 29 % met severity criteria for randomization, and regardless of treatment assignment, WW patients reported fewer anxiety and mood symptoms and better mental HRQoL over the full 24-month follow-up period than highly anxious patients who were randomized at baseline. Telephone-delivered, centralized, stepped CC improves mental HRQoL, anxiety and mood symptoms. These improvements were durable and particularly evident among those most anxious at baseline, and among African-Americans and men. C1 [Rollman, Bruce L.; Belnap, Bea Herbeck; Abebe, Kaleab Z.] Univ Pittsburgh, Sch Med, Ctr Behav Hlth & Smart Technol, Div Gen Internal Med, Suite 600,230 McKee Pl, Pittsburgh, PA 15213 USA. [Mazumdar, Sati] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Biostat, Suite 600,230 McKee Pl, Pittsburgh, PA 15213 USA. [Karp, Jordan F.] Univ Pittsburgh, Sch Med, Dept Psychiat, Suite 600,230 McKee Pl, Pittsburgh, PA 15213 USA. [Karp, Jordan F.] VA Pittsburgh Healthcare Syst, Geriatr Res Educ & Clin Ctr, Pittsburgh, PA USA. [Lenze, Eric J.] Washington Univ, Sch Med, Dept Psychiat, Hlth Mind Lab, St Louis, MO 63110 USA. [Schulberg, Herbert C.] Weill Cornell Med Coll, Dept Psychiat, White Plains, NY USA. RP Rollman, BL (reprint author), Univ Pittsburgh, Sch Med, Ctr Behav Hlth & Smart Technol, Div Gen Internal Med, Suite 600,230 McKee Pl, Pittsburgh, PA 15213 USA. EM rollmanbl@upmc.edu FU National Institute of Mental Health [R01 MH09421, R01 MH093501] FX All work described herein was supported by grants from the National Institute of Mental Health (R01 MH09421 and R01 MH093501). The funding source had no role in the design, conduct, or reporting of our study, or in the preparation, review, or decision to submit this manuscript for publication. NR 41 TC 2 Z9 2 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2017 VL 32 IS 3 BP 245 EP 255 DI 10.1007/s11606-016-3873-1 PG 11 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EM2YI UT WOS:000395181300008 PM 27714649 ER PT J AU Reddy, A Huseman, TL Canamucio, A Marcus, SC Asch, DA Volpp, K Long, JA AF Reddy, Ashok Huseman, Tiffany L. Canamucio, Anne Marcus, Steven C. Asch, David A. Volpp, Kevin Long, Judith A. TI Patient and Partner Feedback Reports to Improve Statin Medication Adherence: A Randomized Control Trial SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE medication adherence; social force; social support; statins ID MYOCARDIAL-INFARCTION; FINANCIAL INCENTIVES; THERAPY; MORTALITY; HEALTH AB Simple nudges such as reminders and feedback reports to either a patient or a partner may facilitate improved medication adherence. To test the impact of a pill bottle used to monitor adherence, deliver a daily alarm, and generate weekly medication adherence feedback reports on statin adherence. Three-month, three-arm randomized clinical trial (ClinicalTrials.gov identifier: NCT02480530). One hundred and twenty-six veterans with known coronary artery disease and poor adherence (medication possession ratio < 80 %). Patients were randomized to one of three groups: (1) a control group (n = 36) that received a pill-monitoring device with no alarms or feedback; (2) an individual feedback group (n = 36) that received a daily alarm and a weekly medication adherence feedback report; and (3) a partner feedback group (n = 54) that received an alarm and a weekly feedback report that was shared with a friend, family member, or a peer. The intervention continued for 3 months, and participants were followed for an additional 3 months after the intervention period. Adherence as measured by pill bottle. Secondary outcomes included change in LDL (mg/dl), patient activation, and social support. During the 3-month intervention period, medication adherence was higher in both feedback arms than in the control arm (individual feedback group 89 %, partner feedback group 86 %, control group 67 %; p < 0.001 and = 0.001). At 6 months, there was no difference in medication adherence between either of the feedback groups and the control (individual feedback 60 %, partner feedback 52 %, control group 54 %; p = 0.75 and 0.97). Daily alarms combined with individual or partner feedback reports improved statin medication adherence. While neither an individual feedback nor partner feedback strategy created a sustainable medication adherence habit, the intervention itself is relatively easy to implement and low cost. C1 [Reddy, Ashok] Univ Washington, Sch Med, Div Gen Internal Med, 1959 NE Pacific St,Suite BB1240,Box 356526, Seattle, WA 98195 USA. [Reddy, Ashok] UW Med Ctr Scholarship Patient Care Qual & Safety, Seattle, WA USA. [Reddy, Ashok] Univ Washington, Sch Med, Dept Med, 1959 NE Pacific St,Suite BB1240,Box 356526, Seattle, WA 98195 USA. [Huseman, Tiffany L.; Canamucio, Anne; Asch, David A.; Volpp, Kevin; Long, Judith A.] Philadelphia VA Med Ctr, VISN Ctr Evaluat PACT 4, Philadelphia, PA USA. [Marcus, Steven C.] Univ Penn, Sch Social Policy & Practice, Philadelphia, PA 19104 USA. [Asch, David A.; Volpp, Kevin; Long, Judith A.] Univ Penn, Perelman Sch Med, Philadelphia, PA 19104 USA. [Asch, David A.; Volpp, Kevin; Long, Judith A.] Univ Penn, Leonard Davis Inst Hlth Econ, Philadelphia, PA 19104 USA. RP Reddy, A (reprint author), Univ Washington, Sch Med, Dept Med, 1959 NE Pacific St,Suite BB1240,Box 356526, Seattle, WA 98195 USA. EM reddya@uw.edu FU Center for the Evaluation of Patient Aligned Care Teams at the Philadelphia VA FX This work was supported by a grant from the Center for the Evaluation of Patient Aligned Care Teams at the Philadelphia VA. NR 24 TC 1 Z9 1 U1 4 U2 4 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2017 VL 32 IS 3 BP 256 EP 261 DI 10.1007/s11606-016-3858-0 PG 6 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EM2YI UT WOS:000395181300009 PM 27612487 ER PT J AU Payne, B Brzezinski, WA Clark, AV Estrada, CA Kraemer, RR AF Payne, Brittany Brzezinski, Walter A. Clark, Amanda V. Estrada, Carlos A. Kraemer, Ryan R. TI Lessons Learned from a Middle-Aged Man with Testicular Pain: Exercises in Clinical Reasoning SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Article DE clinical reasoning; cognitive error; testicular pain; self-reflection ID POLYARTERITIS-NODOSA; DIAGNOSTIC ERRORS; STRATEGIES C1 [Payne, Brittany; Kraemer, Ryan R.] Univ Alabama Birmingham, Tinsley Harrison Internal Med Residency Program, Birmingham, AL USA. [Brzezinski, Walter A.] Med Univ South Carolina, Charleston, SC USA. [Clark, Amanda V.] Louis Stokes Cleveland VA Med Ctr, Cleveland, OH USA. [Clark, Amanda V.] Case Western Reserve Sch Med, Cleveland, OH USA. [Estrada, Carlos A.; Kraemer, Ryan R.] Birmingham Vet Affairs Med Ctr, Birmingham, AL USA. [Estrada, Carlos A.; Kraemer, Ryan R.] Univ Alabama Birmingham, 734 Fac Off Tower,510 20th St South, Birmingham, AL 35294 USA. RP Kraemer, RR (reprint author), Univ Alabama Birmingham, 734 Fac Off Tower,510 20th St South, Birmingham, AL 35294 USA. EM rkraemer@uabmc.edu NR 15 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2017 VL 32 IS 3 BP 355 EP 359 DI 10.1007/s11606-016-3882-0 PG 5 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EM2YI UT WOS:000395181300024 PM 27778213 ER PT J AU Hunt, SC AF Hunt, Stephen C. TI The Patient on the Long Journey Home SO JOURNAL OF GENERAL INTERNAL MEDICINE LA English DT Editorial Material C1 [Hunt, Stephen C.] Univ Washington, Dept Med, VA Puget Sound Hlth Care Syst, OEM Program, 1660 Columbian Way S, Seattle, WA 98108 USA. RP Hunt, SC (reprint author), Univ Washington, Dept Med, VA Puget Sound Hlth Care Syst, OEM Program, 1660 Columbian Way S, Seattle, WA 98108 USA. EM stephen.hunt@va.gov NR 3 TC 0 Z9 0 U1 1 U2 1 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0884-8734 EI 1525-1497 J9 J GEN INTERN MED JI J. Gen. Intern. Med. PD MAR PY 2017 VL 32 IS 3 BP 366 EP 367 DI 10.1007/s11606-016-3908-7 PG 2 WC Health Care Sciences & Services; Medicine, General & Internal SC Health Care Sciences & Services; General & Internal Medicine GA EM2YI UT WOS:000395181300029 PM 27844259 ER PT J AU Kwan, T Floyd, CL Kim, S King, PH AF Kwan, Thaddaeus Floyd, Candace L. Kim, Soojin King, Peter H. TI RNA Binding Protein Human Antigen R Is Translocated in Astrocytes following Spinal Cord Injury and Promotes the Inflammatory Response SO JOURNAL OF NEUROTRAUMA LA English DT Article DE glial cell response to injury; inflammation; molecular biological approaches; spinal cord injury ID FACTOR-KAPPA-B; AMYOTROPHIC-LATERAL-SCLEROSIS; TRAUMATIC BRAIN-INJURY; MESSENGER-RNA; HUR; EXPRESSION; CELLS; REGENERATION; MACROPHAGES; ACTIVATION AB Inflammation plays a prominent role in the events following traumatic injury to the central nervous system (CNS). The initial inflammatory response is driven by mediators such as tumor necrosis factor a and interleukin 1 beta, which are produced by activated astrocytes and microglia at the site of injury. These factors are regulated post-transcriptionally by RNA binding proteins (RBP) that interact with adenylate and uridylate-rich elements (ARE) in the 3'-untranslated region of the messenger RNA (mRNA). Human antigen R (HuR) is one of these RBPs and generally functions as a positive regulator of ARE-containing mRNAs. Here, we hypothesized that HuR plays an important role in the induction of cytokine and chemokines in astrocytes following traumatic injury. Using a mouse model of spinal cord injury, we found HuR to be extensively translocated to the cytoplasm in astrocytes at the level of injury, consistent with its activation. In an in vitro stretch injury model of CNS trauma, we observed a similar cytoplasmic shift of HuR in astrocytes and an attenuation of cytokine induction with HuR knockdown. RNA kinetics and luciferase assays suggested that the effect was more related to transcription than RNA destabilization. A small molecule inhibitor of HuR suppressed cytokine induction of injured astrocytes and reduced chemoattraction for neutrophils and microglia. In summary, HuR is activated in astrocytes in the early stages of CNS trauma and positively regulates the molecular response of key inflammatory mediators in astrocytes. Our findings suggest that HuR may be a therapeutic target in acute CNS trauma for blunting secondary tissue injury triggered by the inflammatory response. C1 [Kwan, Thaddaeus; Kim, Soojin; King, Peter H.] Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35487 USA. [Floyd, Candace L.] Univ Alabama Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA. [King, Peter H.] Univ Alabama Birmingham, Dept Cell & Integrat Biol, Dept Dev & Integrat Biol, Birmingham, AL 35487 USA. [King, Peter H.] Birmingham Vet Affairs Med Ctr, Birmingham, AL 35487 USA. RP King, PH (reprint author), Univ Alabama Birmingham, Dept Neurol, Birmingham, AL 35487 USA.; King, PH (reprint author), Univ Alabama Birmingham, Dept Cell & Integrat Biol, Dept Dev & Integrat Biol, Birmingham, AL 35487 USA.; King, PH (reprint author), Birmingham Vet Affairs Med Ctr, Birmingham, AL 35487 USA. EM phking@uabmc.edu FU UAB Comprehensive Neuroscience Center FX We wish to thank Terry Lewis, PhD, and the UAB Neuroscience Molecular Detection Core Facility (P30 NS47466) for assistance with immunohistochemistry, and Marion Spell and the UAB Center for AIDS Research flow cytometry core for their assistance with FACS analysis. This work was supported by a pilot grant from the UAB Comprehensive Neuroscience Center. NR 58 TC 0 Z9 0 U1 1 U2 1 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD MAR PY 2017 VL 34 IS 6 BP 1249 EP 1259 DI 10.1089/neu.2016.4757 PG 11 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA EN7ZR UT WOS:000396221200012 PM 27852147 ER PT J AU Alexander, M Courtois, F AF Alexander, Marcalee Courtois, Frederique TI Blood Pressure during Sexual Activity after Spinal Cord Injury Inaccurately Portrayed SO JOURNAL OF NEUROTRAUMA LA English DT Letter ID AUTONOMIC DYSREFLEXIA; CARDIOVASCULAR-RESPONSES; SPERM RETRIEVAL; MEN; STIMULATION; EJACULATION C1 [Alexander, Marcalee] Birmingham VA Med Ctr, Dept Rehabilitat Med, Birmingham, AL USA. [Alexander, Marcalee] Univ Alabama Birmingham, Med Sch Birmingham, Dept Phys Med & Rehabil, Birmingham, AL USA. [Alexander, Marcalee] Harvard Univ, Sch Med, Dept Phys Med & Rehabil, Boston, MA USA. [Courtois, Frederique] Univ Quebec Montreal, Fac Sci Humaines, Dept Sexol, CP 8888,Succ,Ctr Ville, Montreal, PQ, Canada. [Courtois, Frederique] Univ Quebec Montreal, Fac Sci Humaines, Dept Psychol, Montreal, PQ, Canada. RP Courtois, F (reprint author), Univ Quebec Montreal, Fac Sci Humaines, Dept Sexol, CP 8888,Succ,Ctr Ville, Montreal, PQ, Canada. EM courtois.frederique@uqam.ca NR 11 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 0897-7151 EI 1557-9042 J9 J NEUROTRAUM JI J. Neurotrauma PD MAR PY 2017 VL 34 IS 6 BP 1289 EP 1290 DI 10.1089/neu.2016.4810 PG 2 WC Critical Care Medicine; Clinical Neurology; Neurosciences SC General & Internal Medicine; Neurosciences & Neurology GA EN7ZR UT WOS:000396221200017 PM 27796188 ER PT J AU Rivera, JC Amuan, ME Morris, RM Johnson, AE Pugh, MJ AF Rivera, Jessica C. Amuan, Megan E. Morris, Ruth M. Johnson, Anthony E. Pugh, Mary Jo TI Arthritis, comorbidities, and care utilization in veterans of operations enduring and Iraqi Freedom SO JOURNAL OF ORTHOPAEDIC RESEARCH LA English DT Article DE veterans health; military health; osteoarthritis; musculoskeletal health care utilization; comorbid arthritis ID MILITARY SERVICE MEMBERS; UNITED-STATES; HEALTH-CARE; OSTEOARTHRITIS; POPULATION; PREVALENCE; DISEASE; FRACTURES; WOUNDS; INJURY AB Veteran populations are known to have frequencies of arthritis higher than civilian populations. The aim of this study is to define the prevalence of arthritis among a cohort of veterans from ongoing U.S. military operations. A retrospective cohort study using Veterans Administration data sources for service connected disability, comorbidities, clinic utilization, and pharmacy utilization was conducted including veterans who deployed in service to operations in Afghanistan or Iraq, comparing veterans with a diagnosis of arthritis, arthritis plus back pain, and veterans with no pain diagnoses. The frequency of arthritis was 11.8%. Veterans with arthritis and arthritis plus back pain had greater frequencies of diabetes, hyperlipidemia, hypertension, and obesity compare to veterans with no pain diagnosis. Veterans with arthritis plus back pain had the highest pain clinic utilization and prescription use of opioids and anti-inflammatories. Veterans with no pain diagnosis had higher frequencies of diagnosis and clinic utilization for mental health disorders. Arthritis is prevalent among the latest generation of combat veterans and is associated with diabetes, obesity, and cardiovascular comorbidities. The need for arthritis care and associated comorbidities is expected to increase as the Veterans Administration and the civilian health care sector assumes care of these veterans. (c) 2016 Orthopaedic Research Society. Published by Wiley Periodicals, Inc. J Orthop Res 35:682-687, 2017. C1 [Rivera, Jessica C.] US Army Inst Surg Res, 3698 Chambers Pass, Jbsa Ft Sam Houston, TX 78234 USA. [Rivera, Jessica C.; Johnson, Anthony E.] San Antonio Mil Med Ctr, Dept Orthopaed Surg, 3698 Chambers Pass, Jbsa Ft Sam Houston, TX 78234 USA. [Amuan, Megan E.] Edith Nourse Roge Mem Vet Hosp, Bedford, MA USA. [Morris, Ruth M.; Pugh, Mary Jo] South Texas Vet Hlth Care Syst, San Antonio, TX USA. RP Rivera, JC (reprint author), US Army Inst Surg Res, 3698 Chambers Pass, Jbsa Ft Sam Houston, TX 78234 USA.; Rivera, JC (reprint author), San Antonio Mil Med Ctr, Dept Orthopaed Surg, 3698 Chambers Pass, Jbsa Ft Sam Houston, TX 78234 USA. EM jessica.c.rivera14.mil@mail.mil NR 34 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0736-0266 EI 1554-527X J9 J ORTHOP RES JI J. Orthop. Res. PD MAR PY 2017 VL 35 IS 3 SI SI BP 682 EP 687 DI 10.1002/jor.23323 PG 6 WC Orthopedics SC Orthopedics GA EP7YY UT WOS:000397594300032 PM 27256517 ER PT J AU LeBlanc, ES Rizzo, JH Pedula, KL Yaffe, K Ensrud, KE Cauley, J Cawthon, PM Cummings, S Hillier, TA AF LeBlanc, Erin S. Rizzo, Joanne H. Pedula, Kathryn L. Yaffe, Kristine Ensrud, Kristine E. Cauley, Jane Cawthon, Peggy M. Cummings, Steven Hillier, Teresa A. CA Study Osteoporotic Fractures SOF R TI Weight Trajectory over 20 Years and Likelihood of Mild Cognitive Impairment or Dementia Among Older Women SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE weight trajectory; dementia; cognitive dysfunction ID BODY-MASS INDEX; INCIDENT ALZHEIMER-DISEASE; POPULATION-BASED COHORT; MATTER VOLUME DEFICITS; CEREBRAL GRAY-MATTER; LATE-LIFE; RISK-FACTORS; ANOREXIA-NERVOSA; CARDIOVASCULAR-HEALTH; POSTMENOPAUSAL WOMEN AB ObjectivesThe association between weight change and cognition is controversial. We examined the association between 20-year weight change and cognitive function in late life. DesignCohort study. SettingStudy of Osteoporotic Fractures (SOF). ParticipantsOne thousand two hundred eighty-nine older, community-dwelling women (mean baseline age 68 (65-81) and 88 (82-102) at cognitive testing). MeasurementsStudy of Osteoporotic Fractures participants had body weight measured repeatedly over 20 years (mean 8 weights). Adjudicated cognitive status was classified as normal (n = 775) or mild cognitive impairment (MCI)/dementia (n = 514) at Year 20. Logistic models were used to evaluate whether absolute weight change, rate of weight loss per year, presence of abrupt, unrecovered weight loss, and weight variability were associated with MCI or dementia. ResultsWomen with greater rate of weight loss over 20 years had increased chance of developing MCI or dementia. In age/education/clinic-adjusted base models, each 0.5 kg/yr decrease resulted in 30% increased odds of MCI/dementia (OR = 1.30 [95% CI: 1.14, 1.49]). After adjustment for age, education, clinic, depression, and walking speed, there was 17% (OR = 1.17 [95% CI: 1.02, 1.35]) increased odds of MCI/dementia for each 0.5 kg/yr decrease in weight. In base models, variability in weight was significant. Each 1% average deviation from each woman's predicted weight curve was associated with 11% increased odds of MCI/dementia (OR = 1.11 [95% CI: 1.04, 1.18]). The estimate was attenuated after full adjustment (OR = 1.06 [95% CI: 0.99, 1.14]). The presence of an abrupt weight decline was not associated with MCI/dementia. ConclusionsRate of weight loss over 20 years was associated with development of MCI or dementia in women surviving past 80 years, suggesting that nutritional status, social-environmental factors, and/or adipose tissue function and structure may affect cognitive function with aging. C1 [LeBlanc, Erin S.; Rizzo, Joanne H.; Pedula, Kathryn L.; Hillier, Teresa A.] Kaiser Permanente Northwest, Ctr Hlth Res, 3800 North Interstate Ave, Portland, OR 97227 USA. [Yaffe, Kristine] Univ Calif San Francisco, Sch Med, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Sch Med, Dept Neurol, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Sch Med, Dept Epidemiol & Biostat, San Francisco, CA USA. [Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA USA. [Ensrud, Kristine E.] Univ Minnesota, Dept Med, Univ Epidemiol & Community Hlth, Ctr Chron Dis Outcomes Res,VA Hlth Care Syst, Box 736 UMHC, Minneapolis, MN 55455 USA. [Cauley, Jane] Univ Pittsburgh, Grad Sch Publ Hlth, Dept Epidemiol, Pittsburgh, PA 15260 USA. [Cawthon, Peggy M.; Cummings, Steven] Calif Pacific Med Ctr, Res Inst, San Francisco, CA USA. [Hillier, Teresa A.] Kaiser Permanente Hawaii, Ctr Hlth Res, Honolulu, HI USA. RP LeBlanc, ES (reprint author), Kaiser Permanente Northwest, Ctr Hlth Res, 3800 North Interstate Ave, Portland, OR 97227 USA. EM erin.s.leblanc@kpchr.org FU Amgen; Astrazeneca; Bristol Meyers Squibb; National Institutes of Health; National Institute on Aging (NIA) [R01 ag005407, R01 ar35582, R01 ar35583, R01 ar35584, R01 ag005394, R01 ag027574, R01 ag027576] FX Dr. LeBlanc's institute has received research funding from Amgen, Astrazeneca, and Bristol Meyers Squibb for unrelated projects on which she was investigator.; The Study of Osteoporotic Fractures (SOF) is supported by the National Institutes of Health. The National Institute on Aging (NIA) provides support under the following grant numbers: R01 ag005407, R01 ar35582, R01 ar35583, R01 ar35584, R01 ag005394, R01 ag027574, and R01 ag027576. NR 69 TC 0 Z9 0 U1 1 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2017 VL 65 IS 3 BP 511 EP 519 DI 10.1111/jgs.14552 PG 9 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EQ0XQ UT WOS:000397794300014 PM 27991654 ER PT J AU Yoshikawa, TT Norman, DC AF Yoshikawa, Thomas T. Norman, Dean C. TI Geriatric Infectious Diseases: Current Concepts on Diagnosis and Management SO JOURNAL OF THE AMERICAN GERIATRICS SOCIETY LA English DT Article DE infection; infectious disease; geriatric; aging; long-term care ID CLOSTRIDIUM-DIFFICILE INFECTION; LONG-TERM-CARE; COMMUNITY-ACQUIRED PNEUMONIA; URINARY-TRACT-INFECTION; NURSING-HOME RESIDENTS; FECAL MICROBIOTA TRANSPLANTATION; CLINICAL-PRACTICE GUIDELINES; OLDER-ADULTS; ASYMPTOMATIC BACTERIURIA; FUNCTIONAL STATUS AB New information on infectious diseases in older adults has become available in the past 20years. In this review, in-depth discussions on the general problem of geriatric infectious diseases (epidemiology, pathogenesis, age-related host defenses, clinical manifestations, diagnostic approach); diagnosis and management of bacterial pneumonia, urinary tract infection, and Clostridium difficile infection; and the unique challenges of diagnosing and managing infections in a long-term care setting are presented. C1 [Yoshikawa, Thomas T.] Dept Vet Affairs Greater Angeles Healthcare Syst, Los Angeles, CA USA. [Yoshikawa, Thomas T.] Univ Calif Los Angeles, David Geffen Sch Med, Los Angeles, CA 90095 USA. [Norman, Dean C.] Dept Vet Affairs San Diego Healthcare Syst, San Diego, CA USA. [Norman, Dean C.] Univ Calif Los Angeles, Los Angeles, CA USA. RP Yoshikawa, TT (reprint author), VA Greater Los Angeles Healthcare Syst, 11300 Wilshire Blvd,Bldg 158-GRECC W 11G, Los Angeles, CA 90073 USA. EM Toyoshikawa@cdrewu.edu NR 97 TC 0 Z9 0 U1 1 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0002-8614 EI 1532-5415 J9 J AM GERIATR SOC JI J. Am. Geriatr. Soc. PD MAR PY 2017 VL 65 IS 3 BP 631 EP 641 DI 10.1111/jgs.14731 PG 11 WC Geriatrics & Gerontology; Gerontology SC Geriatrics & Gerontology GA EQ0XQ UT WOS:000397794300032 PM 28140454 ER PT J AU Cochran, G Gordon, AJ Lo-Ciganic, WH Gellad, WF Frazier, W Lobo, C Chang, CCH Zheng, P Donohue, JM AF Cochran, Gerald Gordon, Adam J. Lo-Ciganic, Wei-Hsuan Gellad, Walid F. Frazier, Winfred Lobo, Carroline Chang, Chung-Chou H. Zheng, Ping Donohue, Julie M. TI An Examination of Claims-based Predictors of Overdose from a Large Medicaid Program SO MEDICAL CARE LA English DT Article DE opioid medication overdose; health claims; opioid medication misuse and abuse ID PRESCRIPTION OPIOID ABUSE; UNITED-STATES; CHRONIC PAIN; PRESCRIBING PATTERNS; IDENTIFY PATIENTS; RISK; DEATHS; MISUSE; CARE; INTERVENTIONS AB Background: Health systems may play an important role in identification of patients at-risk of opioid medication overdose. However, standard measures for identifying overdose risk in administrative data do not exist. Objective: Examine the association between opioid medication overdose and 2 validated measures of nonmedical use of prescription opioids within claims data. Research Design: A longitudinal retrospective cohort study that estimated associations between overdose and nonmedical use. Subjects: Adult Pennsylvania Medicaid program 2007-2012 patients initiating opioid treatment who were: nondual eligible, without cancer diagnosis, and not in long-term care facilities or receiving hospice. Measures: Overdose (International Classification of Disease, ninth edition, prescription opioid poisonings codes), opioid abuse (opioid use disorder diagnosis while possessing an opioid prescription), opioid misuse (a composite indicator of number of opioid prescribers, number of pharmacies, and days supplied), and dose exposure during opioid treatment episodes. Results: A total of 372,347 Medicaid enrollees with 583,013 new opioid treatment episodes were included in the cohort. Opioid overdose was higher among those with abuse (1.5%) compared with those without (0.2%, P<0.001). Overdose was higher among those with probable (1.8%) and possible (0.9%) misuse compared with those without (0.2%, P<0.001). Abuse [adjusted rate ratio (ARR), 1.52; 95% confidence interval (CI), 1.10-2.10), probable misuse (ARR, 1.98; 95% CI, 1.46-2.67), and possible misuse (ARR, 1.76; 95% CI, 1.48-2.09) were associated with significantly more events of opioid medication overdose compared with those without. Conclusions: Claims-based measures can be used by health systems to identify individuals at-risk of overdose who can be targeted for restrictions on opioid prescribing, dispensing, or referral to treatment. C1 [Cochran, Gerald] Univ Pittsburgh, Sch Social Work, 4200 Forbes Ave,2117 CL, Pittsburgh, PA 15260 USA. [Cochran, Gerald] Univ Pittsburgh, Sch Med, Dept Psychiat, Pittsburgh, PA USA. [Cochran, Gerald; Gordon, Adam J.; Gellad, Walid F.; Donohue, Julie M.] Univ Pittsburgh, Ctr Pharmaceut Policy & Prescribing, Pittsburgh, PA USA. [Gordon, Adam J.; Gellad, Walid F.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Gordon, Adam J.; Gellad, Walid F.; Frazier, Winfred] Univ Pittsburgh, Sch Med, Div Gen Internal Med, Pittsburgh, PA USA. [Lo-Ciganic, Wei-Hsuan] Univ Arizona, Coll Pharm, Tucson, AZ 85721 USA. [Lobo, Carroline; Chang, Chung-Chou H.; Zheng, Ping; Donohue, Julie M.] Univ Pittsburgh, Grad Sch Publ Hlth, Pittsburgh, PA USA. [Chang, Chung-Chou H.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. RP Cochran, G (reprint author), Univ Pittsburgh, Sch Social Work, 4200 Forbes Ave,2117 CL, Pittsburgh, PA 15260 USA. EM gcochran@pitt.edu FU Centers for Disease Control and Prevention [U01CE002496] FX G.C., J.M.D, A.J.G., and W.F.G. are supported by a grant from the Centers for Disease Control and Prevention (U01CE002496). The remaining authors declare no conflict of interest. NR 49 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 0025-7079 EI 1537-1948 J9 MED CARE JI Med. Care PD MAR PY 2017 VL 55 IS 3 BP 291 EP 298 PG 8 WC Health Care Sciences & Services; Health Policy & Services; Public, Environmental & Occupational Health SC Health Care Sciences & Services; Public, Environmental & Occupational Health GA EL3GD UT WOS:000394506700013 PM 27984346 ER PT J AU Hernandez-Tejada, MA Acierno, R Sanchez-Carracedo, D AF Hernandez-Tejada, Melba A. Acierno, Ron Sanchez-Carracedo, David TI Addressing Dropout From Prolonged Exposure: Feasibility of Involving Peers During Exposure Trials SO MILITARY PSYCHOLOGY LA English DT Article DE PTSD; peer; social support; dropout; Prolonged Exposure therapy ID POSTTRAUMATIC-STRESS-DISORDER; PTSD TREATMENT; SERVICE; CARE AB Posttraumatic stress disorder ( PTSD) is a significant problem for combat veterans. Fortunately, effective treatments, such as Prolonged Exposure ( PE), are available and widely disseminated in the Veterans Affairs ( VA) health-care system. Nonetheless, despite well-documented effectiveness, attrition remains high at approximately 30% across evidence-based interventions. Early studies indicated that dropout was largely related to stigma and logistical barriers ( e. g., travel time and cost). However, research demonstrates that eliminating these logistical and stigma-based barriers ( e. g., through home-based telemedicine) has little effect on dropout. We surveyed 82 veterans who dropped out of PE treatment regarding reasons for leaving treatment. Approximately half indicated that in vivo homework assignments caused significant problems, and when asked to consider the possibility of peer support during in vivo exposure assignments, 52% indicated that they would consider returning to treatment with such assistance. In response to this feedback, we constructed an in vivo therapy peer support program wherein peers are directly involved with in vivo exposure exercises. The following brief report presents the rationale for, outline of, and initial feasibility data supporting this program to enhance both return to, and completion of, exposure therapy treatment for PTSD. C1 [Hernandez-Tejada, Melba A.; Sanchez-Carracedo, David] Univ Autonoma Barcelona, Dept Clin & Hlth Psychol, Barcelona, Spain. [Hernandez-Tejada, Melba A.; Acierno, Ron] Ralph H Johnson Vet Affairs Med Ctr, Charleston, SC USA. [Acierno, Ron] Med Univ South Carolina, Coll Nursing, 99 Jonathan Lucas St,MSC160, Charleston, SC 29425 USA. RP Hernandez-Tejada, MA (reprint author), Med Univ South Carolina, Coll Nursing, 99 Jonathan Lucas St,MSC160, Charleston, SC 29425 USA. EM hernanma@musc.edu NR 17 TC 0 Z9 0 U1 1 U2 1 PU AMER PSYCHOLOGICAL ASSOC PI WASHINGTON PA 750 FIRST ST NE, WASHINGTON, DC 20002-4242 USA SN 0899-5605 EI 1532-7876 J9 MIL PSYCHOL JI Milit. Psychol. PD MAR PY 2017 VL 29 IS 2 BP 157 EP 163 DI 10.1037/mil0000137 PG 7 WC Psychology, Multidisciplinary SC Psychology GA EN5MR UT WOS:000396050200006 ER PT J AU Rodriguez-Garcia, M Shen, Z Barr, FD Boesch, AW Ackerman, ME Kappes, JC Ochsenbauer, C Wira, CR AF Rodriguez-Garcia, M. Shen, Z. Barr, F. D. Boesch, A. W. Ackerman, M. E. Kappes, J. C. Ochsenbauer, C. Wira, C. R. TI Dendritic cells from the human female reproductive tract rapidly capture and respond to HIV SO MUCOSAL IMMUNOLOGY LA English DT Article ID HUMAN-IMMUNODEFICIENCY-VIRUS; LEUKOCYTE PROTEASE INHIBITOR; MENSTRUAL-CYCLE; PIGTAIL MACAQUES; LANGERHANS CELLS; EX-VIVO; INFECTION; SUSCEPTIBILITY; SUBSETS; TYPE-1 AB Dendritic cells (DCs) throughout the female reproductive tract (FRT) were examined for phenotype, HIV capture ability and innate anti-HIV responses. Two main CD11c(+) DC subsets were identified: CD11b(+) and CD11b(low) DCs. CD11b(+)CD14(+) DCs were the most abundant throughout the tract. A majority of CD11c(+)CD14(+) cells corresponded to CD1c(+) myeloid DCs, whereas the rest lacked CD1c and CD163 expression (macrophage marker) and may represent monocyte-derived cells. In addition, we identified CD103(+) DCs, located exclusively in the endometrium, whereas DC-SIGN(+) DCs were broadly distributed throughout the FRT. Following exposure to GFP-labeled HIV particles, CD14(+) DC-SIGN(+) as well as CD14(+) DC-SIGN(-) cells captured virus, with similar to 30% of these cells representing CD1c(+) myeloid DCs. CD103(+) DCs lacked HIV capture ability. Exposure of FRT DCs to HIV induced secretion of CCL2, CCR5 ligands, interleukin (IL)-8, elafin, and secretory leukocyte peptidase inhibitor (SLPI) within 3 h of exposure, whereas classical pro-inflammatory molecules did not change and interferon-alpha 2 and IL-10 were undetectable. Furthermore, elafin and SLPI upregulation, but not CCL5, were suppressed by estradiol pre-treatment. Our results suggest that specific DC subsets in the FRT have the potential for capture and dissemination of HIV, exert antiviral responses and likely contribute to the recruitment of HIV-target cells through the secretion of innate immune molecules. C1 [Rodriguez-Garcia, M.; Shen, Z.; Barr, F. D.; Wira, C. R.] Geisel Sch Med, Dept Physiol & Neurobiol, Lebanon, NH USA. [Boesch, A. W.; Ackerman, M. E.] Dartmouth Coll, Thayer Sch Engn, Hanover, NH 03755 USA. [Kappes, J. C.; Ochsenbauer, C.] Univ Alabama Birmingham, Dept Med, Res Serv Birmingham, Birmingham, AL USA. [Kappes, J. C.; Ochsenbauer, C.] Univ Alabama Birmingham, UAB Ctr AIDS Res, Birmingham, AL USA. [Kappes, J. C.] Birmingham Vet Affairs Med Ctr, Res Serv Birmingham, Birmingham, AL USA. RP Rodriguez-Garcia, M (reprint author), Geisel Sch Med, Dept Physiol & Neurobiol, Lebanon, NH USA. EM Marta.Rodriguez.Garcia@dartmouth.edu FU NIH [AI102838, AI117739, CA73479, P30 AI27767] FX We thank Dr John Fahey and Dr Yina Huang for critical comments and suggestions. We thank Richard Rossoll for technical assistance and Dr Rakesh Bakshi for help with preparing HIV-GFP VLPs. We thank the study participants, Pathologists, Obstetrics, and Gynecology surgeons, operating room nurses and support personnel at Dartmouth-Hitchcock Medical Center. Flow cytometric analysis was carried out in DartLab, the Immunoassay and Flow Cytometry Shared Resource at the Geisel School of Medicine at Dartmouth. Study supported by NIH grants AI102838 and AI117739 (CRW), CA73479 (JCK), and P30 AI27767 Birmingham Center for AIDS Research-Virology Core (CO; JCK) NR 67 TC 1 Z9 1 U1 4 U2 4 PU NATURE PUBLISHING GROUP PI NEW YORK PA 75 VARICK ST, 9TH FLR, NEW YORK, NY 10013-1917 USA SN 1933-0219 EI 1935-3456 J9 MUCOSAL IMMUNOL JI Mucosal Immunol. PD MAR PY 2017 VL 10 IS 2 BP 531 EP 544 DI 10.1038/mi.2016.72 PG 14 WC Immunology SC Immunology GA EN1ZV UT WOS:000395810000023 PM 27579858 ER PT J AU Chosich, J Bradford, AP Allshouse, AA Reusch, JEB Santoro, N Schauer, IE AF Chosich, Justin Bradford, Andrew P. Allshouse, Amanda A. Reusch, Jane E. B. Santoro, Nanette Schauer, Irene E. TI Acute Recapitulation of the Hyperinsulinemia and Hyperlipidemia Characteristic of Metabolic Syndrome Suppresses Gonadotropins SO OBESITY LA English DT Article ID POLYCYSTIC OVARIAN SYNDROME; MUSCLE INSULIN-RESISTANCE; BODY-MASS INDEX; LUTEINIZING-HORMONE; OBESE WOMEN; MENSTRUAL-CYCLE; LUTEAL-PHASE; INVERSE RELATIONSHIP; FEMALE MICE; GLUCOSE AB Objective: To determine the effect of lipid/heparin versus saline infusion, with or without concurrent euglycemic hyperinsulinemia, on serum follicle-stimulating hormone (FSH) and luteinizing hormone (LH). Obesity is associated with hyperlipidemia, insulin resistance, and relative hypogonadotropic hypogonadism. It was hypothesized that acutely elevated fatty acids and insulin would impair gonadotropin secretion. Methods: Regularly cycling women and men without obesity underwent a crossover 6-hour infusion study over four visits. Participants received infusions of saline-control, lipid/heparin, insulin, and lipid/heparin plus insulin. Serum FSH and LH were measured by immunoassay. Results: In women (n=10), infusion of lipid plus insulin significantly reduced LH, from 4.6 IU/L (3.7-5.4) ( mean [95% confidence interval]) to 3.3 IU/L (2.3-4.4); P=0.03, and FSH, from 3.9 IU/L (3.2-4.6) to 3.1 IU/L (2.3-3.8); P=0.03, compared to saline-control. Similarly, in men ( n=10), LH, 3.3 IU/L (2.4-4.1), and FSH, 2.1 IU/L (1.4-2.8), were significantly reduced after the combined infusion (2.2 [1.3-3.1] IU/L and 1.5 [0.8-2.1] IU/L; P=0.03, P=0.02, respectively). Neither lipid nor insulin alone significantly impacted gonadotropin levels compared to saline-control. Conclusions: Hyperinsulinemia combined with elevated lipids acutely suppresses LH and FSH, providing a possible mechanism underlying the relative hypogonadotropic hypogonadism of obesity. Effects of insulin on the hypothalamic-pituitary-gonadal axis may be dependent on the concomitant metabolic environment. C1 [Chosich, Justin; Bradford, Andrew P.; Santoro, Nanette] Univ Colorado, Sch Med, Dept Obstet & Gynecol, Aurora, CO 80045 USA. [Allshouse, Amanda A.] Colorado Sch Publ Hlth, Dept Biostat & Informat, Aurora, CO USA. [Reusch, Jane E. B.; Schauer, Irene E.] Univ Colorado, Sch Med, Dept Med, Div Endocrinol Metab & Diabet, Aurora, CO USA. [Reusch, Jane E. B.; Schauer, Irene E.] Denver Vet Affairs Med Ctr, Endocrinol Sect, Denver, CO USA. RP Santoro, N (reprint author), Univ Colorado, Sch Med, Dept Obstet & Gynecol, Aurora, CO 80045 USA. EM nanette.santoro@ucdenver.edu FU NIH [U54 HD058155, K23 DK091553, K12 HD057022, TL1 TR001081] FX This work was supported by NIH grants U54 HD058155 (Jeffrey Pollard, PI), K23 DK091553 (Irene E. Schauer, PI), K12 HD057022 (Judy Regensteiner and Nanette Santoro, co-PIs), VA Merit Award (Jane E. B. Reusch, PI), and TL1 TR001081 (Ron Sokol, PI). NR 33 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1930-7381 EI 1930-739X J9 OBESITY JI Obesity PD MAR PY 2017 VL 25 IS 3 BP 553 EP 560 DI 10.1002/oby.21754 PG 8 WC Endocrinology & Metabolism; Nutrition & Dietetics SC Endocrinology & Metabolism; Nutrition & Dietetics GA EQ4IP UT WOS:000398040000014 PM 28158916 ER PT J AU Hawkins, EJ Malte, CA Hagedorn, HJ Berger, D Frank, A Lott, A Achtmeyer, CE Mariano, AJ Saxon, AJ AF Hawkins, Eric J. Malte, Carol A. Hagedorn, Hildi J. Berger, Douglas Frank, Anissa Lott, Aline Achtmeyer, Carol E. Mariano, Anthony J. Saxon, Andrew J. TI Survey of Primary Care and Mental Health Prescribers' Perspectives on Reducing Opioid and Benzodiazepine Co-Prescribing Among Veterans SO PAIN MEDICINE LA English DT Article DE Chronic Pain; Concurrent Opioid and Benzodiazepine Use; Primary Care; Mental Health; Beliefs; Attitudes; High-Risk Conditions ID POSTTRAUMATIC-STRESS-DISORDER; CHRONIC PAIN; GENERAL-PRACTITIONERS; PARIHS FRAMEWORK; PHYSICIANS PERSPECTIVES; OLDER-ADULTS; US VETERANS; IMPLEMENTATION; ATTITUDES; DOCTORS AB Background. Due to the involvement of opioids and benzodiazepines in rising pharmaceutical overdoses, a reduction in coprescribing of these medications is a national priority, particularly among patients with substance use disorders and other high-risk conditions. However, little is known about primary care (PC) and mental health (MH) prescribers' perspectives on these medications and efforts being implemented to reduce coprescribing. Design. An anonymous survey. Setting. One multisite VA health care system. Subjects. Participants were 55 PC and 31 MH prescribers. Methods. Survey development was guided by the Promoting Action on Research Implementation in Health Services (PARIHS) conceptual framework. PC and MH prescribers of opioids or benzodiazepines were invited to complete an anonymous electronic survey. Responses were collapsed to highlight agreement, disagreement, and neutrality and summarized with means and percentages. Results. Over 80% of both prescriber groups reported concern about concurrent use and > 75% strongly agreed with clinical practice guidelines (CPG) that recommend caution in coprescribing among patients with high-risk conditions. More than 40% of both prescriber groups indicated that coprescribing continues because of beliefs that patients appear stable without adverse events and tapering/discontinuation is too difficult. Over 70% of prescribers rated strategies for addressing patients who refuse to discontinue, more time with patients, and identification of high-risk patients as helpful in reducing coprescribing. Conclusion. Despite strong agreement with CPGs, prescribers reported several barriers that contribute to coprescribing of opioids and benzodiazepines and challenge their ability to taper these medications. Multiple interventions are likely needed to reduce opioid and benzodiazepine coprescribing. C1 [Hawkins, Eric J.; Malte, Carol A.; Frank, Anissa; Lott, Aline; Achtmeyer, Carol E.; Saxon, Andrew J.] Seattle Ctr Innovat Veteran Centered & Value Driv, Veteran Affairs VA Puget Sound Hlth Care Syst, HSR&D, Seattle, WA USA. [Hawkins, Eric J.; Malte, Carol A.; Frank, Anissa; Lott, Aline; Achtmeyer, Carol E.; Saxon, Andrew J.] Ctr Excellence Substance Abuse Treatment & Educ, VA Puget Sound Hlth Care Syst Seattle, Div S116ATC, 1660 S Columbian Way, Seattle, WA 98108 USA. [Hawkins, Eric J.; Hagedorn, Hildi J.] VA Qual Enhancement Res Initiat Substance Use Dis, Palo Alto, CA USA. [Hawkins, Eric J.; Mariano, Anthony J.; Saxon, Andrew J.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Hagedorn, Hildi J.] Minneapolis VA Hlth Care Syst, Minneapolis, MN USA. [Berger, Douglas; Achtmeyer, Carol E.] Primary & Specialty Med Care Serv, VA Puget Sound Hlth Care Syst, Seattle, WA USA. [Berger, Douglas] Univ Washington, Dept Med, Seattle, WA 98195 USA. [Mariano, Anthony J.] VA Northwest Vet Integrated Serv Network VISN 20, VA Puget Sound Hlth Care Syst, Seattle, WA USA. RP Hawkins, EJ (reprint author), Ctr Excellence Substance Abuse Treatment & Educ, VA Puget Sound Hlth Care Syst Seattle, Div S116ATC, 1660 S Columbian Way, Seattle, WA 98108 USA. EM Eric.Hawkins@va.gov FU U.S. Department of Veterans Affairs, Veterans Health Administration; VA Center of Excellence in Substance Abuse Treatment Education; VA Health Services Research and Development (HSR&D) Quality Enhancement Research Initiative Rapid Response Project (RRP) [12-527]; Quality Enhancement Research Initiative for Substance Use Disorders (SUD QUERI) FX This material is based upon work supported by the U.S. Department of Veterans Affairs, Veterans Health Administration, the VA Center of Excellence in Substance Abuse Treatment & Education, the VA Health Services Research and Development (HSR&D) Quality Enhancement Research Initiative Rapid Response Project (RRP) # 12-527, and the Quality Enhancement Research Initiative for Substance Use Disorders (SUD QUERI). Supporting organizations had no further role in the study design; in the collection, analysis and interpretation of data; in the writing of the report; or in the decision to submit the paper for publication. NR 58 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD MAR PY 2017 VL 18 IS 3 BP 454 EP 467 DI 10.1093/pm/pnw140 PG 14 WC Medicine, General & Internal SC General & Internal Medicine GA EP0VE UT WOS:000397104000009 PM 27558857 ER PT J AU Brellenthin, AG Crombie, KM Cook, DB Sehgal, N Koltyn, KF AF Brellenthin, Angelique G. Crombie, Kevin M. Cook, Dane B. Sehgal, Nalini Koltyn, Kelli F. TI Psychosocial Influences on Exercise-Induced Hypoalgesia SO PAIN MEDICINE LA English DT Article DE Sex; Family; Psychological; Exercise; Modulation; Catastrophizing ID CONDITIONED PAIN MODULATION; ISOMETRIC-EXERCISE; SEX-DIFFERENCES; POSTOPERATIVE PAIN; TEMPORAL SUMMATION; CATASTROPHIZING SCALE; PSYCHOLOGICAL-FACTORS; QUESTIONNAIRE-III; FAMILY-HISTORY; BLOOD-PRESSURE AB Objective. The purpose of this study was to examine psychosocial influences on exercise-induced hypoalgesia (EIH). Design. Randomized controlled trial. Setting. Clinical research unit in a hospital. Subjects. Fifty-eight healthy men and women (mean age=21 +/- 3 years) participated in this study. Methods. Participants were first asked to complete a series of baseline demographic and psychological questionnaires including the Pain Catastrophizing Scale, the Fear of Pain Questionnaire, and the Family Environment Scale. Following this, they were familiarized with both temporal summation of heat pain and pressure pain testing protocols. During their next session, participants completed the Profile of Mood States, rated the intensity of heat pulses, and indicated their pressure pain thresholds and ratings before and after three minutes of submaximal, isometric exercise. Situational catastrophizing was assessed at the end of the experimental session. Results. Results indicated that experimental pain sensitivity was significantly reduced after exercise (P < 0.05). Men and women did not differ on any of the measured psychosocial variables (P > 0.05). Positive family environments predicted attenuated pain sensitivity and greater EIH, whereas negative and chronic pain-present family environments predicted worse pain and EIH outcomes. Situational catastrophizing and negative mood state also predicted worse pain and EIH outcomes and were additionally associated with increased ratings of perceived exertion and muscle pain during exercise. Conclusions. This study provides preliminary evidence that psychosocial variables, such as the family environment and mood states, can affect both pain sensitivity and the ability to modulate pain through exercise-induced hypoalgesia. C1 [Brellenthin, Angelique G.; Crombie, Kevin M.; Cook, Dane B.; Koltyn, Kelli F.] Univ Wisconsin Madison, Dept Kinesiol, Madison, WI USA. [Sehgal, Nalini] Univ Wisconsin Madison, Dept Rehabil Med, Madison, WI USA. [Cook, Dane B.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. RP Koltyn, KF (reprint author), Univ Wisconsin, 2000 Observ Dr, Madison, WI 53706 USA. EM koltyn@education.wisc.edu FU National Institutes of Health [R21AR057159, 1UL1RR025011] FX This research was supported by National Institutes of Health grants R21AR057159 and 1UL1RR025011. NR 70 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 1526-2375 EI 1526-4637 J9 PAIN MED JI Pain Med. PD MAR PY 2017 VL 18 IS 3 BP 538 EP 550 DI 10.1093/pm/pnw275 PG 13 WC Medicine, General & Internal SC General & Internal Medicine GA EP0VE UT WOS:000397104000016 PM 28034985 ER PT J AU Glynn, SM Marder, SR Noordsy, DL O'Keefe, C Becker, DR Drake, RE Sugar, CA AF Glynn, Shirley M. Marder, Stephen R. Noordsy, Douglas L. O'Keefe, Christopher Becker, Deborah R. Drake, Robert E. Sugar, Catherine A. TI An RCT Evaluating the Effects of Skills Training and Medication Type on Work Outcomes Among Patients With Schizophrenia SO PSYCHIATRIC SERVICES LA English DT Article ID RANDOMIZED CONTROLLED-TRIALS; SEVERE MENTAL-ILLNESS; SUPPORTED EMPLOYMENT; INDIVIDUAL PLACEMENT; WORKPLACE SKILLS; SCALE; MODEL AB Objective: Although supported employment increases job acquisition for people with serious mental illness, data on participants' job tenure have been variable. This study evaluated the effects of a standardized work skills training program (the Workplace Fundamentals Module [WPFM]) on job tenure and other work outcomes among individuals receiving individual placement and support (IPS). The effects of two atypical antipsychotic medications on side effects were also tested. The primary hypothesis testedwas that participants in IPS plus WPFM would have increased job tenure compared with those enrolled in IPS only, and the secondary hypothesis was that different antipsychoticmedicationswould yield unique side effects. Methods: A 232 randomized controlled trial compared work outcomes, including job tenure, of participants receiving IPS with or without WPFM for up to two years after obtaining a job. Participants were also randomly assigned to olanzapine or risperidone. Measures of work outcomes, clinical status, and medication side effects were collected. Results: Among 107 participants, 63% obtained at least one job. WPFM did not increase job tenure (51.53 and 41.37 total weeks worked for IPS only and IPS plus WPFM, respectively) or affect other work outcomes. Participants on olanzapine experienced increased body mass index, whereas those on risperidone lost weight, but medications did not differentially affect clinical or job outcomes. Conclusions: Clinic-based skills training did not improve work outcomes accruing from IPS. Risperidone, compared with olanzapine, may reduce body mass but has no differential effect on other work or clinical outcomes. C1 [Glynn, Shirley M.; Marder, Stephen R.] US Dept Vet Affairs, Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Glynn, Shirley M.; Marder, Stephen R.; Sugar, Catherine A.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. [Noordsy, Douglas L.] Stanford Univ, Sch Med, Dept Psychiat & Behav Sci, Stanford, CA USA. [O'Keefe, Christopher] Southern New Hampshire Univ, Manchester, NH USA. [Becker, Deborah R.; Drake, Robert E.] WESTAT Corp, Rockville Inst, Lebanon, NH USA. [Sugar, Catherine A.] Univ Calif Los Angeles, Fielding Sch Publ Hlth, Dept Biostat, Los Angeles, CA 90024 USA. [Noordsy, Douglas L.; O'Keefe, Christopher; Becker, Deborah R.; Drake, Robert E.] Dartmouth Coll, Geisel Sch Med, Dept Psychiat, Hanover, NH USA. [Becker, Deborah R.; Drake, Robert E.] Dartmouth Coll, Geisel Sch Med, Dept Community & Family Med, Hanover, NH USA. RP Glynn, SM (reprint author), US Dept Vet Affairs, Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA.; Glynn, SM (reprint author), Univ Calif Los Angeles, David Geffen Sch Med, Dept Psychiat & Biobehav Sci, Los Angeles, CA 90095 USA. EM sglynn@ucla.edu FU National Institute of Mental Health [5R0MH 041573-15] FX This research was supported by a National Institute of Mental Health grant (5R0MH 041573-15) to Dr. Marder. The authors thank the employment specialists and staff who worked on the project and Jim Mintz, Ph.D., and Robert P. Liberman, M.D., for their contributions in the development of the study. NR 24 TC 0 Z9 0 U1 1 U2 1 PU AMER PSYCHIATRIC PUBLISHING, INC PI ARLINGTON PA 1000 WILSON BOULEVARD, STE 1825, ARLINGTON, VA 22209-3901 USA SN 1075-2730 EI 1557-9700 J9 PSYCHIAT SERV JI Psychiatr. Serv. PD MAR 1 PY 2017 VL 68 IS 3 BP 271 EP 277 DI 10.1176/appi.ps.201500171 PG 7 WC Health Policy & Services; Public, Environmental & Occupational Health; Psychiatry SC Health Care Sciences & Services; Public, Environmental & Occupational Health; Psychiatry GA EP0RB UT WOS:000397093300012 PM 27799019 ER PT J AU Meyer, OL Sisco, SM Harvey, D Zahodne, LB Glymour, MM Manly, JJ Marsiske, M AF Meyer, Oanh L. Sisco, Shannon M. Harvey, Danielle Zahodne, Laura B. Glymour, M. Maria Manly, Jennifer J. Marsiske, Michael TI Neighborhood Predictors of Cognitive Training Outcomes and Trajectories in ACTIVE SO RESEARCH ON AGING LA English DT Article DE neighborhood; cognition; cognitive training; plasticity; social determinants ID OLDER MEXICAN-AMERICANS; SOCIOECONOMIC-STATUS; AFRICAN-AMERICANS; HEALTH CONSEQUENCES; URBAN NEIGHBORHOOD; ALZHEIMER-DISEASE; ETHNIC PATTERNS; LATE-LIFE; ADULTS; CONTEXT AB We examined the influence of neighborhood socioeconomic position (SEP), racial/ethnic composition, and living in a major city on cognitive trajectories and intervention outcomes. Data came from the Advanced Cognitive Training for Independent and Vital Elderly study (N = 2,438). Mixed effects analyses examined the associations between neighborhood variables and memory, reasoning, speed of processing, and everyday cognition, estimating differences in initial gains (potentially related to practice) and long-term rate of change over 10 years. The effect of reasoning training on initial gain was weaker for individuals in a major city. For everyday cognition, there was a stronger initial gain for memory-trained and control participants in areas with more racial/ethnic minorities and for speed-trained and control individuals in higher SEP areas. The racial/ethnic minority effect was no longer significant after adjustment for multiple comparisons. Neighborhood factors may be more important in practice-related improvement than in long-term change. C1 [Meyer, Oanh L.] Univ Calif Davis, Sch Med, Sacramento, CA 95817 USA. [Harvey, Danielle] Univ Calif Davis, Sch Med, Div Biostat Publ Hlth Sci, Sacramento, CA 95817 USA. [Sisco, Shannon M.] US Dept Vet Affairs, Danville, IL USA. [Zahodne, Laura B.] Columbia Univ, Dept Neurol, Cognit Neurosci Div, New York, NY USA. [Manly, Jennifer J.] Columbia Univ, Neuropsychol, New York, NY USA. [Glymour, M. Maria] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. [Marsiske, Michael] Univ Florida, Coll Publ Hlth & Hlth Profess, Dept Clin & Hlth Psychol, Gainesville, FL USA. RP Meyer, OL (reprint author), Univ Calif Davis, Sch Med, Dept Neurol, Alzheimers Dis Ctr, 4860 Y St, Sacramento, CA 95817 USA. EM olmeyer@ucdavis.edu FU Advanced Psychometrics Methods in Cognitive Aging Research [R13AG030995]; National Institutes of Health [P30AG010129, P30AG043097, UL1 TR 000002]; National Institute on Aging; National Institute of Nursing Research [U01NR04507, U01NR04508, U01AG14260, U01AG14282, U01AG14263, U01AG14289, U01AG14276] FX The author(s) disclosed receipt of the following financial support for the research, authorship, and/or publication of this article: This work was supported by the Advanced Psychometrics Methods in Cognitive Aging Research (R13AG030995) and by National Institutes of Health grants to the University of California, Davis Alzheimer's Disease Center (P30AG010129), the Latino Aging Research Resource Center (P30AG043097), and the Clinical and Translational Science Center (UL1 TR 000002). The ACTIVE intervention trials were supported by grants from the National Institute on Aging and the National Institute of Nursing Research to Hebrew Senior Life (U01NR04507), Indiana University School of Medicine (U01NR04508), Johns Hopkins University (U01AG14260), New England Research Institutes (U01AG14282), Pennsylvania State University (U01AG14263), the University of Alabama at Birmingham (U01AG14289), and the University of Florida (U01AG14276). NR 71 TC 0 Z9 0 U1 1 U2 1 PU SAGE PUBLICATIONS INC PI THOUSAND OAKS PA 2455 TELLER RD, THOUSAND OAKS, CA 91320 USA SN 0164-0275 EI 1552-7573 J9 RES AGING JI Res. Aging PD MAR PY 2017 VL 39 IS 3 BP 443 EP 467 DI 10.1177/0164027515618242 PG 25 WC Gerontology SC Geriatrics & Gerontology GA EN7RE UT WOS:000396199100004 PM 26667987 ER PT J AU Ames, D Tessier, J Erickson, Z Meyer, H Baker, M Gelberg, H Arnold, I Kwan, C Chamberlin, V Rosen, J Shah, C Hellemann, G Lewis, M Nguyen, C Sachinvala, N Amrami, B Pierre, J AF Ames, Donna Tessier, Jillian Erickson, Zachary Meyer, Hilary Baker, Matthew Gelberg, Hollie Arnold, Irina Kwan, Crystal Chamberlin, Valery Rosen, Jennifer Shah, Chandresh Hellemann, Gerhard Lewis, Melissa Nguyen, Charles Sachinvala, Neena Amrami, Binyamin Pierre, Joseph TI THERAPEUTIC LIFESTYLE CHANGES (TLC) FOR ADULTS WITH SERIOUS MENTAL ILLNESS SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 16th International Congress on Schizophrenia Research (ICOSR) CY MAR 24-28, 2017 CL San Diego, CA SP Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Oxford Univ Press C1 [Ames, Donna; Tessier, Jillian; Erickson, Zachary; Meyer, Hilary; Baker, Matthew; Gelberg, Hollie; Arnold, Irina; Kwan, Crystal; Chamberlin, Valery; Shah, Chandresh; Lewis, Melissa; Sachinvala, Neena; Amrami, Binyamin; Pierre, Joseph] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Ames, Donna; Gelberg, Hollie; Chamberlin, Valery; Hellemann, Gerhard; Sachinvala, Neena; Amrami, Binyamin; Pierre, Joseph] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Rosen, Jennifer] VA Northern Calif Healthcare Syst, Martinez, CA USA. [Rosen, Jennifer] Univ Pacific, Sch Pharm, Stockton, CA 95211 USA. [Rosen, Jennifer] Univ Southern Calif, Sch Pharm, Los Angeles, CA USA. [Nguyen, Charles] VA Long Beach Healthcare Syst, Long Beach, CA USA. [Amrami, Binyamin] Western Univ Hlth Sci, Pomona, CA USA. FU US Department of Veterans Affairs Rehabilitation Research and Development Merit Review Award FX Research supported by US Department of Veterans Affairs Rehabilitation Research and Development Merit Review Award. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2017 VL 43 SU 1 MA M14 BP S216 EP S216 PG 1 WC Psychiatry SC Psychiatry GA EP1DS UT WOS:000397126200581 ER PT J AU Buck, K Leonhardt, B George, S James, A Vohs, J Lysaker, P AF Buck, Kelly Leonhardt, Bethany George, Sunita James, Alison Vohs, Jenifer Lysaker, Paul TI METACOGNITIVE DEFICITS IN SCHIZOPHRENIA; COMPARISONS WITH BORDERLINE PERSONALITY DISORDER AND SUBSTANCE USE DISORDER SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 16th International Congress on Schizophrenia Research (ICOSR) CY MAR 24-28, 2017 CL San Diego, CA SP Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Oxford Univ Press C1 [Buck, Kelly] VA Med Ctr, Indianapolis, IN USA. [Leonhardt, Bethany; Vohs, Jenifer; Lysaker, Paul] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. [George, Sunita] Univ Indianapolis, Indianapolis, IN 46227 USA. [James, Alison] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2017 VL 43 SU 1 MA M42 BP S226 EP S226 PG 1 WC Psychiatry SC Psychiatry GA EP1DS UT WOS:000397126200608 ER PT J AU Dunn, W Wynn, JK Rassovsky, Y Wu, A Iacoboni, M Hellemann, G Green, MF AF Dunn, Walter Wynn, Jonathan K. Rassovsky, Yuri Wu, Allan Iacoboni, Marco Hellemann, Gerhard Green, Michael F. TI THE EFFECT OF BILATERAL TRANSCRANIAL DIRECT CURRENT STIMULATION ON TONE MATCHING TASK PERFORMANCE AND MISMATCH NEGATIVITY IN SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 16th International Congress on Schizophrenia Research (ICOSR) CY MAR 24-28, 2017 CL San Diego, CA SP Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Oxford Univ Press C1 Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Wynn, Jonathan K.] VISN 22 MIRECC, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Wynn, Jonathan K.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. [Rassovsky, Yuri] Bar Ilan Univ, Gonda Multidisciplinary Brain Res Ctr, Ramat Gan, Israel. [Wu, Allan; Iacoboni, Marco; Hellemann, Gerhard; Green, Michael F.] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2017 VL 43 SU 1 MA SU103 BP S198 EP S198 PG 1 WC Psychiatry SC Psychiatry GA EP1DS UT WOS:000397126200535 ER PT J AU Ferri, J Fryer, S Roach, BJ Loewy, R Ford, JM Mathalon, D AF Ferri, Jamie Fryer, Susanna Roach, Brian J. Loewy, Rachel Ford, Judith M. Mathalon, Daniel TI THALAMIC DYSCONNECTIVITY IN INDIVIDUALS AT CLINICALLY HIGH RISK FOR SCHIZOPHRENIA AND DURING EARLY ILLNESS SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 16th International Congress on Schizophrenia Research (ICOSR) CY MAR 24-28, 2017 CL San Diego, CA SP Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Oxford Univ Press C1 [Ferri, Jamie; Fryer, Susanna; Roach, Brian J.; Loewy, Rachel; Ford, Judith M.; Mathalon, Daniel] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Loewy, Rachel] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2017 VL 43 SU 1 MA 77 BP S44 EP S44 PG 1 WC Psychiatry SC Psychiatry GA EP1DS UT WOS:000397126200118 ER PT J AU Fryer, S Townsend, JD Ford, JM Roach, BJ Calhoun, VD Pearlson, GD Kiehl, KA Srihari, VH Woods, SW McGlashan, TH Mathalon, DH AF Fryer, Susanna Townsend, Jennifer D. Ford, Judith M. Roach, Brian J. Calhoun, Vince D. Pearlson, Godfrey D. Kiehl, Kent A. Srihari, Vinod H. Woods, Scott W. McGlashan, Thomas H. Mathalon, Daniel H. TI FMRI RESPONSE DURING ERROR PROCESSING IN CLINICAL HIGH RISK AND EARLY ILLNESS SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 16th International Congress on Schizophrenia Research (ICOSR) CY MAR 24-28, 2017 CL San Diego, CA SP Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Oxford Univ Press C1 [Fryer, Susanna; Townsend, Jennifer D.; Ford, Judith M.; Roach, Brian J.; Mathalon, Daniel H.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Townsend, Jennifer D.; Ford, Judith M.; Mathalon, Daniel H.] San Francisco VA Med Ctr, San Francisco, CA USA. [Calhoun, Vince D.; Kiehl, Kent A.] Mind Res Network, Daytona Beach, FL USA. [Calhoun, Vince D.; Kiehl, Kent A.] Univ New Mexico, Albuquerque, NM 87131 USA. [Pearlson, Godfrey D.] Yale Univ, Inst Living, Olin Neuropsychiat Res Ctr, New Haven, CT 06520 USA. [Srihari, Vinod H.; Woods, Scott W.; McGlashan, Thomas H.] Yale Univ, Sch Med, New Haven, CT 06520 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2017 VL 43 SU 1 MA 76 BP S43 EP S44 PG 2 WC Psychiatry SC Psychiatry GA EP1DS UT WOS:000397126200117 ER PT J AU Gelberg, H Erickson, Z Kwan, C Arnold, I Chamberlin, V Rosen, J Shah, C Nguyen, C Hellemann, G Aragaki, D Kunkel, C Lewis, M Sachinvala, N Sonza, P Baker, M Mena, S Meyer, H Tessier, J Pierre, J Ames, D AF Gelberg, Hollie Erickson, Zachary Kwan, Crystal Arnold, Irina Chamberlin, Valery Rosen, Jennifer Shah, Chandresh Nguyen, Charles Hellemann, Gerhard Aragaki, Dixie Kunkel, Charles Lewis, Melissa Sachinvala, Neena Sonza, Patrick Baker, Matthew Mena, Shirley Meyer, Hilary Tessier, Jillian Pierre, Joseph Ames, Donna TI BEHAVIORAL INTERVENTIONS FOR ANTIPSYCHOTIC MEDICATION-ASSOCIATED OBESITY: A RANDOMIZED, CONTROLLED FOUR-SITE TRIAL SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 16th International Congress on Schizophrenia Research (ICOSR) CY MAR 24-28, 2017 CL San Diego, CA SP Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Oxford Univ Press C1 [Gelberg, Hollie; Erickson, Zachary; Kwan, Crystal; Arnold, Irina; Chamberlin, Valery; Shah, Chandresh; Aragaki, Dixie; Kunkel, Charles; Lewis, Melissa; Sachinvala, Neena; Sonza, Patrick; Baker, Matthew; Mena, Shirley; Meyer, Hilary; Tessier, Jillian; Pierre, Joseph; Ames, Donna] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Gelberg, Hollie; Chamberlin, Valery; Hellemann, Gerhard; Aragaki, Dixie; Kunkel, Charles; Sachinvala, Neena; Sonza, Patrick; Pierre, Joseph; Ames, Donna] Univ Calif Los Angeles, Los Angeles, CA 90024 USA. [Rosen, Jennifer] VA Northern Calif Healthcare Syst, Mather, CA USA. [Rosen, Jennifer] Univ Pacific, Sch Pharm, Stockton, CA 95211 USA. [Rosen, Jennifer] Univ Southern Calif, Sch Pharm, Los Angeles, CA USA. [Nguyen, Charles] VA Long Beach Healthcare Syst, Long Beach, CA USA. FU US Department of Veterans Affairs Rehabilitation Research and Development Merit Review Award FX Research supported by US Department of Veterans Affairs Rehabilitation Research and Development Merit Review Award. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2017 VL 43 SU 1 MA SA15 BP S118 EP S118 PG 1 WC Psychiatry SC Psychiatry GA EP1DS UT WOS:000397126200319 ER PT J AU Greenberg, J Wynn, JK Lee, JH Hellemann, G Green, MF AF Greenberg, Jared Wynn, Jonathan K. Lee, Junghee Hellemann, Gerhard Green, Michael F. TI RESILIENCE IN HOMELESS VETERANS WITH AND WITHOUT A HISTORY OF PSYCHOSIS SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 16th International Congress on Schizophrenia Research (ICOSR) CY MAR 24-28, 2017 CL San Diego, CA SP Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Oxford Univ Press C1 [Greenberg, Jared] VA Greater Los Angeles Healthcare Syst VISN 22 MI, Los Angeles, CA USA. [Wynn, Jonathan K.; Green, Michael F.] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Lee, Junghee] Univ Calif Los Angeles, Los Angeles, CA USA. [Hellemann, Gerhard; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. NR 1 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2017 VL 43 SU 1 MA 95 BP S51 EP S51 PG 1 WC Psychiatry SC Psychiatry GA EP1DS UT WOS:000397126200136 ER PT J AU Horton, L Haas, G Stepp, S AF Horton, Leslie Haas, Gretchen Stepp, Stephanie TI CHILDHOOD SOCIAL AND EMOTIONAL FUNCTIONING DEFICITS IN A COMMUNITY SAMPLE OF WOMEN WITH PSYCHOSIS SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 16th International Congress on Schizophrenia Research (ICOSR) CY MAR 24-28, 2017 CL San Diego, CA SP Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Oxford Univ Press C1 [Horton, Leslie] Univ Pittsburgh, Pittsburgh, PA 15260 USA. [Haas, Gretchen] VA Pittsburgh Healthcare Syst, Med Res Serv, Pittsburgh, PA USA. [Haas, Gretchen; Stepp, Stephanie] Univ Pittsburgh, Sch Med, Pittsburgh, PA 15260 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2017 VL 43 SU 1 MA M7 BP S213 EP S213 PG 1 WC Psychiatry SC Psychiatry GA EP1DS UT WOS:000397126200574 ER PT J AU Jacob, M Ford, J Roach, B Calhoun, V Mathalon, D AF Jacob, Michael Ford, Judith Roach, Brian Calhoun, Vince Mathalon, Daniel TI SEMANTIC PRIMING ABNORMALITIES IN SCHIZOPHRENIA: AN ERP-FMRI FUSION STUDY SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 16th International Congress on Schizophrenia Research (ICOSR) CY MAR 24-28, 2017 CL San Diego, CA SP Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Oxford Univ Press C1 [Jacob, Michael; Ford, Judith; Mathalon, Daniel] UCSF, San Francisco, CA USA. [Jacob, Michael; Ford, Judith; Mathalon, Daniel] San Francisco VA Med Ctr, San Francisco, CA USA. [Roach, Brian] SFVAMC, San Francisco, CA USA. [Calhoun, Vince] Univ New Mexico, Mind Res Network, Albuquerque, NM 87131 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2017 VL 43 SU 1 MA 145 BP S76 EP S77 PG 2 WC Psychiatry SC Psychiatry GA EP1DS UT WOS:000397126200206 ER PT J AU Jahshan, C Wynn, JK Dolinsky, M Mathalon, D Green, MF AF Jahshan, Carol Wynn, Jonathan K. Dolinsky, Michelle Mathalon, Daniel Green, Michael F. TI COGNITIVE CORRELATES OF VISUAL CORTICAL PLASTICITY IN SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 16th International Congress on Schizophrenia Research (ICOSR) CY MAR 24-28, 2017 CL San Diego, CA SP Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Oxford Univ Press C1 [Jahshan, Carol] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90024 USA. [Wynn, Jonathan K.] VA Greater Los Angeles Healthcare Syst, VISN MIRECC 22, Los Angeles, CA USA. [Dolinsky, Michelle] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Mathalon, Daniel] UCSF, San Francisco, CA USA. [Mathalon, Daniel] SFVAMC, San Francisco, CA USA. [Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2017 VL 43 SU 1 MA SA70 BP S138 EP S138 PG 1 WC Psychiatry SC Psychiatry GA EP1DS UT WOS:000397126200374 ER PT J AU James, A Johannesen, J Buck, K Lysaker, P AF James, Alison Johannesen, Jason Buck, Kelly Lysaker, Paul TI RELATIVELY MORE INTACT LEVELS OF SOCIAL COGNITION PREDICT FEWER IMPAIRMENTS IN NEUROCOGNITION, METACOGNITION, AND HEALTHIER PERSONALITY FUNCTIONING IN A SAMPLE WITH PROLONGED SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 16th International Congress on Schizophrenia Research (ICOSR) CY MAR 24-28, 2017 CL San Diego, CA SP Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Oxford Univ Press C1 [James, Alison] UCSF, San Francisco, CA USA. [James, Alison] San Francisco VA Med Ctr, San Francisco, CA USA. [Johannesen, Jason] Yale Univ, New Haven, CT 06520 USA. [Buck, Kelly; Lysaker, Paul] Roudebush VA Med Ctr, Indianapolis, IN USA. [Lysaker, Paul] Indiana Univ Sch Med, Indianapolis, IN 46202 USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2017 VL 43 SU 1 MA M121 BP S254 EP S255 PG 2 WC Psychiatry SC Psychiatry GA EP1DS UT WOS:000397126200683 ER PT J AU Jimenez, A Lee, JH Wynn, JK Horan, W Iglesias, J Hoy, J Green, MF AF Jimenez, Amy Lee, Junghee Wynn, Jonathan K. Horan, William Iglesias, Julio Hoy, Jennifer Green, Michael F. TI THE ROLE OF PREFRONTAL CORTEX IN SELF-REFERENTIAL MEMORY RETRIEVAL IN SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 16th International Congress on Schizophrenia Research (ICOSR) CY MAR 24-28, 2017 CL San Diego, CA SP Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Oxford Univ Press C1 [Jimenez, Amy] VA Greater Los Angeles Healthcare Syst Univ Calif, Los Angeles, CA USA. [Lee, Junghee; Iglesias, Julio] Univ Calif Los Angeles, Los Angeles, CA USA. [Wynn, Jonathan K.; Green, Michael F.] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Semel Inst Neurosci & Human Behav, Los Angeles, CA USA. [Horan, William] Univ Calif Los Angeles, Semel Inst, Los Angeles, CA USA. [Hoy, Jennifer] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2017 VL 43 SU 1 MA 56 BP S29 EP S29 PG 1 WC Psychiatry SC Psychiatry GA EP1DS UT WOS:000397126200077 ER PT J AU McCleery, A Wynn, JK Reavis, E Kutasevich, E Morales, J Roach, BJ Mathalon, D Green, MF AF McCleery, Amanda Wynn, Jonathan K. Reavis, Eric Kutasevich, Eugene Morales, Jaime Roach, Brian J. Mathalon, Daniel Green, Michael F. TI CORTICAL PLASTICITY IN SCHIZOPHRENIA: ASSOCIATIONS WITH COGNITION AND COMMUNITY FUNCTIONING SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 16th International Congress on Schizophrenia Research (ICOSR) CY MAR 24-28, 2017 CL San Diego, CA SP Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Oxford Univ Press C1 [McCleery, Amanda; Wynn, Jonathan K.; Reavis, Eric; Kutasevich, Eugene; Morales, Jaime; Green, Michael F.] Univ Calif Los Angeles, Los Angeles, CA USA. [Roach, Brian J.; Mathalon, Daniel] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Mathalon, Daniel] San Francisco VA Med Ctr, San Francisco, CA USA. FU VA Desert Pacific VISN 22 Mental Illness Research, Education, and Clinical Center Pala grant; NIMH Career Development Award [K23MH108829] FX This research was supported by a VA Desert Pacific VISN 22 Mental Illness Research, Education, and Clinical Center Pala grant (PI: McCleery). Dr. McCleery is supported by a NIMH Career Development Award (K23MH108829). NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2017 VL 43 SU 1 MA M72 BP S236 EP S236 PG 1 WC Psychiatry SC Psychiatry GA EP1DS UT WOS:000397126200635 ER PT J AU Ramsay, I Fryer, S Boos, A Roach, BJ Fisher, M Loewy, R Vinogradov, S Mathalon, D AF Ramsay, Ian Fryer, Susanna Boos, Alison Roach, Brian J. Fisher, Melissa Loewy, Rachel Vinogradov, Sophia Mathalon, Daniel TI TARGETED COGNITIVE TRAINING IS NEUROPROTECTIVE AGAINST THALAMIC VOLUME LOSS IN EARLY SCHIZOPHRENIA SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 16th International Congress on Schizophrenia Research (ICOSR) CY MAR 24-28, 2017 CL San Diego, CA SP Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Oxford Univ Press C1 [Ramsay, Ian; Fisher, Melissa; Vinogradov, Sophia] Univ Minnesota, Minneapolis, MN 55455 USA. [Fryer, Susanna; Roach, Brian J.; Loewy, Rachel; Mathalon, Daniel] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Boos, Alison] San Francisco VA Med Ctr, San Francisco, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2017 VL 43 SU 1 MA 90 BP S49 EP S49 PG 1 WC Psychiatry SC Psychiatry GA EP1DS UT WOS:000397126200131 ER PT J AU Wynn, J McCleery, A Szewczyk, W Kutasevich, E Roach, BJ Mathalon, D Green, MF AF Wynn, Jonathan McCleery, Amanda Szewczyk, Warren Kutasevich, Eugene Roach, Brian J. Mathalon, Daniel Green, Michael F. TI DYSFUNCTIONAL PREDICTION ERROR CODING IN SCHIZOPHRENIA: TEST-RETEST RELIABILITY OF AUDITORY MISMATCH NEGATIVITY AND REPETITION POSITIVITY SO SCHIZOPHRENIA BULLETIN LA English DT Meeting Abstract CT 16th International Congress on Schizophrenia Research (ICOSR) CY MAR 24-28, 2017 CL San Diego, CA SP Univ Maryland, Sch Med, Maryland Psychiat Res Ctr, Oxford Univ Press C1 [Wynn, Jonathan] Univ Calif Los Angeles, VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [McCleery, Amanda; Szewczyk, Warren; Kutasevich, Eugene; Green, Michael F.] Univ Calif Los Angeles, Semel Inst Neurosci & Human Behav, Los Angeles, CA 90024 USA. [Roach, Brian J.; Mathalon, Daniel] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Mathalon, Daniel] San Francisco VA Med Ctr, San Francisco, CA USA. [Green, Michael F.] VA Greater Los Angeles Healthcare Syst, VISN MIRECC 22, Los Angeles, CA USA. NR 0 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0586-7614 EI 1745-1701 J9 SCHIZOPHRENIA BULL JI Schizophr. Bull. PD MAR PY 2017 VL 43 SU 1 MA SA68 BP S137 EP S138 PG 2 WC Psychiatry SC Psychiatry GA EP1DS UT WOS:000397126200372 ER PT J AU Pop-Vicas, A Musuuza, JS Schmitz, M Al-Niaimi, A Safdar, N AF Pop-Vicas, Aurora Musuuza, Jackson S. Schmitz, Michelle Al-Niaimi, Ahmed Safdar, Nasia TI Incidence and risk factors for surgical site infection post-hysterectomy in a tertiary care center SO AMERICAN JOURNAL OF INFECTION CONTROL LA English DT Article DE Post-surgical infection; Predictors ID IMPROVEMENT PROJECT; ANTIMICROBIAL-PROPHYLAXIS; WOUND INFECTIONS; UNITED-STATES; SURGERY; DURATION; CEFAZOLIN; COSTS; RATES; SSI AB Background: Preoperative antibiotic prophylaxis and surgical technological advances have greatly reduced, but not totally eliminated surgical site infection (SSI) posthysterectomy. We aimed to identify risk factors for SSI posthysterectomy among women with a high prevalence of gynecologic malignancies, in a tertiary care setting where compliance with the Joint Commission's Surgical Care Improvement Project core measures is excellent. Methods: The study was a matched case-control, 2 controls per case, matched on date of surgery. Study time was January 2, 2012-December 31, 2015. Procedures included abdominal and vaginal hysterectomies (open, laparoscopic, and robotic). SSI (superficial incisional or deep/organ/space) was defined as within 30 days postoperatively, per Centers for Disease Control and Prevention criteria. Statistical analysis included bivariate analysis and conditional logistic regression controlling for demographic and clinical variables, both patient-related and surgery-related, including detailed prophylactic antibiotic exposure. Results: Of the total 1,531 hysterectomies performed, we identified 52 SSIs (3%), with 60% being deep incisional or organ/space infections. All case patients received appropriate preoperative antibiotics (timing, choice, and weight-based dosing). Bivariate analysis showed that higher median weight, higher median Charlson comorbidity index, immune suppressed state, American Society of Anesthesiologists score >= 3, prior surgery within 60 days, clindamycin/gentamicin prophylaxis, surgery involving the omentum or gastrointestinal tract, longer surgery duration, >= 4 surgeons present in the operating room, higher median blood loss, >= 7 catheters or invasive devices in the operating room, and higher median length of hospital stay increased SSI risk (P <.05 for all). Cefazolin preoperative prophylaxis, robot-assisted surgery, and laparoscopic surgery were protective (P <.05 for all). Duration of surgery was the only independent risk factor for SSI identified on multivariate analysis (odds ratio, 3.45; 95% confidence interval, 1.21-9.76; P =.02). Conclusions: In our population of women with multimorbidity and hysterectomies largely due to underlying gynecologic malignancies, duration of surgery, presumed a marker of surgical complexity, is a significant SSI risk factor. The choice of preoperative antibiotic did not alter SSI risk in our study. (C) 2017 Association for Professionals in Infection Control and Epidemiology, Inc. Published by Elsevier Inc. All rights reserved. C1 [Pop-Vicas, Aurora; Safdar, Nasia] Univ Wisconsin, Sch Med & Publ Hlth, Dept Med, Madison, WI USA. [Musuuza, Jackson S.] Univ Wisconsin, Inst Clin & Translat Res, Madison, WI USA. [Schmitz, Michelle; Safdar, Nasia] Univ Wisconsin Hosp & Clin, Dept Infect Control, Madison, WI 53792 USA. [Al-Niaimi, Ahmed] Univ Wisconsin, Dept Obstet & Gynecol, Sch Med & Publ Hlth, Madison, WI 53706 USA. [Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Dept Med, Madison, WI USA. RP Pop-Vicas, A (reprint author), Univ Wisconsin, Sch Med & Publ Hlth, Div Infect Dis, 1685 Highland Ave,5th Fl, Madison, WI 53705 USA. EM popvicas@medicine.wisc.edu NR 31 TC 0 Z9 0 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0196-6553 EI 1527-3296 J9 AM J INFECT CONTROL JI Am. J. Infect. Control PD MAR 1 PY 2017 VL 45 IS 3 BP 284 EP 287 DI 10.1016/j.ajic.2016.10.008 PG 4 WC Public, Environmental & Occupational Health; Infectious Diseases SC Public, Environmental & Occupational Health; Infectious Diseases GA EQ4KU UT WOS:000398046700013 PM 27938988 ER PT J AU Haefeli, J Mabray, MC Whetstone, WD Dhall, SS Pan, JZ Upadhyayula, P Manley, GT Bresnahan, JC Beattie, MS Ferguson, AR Talbott, JF AF Haefeli, J. Mabray, M. C. Whetstone, W. D. Dhall, S. S. Pan, J. Z. Upadhyayula, P. Manley, G. T. Bresnahan, J. C. Beattie, M. S. Ferguson, A. R. Talbott, J. F. TI Multivariate Analysis of MRI Biomarkers for Predicting Neurologic Impairment in Cervical Spinal Cord Injury SO AMERICAN JOURNAL OF NEURORADIOLOGY LA English DT Article ID PRINCIPAL-COMPONENTS-ANALYSIS; OPTIMAL RADIOLOGIC METHOD; CANAL COMPROMISE; REPRODUCIBLE METHOD; COMPRESSION; SEVERITY; RECOVERY; TRAUMA; RELIABILITY; DAMAGE AB BACKGROUND AND PURPOSE: Acute markers of spinal cord injury are essential for both diagnostic and prognostic purposes. The goal of this study was to assess the relationship between early MR imaging biomarkers after acute cervical spinal cord injury and to evaluate their predictive validity of neurologic impairment. MATERIALS AND METHODS: We performed a retrospective cohort study of 95 patients with acute spinal cord injury and preoperative MR imaging within 24 hours of injury. The American Spinal Injury Association Impairment Scale was used as our primary outcome measure to define neurologic impairment. We assessed several MR imaging features of injury, including axial grade (Brain and Spinal Injury Center score), sagittal grade, length of injury, maximum canal compromise, and maximum spinal cord compression. Data-driven nonlinear principal component analysis was followed by correlation and optimal-scaled multiple variable regression to predict neurologic impairment. RESULTS: Nonlinear principal component analysis identified 2 clusters of MR imaging variables related to 1) measures of intrinsic cord signal abnormality and 2) measures of extrinsic cord compression. Neurologic impairment was best accounted for by MR imaging measures of intrinsic cord signal abnormality, with axial grade representing the most accurate predictor of short-term impairment, even when correcting for surgical decompression and degree of cord compression. CONCLUSIONS: This study demonstrates the utility of applying nonlinear principal component analysis for defining the relationship between MR imaging biomarkers in a complex clinical syndrome of cervical spinal cord injury. Of the assessed imaging biomarkers, the intrinsic measures of cord signal abnormality were most predictive of neurologic impairment in acute spinal cord injury, highlighting the value of axial T2 MR imaging. C1 [Haefeli, J.; Dhall, S. S.; Upadhyayula, P.; Manley, G. T.; Bresnahan, J. C.; Beattie, M. S.; Ferguson, A. R.] Univ Calif San Francisco, Dept Neurol Surg, San Francisco, CA USA. [Mabray, M. C.; Talbott, J. F.] Univ Calif San Francisco, Dept Radiol & Biomed Imaging, San Francisco, CA 94143 USA. [Whetstone, W. D.] Univ Calif San Francisco, Dept Emergency Med, San Francisco, CA 94143 USA. [Pan, J. Z.] Univ Calif San Francisco, Dept Anesthesia & Perioperat Care, San Francisco, CA 94143 USA. Zuckerberg San Francisco Gen Hosp, San Francisco, CA USA. [Haefeli, J.; Whetstone, W. D.; Dhall, S. S.; Pan, J. Z.; Upadhyayula, P.; Manley, G. T.; Bresnahan, J. C.; Beattie, M. S.; Ferguson, A. R.; Talbott, J. F.] San Francisco VA Med Ctr, Brain & Spinal Injury Ctr, Weill Inst Neurosci, San Francisco, CA USA. RP Ferguson, AR (reprint author), Zuckerberg San Francisco Gen Hosp, Dept Neurol Surg, Bldg 1,Room 101, San Francisco, CA 94110 USA. EM adam.ferguson@ucsf.edu FU Craig H. Neilsen Foundation; Wings for Life Foundation; Department of Defense [SC120259]; National Institutes of Health T32 Fellowship [5T32EB001631-10]; Craig H. Neilsen Foundation fellowship [313739]; [R01NS067092]; [R01NS088475] FX This work was supported by R01NS067092 (A.R.F.), R01NS088475 (A.R.F.), the Craig H. Neilsen Foundation (A.R.F., J.C.B.), Wings for Life Foundation (A.R.F.), and Department of Defense grant SC120259 (M.S.B., J.C.B.). M.C.M. was supported by a National Institutes of Health T32 Fellowship, 5T32EB001631-10. J.H. was supported by a Craig H. Neilsen Foundation fellowship (313739). NR 42 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC NEURORADIOLOGY PI DENVILLE PA PO BOX 3000, DENVILLE, NJ 07834-9349 USA SN 0195-6108 EI 1936-959X J9 AM J NEURORADIOL JI Am. J. Neuroradiol. PD MAR PY 2017 VL 38 IS 3 BP 648 EP 655 DI 10.3174/ajnr.A5021 PG 8 WC Clinical Neurology; Neuroimaging; Radiology, Nuclear Medicine & Medical Imaging SC Neurosciences & Neurology; Radiology, Nuclear Medicine & Medical Imaging GA EN6JB UT WOS:000396109200040 PM 28007771 ER PT J AU Russell-Puleri, S dela Paz, NG Adams, D Chattopadhyay, M Cancel, L Ebong, E Orr, AW Frangos, JA Tarbell, JM AF Russell-Puleri, Sparkle dela Paz, Nathaniel G. Adams, Diana Chattopadhyay, Mitali Cancel, Limary Ebong, Eno Orr, A. Wayne Frangos, John A. Tarbell, John M. TI Fluid shear stress induces upregulation of COX-2 and PGI(2) release in endothelial cells via a pathway involving PECAM-1, PI3K, FAK, and p38 SO AMERICAN JOURNAL OF PHYSIOLOGY-HEART AND CIRCULATORY PHYSIOLOGY LA English DT Article DE prostaglandin I-2; cyclooxygenase-2; PECAM-1; integrins; shear stress; glycocalyx; syndecan-4; primary cilia ID FOCAL ADHESION KINASE; HEPARAN-SULFATE PROTEOGLYCAN; GENE-EXPRESSION; CYCLOOXYGENASE-2 EXPRESSION; EXTRACELLULAR-MATRIX; SIGNAL-TRANSDUCTION; HEMODYNAMIC FORCES; IN-VIVO; PROSTACYCLIN; INTEGRIN AB Vascular endothelial cells play an important role in the regulation of vascular function in response to mechanical stimuli in both healthy and diseased states. Prostaglandin I-2 (PGI(2)) is an important antiatherogenic prostanoid and vasodilator produced in endothelial cells through the action of the cyclooxygenase (COX) isoenzymes COX-1 and COX-2. However, the mechanisms involved in sustained, shear-induced production of COX-2 and PGI(2) have not been elucidated but are determined in the present study. We used cultured endothelial cells exposed to steady fluid shear stress (FSS) of 10 dyn/cm(2) for 5 h to examine shear stress-induced induction of COX-2/PGI(2). Our results demonstrate the relationship between the mechanosensor platelet endothelial cell adhesion molecule-1 (PECAM-1) and the intracellular mechanoresponsive molecules phosphatidylinositol 3-kinase (PI3K), focal adhesion kinase (FAK), and mitogen-activated protein kinase p38 in the FSS induction of COX-2 expression and PGI2 release. Knockdown of PECAM-1 (small interference RNA) expression inhibited FSS-induced activation of alpha(5)beta(1)-integrin, upregulation of COX-2, and release of PGI(2) in both bovine aortic endothelial cells (BAECs) and human umbilical vein endothelial cells (HUVECs). Furthermore, inhibition of the PI3K pathway (LY294002) substantially inhibited FSS activation of alpha(5)beta(1)-integrin, upregulation of COX-2 gene and protein expression, and release of PGI(2) in BAECs. Inhibition of integrin-associated FAK (PF573228) and MAPK p38 (SB203580) also inhibited the shear-induced upregulation of COX-2. Finally, a PECAM-1(-/-) mouse model was characterized by reduced COX-2 immunostaining in the aorta and reduced plasma PGI(2) levels compared with wild-type mice, as well as complete inhibition of acute flow-induced PGI(2) release compared with wild-type animals. NEW & NOTEWORTHY In this study we determined the major mechanotransduction pathway by which blood flow-driven shear stress activates cyclooxygenase-2 (COX-2) and prostaglandin I-2 (PGI(2)) release in endothelial cells. Our work has demonstrated for the first time that COX-2/PGI(2) mechanotransduction is mediated by the mechanosensor platelet endothelial cell adhesion molecule- 1 (PECAM-1). C1 [Russell-Puleri, Sparkle; Cancel, Limary; Tarbell, John M.] CUNY City Coll, Dept Biomed Engn, Steinman Hall,Rm T-404B Convent Ave,140th St, New York, NY 10031 USA. [dela Paz, Nathaniel G.; Adams, Diana; Frangos, John A.] La Jolla Bioengn Inst, La Jolla, CA USA. [Chattopadhyay, Mitali] James J Peters Veteran Affairs Med Ctr, Bronx, NY USA. [Ebong, Eno] Northeastern Univ, Dept Chem Engn, Boston, MA USA. [Orr, A. Wayne] Louisiana State Univ, Dept Pathol, Shreveport, LA USA. RP Tarbell, JM (reprint author), CUNY City Coll, Dept Biomed Engn, Steinman Hall,Rm T-404B Convent Ave,140th St, New York, NY 10031 USA. EM jtarbell@ccny.cuny.edu FU National Institutes of Health Research Supplement to Promote Diversity in Health Related Research [PA-08-190]; National Heart, Lung, and Blood Institute [R01-HL-094889, R37-HL-040696, R01-HL-098435, R01 HL133497] FX This work was supported by the National Institutes of Health Research Supplement to Promote Diversity in Health Related Research Grant PA-08-190 (to S. Russell-Puleri) and the National Heart, Lung, and Blood Institute Grants R01-HL-094889 (to J. M. Tarbell), MERIT Award R37-HL-040696 (to J. A. Frangos), and R01-HL-098435 and R01 HL133497 (to A. W. Orr). NR 66 TC 0 Z9 0 U1 0 U2 0 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0363-6135 EI 1522-1539 J9 AM J PHYSIOL-HEART C JI Am. J. Physiol.-Heart Circul. Physiol. PD MAR PY 2017 VL 312 IS 3 BP H485 EP H500 DI 10.1152/ajpheart.00035.2016 PG 16 WC Cardiac & Cardiovascular Systems; Physiology; Peripheral Vascular Disease SC Cardiovascular System & Cardiology; Physiology GA EQ1DC UT WOS:000397808500015 PM 28011582 ER PT J AU Tanner, NT Pastis, NJ AF Tanner, Nichole T. Pastis, Nicholas J. TI Chronic Obstructive Pulmonary Disease as a Lung Cancer Risk: Worth Its Weight in "GOLD" SO ANNALS OF THE AMERICAN THORACIC SOCIETY LA English DT Editorial Material C1 [Tanner, Nichole T.; Pastis, Nicholas J.] Med Univ South Carolina, Charleston, SC 29425 USA. [Tanner, Nichole T.] Ralph H Johnson Vet Affairs Hosp, Charleston, SC USA. RP Pastis, NJ (reprint author), Med Univ South Carolina Med, 96 Jonathan Lucas St,MSC 630, Charleston, SC 29425 USA. EM pastisn@musc.edu NR 0 TC 0 Z9 0 U1 0 U2 0 PU AMER THORACIC SOC PI NEW YORK PA 25 BROADWAY, 18 FL, NEW YORK, NY 10004 USA SN 1546-3222 EI 2325-6621 J9 ANN AM THORAC SOC JI Ann. Am. Thoracic Society PD MAR PY 2017 VL 14 IS 3 BP 309 EP 310 DI 10.1513/AnnalsATS.201701-008ED PG 2 WC Respiratory System SC Respiratory System GA EP5PE UT WOS:000397430100003 PM 28248590 ER PT J AU Horner, MD Turner, TH VanKirk, KK Denning, JH AF Horner, Michael David Turner, Travis H. VanKirk, Kathryn K. Denning, John H. TI An Intervention to Decrease the Occurrence of Invalid Data on Neuropsychological Evaluation SO ARCHIVES OF CLINICAL NEUROPSYCHOLOGY LA English DT Article DE Neuropsychology; Neuropsychological assessment; Effort; Malingering; Test performance; Behavioral economics ID INADEQUATE EFFORT; COLLEGE SAMPLES; VALIDITY; PERFORMANCE; EXAGGERATION; MALINGERERS; DETERRENCE; MILITARY; BELIEFS; INJURY AB Objective: This study tested whether patients who were given a handout based on deterrence theory, immediately prior to evaluation, would provide invalid data less frequently than patients who were simply given an informational handout. Method: All outpatients seen for clinical evaluation in a VA Neuropsychology Clinic were randomly given one of the two handouts immediately prior to evaluation. The "Intervention" handout emphasized the importance of trying one's hardest, explicitly listed consequences of valid and invalid responding and asked patients to sign and initial it. The "Control" handout provided general information about neuropsychological evaluation. Examiners were blinded to condition. Patients were excluded from analyses if they were diagnosed with major neurocognitive disorder or could not read the handout. Medical Symptom Validity Test (MSVT) was used to determine performance validity. Results: Groups did not differ on age, education, or litigation status. For the entire sample (N = 251), there was no effect of handout on passing versus failing MSVT. However, among patients who were seeking disability benefits at the time of evaluation (n = 70), the Intervention handout was associated with lower frequency of failing MSVT than the Control handout. Conclusions: This brief, theory-based, cost-free intervention was associated with lower frequency of invalid data among patients seeking disability benefits at the time of clinical evaluation. We suggest methodological modifications that might produce a more potent intervention that could be effective with additional subsets of patients. C1 [Horner, Michael David; Turner, Travis H.; VanKirk, Kathryn K.; Denning, John H.] US Dept Vet Affairs, Ralph H Johnson Vet Affairs Med Ctr, Mental Hlth Serv, Charleston, SC USA. [Horner, Michael David; Turner, Travis H.; VanKirk, Kathryn K.; Denning, John H.] Med Univ South Carolina, Dept Psychiat & Behav Sci, Charleston, SC USA. [Turner, Travis H.] Med Univ South Carolina, Dept Neurosci, Charleston, SC USA. RP Horner, MD (reprint author), Ralph H Johnson VA Med Ctr, Mental Hlth Serv 116, 109 Bee St, Charleston, SC 29401 USA. EM hornermd@musc.edu FU National Academy of Neuropsychology clinical research grant FX This work was supported by a National Academy of Neuropsychology clinical research grant to MDH. NR 35 TC 0 Z9 0 U1 0 U2 0 PU OXFORD UNIV PRESS PI OXFORD PA GREAT CLARENDON ST, OXFORD OX2 6DP, ENGLAND SN 0887-6177 EI 1873-5843 J9 ARCH CLIN NEUROPSYCH JI Arch. Clin. Neuropsychol. PD MAR PY 2017 VL 32 IS 2 BP 228 EP 237 DI 10.1093/arclin/acw094 PG 10 WC Psychology, Clinical; Psychology SC Psychology GA EQ4EG UT WOS:000398026400008 PM 28365748 ER PT J AU Loebel, C Szczesny, SE Cosgrove, BD Alini, M Zenobi-Wong, M Mauck, RL Eglin, D AF Loebel, Claudia Szczesny, Spencer E. Cosgrove, Brian D. Alini, Mauro Zenobi-Wong, Marcy Mauck, Robert L. Eglin, David TI Cross-Linking Chemistry of Tyramine-Modified Hyaluronan Hydrogels Alters Mesenchymal Stem Cell Early Attachment and Behavior SO BIOMACROMOLECULES LA English DT Article ID EXTRACELLULAR-MATRIX; FOCAL ADHESIONS; 3-DIMENSIONAL HYDROGELS; STIFFENING HYDROGELS; SUBSTRATE STIFFNESS; TRACTION STRESSES; MECHANICAL FORCE; ACID HYDROGELS; FATE; ELASTICITY AB Given the significance of hydrogels as cell instructive materials, it is important to understand how differences in their chemical and physical properties are able to direct cell fate. For example, it remains unclear how different hydrogel cross-linking chemistries and gelation mechanisms influence cell behavior. Here, we report on hyaluronan-tyramine (HA-Tyr) hydrogels prepared either with enzymatic cross-linking using horseradish peroxidase and H2O2 or with visible light (500 nm) triggered gelation. We demonstrate that when hydrogels are polymerized to equivalent Young's moduli, the specific cross-linking chemistry of HA-Tyr hydrogels can have a substantial impact on mesenchymal stem cell (MSC) behavior. MSCs cultured on HA-Tyr hydrogels exhibit increased cell spread areas on enzymatically formed substrates relative to photo-cross-linked matrices. While enzymatically formed hydrogels led to MSCs exhibiting greater cell focal adhesion length, MSCs cultured on the photo-cross-linked matrices exhibited smaller cell spread area and shorter focal adhesion length but generated increased traction stress. These findings highlight the importance of understanding hydrogel cross-linking chemistries when the role of biophysical cues in regulating stem cell fate is investigated. C1 [Loebel, Claudia; Alini, Mauro; Eglin, David] AO Res Inst Davos, Clavadelerstr 8, CH-7270 Davos, Switzerland. [Loebel, Claudia; Zenobi-Wong, Marcy] ETH, Dept Hlth Sci & Technol, Cartilage Engn Regenerat, Otto Stern Weg 7, CH-8093 Zurich, Switzerland. [Szczesny, Spencer E.; Cosgrove, Brian D.; Mauck, Robert L.] Univ Penn, Dept Orthopaed Surg, McKay Orthopaed Res Lab, Perelman Sch Med, Philadelphia, PA 19104 USA. [Loebel, Claudia; Szczesny, Spencer E.; Cosgrove, Brian D.; Mauck, Robert L.] Univ Penn, Dept Bioengn, Philadelphia, PA 19104 USA. [Szczesny, Spencer E.; Cosgrove, Brian D.; Mauck, Robert L.] Philadelphia VA Med Ctr, Translat Musculoskeletal Res Ctr, Philadelphia, PA 19104 USA. RP Eglin, D (reprint author), AO Res Inst Davos, Clavadelerstr 8, CH-7270 Davos, Switzerland. EM david.eglin@aofoundation.org OI Szczesny, Spencer/0000-0002-7691-949X FU European Science Foundation, COST Action NAMABIO [C11.0126]; European Society for Biomaterials through the Racquel LeGeros Award FX The authors thank Claire M. McLeod for technical support in AFM measurements and Dr. Christoph Sprecher for helpful discussions concerning image analysis and results. This work was financially supported by the European Science Foundation, COST Action 1005 NAMABIO (Grant No. C11.0126) and the European Society for Biomaterials through the Racquel LeGeros Award 2015 (C.L.) NR 64 TC 0 Z9 0 U1 5 U2 5 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1525-7797 EI 1526-4602 J9 BIOMACROMOLECULES JI Biomacromolecules PD MAR PY 2017 VL 18 IS 3 BP 855 EP 864 DI 10.1021/acs.biomac.6b01740 PG 10 WC Biochemistry & Molecular Biology; Chemistry, Organic; Polymer Science SC Biochemistry & Molecular Biology; Chemistry; Polymer Science GA EO0HT UT WOS:000396379600020 PM 28146630 ER PT J AU Dougherty, RJ Schultz, SA Boots, EA Ellingson, LD Meyer, JD Van Riper, S Stegner, AJ Edwards, DF Oh, JM Einerson, J Korcarz, CE Koscik, RL Dowling, MN Gallagher, CL Carlsson, CM Rowley, HA Bendlin, BB Asthana, S Hermann, BP Sager, MA Stein, JH Johnson, SC Okonkwo, OC Cook, DB AF Dougherty, Ryan J. Schultz, Stephanie A. Boots, Elizabeth A. Ellingson, Laura D. Meyer, Jacob D. Van Riper, Stephanie Stegner, Aaron J. Edwards, Dorothy F. Oh, Jennifer M. Einerson, Jean Korcarz, Claudia E. Koscik, Rebecca L. Dowling, Maritza N. Gallagher, Catherine L. Carlsson, Cynthia M. Rowley, Howard A. Bendlin, Barbara B. Asthana, Sanjay Hermann, Bruce P. Sager, Mark A. Stein, James H. Johnson, Sterling C. Okonkwo, Ozioma C. Cook, Dane B. TI Relationships between cardiorespiratory fitness, hippocampal volume, and episodic memory in a population at risk for Alzheimer's disease SO BRAIN AND BEHAVIOR LA English DT Article DE APOE-e4; cognition; exercise; family history; physical activity ID MILD COGNITIVE IMPAIRMENT; AUTOMATED METHODS FREESURFER; RANDOMIZED CONTROLLED-TRIAL; MAXIMAL AEROBIC CAPACITY; SURFACE-BASED ANALYSIS; VERBAL-LEARNING TEST; PHYSICAL-ACTIVITY; OLDER-ADULTS; SEX-DIFFERENCES; NORMATIVE DATA AB Introduction: Cardiorespiratory fitness (CRF) has been shown to be related to brain health in older adults. In individuals at risk for developing Alzheimer's disease (AD), CRF may be a modifiable risk factor that could attenuate anticipated declines in brain volume and episodic memory. The objective of this study was to determine the association between CRF and both hippocampal volume and episodic memory in a cohort of cognitively healthy older adults with familial and/or genetic risk for Alzheimer's disease (AD). Methods: Eighty-six enrollees from the Wisconsin Registry for Alzheimer's Prevention participated in this study. Participants performed a graded maximal exercise test, underwent a T-1 anatomical magnetic resonance imaging scan, and completed the Rey Auditory Verbal Learning Test (RAVLT). Results: There were no significant relationships between CRF and HV or RAVLT memory scores for the entire sample. When the sample was explored on the basis of gender, CRF was significantly associated with hippocampal volume for women. For men, significant positive associations were observed between CRF and RAVLT memory scores. Summary: These results suggest that CRF may be protective against both hippocampal volume and episodic memory decline in older adults at risk for AD, but that the relationships may be gender specific. C1 [Dougherty, Ryan J.; Meyer, Jacob D.; Van Riper, Stephanie; Stegner, Aaron J.; Cook, Dane B.] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. [Dougherty, Ryan J.; Boots, Elizabeth A.; Oh, Jennifer M.; Gallagher, Catherine L.; Carlsson, Cynthia M.; Bendlin, Barbara B.; Asthana, Sanjay; Johnson, Sterling C.; Okonkwo, Ozioma C.] Univ Wisconsin, Sch Educ, Dept Kinesiol, Madison, WI USA. [Schultz, Stephanie A.; Van Riper, Stephanie; Stegner, Aaron J.; Edwards, Dorothy F.; Rowley, Howard A.; Cook, Dane B.] William S Middleton Mem Vet Adm Med Ctr, Geriatr Res Educ & Clin Ctr, Madison, WI USA. [Schultz, Stephanie A.; Boots, Elizabeth A.; Edwards, Dorothy F.; Oh, Jennifer M.; Gallagher, Catherine L.; Carlsson, Cynthia M.; Bendlin, Barbara B.; Asthana, Sanjay; Hermann, Bruce P.; Sager, Mark A.; Johnson, Sterling C.; Okonkwo, Ozioma C.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Dis Res Ctr, Madison, WI USA. [Schultz, Stephanie A.; Boots, Elizabeth A.; Edwards, Dorothy F.; Oh, Jennifer M.; Koscik, Rebecca L.; Bendlin, Barbara B.; Hermann, Bruce P.; Sager, Mark A.; Johnson, Sterling C.; Okonkwo, Ozioma C.] Univ Wisconsin, Sch Med & Publ Hlth, Wisconsin Alzheimers Inst, Madison, WI USA. [Ellingson, Laura D.] Iowa State Univ, Dept Kinesiol, Coll Human Sci, Ames, IA USA. [Meyer, Jacob D.] Univ Wisconsin, Dept Family Med & Community Hlth, Madison, WI USA. [Einerson, Jean; Korcarz, Claudia E.; Stein, James H.] Univ Wisconsin, Div Cardiol, Sch Med & Publ Hlth, Madison, WI USA. [Dowling, Maritza N.] Univ Wisconsin, Dept Biostat & Med Informat, Sch Med & Publ Hlth, Madison, WI USA. [Hermann, Bruce P.] Univ Wisconsin, Dept Neurol, Sch Med & Publ Hlth, Madison, WI 53706 USA. RP Cook, DB (reprint author), Univ Wisconsin, Dept Kinesiol, Madison, WI 53706 USA. EM dane.cook@wisc.edu FU National Institute on Aging grants [K23 AG045957, R01 AG031790, R01 AG021155, R01 AG027161, P50 AG033514]; University of Wisconsin, Madison [UL1RR025011]; Extendicare Foundation; Alzheimer's Association; Wisconsin Alumni Research Foundation; Helen Bader Foundation; Northwestern Mutual Foundation; Geriatric Research Education and Clinical Center of the William S. Middleton Memorial Veterans Hospital, Madison, WI; University of Wisconsin Department of Family Medicine and Community Health [T32HP10010] FX National Institute on Aging grants, Grant/Award Number: K23 AG045957, R01 AG031790, R01 AG021155, R01 AG027161 and P50 AG033514; University of Wisconsin, Madison, Grant/Award Number: UL1RR025011; Extendicare Foundation; Alzheimer's Association; Wisconsin Alumni Research Foundation; Helen Bader Foundation; Northwestern Mutual Foundation; Geriatric Research Education and Clinical Center of the William S. Middleton Memorial Veterans Hospital, Madison, WI; University of Wisconsin Department of Family Medicine and Community Health, Grant/Award Number: T32HP10010 NR 81 TC 0 Z9 0 U1 5 U2 5 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN, NJ 07030 USA SN 2162-3279 J9 BRAIN BEHAV JI Brain Behav. PD MAR PY 2017 VL 7 IS 3 DI 10.1002/brb3.625 PG 12 WC Behavioral Sciences; Neurosciences SC Behavioral Sciences; Neurosciences & Neurology GA EP7NJ UT WOS:000397564200003 ER PT J AU Armstrong, EJ Graham, L Waldo, SW Valle, JA Maddox, TM Hawn, MT AF Armstrong, Ehrin J. Graham, Laura Waldo, Stephen W. Valle, Javier A. Maddox, Thomas M. Hawn, Mary T. TI Patient and Lesion-Specific Characteristics Predict Risk of Major Adverse Cardiovascular Events Among Patients with Previous Percutaneous Coronary Intervention Undergoing Noncardiac Surgery SO CATHETERIZATION AND CARDIOVASCULAR INTERVENTIONS LA English DT Article DE percutaneous coronary intervention; surgery; operative risk ID DRUG-ELUTING STENTS; ACUTE MYOCARDIAL-INFARCTION; CARDIAC EVENTS; ACUTE CATHETERIZATION; HARMONIZING OUTCOMES; TRIAGE STRATEGY; BARE-METAL; IMPLANTATION; REVASCULARIZATION; THROMBOSIS AB Objectives: To identify predictors of major adverse cardiovascular outcomes (MACE) among patients with prior percutaneous coronary intervention (PCI) who require noncardiac surgery. Background: Patients with prior PCI who undergo noncardiac surgery have an increased risk of postoperative MACE, but few studies have examined the association of PCI lesion characteristics with subsequent operative risk. Methods: Patients were identified using the VA Clinical Assessment, Reporting, and Tracking (CART) program. Patients who underwent noncardiac surgery within 2 years after stent placement were linked to VA and non-VA surgical records. A multivariable logistic regression model was developed to identify predictors of postoperative MACE. Results: Among 12,621 patients with a history of prior PCI who underwent subsequent noncardiac surgery, 570 (4.5%) developed postoperative MACE. The median time from stent placement to surgery was 368 days (IQR 181-528). The strongest predictors of postoperative MACE were urgency of the operation, revised cardiac risk index, the indication for the prior PCI, and timing of the surgery after the PCI. Lesion characteristics independently associated with postoperative MACE included PCI to a distal (AOR 1.43, 95% CI 1.11-1.83) or ostial lesion (AOR 1.52, 95% CI 1.11-2.08), and lesion calcification (AOR 1.29, 95% CI 1.03-1.61), but stent length and target vessel were not independently associated with outcomes. Placement of a bare metal stent was also an independent predictor of MACE after noncardiac surgery (AOR 1.29, 95% CI 1.06-1.57). Conclusions: While patient and operative characteristics are the strongest predictors of MACE after noncardiac surgery, specific lesion characteristics including ostial or distal lesion location and calcification are novel risk factors for postoperative MACE. (C) 2016Wiley Periodicals, Inc. C1 [Armstrong, Ehrin J.; Waldo, Stephen W.; Valle, Javier A.; Maddox, Thomas M.] Denver VA Med Ctr, Cardiol Sect, Aurora, CO USA. [Armstrong, Ehrin J.; Waldo, Stephen W.; Valle, Javier A.; Maddox, Thomas M.] Univ Colorado, Sch Med, Aurora, CO USA. [Graham, Laura; Hawn, Mary T.] Birmingham Vet Adm Hosp, Birmingham, AL USA. [Hawn, Mary T.] Stanford Univ, Dept Surg, Stanford, CA 94305 USA. RP Armstrong, EJ (reprint author), Denver VA Med Ctr, Med, 1055 Clermont St Denver, Denver, CO 80220 USA. EM Ehrin.armstrong@gmail.com FU Veterans Affairs Health Services Research and Development [IIR 09] FX Veterans Affairs Health Services Research and Development; Contract grant number: grant IIR 09 NR 25 TC 1 Z9 1 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1522-1946 EI 1522-726X J9 CATHETER CARDIO INTE JI Catheter. Cardiovasc. Interv. PD MAR 1 PY 2017 VL 89 IS 4 BP 617 EP 627 DI 10.1002/ccd.26624 PG 11 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EP3RV UT WOS:000397300300012 PM 27315550 ER PT J AU Yim, CK Barron, Y Moore, S Murtaugh, C Lala, A Aldridge, M Goldstein, N Gelfman, LP AF Yim, Cindi K. Barron, Yolanda Moore, Stanley Murtaugh, Chris Lala, Anuradha Aldridge, Melissa Goldstein, Nathan Gelfman, Laura P. TI Hospice Enrollment in Patients With Advanced Heart Failure Decreases Acute Medical Service Utilization SO CIRCULATION-HEART FAILURE LA English DT Article DE adult; caregiver; heart failure; hospice; Medicare ID PALLIATIVE CARE; OF-LIFE; CANCER; MANAGEMENT; END; BENEFICIARIES; CAREGIVERS; DIAGNOSIS; ASSOCIATION; DEPRESSION AB Background-Patients with advanced heart failure (HF) enroll in hospice at low rates, and data on their acute medical service utilization after hospice enrollment is limited. Methods and Results-We performed a descriptive analysis of Medicare fee-for-service beneficiaries, with at least one home health claim between July 1, 2009, and June 30, 2010, and at least 2 HF hospitalizations between July 1, 2009, and December 31, 2009, who subsequently enrolled in hospice between July 1, 2009, and December 31, 2009. We estimated panel-negative binomial models on a subset of beneficiaries to compare their acute medical service utilization before and after enrollment. Our sample size included 5073 beneficiaries: 55% were female, 45% were >= 85 years of age, 13% were non-white, and the mean comorbidity count was 2.38 (standard deviation 1.22). The median number of days between the second HF hospital discharge and hospice enrollment was 45. The median number of days enrolled in hospice was 15, and 39% of the beneficiaries died within 7 days of enrollment. During the study period, 11% of the beneficiaries disenrolled from hospice at least once. The adjusted mean number of hospital, intensive care unit, and emergency room admissions decreased from 2.56, 0.87, and 1.17 before hospice enrollment to 0.53, 0.19, and 0.76 after hospice enrollment. Conclusions-Home health care Medicare beneficiaries with advanced HF who enrolled in hospice had lower acute medical service utilization after their enrollment. Their pattern of hospice use suggests that earlier referral and improved retention may benefit this population. Further research is necessary to understand hospice referral and palliative care needs of advanced HF patients. C1 [Lala, Anuradha] Div Cardiol & Populat Hlth Sci & Policy, New York, NY USA. [Aldridge, Melissa; Goldstein, Nathan; Gelfman, Laura P.] Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Yim, Cindi K.] Icahn Sch Med Mt Sinai, New York, NY 10029 USA. [Barron, Yolanda; Murtaugh, Chris] Visiting Nurse Serv New, Ctr Home Care Policy & Res, New York, NY USA. [Aldridge, Melissa; Gelfman, Laura P.] James J Peters VA Med Ctr, Geriatr Res Educ & Clin Ctr, Bronx, NY USA. RP Gelfman, LP (reprint author), Icahn Sch Med Mt Sinai, Dept Geriatr & Palliat Med, One Gustave L Levy Pl,Box 1070, New York, NY 10029 USA. EM laura.gelfman@mssm.edu FU Medical Student Training in Aging Research (MSTAR); National Institute on Aging (NIA) [1K23AG049930]; Mount Sinai Older Adults Independence [P30AG028741]; Agency for Healthcare Research [R01HS020257]; American Federation on Aging Research; National Palliative Care Research Center FX C. K. Yim received support from the Medical Student Training in Aging Research (MSTAR) Fellowship administered by American Federation for Aging (AFAR) and National Institute on Aging (NIA). Dr Gelfman received support from the National Institute on Aging (NIA; 1K23AG049930), The Mount Sinai Older Adults Independence Center (P30AG028741), the American Federation on Aging Research, and the National Palliative Care Research Center. The core data set analyzed in this study was developed as part of a project supported by grant number R01HS020257 from the Agency for Healthcare Research and Quality. NR 43 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1941-3289 EI 1941-3297 J9 CIRC-HEART FAIL JI Circ.-Heart Fail. PD MAR PY 2017 VL 10 IS 3 AR e003335 DI 10.1161/CIRCHEARTFAILURE.116.003335 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EP7UN UT WOS:000397582800008 ER PT J AU Saks, K Amjadi, D D'Souza, SL AF Saks, Karen Amjadi, Darius D'Souza, Sharlene L. TI Eosinophilic Cholecystitis and Enteritis Associated With Ampullary Stenosis SO CLINICAL GASTROENTEROLOGY AND HEPATOLOGY LA English DT Editorial Material ID GASTROENTERITIS C1 [Saks, Karen; Amjadi, Darius; D'Souza, Sharlene L.] Portland VA Med Ctr, Portland, OR 97210 USA. RP Saks, K (reprint author), Portland VA Med Ctr, Portland, OR 97210 USA. NR 7 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1542-3565 EI 1542-7714 J9 CLIN GASTROENTEROL H JI Clin. Gastroenterol. Hepatol. PD MAR PY 2017 VL 15 IS 3 BP XXIII EP XXIV DI 10.1016/j.cgh.2016.11.008 PG 2 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EP2XK UT WOS:000397246700002 PM 27840180 ER PT J AU Tamura, MK Montez-Rath, ME Hall, YN Katz, R O'Hare, AM AF Tamura, Manjula Kurella Montez-Rath, Maria E. Hall, Yoshio N. Katz, Ronit O'Hare, Ann M. TI Advance Directives and End-of-Life Care among Nursing Home Residents Receiving Maintenance Dialysis SO CLINICAL JOURNAL OF THE AMERICAN SOCIETY OF NEPHROLOGY LA English DT Article ID DECISION-MAKING; KIDNEY-DISEASE; HOSPITAL DEATH; QUALITY; INTERVENTION; HEMODIALYSIS; ESRD AB Background and objectives Little is known about the relation between the content of advance directives and downstream treatment decisions among patients receiving maintenance dialysis. In this study, we determined the prevalence of advance directives specifying treatment limitations and/or surrogate decision-makers in the last year of life and their association with end-of-life care among nursing home residents. Design, setting, participants, & measurements Using national data from 2006 to 2007, we compared the content of advance directives among 30,716 nursing home residents receiving dialysis to 30,825 nursing home residents with other serious illnesses during the year before death. Among patients receiving dialysis, we linked the content of advance directives to Medicare claims to ascertain site of death and treatment intensity in the last month of life. Results In the last year of life, 36% of nursing home residents receiving dialysis had a treatment-limiting directive, 22% had a surrogate decision-maker, and 13% had both in adjusted analyses. These estimates were 13%-27%, 5%-11%, and 6%-13% lower, respectively, than for decedents with other serious illnesses. For patients receiving dialysis who had both a treatment-limiting directive and surrogate decision-maker, the adjusted frequency of hospitalization, intensive care unit admission, intensive procedures, and inpatient death were lower by 13%, 17%, 13%, and 14%, respectively, and hospice use and dialysis discontinuation were 5% and 7% higher compared with patients receiving dialysis lacking both components. Conclusions Among nursing home residents receiving dialysis, treatment-limiting directives and surrogates were associated with fewer intensive interventions and inpatient deaths, but were in place much less often than for nursing home residents with other serious illnesses. C1 [Tamura, Manjula Kurella] Palo Alto Vet Affairs Hlth Care Syst, Geriatr Res & Educ Clin Ctr, Palo Alto, CA USA. [Tamura, Manjula Kurella; Montez-Rath, Maria E.] Stanford Univ, Sch Med, Div Nephrol, Palo Alto, CA 94304 USA. [Hall, Yoshio N.; Katz, Ronit; O'Hare, Ann M.] Grp Hlth Cooperat Puget Sound, Dept Med, Seattle, WA USA. [Hall, Yoshio N.; Katz, Ronit; O'Hare, Ann M.] Univ Washington, Dept Med, Kidney Res Inst, Seattle, WA USA. [O'Hare, Ann M.] Vet Affairs Puget Sound Hlth Care Syst, Dept Hosp & Specialty Med, Seattle, WA USA. RP Tamura, MK (reprint author), Vet Affairs Palo Alto Hlth Care Syst, 3801 Miranda Ave, Palo Alto, CA 94304 USA. EM mktamura@stanford.edu FU National Institutes of Diabetes and Digestive and Kidney Diseases [U01DK102150] FX This work is supported by grant U01DK102150 from the National Institutes of Diabetes and Digestive and Kidney Diseases. NR 30 TC 1 Z9 1 U1 0 U2 0 PU AMER SOC NEPHROLOGY PI WASHINGTON PA 1725 I ST, NW STE 510, WASHINGTON, DC 20006 USA SN 1555-9041 EI 1555-905X J9 CLIN J AM SOC NEPHRO JI Clin. J. Am. Soc. Nephrol. PD MAR PY 2017 VL 12 IS 3 BP 435 EP 442 DI 10.2215/CJN.07510716 PG 8 WC Urology & Nephrology SC Urology & Nephrology GA EO6SE UT WOS:000396822000011 ER PT J AU Anderson, LJ Albrecht, ED Garcia, JM AF Anderson, Lindsey J. Albrecht, Eliette D. Garcia, Jose M. TI Update on Management of Cancer-Related Cachexia (vol 19, 2017) SO CURRENT ONCOLOGY REPORTS LA English DT Correction C1 [Anderson, Lindsey J.; Albrecht, Eliette D.; Garcia, Jose M.] VA Puget Sound Hlth Care Syst, Educ & Clin Ctr GRECC, Geriatr Res, Seattle, WA 98108 USA. [Albrecht, Eliette D.] Yale Univ, New Haven, CT 06520 USA. [Garcia, Jose M.] Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98105 USA. RP Garcia, JM (reprint author), VA Puget Sound Hlth Care Syst, Educ & Clin Ctr GRECC, Geriatr Res, Seattle, WA 98108 USA.; Garcia, JM (reprint author), Univ Washington, Sch Med, Dept Med, Div Gerontol & Geriatr Med, Seattle, WA 98105 USA. EM lindsey.anderson5@va.gov; eliette.albrecht@yale.edu; jg77@uw.edu NR 1 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 1523-3790 EI 1534-6269 J9 CURR ONCOL REP JI Curr. Oncol. Rep. PD MAR PY 2017 VL 19 IS 3 AR 22 DI 10.1007/s11912-017-0595-4 PG 1 WC Oncology SC Oncology GA EP2ZB UT WOS:000397251100008 PM 28293870 ER PT J AU Wedzicha, JA Miravitlles, M Hurst, JR Calverley, PMA Albert, RK Anzueto, A Criner, GJ Papi, A Rabe, KF Rigau, D Sliwinski, P Tonia, T Vestbo, J Wilson, KC Krishnan, JA AF Wedzicha, Jadwiga A. Miravitlles, Marc Hurst, John R. Calverley, Peter M. A. Albert, Richard K. Anzueto, Antonio Criner, Gerard J. Papi, Alberto Rabe, Klaus F. Rigau, David Sliwinski, Pawel Tonia, Thomy Vestbo, Jorgen Wilson, Kevin C. Krishnan, Jerry A. TI Management of COPD exacerbations: a European Respiratory Society/American Thoracic Society guideline SO EUROPEAN RESPIRATORY JOURNAL LA English DT Article ID OBSTRUCTIVE PULMONARY-DISEASE; RANDOMIZED CONTROLLED-TRIAL; POSITIVE-PRESSURE VENTILATION; QUALITY-OF-LIFE; STANDARD MEDICAL THERAPY; PLACEBO-CONTROLLED TRIAL; HEALTH-CARE UTILIZATION; NONINVASIVE VENTILATION; HOSPITAL-CARE; REHABILITATION PROGRAM AB This document provides clinical recommendations for treatment of chronic obstructive pulmonary disease (COPD) exacerbations. Comprehensive evidence syntheses, including meta-analyses, were performed to summarise all available evidence relevant to the Task Force's questions. The evidence was appraised using the Grading of Recommendations, Assessment, Development and Evaluation approach and the results were summarised in evidence profiles. The evidence syntheses were discussed and recommendations formulated by a multidisciplinary Task Force of COPD experts. After considering the balance of desirable and undesirable consequences, quality of evidence, feasibility, and acceptability of various interventions, the Task Force made: 1) a strong recommendation for noninvasive mechanical ventilation of patients with acute or acute-on-chronic respiratory failure; 2) conditional recommendations for oral corticosteroids in outpatients, oral rather than intravenous corticosteroids in hospitalised patients, antibiotic therapy, home-based management, and the initiation of pulmonary rehabilitation within 3 weeks after hospital discharge; and 3) a conditional recommendation against the initiation of pulmonary rehabilitation during hospitalisation. The Task Force provided recommendations related to corticosteroid therapy, antibiotic therapy, noninvasive mechanical ventilation, home-based management, and early pulmonary rehabilitation in patients having a COPD exacerbation. These recommendations should be reconsidered as new evidence becomes available. C1 [Wedzicha, Jadwiga A.] Imperial Coll London, Natl Heart & Lung Inst, Airways Dis Sect, London, England. [Miravitlles, Marc] Hosp Univ Vall dHebron, Dept Pneumol, CIBER Enfermedades Resp CIBERES, Barcelona, Spain. [Hurst, John R.] UCL, UCL Resp, London, England. [Calverley, Peter M. A.] Univ Liverpool, Inst Ageing & Chron Dis, Liverpool, Merseyside, England. [Albert, Richard K.] Univ Colorado, Dept Med, Aurora, CO USA. [Anzueto, Antonio] Univ Texas Hlth Sci Ctr San Antonio, San Antonio, TX 78229 USA. [Anzueto, Antonio] South Texas Vet Hlth Care Syst, San Antonio, TX USA. [Criner, Gerard J.] Temple Univ, Lewis Katz Sch Med, Dept Thorac Med & Surg, Philadelphia, PA 19122 USA. [Papi, Alberto] Univ Ferrara, Dept Med Sci, Resp Med, Ferrara, Italy. [Rabe, Klaus F.] Univ Kiel, Dept Internal Med, Kiel, Germany. [Rabe, Klaus F.] German Ctr Lung Res, LungenClin Grosshansdorf, Airway Res Ctr North, Grosshansdorf, Germany. [Rigau, David] Iberoamer Cochrane Ctr, Barcelona, Spain. [Sliwinski, Pawel] Inst TB & Lung Dis, Dept Resp Med 2, Warsaw, Poland. [Tonia, Thomy] Univ Bern, Inst Social & Prevent Med, Bern, Switzerland. [Vestbo, Jorgen] Univ Manchester, Div Infect Immun & Resp Med, Manchester, Lancs, England. [Wilson, Kevin C.] Boston Univ, Sch Med, Dept Med, Boston, MA 02118 USA. [Krishnan, Jerry A.] Univ Illinois Hosp & Hlth Sci Syst, Chicago, IL USA. RP Miravitlles, M (reprint author), Hosp Univ Vall dHebron, Dept Pneumol, Pg Vall dHebron 119-129, Barcelona 08035, Spain. EM mmiravitlles@vhebron.net OI PAPI, ALBERTO/0000-0002-6924-4500 NR 89 TC 0 Z9 0 U1 3 U2 3 PU EUROPEAN RESPIRATORY SOC JOURNALS LTD PI SHEFFIELD PA 442 GLOSSOP RD, SHEFFIELD S10 2PX, ENGLAND SN 0903-1936 EI 1399-3003 J9 EUR RESPIR J JI Eur. Resp. J. PD MAR PY 2017 VL 49 IS 3 AR 1600791 DI 10.1183/13993003.00791-2016 PG 16 WC Respiratory System SC Respiratory System GA EQ2WI UT WOS:000397931500005 ER PT J AU Ialynytchev, A Sear, AM Williams, AR Langland-Orban, B Zhang, NH AF Ialynytchev, Anna Sear, Alan M. Williams, Arthur R. Langland-Orban, Barbara Zhang, Nanhua TI Factors associated with lumbar fusion surgery: a case-control study SO EUROPEAN SPINE JOURNAL LA English DT Article DE Lumbar fusion surgery; Spinal fusion surgery; Lower back surgery ID UNITED-STATES TRENDS; SPINE SURGERY; BACK-PAIN; GUIDELINE; CHARGES AB The objective of this study is to identify the demographic and payer factors that are associated with lumbar fusion surgery. A case-control study was conducted utilizing a population of 38,092 patients from the 2010 Florida Agency for Health Care Administration (AHCA), USA hospital discharge data. The case population included 16,236 records with any of five ICD-9-CM principal procedure codes for initial lumbar fusion. The control group was comprised of 21,856 patients who were admitted for the same principal diagnoses as the cases, but who did not have initial fusion surgery. Logistic regression was used to analyze the association of age, gender, race and principal payer type with initial lumbar fusions. The interaction between age and payer was also examined, as payer type may moderate the association between age and lumbar fusion surgery. Gender, race, principal payer and age were all found to be significantly associated with lumbar fusion surgery. The interaction of payer and age was also found to be significant. Being female was significantly associated with having a fusion (OR = 1.11, 95 % CI 1.07-1.16). The association between age and receiving surgery was greatest for the less than 20 age group (OR = 10.43, 95 % CI 8.74-12.45). Employees and dependents of Federal government agencies (Tricare, etc.) and patients with commercial insurance were significantly associated with surgery (OR = 1.48, 95 % CI 1.29-1.70 and OR = 1.12, 95 % CI 1.04-1.20, respectively). Patients insured through Medicaid (a social health care program for those with low incomes and limited resources), and the uninsured were negatively associated with surgery (OR = 0.53, 95 % CI 0.47-0.60 and OR = 0.52, 95 % CI 0.46-0.58, respectively). Lumbar fusion surgery is not recommended in clinical practice guidelines for the top four principal diagnoses in this study. Yet, patients covered by certain types of insurance were found to be significantly associated with fusion surgery. C1 [Ialynytchev, Anna; Sear, Alan M.; Langland-Orban, Barbara] Univ S Florida, Dept Hlth Policy & Management, 13201 Bruce B. Downs Blvd. MDC 56, Tampa, FL 33612 USA. [Williams, Arthur R.] US Dept Vet Affairs, CINDRR, Tampa, FL 33637 USA. [Williams, Arthur R.] George Mason Univ, Dept Hlth Adm & Policy, Fairfax, VA 22030 USA. [Zhang, Nanhua] Cincinnati Childrens Hosp Med Ctr, Div Biostat & Epidemiol, 3333 Burnet Ave,MLC 5041, Cincinnati, OH 45229 USA. [Zhang, Nanhua] Univ Cincinnati, Dept Pediat, Cincinnati, OH 45229 USA. RP Ialynytchev, A (reprint author), Univ S Florida, Dept Hlth Policy & Management, 13201 Bruce B. Downs Blvd. MDC 56, Tampa, FL 33612 USA. EM annai@mail.usf.edu NR 24 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI NEW YORK PA 233 SPRING ST, NEW YORK, NY 10013 USA SN 0940-6719 EI 1432-0932 J9 EUR SPINE J JI Eur. Spine J. PD MAR PY 2017 VL 26 IS 3 BP 698 EP 707 DI 10.1007/s00586-016-4591-4 PG 10 WC Clinical Neurology; Orthopedics SC Neurosciences & Neurology; Orthopedics GA EN5JR UT WOS:000396042000015 PM 27154167 ER PT J AU Persson, A Back, SE Killeen, TK Brady, KT Schwandt, ML Heilig, M Magnusson, A AF Persson, Anna Back, Sudie E. Killeen, Therese K. Brady, Kathleen T. Schwandt, Melanie L. Heilig, Markus Magnusson, Asa TI Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure ( COPE): A Pilot Study in Alcohol-dependent Women SO JOURNAL OF ADDICTION MEDICINE LA English DT Article DE alcohol dependence; alcohol use disorder; integrated treatment; PTSD; women ID POSTTRAUMATIC-STRESS-DISORDER; NATIONAL EPIDEMIOLOGIC SURVEY; INTERNATIONAL NEUROPSYCHIATRIC INTERVIEW; IDENTIFICATION TEST AUDIT; PSYCHOMETRIC PROPERTIES; TRAUMA EXPOSURE; CONDITIONS-III; DRUG-USE; DSM-IV; THERAPY AB Objectives: Posttraumatic stress disorder (PTSD) and substance use disorders are highly comorbid. Effective treatments are largely lacking. This pilot study evaluated the safety and feasibility of a novel intervention, Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure (COPE), in preparation for a randomized controlled trial. Methods: Twenty-two treatment-seeking women with current DSM-IV-TR PTSD and alcohol dependence (AD) were recruited. Participants received COPE. Safety and feasibility were evaluated, as were efficacy-related outcomes: PTSD and depression symptom severity, alcohol use, craving, and dependence severity. Results: No adverse events occurred. COPE was implemented in routine clinical practice. Among the assessed women, 95.8% were eligible to participate. Treatment attendance and completion were higher than in previous studies. Post treatment, all efficacy-related outcomes, including PTSD and depression symptom severity, alcohol use, craving, and dependence severity, were significantly reduced. Conclusions: COPE was safe and feasible to use. Concerns that trauma-focused, exposure-based therapy might promote relapse in this population appear unwarranted. Our findings provide initial evidence suggestive of COPE efficacy for comorbid PTSD and AD in women. These results provide a strong rationale for investigating the efficacy of COPE for comorbid PTSD and AD in women in a randomized controlled trial. C1 [Persson, Anna; Magnusson, Asa] Karolinska Inst, Dept Clin Neurosci, Box 179 03, S-10401 Stockholm, Sweden. [Persson, Anna; Magnusson, Asa] Stockholm Ctr Dependency Disorders, EWA Outpatient Unit, Stockholm, Sweden. [Back, Sudie E.; Killeen, Therese K.; Brady, Kathleen T.] Med Univ South Carolina, Dept Psychiat, Charleston, SC 29425 USA. [Back, Sudie E.; Brady, Kathleen T.] Ralph H Johnson Vet Affairs VA Med Ctr, Charleston, SC USA. [Schwandt, Melanie L.] NIAAA, Lab Clin & Expt Studies, Bethesda, MD USA. [Heilig, Markus] Linkoping Univ, Dept Clin & Expt Med, Linkoping, Sweden. RP Magnusson, A (reprint author), Karolinska Inst, Dept Clin Neurosci, Box 179 03, S-10401 Stockholm, Sweden.; Magnusson, A (reprint author), Rosenlunds Hosp, Stockholm Ctr Dependency Disorders, EWA Outpatient Unit, Box 179 03, S-11895 Stockholm, Sweden. EM asa.magnusson@ki.se FU Swedish Society of Addiction Medicine; Systembolaget's Alcohol Research Council; Soderstrom-Konigska Foundation FX The work summarized herein was funded by grants from The Swedish Society of Addiction Medicine, Systembolaget's Alcohol Research Council, and the Soderstrom-Konigska Foundation. The above had no involvement in study design, collection, analysis or interpretation of data, the writing of the report, or the decision to submit the article for publication. NR 40 TC 0 Z9 0 U1 1 U2 1 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1932-0620 EI 1935-3227 J9 J ADDICT MED JI J. Addict. Med. PD MAR-APR PY 2017 VL 11 IS 2 BP 119 EP 125 DI 10.1097/ADM.0000000000000286 PG 7 WC Substance Abuse SC Substance Abuse GA EP7ZE UT WOS:000397594900009 PM 28079572 ER PT J AU Matsue, Y ter Maaten, JM Struck, J Metra, M O'Connor, CM Ponikowski, P Teerlink, JR Cotter, G Davison, B Cleland, JG Givertz, MM Bloomfield, DM Dittrich, HC van Veldhuisen, DJ van der Meer, P Damman, K Voors, AA AF Matsue, Yuya ter Maaten, Jozine M. Struck, Joachim Metra, Marco O'Connor, Christopher M. Ponikowski, Piotr Teerlink, John R. Cotter, Gad Davison, Beth Cleland, John G. Givertz, Michael M. Bloomfield, Daniel M. Dittrich, Howard C. van Veldhuisen, Dirk J. van der Meer, Peter Damman, Kevin Voors, Adriaan A. TI Clinical Correlates and Prognostic Value of Proenkephalin in Acute and Chronic Heart Failure SO JOURNAL OF CARDIAC FAILURE LA English DT Article DE Renal function; heart failure; prognosis; enkephalin ID RECEPTOR ANTAGONIST ROLOFYLLINE; GLOMERULAR-FILTRATION-RATE; BLOOD UREA NITROGEN; ACUTE KIDNEY INJURY; RENAL-FUNCTION; MYOCARDIAL-INFARCTION; VOLUME OVERLOAD; MORTALITY; CONGESTION; PROTECT AB Background: Proenkephalin (pro-ENK) has emerged as a novel biomarker associated with both renal function and cardiac function. However, its clinical and prognostic value have not been well evaluated in symptomatic patients with heart failure. Methods and Results: The association between pro-ENK and markers of renal function was evaluated in 95 patients with chronic heart failure who underwent renal hemodynamic measurements, including renal blood flow (RBF) and glomerular filtration rate (GFR) with the use of I-131-Hippuran and I-125-iothalainate clearances, respectively. The association between pro-ENK and clinical outcome in acute heart failure was assessed in another 1589 patients. Pro-ENK was strongly correlated with both RBF (P <.001) and GFR (P <.001), but not with renal tubular markers. In the acute heart failure cohort, pro-ENK was a predictor of death through 180 days, heart failure rehospitalization through 60 days, and death or cardiovascular or renal rehospitalization through day 60 in univariable analyses, but its predictive value was lost in a multivariable model when other renal markers were entered in the model. \ Conclusions: In patients with chronic and acute heart failure, pro-ENK is strongly associated with glomerular function, but not with tubular damage. Pro-ENK provides limited prognostic information in patients with acute heart failure on top of established renal markers. C1 [Matsue, Yuya; ter Maaten, Jozine M.; van Veldhuisen, Dirk J.; van der Meer, Peter; Damman, Kevin; Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands. [Struck, Joachim] Sphingotec GmbH, Hennigsdorf, Germany. [Metra, Marco] Univ Brescia, Brescia, Italy. [O'Connor, Christopher M.] Inova Heart & Vasc Inst, Falls Church, VA USA. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Teerlink, John R.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Teerlink, John R.] San Francisco VA Med Ctr, San Francisco, CA USA. [Cotter, Gad; Davison, Beth] Momentum Res, Durham, NC USA. [Cleland, John G.] Univ Hull, Kingston Upon Hull, Yorks, England. [Givertz, Michael M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA. [Dittrich, Howard C.] Univ Iowa, Carver Coll Med, Cardiovasc Res Ctr, Iowa City, IA USA. RP Voors, AA (reprint author), Univ Med Ctr Groningen, Dept Cardiol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands. EM a.a.voors@umcg.nl OI Matsue, Yuya/0000-0003-2456-8525 FU Novacardia FX The PROTECT trial was supported by Novacardia, a subsidiary of Merck. Alere, Singulex, and Sphingotec kindly provided assays and performed biomarker measurements. NR 22 TC 0 Z9 0 U1 0 U2 0 PU CHURCHILL LIVINGSTONE INC MEDICAL PUBLISHERS PI PHILADELPHIA PA CURTIS CENTER, INDEPENDENCE SQUARE WEST, PHILADELPHIA, PA 19106-3399 USA SN 1071-9164 EI 1532-8414 J9 J CARD FAIL JI J. Card. Fail. PD MAR PY 2017 VL 23 IS 3 BP 231 EP 239 DI 10.1016/j.cardfail.2016.09.007 PG 9 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EQ4BR UT WOS:000398018200006 PM 27663098 ER PT J AU Goodman, M Hazlett, EA AF Goodman, Marianne Hazlett, Erin A. TI Just What is "Dialectical" About Dialectical Behavior Therapy? Reply SO JOURNAL OF CLINICAL PSYCHIATRY LA English DT Letter ID EMOTION REGULATION; VETERANS C1 [Goodman, Marianne; Hazlett, Erin A.] Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA. [Goodman, Marianne; Hazlett, Erin A.] James J Peters VA Med Ctr, VISN Mental Illness Res Educ & Clin Ctr MIRECC 25, Bronx, NY USA. [Goodman, Marianne] James J Peters VA Med Ctr, Outpatient Psychiat, Bronx, NY USA. RP Goodman, M (reprint author), Icahn Sch Med Mt Sinai, Dept Psychiat, New York, NY 10029 USA.; Goodman, M (reprint author), James J Peters VA Med Ctr, VISN Mental Illness Res Educ & Clin Ctr MIRECC 25, Bronx, NY USA.; Goodman, M (reprint author), James J Peters VA Med Ctr, Outpatient Psychiat, Bronx, NY USA. EM marianne.goodman@va.gov FU US Department of Defense [WX81XWH-09-1-0722] FX The study discussed in this letter was supported by US Department of Defense Grant WX81XWH-09-1-0722 (to Dr Goodman, principal investigator). NR 4 TC 0 Z9 0 U1 0 U2 0 PU PHYSICIANS POSTGRADUATE PRESS PI MEMPHIS PA P O BOX 752870, MEMPHIS, TN 38175-2870 USA SN 0160-6689 EI 1555-2101 J9 J CLIN PSYCHIAT JI J. Clin. Psychiatry PD MAR PY 2017 VL 78 IS 3 BP E311 EP E311 DI 10.4088/JCP.16lr11394a PG 1 WC Psychology, Clinical; Psychiatry SC Psychology; Psychiatry GA EQ3NE UT WOS:000397978900013 PM 28394515 ER PT J AU Stephenson, KR Simpson, TL Martinez, ME Kearney, DJ AF Stephenson, Kyle R. Simpson, Tracy L. Martinez, Michelle E. Kearney, David J. TI Changes in Mindfulness and Posttraumatic Stress Disorder Symptoms Among Veterans Enrolled in Mindfulness-Based Stress Reduction SO JOURNAL OF CLINICAL PSYCHOLOGY LA English DT Article DE posttraumatic stress disorder; mindfulness; veterans ID RANDOMIZED CLINICAL-TRIAL; COGNITIVE-BEHAVIORAL THERAPY; EXPOSURE THERAPY; MENTAL-HEALTH; SELF-REPORT; FUNCTIONAL IMPAIRMENT; PTSD; PROGRAM; PARTICIPATION; MECHANISMS AB Objectives: The current study assessed associations between changes in 5 facets of mindfulness (Acting With Awareness, Observing, Describing, Non-Reactivity, and Nonjudgment) and changes in 4 posttraumatic stress disorder (PTSD) symptom clusters (Re-Experiencing, Avoidance, Emotional Numbing, and Hyperarousal symptoms) among veterans participating in mindfulness-based stress reduction (MBSR). Method: Secondary analyses were performed with a combined data set consisting of 2 published and 2 unpublished trials of MBSR conducted at a large Veterans Affairs hospital. The combined sample included 113 veterans enrolled in MBSR who screened positive for PTSD and completed measures of mindfulness and PTSD symptoms before and after the 8-week intervention. Results: Increases in mindfulness were significantly associated with reduced PTSD symptoms. Increases in Acting With Awareness and Non-Reactivity were the facets of mindfulness most strongly and consistently associated with reduced PTSD symptoms. Increases in mindfulness were most strongly related to decreases in Hyperarousal and Emotional Numbing. Conclusions: These results extend previous research, provide preliminary support for changes in mindfulness as a viable mechanism of treatment, and have a number of potential practical and theoretical implications. (C) 2016 Wiley Periodicals, Inc. C1 [Stephenson, Kyle R.; Simpson, Tracy L.; Martinez, Michelle E.; Kearney, David J.] Vet Affairs Puget Sound Healthcare Syst, 1660 South Columbian Way, Seattle, WA 98108 USA. [Stephenson, Kyle R.] Willamette Univ, Dept Psychol, Salem, OR 97301 USA. [Simpson, Tracy L.; Kearney, David J.] Univ Washington, Sch Med, Seattle, WA 98195 USA. RP Kearney, DJ (reprint author), Vet Affairs Puget Sound Healthcare Syst, 1660 South Columbian Way, Seattle, WA 98108 USA. EM david.kearney@va.gov FU U.S. Department of Veterans Affairs, Office of Research and Development, Clinical RD Program FX The study was approved by the institutional review board at VA Puget Sound Health Care System. This material is based upon work supported by the U.S. Department of Veterans Affairs, Office of Research and Development, Clinical R&D Program. NR 54 TC 0 Z9 0 U1 5 U2 5 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0021-9762 EI 1097-4679 J9 J CLIN PSYCHOL JI J. Clin. Psychol. PD MAR PY 2017 VL 73 IS 3 BP 201 EP 217 DI 10.1002/jclp.22323 PG 17 WC Psychology, Clinical SC Psychology GA EQ3UX UT WOS:000397999900001 PM 27152480 ER PT J AU Pottiez, G Yang, L Stewart, T Song, N Aro, P Galasko, DR Quinn, JF Peskind, ER Shi, M Zhang, J AF Pottiez, Gwenael Yang, Li Stewart, Tessandra Song, Ning Aro, Patrick Galasko, Douglas R. Quinn, Joseph F. Peskind, Elaine R. Shi, Min Zhang, Jing TI Mass-Spectrometry-Based Method To Quantify in Parallel Tau and Amyloid beta 1-42 in CSF for the Diagnosis of Alzheimer's Disease SO JOURNAL OF PROTEOME RESEARCH LA English DT Article DE Alzheimer's disease; mass spectrometry; SRM; diagnosis; biomarker; cerebrospinal fluid; tau; amyloid beta; A beta(42) ID MILD COGNITIVE IMPAIRMENT; HUMAN CEREBROSPINAL-FLUID; QUALITY-CONTROL PROGRAM; QUANTIFICATION; BIOMARKERS; PROTEIN; ASSOCIATION; PLASMA; BRAIN; BETA-AMYLOID((1-42)) AB Alzheimer's disease (AD), the most common form of dementia, afflicts about 50 million people worldwide. Currently, AD diagnosis is primarily based on psychological evaluation and can only be confirmed post-mortem. Reliable and objective biomarkers for prognosis and diagnosis have been sought for years. Together, tau and amyloid beta 1-42 (A beta(42)) in cerebrospinal fluid (CSF) have been shown to provide good diagnostic sensitivity and specificity. Additionally, phosphorylated forms of tau, such as tau pS181, have also shown promising results. However, the measurement of such markers currently relies on antibody-based immunoassays that have shown variability, leading to discrepant results across laboratories. To date, mass spectrometry methods developed to evaluate CSF tau and A,1342 are not compatible. We present in this article the development of a mass-spectrometry-based method of quantification for CSF tau and A beta(42) in parallel. The absolute concentrations of tau and A beta(42) we measured are on average 50 ng/mL (7-130 ng/mL) and 7.1 ng/mL (3-13 ng/mL), respectively. Analyses of CSF tau and A beta(42), in a cohort of patients with AD, mild cognitive impairment, and healthy controls (30 subjects), provide significant group differences evaluated with ROC curves (AUC(control-AD) and AUC((control-MCI)) = 1, AUC((MCI-AD))) = 0.76), with at least equivalent diagnostic utility to immunoassay measurements in the same sample set. Finally, a significant and negative correlation was found between the tau and A beta peptides ratio and the disease severity. C1 [Pottiez, Gwenael; Yang, Li; Stewart, Tessandra; Song, Ning; Aro, Patrick; Shi, Min; Zhang, Jing] Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98104 USA. [Galasko, Douglas R.] Univ Calif San Diego, Dept Neurosci, San Diego, CA 92093 USA. [Quinn, Joseph F.] Oregon Hlth & Sci Univ, Dept Neurol, Portland, OR 97239 USA. [Quinn, Joseph F.] Portland VA Med Ctr, Portland, OR 97239 USA. [Peskind, Elaine R.] VA Puget Sound Hlth Care Syst, Northwest Network VISN 20, Mental Illness Res Educ & Clin Ctr, Seattle, WA 98108 USA. [Peskind, Elaine R.] Univ Washington, Dept Psychiat & Behav Sci, Seattle, WA 98195 USA. [Zhang, Jing] Peking Univ, Hlth Sci Ctr, Dept Pathol, Beijing 100083, Peoples R China. [Zhang, Jing] Third Hosp, Beijing 100083, Peoples R China. RP Zhang, J (reprint author), Univ Washington, Sch Med, Dept Pathol, Seattle, WA 98104 USA.; Zhang, J (reprint author), Peking Univ, Hlth Sci Ctr, Dept Pathol, Beijing 100083, Peoples R China.; Zhang, J (reprint author), Third Hosp, Beijing 100083, Peoples R China. EM zhangj@uw.edu FU National Institutes of Health (NIH) [U01 NS091272, U01 NS082137, P30 ES007033-8649, R01 ES016873, R01 ES019277, P50 AG05131]; University of Washington's Proteomics Resource [UWPR95794] FX We thank the participants for their generous donation of samples. This study was supported by grants from the National Institutes of Health (NIH) (U01 NS091272, U01 NS082137, P30 ES007033-8649, R01 ES016873, and R01 ES019277 to J.Z. and P50 AG05131 to D.G.). It was also supported in part by the University of Washington's Proteomics Resource (UWPR95794). The content is solely the responsibility of the authors and does not necessarily represent the official views of the NIH and other sponsors. NR 38 TC 0 Z9 0 U1 7 U2 7 PU AMER CHEMICAL SOC PI WASHINGTON PA 1155 16TH ST, NW, WASHINGTON, DC 20036 USA SN 1535-3893 EI 1535-3907 J9 J PROTEOME RES JI J. Proteome Res. PD MAR PY 2017 VL 16 IS 3 BP 1228 EP 1238 DI 10.1021/acs.jproteome.6b00829 PG 11 WC Biochemical Research Methods SC Biochemistry & Molecular Biology GA EN0UO UT WOS:000395726200010 PM 28112948 ER PT J AU Abbott, DE Voils, CL Fisher, DA Greenberg, CC Safdar, N AF Abbott, Daniel E. Voils, Corrine L. Fisher, Deborah A. Greenberg, Caprice C. Safdar, Nasia TI Socioeconomic disparities, financial toxicity, and opportunities for enhanced system efficiencies for patients with cancer SO JOURNAL OF SURGICAL ONCOLOGY LA English DT Review DE cancer; financial toxicity; geographic disparity; socioeconomic disparities; telehealth ID AFRICAN-AMERICAN WOMEN; INFLUENCE MINORITY USE; LOW HEALTH LITERACY; COLORECTAL-CANCER; BREAST-CANCER; RACIAL DISPARITIES; UNITED-STATES; MEDICARE BENEFICIARIES; ADJUVANT BREAST; CARE REFORM AB Cancer care continues to stress the US healthcare system with increases in life expectancy, cancer prevalence, and survivors' complex needs. These challenges are compounded by socioeconomic, racial, and cultural disparities that are associated with poor clinical outcomes. One innovative and resource-wise strategy to address this demand on the system is expanded use of telehealth. This paradigm has the potential to decrease healthcare and patient out-of-pocket costs and improve patient adherence to recommended treatment and/or surveillance. C1 [Abbott, Daniel E.; Safdar, Nasia] William S Middleton Mem Vet Adm Med Ctr, Cincinnati, OH USA. [Abbott, Daniel E.; Greenberg, Caprice C.] Univ Wisconsin, Sch Med & Publ Hlth, Dept Surg, Madison, WI USA. [Voils, Corrine L.; Fisher, Deborah A.] Durham Vet Affairs Med Ctr, Durham, NC USA. [Voils, Corrine L.; Fisher, Deborah A.] Duke Univ, Dept Med, Durham, NC USA. [Safdar, Nasia] Univ Wisconsin, Dept Med, Sch Med & Publ Hlth, Madison, WI USA. RP Abbott, DE (reprint author), Univ Wisconsin, Sch Med, Dept Surg, Surg, 600 Highland Ave,K4-742, Madison, WI 53792 USA. EM abbott@surgery.wisc.edu FU Department of Veterans Affairs; Research Career Scientist [RCS 14-443] FX Department of Veterans Affairs; Research Career Scientist, Grant number: RCS 14-443 NR 76 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 0022-4790 EI 1096-9098 J9 J SURG ONCOL JI J. Surg. Oncol. PD MAR 1 PY 2017 VL 115 IS 3 BP 250 EP 256 DI 10.1002/jso.24528 PG 7 WC Oncology; Surgery SC Oncology; Surgery GA EP3JP UT WOS:000397278900004 PM 28105638 ER PT J AU Ikonomidis, JS Nadeau, EK Akerman, AW Stroud, RE Mukherjee, R Jones, JA AF Ikonomidis, John S. Nadeau, Elizabeth K. Akerman, Adam W. Stroud, Robert E. Mukherjee, Rupak Jones, Jeffrey A. TI Regulation of membrane type-1 matrix metalloproteinase activity and intracellular localization in clinical thoracic aortic aneurysms SO JOURNAL OF THORACIC AND CARDIOVASCULAR SURGERY LA English DT Article DE aneurysm; MT1-MMP; protein kinase C; remodeling; thoracic aorta ID MARFAN-SYNDROME; TRANSMEMBRANE DOMAIN; EXTRACELLULAR-MATRIX; TISSUE INHIBITOR; CELL INVASION; MURINE MODEL; MT1-MMP; ACTIVATION; EXPRESSION; MMP-2 AB Objective: Membrane type-1 matrix metalloproteinase (MT1-MMP) is elevated during thoracic aortic aneurysm (TAA) development in mouse models, and plays an important role in the activation of matrix metalloproteinase (MMP)-2 and the release of matrix-bound transforming growth factor-b. In this study, we tested the hypothesis that MT1-MMP is subject to protein kinase C (PKC)-mediated regulation, which alters intracellular trafficking and activity with TAAs. Methods: Levels of MMP-2, native and phosphorylated MT1-MMP, and PKC-d were measured in aortic tissue from patients with small TAAs (< 5 cm; n = 8) and large TAAs (> 6.5 cm; n = 8), and compared with values measured in normal controls (n = 8). Cellular localization of green fluorescent protein (GFP)-tagged MT1-MMP was assessed in aortic fibroblasts isolated from control and 4-week TAA mice. The effects of PKC-mediated phosphorylation on MT1-MMP cellular localization and function (active MMP-2 vs phospo-Smad2 abundance) were assessed after treatment with a PKC activator (phorbol-12-myristate-13-acetate [PMA], 100 nM) with and without a PKC-delta-specific inhibitor (rottlerin, 3 mM). Results: Compared with controls, MT1-MMP abundance was increased in aortas from both TAA groups. Active MMP-2 was increased only in the large TAA group. The abundances of phosphorylated MT1-MMP and activated PKC-d were enhanced in the small TAA group compared with the large TAA group. MT1-MMP was localized on the plasma membrane in aortic fibroblasts from control mice and in endosomes from TAA mice. Treatment with PMA induced MT1-MMP-GFP internalization, enhanced phospho-Smad2, and reduced MMP-2 activation, whereas rottlerin pretreatment inhibited these effects. Conclusions: Phosphorylation of MT1-MMP mediates its activity through directing cellular localization, shifting its role from MMP-2 activation to intracellular signaling. Thus, targeted inhibition of MT1-MMP may have therapeutic relevance as an approach to attenuating TAA development. C1 [Ikonomidis, John S.; Nadeau, Elizabeth K.; Akerman, Adam W.; Stroud, Robert E.; Mukherjee, Rupak; Jones, Jeffrey A.] Med Univ South Carolina, Div Cardiothorac Surg, Charleston, SC 29425 USA. [Mukherjee, Rupak; Jones, Jeffrey A.] Ralph H Johnson Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. RP Jones, JA (reprint author), Med Univ South Carolina, Div Cardiothorac Surg Res, Strom Thurmond Bldg,114 Doughty St,Suite 338, Charleston, SC 29425 USA. EM jonesja@musc.edu FU National Institutes of Health (NHLBI) [R01 HL102121]; Department of Veterans Affairs (VA-ORD BLRD Merit) [I01BX000904] FX This work was supported by grants from the National Institutes of Health (NHLBI R01 HL102121, to J.S.I.) and the Department of Veterans Affairs (VA-ORD BLR&D Merit I01BX000904, to J. A. J.). NR 36 TC 1 Z9 1 U1 1 U2 1 PU MOSBY-ELSEVIER PI NEW YORK PA 360 PARK AVENUE SOUTH, NEW YORK, NY 10010-1710 USA SN 0022-5223 EI 1097-685X J9 J THORAC CARDIOV SUR JI J. Thorac. Cardiovasc. Surg. PD MAR PY 2017 VL 153 IS 3 BP 537 EP 546 DI 10.1016/j.jtcvs.2016.10.065 PG 10 WC Cardiac & Cardiovascular Systems; Respiratory System; Surgery SC Cardiovascular System & Cardiology; Respiratory System; Surgery GA EQ1PE UT WOS:000397841200014 PM 27923483 ER PT J AU Allen, SR Pascual, J Martin, N Reilly, P Luckianow, G Datner, E Davis, KA Kaplan, LJ AF Allen, Steven R. Pascual, Jose Martin, Niels Reilly, Patrick Luckianow, Gina Datner, Elizabeth Davis, Kimberly A. Kaplan, Lewis J. TI A novel method of optimizing patient- and family-centered care in the ICU SO JOURNAL OF TRAUMA AND ACUTE CARE SURGERY LA English DT Article DE Patient- and family-centered care; communication; satisfaction; quality ID CRITICALLY-ILL PATIENTS; EVALUATION APACHE IV; LENGTH-OF-STAY; CARDIOPULMONARY-RESUSCITATION; ACUTE PHYSIOLOGY; UNIT PATIENTS; SATISFACTION; NEEDS; GUIDELINES; MORTALITY AB BACKGROUND Patient- and family-centered care permeates critical care where there are often multiple teams involved in management. A method of facilitating information sharing to support shared decision making is essential in appropriately rendering care. This study sought to determine whether incorporating family members on rounds in the intensive care unit (ICU) improves patient and family knowledge and whether doing so improves team time management and satisfaction with the process. METHODS A nonrandomized comparative before-and-after trial of incorporating family members on rounds (July to December 2009 vs January to July 2010) in a single quarternary center's surgical ICU assessed (1) family members' knowledge, (2) nurse's and physician's satisfaction with the intervention, (3) frequency and timing of family meetings, and (4) physician's workflow. RESULTS Intensive care unit demographics and use were similar between time frames. Presurvey (n = 412 family members; 49 nurses) and postsurvey (n = 427 family members; 47 nurses) were coupled with presurvey (n = 5) and postsurvey (n = 6) physicians' informal feedback. Family knowledge of the clinical course and plans increased from 146 (35.4%) of 412 to 374 (87.6%) of 427 (p < 0.0001). Nurses were nearly uniformly satisfied with planned family interaction on rounds (presurvey: 9/49 [18.4%] vs postsurvey: 46/47 [97.9%]; p < 0.0001). Family meetings per week outside of rounds substantially decreased from a mean of 5.3 2.7 to 0.3 0.9; p < 0.001). Goals of therapy including end-of-life care became an element frequently discussed on rounds with families (presurvey: 9.4% +/- 4.7% vs postsurvey: 82.5% +/- 14.8%; p < 0.0001). One intensivist was dissatisfied with the process. CONCLUSION Incorporating family members on rounds in the ICU improves communication and satisfaction and shifts the team's time away from family communication events outside of rounds, condensing most of those activities within the rounding structure. Critical care nurses and intensivists were principally satisfied with the process. LEVEL OF EVIDENCE Therapeutic, level III. C1 [Allen, Steven R.; Pascual, Jose; Martin, Niels; Reilly, Patrick; Datner, Elizabeth; Kaplan, Lewis J.] Univ Penn, Perelman Sch Med, 3900 Woodland Ave, Philadelphia, PA 19104 USA. [Allen, Steven R.; Pascual, Jose; Datner, Elizabeth; Kaplan, Lewis J.] Philadelphia VA Med Ctr, Philadelphia, PA USA. [Luckianow, Gina; Davis, Kimberly A.] Yale Sch Med, New Haven, CT USA. RP Kaplan, LJ (reprint author), Univ Penn, Perelman Sch Med, Div Trauma Surg Crit Care & Emergency Surg, 3900 Woodland Ave, Philadelphia, PA 19104 USA.; Kaplan, LJ (reprint author), Corporal Michael J Crescenz VA Med Ctr, Surg Crit Care Sect, 3900 Woodland Ave, Philadelphia, PA 19104 USA. EM Lewis.Kaplan@uphs.upenn.edu NR 41 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2163-0755 EI 2163-0763 J9 J TRAUMA ACUTE CARE JI J. Trauma Acute Care Surg. PD MAR PY 2017 VL 82 IS 3 BP 582 EP 586 DI 10.1097/TA.0000000000001332 PG 5 WC Critical Care Medicine; Surgery SC General & Internal Medicine; Surgery GA EM8XV UT WOS:000395595300020 PM 28030488 ER PT J AU Hammad, SM Baker, NL El Abiad, JM Spassieva, SD Pierce, JS Rembiesa, B Bielawski, J Lopes-Virella, MF Klein, RL AF Hammad, Samar M. Baker, Nathaniel L. El Abiad, Jad M. Spassieva, Stefanka D. Pierce, Jason S. Rembiesa, Barbara Bielawski, Jacek Lopes-Virella, Maria F. Klein, Richard L. CA DCCT EDIC Grp Investigators TI Increased Plasma Levels of Select Deoxy-ceramide and Ceramide Species are Associated with Increased Odds of Diabetic Neuropathy in Type 1 Diabetes: A Pilot Study SO NEUROMOLECULAR MEDICINE LA English DT Article DE Type 1 diabetes; Neuropathy; Deoxysphingolipid; Ceramide; Deoxy-ceramide; Cysteine ID HEREDITARY SENSORY NEUROPATHY; SERINE PALMITOYLTRANSFERASE; BIOPHYSICAL PROPERTIES; PERIPHERAL NEUROPATHY; CHAIN LENGTH; SPHINGOLIPIDS; LONG; 1-DEOXYSPHINGOLIPIDS; MELLITUS; COMPLICATIONS AB Plasma deoxy-sphingoid bases are elevated in type 2 diabetes patients and correlate with the stage of diabetic distal sensorimotor polyneuropathy; however, associations between deoxy-sphingolipids (DSL) and neuropathy in type 1 diabetes have not been examined. The primary aim of this exploratory pilot study was to assess the associations between multiple sphingolipid species including DSL and free amino acids and the presence of symptomatic neuropathy in a DCCT/EDIC type 1 diabetes subcohort. Using mass spectroscopy, plasma levels of DSL and free amino acids in DCCT/EDIC type 1 diabetes participants (n = 80), with and without symptoms of neuropathy, were investigated. Patient-determined neuropathy was based on 15-item self-administered questionnaire (Michigan Neuropathy Screening Instrument) developed to assess distal symmetrical peripheral neuropathy in diabetes. Patients who scored ae4, or reported inability to sense their feet during walking or to distinguish hot from cold water while bathing were considered neuropathic. Plasma levels of ceramide, sphingomyelin, hexosyl- and lactosylceramide species, and amino acids were measured and analyzed relative to neuropathy status in the patient. Deoxy-C24-ceramide, C24- and C26-ceramide were higher in patients with neuropathy than those without neuropathy. Cysteine was higher in patients with neuropathy. No differences in other sphingolipids or amino acids were detected. The covariate-adjusted Odds Ratios of positive patient-reported neuropathy was associated with increased levels of deoxy-C24-, and deoxy-C24:1-ceramide; C22-, C24-, and C26-ceramide; and cysteine. Plasma deoxy-ceramide and ceramide species may have potential diagnostic and prognostic significance in diabetic neuropathy. C1 [Hammad, Samar M.; El Abiad, Jad M.] Med Univ South Carolina, Dept Regenerat Med & Cell Biol, 173 Ashley Ave,BSB 645,MSC 508, Charleston, SC 29425 USA. [Baker, Nathaniel L.] Med Univ South Carolina, Dept Publ Hlth Sci, 173 Ashley Ave,BSB 645,MSC 508, Charleston, SC 29425 USA. [Spassieva, Stefanka D.] Med Univ South Carolina, Div Hematol Oncol, Dept Med, 173 Ashley Ave,BSB 645,MSC 508, Charleston, SC 29425 USA. [Pierce, Jason S.; Rembiesa, Barbara; Bielawski, Jacek] Med Univ South Carolina, Dept Biochem & Mol Biol, 173 Ashley Ave,BSB 645,MSC 508, Charleston, SC 29425 USA. [Lopes-Virella, Maria F.; Klein, Richard L.] Ralph H Johnson Dept Vet Affairs Med Ctr, Res Serv, Charleston, SC USA. [Klein, Richard L.] Med Univ South Carolina, Dept Med, Div Endocrinol Metab & Med Genet, 173 Ashley Ave,BSB 645,MSC 508, Charleston, SC 29425 USA. RP Hammad, SM (reprint author), Med Univ South Carolina, Dept Regenerat Med & Cell Biol, 173 Ashley Ave,BSB 645,MSC 508, Charleston, SC 29425 USA. EM hammadsm@musc.edu FU NIDDK Diabetic Complications Consortium [DK076169]; National Institutes of Health [P01-HL55782]; Department of Veterans Affairs Merit Review Program; Lipidomics Shared Resource, Hollings Cancer Center [P30 CA138313]; Lipidomics Core in the SC Lipidomics and Pathobiology COBRE, Department Biochemistry, MUSC [P20 RR017677]; National Institute of Diabetes, Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney diseases (NIDDK); National Institutes of Health; National Center for Research Resources through the GCRC program; Genentech, Inc.; NIDDK FX Financial support for this work was provided by the NIDDK Diabetic Complications Consortium (DiaComp, www.diacomp.org), Grant DK076169 (RLK). This work was also supported by the National Institutes of Health Grant P01-HL55782 (MLV). Additional funding was obtained from the Department of Veterans Affairs Merit Review Program (MLV and RLK). The contents of this manuscript do not represent the views of the Department of Veterans Affairs or the United States Government. Sphingolipid analyses were supported in part by the Lipidomics Shared Resource, Hollings Cancer Center (P30 CA138313), and the Lipidomics Core in the SC Lipidomics and Pathobiology COBRE, Department Biochemistry (P20 RR017677), MUSC. The DCCT/EDIC is sponsored through research contracts from the National Institute of Diabetes, Endocrinology and Metabolic Diseases of the National Institute of Diabetes and Digestive and Kidney diseases (NIDDK) and the National Institutes of Health. Additional support was provided by the National Center for Research Resources through the GCRC program and by Genentech, Inc. through a cooperative research and development agreement with the NIDDK. NR 33 TC 0 Z9 0 U1 1 U2 1 PU HUMANA PRESS INC PI TOTOWA PA 999 RIVERVIEW DRIVE SUITE 208, TOTOWA, NJ 07512 USA SN 1535-1084 EI 1559-1174 J9 NEUROMOL MED JI Neuromol. Med. PD MAR PY 2017 VL 19 IS 1 BP 46 EP 56 DI 10.1007/s12017-016-8423-9 PG 11 WC Neurosciences SC Neurosciences & Neurology GA EN5EX UT WOS:000396029500005 PM 27388466 ER PT J AU Gardner, RC Langa, KM Yaffe, K AF Gardner, Raquel C. Langa, Kenneth M. Yaffe, Kristine TI Subjective and objective cognitive function among older adults with a history of traumatic brain injury: A population-based cohort study SO PLOS MEDICINE LA English DT Article ID TBI IDENTIFICATION METHOD; ALZHEIMERS-DISEASE; HEAD-INJURY; RISK-FACTOR; DEMENTIA; RELIABILITY; ASSOCIATION; VETERANS; VALIDITY; HEALTH AB Background Traumatic brain injury (TBI) is extremely common across the lifespan and is an established risk factor for dementia. The cognitive profile of the large and growing population of older adults with prior TBI who do not have a diagnosis of dementia, however, has not been well described. Our aim was to describe the cognitive profile associated with prior TBI exposure among community-dwelling older adults without dementia-an understudied but potentially vulnerable population. Methods and findings In this population-based cohort study, we studied 984 community-dwelling older adults (age 51 y and older and their spouses) without dementia who had been randomly selected from respondents to the 2014 wave of the Health and Retirement Study to participate in a comprehensive TBI survey and who either reported no prior TBI (n = 737) or prior symptomatic TBI resulting in treatment in a hospital (n = 247). Mean time since first TBI was 38 +/- 19 y. Outcomes assessed included measures of global cognitive function, verbal episodic memory, semantic fluency, and calculation as well as a measure of subjective memory ("How would you rate your memory at the present time?"). We compared outcomes between the two TBI groups using regression models adjusting for demographics, medical comorbidities, and depression. Sensitivity analyses were performed stratified by TBI severity (no TBI, TBI without loss of consciousness [LOC], and TBI with LOC). Respondents with TBI were younger (mean age 64 +/- 10 y versus 68 +/- 11 y), were less likely to be female, and had higher prevalence of medical comorbidities and depression than respondents without TBI. Respondents with TBI did not perform significantly differently from respondents without TBI on any measure of objective cognitive function in either raw or adjusted models (fully adjusted: global cognitive function score 15.4 versus 15.2, p = 0.68; verbal episodic memory score 4.4 versus 4.3, p = 0.79; semantic fluency score 15.7 versus 14.0, p = 0.21; calculation impairment 22% versus 26%, risk ratio [RR] [95% CI] = 0.86 [0.67 +/- 1.11], p = 0.24). Sensitivity analyses stratified by TBI severity produced similar results. TBI was associated with significantly increased risk for subjective memory impairment in models adjusted for demographics and medical comorbidities (29% versus 24%; RR [95% CI]: 1.26 [1.02 +/- 1.57], p = 0.036). After further adjustment for active depression, however, risk for subjective memory impairment was no longer significant (RR [95% CI]: 1.18 [0.95 +/- 1.47], p = 0.13). Sensitivity analyses revealed that risk of subjective memory impairment was increased only among respondents with TBI with LOC and not among those with TBI without LOC. Furthermore, the risk of subjective memory impairment was significantly greater among those with TBI with LOC versus those without TBI even after adjustment for depression (RR [95% CI]: partially adjusted, 1.38 [1.09 +/- 1.74], p = 0.008; fully adjusted, 1.28 [1.01 +/- 1.61], p = 0.039). Conclusions In this population-based study of community-dwelling older adults without dementia, those with prior TBI with LOC were more likely to report subjective memory impairment compared to those without TBI even after adjustment for demographics, medical comorbidities, and active depression. Lack of greater objective cognitive impairment among those with versus without TBI may be due to poor sensitivity of the cognitive battery or survival bias, or may suggest that post-TBI cognitive impairment primarily affects executive function and processing speed, which were not rigorously assessed in this study. Our findings show that among community-dwelling non-demented older adults, history of TBI is common but may not preferentially impact cognitive domains of episodic memory, attention, working memory, verbal semantic fluency, or calculation. C1 [Gardner, Raquel C.; Yaffe, Kristine] Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94143 USA. [Gardner, Raquel C.; Yaffe, Kristine] San Francisco VA Med Ctr, San Francisco, CA 94121 USA. [Langa, Kenneth M.] Univ Michigan Hlth Syst, Div Gen Med, Ann Arbor, MI USA. [Langa, Kenneth M.] Vet Affairs Ctr Practice Management & Outcomes Re, Ann Arbor, MI USA. [Langa, Kenneth M.] Univ Michigan, Inst Social Res, Ann Arbor, MI USA. [Langa, Kenneth M.] Univ Michigan, Inst Gerontol, Ann Arbor, MI 48109 USA. [Langa, Kenneth M.] Univ Michigan, Inst Healthcare Policy & Innovat, Ann Arbor, MI 48109 USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. [Yaffe, Kristine] Univ Calif San Francisco, Dept Epidemiol & Biostat, San Francisco, CA 94143 USA. RP Gardner, RC (reprint author), Univ Calif San Francisco, Dept Neurol, Memory & Aging Ctr, San Francisco, CA 94143 USA.; Gardner, RC (reprint author), San Francisco VA Med Ctr, San Francisco, CA 94121 USA. EM raquel.gardner@ucsf.edu FU National Institute of Neurological Disorders and Stroke [K23 NS095755]; National Institute on Aging [K24 AG031155, U01 AG009740]; American Federation for Aging Research [K23 NS095755]; Weill Institute for Neurosciences; Departments of Defense and Veterans Affairs [W81XWH-12-1-0581, W81XWH-12-PHTBI-CENC] FX This work was supported by the National Institute of Neurological Disorders and Stroke (Beeson K23 NS095755 to RCG), National Institute on Aging (K24 AG031155 to KY); the American Federation for Aging Research (K23 NS095755 to RCG); the Weill Institute for Neurosciences (to RCG), and the Departments of Defense and Veterans Affairs (W81XWH-12-1-0581 and W81XWH-12-PHTBI-CENC to KY). The Health and Retirement Study is funded by the National Institute on Aging (U01 AG009740), and performed at the Institute for Social Research, University of Michigan. The funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript. NR 59 TC 0 Z9 0 U1 2 U2 2 PU PUBLIC LIBRARY SCIENCE PI SAN FRANCISCO PA 1160 BATTERY STREET, STE 100, SAN FRANCISCO, CA 94111 USA SN 1549-1676 J9 PLOS MED JI PLos Med. PD MAR PY 2017 VL 14 IS 3 AR e1002246 DI 10.1371/journal.pmed.1002246 PG 16 WC Medicine, General & Internal SC General & Internal Medicine GA EQ2NJ UT WOS:000397906100004 PM 28267747 ER PT J AU Fisher, M Nahum, M Howard, E Rowlands, A Brandrett, B Kermott, A Woolley, J Vinogradov, S AF Fisher, Melissa Nahum, Mor Howard, Elizabeth Rowlands, Abby Brandrett, Benjamin Kermott, Amy Woolley, Joshua Vinogradov, Sophia TI Supplementing Intensive Targeted Computerized Cognitive Training With Social Cognitive Exercises for People With Schizophrenia: An Interim Report SO PSYCHIATRIC REHABILITATION JOURNAL LA English DT Article DE cognitive remediation; emotion perception; motivation; neuroplasticity; social cognition ID NEUROCOGNITIVE DEFICITS; SCALE DEVELOPMENT; MENTAL-ILLNESS; VERBAL MEMORY; NEURAL BASIS; MOTIVATION; REMEDIATION; PSYCHOSIS; ANHEDONIA; PLEASURE AB Objective: Individuals with schizophrenia demonstrate cognitive, social cognitive, and motivational deficits that contribute to impairment in real-world functioning. In the current study, we investigated the effects of supplementing computerized neurocognitive training with social cognitive exercises, as compared with neurocognitive training alone. Method: In this ongoing, double-blind, randomized controlled trial of 111 participants with psychosis, we compare the effects of supplementing intensive targeted cognitive training with social cognitive training exercises (TCT + SCT) with the effects of targeted cognitive training alone (TCT-only). Participants were assessed on cognition, symptoms, functional capacity, and functional outcomes, as well as social cognition and measures related to reward processing. Results: Both treatment groups showed significant improvement in multiple cognitive domains and improvement in functional capacity. However, as predicted, TCT + SCT group participants showed significant improvement in prosody identification and reward processing relative to TCT-only participants. Conclusions and Implications for Practice: Our findings indicate that supplementing intensive computerized cognitive training with social cognitive exercises in people with psychosis confers greater benefits in prosody identification and reward processing relative to cognitive training alone, even though both approaches drive significant improvements in cognition and functional capacity. Impairments in both prosody identification and reward processing have been associated with greater negative symptoms and poorer functional outcomes in schizophrenia, raising the possibility that this form of treatment may lead to better long-term outcomes than traditional cognitive training approaches. Follow-up assessments will determine whether results are durable and generalize over time to improvements in symptoms and functioning. C1 [Fisher, Melissa] Univ Minnesota, Minneapolis, MN 55455 USA. [Nahum, Mor] Posit Sci Inc, San Francisco, CA USA. [Howard, Elizabeth; Rowlands, Abby; Brandrett, Benjamin; Kermott, Amy; Woolley, Joshua] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Howard, Elizabeth; Rowlands, Abby; Brandrett, Benjamin; Kermott, Amy; Woolley, Joshua] San Francisco VA Med Ctr, San Francisco, CA USA. [Vinogradov, Sophia] Univ Minnesota, Minneapolis, MN 55455 USA. [Vinogradov, Sophia] Univ Calif San Francisco, San Francisco, CA 94143 USA. RP Vinogradov, S (reprint author), Univ Minnesota Med Sch, Dept Psychiat, F282-2A West,2450 Riverside Ave, Minneapolis, MN 55454 USA. EM svinogra@umn.edu FU PI on an NIMH SBIR grant FX Fisher is a Co-Investigator on an NIMH SBIR grant to PositScience, and does not hold any financial interest in the company. Nahum is a consultant to PositScience, and the PI on an NIMH SBIR grant to PositScience. She does not hold any financial interest in the company. Vinogradov is a site PI on an NIMH SBIR grant to PositScience. She also consults on the cognitive training software developed by PositScience. Vinogradov does not hold a financial interest in the company. NR 73 TC 1 Z9 1 U1 0 U2 0 PU CENTER PSYCHIATRIC REHABILITATION PI BOSTON PA BOSTON UNIV, 930 COMMONWEALTH AVE, BOSTON, MA 02215 USA SN 1095-158X EI 1559-3126 J9 PSYCHIATR REHABIL J JI Psychiatr. Rehabil. J. PD MAR PY 2017 VL 40 IS 1 SI SI BP 21 EP 32 DI 10.1037/pg0000244 PG 12 WC Psychiatry; Rehabilitation SC Psychiatry; Rehabilitation GA EQ4BN UT WOS:000398017800004 PM 28368179 ER PT J AU Goldstein, LA Dinh, J Donalson, R Hebenstreit, CL Maguen, S AF Goldstein, Lizabeth A. Dinh, Julie Donalson, Rosemary Hebenstreit, Claire L. Maguen, Shira TI Impact of military trauma exposures on posttraumatic stress and depression in female veterans SO PSYCHIATRY RESEARCH LA English DT Article DE Combat; Military sexual trauma; PTSD; Veterans; Women ID MENTAL-HEALTH DIAGNOSES; WAR-I VETERANS; GENDER-DIFFERENCES; SEXUAL ASSAULT; GULF-WAR; AFGHANISTAN VETERANS; RESILIENCE FACTORS; OEF/OIF VETERANS; COMBAT EXPOSURE; WOMEN VETERANS AB Previous research has demonstrated the deleterious effects of traumatic military experiences on symptoms of posttraumatic stress disorder (PTSD) and depression in female veterans. However, more research is needed to identify the unique predictors of distressing psychological symptoms when both combat-related and sexual trauma are considered, particularly as women's combat exposure in the military increases. Female veterans who had attended at least one appointment at a large Veterans Health Administration medical center were invited to complete questionnaires about traumatic military exposures and psychiatric symptoms. A total of 403 veterans responded, with 383 respondents' data used in analyses. Multiple regression analyses were conducted with trauma exposure items entered simultaneously to determine their association with symptoms of (1) PTSD and (2) depression. Sexual assault had the strongest relationship with both posttraumatic and depressive symptoms. Sexual assault, sexual harassment, feeling in danger of being killed, and seeing others killed/injured were associated with symptoms of PTSD, but only sexual assault and sexual harassment were associated with symptoms of depression, even when accounting for several aspects of combat exposure. Improving assessment for trauma exposure and developing treatments personalized to type of trauma experienced are important clinical research priorities as female service members' roles in the military expand. C1 [Goldstein, Lizabeth A.; Dinh, Julie; Donalson, Rosemary; Hebenstreit, Claire L.; Maguen, Shira] San Francisco VA Med Ctr, 116P,4150 Clement St, San Francisco, CA 94121 USA. [Goldstein, Lizabeth A.; Hebenstreit, Claire L.; Maguen, Shira] Univ Calif San Francisco, Dept Psychiat, San Francisco, CA USA. RP Goldstein, LA (reprint author), San Francisco VA Med Ctr, 116P,4150 Clement St, San Francisco, CA 94121 USA. EM Lizabeth.Goldstein2@va.gov FU Veterans Health and Integration Program (VEEP) FX This research was supported by the Veterans Health and Integration Program (VEEP; PI: Dr. Maguen). Writing of this manuscript was supported by the Department of Veterans Affairs Office of Academic Affiliations, Advanced Fellowship Program in Mental Illness Research and Treatment (Dr. Goldstein) and Advanced Fellowship Program in Women's Health (Dr. Hebenstreit). The funding sources did not have any role in the conduct of the research or the preparation of this article. NR 38 TC 0 Z9 0 U1 5 U2 5 PU ELSEVIER IRELAND LTD PI CLARE PA ELSEVIER HOUSE, BROOKVALE PLAZA, EAST PARK SHANNON, CO, CLARE, 00000, IRELAND SN 0165-1781 J9 PSYCHIAT RES JI Psychiatry Res. PD MAR PY 2017 VL 249 BP 281 EP 285 DI 10.1016/j.psychres.2017.01.009 PG 5 WC Psychiatry SC Psychiatry GA EP4VI UT WOS:000397377600043 PM 28135599 ER PT J AU Yuan, F Xiong, GX Cohen, NA Cohen, AS AF Yuan, Feng Xiong, Guoxiang Cohen, Noam A. Cohen, Andakiva S. TI Optimized Protocol of Methanol Treatment for Immunofluorescent Staining in Fixed Brain Slices SO APPLIED IMMUNOHISTOCHEMISTRY & MOLECULAR MORPHOLOGY LA English DT Article DE brain ventricle; cilia; gamma-tubulin; beta-tubulin; immunohistochemistry ID IMMUNOHISTOCHEMISTRY; FIXATION; IMMUNOREACTIVITY; GUSTDUCIN; FORMALIN AB We optimized methanol treatment in paraformaldehyde- fixed slices for immunofluorescent staining of ependymal basal bodies in brain ventricles. As 100% methanol induced severe deformations to the slices (including rolling and folding over), we tried to decrease methanol concentration. We found that 33.3% to 75% methanol could result in ideal immunostaining of basal bodies without inducing obvious deformations. Instead of treating slices at -20 degrees C (without proper cryoprotection measurements) as suggested in previous studies, we carried out methanol treatment at room temperature. Our modified protocol can not only raise immunostaining efficiency in tissue slices, it may also prevent potential freezing damages to the samples. C1 [Yuan, Feng] Hosp Tongji Univ, Dept Orthoped, Shanghai, Peoples R China. [Xiong, Guoxiang; Cohen, Andakiva S.] Univ Penn, Perelman Sch Med, Div Neurol, Childrens Hosp Philadelphia, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Univ Penn, Perelman Sch Med, Philadelphia Vet Affairs Med Ctr, Philadelphia, PA 19104 USA. [Cohen, Noam A.] Univ Penn, Perelman Sch Med, Dept Otorhinolaryngol Head & Neck Surg, Philadelphia, PA 19104 USA. [Cohen, Andakiva S.] Univ Penn, Perelman Sch Med, Dept Pediat, Philadelphia, PA 19104 USA. RP Xiong, GX (reprint author), Childrens Hosp Philadelphia, Div Neurol, Philadelphia, PA 19104 USA. EM xiong@email.chop.edu FU NICHD NIH HHS [R37 HD059288]; NINDS NIH HHS [R01 NS069629] NR 13 TC 1 Z9 1 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 1541-2016 EI 1533-4058 J9 APPL IMMUNOHISTO M M JI Appl. Immunohistochem. PD MAR PY 2017 VL 25 IS 3 BP 221 EP 224 PG 4 WC Anatomy & Morphology; Medical Laboratory Technology; Pathology SC Anatomy & Morphology; Medical Laboratory Technology; Pathology GA EN3VR UT WOS:000395936500013 PM 26509907 ER PT J AU Campbell, SB Renshaw, KD Kashdan, TB Curby, TW Carter, SP AF Campbell, Sarah B. Renshaw, Keith D. Kashdan, Todd B. Curby, Timothy W. Carter, Sarah P. TI A Daily Diary Study of Posttraumatic Stress Symptoms and Romantic Partner Accommodation SO BEHAVIOR THERAPY LA English DT Article DE PTSD; romantic relationships; accommodation; maintenance ID SOCIAL SUPPORT; DISORDER; PTSD; VETERANS; EXPOSURE; OUTCOMES; THERAPY; COMBAT; SCALE; COMMUNICATION AB Little is known about the role of romantic partner symptom accommodation in PTSD symptom maintenance. To explore the bidirectional associations of posttraumatic stress disorder (PTSD) symptoms and romantic partner symptom accommodation over time, military servicemen (n = 64) with symptoms of PTSD and their cohabiting heterosexual civilian romantic partners (n = 64) completed a 2-week daily diary study. Cross-lagged, autoregressive models assessed the stability of men's PTSD symptoms and partners' accommodation, as well as the prospective associations of earlier PTSD symptoms with later accommodation and vice versa. Analyses used Bayesian estimation to provide point estimates (b) and Credible Intervals (CIs). In all models, PTSD symptoms (total and individual clusters) were highly stable (b = 0.91; CI: 0.88-0.95), and accommodation was moderately stable (b = 0.48; CI: 0.40-0.54). In all models, earlier PTSD symptoms (total and clusters) were significantly, positively associated with later accommodation (b = 0.04; CI: 0.02-0.07). In contrast, earlier accommodation was significantly associated only with later situational avoidance (b = 0.02; CI: 0.00-0.07). Thus, PTSD symptoms may lead to subsequent accommodating behaviors in romantic partners, but partner accommodation seems to contribute only to survivors' future situational avoidance symptoms. The findings reinforce the notion that PTSD symptoms have an impact on relationship behaviors, and that accommodation from partners may sustain avoidant behaviors in particular. Clinicians should attend to romantic partners' accommodating behaviors when working with survivors. C1 [Campbell, Sarah B.; Renshaw, Keith D.; Kashdan, Todd B.; Curby, Timothy W.; Carter, Sarah P.] George Mason Univ, Fairfax, VA 22030 USA. RP Campbell, SB (reprint author), VA Puget Sound Hlth Care Syst, Seattle Div, 1660 S Columbian Way,116MHC, Seattle, WA 98108 USA. EM scampbep@gmu.edu FU National Institute of Mental Health under Ruth L. Kirschstein National Research Service Award [1F31MH098581-01A1]; International Society of Traumatic Stress Studies; American Psychological Foundation FX This research was supported in part by grants from the National Institute of Mental Health under Ruth L. Kirschstein National Research Service Award number 1F31MH098581-01A1, the International Society of Traumatic Stress Studies, and the American Psychological Foundation awarded to Sarah B. Campbell, M.A. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health. NR 60 TC 0 Z9 0 U1 1 U2 1 PU ASSOC ADV BEHAVIOR THERAPY PI NEW YORK PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA SN 0005-7894 EI 1878-1888 J9 BEHAV THER JI Behav. Therapy PD MAR PY 2017 VL 48 IS 2 BP 222 EP 234 PG 13 WC Psychology, Clinical SC Psychology GA EO6KA UT WOS:000396799700008 PM 28270332 ER PT J AU Knobloch-Fedders, LM Caska-Wallace, C Smith, TW Renshaw, K AF Knobloch-Fedders, Lynne M. Caska-Wallace, Catherine Smith, Timothy W. Renshaw, Keith TI Battling on the Home Front: Posttraumatic Stress Disorder and Conflict Behavior Among Military Couples SO BEHAVIOR THERAPY LA English DT Article DE couples; PTSD; military; interpersonal behavior; Structural Analysis of Social Behavior ID ADMINISTERED PTSD SCALE; RELATIONSHIP QUALITY; COMBAT VETERANS; STRUCTURAL-ANALYSIS; INTIMATE PARTNERS; DEPRESSION; SYMPTOMS; DISTRESS; IMPACT; QUESTIONNAIRE AB This study evaluated interpersonal behavior differences among male military service members with and without PTSD and their female partners. Couples (N= 64) completed a 17-minute videotaped conflict discussion, and their interaction behavior was coded using the circumplex-based Structural Analysis of Social Behavior model (SASB; Benjamin, 1979, 1987, 2000). Within couples, the behavior of partners was very similar. Compared to military couples without PTSD, couples with PTSD displayed more interpersonal hostility and control. Couples with PTSD also exhibited more sulking, blaming, and controlling behavior, and less affirming and connecting behavior, than couples without PTSD. Results advance our understanding of the relational impacts of PTSD on military service members and their partners, and underscore the value of couple-based interventions for PTSD in the context of relationship distress. C1 [Knobloch-Fedders, Lynne M.] Northwestern Univ, Family Inst, Evanston, IL 60208 USA. [Caska-Wallace, Catherine] Univ Washington, VA Puget Sound Hlth Care Syst, Mental Hlth Serv, Seattle Div, Seattle, WA 98195 USA. [Smith, Timothy W.] Univ Utah, Salt Lake City, UT 84112 USA. [Renshaw, Keith] George Mason Univ, Fairfax, VA 22030 USA. RP Knobloch-Fedders, LM (reprint author), Northwestern Univ, Family Inst, Bette D Harris Ctr, 618 Lib Pl, Evanston, IL USA. EM l-knobloch@northwestern.edu FU American Psychological Association's Division 19 (Society for Military Psychology) Member / Affiliate Member Research Grant Award; National Institute of Mental Health grant [1F31MH091915-01A1] FX This study was funded in part by the 2014 American Psychological Association's Division 19 (Society for Military Psychology) Member / Affiliate Member Research Grant Award, and by National Institute of Mental Health grant 1F31MH091915-01A1. NR 65 TC 0 Z9 0 U1 1 U2 1 PU ASSOC ADV BEHAVIOR THERAPY PI NEW YORK PA 305 7TH AVE #16A, NEW YORK, NY 10001-6008 USA SN 0005-7894 EI 1878-1888 J9 BEHAV THER JI Behav. Therapy PD MAR PY 2017 VL 48 IS 2 BP 247 EP 261 PG 15 WC Psychology, Clinical SC Psychology GA EO6KA UT WOS:000396799700010 PM 28270334 ER PT J AU Askenazi, DJ Heung, M Connor, MJ Basu, RK Cerda, J Doi, K Koyner, JL Bihorac, A Golestaneh, L Vijayan, A Okusa, MD Faubel, S AF Askenazi, D. J. Heung, Michael Connor, Michael J., Jr. Basu, Rajit K. Cerda, Jorge Doi, Kent Koyner, Jay L. Bihorac, Azra Golestaneh, Ladan Vijayan, Anitha Okusa, Mark D. Faubel, Sarah CA Amer Soc Nephrology Acute Kidney Injury Adv TI Optimal Role of the Nephrologist in the Intensive Care Unit SO BLOOD PURIFICATION LA English DT Article DE Critical care nephrology; Quality Improvement; Acute kidney injury; Education; Renal replacement therapy ID ACUTE KIDNEY INJURY; RENAL-REPLACEMENT THERAPY; CRITICALLY-ILL PATIENTS; CYCLE ARREST BIOMARKERS; FUROSEMIDE STRESS TEST; DIALYSIS FACILITY; MEDICAL DIRECTOR; MORTALITY; AKI; SURGERY AB As advances in Critical Care Medicine continue, critically ill patients are surviving despite the severity of their illness. The incidence of acute kidney injury (AKI) has increased, and its impact on clinical outcomes as well as medical expenditures has been established. The role, indications and technological advancements of renal replacement therapy (RRT) have evolved, allowing more effective therapies with less complications. With these changes, Critical Care Nephrology has become an established specialty, and ongoing collaborations between critical care physicians and nephrologist have improved education of multi-disciplinary team members and patient care in the ICU. Multidisciplinary programs to support these changes have been stablished in some hospitals to maximize the delivery of care, while other programs have continue to struggle in their ability to acquire the necessary resources to maximize outcomes, educate their staff, and develop quality initiatives to evaluate and drive improvements. Clearly, the role of the nephrologist in the ICU has evolved, and varies widely among institutions. This special article will provide insights that will hopefully optimize the role of the nephrologist as the leader of the acute care nephrology program, as clinician for critically ill patients, and as teacher for all members of the health care team. (C) 2016 S. Karger AG, Basel C1 [Askenazi, D. J.] Univ Alabama Birmingham, Dept Pediat, Div Pediat Nephrol, ACC 516,1600 7th Ave South, Birmingham, AL 35233 USA. [Heung, Michael] Univ Michigan, Dept Med, Div Nephrol, Ann Arbor, MI 48109 USA. [Connor, Michael J., Jr.] Emory Univ, Dept Med, Div Renal Med, Atlanta, GA 30322 USA. [Basu, Rajit K.] Cincinnati Childrens Hosp Ctr, Ctr Acute Care Nephrol, Cincinnati, OH USA. [Cerda, Jorge] Albany Med Coll, Dept Med, Albany, NY 12208 USA. [Koyner, Jay L.] Univ Chicago, Dept Med, Nephrol Sect, 5841 S Maryland Ave, Chicago, IL 60637 USA. [Bihorac, Azra] Univ Florida, Dept Anesthesiol, Gainesville, FL USA. [Golestaneh, Ladan] Albert Einstein Coll Med, Dept Clin Med, Div Nephrol, Bronx, NY 10467 USA. [Vijayan, Anitha] Washington Univ, Div Nephrol, St Louis, MO USA. [Okusa, Mark D.] Univ Virginia Hlth Syst, Div Nephrol, Charlottesville, VA USA. [Faubel, Sarah] Univ Colorado, Dept Med, Denver, CO USA. [Faubel, Sarah] Denver VA Med Ctr, Denver, CO USA. [Doi, Kent] Tokyo Univ Hosp, Dept Emergency & Crit Care Med, Bunkyo Ku, Tokyo, Japan. RP Askenazi, DJ (reprint author), Univ Alabama Birmingham, Dept Pediat, Div Pediat Nephrol, ACC 516,1600 7th Ave South, Birmingham, AL 35233 USA. EM daskenazi@peds.uab.edu OI Bihorac, Azra/0000-0002-5745-2863 FU NCATS NIH HHS [UL1 TR001417]; NIDDK NIH HHS [R01 DK103608]; NIGMS NIH HHS [P50 GM111152, R01 GM110240] NR 55 TC 0 Z9 0 U1 0 U2 0 PU KARGER PI BASEL PA ALLSCHWILERSTRASSE 10, CH-4009 BASEL, SWITZERLAND SN 0253-5068 EI 1421-9735 J9 BLOOD PURIFICAT JI Blood Purif. PD MAR PY 2017 VL 43 IS 1-3 BP 68 EP 77 DI 10.1159/000452317 PG 10 WC Hematology; Urology & Nephrology SC Hematology; Urology & Nephrology GA EN4AA UT WOS:000395948100009 PM 27923227 ER PT J AU Garrido, MM Prigerson, HG Neupane, S Penrod, JD Johnson, CE Boockvar, KS AF Garrido, Melissa M. Prigerson, Holly G. Neupane, Suvam Penrod, Joan D. Johnson, Christopher E. Boockvar, Kenneth S. TI Mental Illness and Mental Healthcare Receipt among Hospitalized Veterans with Serious Physical Illnesses SO JOURNAL OF PALLIATIVE MEDICINE LA English DT Article DE depression; hospitalized; mental health; veterans ID OBSESSIVE-COMPULSIVE DISORDER; POSTTRAUMATIC-STRESS-DISORDER; ADMINISTRATIVE DATA; PHARMACOLOGICAL-TREATMENT; PSYCHIATRIC COMORBIDITY; ANXIETY DISORDERS; PALLIATIVE CARE; ADVANCED CANCER; HEART-FAILURE; DEPRESSION AB Background: Psychosocial distress among patients with limited life expectancy influences treatment decisions, treatment adherence, and physical health. Veterans may be at elevated risk of psychosocial distress at the end of life, and understanding their mental healthcare needs may help identify hospitalized patients to whom psychiatric services should be targeted. Objective: To examine mental illness prevalence and mental health treatment rates among a national sample of hospitalized veterans with serious physical illnesses. Design, Subjects, and Measurements: This was a retrospective study of 11,286 veterans hospitalized in a Veterans Health Administration acute care facility in fiscal year 2011 with diagnoses of advanced cancer, congestive heart failure, chronic obstructive pulmonary disease, and/or advanced HIV/AIDS. Prevalent and incident mental illness diagnoses during and before hospitalization and rates of psychotherapy and psychotropic use among patients with incident depression and anxiety were measured. Results: At least one-quarter of the patients in our sample had a mental illness or substance use disorder. The most common diagnoses at hospitalization were depression (11.4%), followed by alcohol abuse or dependence (5.5%), and post-traumatic stress disorder (4.9%). Of the 831 patients with incident past-year depression and 258 with incident past-year anxiety, nearly two-thirds received at least some psychotherapy or guideline-concordant medication within 90 days of diagnosis. Of 191 patients with incident depression and 47 with incident anxiety at time of hospitalization, fewer than half received mental healthcare before discharge. Conclusions: Many veterans hospitalized with serious physical illnesses have comorbid mental illnesses and may benefit from depression and anxiety treatment. C1 [Garrido, Melissa M.; Penrod, Joan D.; Boockvar, Kenneth S.] James J Peters VA Med Ctr, GRECC, Bronx, NY USA. [Garrido, Melissa M.; Neupane, Suvam; Penrod, Joan D.; Boockvar, Kenneth S.] Icahn Sch Med Mt Sinai, Brookdale Dept Geriatr & Palliat Med, New York, NY 10029 USA. [Prigerson, Holly G.] Weill Cornell Med Coll, Cornell Ctr Res End Life Care, New York, NY USA. [Johnson, Christopher E.] Univ Louisville, Dept Hlth Management & Syst Sci, Louisville, KY 40292 USA. [Boockvar, Kenneth S.] Jewish Home Lifecare, New York, NY USA. RP Garrido, MM (reprint author), James J Peters VA Med Ctr, GRECC 4A-17,130 W Kingsbridge Rd, Bronx, NY 10468 USA. EM melissa.garrido@mssm.edu FU VA HSRD [CDA 11-201/CDP 12-255]; NIH [CA197730, MH095378, MD007652]; American Federation for Aging Research FX Dr. M.M.G. is supported by a career development award from VA HSR&D (CDA 11-201/CDP 12-255). Dr. H.G.P. is supported by the following NIH Grant Nos.: CA197730, MH095378, and MD007652. Mr. S.N. is supported by the American Federation for Aging Research. NR 35 TC 0 Z9 0 U1 0 U2 0 PU MARY ANN LIEBERT, INC PI NEW ROCHELLE PA 140 HUGUENOT STREET, 3RD FL, NEW ROCHELLE, NY 10801 USA SN 1096-6218 EI 1557-7740 J9 J PALLIAT MED JI J. Palliat. Med. PD MAR PY 2017 VL 30 IS 3 BP 247 EP 252 DI 10.1089/jpm.2016.0261 PG 6 WC Health Care Sciences & Services SC Health Care Sciences & Services GA EM6FC UT WOS:000395407200010 ER PT J AU Shatzel, JJ Taylor, JA AF Shatzel, Joseph J. Taylor, Jason A. TI Syndromes of Thrombotic Microangiopathy SO MEDICAL CLINICS OF NORTH AMERICA LA English DT Article DE Thrombotic thrombocytopenic purpura (TTP); Hemolytic uremic syndrome (HUS); Microangiopathic hemolytic anemia (MAHA); Atypical hemolytic uremic syndrome (aHUS); Pregnancy induced microangiopathic hemolytic anemia; Transplant induced microangiopathic hemolytic anemia ID HEMOLYTIC-UREMIC SYNDROME; VON-WILLEBRAND-FACTOR; BONE-MARROW-TRANSPLANTATION; FACTOR-CLEAVING PROTEASE; THERAPEUTIC PLASMA-EXCHANGE; STEM-CELL TRANSPLANTATION; ACUTE FATTY LIVER; SINGLE-CENTER EXPERIENCE; SERUM LACTATE-DEHYDROGENASE; THROMBOCYTOPENIC PURPURA AB Thrombotic thrombocytopenia purpura (TTP) and the hemolytic uremic syndrome (HUS) are rare thrombotic microangiopathies that can be rapidly fatal. Although the acquired versions of TTP and HUS are generally highest on this broad differential, multiple rarer entities can produce a clinical picture similar to TTP/HUS, including microangiopathic hemolysis, renal failure, and neurologic compromise. More recent analysis has discovered a host of genetic factors that can produce microangiopathic hemolytic syndromes. This article discusses the current understanding of thrombotic microangiopathy and outlines the pathophysiology and causative agents associated with each distinct syndrome as well as the most accepted treatments. C1 [Shatzel, Joseph J.] Oregon Hlth & Sci Univ, Knight Canc Inst, Div Hematol & Med Oncol, 3181 Southwest Sam Jackson Pk Rd, Portland, OR 97239 USA. [Taylor, Jason A.] Oregon Hlth & Sci Univ, Portland VA Med Ctr, Hemophilia Ctr, Knight Canc Inst,Div Hematol & Med Oncol, 3181 Southwest Sam Jackson Pk Road,L586, Portland, OR 97239 USA. RP Taylor, JA (reprint author), Oregon Hlth & Sci Univ, Portland VA Med Ctr, Hemophilia Ctr, Knight Canc Inst,Div Hematol & Med Oncol, 3181 Southwest Sam Jackson Pk Road,L586, Portland, OR 97239 USA. EM taylojas@ohsu.edu NR 183 TC 0 Z9 0 U1 1 U2 1 PU W B SAUNDERS CO-ELSEVIER INC PI PHILADELPHIA PA 1600 JOHN F KENNEDY BOULEVARD, STE 1800, PHILADELPHIA, PA 19103-2899 USA SN 0025-7125 EI 1557-9859 J9 MED CLIN N AM JI Med. Clin. N. Am. PD MAR PY 2017 VL 101 IS 2 BP 395 EP + DI 10.1016/j.mcna.2016.09.010 PG 22 WC Medicine, General & Internal SC General & Internal Medicine GA EN7KD UT WOS:000396180800011 ER PT J AU Church, LWP Chopra, A Judson, MA AF Church, L. W. Preston Chopra, Amit Judson, Marc A. TI Paradoxical Reactions and the Immune Reconstitution Inflammatory Syndrome SO MICROBIOLOGY SPECTRUM LA English DT Article ID ACTIVE ANTIRETROVIRAL THERAPY; HUMAN-IMMUNODEFICIENCY-VIRUS; MYCOBACTERIUM-AVIUM COMPLEX; HIV-INFECTED PATIENTS; KIDNEY-TRANSPLANT RECIPIENT; OF-THE-LITERATURE; PULMONARY SARCOIDOSIS; ACQUIRED-IMMUNODEFICIENCY; MILIARY TUBERCULOSIS; INTERFERON-GAMMA AB In HIV-infected individuals, paradoxical reactions after the initiation of antiretroviral therapy (ART) are associated with a variety of underlying infections and have been called the immune reconstitution inflammatory syndrome (IRIS). In cases of IRIS associated with tuberculosis (TB), two distinct patterns of disease are recognized: (i) the progression of subclinical TB to clinical disease after the initiation of ART, referred to as unmasking, and (ii) the progression or appearance of new clinical and/or radiographic disease in patients with previously recognized TB after the initiation of ART, the classic or "paradoxical" TB-IRIS. IRIS can potentially occur in all granulomatous diseases, not just infectious ones. All granulomatous diseases are thought to result from interplay of inflammatory cells and mediators. One of the inflammatory cells thought to be integral to the development of the granuloma is the CD4 T lymphocyte. Therefore, HIV-infected patients with noninfectious granulomatous diseases such as sarcoidosis may also develop IRIS reactions. Here, we describe IRIS in HIV-infected patients with TB and sarcoidosis and review the basic clinical and immunological aspects of these phenomena. C1 [Church, L. W. Preston] Ralph H Johnson VA Med Ctr, Charleston, SC 29425 USA. [Chopra, Amit; Judson, Marc A.] Albany Med Coll, Div Pulm & Crit Care Med, Albany, NY 12208 USA. RP Judson, MA (reprint author), Albany Med Coll, Div Pulm & Crit Care Med, Albany, NY 12208 USA. EM judsonm@mail.amc.edu NR 113 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA EI 2165-0497 J9 MICROBIOL SPECTR JI Microbiol. Spectr. PD MAR PY 2017 VL 5 IS 2 AR UNSP TNMI7-0033-2016 DI 10.1128/microbiolspec.TNMI7-0033-2016 PG 15 WC Microbiology SC Microbiology GA EP3IE UT WOS:000397275200004 ER PT J AU Bauman, WA Krassioukov, A Biering-Sorensen, F AF Bauman, W. A. Krassioukov, A. Biering-Sorensen, F. TI Version 2.0 of the international spinal cord injury endocrinology and metabolic function basic data set SO SPINAL CORD LA English DT Letter C1 [Bauman, W. A.] James J Peters Vet Affairs Med Ctr, Natl Ctr Med Consequences Spinal Cord Injury, Bronx, NY 10468 USA. [Krassioukov, A.] Univ British Columbia, Int Collaborat Repair Discoveries ICORD, Div Phys Med & Rehabil,Auton Res Unit,Dept Med, Spinal Cord Program,GF Strong Rehabil Ctr, Vancouver, BC, Canada. [Krassioukov, A.] Univ Western Ontario, London, ON, Canada. [Biering-Sorensen, F.] Univ Copenhagen, Clin Spinal Cord Injuries, Rigshosp, Copenhagen, Denmark. RP Bauman, WA (reprint author), James J Peters Vet Affairs Med Ctr, Natl Ctr Med Consequences Spinal Cord Injury, Bronx, NY 10468 USA. EM William.Bauman@va.gov NR 4 TC 0 Z9 0 U1 0 U2 0 PU NATURE PUBLISHING GROUP PI LONDON PA MACMILLAN BUILDING, 4 CRINAN ST, LONDON N1 9XW, ENGLAND SN 1362-4393 EI 1476-5624 J9 SPINAL CORD JI Spinal Cord PD MAR PY 2017 VL 55 IS 3 BP 327 EP 328 DI 10.1038/sc.2016.105 PG 2 WC Clinical Neurology; Rehabilitation SC Neurosciences & Neurology; Rehabilitation GA EN3RA UT WOS:000395924400020 PM 27401128 ER PT J AU Johnson, TJ Winger, DG Hickey, RW Switzer, GE Miller, E Nguyen, MB Saladino, RA Hausmann, LRM AF Johnson, Tiffani J. Winger, Daniel G. Hickey, Robert W. Switzer, Galen E. Miller, Elizabeth Nguyen, Margaret B. Saladino, Richard A. Hausmann, Leslie R. M. TI Comparison of Physician Implicit Racial Bias Toward Adults Versus Children SO ACADEMIC PEDIATRICS LA English DT Article DE implicit bias; pediatric health care disparities; physician implicit attitudes; racial bias; racial disparities ID ASSOCIATION TEST; ACHIEVEMENT GAP; EXPLICIT ATTITUDES; AFRICAN-AMERICANS; UNCONSCIOUS RACE; MEDICAL-STUDENTS; DECISION-MAKING; HEALTH-CARE; BLACK; STEREOTYPES AB BACKGROUND AND OBJECTIVES: The general population and most physicians have implicit racial bias against black adults. Pediatricians also have implicit bias against black adults, albeit less than other specialties. There is no published research on the implicit racial attitudes of pediatricians or other physicians toward children. Our objectives were to compare implicit racial bias toward adults versus children among resident physicians working in a pediatric emergency department, and to assess whether bias varied by specialty (pediatrics, emergency medicine, or other), gender, race, age, and year of training. METHODS: We measured implicit racial bias of residents before a pediatric emergency department shift using the Adult and Child Race Implicit Association Tests (IATs). Generalized linear models compared Adult and Child IAT scores and determined the association of participant demographics with Adult and Child IAT scores. RESULTS: Among 91 residents, we found moderate pro-white/anti-black bias on both the Adult (mean = 0.49, standard deviation = 0.34) and Child Race IAT (mean = 0.55, standard deviation = 0.37). There was no significant difference between Adult and Child Race IAT scores (difference = 0.06, P = .15). Implicit bias was not associated with resident demographic characteristics, including specialty. CONCLUSIONS: This is the first study demonstrating that resident physicians have implicit racial bias against black children, similar to levels of bias against black adults. Bias in our study did not vary by resident demographic characteristics, including specialty, suggesting that pediatric residents are as susceptible as other physicians to implicit bias. Future studies are needed to explore how physicians' implicit attitudes toward parents and children may impact inequities in pediatric health care. C1 [Johnson, Tiffani J.; Hickey, Robert W.; Nguyen, Margaret B.; Saladino, Richard A.] Univ Pittsburgh, Div Pediat Emergency Med, Pittsburgh, PA USA. [Miller, Elizabeth] Univ Pittsburgh, Div Adolescent & Young Adult Med, Pittsburgh, PA USA. [Winger, Daniel G.] Univ Pittsburgh, Childrens Hosp Pittsburgh, Clin & Translat Sci Inst, Pittsburgh, PA USA. [Switzer, Galen E.; Hausmann, Leslie R. M.] Univ Pittsburgh, Div Gen Internal Med, Pittsburgh, PA USA. [Switzer, Galen E.; Hausmann, Leslie R. M.] Vet Affairs Pittsburgh Healthcare Syst, Ctr Hlth Equity Res & Promot, Pittsburgh, PA USA. RP Johnson, TJ (reprint author), Childrens Hosp Philadelphia, PolicyLab, 3535 Market St,Room 1425, Philadelphia, PA 19104 USA. EM johnsont6@email.chop.edu FU RWJF [AMFDP 72430]; National Institutes of Health [UL 1-TR-000005]; [T32 HS 017587]; [K12 HL109009] FX We thank Dennis Durbin, MD, MSCE, Children's Hospital of Philadelphia, for his critical review of the manuscript. Supported in part by grants T32 HS 017587, K12 HL109009, and RWJF AMFDP 72430 (to TJJ); and by the National Institutes of Health through grant UL 1-TR-000005 to the University of Pittsburgh Clinical and Translational Science Institute. The sponsoring agencies had no role in the design and conduct of the study; in the collection, management, analysis, and interpretation of the data; or in the preparation, review, or approval of the manuscript. The content of this article is solely the responsibility of the authors and does not necessarily represent the official views of the sponsoring agency. NR 41 TC 0 Z9 0 U1 5 U2 5 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1876-2859 EI 1876-2867 J9 ACAD PEDIATR JI Acad. Pediatr. PD MAR PY 2017 VL 17 IS 2 BP 120 EP 126 PG 7 WC Pediatrics SC Pediatrics GA EM9GB UT WOS:000395618700004 PM 27620844 ER PT J AU Byers, AL Lai, AX Bruce, ML AF Byers, Amy L. Lai, Amy X. Bruce, Martha L. TI Timing of Mental Health Services Use: Reducing the Risk of Late-life Suicidal Behavior SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry (AAGP) on Integrated Geriatric Mental Health Care Through Innovation CY MAR 24-27, 2017 CL Dallas, TX SP Amer Assoc Geriatr Psychiat C1 [Byers, Amy L.] Univ Calif San Francisco, San Francisco, CA 94143 USA. [Byers, Amy L.; Lai, Amy X.] San Francisco VA Med Ctr, San Francisco, CA USA. [Bruce, Martha L.] Dartmouth Coll, Geisel Sch Med, Hanover, NH 03755 USA. FU NIH [MD007019] FX This work is supported by a NIH R01 grant (MD007019) that is administered by the Northern California Institute for Research and Education through resources from the San Francisco Veterans Affairs Medical Center. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2017 VL 25 IS 3 SU S MA NR 21 BP S135 EP S136 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA EP1IG UT WOS:000397138000133 ER PT J AU Gebara, MA DiNapoli, E Kho, T Karp, J Gildengers, A Butters, MA Albert, S Reynoldsiii, CF AF Gebara, Marie Anne DiNapoli, Elizabeth Kho, Terry Karp, Jordan Gildengers, Ariel Butters, Meryl A. Albert, Stven Reynoldsiii, Charles F. TI Depression Prevention in Older Adults: Changes in Mood and Sleep SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry (AAGP) on Integrated Geriatric Mental Health Care Through Innovation CY MAR 24-27, 2017 CL Dallas, TX SP Amer Assoc Geriatr Psychiat C1 [Gebara, Marie Anne; DiNapoli, Elizabeth] VA Pittsburgh Healthcare Syst, Mental Illness Res Educ & Clin Ctr, Pittsburgh, PA USA. [Gebara, Marie Anne; Kho, Terry; Karp, Jordan; Gildengers, Ariel; Butters, Meryl A.; Albert, Stven; Reynoldsiii, Charles F.] Univ Pittsburgh, Sch Med, Pittsburgh, PA USA. NR 0 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2017 VL 25 IS 3 SU S MA EI 3 BP S64 EP S65 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA EP1IG UT WOS:000397138000061 ER PT J AU Kasckow, J Reynolds, CF Karp, J Chickering, S Morse, J AF Kasckow, John Reynolds, Charles F., III Karp, Jordan Chickering, Sunita Morse, Jennifer TI Problem Solving Therapy Improves Social Problem Solving Skills in Older Adults with Depression and Low Back Pain SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry (AAGP) on Integrated Geriatric Mental Health Care Through Innovation CY MAR 24-27, 2017 CL Dallas, TX SP Amer Assoc Geriatr Psychiat C1 [Kasckow, John; Reynolds, Charles F., III; Karp, Jordan; Chickering, Sunita] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Kasckow, John; Karp, Jordan] VA Pittsburgh Hlth Care Syst, Pittsburgh, PA USA. [Morse, Jennifer] Chatham Univ, Pittsburgh, PA USA. FU [AG033575]; [MH101371] FX This research was funded by: AG033575 and MH101371. NR 0 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2017 VL 25 IS 3 SU S MA NR 2 BP S116 EP S117 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA EP1IG UT WOS:000397138000114 ER PT J AU Kasckow, J Gebara, MA Mulsant, BH Lenze, E AF Kasckow, John Gebara, Marie Anne Mulsant, Benoit H. Lenze, Eric TI ADVANCES IN PHARMACOTHERAPY OF LATE-LIFE DEPRESSION SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry (AAGP) on Integrated Geriatric Mental Health Care Through Innovation CY MAR 24-27, 2017 CL Dallas, TX SP Amer Assoc Geriatr Psychiat C1 [Kasckow, John] Univ Pittsburgh, Med Ctr, Pittsburgh, PA USA. [Gebara, Marie Anne] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. [Mulsant, Benoit H.; Lenze, Eric] Univ Toronto, Toronto, ON, Canada. FU Bristol-Myers Squibb; Eli Lilli; NIH; CAMH Foundation; Lundbeck; Takeda FX Bristol-Myers Squibb-Medications for a NIH-funded clinical trial; Eli Lilli-Medications for a NIH-funded clinical trial; Pfizer-Medications for a NIH-funded clinical trial; Capital Solution Design LLC-Software used in study funded by CAMH Foundation; Lundbeck-co-funding for IISR; Takeda-co-funding for IISR NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2017 VL 25 IS 3 SU S MA 107 BP S7 EP S7 PG 1 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA EP1IG UT WOS:000397138000009 ER PT J AU Radue, RM Boyle, LL Welch, L Eastman, A Schroeder, R Hermann, C Barczi, S AF Radue, Rebecca M. Boyle, Lisa L. Welch, Lauren Eastman, Alexis Schroeder, Rebecca Hermann, Carol Barczi, Steve TI Interprofessional Learners' Performance in a Late Life Depression Simulated-Patient Assessment: Preliminary Results From the GEAR-UP Project SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry (AAGP) on Integrated Geriatric Mental Health Care Through Innovation CY MAR 24-27, 2017 CL Dallas, TX SP Amer Assoc Geriatr Psychiat C1 [Radue, Rebecca M.; Boyle, Lisa L.; Barczi, Steve] Univ Wisconsin, Madison, WI USA. [Boyle, Lisa L.; Welch, Lauren; Eastman, Alexis; Schroeder, Rebecca; Hermann, Carol; Barczi, Steve] William S Middleton Mem Vet Adm Med Ctr, Madison, WI USA. FU William S. Middleton Veterans Administration (VA) Geriatric Research, Education and Clinical Center (GRECC) & University ofWisconsin (UW) Department of Medicine, Madison, WI; Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) [U1QHP28712] FX This research was funded by: William S. Middleton Veterans Administration (VA) Geriatric Research, Education and Clinical Center (GRECC) & University ofWisconsin (UW) Department of Medicine, Madison, WI-This project was supported by the Health Resources and Services Administration (HRSA) of the U.S. Department of Health and Human Services (HHS) under grant U1QHP28712 (Geriatrics Workforce Enhancement Program). The information or content and conclusions contained herein are those of the authors and should not be construed as the official position or policy of, nor should any endorsements be inferred by HRSA, HHS or the U.S. Government. NR 0 TC 0 Z9 0 U1 0 U2 0 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2017 VL 25 IS 3 SU S MA EI 56 BP S113 EP S115 PG 3 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA EP1IG UT WOS:000397138000111 ER PT J AU Renn, BN Ali, AA Thielke, S Catic, A Martini, SR Mitchell, BG Kunik, M AF Renn, Brenna N. Ali, Ali Asghar Thielke, Stephen Catic, Angela Martini, Sharyl R. Mitchell, Brian G. Kunik, Mark TI A Review of Cholinesterase Inhibitor Discontinuation in Alzheimer's Disease: Should Clinicians Ever Stop Treatment? SO AMERICAN JOURNAL OF GERIATRIC PSYCHIATRY LA English DT Meeting Abstract CT Annual Meeting of the American-Association-for-Geriatric-Psychiatry (AAGP) on Integrated Geriatric Mental Health Care Through Innovation CY MAR 24-27, 2017 CL Dallas, TX SP Amer Assoc Geriatr Psychiat C1 [Renn, Brenna N.; Thielke, Stephen] Univ Washington, Seattle, WA 98195 USA. [Ali, Ali Asghar; Martini, Sharyl R.; Mitchell, Brian G.; Kunik, Mark] Baylor Coll Med, Houston, TX 77030 USA. [Ali, Ali Asghar; Catic, Angela; Mitchell, Brian G.] Michael E DeBakey VA Med Ctr, Houston, TX USA. [Thielke, Stephen] VA Puget Sound Healthcare Syst, Seattle, WA USA. [Kunik, Mark] VA HSR&D Houston Ctr Innovat, Houston, TX USA. NR 0 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1064-7481 EI 1545-7214 J9 AM J GERIAT PSYCHIAT JI Am. J. Geriatr. Psychiatr. PD MAR PY 2017 VL 25 IS 3 SU S MA EI 19 BP S80 EP S81 PG 2 WC Geriatrics & Gerontology; Gerontology; Psychiatry SC Geriatrics & Gerontology; Psychiatry GA EP1IG UT WOS:000397138000077 ER PT J AU Ahmad, I Zelnick, LR Robinson, NR Hung, AM Kestenbaum, B Utzschneider, KM Kahn, SE de Boer, IH AF Ahmad, Iram Zelnick, Leila R. Robinson, Nicole R. Hung, Adriana M. Kestenbaum, Bryan Utzschneider, Kristina M. Kahn, Steven E. de Boer, Ian. H. TI Chronic kidney disease and obesity bias surrogate estimates of insulin sensitivity compared with the hyperinsulinemic euglycemic clamp SO AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM LA English DT Article ID GLUCOSE-TOLERANCE TEST; RENAL-DISEASE; FATTY-ACIDS; RESISTANCE; CLEARANCE; INDEX; HOMEOSTASIS; SECRETION; VALIDATION; METABOLISM AB Insulin sensitivity can be measured by procedures such as the hyperinsulinemic euglycemic clamp or by using surrogate indices. Chronic kidney disease (CKD) and obesity may differentially affect these measurements because of changes in insulin kinetics and organ-specific effects on insulin sensitivity. In a cross-sectional study of 59 subjects with nondiabetic CKD [estimated glomerular filtration rate: (GFR) , 60 ml.min(-1.)1.73 m(2)] and 39 matched healthy controls, we quantified insulin sensitivity by clamp (SIclamp), oral glucose tolerance test, and fasting glucose and insulin. We compared surrogate insulin sensitivity indices to SIclamp using descriptive statistics, graphical analyses, correlation coefficients, and linear regression. Mean age was 62.6 yr; 48% of the participants were female, and 77% were Caucasian. Insulin sensitivity indices were 8-38% lower in participants with vs. without CKD and 13-59% lower in obese compared with nonobese participants. Correlations of surrogate indices with SIclamp did not differ significantly by CKD or obesity status. Adjusting for SIclamp in addition to demographic factors, Matsuda index was 15% lower in participants with vs. without CKD (P = 0.09) and 36% lower in participants with vs. without obesity (P = 0.0001), whereas 1/HOMA-IR was 23% lower in participants with vs. without CKD (P = 0.02) and 46% lower in participants with vs. without obesity (P = 0.0001). We conclude that CKD and obesity do not significantly alter correlations of surrogate insulin sensitivity indices with SIclamp, but they do bias surrogate measurements of insulin sensitivity toward lower values. This bias may be due to differences in insulin kinetics or organ-specific responses to insulin. C1 [Ahmad, Iram; Utzschneider, Kristina M.; Kahn, Steven E.] Univ Washington, Dept Med, Div Metab Endocrinol & Nutr, Seattle, WA USA. [Ahmad, Iram; Zelnick, Leila R.; Robinson, Nicole R.; Kestenbaum, Bryan; de Boer, Ian. H.] Univ Washington, Dept Med, Div Nephrol, Kidney Res Inst, Seattle, WA 98195 USA. [Hung, Adriana M.] Vanderbilt Univ, Sch Med, Div Nephrol & Hypertens, Nashville, TN 37212 USA. [Utzschneider, Kristina M.; Kahn, Steven E.; de Boer, Ian. H.] Vet Affairs Puget Sound Hlth Care Syst, Seattle, WA USA. RP Ahmad, I (reprint author), Kidney Res Inst, 325 9th Ave,Box 359606, Seattle, WA 98104 USA. EM iram@uw.edu FU National Institute of Diabetes and Digestive and Kidney Diseases [R01-DK-087726]; Department of Veterans Affairs; National Institutes of Health Grants [UL1-TR-000423, P01-DK-017047, P30-DK-035816, R01-DK-088762, R01-DK-099199, T32-DK-007247]; unrestricted fund from the Northwest Kidney Center FX The SUGAR study was funded primarily by Grant no. R01-DK-087726 from the National Institute of Diabetes and Digestive and Kidney Diseases. Additional support came from the Department of Veterans Affairs, National Institutes of Health Grants UL1-TR-000423, P01-DK-017047, P30-DK-035816, R01-DK-088762, R01-DK-099199, and T32-DK-007247, and an unrestricted fund from the Northwest Kidney Center. NR 37 TC 0 Z9 0 U1 1 U2 1 PU AMER PHYSIOLOGICAL SOC PI BETHESDA PA 9650 ROCKVILLE PIKE, BETHESDA, MD 20814 USA SN 0193-1849 EI 1522-1555 J9 AM J PHYSIOL-ENDOC M JI Am. J. Physiol.-Endocrinol. Metab. PD MAR PY 2017 VL 312 IS 3 BP E175 EP E182 DI 10.1152/ajpendo.00394.2016 PG 8 WC Endocrinology & Metabolism; Physiology SC Endocrinology & Metabolism; Physiology GA EN1YD UT WOS:000395805500005 PM 28073780 ER PT J AU Jaconis, M Ana, EJS Killeen, TK Badour, CL Back, SE AF Jaconis, Maryanne Ana, Elizabeth J. Santa Killeen, Therese K. Badour, Christal L. Back, Sudie E. TI Case-Series: Concurrent Treatment of PTSD and Alcohol Use Disorder via Telehealth in a Female Iraq Veteran SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID POSTTRAUMATIC-STRESS-DISORDER; PROLONGED EXPOSURE THERAPY; DEPENDENCE AB Background and Objectives: A growing literature provides evidence for the use of integrated treatments (e.g., Concurrent Treatment of PTSD and Substance Use Disorders Using Prolonged Exposure; COPE); however, no known studies have applied COPE via telehealth. Method: COPE was delivered via telehealth to treat one black female veteran with combat trauma and alcohol use disorder. Results: The patient demonstrated significant reductions in alcohol consumption and PTSD and depressive symptoms. Conclusions and Scientific Significance: Although preliminary, findings demonstrate that integrated treatment via telehealth is feasible and effective, and may be useful for female veterans reluctant to seek services at male-dominated VAMCs. C1 [Jaconis, Maryanne; Ana, Elizabeth J. Santa; Killeen, Therese K.; Back, Sudie E.] Med Univ South Carolina, Dept Psychiat & Behav Sci, Addict Sci Div, Charleston, SC USA. [Jaconis, Maryanne] Univ Wyoming, Dept Psychol, Laramie, WY 82071 USA. [Jaconis, Maryanne] VA Portland Hlth Care Syst, 3710 SW US Vet Hosp Rd,P3MHN, Portland, OR 97202 USA. [Ana, Elizabeth J. Santa; Killeen, Therese K.; Back, Sudie E.] Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Badour, Christal L.] Univ Kentucky, Dept Psychol, Lexington, KY 40506 USA. RP Jaconis, M (reprint author), VA Portland Hlth Care Syst, 3710 SW US Vet Hosp Rd,P3MHN, Portland, OR 97202 USA. EM maryanne.jaconis@va.gov FU NIDA [T32 DA007288] FX This publication was supported by NIDA grant T32 DA007288 (Jaconis). NR 11 TC 0 Z9 0 U1 1 U2 1 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 EI 1521-0391 J9 AM J ADDICTION JI Am. J. Addict. PD MAR PY 2017 VL 26 IS 2 BP 112 EP 114 DI 10.1111/ajad.12481 PG 3 WC Substance Abuse SC Substance Abuse GA EP3QK UT WOS:000397296600002 PM 28118514 ER PT J AU Capurso, NA AF Capurso, Noah A. TI Case-Series: Naltrexone for the Treatment of Comorbid Tobacco and Pornography Addiction SO AMERICAN JOURNAL ON ADDICTIONS LA English DT Article ID SMOKING-CESSATION; CONTROLLED-TRIAL; ALCOHOL; AUGMENTATION; DISORDER; BEHAVIOR AB Background and Objectives: Co-occurring addictive disorders are common, however treatment strategies for this population have not been extensively studied. This is especially the case for behavioral addictions. Methods: We present a patient (N = 1) with tobacco use disorder and problematic pornography use treated with naltrexone. Results: Naltrexone treatment resulted in a decrease in pornography viewing and cigarette smoking, however had the adverse effect of anhedonia. A lower dose modestly impacted pornography viewing but not smoking. Discussions and Conclusions: Relevant literature regarding co-occurring addictions as well as use of naltrexone is reviewed. Scientific Significance: This report represents the first case of tobacco and pornography co-addiction in the literature and supports the assertion that treatment of one addictive disorder can benefit another in the dually addicted patient. The efficacy of naltrexone for smoking is notable as previous studies of naltrexone in smoking have been disappointing. This case suggests future treatment strategies for comorbid addictions. C1 [Capurso, Noah A.] Yale Univ, Sch Med, Dept Psychiat, 300 George St,Suite 901, New Haven, CT 06520 USA. [Capurso, Noah A.] VA Connecticut Healthcare Syst, US Dept Vet Affairs, West Haven, CT USA. RP Capurso, NA (reprint author), Yale Univ, Sch Med, Dept Psychiat, 300 George St,Suite 901, New Haven, CT 06520 USA. EM noah.capurso@yale.edu NR 20 TC 0 Z9 0 U1 2 U2 2 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1055-0496 EI 1521-0391 J9 AM J ADDICTION JI Am. J. Addict. PD MAR PY 2017 VL 26 IS 2 BP 115 EP 117 DI 10.1111/ajad.12501 PG 3 WC Substance Abuse SC Substance Abuse GA EP3QK UT WOS:000397296600003 PM 28106937 ER PT J AU Shields, RK Chen, L Cheng, SJ Chavda, KD Press, EG Snyder, A Pandey, R Doi, Y Kreiswirth, BN Nguyen, MH Clancy, CJ AF Shields, Ryan K. Chen, Liang Cheng, Shaoji Chavda, Kalyan D. Press, Ellen G. Snyder, Avin Pandey, Ruchi Doi, Yohei Kreiswirth, Barry N. Nguyen, M. Hong Clancy, Cornelius J. TI Emergence of Ceftazidime-Avibactam Resistance Due to Plasmid-Borne bla(KPC-3) Mutations during Treatment of Carbapenem-Resistant Klebsiella pneumoniae Infections SO ANTIMICROBIAL AGENTS AND CHEMOTHERAPY LA English DT Article DE ceftazidime-avibactam; resistance; carbapenem-resistant Enterobacteriaceae; Klebsiella pneumoniae; Klebsiella pneumoniae carbapenemase,sequence type 258 ID SEQUENCE TYPE 258; BETA-LACTAMASE; US HOSPITALS; ENTEROBACTERIACEAE; KPC; BACTEREMIA; MORTALITY; EVOLUTION; VARIANTS; THERAPY AB Ceftazidime-avibactam is a novel beta lactam/ beta-lactamase inhibitor with activity against carbapenem-resistant Enterobacteriaceae (CRE) that produce Kleb-siella pneumoniae carbapenemase (KPC). We report the first cases of ceftazidimeavibactam resistance to develop during treatment of CRE infections and identify resistance mechanisms. Ceftazidime-avibactam-resistant K. pneumoniae emerged in three patients after ceftazidime-avibactam treatment for 10 to 19 days. Wholegenome sequencing (WGS) of longitudinal ceftazidime-avibactam-susceptible and -resistant K. pneumoniae isolates was used to identify potential resistance mechanisms. WGS identified mutations in plasmid-borne bla(KPC-3), which were not present in baseline isolates. bla(KPC-3) mutations emerged independently in isolates of a novel sequence type 258 sublineage and resulted in variant KPC-3 enzymes. The mutations were validated as resistance determinants by measuring MICs of ceftazidime-avibactam and other agents following targeted gene disruption in K. pneumoniae, plasmid transfer, and blaKPC cloning into competent Escherichia coli. In rank order, the impact of KPC-3 variants on ceftazidime-avibactam MICs was as follows: D179Y/T243M double substitution > D179Y > V240G. Remarkably, mutations reduced meropenem MICs >= 4-fold from baseline, restoring susceptibility in K. pneumoniae from two patients. Cefepime and ceftriaxone MICs were also reduced >= 4-fold against D179Y/T243M and D179Y variant isolates, but susceptibility was not restored. Reverse transcription-PCR revealed that expression of bla(KPC-3) encoding D179Y/T243M and D179Y variants was diminished compared to bla(KPC-3) expression in baseline isolates. In conclusion, the development of resistance-conferring bla(KPC-3) mutations in K. pneumoniae within 10 to 19 days of ceftazidime-avibactam exposure is troubling, but clinical impact may be ameliorated if carbapenem susceptibility is restored in certain isolates. C1 [Shields, Ryan K.; Cheng, Shaoji; Press, Ellen G.; Snyder, Avin; Doi, Yohei; Nguyen, M. Hong; Clancy, Cornelius J.] Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA. [Shields, Ryan K.; Nguyen, M. Hong; Clancy, Cornelius J.] Univ Pittsburgh, Med Ctr, XDR Pathogen Lab, Pittsburgh, PA 15260 USA. [Chen, Liang; Chavda, Kalyan D.; Pandey, Ruchi; Kreiswirth, Barry N.] Rutgers State Univ, New Jersey Med Sch, Publ Hlth Res Inst, TB Ctr, Newark, NJ USA. [Clancy, Cornelius J.] VA Pittsburgh Healthcare Syst, Pittsburgh, PA USA. RP Nguyen, MH (reprint author), Univ Pittsburgh, Dept Med, Pittsburgh, PA 15260 USA.; Nguyen, MH (reprint author), Univ Pittsburgh, Med Ctr, XDR Pathogen Lab, Pittsburgh, PA 15260 USA. EM mhn5@pitt.edu FU National Institutes of Health [K08AI114883, R21AI117338, R01AI090155, UM1AI104681, R21AI111037] FX This work was funded, in part, by grants from the National Institutes of Health (K08AI114883 to R.K.S., R21AI117338 to L.C., R01AI090155 to B.N.K., UM1AI104681 to M.H.N., and R21AI111037 to C.J.C.). NR 41 TC 1 Z9 1 U1 1 U2 1 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0066-4804 EI 1098-6596 J9 ANTIMICROB AGENTS CH JI Antimicrob. Agents Chemother. PD MAR PY 2017 VL 61 IS 3 AR e02097-16 DI 10.1128/AAC.02097-16 PG 11 WC Microbiology; Pharmacology & Pharmacy SC Microbiology; Pharmacology & Pharmacy GA EL4QM UT WOS:000394605900054 ER PT J AU Locke, FL Pidala, J Storer, B Martin, PJ Pulsipher, MA Chauncey, TR Jacobsen, N Kroger, N Walker, I Light, S Shaw, BE Beato, F Laport, GG Nademanee, A Keating, A Socie, G Anasetti, C AF Locke, Frederick L. Pidala, Joseph Storer, Barry Martin, Paul J. Pulsipher, Michael A. Chauncey, Thomas R. Jacobsen, Niels Kroeger, Nicolaus Walker, Irwin Light, Susan Shaw, Bronwen E. Beato, Francisca Laport, Ginna G. Nademanee, Auayporn Keating, Armand Socie, Gerard Anasetti, Claudio TI CD25 Blockade Delays Regulatory T Cell Reconstitution and Does Not Prevent Graft-versus-Host Disease After Allogeneic Hematopoietic Cell Transplantation SO BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION LA English DT Article DE Antitumor immunity; Daclizumab; Regulatory T cells ID BONE-MARROW-TRANSPLANTATION; STEROID-REFRACTORY ACUTE; PERIPHERAL-BLOOD; MONOCLONAL-ANTIBODY; IMPROVED SURVIVAL; UNRELATED DONORS; STEM-CELLS; DACLIZUMAB; IMMUNOTHERAPY; RECIPIENTS AB Daclizumab, a humanized monoclonal antibody, binds CD25 and blocks formation of the IL-2 receptor on T cells. A study of daclizumab as acute graft-versus-host disease (GVHD) prophylaxis after unrelated bone marrow transplantation was conducted before the importance of CD25(+)FOXP3(+) regulatory T cells (Tregs) was recognized. Tregs can abrogate the onset of GVHD. The relation between Tregs and a graft-versus-malignancy effect is not fully understood. An international, multicenter, double-blind clinical trial randomized 210 adult or pediatric patients to receive 5 weekly doses of daclizumab at 0.3 mg/kg (n = 69) or 1.2 mg/kg (n = 76) or placebo (n = 65) after unrelated marrow transplantation for treatment of hematologic malignancies or severe aplas-, tic anemia. The risk of acute GVHD did not differ among the groups (P =.68). Long-terrri follow-up of clinical outcomes and correlative analysis of peripheral blood T cell phenotype suggested that the patients treated with daclizumab had an increased risk of chronic GVHD (hazard ratio [HR]. 1.49; 95% confidence interval [CI], 1.0 to 2.3; P =.08) and a decreased risk of relapse (HR, 0.57; 95% CI, 0.3 to 1.0; P =.05), but similar survival (HR, 0.89; 95% CI, 0.6 to 1.3; P =.53). T cells from a subset of patients (n = 107) were analyzed by flow cytometry. Compared with placebo, treatment with daclizumab decreased the proportion of Tregs among CD4 T cells at days 11-35 and increased the proportion of central memory cells among CD4 T cells at 1 year. Prophylactic administration of daclizumab does not prevent acute GVHD, but may increase the risk of chronic GVHD and decrease the risk of relapse. By delaying Treg reconstitution and promoting immunologic memory, anti-CD25 therapy may augment alloreactivity and antitumor immunity. (C) 2017 Published by Elsevier Inc. on behalf of the American Society for Blood and Marrow Transplantation. C1 [Locke, Frederick L.; Pidala, Joseph; Beato, Francisca; Anasetti, Claudio] H Lee Moffitt Canc Ctr & Res Inst, Blood & Marrow Transplantat Program, Tampa, FL USA. [Storer, Barry; Martin, Paul J.] Fred Hutchinson Canc Res Ctr, Div Clin Res, 1124 Columbia St, Seattle, WA 98104 USA. [Martin, Paul J.; Chauncey, Thomas R.] Univ Washington, Dept Med, Div Oncol, Seattle, WA 98195 USA. [Pulsipher, Michael A.] Univ Utah, Huntsman Canc Inst, Med Ctr, Blood & Marrow Transplant Program, Salt Lake City, UT 84112 USA. [Chauncey, Thomas R.] VA Puget Sound Hlth Care Syst, Canc Care Div, Seattle, WA USA. [Jacobsen, Niels] Rigshospitalet, Dept Hematol, Copenhagen, Denmark. [Kroeger, Nicolaus] Univ Med Ctr Hamburg Eppendorf, Ctr Oncol, Dept Stem Cell Transplantat, Hamburg, Germany. [Walker, Irwin] McMaster Univ, Dept Med, Hamilton, ON L8N 3Z5, Canada. [Light, Susan] Hoffman La Roche, Nutley, NJ USA. [Shaw, Bronwen E.] Royal Marsden Hosp, Haemato Oncol Unit, Downs Rd, Sutton SM2 5NG, Surrey, England. [Laport, Ginna G.] Stanford Univ, Div Blood & Marrow Transplantat, Stanford, CA 94305 USA. [Nademanee, Auayporn] Hematol Malignancies & Stem Cell Transplantat Ins, City Hope, Duarte, CA USA. [Keating, Armand] Princess Margaret Hosp, Blood & Marrow Transplant Ctr, Dept Hematol, Toronto, ON M4X 1K9, Canada. [Socie, Gerard] Hosp St Louis, Dept Hematol Transplantat, Paris, France. RP Anasetti, C (reprint author), H Lee Moffitt Canc Ctr & Res Inst, Blood & Marrow Transplantat Program, Tampa, FL USA. EM claudio.anasetti@moffitt.org NR 46 TC 0 Z9 0 U1 2 U2 2 PU ELSEVIER SCIENCE INC PI NEW YORK PA 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA SN 1083-8791 EI 1523-6536 J9 BIOL BLOOD MARROW TR JI Biol. Blood Marrow Transplant. PD MAR PY 2017 VL 23 IS 3 BP 405 EP 411 DI 10.1016/j.bbmt.2016.12.624 PG 7 WC Hematology; Immunology; Transplantation SC Hematology; Immunology; Transplantation GA EM5QL UT WOS:000395367300006 PM 28007665 ER PT J AU Stewart, IJ Sosnov, JA Snow, BD Batou, A Howard, JT Janak, JC Bollinger, M Chung, KK AF Stewart, Ian J. Sosnov, Jonathan A. Snow, Brian D. Batou, Augen Howard, Jeffrey T. Janak, Jud C. Bollinger, Mary Chung, Kevin K. TI Hypertension after injury among burned combat veterans: A retrospective cohort study SO BURNS LA English DT Article DE Burns; Hypertension; Acute kidney injury; War; Veterans ID CARDIOVASCULAR-DISEASE; CHILDREN; SYSTEM; PREVALENCE; SURVIVORS; RISK AB Background: The long-term health effects of burn are poorly understood. We sought to evaluate the relationship between burn and the subsequent development of hypertension. Methods: Retrospective cohort study of patients admitted to our burn center from 2003 to 2010. Data collected included demographic variables, burn size, injury severity score, presence of inhalation injury, serum creatinine, need for renal replacement therapy, as well as days spent in the hospital, in the intensive care unit and on mechanical ventilation. Data for the subsequent diagnosis of hypertension was obtained from medical records. Cox proportional hazard regression models were performed to determine what factors were associated with hypertension. Results: Of the 711 patients identified, 670 were included for analysis after exclusions. After adjustment, only age (HR 1.06 per one year increase, 95% confidence interval 1.03-1.08; p<0.001), percentage of total body surface area burned (HR 1.11 per 5% increase, 95% confidence interval 1.04-1.19; p=0.002) and acute kidney injury (HR 1.68, 95% confidence interval 1.05-2.69; p=0.03) were associated with hypertension. Conclusion: Burn size is independently associated with the subsequent risk of hypertension in combat casualties. Clinical support for primary prevention techniques to reduce the incidence of hypertension specific to burn patients may be warranted. Published by Elsevier Ltd. C1 [Stewart, Ian J.] David Grant USAF Med Ctr, Clin Invest Facil, 101 Bodin Circle, Travis AFB, CA 94535 USA. [Stewart, Ian J.; Sosnov, Jonathan A.; Chung, Kevin K.] Uniformed Serv Univ Hlth Sci, 4301 Jones Bridge Rd, Bethesda, MD 20814 USA. [Sosnov, Jonathan A.] San Antonio Mil Med Ctr, 3551 Roger Brooke Dr, Ft Sam Houston, TX 78219 USA. [Snow, Brian D.] Wright Patterson Med Ctr, 4881 Sugar Maple Dr, Wright Patterson AFB, OH 45433 USA. [Batou, Augen] Mike OCallaghan Fed Med Ctr, 4700 N Las Vegas Blvd, Nellis AFB, NV 89191 USA. [Howard, Jeffrey T.; Janak, Jud C.; Chung, Kevin K.] US Army, Inst Surg Res, 3698 Chambers Rd, Ft Sam Houston, TX 78234 USA. [Bollinger, Mary] South Texas Vet Hlth Care Syst, 7400 Merton Minter Blvd, San Antonio, TX 78229 USA. RP Stewart, IJ (reprint author), David Grant USAF Med Ctr, 101 Bodin Circle, Travis AFB, CA 94535 USA. EM ian.stewart@us.af.mil NR 29 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0305-4179 EI 1879-1409 J9 BURNS JI Burns PD MAR PY 2017 VL 43 IS 2 BP 290 EP 296 DI 10.1016/j.burns.2016.10.005 PG 7 WC Critical Care Medicine; Dermatology; Surgery SC General & Internal Medicine; Dermatology; Surgery GA EN2LI UT WOS:000395841300006 PM 28029474 ER PT J AU Shen, H Monto, A AF Shen, H. Monto, A. TI Identifying Drug-Induced Liver Illness (DILI) with Computerized Information Extraction: No More Dilly-Dallying SO DIGESTIVE DISEASES AND SCIENCES LA English DT Editorial Material C1 [Shen, H.; Monto, A.] Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA. [Shen, H.; Monto, A.] San Francisco VA Med Ctr, Med 111A, 4150 Clement St, San Francisco, CA 94121 USA. RP Shen, H (reprint author), Univ Calif San Francisco, Dept Med, San Francisco, CA 94143 USA.; Shen, H (reprint author), San Francisco VA Med Ctr, Med 111A, 4150 Clement St, San Francisco, CA 94121 USA. EM Hui.Shen@ucsf.edu NR 9 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD MAR PY 2017 VL 62 IS 3 BP 564 EP 566 DI 10.1007/s10620-016-4359-z PG 3 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EL9YB UT WOS:000394974900002 PM 27943016 ER PT J AU Fuller, G Bolus, R Whitman, C Talley, J Erder, MH Joseph, A Silberg, DG Spiegel, B AF Fuller, Garth Bolus, Roger Whitman, Cynthia Talley, Jennifer Erder, M. Haim Joseph, Alain Silberg, Debra G. Spiegel, Brennan TI PRISM, a Patient-Reported Outcome Instrument, Accurately Measures Symptom Change in Refractory Gastroesophageal Reflux Disease SO DIGESTIVE DISEASES AND SCIENCES LA English DT Article DE Gastroesophageal reflux; Proton pump inhibitors; Patient-reported outcomes; Qualitative research; Psychometrics; Validation studies; US Food and Drug Administration ID INFORMATION-SYSTEM PROMIS; PUMP INHIBITOR THERAPY; PRIMARY-CARE; CLINICAL-TRIALS; QUESTIONNAIRE; RESPONDERS; PERSISTENT AB Most patients with gastroesophageal reflux disease (GERD) experience relief following treatment with proton pump inhibitors (PPIs) (Vakil et al. in Am J Gastroenterol 101:1900-1920, 2006; Everhart and Ruhl in Gastroenterology 136:376-386, 2009). As many as 17-44% of patients, however, exhibit only partial response to therapy. Most extant GERD patient-reported outcome (PRO) instruments fail to meet development best practices as described by the FDA (Talley and Wiklund in Qual Life Res 14:21-33, 2005; Van Pinxteren et al. in Cochrane Database Syst Rev 18:CD002095, 2004; El-Serag et al. in Aliment Pharmacol Ther 32:720-737, 2010). To develop and validate a PRO instrument for clinical trials involving patients with GERD who are PPI partial responders. We prepared a systematic literature review, held patient focus groups, convened an expert panel, and conducted cognitive interviews to establish content validity. Eligible participants took PPI therapy for at least 8 weeks, had undergone an upper endoscopy, and scored at least 8 points on the GerdQ [6]. Qualitative data guided development of 26 draft items. Items were reviewed by expert panels and debriefed with patients. The resulting 21-item instrument underwent psychometric evaluation during a Phase IIB trial. During the trial, confirmatory factor analysis (n = 220) resulted in a four-factor model displaying the highest goodness of fit. All domains had a high inter-item correlation (Cronbach's alpha > 0.8). Test-retest reliability and convergent validity were strong, with highly significant (p < 0.01) correlations between average weekly PRISM scores and severity anchors and significant (p < 0.05) correlations with anchor subscales. Cumulative distribution functions revealed significant differences between responders and non-responders. Analysis in a clinical trial setting demonstrated strong psychometric properties suggesting validity of PRISM. Developed in line with FDA guidance on PROs, PRISM represents an important new outcome measure for patients with GERD with a partial response to PPI therapy. C1 [Fuller, Garth; Bolus, Roger; Whitman, Cynthia; Talley, Jennifer; Spiegel, Brennan] CS CORE, 116 N Robertson Blvd Suite 400, Los Angeles, CA 90048 USA. [Bolus, Roger; Spiegel, Brennan] UCLA Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA. [Erder, M. Haim; Silberg, Debra G.] MH Erder Hlth Econ Inc, Livingston, NJ USA. [Joseph, Alain] Shire, Zahlerweg 10, CH-6300 Zug, Switzerland. [Spiegel, Brennan] Cedars Sinai Med Ctr, Dept Med, Cedars Sinai Hlth Syst, Los Angeles, CA 90048 USA. [Spiegel, Brennan] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. [Bolus, Roger] 1016 Quail Gardens Ct, Encinitas, CA 92024 USA. [Whitman, Cynthia] 44 16th St, Hermosa Beach, CA 90254 USA. RP Spiegel, B (reprint author), CS CORE, 116 N Robertson Blvd Suite 400, Los Angeles, CA 90048 USA.; Spiegel, B (reprint author), UCLA Fielding Sch Publ Hlth, Los Angeles, CA 90095 USA.; Spiegel, B (reprint author), Cedars Sinai Med Ctr, Dept Med, Cedars Sinai Hlth Syst, Los Angeles, CA 90048 USA.; Spiegel, B (reprint author), VA Greater Los Angeles Healthcare Syst, Los Angeles, CA 90073 USA. EM garth.fuller@cshs.org; rbolus@netzero.net; cwhitman@psi.org; Jennifer.Soares@cshs.org; hmerder@gmail.com; ajoseph@shire.com; dsilberg@shire.com; brennan.spiegel@cshs.org FU Shire-Movetis NV FX Support for this study was provided by a research grant from Shire-Movetis NV. NR 23 TC 0 Z9 0 U1 0 U2 0 PU SPRINGER PI DORDRECHT PA VAN GODEWIJCKSTRAAT 30, 3311 GZ DORDRECHT, NETHERLANDS SN 0163-2116 EI 1573-2568 J9 DIGEST DIS SCI JI Dig. Dis. Sci. PD MAR PY 2017 VL 62 IS 3 BP 593 EP 606 DI 10.1007/s10620-016-4440-7 PG 14 WC Gastroenterology & Hepatology SC Gastroenterology & Hepatology GA EL9YB UT WOS:000394974900008 PM 28116591 ER PT J AU Everett, CJ Thompson, OM Dismuke, CE AF Everett, Charles J. Thompson, Olivia M. Dismuke, Clara E. TI Exposure to DDT and diabetic nephropathy among Mexican Americans in the 1999-2004 National Health and Nutrition Examination Survey SO ENVIRONMENTAL POLLUTION LA English DT Article DE DDT (dichlorodiphenyltrichloroethane); DDE (dichlorodiphenyldichloroethylene); Diabetes; Kidney disease ID CHRONIC KIDNEY-DISEASE; ORGANOCHLORINE PESTICIDES; BREAST-CANCER; ASSOCIATION; ACCULTURATION; POLYMORPHISM; PREVALENCE; HISPANICS; TRENDS; WOMEN AB Concentrations of the pesticide DDT (dichlorodiphenyltrichloroethane) and its metabolite DDE (dichlorodiphenyldichloroethylene), in the blood of Mexican Americans, were evaluated to determine their relationships with diabetes and diabetic nephropathy. The data were derived from the National Health and Nutrition Examination Survey (NHANES) 1999-2004 (unweighted N = 1,411, population estimate = 13,760,609). The sample included teens, 12-19 years old, which accounted for 19.8% of the data. The time of the study overlapped the banning of DDT in Mexico in the year 2000, and those participants born in Mexico were exposed to DDT before they immigrated to the US. We sought to better understand the relationship of DDT with diabetes in a race/ethnicity group prone to develop diabetes and exposed to DDT. In this study, nephropathy was defined as urinary albumin to creatinine ratio >30 mg/g, representing microalbuminuria and macroalbuminuria, and total diabetes was defined as diagnosed and undiagnosed diabetes (glycohemoglobin, A1c >= 6.5%). The proportion with the isomer p,p'-DDT >0.086 ng/g (above the maximum limit of detection) was 13.3% for Mexican Americans born in the US, and 36.9% for those born in Mexico. Levels of p,p'-DDT >0.086 ng/g were associated with total diabetes with nephropathy (odds ratio = 4.42, 95% CI 2.23-8.76), and with total diabetes without nephropathy (odds ratio = 2.02, 95% CI 1.19-3.44). The third quartile of p,p'-DDE (2.99-7.67 ng/g) and the fourth quartile of p,p'-DDE (>= 7.68 ng/g) were associated with diabetic nephropathy and had odds ratios of 5.32 (95% CI 1.05-26.87) and 14.95 (95% CI 2.96-75.48) compared to less than the median, respectively, whereas p,p'-DDE was not associated with total diabetes without nephropathy. The findings of this study differ from those of a prior investigation of the general adult US population in that there were more associations found with the Mexican Americans sample. Published by Elsevier Ltd. C1 [Everett, Charles J.; Dismuke, Clara E.] US Dept Vet Affairs, Ralph H Johnson VA Med Ctr, Charleston, SC USA. [Thompson, Olivia M.] Coll Charleston, Mayor Joseph P Riley Inst Livable Commun, Charleston, SC USA. [Everett, Charles J.] Med Univ S Carolina, Dept Publ Hlth Sci, Charleston, SC USA. [Everett, Charles J.; Dismuke, Clara E.] Ralph H Johnson VA Med Ctr, 109 Bee St,Mail Code 151, Charleston, SC 29401 USA. RP Everett, CJ; Thompson, OM; Dismuke, CE (reprint author), Ralph H Johnson VA Med Ctr, 109 Bee St,Mail Code 151, Charleston, SC 29401 USA. EM Charles.Everett@va.gov; thompsonom@cofc.edu; Clara.Dismuke@va.gov NR 30 TC 0 Z9 0 U1 1 U2 1 PU ELSEVIER SCI LTD PI OXFORD PA THE BOULEVARD, LANGFORD LANE, KIDLINGTON, OXFORD OX5 1GB, OXON, ENGLAND SN 0269-7491 EI 1873-6424 J9 ENVIRON POLLUT JI Environ. Pollut. PD MAR PY 2017 VL 222 BP 132 EP 137 DI 10.1016/j.envPol.2016.12.069 PG 6 WC Environmental Sciences SC Environmental Sciences & Ecology GA EM5OJ UT WOS:000395360900016 PM 28065571 ER PT J AU Winkelman, WD Huang, AJ Schembri, M Rogers, RG Richter, H Myers, DL Kraus, SR Johnson, KC Hess, R Gregory, T Bradley, CS Arya, L Brown, JS Subak, LL AF Winkelman, William D. Huang, Alison J. Schembri, Michael Rogers, Rebecca G. Richter, Holly Myers, Deborah L. Kraus, Stephen R. Johnson, Karen C. Hess, Rachel Gregory, Tomas Bradley, Catherine S. Arya, Lily Brown, Janette S. Subak, Leslee L. TI Modifiers of Response to Treatment With Fesoterodine for Urgency-Predominant Urinary Incontinence in a Randomized Controlled Trial SO FEMALE PELVIC MEDICINE AND RECONSTRUCTIVE SURGERY LA English DT Article; Proceedings Paper CT Annual Scientific Meeting of the American-Urogynecologic-Society (AUGS) CY SEP 27-OCT 01, 2016 CL Denver, CO SP Amer Urogynecol Soc DE fesoterodine; predictors of treatment response; urgency urinary incontinence ID OVERACTIVE BLADDER; TOLERABILITY; EFFICACY; PLACEBO; SAFETY; PHARMACOKINETICS; TOLTERODINE; SOLIFENACIN; PREVALENCE; VALIDATION AB Objective: The aim of this studywas to identify clinical and demographic characteristics that moderate response to treatment with fesoterodine among women with a diagnosis of urgency-predominant urinary incontinence. Methods: A multicenter, double-blinded, 12-week randomized controlled trial of pharmacologic therapy for urgency-predominant urinary incontinence in community-dwelling women diagnosed by the 3-item Incontinence Questionnaire (3IQ) was previously performed. Participants (N = 645) were randomized to fesoterodine therapy (4-8 mg daily; n = 322) or placebo (n = 323). Urinary incontinence was assessed by 3-day voiding diaries. In this secondary analysis, a "responder" was defined as reduction of 50% or greater in overall incontinence episode frequency compared with baseline. Clinical and demographic characteristics that may moderate treatment response were assessed by testing for interaction between characteristics and intervention in logit models of responders, adjusting for clinical site. Results: Participants' ages were a mean of 56 (SD, 14) years, 68% were white race, and they had a mean of 3.9 (SD, 3.0) urgency incontinence episodes per day. There were no baseline differences in demographic, clinical, or incontinence characteristics between treatment and placebo groups or between responders and nonresponders. There was an increase in the proportion of responders to fesoterodine with increasing age (P = 0.04) and parity (0.04) and among married women (P = 0.03), but no effect modification was observed by race/ethnicity, body mass index, education, employment status, or alcohol or tobacco use. Conclusions: In ambulatory women with urgency-predominant urinary incontinence, older age, being married, and higher parity significantly moderated and potentiated the effects of pharmacologic therapy on incontinence frequency. This study identifies certain populations who may have increased responsiveness to treatment with antimuscarinic therapy andmay be used to inform and guide future therapy. C1 [Winkelman, William D.; Huang, Alison J.; Schembri, Michael; Brown, Janette S.; Subak, Leslee L.] Univ Calif San Francisco, Irene Betty Moore Womens Hosp, Dept Obstet Gynecol & Reprod Med, San Francisco, CA 94143 USA. [Rogers, Rebecca G.] Univ New Mexico, Albuquerque, NM 87131 USA. [Richter, Holly] Univ Alabama Birmingham, Birmingham, AL USA. [Myers, Deborah L.] Brown Univ, Providence, RI 02912 USA. [Kraus, Stephen R.] UT Hlth Sci Ctr, San Antonio, TX USA. [Johnson, Karen C.] Univ Tennessee, Hlth Sci Ctr, Memphis, TN USA. [Hess, Rachel] Univ Utah, Salt Lake City, UT USA. [Gregory, Tomas] Oregon Hlth & Sci Univ, Portland, OR 97201 USA. [Bradley, Catherine S.] Univ Iowa, Iowa City, IA USA. [Arya, Lily] Univ Penn, Philadelphia, PA 19104 USA. [Subak, Leslee L.] San Francisco VA Med Ctr, San Francisco, CA USA. RP Subak, LL (reprint author), UCSF Womens Hlth Clin Res Ctr, 550 16th St,6th Floor, San Francisco, CA 94143 USA. EM Leslee.Subak@ucsf.edu FU Pfizer, Inc; NIDDK [K24 DK080775]; Astellas, Inc.; US National Institutes of Health [RR024130, 1K23AG038335-01A1, 2K24DK080775-06]; Astellas FX L.L.S., J.S.B., and A.J.H. have received a University of California San Francisco research grant from Pfizer, Inc, to conduct research related to urinary incontinence. Pfizer, Inc, provided funding for the study and the study medication but did not provide other input into the design of the study; collection, analysis, or interpretation of data; writing of the report; or the decision to submit the paper for publication. L.L.S. is additionally supported by NIDDK K24 DK080775. L.L.S. had full access to all the data in the study and takes responsibility for the integrity of the data and the accuracy of the data analysis. No manuscript preparation assistance was provided by the study funders. L.L.S. and A.J.H. receive investigator-initiated trial funding from Astellas, Inc. A.J.H. was additionally supported by grants RR024130 and 1K23AG038335-01A1 and L.L.S. from 2K24DK080775-06 from the US National Institutes of Health; however, the views expressed in this article do not necessarily represent those of the National Institutes of Health. L. A. has received a research grant from Pfizer, Inc. H.R. has received a research grant and participated in a speaker's bureau for Pfizer, Inc; received a research grant and participated in an advisory board for Astellas; and served as a consultant for Uromedica and GlaxoSmithKline. S.R.K. has served as a consultant for Pfizer, Inc, and Allergan and has been a course director and teaching faculty member for Laborie. The other authors declare that they have nothing to disclose. NR 21 TC 0 Z9 0 U1 0 U2 0 PU LIPPINCOTT WILLIAMS & WILKINS PI PHILADELPHIA PA TWO COMMERCE SQ, 2001 MARKET ST, PHILADELPHIA, PA 19103 USA SN 2151-8378 EI 2154-4212 J9 FEMALE PELVIC MED RE JI Female Pelvic Med. Reconstr. Surg. PD MAR-APR PY 2017 VL 23 IS 2 BP 151 EP 156 DI 10.1097/SPV.0000000000000396 PG 6 WC Obstetrics & Gynecology SC Obstetrics & Gynecology GA EM8RX UT WOS:000395579800017 PM 28118174 ER PT J AU Matsue, Y van der Meer, P Damman, K Metra, M O'Connor, CM Ponikowski, P Teerlink, JR Cotter, G Davison, B Cleland, JG Givertz, MM Bloomfield, DM Dittrich, HC Gansevoort, RT Bakker, SJL van der Harst, P Hillege, HL van Veldhuisen, DJ Voors, AA AF Matsue, Yuya van der Meer, Peter Damman, Kevin Metra, Marco O'Connor, Christopher M. Ponikowski, Piotr Teerlink, John R. Cotter, Gad Davison, Beth Cleland, John G. Givertz, Michael M. Bloomfield, Daniel M. Dittrich, Howard C. Gansevoort, Ron T. Bakker, Stephan J. L. van der Harst, Pim Hillege, Hans L. van Veldhuisen, Dirk J. Voors, Adriaan A. TI Blood urea nitrogen-to-creatinine ratio in the general population and in patients with acute heart failure SO HEART LA English DT Article ID MUSCLE PROTEIN-SYNTHESIS; RECEPTOR ANTAGONIST ROLOFYLLINE; RENAL-FUNCTION; NITROGEN/CREATININE RATIO; POSTABSORPTIVE STATE; VOLUME OVERLOAD; MORTALITY; DYSFUNCTION; WOMEN; RISK AB Objective The blood urea nitrogen-to-creatinine (BUN/creatinine) ratio has been proposed as a useful parameter in acute heart failure (AHF), but data on the normal range and the added value of the ratio compared with its separate components in patients with AHF are lacking. The aim of this study is to define the normal range of BUN/creatinine ratio and to investigate its clinical significance in patients with AHF. Methods In 4484 subjects from the general population without cardiovascular comorbidities, we calculated agespecific and sex-specific normal values of the BUN/creatinine ratio, deriving a higher and lower than normal range of BUN/creatinine ratio (exceeding the 95% prediction intervals). Association of abnormal range to prognosis was tested in 2033 patients with AHF for the outcome of all-cause death through 180 days, death or cardiovascular or renal rehospitalisation through 60 days and heart failure (HF) rehospitalisation within 60 days. Results In a cohort of patients with AHF, 482 (24.6%) and 28 (1.4%) patients with HF were classified into higher and lower than normal range groups, respectively. In Cox regression analysis, higher than normal range of BUN/creatinine ratio group was an independent predictor for all-cause death (HR: 1.86, 95% CI 1.29 to 2.66) and death or cardiovascular or renal rehospitalisation (HR: 1.37, 95% CI 1.03 to 1.82), but not for HF rehospitalisation (HR: 1.23, 95% CI 0.81 to 1.86) after adjustment for other prognostic factors including both creatinine and BUN. Conclusions In patients with AHF, BUN/creatinine higher than age-specific and sex-specific normal range is associated with worse prognosis independently from both creatinine and BUN. C1 [Matsue, Yuya; van der Meer, Peter; Damman, Kevin; van der Harst, Pim; Hillege, Hans L.; van Veldhuisen, Dirk J.; Voors, Adriaan A.] Univ Groningen, Univ Med Ctr Groningen, Dept Cardiol, Groningen, Netherlands. [Metra, Marco] Univ Brescia, Dept Expt & Clin Med, Brescia, Italy. [O'Connor, Christopher M.] Inova Heart & Vasc Inst, Falls Church, VA USA. [Ponikowski, Piotr] Med Univ, Clin Mil Hosp, Wroclaw, Poland. [Teerlink, John R.] Univ Calif San Francisco, San Francisco Vet Affairs Med Ctr, San Francisco, CA 94143 USA. [Cotter, Gad; Davison, Beth] Momentum Res, Durham, NC USA. [Cleland, John G.] Imperial Coll, Royal Brompton Hosp, Natl Heart & Lung Inst, London, England. [Cleland, John G.] Imperial Coll, Harefield Hosp, London, England. [Givertz, Michael M.] Brigham & Womens Hosp, 75 Francis St, Boston, MA 02115 USA. [Bloomfield, Daniel M.] Merck Res Labs, Rahway, NJ USA. [Dittrich, Howard C.] Univ Iowa, Carver Coll Med, Cardiovasc Res Ctr, Iowa City, IA USA. [Gansevoort, Ron T.; Bakker, Stephan J. L.] Univ Groningen, Univ Med Ctr Groningen, Dept Nephrol, Groningen, Netherlands. [Bakker, Stephan J. L.] Top Inst Food & Nutr, Wageningen, Netherlands. [Hillege, Hans L.] Univ Groningen, Univ Med Ctr Groningen, Dept Epidemiol, Groningen, Netherlands. RP Voors, AA (reprint author), Univ Med Ctr Groningen, Dept Cardiol, Hanzepl 1, NL-9713 GZ Groningen, Netherlands. EM a.a.voors@umcg.nl OI Matsue, Yuya/0000-0003-2456-8525 FU NovaCardia; Merck FX The PROTECT trial was supported by NovaCardia, a subsidiary of Merck. Alere, Singulex and Sphingotec kindly provided assays and performed biomarker measurements. NR 30 TC 0 Z9 0 U1 2 U2 2 PU BMJ PUBLISHING GROUP PI LONDON PA BRITISH MED ASSOC HOUSE, TAVISTOCK SQUARE, LONDON WC1H 9JR, ENGLAND SN 1355-6037 EI 1468-201X J9 HEART JI Heart PD MAR PY 2017 VL 103 IS 6 DI 10.1136/heartjnl-2016-310112 PG 7 WC Cardiac & Cardiovascular Systems SC Cardiovascular System & Cardiology GA EN0AI UT WOS:000395672300004 ER PT J AU Noto, MJ Becker, KW Boyd, KL Schmidt, AM Skaar, EP AF Noto, Michael J. Becker, Kyle W. Boyd, Kelli L. Schmidt, Ann Marie Skaar, Eric P. TI RAGE-Mediated Suppression of Interleukin-10 Results in Enhanced Mortality in a Murine Model of Acinetobacter baumannii Sepsis SO INFECTION AND IMMUNITY LA English DT Article DE Acinetobacter baumannii; IL-10; innate immunity; pneumonia; RAGE; receptor for advanced glycation end products; sepsis ID GLYCATION END-PRODUCTS; FACTOR-KAPPA-B; PNEUMOCOCCAL PNEUMONIA; IMMUNE-RESPONSE; SEPTIC SHOCK; RECEPTOR; ACTIVATION; INFECTION; PATHOGENESIS; MICE AB The receptor for advanced glycation end products (RAGE) is a pattern recognition receptor capable of recognizing multiple pathogen-associated and dangerassociated molecular patterns that contributes to the initiation and potentiation of inflammation in many disease processes. During infection, RAGE functions to either exacerbate disease severity or enhance pathogen clearance depending on the pathogen studied. Acinetobacter baumannii is an opportunistic human pathogen capable of causing severe infections, including pneumonia and sepsis, in impaired hosts. The role of RAGE signaling in response to opportunistic bacterial infections is largely unknown. In murine models of A. baumannii pneumonia, RAGE signaling alters neither inflammation nor bacterial clearance. In contrast, RAGE(-/-) mice systemically infected with A. baumannii exhibit increased survival and reduced bacterial burdens in the liver and spleen. The increased survival of RAGE(-/-) mice is associated with increased circulating levels of the anti-inflammatory cytokine interleukin-10 (IL-10). Neutralization of IL-10 in RAGE(-/-) mice results in decreased survival during systemic A. baumannii infection that mirrors that of wild-type (WT) mice, and exogenous IL-10 administration to WT mice enhances survival in this model. These findings demonstrate the role for RAGE-dependent IL-10 suppression as a key modulator of mortality from Gram-negative sepsis. C1 [Noto, Michael J.] Vanderbilt Univ, Ctr Med, Div Allergy Pulm & Crit Care Med, Dept Med, Nashville, TN 37232 USA. [Becker, Kyle W.; Boyd, Kelli L.; Skaar, Eric P.] Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA. [Schmidt, Ann Marie] NYU, Langone Med Ctr, New York, NY USA. [Skaar, Eric P.] US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN USA. RP Skaar, EP (reprint author), Vanderbilt Univ, Med Ctr, Dept Pathol Microbiol & Immunol, Nashville, TN USA.; Skaar, EP (reprint author), US Dept Vet Affairs, Tennessee Valley Healthcare Syst, Nashville, TN USA. EM eric.skaar@vanderbilt.edu FU Department of Veterans Affairs Merit Award [INFB024-13F]; Cystic Fibrosis Foundation [NOTO15D0]; National Institutes of Health [2T32HL087738-06]; [5RO1AI101171] FX We thank members of the Skaar laboratory for review of the manuscript. This research was supported by Department of Veterans Affairs Merit Award INFB024-13F and grant 5RO1AI101171 to E.P.S. and Cystic Fibrosis Foundation award NOTO15D0 and National Institutes of Health grant 2T32HL087738-06 to M.J.N.E.P.S. is a Burroughs Wellcome Fellow in the Pathogenesis of Infectious Diseases. We declare that we have no conflicts of interest. NR 50 TC 0 Z9 0 U1 0 U2 0 PU AMER SOC MICROBIOLOGY PI WASHINGTON PA 1752 N ST NW, WASHINGTON, DC 20036-2904 USA SN 0019-9567 EI 1098-5522 J9 INFECT IMMUN JI Infect. Immun. PD MAR PY 2017 VL 85 IS 3 AR e00954-16 DI 10.1128/IAI.00954-16 PG 9 WC Immunology; Infectious Diseases SC Immunology; Infectious Diseases GA EL4SU UT WOS:000394612000016 ER PT J AU Okland, T Karimkhani, C Pederson, H Boyers, LN Sawyer, MD Rove, KO Kenny, MC Steinberg, S Naghavi, M Dellavalle, RP AF Okland, Tyler Karimkhani, Chante Pederson, Hannah Boyers, Lindsay N. Sawyer, Mark D. Rove, Kyle O. Kenny, McCabe C. Steinberg, Steven Naghavi, Mohsen Dellavalle, Robert P. TI Research prioritization of men's health and urologic diseases SO INTERNATIONAL BRAZ J UROL LA English DT Article DE Men's Health; Urologic Diseases; Neoplasms; Infertility; Male ID SYSTEMATIC-REVIEWS; GLOBAL BURDEN; COCHRANE-DATABASE; RESEARCH GAPS; TRIALS AB Objectives: We sought to determine whether disease representation in the Cochrane Database of Systematic Reviews (CDSR) reflects disease burden, measured by the Global Burden of Disease (GBD) Study as disability-adjusted life-years (DALYs). Materials and Methods: Two investigators performed independent assessment of ten men's health and urologic diseases (MHUDs) in CDSR for systematic review and protocol representation, which were compared with percentage of total 2010 DALYs for the ten conditions. Data were analyzed for correlation using Spearman rank analysis. Results: Nine of ten MHUDs were represented by at least one CDSR review. There was a poor and statistically insignificant positive correlation between CDSR representation and disease burden (rho = 0.42, p = 0.23). CDSR representation was aligned with disease burden for three conditions, greater than disease burden for one condition, and less than disease burden for six conditions. Conclusions: These results yield high-quality estimates to inform future research prioritization for MHUDs. While prioritization processes are complex and multi-faceted, disease burden should be strongly considered. Awareness of research priority setting has the potential to minimize research disparities on a global scale. C1 [Okland, Tyler; Pederson, Hannah] Univ Colorado, Sch Med, Aurora, CO USA. [Karimkhani, Chante] Columbia Univ, Coll Phys & Surg, New York, NY USA. [Boyers, Lindsay N.] Georgetown Univ, Sch Med, Washington, DC USA. [Sawyer, Mark D.; Steinberg, Steven] Eastern Colorado Hlth Care Syst, Urol Serv, US Dept Vet Affairs, Denver, CO USA. [Rove, Kyle O.; Kenny, McCabe C.; Steinberg, Steven] Univ Colorado, Dept Urol, Anschutz Med Campus, Aurora, CO USA. [Naghavi, Mohsen] Univ Washington, Inst Hlth Metr & Evaluat, Seattle, WA 98195 USA. [Dellavalle, Robert P.] Univ Colorado, Dept Dermatol, Anschutz Med Campus, Aurora, CO USA. [Dellavalle, Robert P.] Eastern Colorado Hlth Care Syst, Dermatol Serv, US Dept Vet, Denver, CO USA. [Dellavalle, Robert P.] Univ Colorado, Dept Epidemiol, Colorado Sch Publ Hlth, Anschutz Med Campus, Aurora, CO USA. RP Dellavalle, RP (reprint author), US Dept Vet Affairs, Med Ctr, Dermatol Serv, 1055 Clermont St,Box 165, Denver, CO 80220 USA. EM robert.dellavalle@ucdenver.edu FU Bill and Melinda Gates Foundation; CDC; National Institutes of Health FX There was no direct funding to the current study. The Global Burden of Disease study received funding from the Bill and Melinda Gates Foundation (PI: Christopher J.L. Murray). Lindsay Boyers, Mark Sawyer, and Robert Dellavalle are employees of the U.S. Department of Veterans Affairs. The U.S. Department of Veterans Affairs had no role in the design and execution of the study. Robert Dellavalle is supported by grants from the CDC and National Institutes of Health. Tyler Okland, Chante Karimkhani, Hannah Pederson, Lindsay Boyers, Mohsen Naghavi, and Mark Sawyer report no relevant disclosures. Any opinions expressed herein do not necessarily reflect the opinions of the CDC or the Department of Veterans Affairs. NR 15 TC 0 Z9 0 U1 0 U2 0 PU BRAZILIAN SOC UROL PI RIO DE JANEIRO PA RUA BAMBINA, 153, RIO DE JANEIRO, 2251-050, BRAZIL SN 1677-5538 EI 1677-6119 J9 INT BRAZ J UROL JI Int. Braz J Urol PD MAR-APR PY 2017 VL 43 IS 2 BP 289 EP 303 DI 10.1590/S1677-5538.IBJU.2016.0047 PG 15 WC Urology & Nephrology SC Urology & Nephrology GA EN4UR UT WOS:000396002900017 PM 28128909 ER PT J AU Halaney, DL Sanyal, A Nafissi, NA Escobedo, D Goros, M Michalek, J Acevedo, PJ Perez, W Escobar, GP Feldman, MD Han, HC AF Halaney, David L. Sanyal, Arnav Nafissi, Navid A. Escobedo, Daniel Goros, Martin Michalek, Joel Acevedo, Pedro J. Perez, William Escobar, G. Patricia Feldman, Marc D. Han, Hai-Chao TI The Effect of Trabeculae Carneae on Left Ventricular Diastolic Compliance: Improvement in Compliance With Trabecular Cutting SO JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME LA English DT Article DE trabeculae carneae; LV compliance; wall stress; stiffness; hypertrophy; surgery ID NON-COMPACTION CARDIOMYOPATHY; DIFFERENT CARDIAC-DISEASES; HEART-FAILURE; MAGNETIC-RESONANCE; EJECTION FRACTION; PAPILLARY-MUSCLES; EUROPEAN-SOCIETY; OF-CARDIOLOGY; TASK-FORCE; QUANTIFICATION AB The role of trabeculae carneae in modulating left ventricular (LV) diastolic compliance remains unclear. The objective of this study was to determine the contribution of trabeculae carneae to the LV diastolic compliance. LV pressure-volume compliance curves were measured in six human heart explants from patients with LV hypertrophy at baseline and following trabecular cutting. The effect of trabecular cutting was also analyzed with finite-element model (FEM) simulations. Our results demonstrated that LV compliance improved after trabecular cutting (p < 0.001). Finite-element simulations further demonstrated that stiffer trabeculae reduce LV compliance further, and that the presence of trabeculae reduced the wall stress in the apex. In conclusion, we demonstrate that integrity of the LV and trabeculae is important to maintain LV stiffness and loss in trabeculae leads to more LV compliance. C1 [Halaney, David L.; Nafissi, Navid A.; Escobedo, Daniel; Escobar, G. Patricia; Feldman, Marc D.] Univ Texas Hlth Sci, Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA. [Halaney, David L.; Escobedo, Daniel; Feldman, Marc D.] South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA. [Sanyal, Arnav; Han, Hai-Chao] Univ Texas San Antonio, Dept Mech Engn, San Antonio, TX 78249 USA. [Goros, Martin; Michalek, Joel] Univ Texas Hlth Sci, Ctr San Antonio, Dept Epidemiol & Biostat, San Antonio, TX 78229 USA. [Acevedo, Pedro J.] Univ Environm & Appl Sci UDCA, Dept Anat, Bogota, Colombia. [Perez, William] Univ Republica, Fac Vet Med, Dept Anat, Montevideo 11200, Uruguay. RP Feldman, MD (reprint author), Univ Texas Hlth Sci, Ctr San Antonio, Dept Med, San Antonio, TX 78229 USA.; Feldman, MD (reprint author), South Texas Vet Hlth Care Syst, Dept Vet Affairs, San Antonio, TX 78229 USA. OI Perez, William/0000-0002-9647-4731 FU South Texas Veterans Health Care System (VA Merit Grant, San Antonio, TX); Janey and Dolph Briscoe Center for Cardiovascular Research (San Antonio, TX); National Heart, Lung, and Blood Institute [HL095852]; Clayton Foundation; AHA National Innovation Award [15IRG23320009]; Office of the Vice President for Research of the University of Texas at San Antonio FX This work was supported by the South Texas Veterans Health Care System (VA Merit Grant, San Antonio, TX), the Janey and Dolph Briscoe Center for Cardiovascular Research (San Antonio, TX), Grant No. HL095852 from the National Heart, Lung, and Blood Institute, the Clayton Foundation, and an AHA National Innovation Award (15IRG23320009). This project was also funded in part by the GREAT program from the Office of the Vice President for Research of the University of Texas at San Antonio. NR 41 TC 0 Z9 0 U1 1 U2 1 PU ASME PI NEW YORK PA TWO PARK AVE, NEW YORK, NY 10016-5990 USA SN 0148-0731 EI 1528-8951 J9 J BIOMECH ENG-T ASME JI J. Biomech. Eng.-Trans. ASME PD MAR PY 2017 VL 139 IS 3 AR 031012 DI 10.1115/1.4035585 PG 8 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA EM2XR UT WOS:000395179600012 ER PT J AU Telfer, S Kindig, MW Sangeorzan, BJ Ledoux, WR AF Telfer, Scott Kindig, Matthew W. Sangeorzan, Bruce J. Ledoux, William R. TI Metatarsal Shape and Foot Type: A Geometric Morphometric Analysis SO JOURNAL OF BIOMECHANICAL ENGINEERING-TRANSACTIONS OF THE ASME LA English DT Article DE foot type; bone morphology; pes planus; pes cavus; metatarsal ID LOWER-LIMB KINEMATICS; PLANTAR PRESSURE; STATISTICAL SHAPE; FRAMINGHAM FOOT; BONE MORPHOLOGY; CAVUS FOOT; PES PLANUS; WALKING; POSTURE; DEFORMITY AB Planus and cavus foot types have been associated with an increased risk of pain and disability. Improving our understanding of the geometric differences between bones in different foot types may provide insights into injury risk profiles and have implications for the design of musculoskeletal and finite-element models. In this study, we performed a geometric morphometric analysis on the geometry of metatarsal bones from 65 feet, segmented from computed tomography (CT) scans. These were categorized into four foot types: pes cavus, neutrally aligned, asymptomatic pes planus, and symptomatic pes planus. Generalized procrustes analysis (GPA) followed by permutation tests was used to determine significant shape differences associated with foot type and sex, and principal component analysis was used to find the modes of variation for each metatarsal. Significant shape differences were found between foot types for all the metatarsals (p < 0.01), most notably in the case of the second metatarsal which showed significant pairwise differences across all the foot types. Analysis of the principal components of variation showed pes cavus bones to have reduced cross-sectional areas in the sagittal and frontal planes. The first (p = 0.02) and fourth metatarsals (p = 0.003) were found to have significant sex-based differences, with first metatarsals from females shown to have reduced width, and fourth metatarsals from females shown to have reduced frontal and sagittal plane cross-sectional areas. Overall, these findings suggest that metatarsal bones have distinct morphological characteristics that are associated with foot type and sex, with implications for our understanding of anatomy and numerical modeling of the foot. C1 [Telfer, Scott; Sangeorzan, Bruce J.; Ledoux, William R.] Univ Washington, Dept Orthopaed & Sports Med, Box 356500,1959 Northeasr Pacific St, Seattle, WA 98195 USA. [Kindig, Matthew W.; Ledoux, William R.] VA Puget Sound, RR&D Ctr Excellence, Seattle, WA 98108 USA. [Ledoux, William R.] Univ Washington, Dept Mech Engn, Seattle, WA 98195 USA. RP Telfer, S (reprint author), Univ Washington, Dept Orthopaed & Sports Med, Box 356500,1959 Northeasr Pacific St, Seattle, WA 98195 USA. EM telfers@uw.edu NR 45 TC 0 Z9 0 U1 4 U2 4 PU ASME PI NEW YORK PA TWO PARK AVE, NEW YORK, NY 10016-5990 USA SN 0148-0731 EI 1528-8951 J9 J BIOMECH ENG-T ASME JI J. Biomech. Eng.-Trans. ASME PD MAR PY 2017 VL 139 IS 3 AR 031008 DI 10.1115/1.4035077 PG 8 WC Biophysics; Engineering, Biomedical SC Biophysics; Engineering GA EM2XR UT WOS:000395179600008 ER PT J AU Ripley, B Levin, D Kelil, T Hermsen, JL Kim, S Maki, JH Wilson, GJ AF Ripley, Beth Levin, Dmitry Kelil, Tatiana Hermsen, Joshua L. Kim, Sooah Maki, Jeffrey H. Wilson, Gregory J. TI 3D Printing From MRI Data: Harnessing Strengths and Minimizing Weaknesses SO JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Article DE 3D printing; 3D printing; dditive manufacturing; MRI ID 3-DIMENSIONAL PRINTERS; TEMPORAL BONE; LONG BONES; RECONSTRUCTION; MODELS; ACCURACY; BRAIN; SEGMENTATION; REPLACEMENT; ANGIOGRAPHY AB 3D printing facilitates the creation of accurate physical models of patient-specific anatomy from medical imaging datasets. While the majority of models to date are created from computed tomography (CT) data, there is increasing interest in creating models from other datasets, such as ultrasound and magnetic resonance imaging (MRI). MRI, in particular, holds great potential for 3D printing, given its excellent tissue characterization and lack of ionizing radiation. There are, however, challenges to 3D printing from MRI data as well. Here we review the basics of 3D printing, explore the current strengths and weaknesses of printing from MRI data as they pertain to model accuracy, and discuss considerations in the design of MRI sequences for 3D printing. Finally, we explore the future of 3D printing and MRI, including creative applications and new materials. C1 [Ripley, Beth; Kim, Sooah; Maki, Jeffrey H.; Wilson, Gregory J.] Univ Washington, Dept Radiol, Seattle, WA 98195 USA. [Levin, Dmitry] Univ Washington, Dept Med, Div Cardiol, Seattle, WA USA. [Kelil, Tatiana] Harvard Med Sch, Brigham & Womens Hosp, Dept Radiol, Boston, MA USA. [Hermsen, Joshua L.] Univ Washington, Dept Surg, Div Cardiothorac Surg, Seattle, WA 98195 USA. [Ripley, Beth] VA Puget Sound Hlth Care Syst, Dept Radiol, Seattle, WA 98108 USA. RP Ripley, B (reprint author), 1959 Pacific Ave NE, Seattle, WA 98195 USA. NR 69 TC 0 Z9 0 U1 6 U2 6 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-1807 EI 1522-2586 J9 J MAGN RESON IMAGING JI J. Magn. Reson. Imaging PD MAR PY 2017 VL 45 IS 3 BP 635 EP 645 DI 10.1002/jmri.25526 PG 11 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EL4QF UT WOS:000394605200001 PM 27875009 ER PT J AU Nguyen, KL Yoshida, T Han, F Ayad, I Reemtsen, BL Salusky, IB Satou, GM Hu, P Finn, JP AF Nguyen, Kim-Lien Yoshida, Takegawa Han, Fei Ayad, Ihab Reemtsen, Brian L. Salusky, Isidro B. Satou, Gary M. Hu, Peng Finn, J. Paul TI MRI With Ferumoxytol: A Single Center Experience of Safety Across the Age Spectrum SO JOURNAL OF MAGNETIC RESONANCE IMAGING LA English DT Article ID AMBULATORY BLOOD-PRESSURE; IRON-DEFICIENCY ANEMIA; CHRONIC KIDNEY-DISEASE; YOUNG-ADULTS; PHYSICOCHEMICAL PROPERTIES; HEMODIALYSIS-PATIENTS; CONTRAST AGENTS; HIGH-RESOLUTION; UNITED-STATES; POOL AGENT AB Purpose: To summarize our single-center safety experience with the off-label use of ferumoxytol for magnetic resonance imaging (MRI) and to compare the effects of ferumoxytol on monitored physiologic indices in patients under anesthesia with those of gadofosveset trisodium. Materials and Methods: Consecutive patients who underwent ferumoxytol-enhanced (FE) MRI exams were included. Adverse events (AEs) were classified according to the Common Terminology Criteria for Adverse Events v4.0. In a subgroup of patients examined under general anesthesia, recording of blood pressure, heart rate, oxygen saturation, and end-tidal CO2 was performed. A comparable group of 23 patients who underwent gadofosveset-enhanced (GE) MRI under anesthesia with similar monitoring was also analyzed. Results: In all, 217 unique patients, ages 3 days to 94 years, underwent FE-MRI. No ferumoxytol-related severe, life-threatening, or fatal AEs occurred acutely or at follow-up. Two patients developed ferumoxytol-related nausea. Between-group (FE- vs. GE-MRI) comparisons showed no statistical difference in heart rate (P = 0.69, 95% confidence interval [CI] 96-113 bpm), mean arterial blood pressure (MAP) (P = 0.74, 95% CI 44-52 mmHg), oxygen saturation (P = 0.76, 95% CI 94-98%), and end-tidal CO2 (P = 0.73, 95% CI 31-37 mmHg). No significant change in MAP (P = 0.12, 95% CI 50-58 mmHg) or heart rate (P=0.25, 95% CI 91-105 bpm) was noted between slow infusion of ferumoxytol (n = 113) vs. bolus injection (n = 104). Conclusion: In our single-center experience, no serious AEs occurred with the diagnostic use of ferumoxytol across a wide spectrum of age, renal function, and indications. Because of the limited sample size, firm conclusions cannot be drawn about the generalizability of our results. Thus, vigilance and monitoring are recommended to mitigate potential rare adverse reactions. C1 [Nguyen, Kim-Lien; Yoshida, Takegawa; Han, Fei; Hu, Peng; Finn, J. Paul] Univ Calif Los Angeles, David Geffen Sch Med, Diagnost Cardiovasc Imaging Lab, Los Angeles, CA 90095 USA. [Nguyen, Kim-Lien] Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiol, Los Angeles, CA 90095 USA. [Nguyen, Kim-Lien] VA Greater Los Angeles Healthcare Syst, Los Angeles, CA USA. [Yoshida, Takegawa; Han, Fei; Hu, Peng; Finn, J. Paul] Univ Calif Los Angeles, David Geffen Sch Med, Dept Radiol, Los Angeles, CA 90095 USA. [Ayad, Ihab] Univ Calif Los Angeles, David Geffen Sch Med, Dept Anesthesiol, Los Angeles, CA 90095 USA. [Salusky, Isidro B.; Satou, Gary M.] Univ Calif Los Angeles, David Geffen Sch Med, Dept Pediat, Los Angeles, CA 90095 USA. [Reemtsen, Brian L.] Univ Calif Los Angeles, David Geffen Sch Med, Div Cardiothorac Surg, Los Angeles, CA 90095 USA. RP Finn, JP (reprint author), Univ Calif Los Angeles, Dept Radiol Sci, Peter V Ueberroth Bldg Suite 3371, Los Angeles, CA 90095 USA. EM pfinn@mednet.ucla.edu OI Nguyen, Kim-Lien/0000-0002-8854-2976 FU National Heart, Lung, and Blood Institute [R01HL127153]; NIH/ National Center for Advancing Translational Science (NCATS) CTSI [UL1TR000124] FX Contract grant sponsor: National Heart, Lung, and Blood Institute; contract grant number: R01HL127153; Contract grant sponsor: REDCap hosting by the NIH/ National Center for Advancing Translational Science (NCATS) CTSI; contract grant number: UL1TR000124. NR 51 TC 1 Z9 1 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1053-1807 EI 1522-2586 J9 J MAGN RESON IMAGING JI J. Magn. Reson. Imaging PD MAR PY 2017 VL 45 IS 3 BP 804 EP 812 DI 10.1002/jmri.25412 PG 9 WC Radiology, Nuclear Medicine & Medical Imaging SC Radiology, Nuclear Medicine & Medical Imaging GA EL4QF UT WOS:000394605200019 PM 27480885 ER PT J AU Rogal, S Dew, MA DiMartini, A AF Rogal, Shari Dew, Mary Amanda DiMartini, Andrea TI High-Dose Opioid Use and Liver Transplantation: An Underestimated Problem? SO LIVER TRANSPLANTATION LA English DT Editorial Material ID KIDNEY-TRANSPLANTATION; CIRRHOSIS; PAIN C1 [Rogal, Shari] VA Pittsburgh Healthcare Syst, Ctr Hlth Equ Res & Promot, Pittsburgh, PA USA. [Rogal, Shari; DiMartini, Andrea] Univ Pittsburgh, Dept Surg, Pittsburgh, PA USA. [Rogal, Shari] Univ Pittsburgh, Dept Gastroenterol Hepatol & Nutr, Pittsburgh, PA USA. [Dew, Mary Amanda; DiMartini, Andrea] Univ Pittsburgh, Dept Psychiat, Pittsburgh, PA USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Psychol, Pittsburgh, PA 15260 USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Epidemiol, Pittsburgh, PA 15261 USA. [Dew, Mary Amanda] Univ Pittsburgh, Dept Biostat, Pittsburgh, PA 15261 USA. RP DiMartini, A (reprint author), Western Psychiat Inst & Clin, 3811 OHara St, Pittsburgh, PA 15213 USA. EM dimartiniaf@upmc.edu FU VA Pittsburgh Healthcare System FX This material is the result of work supported with resources and the use of facilities at the VA Pittsburgh Healthcare System. The views expressed in this article are those of the authors and do not necessarily reflect the position or policy of the Department of Veterans Affairs. NR 13 TC 0 Z9 0 U1 0 U2 0 PU WILEY PI HOBOKEN PA 111 RIVER ST, HOBOKEN 07030-5774, NJ USA SN 1527-6465 EI 1527-6473 J9 LIVER TRANSPLANT JI Liver Transplant. PD MAR PY 2017 VL 23 IS 3 BP 285 EP 287 DI 10.1002/lt.24731 PG 3 WC Gastroenterology & Hepatology; Surgery; Transplantation SC Gastroenterology & Hepatology; Surgery; Transplantation GA EM0BO UT WOS:000394984000001 PM 28133898 ER PT J AU Han, CJ Kohen, R Jun, S Jarrett, ME Cain, KC Burr, R Heitkemper, MM AF Han, Claire J. Kohen, Ruth Jun, Sangeun Jarrett, Monica E. Cain, Kevin C. Burr, Robert Heitkemper, Margaret M. TI COMT Val158Met Polymorphism and Symptom Improvement Following a Cognitively Focused Intervention for Irritable Bowel Syndrome SO NURSING RESEARCH LA English DT Article DE catechol-O-methyltransferase (COMT) polymorphism; cognitive behavioral therapy; digestive signs and symptoms; irritable bowel syndrome; self-management ID SELF-MANAGEMENT; GASTROINTESTINAL SYMPTOMS; LIFE STRESS; WOMEN; TRIAL; P